data_2k2p_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2k2p _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.222 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.428 HD12 ' HB3' ' A' ' 70' ' ' ALA . 4.3 mm? -79.4 164.29 24.12 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.324 0.65 . . . . 0.0 111.023 -176.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 29.5 p -152.47 110.67 3.69 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 123.803 0.841 . . . . 0.0 108.82 178.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -110.35 116.44 31.45 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 123.702 0.801 . . . . 0.0 109.357 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 26.4 p80 -82.11 90.69 6.57 Favored 'General case' 0 CA--C 1.552 1.056 0 CA-C-O 122.615 1.198 . . . . 0.0 110.384 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.431 HG23 HD12 ' A' ' 77' ' ' ILE . 39.7 t -84.21 87.37 2.26 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 172.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.13 -5.67 43.12 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-N 115.646 -0.707 . . . . 0.0 112.758 -173.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -86.55 -22.11 26.51 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.35 0.66 . . . . 0.0 110.672 173.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.625 ' SD ' ' HB3' ' A' ' 55' ' ' ALA . 50.4 ttp -65.09 109.19 2.08 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 123.489 0.716 . . . . 0.0 111.453 -174.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 25.5 p -117.52 128.3 54.83 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.106 0.962 . . . . 0.0 109.434 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.406 ' SG ' ' HB2' ' A' ' 35' ' ' HIS . 8.8 p 65.68 159.36 0.12 Allowed 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 126.034 1.733 . . . . 0.0 113.718 176.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.505 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -67.44 -9.08 54.2 Favored Glycine 0 C--N 1.353 1.481 0 CA-C-N 115.104 -0.953 . . . . 0.0 114.306 -178.65 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . 0.406 ' HB2' ' SG ' ' A' ' 33' ' ' CYS . 29.4 m170 -71.15 -44.43 65.55 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 117.482 0.641 . . . . 0.0 110.216 173.165 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 59.0 m -83.82 -32.47 25.28 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.234 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.505 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -70.05 -34.77 73.66 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.009 176.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.04 -44.96 96.55 Favored Glycine 0 C--N 1.347 1.192 0 O-C-N 124.039 0.837 . . . . 0.0 113.472 -176.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.5 p -68.16 -30.03 46.53 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.064 0 C-N-CA 122.698 0.399 . . . . 0.0 111.384 -178.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.567 HD11 ' SD ' ' A' ' 31' ' ' MET . 66.4 mt -66.39 -47.79 82.9 Favored 'Isoleucine or valine' 0 C--N 1.356 0.864 0 C-N-CA 123.149 0.58 . . . . 0.0 110.013 175.086 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 60.5 mtpt -57.43 -48.17 79.83 Favored 'General case' 0 C--N 1.349 0.566 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.224 178.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.93 -34.06 87.45 Favored Glycine 0 C--N 1.346 1.106 0 O-C-N 124.246 0.966 . . . . 0.0 112.966 -178.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.44 -54.76 35.37 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.072 0.549 . . . . 0.0 110.849 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.534 HG21 HG11 ' A' ' 64' ' ' VAL . 58.3 mt -72.45 -43.7 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 CA-C-N 115.672 -0.694 . . . . 0.0 112.127 -176.003 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -64.79 -38.02 89.58 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 124.219 1.008 . . . . 0.0 112.67 -174.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -76.03 -37.02 58.86 Favored 'General case' 0 N--CA 1.481 1.114 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.212 -179.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 42.7 m -71.12 -40.15 71.6 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 123.011 0.524 . . . . 0.0 110.63 177.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 48.2 t -121.39 94.54 48.64 Favored Pre-proline 0 N--CA 1.48 1.051 0 C-N-CA 123.58 0.752 . . . . 0.0 109.931 -177.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -62.25 104.29 0.34 Allowed 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.563 2.175 . . . . 0.0 111.174 169.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.56 -0.15 11.18 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-O 119.593 -0.559 . . . . 0.0 113.291 -177.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -83.96 108.71 17.1 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 169.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.426 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -78.49 95.97 5.29 Favored 'General case' 0 C--N 1.348 0.543 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 -178.679 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.498 HG11 HG13 ' A' ' 64' ' ' VAL . 27.7 m -88.95 131.49 36.15 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.754 0 C-N-CA 123.701 0.8 . . . . 0.0 111.027 -171.118 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 3.5 t-160 -143.22 99.92 3.53 Favored 'General case' 0 C--N 1.346 0.421 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 167.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.625 ' HB3' ' SD ' ' A' ' 31' ' ' MET . . . -92.51 113.75 26.11 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 172.079 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -106.9 120.49 47.95 Favored Pre-proline 0 N--CA 1.467 0.394 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -172.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -63.11 -35.31 65.44 Favored 'Trans proline' 0 C--N 1.37 1.698 0 C-N-CA 122.73 2.287 . . . . 0.0 113.493 -179.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.52 -35.2 46.62 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 123.272 0.629 . . . . 0.0 112.148 -174.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.2 t -91.43 -19.61 22.67 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 123.18 0.592 . . . . 0.0 110.225 178.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.1 mpt_? 60.79 33.82 19.96 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 125.034 1.334 . . . . 0.0 110.824 -177.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 27.3 m -124.69 131.52 53.46 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 122.677 0.391 . . . . 0.0 110.683 -170.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.556 HG23 HG22 ' A' ' 40' ' ' ILE . 44.0 t -105.87 105.57 18.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 173.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.3 m -99.71 136.12 32.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.284 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.534 HG11 HG21 ' A' ' 44' ' ' ILE . 17.3 m -131.0 109.36 16.45 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.909 0 C-N-CA 123.399 0.68 . . . . 0.0 109.434 179.22 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -92.79 157.74 23.76 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.474 -176.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.21 0.43 89.53 Favored Glycine 0 C--N 1.345 1.049 0 CA-C-O 119.932 -0.371 . . . . 0.0 114.023 177.176 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.4 m -124.14 144.7 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.625 0.77 . . . . 0.0 110.147 -176.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 14.9 m -108.86 -17.71 13.87 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.599 0.759 . . . . 0.0 110.225 176.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.423 ' O ' HG12 ' A' ' 73' ' ' ILE . 6.5 m-20 -78.77 76.54 5.26 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.347 1.059 . . . . 0.0 111.035 -172.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.428 ' HB3' HD12 ' A' ' 24' ' ' LEU . . . -60.59 -41.5 94.83 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.108 0.963 . . . . 0.0 111.602 -179.635 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -65.54 -41.47 92.99 Favored 'General case' 0 N--CA 1.471 0.581 0 O-C-N 124.206 0.942 . . . . 0.0 111.044 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.419 ' O ' HG13 ' A' ' 76' ' ' ILE . 77.8 t60 -63.28 -50.69 69.12 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.501 0.72 . . . . 0.0 110.741 178.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.5 HG21 HG21 ' A' ' 64' ' ' VAL . 40.7 mm -58.57 -42.3 84.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 O-C-N 123.826 0.704 . . . . 0.0 110.142 179.411 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.61 -37.97 80.04 Favored 'General case' 0 N--CA 1.476 0.836 0 O-C-N 124.329 1.018 . . . . 0.0 111.648 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 12.3 mm-40 -64.67 -40.14 94.91 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.479 0.712 . . . . 0.0 111.166 177.516 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.509 HG23 ' HA ' ' A' ' 44' ' ' ILE . 33.9 mt -67.19 -51.54 52.36 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 C-N-CA 123.149 0.58 . . . . 0.0 111.356 -177.144 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.431 HD12 HG23 ' A' ' 28' ' ' VAL . 8.3 tt -71.08 -29.88 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.234 0 C-N-CA 123.379 0.671 . . . . 0.0 111.836 -176.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.452 ' HA ' ' O ' ' A' ' 82' ' ' TYR . 2.9 t -75.25 -28.9 60.03 Favored 'General case' 0 N--CA 1.48 1.054 0 N-CA-C 110.364 -0.236 . . . . 0.0 110.364 175.079 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.32 -26.17 66.38 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.355 0.662 . . . . 0.0 110.644 172.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -76.76 -8.72 57.84 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 123.377 0.671 . . . . 0.0 111.455 173.323 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.3 25.05 24.95 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 116.561 -0.291 . . . . 0.0 113.208 176.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.452 ' O ' ' HA ' ' A' ' 78' ' ' THR . 95.9 m-85 -120.43 155.06 34.27 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.526 0.73 . . . . 0.0 110.236 179.379 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 73.1 p -89.79 111.14 44.48 Favored Pre-proline 0 CA--C 1.553 1.086 0 C-N-CA 123.271 0.628 . . . . 0.0 110.415 -176.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -78.89 79.5 3.36 Favored 'Trans proline' 0 C--N 1.377 2.043 0 C-N-CA 122.906 2.404 . . . . 0.0 111.878 178.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 35.0 mm-40 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.794 -0.622 . . . . 0.0 109.844 -176.661 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.799 0 N-CA-C 111.706 -0.558 . . . . 0.0 111.706 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -82.34 109.61 16.75 Favored 'General case' 0 CA--C 1.548 0.895 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.7 m -92.51 118.6 31.14 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 123.79 0.836 . . . . 0.0 110.748 -172.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -106.29 110.76 23.1 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.781 0.832 . . . . 0.0 109.939 178.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 50.2 m80 -81.82 94.38 7.04 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 177.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.48 ' O ' ' HB3' ' A' ' 60' ' ' ARG . 20.0 t -93.51 94.38 4.61 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.798 0 C-N-CA 124.356 1.062 . . . . 0.0 108.397 178.451 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -71.68 -12.72 61.47 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -175.003 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -85.5 -19.0 31.86 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 123.812 0.845 . . . . 0.0 110.951 174.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 25.2 ttt -55.33 128.64 35.11 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 124.334 1.054 . . . . 0.0 112.266 -175.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.3 p -88.47 162.18 16.61 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 124.438 1.095 . . . . 0.0 110.087 172.595 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 57.3 m -66.56 -162.75 0.02 OUTLIER 'General case' 0 CA--C 1.564 1.505 0 C-N-CA 124.986 1.314 . . . . 0.0 114.035 -169.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -56.69 -22.73 41.18 Favored Glycine 0 C--N 1.364 2.094 0 N-CA-C 115.722 1.049 . . . . 0.0 115.722 -171.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 48.9 t-80 -64.63 -28.77 69.84 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.777 0.831 . . . . 0.0 111.882 177.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 61.3 m -119.2 19.26 12.9 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.985 0.914 . . . . 0.0 111.26 179.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.37 -34.36 70.37 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 122.583 0.353 . . . . 0.0 111.047 177.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.08 -35.93 91.23 Favored Glycine 0 C--N 1.349 1.279 0 O-C-N 123.929 0.768 . . . . 0.0 114.779 -173.295 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.84 -38.71 76.48 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 123.102 0.561 . . . . 0.0 111.025 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 35.3 mt -73.09 -42.36 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.454 0.702 . . . . 0.0 110.242 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -55.5 -54.08 48.32 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.121 171.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.05 -30.56 78.11 Favored Glycine 0 C--N 1.345 1.032 0 O-C-N 124.788 1.305 . . . . 0.0 113.767 -172.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.6 -56.69 18.85 Favored 'General case' 0 C--N 1.352 0.7 0 C-N-CA 122.899 0.479 . . . . 0.0 110.629 178.059 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.521 ' HA ' HG22 ' A' ' 76' ' ' ILE . 57.7 mt -76.03 -42.35 38.65 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.693 -174.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -62.29 -48.28 80.57 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.1 0.96 . . . . 0.0 112.255 -173.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -73.4 -25.69 60.65 Favored 'General case' 0 N--CA 1.48 1.075 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.43 -176.118 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 43.0 m -80.63 -41.84 23.18 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 123.022 0.529 . . . . 0.0 110.576 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.9 t -123.3 94.84 46.3 Favored Pre-proline 0 N--CA 1.479 1.01 0 C-N-CA 123.584 0.754 . . . . 0.0 109.378 -178.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -67.07 118.4 5.54 Favored 'Trans proline' 0 C--N 1.373 1.863 0 C-N-CA 122.579 2.186 . . . . 0.0 110.899 172.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.82 -25.48 7.17 Favored Glycine 0 C--N 1.347 1.141 0 CA-C-O 119.795 -0.447 . . . . 0.0 112.511 -174.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -73.81 106.17 5.42 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 174.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -79.8 99.91 7.72 Favored 'General case' 0 C--N 1.346 0.45 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -177.093 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.431 HG11 HG12 ' A' ' 64' ' ' VAL . 16.6 m -86.51 111.86 22.02 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.937 0 CA-C-O 121.539 0.685 . . . . 0.0 111.156 -169.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 64.9 t60 -109.22 99.24 8.54 Favored 'General case' 0 C--N 1.344 0.348 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.77 115.44 22.22 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 175.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -106.88 102.72 43.99 Favored Pre-proline 0 N--CA 1.474 0.739 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -56.26 -39.81 88.84 Favored 'Trans proline' 0 C--N 1.373 1.837 0 C-N-CA 123.084 2.522 . . . . 0.0 113.746 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.44 -44.62 64.49 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 123.383 0.673 . . . . 0.0 111.978 -171.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 21.1 t -95.39 -9.94 31.38 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.855 0.862 . . . . 0.0 110.606 -178.404 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.48 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 60.59 41.5 15.34 Favored 'General case' 0 N--CA 1.484 1.266 0 C-N-CA 125.266 1.426 . . . . 0.0 110.165 -179.319 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.5 m -123.13 120.44 33.25 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.642 0.377 . . . . 0.0 111.285 -167.368 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.6 t -98.97 105.38 17.29 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 175.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.2 t -102.5 118.79 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 -175.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.502 HG13 HG23 ' A' ' 44' ' ' ILE . 17.1 m -103.86 108.94 25.74 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.068 0 CA-C-O 121.581 0.705 . . . . 0.0 110.707 -178.136 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -85.59 149.38 23.49 Favored Glycine 0 C--N 1.35 1.312 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.412 -179.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.69 -26.03 13.91 Favored Glycine 0 N--CA 1.472 1.066 0 C-N-CA 122.955 0.312 . . . . 0.0 112.417 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 34.6 m -122.19 142.99 36.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 124.368 1.067 . . . . 0.0 109.705 -177.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 69.1 m -124.53 -0.52 8.12 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 123.518 0.727 . . . . 0.0 111.427 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 15.3 p-10 -78.42 83.94 4.61 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-O 122.603 1.192 . . . . 0.0 110.505 -178.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.37 -41.26 96.8 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 113.54 -1.664 . . . . 0.0 113.217 -170.483 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -63.02 -44.43 96.0 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.81 0.844 . . . . 0.0 111.648 -174.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.416 ' O ' HG13 ' A' ' 76' ' ' ILE . 32.1 m170 -66.25 -47.52 73.47 Favored 'General case' 0 N--CA 1.475 0.78 0 O-C-N 123.521 0.513 . . . . 0.0 110.896 179.315 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 29.3 mm -58.93 -39.2 77.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 123.795 0.684 . . . . 0.0 110.344 178.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.71 -38.21 89.52 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 124.156 0.982 . . . . 0.0 111.336 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -63.97 -39.37 93.98 Favored 'General case' 0 N--CA 1.482 1.169 0 O-C-N 123.619 0.574 . . . . 0.0 111.116 176.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.521 HG22 ' HA ' ' A' ' 44' ' ' ILE . 57.4 mt -68.15 -51.33 49.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 123.42 0.688 . . . . 0.0 111.268 -175.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 10.9 tt -68.63 -36.14 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.447 -175.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.0 t -71.97 -27.5 62.81 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 122.663 0.385 . . . . 0.0 110.311 177.501 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.46 -29.85 70.07 Favored 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 123.562 0.745 . . . . 0.0 111.401 174.407 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -78.03 -3.12 40.53 Favored 'General case' 0 N--CA 1.48 1.056 0 C-N-CA 123.432 0.693 . . . . 0.0 111.606 173.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.67 -9.54 60.46 Favored Glycine 0 C--N 1.343 0.969 0 CA-C-O 119.716 -0.491 . . . . 0.0 113.159 176.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -96.53 103.2 15.09 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 117.442 0.621 . . . . 0.0 109.722 -179.054 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 33.5 p -78.95 112.82 30.49 Favored Pre-proline 0 CA--C 1.553 1.063 0 C-N-CA 124.415 1.086 . . . . 0.0 109.87 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -76.77 -2.06 12.25 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 122.751 2.3 . . . . 0.0 113.421 179.199 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 . . . . . 0 C--O 1.256 1.396 0 C-N-CA 124.034 0.934 . . . . 0.0 109.933 175.14 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.006 0 CA-C-O 120.656 0.031 . . . . 0.0 113.159 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 67.6 mt -99.56 107.1 19.18 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.597 0.759 . . . . 0.0 109.615 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 30.1 p -92.05 110.81 22.18 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.046 0.538 . . . . 0.0 110.6 -177.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -104.21 105.03 15.04 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 123.353 0.661 . . . . 0.0 109.375 176.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 27.8 t60 -81.66 94.21 6.91 Favored 'General case' 0 CA--C 1.538 0.494 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.284 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.543 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 32.8 t -88.62 102.39 12.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.709 0 CA-C-N 114.964 -1.016 . . . . 0.0 108.618 -179.502 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -70.82 -22.76 62.3 Favored 'General case' 0 N--CA 1.485 1.322 0 CA-C-O 121.105 0.479 . . . . 0.0 110.923 177.774 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -75.62 -13.93 60.36 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.29 1.036 . . . . 0.0 111.244 175.292 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.543 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 27.5 ttt -58.99 122.07 12.79 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 123.371 0.669 . . . . 0.0 112.145 -173.359 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 14.8 t -85.31 163.48 18.57 Favored 'General case' 0 CA--C 1.549 0.908 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.884 173.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.509 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 28.7 p -66.41 -177.02 0.5 Allowed 'General case' 0 CA--C 1.554 1.12 0 C-N-CA 123.769 0.827 . . . . 0.0 113.015 -175.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.48 ' HA2' ' HB1' ' A' ' 37' ' ' ALA . . . -56.79 -15.38 12.54 Favored Glycine 0 C--N 1.357 1.734 0 N-CA-C 116.247 1.259 . . . . 0.0 116.247 -169.061 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -57.68 -42.99 84.76 Favored 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 117.61 0.705 . . . . 0.0 111.308 177.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 47.7 t -124.9 0.53 8.0 Favored 'General case' 0 CA--C 1.548 0.901 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.421 -177.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.48 ' HB1' ' HA2' ' A' ' 34' ' ' GLY . . . -64.64 -30.91 71.94 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 122.709 0.404 . . . . 0.0 110.624 173.189 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.53 -30.92 77.27 Favored Glycine 0 C--N 1.352 1.431 0 CA-C-N 115.794 -0.639 . . . . 0.0 113.265 174.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 42.8 t -69.13 -41.02 81.28 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 174.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 71.1 mt -58.26 -41.12 80.25 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.925 0 C-N-CA 124.078 0.951 . . . . 0.0 110.684 175.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.443 ' HB3' HG21 ' A' ' 53' ' ' VAL . 98.9 mttt -60.89 -58.92 6.42 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.572 0.749 . . . . 0.0 110.162 177.203 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.99 -30.6 70.38 Favored Glycine 0 C--N 1.351 1.372 0 O-C-N 124.68 1.238 . . . . 0.0 113.774 -173.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.59 -53.23 60.72 Favored 'General case' 0 C--N 1.35 0.62 0 C-N-CA 123.577 0.751 . . . . 0.0 110.557 176.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.545 HG22 HG12 ' A' ' 64' ' ' VAL . 72.8 mt -69.41 -46.64 76.02 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-N 114.847 -1.07 . . . . 0.0 112.465 -177.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -61.46 -46.24 90.89 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 123.504 0.722 . . . . 0.0 112.712 -175.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 12.8 mptt -83.52 -14.63 51.86 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.575 -171.102 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.5 m -87.4 -49.97 6.87 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 171.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 54.2 t -113.74 96.79 42.19 Favored Pre-proline 0 N--CA 1.475 0.821 0 C-N-CA 124.372 1.069 . . . . 0.0 108.959 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -66.14 140.09 58.11 Favored 'Trans proline' 0 C--N 1.376 1.987 0 C-N-CA 122.458 2.105 . . . . 0.0 111.271 176.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.54 -10.73 68.92 Favored Glycine 0 C--N 1.34 0.773 0 CA-C-O 119.571 -0.572 . . . . 0.0 112.938 -177.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -72.25 106.02 4.26 Favored 'General case' 0 C--N 1.355 0.828 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 174.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -83.83 99.92 10.63 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.56 HG12 HG11 ' A' ' 64' ' ' VAL . 26.9 m -85.31 135.82 24.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.541 0 CA-C-O 121.197 0.522 . . . . 0.0 110.763 -172.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 18.1 t-80 -126.19 95.55 4.42 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 167.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.51 112.88 24.77 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 177.662 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.442 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 9.6 t70 -112.43 108.38 54.55 Favored Pre-proline 0 CA--C 1.533 0.298 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 -175.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.509 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 71.4 Cg_exo -52.87 -35.73 71.51 Favored 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 123.223 2.615 . . . . 0.0 114.169 178.23 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.53 -31.3 47.47 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 123.061 0.544 . . . . 0.0 112.141 -177.088 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.442 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 19.5 m -91.31 -20.31 22.01 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 122.81 0.444 . . . . 0.0 111.039 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.4 mpt_? 57.88 46.09 17.35 Favored 'General case' 0 N--CA 1.483 1.188 0 C-N-CA 124.477 1.111 . . . . 0.0 110.033 -177.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.8 m -142.26 129.94 21.54 Favored 'General case' 0 C--N 1.351 0.657 0 C-N-CA 123.04 0.536 . . . . 0.0 110.735 -173.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 18.8 t -108.69 106.51 20.83 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 124.068 0.947 . . . . 0.0 108.858 174.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 25.9 t -97.97 118.68 44.89 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 123.76 0.824 . . . . 0.0 109.464 -179.687 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.56 HG11 HG12 ' A' ' 53' ' ' VAL . 35.9 m -106.89 114.61 46.44 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.014 0 CA-C-O 121.5 0.667 . . . . 0.0 110.912 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -97.17 161.29 21.57 Favored Glycine 0 C--N 1.345 1.066 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.278 -178.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 81.27 -4.79 70.2 Favored Glycine 0 N--CA 1.476 1.315 0 N-CA-C 114.149 0.419 . . . . 0.0 114.149 178.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.19 152.81 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 123.851 0.861 . . . . 0.0 110.141 -177.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.1 t -125.66 19.79 7.92 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 123.742 0.817 . . . . 0.0 109.79 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.451 ' O ' HG12 ' A' ' 73' ' ' ILE . 3.3 m-20 -96.24 66.86 2.51 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 123.564 0.745 . . . . 0.0 109.41 -177.301 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.0 -46.06 89.47 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 123.178 0.591 . . . . 0.0 112.196 -171.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.14 -42.23 99.04 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 123.78 0.675 . . . . 0.0 110.518 179.059 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.462 ' O ' HG13 ' A' ' 76' ' ' ILE . 11.8 m170 -66.15 -45.0 82.51 Favored 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.315 -176.616 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.474 HG13 HG23 ' A' ' 64' ' ' VAL . 47.8 mm -61.03 -40.81 86.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 C-N-CA 123.323 0.649 . . . . 0.0 110.561 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.25 -37.41 87.13 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 123.606 0.762 . . . . 0.0 111.23 179.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -67.03 -34.5 77.84 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 123.386 0.674 . . . . 0.0 111.557 176.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.462 HG13 ' O ' ' A' ' 72' ' ' HIS . 72.9 mt -68.79 -53.99 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 C-N-CA 123.311 0.645 . . . . 0.0 111.211 -178.34 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.0 tt -63.71 -36.25 75.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.955 -175.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 t -74.27 -29.49 61.69 Favored 'General case' 0 CA--C 1.551 1.013 0 C-N-CA 122.013 0.125 . . . . 0.0 110.93 177.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.09 -22.53 61.34 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 123.204 0.602 . . . . 0.0 110.892 174.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -79.95 -8.73 59.5 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 123.499 0.719 . . . . 0.0 111.209 172.119 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 97.38 22.85 15.63 Favored Glycine 0 C--N 1.351 1.388 0 CA-C-N 116.104 -0.498 . . . . 0.0 113.055 175.257 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -127.61 105.97 8.84 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 24.0 p -75.77 116.09 52.09 Favored Pre-proline 0 CA--C 1.55 0.959 0 C-N-CA 122.835 0.454 . . . . 0.0 110.809 -174.233 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.458 ' HA ' HG11 ' A' ' 28' ' ' VAL . 76.5 Cg_endo -78.09 -8.81 16.6 Favored 'Trans proline' 0 C--N 1.382 2.302 0 C-N-CA 123.143 2.562 . . . . 0.0 112.985 -176.794 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 . . . . . 0 C--O 1.25 1.102 0 C-N-CA 124.281 1.032 . . . . 0.0 108.957 -175.896 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.243 0.666 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.488 HD12 ' HA ' ' A' ' 70' ' ' ALA . 34.9 mt -80.15 107.23 12.78 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -174.791 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.2 m -102.63 130.09 49.41 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.19 0.596 . . . . 0.0 109.81 -172.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -128.4 114.53 16.94 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.68 0.792 . . . . 0.0 110.514 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 47.0 m80 -81.63 111.86 18.3 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 171.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.7 t -107.9 100.63 11.13 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -176.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -69.06 -23.15 64.0 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.428 0.691 . . . . 0.0 110.927 175.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -74.3 -19.47 60.47 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.421 0.688 . . . . 0.0 110.625 177.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.486 ' HG3' ' HB2' ' A' ' 36' ' ' CYS . 20.4 ttt -82.67 133.82 35.16 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.215 1.006 . . . . 0.0 110.15 176.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 28.0 p -117.83 95.0 4.73 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 170.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.615 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 58.0 m 46.01 -142.69 0.31 Allowed 'General case' 0 CA--C 1.568 1.658 0 C-N-CA 125.017 1.327 . . . . 0.0 114.19 168.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.61 -24.48 64.16 Favored Glycine 0 C--N 1.362 2.019 0 C-N-CA 123.705 0.669 . . . . 0.0 114.292 -179.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -56.47 -37.94 71.02 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 123.28 0.632 . . . . 0.0 111.668 175.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.486 ' HB2' ' HG3' ' A' ' 31' ' ' MET . 80.9 m -104.11 -19.1 14.28 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 122.943 0.497 . . . . 0.0 111.571 -178.333 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -56.05 -42.72 77.03 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -173.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -61.76 -50.83 62.05 Favored Glycine 0 CA--C 1.535 1.286 0 O-C-N 123.31 0.381 . . . . 0.0 113.587 -177.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m -75.28 -34.24 30.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 C-N-CA 123.365 0.666 . . . . 0.0 112.161 -177.365 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 9.6 tt -74.84 -34.96 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 C-N-CA 123.11 0.564 . . . . 0.0 110.721 -174.387 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -71.81 -47.64 51.86 Favored 'General case' 0 C--N 1.351 0.659 0 C-N-CA 123.604 0.762 . . . . 0.0 109.657 173.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.44 -30.03 75.11 Favored Glycine 0 C--N 1.349 1.301 0 O-C-N 124.35 1.031 . . . . 0.0 113.359 -179.039 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.89 -54.65 43.64 Favored 'General case' 0 C--N 1.348 0.505 0 C-N-CA 123.386 0.674 . . . . 0.0 110.239 177.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.607 HG23 HG13 ' A' ' 64' ' ' VAL . 48.0 mt -74.03 -46.17 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.529 -175.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -59.97 -51.85 67.9 Favored 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.18 0.992 . . . . 0.0 112.371 -173.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.7 mptp? -75.95 -13.83 60.24 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 122.458 0.303 . . . . 0.0 111.721 -175.167 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 86.4 m -89.02 -39.27 13.8 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 123.117 0.567 . . . . 0.0 110.252 175.321 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 97.4 t -124.73 89.65 52.08 Favored Pre-proline 0 N--CA 1.479 0.977 0 C-N-CA 123.951 0.901 . . . . 0.0 109.022 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -60.17 113.44 1.67 Allowed 'Trans proline' 0 C--N 1.376 2.011 0 C-N-CA 122.845 2.364 . . . . 0.0 111.14 171.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.76 -14.85 9.1 Favored Glycine 0 C--N 1.342 0.87 0 CA-C-O 119.633 -0.537 . . . . 0.0 113.012 -176.274 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.79 106.8 9.86 Favored 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 173.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.476 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -76.27 99.54 4.8 Favored 'General case' 0 C--N 1.349 0.586 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.415 HG13 HG12 ' A' ' 64' ' ' VAL . 16.8 m -86.33 131.71 33.98 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 C-N-CA 123.29 0.636 . . . . 0.0 111.043 -172.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 43.9 t-80 -136.55 99.42 4.07 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 174.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.47 ' HB2' ' HE3' ' A' ' 31' ' ' MET . . . -96.72 114.34 25.97 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 174.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -94.06 120.95 65.08 Favored Pre-proline 0 N--CA 1.471 0.589 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -174.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.615 ' HA ' ' HA ' ' A' ' 33' ' ' CYS . 51.1 Cg_exo -57.54 -38.25 94.47 Favored 'Trans proline' 0 C--N 1.374 1.907 0 C-N-CA 123.103 2.536 . . . . 0.0 114.417 177.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.72 -35.38 52.05 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.032 0.533 . . . . 0.0 111.62 -174.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 16.5 m -97.69 -20.94 17.29 Favored 'General case' 0 N--CA 1.482 1.151 0 C-N-CA 123.564 0.746 . . . . 0.0 111.718 -175.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.9 mpt_? 56.91 32.63 21.83 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 125.108 1.363 . . . . 0.0 110.947 -171.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.9 m -110.35 118.98 37.77 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 123.377 0.671 . . . . 0.0 110.055 -172.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 20.9 t -101.49 107.24 21.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 177.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 21.9 t -105.5 135.3 44.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 123.785 0.834 . . . . 0.0 108.754 -179.044 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.607 HG13 HG23 ' A' ' 44' ' ' ILE . 18.8 m -121.7 123.0 68.42 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 C-N-CA 123.196 0.598 . . . . 0.0 110.404 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -99.74 156.74 19.76 Favored Glycine 0 C--N 1.347 1.165 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.095 -179.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.5 -18.2 43.89 Favored Glycine 0 N--CA 1.474 1.225 0 C-N-CA 123.121 0.391 . . . . 0.0 113.451 177.478 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.8 m -115.68 146.86 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 124.092 0.957 . . . . 0.0 109.741 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 69.8 m -116.54 -20.47 9.61 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.722 0.809 . . . . 0.0 112.439 -175.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -75.95 86.3 2.88 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 122.776 0.43 . . . . 0.0 110.481 178.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.488 ' HA ' HD12 ' A' ' 24' ' ' LEU . . . -62.98 -29.01 70.49 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.431 0.692 . . . . 0.0 111.116 175.718 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.3 -51.38 67.89 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 124.402 1.081 . . . . 0.0 111.117 177.058 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.422 ' O ' HG13 ' A' ' 76' ' ' ILE . 28.2 m-70 -63.09 -48.01 80.43 Favored 'General case' 0 N--CA 1.482 1.155 0 O-C-N 123.592 0.558 . . . . 0.0 110.838 -178.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.437 HG23 HG23 ' A' ' 64' ' ' VAL . 49.5 mm -61.22 -40.62 86.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 124.068 0.855 . . . . 0.0 110.436 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.73 -39.69 92.46 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 123.95 0.781 . . . . 0.0 111.333 179.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.9 mm-40 -62.59 -39.5 93.91 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.491 0.716 . . . . 0.0 111.206 178.089 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.52 HG21 ' HA ' ' A' ' 44' ' ' ILE . 53.8 mt -68.02 -53.86 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 O-C-N 123.747 0.654 . . . . 0.0 110.959 -179.16 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 15.9 tt -70.28 -29.15 38.12 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.71 -173.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.5 t -76.07 -31.69 58.89 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 110.156 -0.312 . . . . 0.0 110.156 175.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.69 -21.43 64.42 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 123.671 0.788 . . . . 0.0 111.64 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -74.24 -3.69 31.48 Favored 'General case' 0 CA--C 1.555 1.15 0 C-N-CA 123.538 0.735 . . . . 0.0 112.189 176.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 101.77 23.11 9.56 Favored Glycine 0 C--N 1.351 1.4 0 C-N-CA 123.065 0.364 . . . . 0.0 112.885 178.368 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -119.3 175.83 5.62 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.992 0.917 . . . . 0.0 109.02 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 96.0 m -148.43 83.8 6.91 Favored Pre-proline 0 N--CA 1.479 0.994 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 171.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_exo -70.79 -67.31 0.03 OUTLIER 'Trans proline' 0 C--N 1.369 1.646 0 C-N-CA 122.449 2.1 . . . . 0.0 112.487 177.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 . . . . . 0 C--O 1.257 1.451 0 C-N-CA 125.154 1.382 . . . . 0.0 110.926 -171.787 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.599 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.411 HD12 ' HA ' ' A' ' 70' ' ' ALA . 34.1 mt -88.99 108.21 19.46 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.4 p -92.38 111.32 22.85 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 122.883 0.473 . . . . 0.0 110.555 -177.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -106.19 124.81 50.17 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 123.88 0.872 . . . . 0.0 109.746 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 32.3 m-70 -84.05 136.81 33.88 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 175.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 p -157.34 97.05 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.978 0 C-N-CA 124.066 0.946 . . . . 0.0 109.049 -176.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -69.8 -29.4 66.69 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.418 -176.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -74.4 -9.85 59.0 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.164 0.586 . . . . 0.0 112.018 -178.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.592 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 56.1 ttp -72.62 113.08 9.26 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 120.93 0.395 . . . . 0.0 110.557 177.132 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 63.2 p -77.51 166.34 23.2 Favored 'General case' 0 CA--C 1.549 0.917 0 C-N-CA 124.013 0.925 . . . . 0.0 109.923 168.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 28.0 p -57.11 -169.73 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 124.089 0.956 . . . . 0.0 112.647 175.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.69 3.45 0.63 Allowed Glycine 0 C--N 1.357 1.721 0 N-CA-C 115.916 1.127 . . . . 0.0 115.916 -174.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -63.27 -44.74 94.25 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.743 0.817 . . . . 0.0 110.844 166.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 43.5 t -141.42 9.56 2.05 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 123.136 0.575 . . . . 0.0 111.996 -176.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.58 -30.95 69.83 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 122.836 0.454 . . . . 0.0 110.754 173.191 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.53 -20.87 53.09 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 114.996 -1.002 . . . . 0.0 114.256 176.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.485 HG13 ' HB2' ' A' ' 80' ' ' ALA . 57.9 t -65.41 -44.32 94.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 122.871 0.468 . . . . 0.0 110.138 174.233 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.676 HG22 HG22 ' A' ' 62' ' ' VAL . 44.1 mt -69.61 -54.44 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 C-N-CA 123.3 0.64 . . . . 0.0 110.661 175.431 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.51 ' HB3' ' HZ1' ' A' ' 41' ' ' LYS . 9.7 mtpm? -56.68 -51.83 67.28 Favored 'General case' 0 C--N 1.348 0.507 0 O-C-N 124.517 1.136 . . . . 0.0 110.269 -174.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.467 ' O ' ' HD3' ' A' ' 46' ' ' LYS . . . -61.94 -40.16 98.5 Favored Glycine 0 C--N 1.343 0.917 0 O-C-N 124.963 1.414 . . . . 0.0 112.867 178.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.74 -53.5 57.05 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 117.129 0.464 . . . . 0.0 111.001 179.138 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.55 HG21 HG12 ' A' ' 64' ' ' VAL . 68.4 mt -62.08 -39.93 85.6 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.967 -179.174 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.432 ' HG3' ' O ' ' A' ' 41' ' ' LYS . 76.9 mt-10 -62.02 -50.46 71.94 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 123.171 0.588 . . . . 0.0 112.068 179.623 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.467 ' HD3' ' O ' ' A' ' 42' ' ' GLY . 13.3 mptt -73.03 -28.07 62.13 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.496 -171.528 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.1 m -85.2 -41.01 16.02 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 122.814 0.445 . . . . 0.0 110.32 177.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.0 103.51 23.53 Favored Pre-proline 0 N--CA 1.483 1.216 0 C-N-CA 124.156 0.982 . . . . 0.0 109.807 -178.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -66.91 136.58 41.97 Favored 'Trans proline' 0 C--N 1.374 1.919 0 C-N-CA 122.781 2.321 . . . . 0.0 111.687 172.059 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.2 -4.75 67.68 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-O 119.787 -0.452 . . . . 0.0 113.963 175.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.65 106.68 9.61 Favored 'General case' 0 C--N 1.35 0.619 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 173.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.427 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -77.14 99.54 5.43 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -177.095 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.417 HG11 HG11 ' A' ' 64' ' ' VAL . 27.8 m -85.26 127.47 39.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.805 0 C-N-CA 123.134 0.574 . . . . 0.0 110.877 -171.065 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . 0.423 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 29.2 t60 -131.67 96.98 4.08 Favored 'General case' 0 C--N 1.345 0.372 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 176.12 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.592 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -93.71 113.67 25.79 Favored 'General case' 0 C--O 1.24 0.588 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 176.073 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -99.72 114.88 65.88 Favored Pre-proline 0 N--CA 1.468 0.428 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -177.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -60.54 -40.34 57.36 Favored 'Trans proline' 0 C--N 1.373 1.863 0 C-N-CA 123.009 2.473 . . . . 0.0 112.822 -176.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -74.38 -47.74 32.22 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.639 0.775 . . . . 0.0 111.285 -176.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.2 m -81.31 -15.65 54.8 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 123.74 0.816 . . . . 0.0 111.459 -176.122 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 63.0 29.44 16.43 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 124.642 1.177 . . . . 0.0 111.389 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 33.1 m -122.79 122.76 39.46 Favored 'General case' 0 N--CA 1.479 1.001 0 O-C-N 121.808 -0.558 . . . . 0.0 111.57 -169.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.676 HG22 HG22 ' A' ' 40' ' ' ILE . 40.5 t -99.09 106.38 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 123.952 0.901 . . . . 0.0 108.972 173.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.1 t -100.49 123.21 53.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.55 HG12 HG21 ' A' ' 44' ' ' ILE . 17.0 m -111.5 109.0 26.9 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.955 0 CA-C-O 121.478 0.656 . . . . 0.0 110.18 179.377 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.46 150.78 20.99 Favored Glycine 0 C--N 1.346 1.125 0 CA-C-N 115.604 -0.725 . . . . 0.0 112.581 -176.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.19 -23.68 30.47 Favored Glycine 0 C--N 1.343 0.967 0 C-N-CA 123.089 0.375 . . . . 0.0 112.999 177.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 22.4 m -105.52 151.14 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 123.992 0.917 . . . . 0.0 110.153 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 17.9 m -126.85 -2.61 6.56 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 124.005 0.922 . . . . 0.0 110.332 -178.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -87.33 73.02 9.72 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 124.522 1.129 . . . . 0.0 110.266 -177.219 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.411 ' HA ' HD12 ' A' ' 24' ' ' LEU . . . -63.99 -29.29 70.46 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-N 114.907 -1.042 . . . . 0.0 112.373 -174.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -63.68 -49.45 73.12 Favored 'General case' 0 N--CA 1.474 0.764 0 O-C-N 123.763 0.665 . . . . 0.0 110.819 177.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.5 ' O ' HG13 ' A' ' 76' ' ' ILE . 39.8 m170 -59.35 -54.93 41.14 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 123.552 0.532 . . . . 0.0 110.463 177.81 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.523 HG21 HG21 ' A' ' 64' ' ' VAL . 41.4 mm -57.8 -40.27 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 O-C-N 124.438 1.086 . . . . 0.0 110.785 -174.282 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.26 -40.14 89.29 Favored 'General case' 0 N--CA 1.48 1.067 0 O-C-N 124.022 0.826 . . . . 0.0 111.429 178.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -68.23 -32.09 72.05 Favored 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 123.181 0.592 . . . . 0.0 111.292 178.05 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.5 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.3 mt -74.75 -48.66 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 122.986 0.514 . . . . 0.0 111.21 -177.094 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.436 HG22 ' O ' ' A' ' 73' ' ' ILE . 8.5 tt -67.37 -32.39 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 C-N-CA 123.259 0.623 . . . . 0.0 111.257 -177.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -75.12 -31.05 61.02 Favored 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 110.364 -0.236 . . . . 0.0 110.364 175.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.95 -18.49 64.09 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 123.537 0.735 . . . . 0.0 111.747 176.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.485 ' HB2' HG13 ' A' ' 39' ' ' VAL . . . -75.89 0.58 17.76 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 123.664 0.786 . . . . 0.0 112.291 176.441 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 95.9 17.04 36.59 Favored Glycine 0 C--N 1.351 1.377 0 C-N-CA 122.861 0.267 . . . . 0.0 112.528 179.597 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -120.78 178.36 4.73 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 124.361 1.064 . . . . 0.0 109.686 -177.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 39.0 m -139.41 111.81 7.77 Favored Pre-proline 0 N--CA 1.479 1.001 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 173.333 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -66.44 120.37 7.49 Favored 'Trans proline' 0 C--N 1.382 2.305 0 C-N-CA 122.355 2.037 . . . . 0.0 110.812 171.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 . . . . . 0 CA--C 1.555 1.167 0 C-N-CA 124.187 0.995 . . . . 0.0 109.493 -175.682 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.419 ' HA2' ' HA2' ' A' ' 65' ' ' GLY . . . . . . . . 0 N--CA 1.466 0.65 0 N-CA-C 112.165 -0.374 . . . . 0.0 112.165 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.454 HD13 ' HA ' ' A' ' 70' ' ' ALA . 59.4 mt -81.42 111.59 17.91 Favored 'General case' 0 N--CA 1.47 0.568 0 C-N-CA 124.059 0.944 . . . . 0.0 110.108 179.433 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.4 t -83.72 129.62 34.95 Favored 'General case' 0 CA--C 1.549 0.922 0 C-N-CA 123.556 0.742 . . . . 0.0 110.516 -177.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -125.84 108.44 11.47 Favored 'General case' 0 N--CA 1.492 1.636 0 C-N-CA 123.338 0.655 . . . . 0.0 110.919 177.545 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 75.9 t60 -82.88 105.58 14.01 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.531 1.132 . . . . 0.0 110.308 -175.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.626 HG13 ' HB3' ' A' ' 82' ' ' TYR . 30.1 t -120.7 94.97 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 C-N-CA 123.214 0.606 . . . . 0.0 109.729 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -69.65 -24.75 63.66 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 123.034 0.533 . . . . 0.0 112.186 -177.306 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -74.98 -20.11 59.81 Favored 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 123.737 0.815 . . . . 0.0 111.163 -179.142 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.414 ' SD ' HD12 ' A' ' 40' ' ' ILE . 12.9 ttt -73.26 139.34 46.09 Favored 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 124.303 1.041 . . . . 0.0 110.786 176.495 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 15.1 t -103.01 163.39 12.24 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 123.917 0.887 . . . . 0.0 109.195 170.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 23.3 p -66.98 -97.46 0.0 OUTLIER 'General case' 0 CA--C 1.563 1.467 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -174.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.48 -32.74 64.51 Favored Glycine 0 C--N 1.349 1.3 0 N-CA-C 114.673 0.629 . . . . 0.0 114.673 -166.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 72.1 m-70 -74.01 -14.34 61.0 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.514 0.726 . . . . 0.0 111.869 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.6 t -122.54 -7.1 8.64 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 122.977 0.511 . . . . 0.0 111.688 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -57.67 -55.7 31.5 Favored 'General case' 0 N--CA 1.481 1.088 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -171.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.83 -38.17 95.23 Favored Glycine 0 N--CA 1.47 0.903 0 N-CA-C 114.255 0.462 . . . . 0.0 114.255 -174.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.5 p -75.15 -40.37 44.06 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.15 0 C-N-CA 122.785 0.434 . . . . 0.0 111.733 -176.125 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.423 HD11 HD11 ' A' ' 77' ' ' ILE . 13.0 tt -75.05 -35.88 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 122.802 0.441 . . . . 0.0 110.79 -178.211 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.467 ' HB3' HG22 ' A' ' 53' ' ' VAL . 97.2 mttt -65.21 -52.29 55.66 Favored 'General case' 0 C--N 1.353 0.729 0 CA-C-N 115.771 -0.649 . . . . 0.0 109.471 174.584 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.91 -29.31 67.48 Favored Glycine 0 C--N 1.352 1.43 0 O-C-N 124.813 1.321 . . . . 0.0 113.517 -178.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.35 -54.96 40.85 Favored 'General case' 0 C--N 1.352 0.693 0 C-N-CA 123.375 0.67 . . . . 0.0 110.476 175.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.582 HG23 HG11 ' A' ' 64' ' ' VAL . 66.6 mt -73.2 -45.72 52.65 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 CA-C-N 115.529 -0.759 . . . . 0.0 112.031 -179.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -63.05 -45.7 90.99 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 124.72 1.208 . . . . 0.0 111.275 -167.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -70.95 -27.45 63.75 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.853 0.461 . . . . 0.0 111.698 -178.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 33.2 m -81.51 -33.89 31.58 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 122.648 0.379 . . . . 0.0 110.833 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.3 t -124.75 95.0 43.34 Favored Pre-proline 0 N--CA 1.48 1.073 0 C-N-CA 123.32 0.648 . . . . 0.0 109.688 178.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -65.88 111.22 1.89 Allowed 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 122.699 2.266 . . . . 0.0 110.861 173.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.5 -12.1 9.59 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-O 119.514 -0.603 . . . . 0.0 113.281 -176.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -76.87 106.28 8.45 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 173.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.21 100.16 8.17 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -178.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.467 HG22 ' HB3' ' A' ' 41' ' ' LYS . 15.3 m -84.39 132.99 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 123.78 0.832 . . . . 0.0 110.649 -170.423 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -141.48 101.81 4.07 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 122.903 0.481 . . . . 0.0 109.756 -176.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.25 130.32 35.07 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 109.643 -0.502 . . . . 0.0 109.643 176.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -105.48 108.59 61.8 Favored Pre-proline 0 CA--C 1.541 0.628 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 176.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -47.34 -44.94 23.65 Favored 'Trans proline' 0 C--N 1.374 1.901 0 C-N-CA 124.126 3.218 . . . . 0.0 115.396 178.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.31 -41.57 40.16 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.485 0.714 . . . . 0.0 112.233 -173.17 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.8 t -93.37 -13.93 27.46 Favored 'General case' 0 N--CA 1.482 1.141 0 C-N-CA 123.496 0.718 . . . . 0.0 111.558 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.409 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 2.7 mpt_? 57.17 45.98 19.68 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 125.036 1.334 . . . . 0.0 110.8 -178.12 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 78.9 m -122.75 126.61 47.83 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.88 -170.402 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 40.5 t -98.44 108.27 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 173.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.0 t -100.58 123.11 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 C-N-CA 124.035 0.934 . . . . 0.0 108.609 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.582 HG11 HG23 ' A' ' 44' ' ' ILE . 31.4 m -112.57 109.07 27.23 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 C-N-CA 123.669 0.787 . . . . 0.0 110.666 -176.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.419 ' HA2' ' HA2' ' A' ' 23' ' ' GLY . . . -88.62 160.24 30.05 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 115.584 -0.735 . . . . 0.0 113.049 -177.335 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 78.55 4.59 87.63 Favored Glycine 0 C--N 1.343 0.92 0 N-CA-C 114.356 0.502 . . . . 0.0 114.356 175.546 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 23.4 m -131.8 150.79 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.854 0 C-N-CA 123.796 0.838 . . . . 0.0 109.4 -178.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 30.8 t -116.1 -8.41 11.8 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 124.1 0.96 . . . . 0.0 111.06 -176.657 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -80.92 72.34 7.92 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.751 0.821 . . . . 0.0 110.893 -175.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.454 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -60.38 -41.43 93.74 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.149 0.58 . . . . 0.0 111.065 -178.281 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.468 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.22 -47.83 80.85 Favored 'General case' 0 CA--C 1.541 0.6 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.134 179.094 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.431 ' O ' HG13 ' A' ' 76' ' ' ILE . 45.0 t-80 -64.64 -45.24 87.64 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.167 0.587 . . . . 0.0 111.559 -176.186 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.484 HG21 HG22 ' A' ' 64' ' ' VAL . 48.5 mm -60.86 -41.03 87.18 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 O-C-N 123.552 0.533 . . . . 0.0 109.892 178.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.15 -35.31 76.74 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 115.305 -0.861 . . . . 0.0 111.751 178.49 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.468 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 17.5 mm-40 -65.52 -41.13 93.48 Favored 'General case' 0 N--CA 1.48 1.034 0 C-N-CA 123.457 0.703 . . . . 0.0 110.923 177.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.431 HG13 ' O ' ' A' ' 72' ' ' HIS . 35.5 mt -66.37 -50.05 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.021 -177.126 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.423 HD11 HD11 ' A' ' 40' ' ' ILE . 15.9 tt -72.66 -31.17 36.13 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.949 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.429 -172.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.5 t -74.54 -29.57 61.43 Favored 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 175.095 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.43 -19.62 60.92 Favored 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 123.563 0.745 . . . . 0.0 111.27 173.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -80.4 -5.31 56.27 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.565 0.746 . . . . 0.0 111.21 172.107 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.0 22.72 32.0 Favored Glycine 0 C--N 1.35 1.358 0 O-C-N 123.372 0.42 . . . . 0.0 112.903 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.626 ' HB3' HG13 ' A' ' 28' ' ' VAL . 81.7 m-85 -127.46 115.07 18.33 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.659 0.784 . . . . 0.0 110.51 -176.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 34.8 p -71.16 111.78 11.21 Favored Pre-proline 0 CA--C 1.549 0.916 0 C-N-CA 124.296 1.039 . . . . 0.0 110.987 -177.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.418 ' HA ' HG22 ' A' ' 28' ' ' VAL . 93.8 Cg_endo -80.6 150.14 18.96 Favored 'Trans proline' 0 C--N 1.372 1.803 0 C-N-CA 122.323 2.016 . . . . 0.0 111.824 177.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 . . . . . 0 CA--C 1.559 1.3 0 C-N-CA 124.703 1.201 . . . . 0.0 111.437 173.536 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.858 0 N-CA-C 110.35 -1.1 . . . . 0.0 110.35 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 46.8 mt -83.1 105.84 14.41 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 174.278 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.1 m -93.83 111.4 23.09 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -176.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -103.26 100.96 10.88 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 177.244 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 77.0 t60 -82.47 91.71 6.92 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 -179.202 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.581 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 15.9 t -74.37 93.62 0.75 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 N-CA-C 106.855 -1.535 . . . . 0.0 106.855 172.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -63.75 -20.81 66.04 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 112.693 0.627 . . . . 0.0 112.693 -171.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 10.6 p-10 -111.34 23.6 13.82 Favored 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 124.089 0.956 . . . . 0.0 110.789 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.581 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 23.9 ttt -57.73 142.01 46.74 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 124.389 1.076 . . . . 0.0 113.325 -173.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 41.3 p -81.32 144.4 31.53 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.547 173.204 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.418 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 49.8 t -73.04 -170.51 0.75 Allowed 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 123.882 0.873 . . . . 0.0 110.078 177.137 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -49.35 -24.9 5.55 Favored Glycine 0 C--N 1.356 1.657 0 N-CA-C 116.623 1.409 . . . . 0.0 116.623 -171.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 40.9 m170 -58.53 -33.75 70.22 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 123.498 0.719 . . . . 0.0 112.558 177.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 63.8 m -137.92 15.95 2.86 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 122.997 0.519 . . . . 0.0 111.739 178.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.4 -34.04 63.19 Favored 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 122.614 0.366 . . . . 0.0 110.96 174.1 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.94 -37.91 93.69 Favored Glycine 0 C--N 1.347 1.161 0 O-C-N 123.825 0.703 . . . . 0.0 113.768 -176.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 9.2 p -69.48 -28.46 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 122.943 0.497 . . . . 0.0 110.883 177.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.2 mt -67.93 -41.82 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 123.224 0.61 . . . . 0.0 109.974 175.298 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -62.24 -52.05 65.28 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 123.811 0.844 . . . . 0.0 110.177 177.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.82 -31.1 78.69 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 114.414 -1.266 . . . . 0.0 113.063 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.38 -50.92 68.46 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.975 0.91 . . . . 0.0 110.831 179.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.514 HG23 HG12 ' A' ' 64' ' ' VAL . 64.3 mt -74.37 -51.4 23.3 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.644 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -56.16 -54.67 42.38 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 124.358 1.063 . . . . 0.0 112.745 -170.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -69.79 -13.72 62.42 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 122.889 0.476 . . . . 0.0 112.107 -175.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 61.2 m -90.51 -37.74 13.68 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 123.341 0.656 . . . . 0.0 110.442 177.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.5 m -133.54 92.1 24.63 Favored Pre-proline 0 CA--C 1.556 1.176 0 C-N-CA 123.474 0.71 . . . . 0.0 110.491 179.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -58.03 135.08 66.38 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 122.604 2.203 . . . . 0.0 111.555 171.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 110.62 -29.58 8.89 Favored Glycine 0 C--N 1.341 0.847 0 N-CA-C 111.87 -0.492 . . . . 0.0 111.87 -177.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -74.02 106.86 5.89 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 175.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.451 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -78.06 99.34 6.08 Favored 'General case' 0 C--N 1.345 0.407 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -179.057 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.463 HG12 HG11 ' A' ' 64' ' ' VAL . 27.2 m -84.51 129.42 37.7 Favored 'Isoleucine or valine' 0 C--O 1.239 0.546 0 C-N-CA 123.1 0.56 . . . . 0.0 110.015 -171.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . 0.409 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 41.1 t60 -133.68 96.01 3.6 Favored 'General case' 0 CA--C 1.518 -0.283 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 175.439 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.1 113.91 26.31 Favored 'General case' 0 C--O 1.243 0.755 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 173.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -105.35 105.54 52.6 Favored Pre-proline 0 N--CA 1.466 0.337 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 -175.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.418 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 76.4 Cg_exo -53.39 -38.1 82.25 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 123.236 2.624 . . . . 0.0 113.72 179.331 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.8 -45.21 62.31 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 123.215 0.606 . . . . 0.0 111.413 -176.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.9 m -84.08 -17.89 38.75 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.417 0.687 . . . . 0.0 111.552 -177.28 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.538 ' HD2' ' HB3' ' A' ' 31' ' ' MET . 66.6 mmt-85 64.29 37.49 8.54 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 124.633 1.173 . . . . 0.0 110.367 -178.58 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.1 m -137.9 122.88 19.02 Favored 'General case' 0 CA--C 1.55 0.965 0 O-C-N 122.025 -0.422 . . . . 0.0 111.603 -169.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 54' ' ' HIS . 18.5 t -99.45 106.37 18.91 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 C-N-CA 124.142 0.977 . . . . 0.0 109.204 175.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.8 t -104.95 123.47 59.04 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 123.728 0.811 . . . . 0.0 109.073 -176.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.514 HG12 HG23 ' A' ' 44' ' ' ILE . 27.8 m -108.56 122.5 63.19 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.909 0 C-N-CA 123.038 0.535 . . . . 0.0 110.521 177.42 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -102.43 153.3 18.44 Favored Glycine 0 C--N 1.345 1.075 0 CA-C-N 115.981 -0.554 . . . . 0.0 112.872 -176.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.7 -24.77 22.12 Favored Glycine 0 N--CA 1.471 1.027 0 C-N-CA 123.173 0.416 . . . . 0.0 112.856 177.212 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 35.3 m -111.69 149.05 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.987 0.915 . . . . 0.0 109.473 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.5 m -121.74 20.82 10.92 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 123.656 0.782 . . . . 0.0 110.416 -178.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -96.65 73.56 2.71 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 124.367 1.067 . . . . 0.0 109.506 -173.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.34 -53.38 58.97 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 123.721 0.809 . . . . 0.0 112.642 -170.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.42 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -62.9 -40.52 97.82 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 123.481 0.712 . . . . 0.0 111.031 -178.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 55.7 t60 -61.66 -50.35 72.85 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.967 0.907 . . . . 0.0 111.205 -177.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 39.6 mm -64.99 -39.93 87.35 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.083 179.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.13 -37.11 79.09 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 123.985 0.803 . . . . 0.0 111.128 179.093 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.42 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 39.5 mm-40 -66.29 -40.02 89.77 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 123.625 0.77 . . . . 0.0 111.288 176.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.446 HG21 ' HA ' ' A' ' 44' ' ' ILE . 65.6 mt -64.08 -52.95 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 O-C-N 123.606 0.566 . . . . 0.0 111.17 -179.215 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 8.0 tt -66.8 -37.88 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.313 -175.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.5 t -73.84 -29.64 62.24 Favored 'General case' 0 CA--C 1.552 1.037 0 C-N-CA 122.384 0.273 . . . . 0.0 110.296 179.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.71 -22.24 61.67 Favored 'General case' 0 N--CA 1.484 1.256 0 C-N-CA 123.628 0.771 . . . . 0.0 111.238 174.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.43 -6.08 52.15 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.503 0.721 . . . . 0.0 111.396 172.242 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 93.87 8.17 60.75 Favored Glycine 0 C--N 1.345 1.068 0 CA-C-O 119.89 -0.394 . . . . 0.0 112.933 177.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -117.0 103.22 10.04 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 176.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.4 t -83.59 118.53 71.74 Favored Pre-proline 0 CA--C 1.554 1.119 0 C-N-CA 123.267 0.627 . . . . 0.0 110.389 -176.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -70.75 -42.6 2.28 Favored 'Trans proline' 0 C--N 1.377 2.076 0 C-N-CA 122.409 2.072 . . . . 0.0 111.716 173.274 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 . . . . . 0 C--O 1.253 1.279 0 C-N-CA 124.767 1.227 . . . . 0.0 108.102 172.379 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.401 ' HA2' ' HA2' ' A' ' 65' ' ' GLY . . . . . . . . 0 N--CA 1.467 0.721 0 N-CA-C 112.058 -0.417 . . . . 0.0 112.058 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.403 HD12 ' HA ' ' A' ' 70' ' ' ALA . 47.6 mt -80.32 108.6 14.07 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 123.809 0.844 . . . . 0.0 110.141 -178.018 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 21.0 p -88.44 124.25 33.78 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 123.623 0.769 . . . . 0.0 110.978 -178.383 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -121.55 112.72 18.83 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 123.729 0.812 . . . . 0.0 110.401 -179.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 69.3 m80 -83.59 104.23 13.55 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.318 0.647 . . . . 0.0 110.173 177.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.541 HG13 ' HB3' ' A' ' 82' ' ' TYR . 98.8 t -90.07 128.3 42.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 C-N-CA 123.404 0.681 . . . . 0.0 109.176 174.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -64.44 -39.85 94.61 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 123.563 0.745 . . . . 0.0 112.286 -176.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -104.83 -6.47 20.21 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 113.302 0.852 . . . . 0.0 113.302 -166.169 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 24.1 ptm -65.45 133.38 51.18 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-O 121.318 0.58 . . . . 0.0 111.355 -174.236 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 72.9 p -107.55 161.62 14.69 Favored 'General case' 0 CA--C 1.547 0.856 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 171.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 24.6 p -74.87 -109.29 0.01 OUTLIER 'General case' 0 CA--C 1.563 1.479 0 N-CA-C 113.951 1.093 . . . . 0.0 113.951 -166.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -75.96 5.21 41.98 Favored Glycine 0 N--CA 1.478 1.474 0 N-CA-C 117.422 1.729 . . . . 0.0 117.422 -154.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 65.7 m80 -110.13 -31.02 7.5 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-N 118.118 0.959 . . . . 0.0 110.548 175.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.4 m -102.0 -8.87 21.12 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.621 0.769 . . . . 0.0 110.936 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -61.5 -46.38 90.26 Favored 'General case' 0 C--N 1.354 0.771 0 C-N-CA 123.803 0.841 . . . . 0.0 110.347 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.55 -27.57 72.71 Favored Glycine 0 C--N 1.343 0.946 0 O-C-N 123.977 0.798 . . . . 0.0 113.846 -178.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 53.0 t -72.04 -46.6 58.59 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.963 0 C-N-CA 123.196 0.598 . . . . 0.0 109.771 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.432 HG21 HG21 ' A' ' 62' ' ' VAL . 75.7 mt -59.98 -55.23 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.669 176.298 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -61.51 -43.43 98.88 Favored 'General case' 0 C--O 1.219 -0.503 0 CA-C-N 114.794 -1.094 . . . . 0.0 110.918 -176.18 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.86 -42.57 98.38 Favored Glycine 0 C--N 1.345 1.051 0 O-C-N 124.068 0.855 . . . . 0.0 112.366 -179.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.32 -55.11 31.34 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 122.89 0.476 . . . . 0.0 110.815 -179.454 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.54 HG23 HG12 ' A' ' 64' ' ' VAL . 82.4 mt -64.45 -51.13 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 C-N-CA 123.758 0.823 . . . . 0.0 112.297 -176.731 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -60.68 -45.58 93.6 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 124.316 1.046 . . . . 0.0 112.222 -173.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.3 mptp? -78.72 -21.09 48.6 Favored 'General case' 0 N--CA 1.484 1.234 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -173.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 38.5 m -85.33 -39.17 17.96 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 122.899 0.48 . . . . 0.0 110.319 177.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.1 t -118.46 86.53 28.59 Favored Pre-proline 0 CA--C 1.548 0.876 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 174.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo -61.76 106.77 0.46 Allowed 'Trans proline' 0 C--N 1.378 2.111 0 C-N-CA 122.952 2.435 . . . . 0.0 112.813 -174.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.88 7.93 8.37 Favored Glycine 0 C--N 1.341 0.859 0 CA-C-N 115.638 -0.71 . . . . 0.0 113.173 -179.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.19 107.47 9.6 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 176.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.415 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -75.58 96.37 3.52 Favored 'General case' 0 C--N 1.352 0.693 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 -177.388 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.43 HG13 HG11 ' A' ' 64' ' ' VAL . 5.0 m -87.29 133.14 30.89 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.587 -168.737 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 75.6 t60 -138.62 99.25 3.77 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 174.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.78 115.3 23.34 Favored 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 173.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -96.94 120.77 60.92 Favored Pre-proline 0 N--CA 1.478 0.951 0 CA-C-O 118.975 -0.536 . . . . 0.0 109.919 -173.175 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -55.75 -48.97 17.33 Favored 'Trans proline' 0 C--N 1.381 2.27 0 C-N-CA 123.598 2.865 . . . . 0.0 114.025 178.095 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -75.09 -42.85 55.82 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.116 -170.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 19.5 m -93.31 -14.94 26.32 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.595 0.758 . . . . 0.0 112.125 -171.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 11.4 mpt_? 59.42 40.43 20.83 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 123.866 0.866 . . . . 0.0 110.273 -175.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.9 m -121.31 118.87 30.61 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.119 0.568 . . . . 0.0 111.275 -169.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.432 HG21 HG21 ' A' ' 40' ' ' ILE . 42.8 t -97.88 105.92 17.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 175.168 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 6.3 t -102.02 123.19 55.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 -176.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.54 HG12 HG23 ' A' ' 44' ' ' ILE . 19.1 m -117.39 109.22 26.91 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 CA-C-O 121.512 0.672 . . . . 0.0 110.787 -176.478 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.401 ' HA2' ' HA2' ' A' ' 23' ' ' GLY . . . -90.76 161.98 28.67 Favored Glycine 0 C--N 1.344 0.994 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.775 -176.62 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.7 0.65 74.8 Favored Glycine 0 C--N 1.346 1.106 0 CA-C-O 119.995 -0.336 . . . . 0.0 113.824 177.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.99 149.05 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 123.826 0.85 . . . . 0.0 109.987 -177.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 45.7 m -114.88 4.76 14.94 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.797 0.839 . . . . 0.0 110.359 176.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.576 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 5.6 m-20 -83.12 68.6 9.63 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.015 0.926 . . . . 0.0 111.014 -172.352 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.403 ' HA ' HD12 ' A' ' 24' ' ' LEU . . . -61.25 -45.11 95.86 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.12 0.568 . . . . 0.0 111.681 -175.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -66.43 -44.14 83.7 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.235 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.576 ' HB2' ' HB3' ' A' ' 69' ' ' ASP . 26.1 m80 -62.48 -52.45 63.47 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 122.968 0.507 . . . . 0.0 111.271 -178.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 69' ' ' ASP . 48.6 mm -57.52 -43.13 82.43 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 O-C-N 123.817 0.698 . . . . 0.0 110.09 -177.395 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.82 -38.93 83.4 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 124.403 1.064 . . . . 0.0 111.764 178.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 43.8 mm-40 -68.87 -36.06 77.65 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.42 0.688 . . . . 0.0 111.748 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.482 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.6 mt -69.59 -51.69 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.989 0 C-N-CA 122.743 0.417 . . . . 0.0 110.186 -177.095 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 12.4 tt -70.43 -30.55 43.38 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.071 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.536 -174.544 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 3.8 t -74.86 -30.3 61.29 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 176.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -74.39 -23.04 58.92 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.557 0.743 . . . . 0.0 110.533 173.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.55 -6.99 55.59 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 123.32 0.648 . . . . 0.0 111.207 172.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 100.03 9.55 48.31 Favored Glycine 0 C--N 1.352 1.469 0 CA-C-O 119.797 -0.446 . . . . 0.0 113.727 173.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.541 ' HB3' HG13 ' A' ' 28' ' ' VAL . 84.9 m-85 -109.09 121.5 45.29 Favored 'General case' 0 N--CA 1.481 1.079 0 C-N-CA 123.715 0.806 . . . . 0.0 109.289 -178.218 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 31.3 m -88.18 103.4 5.03 Favored Pre-proline 0 CA--C 1.559 1.325 0 C-N-CA 123.868 0.867 . . . . 0.0 111.396 -175.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -91.01 -74.65 0.0 OUTLIER 'Trans proline' 0 C--N 1.376 2.023 0 C-N-CA 123.564 2.843 . . . . 0.0 112.477 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 . . . . . 0 CA--C 1.554 1.109 0 C-N-CA 125.54 1.536 . . . . 0.0 111.372 -179.353 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.691 0 N-CA-C 112.739 -0.144 . . . . 0.0 112.739 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.543 HD11 ' HA ' ' A' ' 70' ' ' ALA . 56.1 mt -79.78 109.83 14.57 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 123.788 0.835 . . . . 0.0 109.848 -176.764 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.543 ' HA ' HG11 ' A' ' 63' ' ' VAL . 19.6 p -92.17 109.03 20.39 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.001 0.52 . . . . 0.0 111.405 -174.282 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 88.9 m-85 -105.17 110.29 22.61 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.162 0.585 . . . . 0.0 109.954 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 11.7 m170 -82.49 92.49 7.08 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.448 HG23 ' HB3' ' A' ' 84' ' ' PRO . 31.0 t -83.27 105.48 13.03 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.256 -175.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -79.22 -10.76 59.9 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 122.774 0.43 . . . . 0.0 111.515 -176.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -93.41 -0.8 56.38 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 123.813 0.845 . . . . 0.0 111.476 173.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.487 ' HB3' ' HB3' ' A' ' 60' ' ' ARG . 26.7 ttt -73.62 137.36 44.16 Favored 'General case' 0 CA--C 1.543 0.679 0 CA-C-O 121.58 0.705 . . . . 0.0 111.754 -176.445 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.0 t -110.1 164.47 12.6 Favored 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 125.507 1.523 . . . . 0.0 109.054 175.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.479 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 60.1 m -59.0 -178.6 0.05 Allowed 'General case' 0 CA--C 1.559 1.318 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -53.95 -21.56 17.23 Favored Glycine 0 C--N 1.353 1.49 0 N-CA-C 116.682 1.433 . . . . 0.0 116.682 -169.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 33.1 m170 -62.54 -21.35 65.48 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 123.532 0.733 . . . . 0.0 112.797 -177.427 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 53.2 t -139.12 17.7 2.61 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 123.434 0.694 . . . . 0.0 110.811 178.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.85 -31.45 69.3 Favored 'General case' 0 N--CA 1.482 1.126 0 C-N-CA 123.03 0.532 . . . . 0.0 111.811 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.76 -23.49 74.04 Favored Glycine 0 C--N 1.347 1.174 0 O-C-N 123.471 0.482 . . . . 0.0 113.586 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 92.1 t -69.47 -40.47 79.85 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.616 0.767 . . . . 0.0 109.873 173.373 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 23.2 mt -72.24 -40.7 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 CA-C-N 114.72 -1.127 . . . . 0.0 109.91 -177.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -59.65 -54.79 42.33 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 114.664 -1.153 . . . . 0.0 109.999 172.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.59 -30.05 71.13 Favored Glycine 0 C--N 1.349 1.26 0 O-C-N 124.604 1.19 . . . . 0.0 113.389 -175.751 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.46 -53.59 54.43 Favored 'General case' 0 C--N 1.351 0.658 0 C-N-CA 124.146 0.978 . . . . 0.0 110.9 176.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.456 HD13 HD12 ' A' ' 77' ' ' ILE . 64.2 mt -75.22 -59.06 3.61 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.572 178.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -50.02 -48.15 52.81 Favored 'General case' 0 N--CA 1.483 1.19 0 C-N-CA 126.215 1.806 . . . . 0.0 113.688 -169.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.4 mptt -69.45 -38.17 77.67 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 122.792 0.437 . . . . 0.0 111.407 -178.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.9 m -73.35 -33.08 64.89 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 123.219 0.607 . . . . 0.0 111.02 -178.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 3.9 m -136.32 81.6 36.93 Favored Pre-proline 0 CA--C 1.556 1.201 0 C-N-CA 124.066 0.946 . . . . 0.0 110.537 178.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_exo -62.91 123.04 11.56 Favored 'Trans proline' 0 C--N 1.381 2.253 0 C-N-CA 122.827 2.351 . . . . 0.0 111.308 174.035 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.77 -24.59 7.48 Favored Glycine 0 C--N 1.342 0.899 0 CA-C-O 119.866 -0.408 . . . . 0.0 112.234 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.21 104.86 5.95 Favored 'General case' 0 C--N 1.354 0.761 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 172.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.52 100.41 2.73 Favored 'General case' 0 C--N 1.348 0.525 0 C-N-CA 123.318 0.647 . . . . 0.0 110.529 -173.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.409 HG12 HG13 ' A' ' 64' ' ' VAL . 27.1 m -85.36 134.24 27.59 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 O-C-N 123.603 0.564 . . . . 0.0 110.744 -173.28 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 44.0 t-80 -135.69 99.89 4.32 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 169.256 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.67 116.32 23.14 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 115.021 -0.99 . . . . 0.0 108.949 178.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -103.27 105.85 48.48 Favored Pre-proline 0 N--CA 1.478 0.944 0 CA-C-O 118.47 -0.776 . . . . 0.0 108.973 -177.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.479 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 72.4 Cg_exo -54.79 -41.88 73.97 Favored 'Trans proline' 0 C--N 1.378 2.127 0 C-N-CA 123.178 2.585 . . . . 0.0 114.67 179.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -67.78 -45.57 74.48 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 123.114 0.565 . . . . 0.0 111.75 -173.274 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.4 t -89.88 -18.93 25.24 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 123.686 0.794 . . . . 0.0 111.089 -178.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.487 ' HB3' ' HB3' ' A' ' 31' ' ' MET . 0.2 OUTLIER 61.28 47.1 7.25 Favored 'General case' 0 N--CA 1.482 1.138 0 C-N-CA 124.699 1.2 . . . . 0.0 110.272 -175.676 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 54.1 m -128.84 115.16 17.48 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 123.178 0.591 . . . . 0.0 110.246 -173.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 25.4 t -98.56 108.53 22.28 Favored 'Isoleucine or valine' 0 C--O 1.24 0.6 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 175.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.543 HG11 ' HA ' ' A' ' 25' ' ' SER . 34.7 m -99.46 136.08 32.11 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.201 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.453 HG11 HG23 ' A' ' 44' ' ' ILE . 21.4 m -119.16 133.84 64.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.345 0.658 . . . . 0.0 110.181 -178.364 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -113.0 153.31 17.62 Favored Glycine 0 C--N 1.35 1.311 0 CA-C-N 116.303 -0.408 . . . . 0.0 112.787 -175.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.7 14.5 82.34 Favored Glycine 0 C--N 1.348 1.23 0 N-CA-C 113.945 0.338 . . . . 0.0 113.945 175.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 3.6 m -129.54 134.8 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 123.85 0.86 . . . . 0.0 110.245 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.6 m -95.52 -23.85 16.9 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 123.686 0.794 . . . . 0.0 111.099 176.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -79.05 87.25 4.84 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-O 121.141 0.496 . . . . 0.0 111.3 -175.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.543 ' HA ' HD11 ' A' ' 24' ' ' LEU . . . -70.63 -46.1 63.97 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.943 -175.438 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -61.6 -36.61 81.2 Favored 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.961 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 74.7 t60 -63.11 -51.68 65.61 Favored 'General case' 0 N--CA 1.473 0.715 0 O-C-N 123.856 0.722 . . . . 0.0 110.852 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.429 HG22 HG22 ' A' ' 64' ' ' VAL . 41.7 mm -59.45 -42.32 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 123.646 0.591 . . . . 0.0 110.379 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.0 -41.42 98.04 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.375 -177.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 54.8 mm-40 -63.24 -39.97 96.12 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.464 0.706 . . . . 0.0 111.607 178.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 85.5 mt -61.78 -54.25 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.403 0.681 . . . . 0.0 111.41 -178.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.456 HD12 HD13 ' A' ' 44' ' ' ILE . 14.0 tt -73.84 -33.13 36.45 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.913 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.7 -171.53 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.9 t -71.76 -29.26 64.31 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 176.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.07 -22.99 63.0 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.803 0.841 . . . . 0.0 111.167 173.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -82.93 -3.09 56.63 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 123.751 0.82 . . . . 0.0 111.774 175.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.22 -6.23 59.54 Favored Glycine 0 C--N 1.348 1.217 0 CA-C-O 120.155 -0.247 . . . . 0.0 113.311 178.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -106.07 103.15 12.57 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -178.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 53.0 m -94.4 114.2 62.77 Favored Pre-proline 0 CA--C 1.553 1.085 0 C-N-CA 123.201 0.6 . . . . 0.0 111.633 -171.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.448 ' HB3' HG23 ' A' ' 28' ' ' VAL . 25.4 Cg_endo -95.99 -11.11 0.84 Allowed 'Trans proline' 0 C--N 1.377 2.031 0 C-N-CA 123.27 2.647 . . . . 0.0 113.328 167.227 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 . . . . . 0 C--O 1.251 1.157 0 C-N-CA 124.006 0.922 . . . . 0.0 108.699 -173.785 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.559 0 CA-C-O 120.991 0.217 . . . . 0.0 113.369 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.452 HD13 ' HA ' ' A' ' 70' ' ' ALA . 32.2 mt -87.72 116.93 26.2 Favored 'General case' 0 C--O 1.239 0.522 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 175.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 28.6 p -92.13 111.32 22.83 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 122.871 0.468 . . . . 0.0 111.214 -173.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -108.95 133.64 52.69 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.274 1.029 . . . . 0.0 108.809 175.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 18.6 p80 -125.89 137.1 53.71 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.258 0.623 . . . . 0.0 109.803 -176.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.76 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 67.0 t -117.51 120.02 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 N-CA-C 107.162 -1.421 . . . . 0.0 107.162 170.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -70.68 -21.97 62.52 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -175.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -89.56 -8.61 52.31 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 123.411 0.685 . . . . 0.0 111.009 177.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.76 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 25.7 ttt -56.14 106.67 0.29 Allowed 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.911 0.884 . . . . 0.0 112.341 -170.439 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 67.1 p -70.94 162.24 29.68 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 123.651 0.78 . . . . 0.0 109.284 167.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 79.5 m -61.39 -104.86 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 123.488 0.715 . . . . 0.0 111.808 -177.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.49 -30.9 75.51 Favored Glycine 0 C--N 1.353 1.489 0 CA-C-N 119.391 0.996 . . . . 0.0 113.603 -172.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 21.7 t-80 -62.73 -30.11 71.18 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 123.98 0.912 . . . . 0.0 112.659 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.63 ' SG ' ' HG3' ' A' ' 31' ' ' MET . 51.9 t -106.16 -31.25 8.77 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 122.51 0.324 . . . . 0.0 110.44 179.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -62.94 -49.6 74.11 Favored 'General case' 0 C--N 1.356 0.851 0 C-N-CA 123.466 0.707 . . . . 0.0 111.698 -175.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.8 -37.08 75.53 Favored Glycine 0 C--N 1.347 1.165 0 O-C-N 123.979 0.799 . . . . 0.0 113.84 -177.071 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.48 HG13 ' HB3' ' A' ' 80' ' ' ALA . 42.7 t -71.6 -51.26 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 123.318 0.647 . . . . 0.0 110.526 -179.021 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.66 HG23 HG23 ' A' ' 62' ' ' VAL . 64.7 mt -64.81 -53.93 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 CA-C-N 115.443 -0.798 . . . . 0.0 111.646 -176.017 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 48.6 mtmt -57.84 -46.89 84.12 Favored 'General case' 0 N--CA 1.474 0.746 0 O-C-N 123.889 0.743 . . . . 0.0 110.064 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.31 -36.74 93.5 Favored Glycine 0 C--N 1.351 1.41 0 O-C-N 124.346 1.028 . . . . 0.0 113.142 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -67.42 -54.02 24.05 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 122.743 0.417 . . . . 0.0 111.121 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.57 HG22 HG11 ' A' ' 64' ' ' VAL . 63.9 mt -67.36 -42.88 87.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 C-N-CA 123.275 0.63 . . . . 0.0 111.563 -176.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -61.33 -47.53 85.48 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.877 0.871 . . . . 0.0 111.626 -177.69 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -73.13 -37.06 66.79 Favored 'General case' 0 N--CA 1.48 1.035 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.942 -176.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 58.8 m -73.61 -40.99 63.41 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 122.658 0.383 . . . . 0.0 111.149 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.409 HG11 HG12 ' A' ' 67' ' ' VAL . 24.2 t -114.08 102.69 55.02 Favored Pre-proline 0 N--CA 1.481 1.084 0 C-N-CA 123.185 0.594 . . . . 0.0 110.277 -176.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -68.16 107.03 1.47 Allowed 'Trans proline' 0 C--N 1.373 1.826 0 C-N-CA 122.717 2.278 . . . . 0.0 111.123 173.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.16 -10.94 10.8 Favored Glycine 0 C--N 1.345 1.076 0 CA-C-O 119.251 -0.749 . . . . 0.0 113.619 178.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.41 106.6 7.04 Favored 'General case' 0 N--CA 1.479 0.977 0 CA-C-N 117.833 0.816 . . . . 0.0 109.038 174.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.58 99.03 7.89 Favored 'General case' 0 N--CA 1.465 0.31 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 -178.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.501 HG11 HG13 ' A' ' 64' ' ' VAL . 26.9 m -86.51 134.17 28.05 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 C-N-CA 123.412 0.685 . . . . 0.0 110.366 -174.353 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 43.6 t-80 -142.81 102.16 3.98 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 172.46 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -89.61 115.79 27.27 Favored 'General case' 0 C--O 1.239 0.509 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 171.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.415 ' HA ' ' HD2' ' A' ' 57' ' ' PRO . 20.0 t70 -92.08 114.27 61.63 Favored Pre-proline 0 CA--C 1.546 0.8 0 CA-C-O 118.142 -0.932 . . . . 0.0 109.549 -177.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 56' ' ' ASP . 7.3 Cg_endo -47.27 -33.6 16.61 Favored 'Trans proline' 0 C--N 1.381 2.259 0 C-N-CA 124.612 3.542 . . . . 0.0 115.29 178.267 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.47 -44.32 24.88 Favored 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -177.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.1 t -93.27 -23.38 18.53 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.405 0.682 . . . . 0.0 111.955 -173.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.549 ' NH2' ' HE3' ' A' ' 31' ' ' MET . 11.7 mmm180 57.63 41.29 25.78 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 125.596 1.558 . . . . 0.0 111.578 -173.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.8 m -119.26 127.69 53.47 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 123.286 0.635 . . . . 0.0 110.028 -177.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.66 HG23 HG23 ' A' ' 40' ' ' ILE . 21.6 t -99.59 106.17 18.63 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 C-N-CA 124.658 1.183 . . . . 0.0 108.951 177.124 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 25.7 m -94.11 135.43 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 175.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.57 HG11 HG22 ' A' ' 44' ' ' ILE . 22.2 m -120.87 107.88 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-O 121.674 0.749 . . . . 0.0 110.017 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.71 152.4 21.85 Favored Glycine 0 C--N 1.346 1.115 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.789 -175.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.8 -24.47 26.08 Favored Glycine 0 C--N 1.344 0.997 0 C-N-CA 123.042 0.353 . . . . 0.0 113.036 178.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.409 HG12 HG11 ' A' ' 48' ' ' VAL . 27.4 m -111.24 145.64 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 123.904 0.881 . . . . 0.0 110.135 -177.473 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t -117.71 10.01 13.21 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 123.624 0.77 . . . . 0.0 109.771 176.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -86.58 74.83 9.81 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.222 1.009 . . . . 0.0 109.522 -176.083 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.452 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -63.79 -47.37 81.16 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.39 0.676 . . . . 0.0 112.252 -172.191 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.498 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.47 -39.64 94.99 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 123.113 0.565 . . . . 0.0 110.788 -179.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 74.1 t60 -63.13 -51.69 65.51 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.286 1.034 . . . . 0.0 111.279 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.444 ' O ' HG22 ' A' ' 77' ' ' ILE . 41.3 mm -60.75 -38.47 78.88 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 O-C-N 123.744 0.652 . . . . 0.0 109.962 179.113 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.81 -36.74 79.8 Favored 'General case' 0 N--CA 1.476 0.856 0 O-C-N 124.247 0.967 . . . . 0.0 111.837 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.498 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 11.7 mm-40 -69.35 -34.78 75.11 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.16 0.584 . . . . 0.0 111.26 177.537 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 71.5 mt -71.75 -48.44 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 C-N-CA 123.441 0.696 . . . . 0.0 111.961 -177.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.456 ' HB ' HD11 ' A' ' 44' ' ' ILE . 5.0 tt -66.53 -37.27 79.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.184 0 C-N-CA 122.871 0.469 . . . . 0.0 110.851 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 t -71.18 -29.61 65.39 Favored 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 122.463 0.305 . . . . 0.0 110.379 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.61 -24.27 62.71 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 123.751 0.82 . . . . 0.0 111.373 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.48 ' HB3' HG13 ' A' ' 39' ' ' VAL . . . -75.02 -6.09 47.52 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.389 0.675 . . . . 0.0 111.578 175.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.29 1.38 56.85 Favored Glycine 0 C--N 1.35 1.325 0 CA-C-O 119.884 -0.398 . . . . 0.0 112.98 176.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -120.31 104.71 10.26 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 178.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.7 t -86.32 116.96 67.83 Favored Pre-proline 0 CA--C 1.554 1.119 0 C-N-CA 123.397 0.679 . . . . 0.0 110.354 -178.642 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -79.88 148.67 19.94 Favored 'Trans proline' 0 C--N 1.375 1.961 0 C-N-CA 122.742 2.294 . . . . 0.0 111.571 174.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.4 mp0 . . . . . 0 C--O 1.251 1.148 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -176.789 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.57 0 N-CA-C 111.412 -0.675 . . . . 0.0 111.412 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.412 HD12 ' HA ' ' A' ' 70' ' ' ALA . 34.0 mt -88.99 108.24 19.47 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.3 p -92.36 111.35 22.89 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 122.844 0.458 . . . . 0.0 110.606 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -106.24 124.88 50.28 Favored 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 123.862 0.865 . . . . 0.0 109.72 179.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 32.1 m-70 -84.03 136.77 33.91 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 175.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 p -157.31 96.98 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.091 0.957 . . . . 0.0 109.059 -176.364 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -69.79 -29.46 66.77 Favored 'General case' 0 N--CA 1.479 1.007 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.443 -176.21 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.5 m-20 -74.29 -9.84 59.01 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.164 0.586 . . . . 0.0 112.104 -178.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.593 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 56.3 ttp -72.69 113.06 9.3 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-O 120.944 0.402 . . . . 0.0 110.536 177.145 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 62.7 p -77.51 166.36 23.17 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 123.993 0.917 . . . . 0.0 109.912 168.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 27.9 p -57.11 -169.69 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 124.121 0.968 . . . . 0.0 112.6 175.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.73 3.5 0.64 Allowed Glycine 0 C--N 1.357 1.732 0 N-CA-C 115.922 1.129 . . . . 0.0 115.922 -174.021 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -63.3 -44.72 94.22 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.786 0.834 . . . . 0.0 110.798 166.031 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 43.6 t -141.47 9.51 2.03 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 123.189 0.596 . . . . 0.0 111.987 -176.018 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.65 -30.89 69.69 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 122.814 0.446 . . . . 0.0 110.732 173.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.58 -20.84 53.15 Favored Glycine 0 C--N 1.348 1.238 0 CA-C-N 114.997 -1.001 . . . . 0.0 114.262 176.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.488 HG13 ' HB2' ' A' ' 80' ' ' ALA . 57.8 t -65.48 -44.25 94.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 122.851 0.461 . . . . 0.0 110.128 174.221 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.679 HG22 HG22 ' A' ' 62' ' ' VAL . 43.7 mt -69.7 -54.4 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 C-N-CA 123.322 0.649 . . . . 0.0 110.619 175.457 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.512 ' HB3' ' HZ1' ' A' ' 41' ' ' LYS . 9.7 mtpm? -56.68 -51.93 66.87 Favored 'General case' 0 C--N 1.347 0.487 0 O-C-N 124.439 1.087 . . . . 0.0 110.216 -174.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.47 ' O ' ' HD3' ' A' ' 46' ' ' LYS . . . -61.87 -40.18 98.5 Favored Glycine 0 C--N 1.342 0.886 0 O-C-N 124.984 1.428 . . . . 0.0 112.822 178.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.79 -53.48 57.32 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-N 117.161 0.48 . . . . 0.0 110.955 179.181 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.546 HG21 HG12 ' A' ' 64' ' ' VAL . 68.3 mt -62.11 -39.9 85.54 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.823 0 CA-C-N 115.43 -0.805 . . . . 0.0 111.972 -179.163 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.434 ' HG3' ' O ' ' A' ' 41' ' ' LYS . 76.8 mt-10 -62.0 -50.46 71.96 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 123.157 0.583 . . . . 0.0 112.108 179.582 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.47 ' HD3' ' O ' ' A' ' 42' ' ' GLY . 13.3 mptt -73.0 -28.11 62.18 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.52 -171.536 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.1 m -85.15 -41.06 16.02 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 122.815 0.446 . . . . 0.0 110.291 177.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.2 t -127.03 103.58 23.39 Favored Pre-proline 0 N--CA 1.483 1.213 0 C-N-CA 124.117 0.967 . . . . 0.0 109.772 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -66.91 136.58 41.99 Favored 'Trans proline' 0 C--N 1.374 1.906 0 C-N-CA 122.772 2.315 . . . . 0.0 111.684 172.037 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.18 -4.74 67.73 Favored Glycine 0 C--N 1.346 1.084 0 CA-C-O 119.769 -0.462 . . . . 0.0 113.948 175.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.61 106.68 9.56 Favored 'General case' 0 C--N 1.351 0.649 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 173.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.43 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -77.15 99.52 5.43 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -177.063 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.417 HG11 HG11 ' A' ' 64' ' ' VAL . 27.7 m -85.28 127.45 39.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 123.123 0.569 . . . . 0.0 110.886 -171.089 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . 0.426 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 29.2 t60 -131.62 96.95 4.08 Favored 'General case' 0 C--N 1.345 0.391 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 176.069 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.593 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -93.6 113.59 25.73 Favored 'General case' 0 C--O 1.241 0.646 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 176.031 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -99.66 114.83 65.86 Favored Pre-proline 0 N--CA 1.468 0.433 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 -177.397 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.52 -40.4 57.12 Favored 'Trans proline' 0 C--N 1.373 1.829 0 C-N-CA 123.011 2.474 . . . . 0.0 112.767 -176.234 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -74.31 -47.8 32.4 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 123.619 0.767 . . . . 0.0 111.31 -176.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.1 m -81.26 -15.65 54.94 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.7 0.8 . . . . 0.0 111.455 -176.111 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.7 mmt180 62.97 29.43 16.46 Favored 'General case' 0 N--CA 1.487 1.421 0 C-N-CA 124.63 1.172 . . . . 0.0 111.437 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 33.2 m -122.79 122.76 39.47 Favored 'General case' 0 N--CA 1.479 1.017 0 O-C-N 121.825 -0.547 . . . . 0.0 111.521 -169.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.679 HG22 HG22 ' A' ' 40' ' ' ILE . 40.5 t -99.11 106.4 18.86 Favored 'Isoleucine or valine' 0 C--N 1.35 0.608 0 C-N-CA 123.943 0.897 . . . . 0.0 108.977 173.279 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.0 t -100.41 123.2 53.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.617 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.546 HG12 HG21 ' A' ' 44' ' ' ILE . 17.0 m -111.56 108.94 26.77 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.994 0 CA-C-O 121.475 0.655 . . . . 0.0 110.158 179.393 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.44 150.84 21.03 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.549 -176.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.13 -23.67 30.4 Favored Glycine 0 C--N 1.344 0.984 0 C-N-CA 123.104 0.383 . . . . 0.0 113.051 177.037 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 22.4 m -105.54 151.13 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 123.969 0.908 . . . . 0.0 110.151 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.0 m -126.84 -2.55 6.57 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 124.005 0.922 . . . . 0.0 110.36 -178.658 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -87.35 73.0 9.71 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.54 1.136 . . . . 0.0 110.247 -177.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.412 ' HA ' HD12 ' A' ' 24' ' ' LEU . . . -64.01 -29.17 70.35 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 114.907 -1.042 . . . . 0.0 112.453 -174.747 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -63.76 -49.37 73.25 Favored 'General case' 0 N--CA 1.474 0.745 0 O-C-N 123.799 0.687 . . . . 0.0 110.863 177.545 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.501 ' O ' HG13 ' A' ' 76' ' ' ILE . 39.9 m170 -59.41 -54.93 41.05 Favored 'General case' 0 N--CA 1.478 0.957 0 O-C-N 123.488 0.493 . . . . 0.0 110.474 177.772 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.527 HG21 HG21 ' A' ' 64' ' ' VAL . 41.4 mm -57.74 -40.27 74.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 O-C-N 124.343 1.027 . . . . 0.0 110.811 -174.352 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.33 -40.11 89.47 Favored 'General case' 0 N--CA 1.48 1.029 0 O-C-N 124.039 0.837 . . . . 0.0 111.397 178.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -68.3 -32.05 71.92 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 123.181 0.593 . . . . 0.0 111.291 178.071 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.501 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.5 mt -74.77 -48.62 32.99 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 C-N-CA 122.951 0.5 . . . . 0.0 111.245 -177.125 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.437 HG22 ' O ' ' A' ' 73' ' ' ILE . 8.5 tt -67.38 -32.36 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 C-N-CA 123.254 0.622 . . . . 0.0 111.253 -177.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -75.12 -31.02 61.01 Favored 'General case' 0 CA--C 1.549 0.917 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -69.0 -18.46 64.05 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.494 0.718 . . . . 0.0 111.737 176.115 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.488 ' HB2' HG13 ' A' ' 39' ' ' VAL . . . -75.91 0.67 17.48 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 123.645 0.778 . . . . 0.0 112.269 176.414 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 95.84 16.97 37.0 Favored Glycine 0 C--N 1.35 1.328 0 C-N-CA 122.801 0.239 . . . . 0.0 112.544 179.63 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -120.76 178.38 4.72 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.361 1.065 . . . . 0.0 109.714 -177.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 39.3 m -139.41 111.83 7.78 Favored Pre-proline 0 N--CA 1.479 0.977 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 173.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -66.47 120.33 7.45 Favored 'Trans proline' 0 C--N 1.381 2.285 0 C-N-CA 122.423 2.082 . . . . 0.0 110.779 171.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 . . . . . 0 C--O 1.251 1.166 0 C-N-CA 124.212 1.005 . . . . 0.0 109.526 -175.652 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.938 0 N-CA-C 110.971 -0.851 . . . . 0.0 110.971 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -87.65 115.62 25.22 Favored 'General case' 0 N--CA 1.479 1.025 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -173.224 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 76.4 p -91.06 121.45 32.87 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 123.363 0.665 . . . . 0.0 111.337 -176.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -106.89 130.27 54.59 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.783 0.833 . . . . 0.0 109.563 175.546 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 9.8 m-70 -90.46 120.64 31.74 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 173.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.457 HG22 HD12 ' A' ' 40' ' ' ILE . 25.7 t -111.24 91.77 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 N-CA-C 104.765 -2.309 . . . . 0.0 104.765 160.413 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -68.62 -16.29 63.8 Favored 'General case' 0 CA--C 1.548 0.881 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -159.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -109.7 8.78 24.91 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.258 0.623 . . . . 0.0 111.472 -178.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 56.8 ttp -73.91 99.05 3.14 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.61 0.764 . . . . 0.0 109.843 176.06 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.0 t -101.3 104.57 15.59 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 123.103 0.561 . . . . 0.0 109.569 178.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.497 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 17.0 t 64.83 -170.99 0.19 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.382 1.073 . . . . 0.0 111.888 176.647 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.546 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -62.27 -6.36 10.33 Favored Glycine 0 C--N 1.355 1.599 0 CA-C-O 119.203 -0.776 . . . . 0.0 114.391 178.379 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 41.2 m80 -50.22 -40.17 46.62 Favored 'General case' 0 C--N 1.365 1.278 0 C-N-CA 124.274 1.03 . . . . 0.0 111.736 172.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -118.83 -31.6 4.75 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.151 0.58 . . . . 0.0 110.892 176.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.546 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -57.91 -34.16 69.54 Favored 'General case' 0 N--CA 1.481 1.109 0 C-N-CA 123.458 0.703 . . . . 0.0 112.699 -176.092 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -58.7 -52.45 53.02 Favored Glycine 0 C--N 1.348 1.246 0 O-C-N 123.842 0.713 . . . . 0.0 114.347 -177.106 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.3 p -69.83 -30.53 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 C-N-CA 123.012 0.525 . . . . 0.0 111.561 -177.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.632 HG22 HG22 ' A' ' 62' ' ' VAL . 83.4 mt -70.23 -47.21 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 123.082 0.553 . . . . 0.0 110.666 179.216 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -61.38 -44.24 97.5 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.639 0.775 . . . . 0.0 110.467 178.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.14 -36.43 93.23 Favored Glycine 0 C--N 1.348 1.197 0 O-C-N 124.202 0.939 . . . . 0.0 112.899 176.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.05 -53.77 50.91 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 123.376 0.671 . . . . 0.0 110.878 -178.359 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.514 HG23 HG12 ' A' ' 64' ' ' VAL . 64.0 mt -72.82 -46.27 53.6 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.936 -175.007 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -66.93 -39.23 87.29 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 123.551 0.74 . . . . 0.0 112.249 -172.146 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.1 mptp? -83.58 -14.34 52.32 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -176.652 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 54.5 m -90.24 -39.06 13.01 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 122.98 0.512 . . . . 0.0 109.802 173.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 91.4 t -121.01 96.38 48.57 Favored Pre-proline 0 N--CA 1.48 1.028 0 C-N-CA 123.939 0.896 . . . . 0.0 109.323 -179.538 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.93 113.0 3.26 Favored 'Trans proline' 0 C--N 1.37 1.662 0 C-N-CA 122.346 2.031 . . . . 0.0 110.589 175.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.39 -11.42 9.75 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-O 119.575 -0.57 . . . . 0.0 112.722 -176.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -78.42 106.89 10.67 Favored 'General case' 0 C--N 1.356 0.871 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 171.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.72 99.09 4.97 Favored 'General case' 0 C--N 1.349 0.577 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.0 m -85.49 123.63 39.5 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 CA-C-O 121.023 0.439 . . . . 0.0 110.155 -172.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 71.9 t60 -131.79 97.88 4.31 Favored 'General case' 0 C--N 1.343 0.32 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -176.496 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.4 114.52 28.86 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -178.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.436 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 13.5 t70 -99.56 127.12 35.08 Favored Pre-proline 0 CA--C 1.54 0.586 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -177.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.497 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 30.8 Cg_endo -61.62 -41.16 41.32 Favored 'Trans proline' 0 C--N 1.377 2.074 0 C-N-CA 123.105 2.537 . . . . 0.0 113.23 179.264 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.19 -35.28 48.8 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.728 0.811 . . . . 0.0 111.944 -174.521 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.436 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 19.2 m -88.83 -22.07 23.39 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.443 0.697 . . . . 0.0 111.061 -177.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? 57.99 41.07 24.9 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 124.653 1.181 . . . . 0.0 110.744 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 80.8 m -132.81 121.83 23.56 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.882 -171.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.632 HG22 HG22 ' A' ' 40' ' ' ILE . 21.1 t -98.89 104.7 16.32 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 C-N-CA 124.426 1.091 . . . . 0.0 108.638 173.828 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.8 t -95.48 131.35 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 108.023 -1.102 . . . . 0.0 108.023 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.514 HG12 HG23 ' A' ' 44' ' ' ILE . 26.2 m -111.58 109.97 30.46 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.869 0 CA-C-O 121.636 0.731 . . . . 0.0 109.84 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -89.77 149.83 20.73 Favored Glycine 0 C--N 1.346 1.1 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.733 -174.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 86.3 -20.04 24.03 Favored Glycine 0 C--N 1.341 0.84 0 C-N-CA 123.055 0.359 . . . . 0.0 112.879 -178.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 30.3 m -123.75 145.96 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 124.46 1.104 . . . . 0.0 108.881 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.6 m -130.19 -6.63 4.34 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 123.545 0.738 . . . . 0.0 111.302 -176.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -75.88 84.24 2.81 Favored 'General case' 0 CA--C 1.55 0.96 0 CA-C-O 122.338 1.066 . . . . 0.0 110.351 -178.095 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.81 -40.55 95.65 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 113.911 -1.495 . . . . 0.0 112.869 -171.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -58.75 -46.88 86.43 Favored 'General case' 0 N--CA 1.479 0.994 0 O-C-N 124.11 0.881 . . . . 0.0 111.882 -176.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 72.7 t60 -66.97 -50.78 61.24 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.023 -178.324 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 36.8 mm -59.88 -37.35 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 O-C-N 123.67 0.606 . . . . 0.0 110.407 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.43 -37.71 88.36 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 123.858 0.863 . . . . 0.0 111.736 -179.522 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 45.0 mm-40 -65.07 -35.86 82.5 Favored 'General case' 0 N--CA 1.476 0.825 0 O-C-N 123.685 0.615 . . . . 0.0 111.036 176.465 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 62.3 mt -67.99 -49.46 68.11 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.236 0 C-N-CA 123.112 0.565 . . . . 0.0 111.495 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.4 tt -71.4 -35.42 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 C-N-CA 123.182 0.593 . . . . 0.0 111.516 -176.341 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.2 t -71.63 -28.86 64.07 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 176.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.72 -26.8 65.44 Favored 'General case' 0 C--N 1.358 0.963 0 C-N-CA 123.592 0.757 . . . . 0.0 111.006 173.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.92 -3.16 33.89 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.513 0.725 . . . . 0.0 111.822 174.052 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 94.51 12.69 55.59 Favored Glycine 0 C--N 1.348 1.221 0 CA-C-O 119.713 -0.493 . . . . 0.0 113.058 175.437 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -128.5 105.81 8.56 Favored 'General case' 0 N--CA 1.483 1.224 0 CA-C-N 117.401 0.601 . . . . 0.0 109.919 179.247 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.9 t -76.4 123.93 87.92 Favored Pre-proline 0 CA--C 1.556 1.173 0 C-N-CA 123.253 0.621 . . . . 0.0 110.619 -178.099 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -79.08 173.99 12.71 Favored 'Trans proline' 0 C--N 1.373 1.824 0 C-N-CA 122.695 2.264 . . . . 0.0 111.37 168.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 . . . . . 0 C--O 1.25 1.118 0 C-N-CA 123.444 0.698 . . . . 0.0 109.331 -177.225 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.439 0 N-CA-C 112.038 -0.425 . . . . 0.0 112.038 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -134.93 132.44 38.45 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-N 117.245 0.523 . . . . 0.0 109.826 -172.684 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.6 t -104.55 134.45 47.71 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 123.911 0.885 . . . . 0.0 110.709 -177.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -135.59 118.97 16.77 Favored 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 124.156 0.982 . . . . 0.0 109.237 173.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.552 ' HA ' ' HA ' ' A' ' 61' ' ' THR . 35.2 p-80 -92.26 118.38 30.82 Favored 'General case' 0 N--CA 1.477 0.898 0 CA-C-N 118.657 0.662 . . . . 0.0 109.984 175.32 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.418 ' O ' ' HB3' ' A' ' 60' ' ' ARG . 39.7 t -96.27 97.22 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 170.613 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -61.01 -26.92 67.94 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 123.556 0.743 . . . . 0.0 111.864 -176.375 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -80.16 -19.69 46.58 Favored 'General case' 0 CA--C 1.553 1.061 0 C-N-CA 124.147 0.979 . . . . 0.0 111.496 -178.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 62.9 ttp -68.7 129.72 40.75 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.655 0.782 . . . . 0.0 112.235 -175.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.3 p -85.43 169.88 13.23 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 124.333 1.053 . . . . 0.0 109.987 170.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 35.0 t -56.11 -151.7 0.0 OUTLIER 'General case' 0 CA--C 1.581 2.159 0 C-N-CA 125.078 1.351 . . . . 0.0 113.178 178.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -62.0 -2.66 3.99 Favored Glycine 0 C--N 1.356 1.688 0 N-CA-C 116.144 1.218 . . . . 0.0 116.144 -171.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -77.28 -22.79 51.54 Favored 'General case' 0 CA--C 1.552 1.021 0 CA-C-N 117.67 0.735 . . . . 0.0 112.208 178.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 19.3 p -124.41 -5.59 7.69 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 122.439 0.296 . . . . 0.0 111.597 177.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -64.65 -31.16 72.26 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.416 0.686 . . . . 0.0 112.498 -175.132 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.08 -50.46 67.58 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 114.565 0.586 . . . . 0.0 114.565 -174.052 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.3 m -66.35 -31.97 55.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 123.093 0.557 . . . . 0.0 112.119 -178.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.436 HG21 HG21 ' A' ' 62' ' ' VAL . 76.1 mt -72.22 -54.97 14.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.694 0 C-N-CA 123.884 0.874 . . . . 0.0 110.17 -177.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -61.33 -42.51 98.8 Favored 'General case' 0 CA--C 1.537 0.456 0 CA-C-N 114.343 -1.299 . . . . 0.0 110.79 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -68.07 -34.01 80.34 Favored Glycine 0 C--N 1.342 0.897 0 O-C-N 124.16 0.913 . . . . 0.0 113.131 -178.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -65.08 -53.75 40.74 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.789 0.435 . . . . 0.0 110.514 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.545 ' HA ' HG21 ' A' ' 76' ' ' ILE . 62.9 mt -63.98 -40.87 90.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.719 -178.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -64.68 -43.67 92.81 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.308 0.643 . . . . 0.0 111.549 -179.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -81.76 -18.56 43.79 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -175.108 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 36.8 m -87.26 -40.98 14.03 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 175.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.7 t -121.83 88.9 47.69 Favored Pre-proline 0 N--CA 1.48 1.069 0 C-N-CA 123.872 0.869 . . . . 0.0 108.831 174.067 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -60.94 113.18 1.61 Allowed 'Trans proline' 0 C--N 1.375 1.93 0 C-N-CA 122.632 2.222 . . . . 0.0 111.588 175.01 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.5 -5.37 11.86 Favored Glycine 0 C--N 1.341 0.856 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.804 -176.163 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -78.07 106.84 10.21 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 173.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.03 96.82 3.88 Favored 'General case' 0 C--N 1.351 0.658 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.451 HG13 HG13 ' A' ' 64' ' ' VAL . 7.8 m -88.85 134.83 27.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.729 -172.505 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -142.08 101.45 3.93 Favored 'General case' 0 C--N 1.352 0.684 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 176.621 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.12 114.69 22.44 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 173.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -93.41 130.35 35.79 Favored Pre-proline 0 CA--C 1.542 0.666 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 -175.071 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -64.86 -53.65 0.88 Allowed 'Trans proline' 0 C--N 1.372 1.797 0 C-N-CA 122.634 2.223 . . . . 0.0 113.058 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.82 -36.02 50.66 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.266 -170.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 26.3 t -87.6 -18.25 30.1 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 123.432 0.693 . . . . 0.0 110.685 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.418 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 10.4 mpt_? 60.94 31.36 19.97 Favored 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 124.467 1.107 . . . . 0.0 111.268 -176.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' THR . . . . . 0.552 ' HA ' ' HA ' ' A' ' 27' ' ' HIS . 53.8 m -116.53 122.45 44.74 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -168.534 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.436 HG21 HG21 ' A' ' 40' ' ' ILE . 31.6 t -96.75 106.38 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 172.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 18.8 t -102.24 131.83 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.529 HG23 HG13 ' A' ' 73' ' ' ILE . 35.6 m -105.43 139.41 26.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 C-N-CA 123.422 0.689 . . . . 0.0 109.535 174.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -118.36 151.03 18.0 Favored Glycine 0 C--N 1.341 0.859 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.058 -175.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 79.32 -12.04 27.98 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-O 120.142 -0.255 . . . . 0.0 113.092 -177.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 33.3 m -132.65 131.12 59.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 C-N-CA 124.406 1.083 . . . . 0.0 108.787 -178.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t -112.43 10.67 19.81 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.657 0.783 . . . . 0.0 110.121 -177.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.421 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 3.2 m-20 -70.57 87.37 0.66 Allowed 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 124.14 0.976 . . . . 0.0 110.922 -176.069 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.5 -58.16 9.65 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 122.793 0.437 . . . . 0.0 112.168 -173.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -64.66 -36.42 84.2 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.048 0.539 . . . . 0.0 111.648 -175.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.421 ' HB2' ' HB3' ' A' ' 69' ' ' ASP . 65.2 m170 -65.29 -55.38 18.64 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 123.029 0.532 . . . . 0.0 111.111 -179.522 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.529 HG13 HG23 ' A' ' 64' ' ' VAL . 47.8 mm -60.93 -40.26 84.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 O-C-N 123.856 0.723 . . . . 0.0 110.316 -177.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.0 -38.38 82.45 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.17 0.988 . . . . 0.0 111.707 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 35.5 mm-40 -69.14 -35.93 76.89 Favored 'General case' 0 N--CA 1.475 0.822 0 O-C-N 123.511 0.507 . . . . 0.0 111.768 179.095 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.545 HG21 ' HA ' ' A' ' 44' ' ' ILE . 43.9 mt -65.82 -50.24 71.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 CA-C-O 121.152 0.501 . . . . 0.0 110.863 -178.402 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.407 ' HB ' HD11 ' A' ' 44' ' ' ILE . 12.3 tt -73.75 -32.81 36.03 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 CA-C-N 115.138 -0.937 . . . . 0.0 111.885 -173.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.1 t -72.76 -29.63 63.47 Favored 'General case' 0 N--CA 1.484 1.245 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 174.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.41 -28.93 67.51 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.179 0.592 . . . . 0.0 110.589 173.063 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.24 -5.94 47.14 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 123.538 0.735 . . . . 0.0 111.755 175.615 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.91 21.16 40.37 Favored Glycine 0 C--N 1.348 1.214 0 O-C-N 123.141 0.275 . . . . 0.0 112.993 176.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -128.02 114.49 17.17 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 123.472 0.709 . . . . 0.0 109.381 178.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.3 t -70.28 114.13 23.41 Favored Pre-proline 0 CA--C 1.561 1.383 0 C-N-CA 123.332 0.653 . . . . 0.0 111.117 -176.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.401 ' HA ' HG23 ' A' ' 28' ' ' VAL . 73.5 Cg_endo -71.53 -19.26 28.57 Favored 'Trans proline' 0 C--N 1.384 2.415 0 C-N-CA 122.856 2.37 . . . . 0.0 112.836 -177.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 . . . . . 0 C--O 1.246 0.896 0 C-N-CA 124.319 1.048 . . . . 0.0 108.8 -178.436 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.019 0 N-CA-C 113.573 0.189 . . . . 0.0 113.573 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.405 HD12 ' HA ' ' A' ' 70' ' ' ALA . 72.5 mt -108.29 107.55 18.2 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 123.714 0.806 . . . . 0.0 109.059 177.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.4 m -95.35 114.16 25.91 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.232 0.613 . . . . 0.0 110.822 -173.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -109.72 106.45 16.1 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 123.97 0.908 . . . . 0.0 110.481 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 16.3 m-70 -83.1 91.31 7.19 Favored 'General case' 0 N--CA 1.479 0.976 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 176.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.448 HG22 ' HA ' ' A' ' 84' ' ' PRO . 47.7 t -82.29 97.58 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 176.434 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -66.33 -24.9 66.61 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 123.23 0.612 . . . . 0.0 112.346 -171.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -87.74 -11.66 47.53 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 122.97 0.508 . . . . 0.0 111.636 177.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.506 ' HG3' ' HB2' ' A' ' 36' ' ' CYS . 13.0 ttt -71.38 137.99 48.82 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.157 0.583 . . . . 0.0 109.553 169.416 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.6 t -129.87 98.48 4.8 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 123.638 0.775 . . . . 0.0 109.911 176.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.42 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 59.6 m 54.64 -154.84 0.26 Allowed 'General case' 0 CA--C 1.557 1.244 0 C-N-CA 124.695 1.198 . . . . 0.0 112.843 173.236 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.489 ' HA2' ' HB2' ' A' ' 37' ' ' ALA . . . -58.06 -26.5 58.5 Favored Glycine 0 C--N 1.361 1.946 0 C-N-CA 123.697 0.665 . . . . 0.0 114.097 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 14.2 t-80 -56.54 -32.78 65.45 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.383 1.073 . . . . 0.0 111.793 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.506 ' HB2' ' HG3' ' A' ' 31' ' ' MET . 62.1 m -111.15 -18.18 13.05 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.181 0.592 . . . . 0.0 111.423 178.465 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.489 ' HB2' ' HA2' ' A' ' 34' ' ' GLY . . . -64.47 -47.16 80.02 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 123.231 0.612 . . . . 0.0 112.321 -176.247 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.26 -46.13 92.01 Favored Glycine 0 N--CA 1.475 1.281 0 O-C-N 123.995 0.809 . . . . 0.0 114.147 -172.424 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -68.22 -31.7 52.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.011 0 C-N-CA 123.626 0.77 . . . . 0.0 111.017 -179.404 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.74 HG23 HG22 ' A' ' 62' ' ' VAL . 65.8 mt -69.31 -43.99 80.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 123.641 0.777 . . . . 0.0 111.05 175.417 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.445 ' HG3' ' O ' ' A' ' 37' ' ' ALA . 95.1 mttt -58.2 -47.23 84.1 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.575 0.75 . . . . 0.0 109.546 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.65 -36.14 92.95 Favored Glycine 0 C--N 1.348 1.234 0 O-C-N 124.466 1.104 . . . . 0.0 112.824 178.32 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.38 -55.5 27.32 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 122.852 0.461 . . . . 0.0 111.142 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.498 HG23 HG13 ' A' ' 64' ' ' VAL . 57.6 mt -69.74 -47.12 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.743 -176.109 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -57.84 -50.07 74.55 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.038 0.935 . . . . 0.0 111.955 -176.149 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -70.52 -26.44 63.58 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.032 -174.357 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 47.4 m -86.13 -42.22 14.06 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.733 0.413 . . . . 0.0 110.995 -178.196 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.9 m -132.05 86.44 47.15 Favored Pre-proline 0 CA--C 1.561 1.37 0 C-N-CA 123.752 0.821 . . . . 0.0 110.702 -179.41 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -56.63 123.97 15.12 Favored 'Trans proline' 0 C--N 1.377 2.04 0 C-N-CA 123.039 2.492 . . . . 0.0 111.372 169.475 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.79 -22.34 8.17 Favored Glycine 0 N--CA 1.473 1.116 0 CA-C-O 119.979 -0.345 . . . . 0.0 112.313 -175.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.1 106.94 6.85 Favored 'General case' 0 C--N 1.355 0.808 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 175.671 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.09 100.77 9.2 Favored 'General case' 0 C--N 1.342 0.275 0 C-N-CA 123.729 0.812 . . . . 0.0 109.488 -177.43 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.473 HG12 HG12 ' A' ' 64' ' ' VAL . 35.2 m -84.57 134.59 26.65 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 123.059 0.543 . . . . 0.0 110.16 -172.477 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 48.4 t-80 -136.36 97.49 3.6 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 172.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.424 ' HB3' ' HE2' ' A' ' 31' ' ' MET . . . -92.2 114.33 26.84 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -86.29 123.71 71.09 Favored Pre-proline 0 CA--C 1.542 0.64 0 CA-C-O 118.567 -0.73 . . . . 0.0 109.058 -173.222 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.42 ' HA ' ' HA ' ' A' ' 33' ' ' CYS . 21.5 Cg_endo -58.84 -45.67 27.54 Favored 'Trans proline' 0 C--N 1.372 1.81 0 C-N-CA 122.863 2.375 . . . . 0.0 112.861 179.118 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.31 -45.88 21.57 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.411 0.685 . . . . 0.0 111.815 -173.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 17.0 m -90.05 -5.8 56.21 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 123.479 0.712 . . . . 0.0 112.285 -172.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 40.69 45.01 1.96 Allowed 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 125.676 1.59 . . . . 0.0 112.548 -172.329 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 59.2 m -114.39 118.58 34.24 Favored 'General case' 0 C--N 1.346 0.444 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.413 -175.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.74 HG22 HG23 ' A' ' 40' ' ' ILE . 27.9 t -97.32 105.84 17.71 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 177.147 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 21.6 t -98.56 119.46 46.58 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 C-N-CA 123.956 0.903 . . . . 0.0 109.333 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.498 HG13 HG23 ' A' ' 44' ' ' ILE . 28.2 m -110.09 112.07 38.91 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.865 0 CA-C-O 121.562 0.696 . . . . 0.0 110.712 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.4 170.16 31.03 Favored Glycine 0 C--N 1.344 1.007 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.603 176.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.73 -5.92 49.9 Favored Glycine 0 N--CA 1.472 1.066 0 N-CA-C 114.069 0.388 . . . . 0.0 114.069 177.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 18.1 m -128.89 148.37 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 124.773 1.229 . . . . 0.0 109.415 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.3 t -114.47 0.15 13.94 Favored 'General case' 0 N--CA 1.482 1.159 0 C-N-CA 123.604 0.761 . . . . 0.0 110.366 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.414 ' O ' HG12 ' A' ' 73' ' ' ILE . 3.4 m-20 -91.18 70.95 6.24 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.099 0.959 . . . . 0.0 110.231 -169.703 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.405 ' HA ' HD12 ' A' ' 24' ' ' LEU . . . -58.94 -49.78 76.55 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 123.409 0.684 . . . . 0.0 112.575 -174.163 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.66 91.09 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.69 0.796 . . . . 0.0 111.511 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.407 ' O ' HG13 ' A' ' 76' ' ' ILE . 74.8 t60 -66.39 -46.7 75.76 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.017 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.482 HG21 HG22 ' A' ' 64' ' ' VAL . 47.4 mm -60.59 -39.15 80.48 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 O-C-N 123.702 0.626 . . . . 0.0 109.671 177.589 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -58.07 -38.71 76.86 Favored 'General case' 0 N--CA 1.473 0.682 0 O-C-N 124.147 0.905 . . . . 0.0 111.641 178.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -67.94 -38.48 82.89 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 123.261 0.624 . . . . 0.0 111.192 176.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.486 HG21 ' HA ' ' A' ' 44' ' ' ILE . 64.7 mt -68.46 -50.04 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 C-N-CA 123.279 0.631 . . . . 0.0 111.528 -177.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.439 HG21 ' HD3' ' A' ' 84' ' ' PRO . 13.5 tt -69.37 -35.3 66.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 123.373 0.669 . . . . 0.0 111.318 -175.812 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.4 t -70.11 -29.32 66.24 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 122.207 0.203 . . . . 0.0 110.527 176.43 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.31 -17.48 64.78 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 123.51 0.724 . . . . 0.0 112.23 176.167 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -85.98 5.12 34.72 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.574 0.749 . . . . 0.0 111.355 172.408 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.36 2.55 79.71 Favored Glycine 0 C--N 1.347 1.171 0 CA-C-O 119.424 -0.653 . . . . 0.0 113.697 178.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.437 ' HB3' HG11 ' A' ' 28' ' ' VAL . 84.2 m-85 -119.16 105.48 11.42 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 117.917 0.858 . . . . 0.0 109.651 -177.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.0 t -86.87 127.72 58.79 Favored Pre-proline 0 CA--C 1.55 0.959 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.88 -170.483 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.448 ' HA ' HG22 ' A' ' 28' ' ' VAL . 57.3 Cg_endo -69.97 -36.97 9.32 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.529 2.153 . . . . 0.0 112.159 177.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.5 mm-40 . . . . . 0 C--O 1.251 1.142 0 C-N-CA 125.078 1.351 . . . . 0.0 111.302 -177.967 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.101 0 N-CA-C 112.549 -0.221 . . . . 0.0 112.549 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.505 HD13 ' HA ' ' A' ' 70' ' ' ALA . 25.1 mt -96.74 108.61 21.29 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.857 0.863 . . . . 0.0 110.34 -175.616 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.2 t -86.92 119.68 27.4 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 123.275 0.63 . . . . 0.0 109.913 177.655 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -112.79 118.02 33.8 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.558 0.743 . . . . 0.0 109.658 175.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 44.9 p-80 -83.75 88.3 7.08 Favored 'General case' 0 CA--C 1.546 0.817 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 175.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.506 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 35.3 t -80.79 104.39 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -172.196 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -73.31 -16.44 61.37 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 115.668 -0.696 . . . . 0.0 112.051 -175.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 35.8 t70 -106.71 16.33 24.59 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.361 0.664 . . . . 0.0 110.534 179.325 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.506 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 25.1 ttt -71.31 136.13 47.72 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 121.012 0.434 . . . . 0.0 111.516 -176.432 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 20.3 p -86.88 162.04 17.95 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.16 0.984 . . . . 0.0 110.913 173.187 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 61.2 m -74.89 -167.41 0.58 Allowed 'General case' 0 CA--C 1.561 1.376 0 C-N-CA 123.663 0.785 . . . . 0.0 111.756 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -57.66 -29.04 60.73 Favored Glycine 0 C--N 1.355 1.635 0 N-CA-C 115.695 1.038 . . . . 0.0 115.695 -172.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -69.3 -22.92 63.76 Favored 'General case' 0 N--CA 1.486 1.364 0 CA-C-N 117.428 0.614 . . . . 0.0 112.371 -176.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.7 m -123.24 13.14 9.59 Favored 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 123.636 0.774 . . . . 0.0 110.955 176.567 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -65.97 -41.64 90.9 Favored 'General case' 0 C--N 1.357 0.922 0 C-N-CA 123.131 0.572 . . . . 0.0 111.392 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.38 -25.61 67.02 Favored Glycine 0 N--CA 1.473 1.129 0 O-C-N 123.134 0.271 . . . . 0.0 113.699 -179.204 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.75 -50.07 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 123.404 0.682 . . . . 0.0 110.808 177.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 15.1 tt -67.99 -32.95 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 C-N-CA 123.025 0.53 . . . . 0.0 110.596 -177.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.426 ' HB3' HG21 ' A' ' 53' ' ' VAL . 96.1 mttt -64.23 -53.17 53.29 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 123.634 0.774 . . . . 0.0 109.56 168.478 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.404 ' HA2' ' HB3' ' A' ' 45' ' ' GLU . . . -59.06 -29.83 65.93 Favored Glycine 0 C--N 1.358 1.77 0 O-C-N 124.873 1.358 . . . . 0.0 114.046 -173.132 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.87 -54.15 48.05 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 123.818 0.847 . . . . 0.0 110.665 177.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.55 HG21 HG13 ' A' ' 64' ' ' VAL . 60.2 mt -75.21 -41.91 44.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.814 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.404 ' HB3' ' HA2' ' A' ' 42' ' ' GLY . 17.6 tp10 -54.26 -51.14 65.49 Favored 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 125.418 1.487 . . . . 0.0 112.282 -174.632 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? -79.64 -25.85 41.25 Favored 'General case' 0 N--CA 1.483 1.176 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.84 -175.439 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 87.0 m -76.77 -48.14 19.56 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-O 120.814 0.34 . . . . 0.0 110.673 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.511 HG12 HG11 ' A' ' 67' ' ' VAL . 56.5 t -112.22 110.23 53.72 Favored Pre-proline 0 N--CA 1.475 0.78 0 C-N-CA 123.459 0.704 . . . . 0.0 109.432 -178.424 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -72.41 110.32 2.95 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.403 2.069 . . . . 0.0 111.342 172.099 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 117.1 -2.57 19.16 Favored Glycine 0 C--N 1.342 0.867 0 CA-C-O 119.382 -0.677 . . . . 0.0 113.548 179.191 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -80.22 105.95 11.87 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 173.308 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.72 99.64 8.32 Favored 'General case' 0 C--N 1.346 0.44 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -177.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.465 HG12 HG12 ' A' ' 64' ' ' VAL . 29.3 m -84.74 129.43 37.71 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-O 121.235 0.54 . . . . 0.0 110.446 -174.077 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 63.8 t60 -125.61 97.97 5.38 Favored 'General case' 0 C--O 1.225 -0.213 0 N-CA-C 106.211 -1.774 . . . . 0.0 106.211 174.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.436 ' HB3' ' HE1' ' A' ' 31' ' ' MET . . . -109.84 113.89 27.01 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 -179.176 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . 0.424 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 11.1 t70 -105.76 119.86 51.11 Favored Pre-proline 0 N--CA 1.468 0.469 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -175.126 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -63.37 -33.77 68.8 Favored 'Trans proline' 0 C--N 1.375 1.927 0 C-N-CA 122.989 2.459 . . . . 0.0 113.088 -176.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.88 -45.64 23.6 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.127 0.571 . . . . 0.0 111.083 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.424 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 35.4 m -80.35 -23.95 40.18 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 123.253 0.621 . . . . 0.0 111.568 -174.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.459 ' HA ' ' SD ' ' A' ' 31' ' ' MET . 37.5 mmt180 65.08 35.41 8.01 Favored 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 124.71 1.204 . . . . 0.0 111.093 -177.464 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 11.9 m -122.8 117.97 26.89 Favored 'General case' 0 C--O 1.241 0.609 0 C-N-CA 123.029 0.532 . . . . 0.0 110.778 -171.058 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 45.9 t -103.76 106.71 20.72 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 172.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 24.9 t -105.11 130.25 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 124.452 1.101 . . . . 0.0 109.099 -179.238 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.55 HG13 HG21 ' A' ' 44' ' ' ILE . 17.6 m -117.63 109.52 27.79 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.023 0 CA-C-O 121.419 0.628 . . . . 0.0 111.107 -178.32 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -86.87 161.01 32.95 Favored Glycine 0 C--N 1.346 1.114 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.817 178.501 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 83.09 -11.3 55.37 Favored Glycine 0 N--CA 1.472 1.035 0 CA-C-O 119.806 -0.441 . . . . 0.0 113.62 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.511 HG11 HG12 ' A' ' 48' ' ' VAL . 30.6 m -128.89 150.85 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.272 0 C-N-CA 124.022 0.929 . . . . 0.0 109.935 -176.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 29.1 t -124.85 -2.89 7.75 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.749 0.82 . . . . 0.0 111.586 -174.199 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.485 ' HB3' ' HB3' ' A' ' 72' ' ' HIS . 6.1 m-20 -79.24 82.05 5.43 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 123.493 0.717 . . . . 0.0 109.999 -178.592 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.505 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -62.93 -49.28 75.39 Favored 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 123.231 0.612 . . . . 0.0 112.068 -172.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.455 ' O ' ' HG3' ' A' ' 75' ' ' GLU . . . -65.68 -39.35 91.23 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.62 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.485 ' HB3' ' HB3' ' A' ' 69' ' ' ASP . 79.5 t60 -70.25 -42.09 72.64 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 123.596 0.758 . . . . 0.0 112.239 -175.493 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.515 HG21 HG23 ' A' ' 64' ' ' VAL . 33.8 mm -63.74 -37.61 80.15 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 175.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.54 -33.31 74.65 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.226 176.44 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.455 ' HG3' ' O ' ' A' ' 71' ' ' ALA . 46.5 mt-10 -64.73 -41.41 95.98 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 123.191 0.596 . . . . 0.0 110.541 174.595 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 70.0 mt -69.46 -47.33 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.406 0.682 . . . . 0.0 111.265 -175.222 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 15.1 tt -74.33 -26.85 20.84 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.02 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.179 -176.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.505 ' HA ' ' O ' ' A' ' 82' ' ' TYR . 2.3 t -75.69 -29.35 58.99 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 175.236 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.51 -18.28 64.35 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.681 0.792 . . . . 0.0 111.566 175.297 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -79.83 3.35 19.91 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.814 0.845 . . . . 0.0 112.219 174.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.32 5.56 75.75 Favored Glycine 0 C--N 1.349 1.255 0 CA-C-O 120.216 -0.213 . . . . 0.0 113.024 179.294 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.505 ' O ' ' HA ' ' A' ' 78' ' ' THR . 91.7 m-85 -100.13 162.22 13.11 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.897 0.879 . . . . 0.0 110.047 178.216 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 32.4 p -121.52 103.31 41.32 Favored Pre-proline 0 CA--C 1.55 0.947 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 171.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -60.84 -40.24 55.31 Favored 'Trans proline' 0 C--N 1.387 2.602 0 C-N-CA 123.061 2.508 . . . . 0.0 112.33 175.505 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 64.7 mm-40 . . . . . 0 CA--C 1.552 1.041 0 C-N-CA 124.769 1.228 . . . . 0.0 110.755 -178.04 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.346 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.459 HD12 ' HA ' ' A' ' 70' ' ' ALA . 25.9 mt -92.14 115.09 27.78 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 123.912 0.885 . . . . 0.0 109.579 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 47.0 t -83.53 123.05 29.35 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 122.875 0.47 . . . . 0.0 110.24 -179.297 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -125.43 101.38 6.92 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.815 0.846 . . . . 0.0 109.032 174.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 61' ' ' THR . 9.5 p80 -93.82 100.15 12.39 Favored 'General case' 0 CA--C 1.547 0.843 0 CA-C-O 121.503 0.668 . . . . 0.0 110.384 -174.158 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.526 ' O ' ' HB3' ' A' ' 60' ' ' ARG . 92.0 t -82.34 106.04 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 172.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -79.63 -7.75 58.75 Favored 'General case' 0 N--CA 1.485 1.308 0 CA-C-N 118.292 0.496 . . . . 0.0 112.137 -176.281 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -95.15 12.29 29.25 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 123.638 0.775 . . . . 0.0 111.071 171.308 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.435 ' SD ' ' HA ' ' A' ' 60' ' ' ARG . 27.6 ttt -70.9 143.51 50.96 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.541 0.736 . . . . 0.0 111.764 -176.759 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 17.2 p -125.88 165.88 17.91 Favored 'General case' 0 C--O 1.243 0.725 0 C-N-CA 125.161 1.384 . . . . 0.0 108.61 176.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 31.6 p -53.41 179.51 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -173.136 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.49 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -43.94 -26.6 0.85 Allowed Glycine 0 C--N 1.36 1.881 0 N-CA-C 117.603 1.801 . . . . 0.0 117.603 -166.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 69.4 t60 -55.97 -54.77 40.73 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 124.081 0.952 . . . . 0.0 111.061 176.109 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 42.6 t -96.91 -20.91 17.79 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.488 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.49 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -64.81 -36.04 83.03 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 123.068 0.547 . . . . 0.0 110.802 175.684 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.95 -24.82 73.17 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.425 -0.807 . . . . 0.0 113.169 176.103 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 43.3 t -74.5 -38.95 47.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.404 0.682 . . . . 0.0 110.237 176.094 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 22.5 mt -63.98 -47.42 90.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-O 121.455 0.645 . . . . 0.0 109.536 176.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.628 ' HZ3' ' HB3' ' A' ' 41' ' ' LYS . 9.4 mtpm? -59.23 -47.78 84.08 Favored 'General case' 0 C--N 1.35 0.588 0 CA-C-N 114.285 -1.325 . . . . 0.0 110.852 176.107 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.22 -33.03 86.14 Favored Glycine 0 C--N 1.345 1.081 0 O-C-N 124.502 1.126 . . . . 0.0 113.094 -175.396 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -60.49 -54.61 43.47 Favored 'General case' 0 C--N 1.348 0.515 0 C-N-CA 123.133 0.573 . . . . 0.0 110.521 178.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.511 HG21 HG12 ' A' ' 64' ' ' VAL . 54.7 mt -72.55 -45.72 57.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.804 -175.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -64.22 -41.14 97.15 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.947 0.899 . . . . 0.0 111.92 -171.228 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -76.22 -34.75 59.24 Favored 'General case' 0 N--CA 1.481 1.076 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.221 -178.634 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 86.7 m -72.91 -45.84 55.96 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 122.435 0.294 . . . . 0.0 110.744 -178.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 78.0 t -120.5 94.23 48.7 Favored Pre-proline 0 N--CA 1.478 0.933 0 C-N-CA 123.679 0.791 . . . . 0.0 109.054 176.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_exo -64.12 123.87 12.57 Favored 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 122.549 2.166 . . . . 0.0 110.622 169.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 119.68 -20.28 9.45 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 112.108 -0.397 . . . . 0.0 112.108 -174.364 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -79.72 105.7 11.21 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 174.419 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.36 98.25 8.09 Favored 'General case' 0 C--N 1.342 0.259 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -178.026 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.526 HG13 HG11 ' A' ' 64' ' ' VAL . 15.6 m -85.06 116.07 27.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 C-N-CA 123.513 0.725 . . . . 0.0 110.097 -172.449 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 54.9 t-80 -112.55 99.22 7.79 Favored 'General case' 0 C--N 1.347 0.472 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 176.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.34 127.68 34.13 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -111.2 108.11 57.22 Favored Pre-proline 0 CA--C 1.537 0.471 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 175.147 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -64.03 -33.48 62.18 Favored 'Trans proline' 0 C--N 1.367 1.521 0 C-N-CA 122.678 2.252 . . . . 0.0 112.86 -178.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.76 -39.67 43.48 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.46 0.704 . . . . 0.0 111.85 -175.209 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.3 t -92.82 -15.02 26.99 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 123.712 0.805 . . . . 0.0 110.851 -178.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.526 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 63.52 45.26 4.82 Favored 'General case' 0 CA--C 1.554 1.1 0 C-N-CA 124.452 1.101 . . . . 0.0 110.421 -179.272 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' THR . . . . . 0.423 ' HA ' ' HA ' ' A' ' 27' ' ' HIS . 17.8 m -132.85 120.9 22.15 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -170.72 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 47.4 t -104.18 108.28 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 123.686 0.794 . . . . 0.0 109.458 173.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 43.1 t -104.07 121.59 55.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.893 0.877 . . . . 0.0 109.551 -177.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.526 HG11 HG13 ' A' ' 53' ' ' VAL . 27.0 m -102.45 114.43 41.9 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 CA-C-O 121.427 0.632 . . . . 0.0 111.151 -176.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.83 160.37 24.21 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.064 179.129 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 83.22 -11.75 53.64 Favored Glycine 0 N--CA 1.474 1.232 0 CA-C-N 116.695 0.248 . . . . 0.0 113.68 177.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 31.3 m -126.62 142.22 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 124.474 1.11 . . . . 0.0 109.064 178.665 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.2 m -113.25 3.59 16.06 Favored 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 123.352 0.661 . . . . 0.0 110.487 178.403 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -82.44 79.18 8.95 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.129 0.972 . . . . 0.0 110.432 -174.39 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.459 ' HA ' HD12 ' A' ' 24' ' ' LEU . . . -63.77 -37.92 89.18 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 122.86 0.464 . . . . 0.0 111.719 -175.479 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.498 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -65.44 -47.19 77.02 Favored 'General case' 0 N--CA 1.475 0.818 0 O-C-N 123.551 0.532 . . . . 0.0 110.718 179.363 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 17.3 m-70 -58.24 -52.9 63.64 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 123.6 0.76 . . . . 0.0 111.11 -177.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.435 HG13 HG23 ' A' ' 64' ' ' VAL . 47.6 mm -62.02 -38.88 81.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.079 -178.534 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.84 -40.47 88.62 Favored 'General case' 0 C--N 1.354 0.779 0 O-C-N 124.063 0.852 . . . . 0.0 111.118 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.498 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 39.8 mm-40 -61.51 -45.82 92.58 Favored 'General case' 0 N--CA 1.479 1.003 0 O-C-N 123.872 0.733 . . . . 0.0 110.393 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.442 HG23 ' HA ' ' A' ' 44' ' ' ILE . 46.5 mt -63.67 -53.73 41.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 115.212 -0.903 . . . . 0.0 111.551 -175.684 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 14.0 tt -67.7 -37.67 79.01 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.635 -171.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.6 t -75.08 -29.18 60.58 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 122.483 0.313 . . . . 0.0 110.481 178.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.78 -29.75 69.02 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 123.585 0.754 . . . . 0.0 110.742 175.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.4 -2.18 33.9 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 123.576 0.75 . . . . 0.0 111.485 174.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 96.88 -11.38 66.15 Favored Glycine 0 C--N 1.351 1.394 0 C-N-CA 123.093 0.378 . . . . 0.0 113.003 176.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 60.9 m-85 -91.08 104.76 17.3 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -175.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.8 m -77.12 110.92 13.6 Favored Pre-proline 0 CA--C 1.551 1.007 0 C-N-CA 123.917 0.887 . . . . 0.0 110.02 -176.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -83.13 -18.03 6.39 Favored 'Trans proline' 0 C--N 1.373 1.826 0 C-N-CA 122.56 2.173 . . . . 0.0 113.222 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 . . . . . 0 C--O 1.245 0.858 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.283 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.731 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.42 HD12 ' HA ' ' A' ' 70' ' ' ALA . 52.5 mt -78.98 107.91 12.07 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -178.513 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 20.1 m -95.06 110.74 22.63 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 122.467 0.307 . . . . 0.0 110.706 -173.019 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -107.13 146.36 31.37 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 124.068 0.947 . . . . 0.0 109.351 178.41 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -124.52 136.05 53.68 Favored 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.475 HG23 ' HB3' ' A' ' 84' ' ' PRO . 86.3 t -125.79 126.69 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 123.592 0.757 . . . . 0.0 111.407 -170.521 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -71.73 -37.62 70.57 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.217 0.607 . . . . 0.0 111.548 177.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -75.02 -21.68 58.93 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 123.054 0.542 . . . . 0.0 112.258 -173.303 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.509 ' HG3' ' SG ' ' A' ' 36' ' ' CYS . 27.2 ttt -65.76 120.17 12.53 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.158 0.983 . . . . 0.0 111.043 -174.665 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 p -127.35 95.61 4.32 Favored 'General case' 0 CA--C 1.548 0.883 0 C-N-CA 122.717 0.407 . . . . 0.0 110.957 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 12.5 t 50.32 -147.94 0.34 Allowed 'General case' 0 CA--C 1.572 1.792 0 C-N-CA 125.349 1.459 . . . . 0.0 113.995 167.129 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -62.15 -28.64 71.01 Favored Glycine 0 C--N 1.357 1.722 0 N-CA-C 115.118 0.807 . . . . 0.0 115.118 -173.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 46.6 m170 -64.51 -29.05 70.08 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 123.451 0.7 . . . . 0.0 112.099 -178.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.509 ' SG ' ' HG3' ' A' ' 31' ' ' MET . 30.6 p -100.29 -18.74 16.68 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 122.768 0.427 . . . . 0.0 111.102 179.377 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -55.54 -54.77 39.85 Favored 'General case' 0 C--N 1.358 0.944 0 O-C-N 124.012 0.82 . . . . 0.0 112.563 -166.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.27 -35.55 92.11 Favored Glycine 0 C--N 1.343 0.946 0 O-C-N 123.178 0.299 . . . . 0.0 113.43 -176.561 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 49.0 t -72.2 -47.53 53.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 123.067 0.547 . . . . 0.0 111.075 -178.295 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.414 HD12 HD12 ' A' ' 77' ' ' ILE . 14.2 tt -67.91 -32.33 55.92 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 123.803 0.841 . . . . 0.0 111.239 -174.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -63.51 -59.25 4.89 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 123.656 0.782 . . . . 0.0 110.06 172.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.88 -30.93 78.16 Favored Glycine 0 C--N 1.353 1.477 0 CA-C-N 114.548 -1.205 . . . . 0.0 113.919 -170.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.82 -51.57 68.47 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 124.022 0.929 . . . . 0.0 110.567 -179.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.585 HG23 HG12 ' A' ' 64' ' ' VAL . 65.3 mt -73.95 -50.57 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 123.447 0.699 . . . . 0.0 111.334 178.872 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -58.73 -44.55 90.48 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 124.471 1.108 . . . . 0.0 112.808 -165.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.2 mptp? -81.05 -27.06 35.88 Favored 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.34 -175.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 91.2 m -74.38 -37.92 63.3 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 123.054 0.542 . . . . 0.0 110.66 179.339 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 95.5 t -124.46 95.07 43.76 Favored Pre-proline 0 N--CA 1.478 0.973 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 174.203 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -59.14 124.25 15.22 Favored 'Trans proline' 0 C--N 1.376 2.011 0 C-N-CA 122.998 2.466 . . . . 0.0 111.385 170.734 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.76 -8.16 36.66 Favored Glycine 0 C--N 1.343 0.937 0 CA-C-O 119.601 -0.555 . . . . 0.0 112.935 -176.017 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -83.83 105.98 15.16 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 171.495 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -88.08 101.91 14.26 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.41 0.684 . . . . 0.0 109.591 -177.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.472 HG11 HG11 ' A' ' 64' ' ' VAL . 31.6 m -83.01 130.83 35.06 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.339 0.59 . . . . 0.0 110.492 -171.649 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . 0.467 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 24.7 t60 -120.72 96.41 5.11 Favored 'General case' 0 C--O 1.219 -0.528 0 N-CA-C 106.307 -1.738 . . . . 0.0 106.307 170.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.17 114.79 27.43 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -98.03 112.65 62.39 Favored Pre-proline 0 N--CA 1.47 0.529 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -57.02 -51.25 9.25 Favored 'Trans proline' 0 C--N 1.377 2.053 0 C-N-CA 122.616 2.211 . . . . 0.0 113.142 -175.775 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.67 -42.01 68.01 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 123.497 0.719 . . . . 0.0 112.465 -171.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.1 t -89.3 -12.74 39.71 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.07 0.548 . . . . 0.0 111.242 -178.462 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.4 mpt_? 65.16 30.55 11.39 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 124.269 1.027 . . . . 0.0 111.891 177.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 16.7 m -110.94 109.83 20.15 Favored 'General case' 0 CA--C 1.544 0.737 0 O-C-N 122.258 -0.276 . . . . 0.0 110.952 -169.118 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 54' ' ' HIS . 39.3 t -98.92 105.39 17.3 Favored 'Isoleucine or valine' 0 C--N 1.352 0.699 0 C-N-CA 123.804 0.842 . . . . 0.0 109.242 177.108 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 22.6 t -99.61 117.92 45.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.749 0.82 . . . . 0.0 109.083 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.585 HG12 HG23 ' A' ' 44' ' ' ILE . 30.5 m -104.74 115.24 46.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 123.402 0.681 . . . . 0.0 109.996 -179.399 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -101.07 145.4 16.98 Favored Glycine 0 C--N 1.348 1.229 0 CA-C-N 116.143 -0.48 . . . . 0.0 112.671 -177.356 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 95.71 3.31 61.0 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 123.073 0.368 . . . . 0.0 113.659 176.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.3 m -130.54 147.44 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.739 0.816 . . . . 0.0 110.249 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.8 m -112.27 4.83 17.99 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 123.071 0.549 . . . . 0.0 110.708 179.065 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.529 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 3.0 m-20 -89.36 68.71 8.01 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.922 0.889 . . . . 0.0 110.39 -175.027 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.42 ' HA ' HD12 ' A' ' 24' ' ' LEU . . . -62.11 -39.49 92.69 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.452 0.701 . . . . 0.0 111.285 -177.282 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -66.81 -42.49 85.81 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.719 0.808 . . . . 0.0 111.376 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.529 ' HB2' ' HB3' ' A' ' 69' ' ' ASP . 18.8 m80 -63.63 -52.98 58.44 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 122.793 0.437 . . . . 0.0 110.726 178.242 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.489 HG21 HG21 ' A' ' 64' ' ' VAL . 47.2 mm -58.89 -42.44 85.83 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 O-C-N 123.93 0.769 . . . . 0.0 110.52 -176.235 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -58.1 -41.87 84.46 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.143 0.977 . . . . 0.0 111.387 178.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 60.1 mm-40 -70.12 -33.82 72.31 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.264 178.177 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.441 HG13 ' O ' ' A' ' 72' ' ' HIS . 75.4 mt -68.11 -51.31 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 CA-C-O 121.025 0.44 . . . . 0.0 110.554 -179.173 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.584 HG22 ' HG3' ' A' ' 84' ' ' PRO . 16.7 tt -69.25 -32.34 53.32 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 CA-C-N 115.165 -0.925 . . . . 0.0 111.438 -175.138 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 t -76.52 -31.59 57.75 Favored 'General case' 0 N--CA 1.477 0.913 0 O-C-N 122.283 -0.26 . . . . 0.0 111.076 175.346 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.46 -16.12 62.35 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 123.492 0.717 . . . . 0.0 110.904 176.395 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -80.61 5.33 15.78 Favored 'General case' 0 CA--C 1.555 1.157 0 C-N-CA 123.763 0.825 . . . . 0.0 111.581 173.16 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.93 -0.74 73.36 Favored Glycine 0 C--N 1.353 1.482 0 C-N-CA 123.117 0.389 . . . . 0.0 113.15 176.41 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.427 ' HB3' HG13 ' A' ' 28' ' ' VAL . 95.7 m-85 -86.15 165.61 16.43 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 123.392 0.677 . . . . 0.0 110.48 179.355 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 33.5 p -122.82 81.2 49.38 Favored Pre-proline 0 CA--C 1.559 1.326 0 C-N-CA 123.174 0.59 . . . . 0.0 111.619 -176.404 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.584 ' HG3' HG22 ' A' ' 77' ' ' ILE . 43.0 Cg_endo -88.27 171.95 5.27 Favored 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.901 2.401 . . . . 0.0 112.178 169.816 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 . . . . . 0 C--O 1.246 0.891 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 176.452 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.14 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.0 107.48 12.82 Favored 'General case' 0 CA--C 1.548 0.883 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 179.24 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 24.9 p -93.37 111.97 23.77 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 123.606 0.762 . . . . 0.0 111.42 -173.269 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -99.68 141.23 32.76 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 175.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 65.8 m80 -115.46 100.7 8.28 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -175.041 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.527 HG22 ' HB3' ' A' ' 82' ' ' TYR . 2.7 p -113.41 97.78 6.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 C-N-CA 124.19 0.996 . . . . 0.0 109.753 -178.658 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -70.71 -17.8 62.81 Favored 'General case' 0 CA--C 1.551 0.989 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.966 176.676 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.37 -12.4 60.81 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 123.889 0.876 . . . . 0.0 111.384 176.574 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.484 ' SD ' ' HB3' ' A' ' 55' ' ' ALA . 60.0 ttp -80.19 98.98 7.57 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 173.749 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.408 ' O ' ' SG ' ' A' ' 33' ' ' CYS . 30.4 p -94.18 102.67 14.71 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.213 0.605 . . . . 0.0 110.159 178.216 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.408 ' SG ' ' O ' ' A' ' 32' ' ' THR . 14.7 p 66.67 178.32 0.22 Allowed 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 126.567 1.947 . . . . 0.0 113.153 175.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -60.95 -22.79 60.66 Favored Glycine 0 C--N 1.359 1.82 0 CA-C-N 115.118 -0.946 . . . . 0.0 113.973 -178.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 13.0 t-160 -60.61 -42.76 97.47 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 123.894 0.878 . . . . 0.0 111.013 175.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 81.1 m -87.93 -21.59 24.82 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 123.032 0.533 . . . . 0.0 111.256 178.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . 0.468 ' HA ' ' SD ' ' A' ' 31' ' ' MET . . . -66.02 -46.88 76.32 Favored 'General case' 0 C--N 1.349 0.546 0 C-N-CA 123.318 0.647 . . . . 0.0 111.01 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.82 -29.29 73.6 Favored Glycine 0 C--N 1.349 1.303 0 O-C-N 124.052 0.845 . . . . 0.0 113.546 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 58.3 t -63.29 -44.85 99.34 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.634 0.774 . . . . 0.0 110.087 175.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.609 HG23 HG22 ' A' ' 62' ' ' VAL . 62.6 mt -70.4 -39.33 76.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.852 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.428 ' HG3' ' O ' ' A' ' 37' ' ' ALA . 96.3 mttt -59.12 -49.84 76.33 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 123.125 0.57 . . . . 0.0 110.087 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.77 -38.66 96.86 Favored Glycine 0 C--N 1.344 0.974 0 O-C-N 124.28 0.987 . . . . 0.0 112.522 178.173 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.35 -55.06 31.65 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.63 0.772 . . . . 0.0 111.822 -176.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.5 ' HA ' HG22 ' A' ' 76' ' ' ILE . 69.7 mt -70.15 -55.71 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 123.241 0.616 . . . . 0.0 111.247 -178.46 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -60.1 -40.88 91.17 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 123.767 0.827 . . . . 0.0 112.791 -169.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -74.23 -30.91 62.38 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 122.45 0.3 . . . . 0.0 111.642 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 91.7 m -72.9 -42.63 63.36 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 121.053 0.454 . . . . 0.0 110.257 176.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.0 m -131.48 87.54 46.33 Favored Pre-proline 0 CA--C 1.553 1.074 0 C-N-CA 123.618 0.767 . . . . 0.0 110.52 -178.329 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -57.76 138.09 84.37 Favored 'Trans proline' 0 C--N 1.38 2.186 0 C-N-CA 122.6 2.2 . . . . 0.0 111.345 171.288 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 108.75 -23.87 23.05 Favored Glycine 0 N--CA 1.467 0.721 0 O-C-N 123.403 0.44 . . . . 0.0 112.02 -175.227 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -76.79 107.21 8.95 Favored 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 173.632 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.8 99.43 8.27 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.264 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.486 HG11 HG12 ' A' ' 64' ' ' VAL . 23.4 m -86.32 128.58 39.32 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 C-N-CA 123.199 0.6 . . . . 0.0 111.191 -171.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . 0.444 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 18.7 t60 -127.85 98.22 5.09 Favored 'General case' 0 C--O 1.223 -0.304 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 175.126 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.484 ' HB3' ' SD ' ' A' ' 31' ' ' MET . . . -100.73 112.82 25.29 Favored 'General case' 0 C--O 1.241 0.643 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.357 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -102.72 114.73 65.14 Favored Pre-proline 0 CA--C 1.538 0.519 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -170.269 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -62.14 -34.4 79.34 Favored 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 122.812 2.341 . . . . 0.0 113.213 -178.448 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.04 -46.1 30.95 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.166 0.586 . . . . 0.0 111.295 -175.525 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.5 t -89.23 -16.75 30.53 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.404 0.682 . . . . 0.0 111.739 -175.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.7 mpt_? 61.57 39.85 14.2 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.331 1.052 . . . . 0.0 111.029 -176.643 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 50.0 m -126.26 118.89 26.06 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 122.75 0.42 . . . . 0.0 111.289 -172.712 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.609 HG22 HG23 ' A' ' 40' ' ' ILE . 38.7 t -100.0 105.71 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 123.728 0.811 . . . . 0.0 109.434 173.288 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 20.8 t -100.19 127.65 52.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 C-N-CA 123.791 0.836 . . . . 0.0 109.02 -178.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.493 HG21 HG13 ' A' ' 73' ' ' ILE . 17.4 m -111.2 109.95 30.41 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.656 0.741 . . . . 0.0 109.95 178.115 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -88.62 153.88 24.42 Favored Glycine 0 C--N 1.346 1.097 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.976 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.47 -14.55 45.58 Favored Glycine 0 N--CA 1.472 1.068 0 C-N-CA 122.888 0.28 . . . . 0.0 113.236 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.7 m -130.87 135.76 59.48 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.75 0 C-N-CA 124.457 1.103 . . . . 0.0 109.156 179.404 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 51.0 m -116.41 17.75 15.39 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.359 0.664 . . . . 0.0 109.913 176.012 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -80.25 77.05 7.02 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.292 1.037 . . . . 0.0 109.574 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.8 -42.96 94.59 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.496 0.718 . . . . 0.0 111.622 -175.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.424 ' O ' ' HG3' ' A' ' 75' ' ' GLU . . . -62.63 -46.08 89.9 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.941 0.897 . . . . 0.0 111.289 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 11.6 m170 -62.04 -54.75 37.08 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.666 0.787 . . . . 0.0 110.442 -176.635 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.493 HG13 HG21 ' A' ' 64' ' ' VAL . 45.3 mm -64.01 -40.0 87.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.319 -175.124 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.7 -39.6 89.12 Favored 'General case' 0 N--CA 1.476 0.875 0 O-C-N 123.966 0.792 . . . . 0.0 111.18 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.424 ' HG3' ' O ' ' A' ' 71' ' ' ALA . 46.3 mt-10 -61.98 -39.19 91.34 Favored 'General case' 0 N--CA 1.479 1.021 0 O-C-N 123.803 0.689 . . . . 0.0 111.16 176.28 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.5 HG22 ' HA ' ' A' ' 44' ' ' ILE . 62.4 mt -68.77 -51.9 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 O-C-N 123.636 0.585 . . . . 0.0 111.259 -176.75 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.517 HD12 ' HB3' ' A' ' 84' ' ' PRO . 6.3 tt -68.61 -31.77 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.27 0 C-N-CA 123.075 0.55 . . . . 0.0 111.569 -176.398 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -74.8 -30.78 61.53 Favored 'General case' 0 N--CA 1.483 1.183 0 O-C-N 122.202 -0.311 . . . . 0.0 110.426 176.42 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.09 -22.9 61.28 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 123.069 0.548 . . . . 0.0 110.296 172.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.31 -16.75 60.4 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 123.801 0.84 . . . . 0.0 111.832 174.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.34 22.53 12.68 Favored Glycine 0 C--N 1.348 1.223 0 O-C-N 123.405 0.44 . . . . 0.0 113.141 178.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.527 ' HB3' HG22 ' A' ' 28' ' ' VAL . 80.1 m-85 -128.56 133.29 48.33 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 123.913 0.885 . . . . 0.0 110.024 179.034 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 27.7 p -89.58 107.79 20.94 Favored Pre-proline 0 CA--C 1.552 1.036 0 C-N-CA 123.593 0.757 . . . . 0.0 110.605 -179.78 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.517 ' HB3' HD12 ' A' ' 77' ' ' ILE . 64.3 Cg_endo -78.33 -8.11 16.16 Favored 'Trans proline' 0 C--N 1.376 1.975 0 C-N-CA 122.748 2.299 . . . . 0.0 113.622 178.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 . . . . . 0 C--O 1.248 1.001 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 -173.378 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.862 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.417 HD12 HG23 ' A' ' 67' ' ' VAL . 37.3 mt -93.08 111.47 23.11 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 124.196 0.998 . . . . 0.0 110.359 -175.279 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.405 ' HG ' HG11 ' A' ' 63' ' ' VAL . 29.1 m -94.38 115.77 28.03 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.011 0.524 . . . . 0.0 111.054 -175.215 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -107.91 116.44 31.95 Favored 'General case' 0 N--CA 1.484 1.264 0 C-N-CA 123.959 0.904 . . . . 0.0 109.79 177.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 22.9 m170 -82.17 90.34 6.57 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.409 ' HA ' ' HA ' ' A' ' 84' ' ' PRO . 10.6 t -85.3 92.56 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -178.262 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -68.82 -19.26 64.27 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 123.904 0.882 . . . . 0.0 112.144 -172.093 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -89.15 -8.1 54.37 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.872 0.869 . . . . 0.0 111.917 178.287 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.508 ' HE3' ' SG ' ' A' ' 33' ' ' CYS . 26.4 ttt -75.15 126.52 31.19 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.804 0.841 . . . . 0.0 112.557 -173.051 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.8 t -108.49 97.91 7.51 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 164.014 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.508 ' SG ' ' HE3' ' A' ' 31' ' ' MET . 81.5 m -46.52 -64.07 0.85 Allowed 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 125.543 1.537 . . . . 0.0 114.267 -167.421 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.56 -25.2 75.07 Favored Glycine 0 CA--C 1.532 1.142 0 N-CA-C 114.013 0.365 . . . . 0.0 114.013 -175.315 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 15.4 m-70 -93.99 -7.59 42.38 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 123.253 0.621 . . . . 0.0 112.109 -177.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 42.1 t -133.19 9.44 4.09 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.116 0.566 . . . . 0.0 111.099 -175.718 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -56.55 -53.61 55.55 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 123.838 0.855 . . . . 0.0 113.117 -169.721 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.99 -40.45 98.24 Favored Glycine 0 C--N 1.344 0.979 0 O-C-N 123.36 0.413 . . . . 0.0 114.121 -173.603 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.7 p -76.92 -42.51 32.62 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 C-N-CA 123.111 0.564 . . . . 0.0 112.221 -176.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 12.3 tt -73.22 -37.02 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 122.495 0.318 . . . . 0.0 110.809 -174.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.52 -43.47 55.75 Favored 'General case' 0 C--N 1.35 0.622 0 C-N-CA 123.136 0.575 . . . . 0.0 109.661 175.348 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.87 -30.58 78.1 Favored Glycine 0 C--N 1.351 1.393 0 O-C-N 124.494 1.121 . . . . 0.0 113.531 -177.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -61.28 -54.26 46.3 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 123.469 0.708 . . . . 0.0 110.591 177.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.517 ' HA ' HG23 ' A' ' 76' ' ' ILE . 59.0 mt -72.61 -46.81 53.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.163 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -58.54 -50.81 72.44 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 124.034 0.934 . . . . 0.0 112.26 -174.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -77.07 -20.7 55.47 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 119.42 -0.324 . . . . 0.0 111.505 -172.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 85.2 m -79.22 -45.76 19.19 Favored 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 174.362 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 15.8 m -126.74 81.59 68.7 Favored Pre-proline 0 CA--C 1.555 1.168 0 C-N-CA 123.598 0.759 . . . . 0.0 110.01 178.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -60.26 121.45 9.8 Favored 'Trans proline' 0 C--N 1.383 2.385 0 C-N-CA 122.995 2.463 . . . . 0.0 112.144 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.78 -11.57 10.16 Favored Glycine 0 C--N 1.345 1.075 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.704 -176.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -72.32 107.41 4.91 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 176.07 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -77.15 100.15 5.65 Favored 'General case' 0 C--N 1.348 0.507 0 C-N-CA 123.111 0.564 . . . . 0.0 109.856 -176.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.483 HG13 HG13 ' A' ' 64' ' ' VAL . 33.5 m -85.2 137.37 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 123.386 0.674 . . . . 0.0 109.949 -173.63 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . 0.491 ' HB2' ' HB ' ' A' ' 63' ' ' VAL . 78.7 m80 -130.37 101.78 5.9 Favored 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -178.643 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.26 120.87 34.04 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.672 0.789 . . . . 0.0 109.958 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -111.07 103.49 54.94 Favored Pre-proline 0 CA--C 1.55 0.959 0 CA-C-O 118.54 -0.743 . . . . 0.0 109.609 -178.144 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.503 ' HA ' ' SG ' ' A' ' 33' ' ' CYS . 38.0 Cg_exo -39.74 -44.82 3.5 Favored 'Trans proline' 0 C--N 1.376 2.003 0 C-N-CA 124.539 3.493 . . . . 0.0 115.88 172.178 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.24 -46.53 22.86 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 122.715 0.406 . . . . 0.0 111.525 -175.199 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.9 t -91.8 -7.01 50.74 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.359 0.664 . . . . 0.0 111.91 -173.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 40.91 45.65 2.22 Favored 'General case' 0 N--CA 1.505 2.28 0 C-N-CA 126.248 1.819 . . . . 0.0 112.197 -173.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.8 m -112.81 134.2 54.44 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.342 -175.286 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 51.4 t -103.38 105.57 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 168.243 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.491 ' HB ' ' HB2' ' A' ' 54' ' ' HIS . 14.4 t -94.47 119.93 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 175.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.514 HG11 HG21 ' A' ' 44' ' ' ILE . 15.7 m -106.29 116.96 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 CA-C-O 121.296 0.57 . . . . 0.0 110.5 -179.325 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.26 152.59 20.47 Favored Glycine 0 C--N 1.347 1.178 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.309 -175.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.04 -26.97 14.28 Favored Glycine 0 N--CA 1.471 0.989 0 C-N-CA 123.304 0.478 . . . . 0.0 112.883 177.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.417 HG23 HD12 ' A' ' 24' ' ' LEU . 28.4 m -101.98 155.16 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 124.412 1.085 . . . . 0.0 110.372 -176.035 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.1 m -135.7 23.59 3.38 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.78 0.832 . . . . 0.0 110.292 -177.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -119.53 71.54 0.88 Allowed 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 124.388 1.075 . . . . 0.0 109.697 -176.073 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.91 -34.94 75.45 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 115.049 -0.978 . . . . 0.0 112.561 -174.181 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.459 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.36 -43.74 96.79 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.271 0.629 . . . . 0.0 110.632 178.076 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.41 ' O ' HG13 ' A' ' 76' ' ' ILE . 14.9 m-70 -67.16 -43.97 80.91 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 123.467 0.707 . . . . 0.0 111.061 -177.41 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 45.4 mm -62.38 -40.64 88.7 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 O-C-N 123.739 0.649 . . . . 0.0 110.105 179.097 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.44 -38.17 86.2 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.811 178.201 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.459 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 45.3 mm-40 -62.53 -40.0 95.36 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.773 0.829 . . . . 0.0 111.204 176.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.517 HG23 ' HA ' ' A' ' 44' ' ' ILE . 73.4 mt -66.36 -54.89 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 123.717 0.636 . . . . 0.0 110.8 -176.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 12.6 tt -66.94 -34.48 70.23 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.643 -173.206 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 7.7 t -74.5 -30.3 61.76 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 110.526 -0.175 . . . . 0.0 110.526 177.67 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.73 -24.41 61.78 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 123.522 0.729 . . . . 0.0 110.826 175.292 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -71.72 -19.15 62.09 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 123.523 0.729 . . . . 0.0 111.142 172.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 101.6 16.65 23.82 Favored Glycine 0 C--N 1.348 1.242 0 CA-C-N 115.857 -0.61 . . . . 0.0 112.457 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -122.63 103.63 8.8 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.3 t -80.03 125.24 82.18 Favored Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.387 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.409 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 24.0 Cg_exo -63.95 -76.51 0.02 OUTLIER 'Trans proline' 0 C--N 1.38 2.195 0 C-N-CA 122.539 2.159 . . . . 0.0 112.912 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 . . . . . 0 C--O 1.252 1.21 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -170.385 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.718 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.451 HD11 ' HA ' ' A' ' 70' ' ' ALA . 47.9 mt -84.68 110.04 18.46 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.153 0.981 . . . . 0.0 110.752 -178.133 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.8 p -90.8 111.13 22.39 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 123.36 0.664 . . . . 0.0 111.952 -174.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -108.61 114.77 28.86 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 123.858 0.863 . . . . 0.0 109.998 177.399 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 11.5 m-70 -82.93 136.2 34.65 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 123.052 0.541 . . . . 0.0 109.782 178.29 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.571 HG22 ' HA ' ' A' ' 84' ' ' PRO . 85.2 t -139.83 97.14 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 172.092 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.79 -6.25 43.53 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -175.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -88.69 -19.37 26.23 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.343 0.657 . . . . 0.0 110.732 176.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.563 ' SD ' HG23 ' A' ' 40' ' ' ILE . 53.8 ttp -68.33 97.33 0.73 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 122.996 0.518 . . . . 0.0 109.811 178.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 25.9 p -82.44 94.05 7.35 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 179.212 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.41 ' SG ' ' HB3' ' A' ' 57' ' ' PRO . 58.6 m 41.5 -139.29 0.13 Allowed 'General case' 0 CA--C 1.568 1.642 0 C-N-CA 125.831 1.652 . . . . 0.0 113.213 173.357 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.52 -22.23 65.56 Favored Glycine 0 C--N 1.362 1.994 0 N-CA-C 114.638 0.615 . . . . 0.0 114.638 -178.678 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 30.0 t-80 -59.09 -35.95 74.3 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 123.614 0.766 . . . . 0.0 111.937 178.459 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 62.4 m -112.51 -14.51 13.21 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 122.894 0.478 . . . . 0.0 111.755 -178.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -60.5 -41.86 95.19 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -172.17 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.05 -48.55 82.52 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 113.806 0.283 . . . . 0.0 113.806 -174.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.3 p -75.58 -39.71 40.29 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.143 0 C-N-CA 123.557 0.743 . . . . 0.0 112.108 -177.36 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.563 HG23 ' SD ' ' A' ' 31' ' ' MET . 13.5 tt -67.17 -39.31 82.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 122.832 0.453 . . . . 0.0 111.124 -176.165 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.552 ' HB3' HG21 ' A' ' 53' ' ' VAL . 9.2 mtmp? -75.81 -44.32 41.81 Favored 'General case' 0 C--N 1.348 0.526 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.423 176.17 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.22 -30.21 63.94 Favored Glycine 0 C--N 1.357 1.717 0 O-C-N 124.786 1.304 . . . . 0.0 113.678 -175.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.66 -52.08 65.07 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.423 0.689 . . . . 0.0 110.509 172.141 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.539 HG21 HG12 ' A' ' 64' ' ' VAL . 57.8 mt -72.2 -40.55 66.06 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.566 -178.153 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -63.2 -50.45 70.22 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.647 0.779 . . . . 0.0 112.383 -175.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -71.94 -31.34 66.23 Favored 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.079 -174.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 46.7 m -76.07 -42.45 47.38 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.924 0.49 . . . . 0.0 110.37 176.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 41.2 t -125.0 93.06 46.47 Favored Pre-proline 0 N--CA 1.48 1.028 0 C-N-CA 123.77 0.828 . . . . 0.0 109.636 -173.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -68.02 113.29 2.98 Favored 'Trans proline' 0 C--N 1.371 1.762 0 C-N-CA 122.492 2.128 . . . . 0.0 110.113 170.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.18 -9.25 10.27 Favored Glycine 0 C--N 1.344 0.984 0 CA-C-O 119.525 -0.597 . . . . 0.0 113.411 -176.196 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -82.81 105.52 13.89 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 170.053 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.53 101.51 10.77 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 123.392 0.677 . . . . 0.0 109.807 -176.454 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . 0.552 HG21 ' HB3' ' A' ' 41' ' ' LYS . 20.8 m -84.29 135.75 24.19 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 C-N-CA 123.634 0.774 . . . . 0.0 110.969 -171.149 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 76.3 m80 -134.18 94.95 3.32 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.233 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.01 117.08 29.48 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -95.51 124.73 52.17 Favored Pre-proline 0 CA--C 1.543 0.676 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -179.45 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.41 ' HB3' ' SG ' ' A' ' 33' ' ' CYS . 51.6 Cg_exo -57.91 -47.43 20.74 Favored 'Trans proline' 0 C--N 1.373 1.825 0 C-N-CA 122.962 2.442 . . . . 0.0 113.192 177.127 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.3 -53.17 8.6 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 123.168 0.587 . . . . 0.0 111.85 -173.109 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.0 t -80.1 -13.16 59.5 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.864 0.866 . . . . 0.0 111.765 -175.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 25.7 mmt180 65.78 23.57 11.46 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.482 1.113 . . . . 0.0 112.478 174.243 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 40.0 m -109.73 126.61 53.9 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 122.63 0.372 . . . . 0.0 111.77 -169.411 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 45.8 t -98.15 105.47 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 123.955 0.902 . . . . 0.0 108.634 170.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 15.4 t -95.53 119.55 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 123.829 0.852 . . . . 0.0 109.209 179.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . 0.539 HG12 HG21 ' A' ' 44' ' ' ILE . 28.1 m -103.2 109.7 27.66 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 123.571 0.749 . . . . 0.0 110.457 179.277 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -94.22 150.08 19.65 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.399 -177.13 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.2 -25.11 27.18 Favored Glycine 0 C--N 1.343 0.953 0 CA-C-O 120.194 -0.226 . . . . 0.0 112.547 177.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.4 m -103.17 148.81 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 123.991 0.917 . . . . 0.0 109.785 178.303 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.6 t -123.2 1.24 9.11 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 123.366 0.667 . . . . 0.0 111.034 -174.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -102.66 83.68 2.3 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 124.353 1.061 . . . . 0.0 110.341 -174.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.451 ' HA ' HD11 ' A' ' 24' ' ' LEU . . . -64.89 -36.7 85.22 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 114.307 -1.315 . . . . 0.0 112.8 -172.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.466 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -64.93 -44.31 89.93 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.04 0.536 . . . . 0.0 110.797 -177.844 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.414 ' O ' HG13 ' A' ' 76' ' ' ILE . 78.9 m-70 -62.03 -49.45 75.95 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 123.658 0.599 . . . . 0.0 110.925 179.156 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.509 HG23 HG22 ' A' ' 64' ' ' VAL . 42.7 mm -59.77 -40.28 82.09 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 O-C-N 123.875 0.734 . . . . 0.0 110.227 -179.699 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.93 -36.01 82.01 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.737 0.815 . . . . 0.0 111.11 178.361 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.466 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 26.5 mm-40 -69.05 -35.94 77.14 Favored 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 123.294 0.638 . . . . 0.0 111.395 178.053 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . 0.417 HD11 ' HA ' ' A' ' 73' ' ' ILE . 74.7 mt -68.42 -53.05 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 123.464 0.705 . . . . 0.0 110.578 -178.632 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 13.6 tt -66.05 -35.71 75.7 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.984 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.361 -175.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.8 t -75.15 -30.09 60.66 Favored 'General case' 0 N--CA 1.479 0.999 0 C-N-CA 122.471 0.308 . . . . 0.0 110.887 178.295 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.8 -19.73 60.67 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 123.369 0.668 . . . . 0.0 110.945 175.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -78.15 -9.73 59.31 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.745 0.818 . . . . 0.0 111.473 172.627 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 102.47 -11.45 56.66 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-O 119.717 -0.491 . . . . 0.0 112.951 179.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -92.86 105.93 17.98 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.442 0.697 . . . . 0.0 110.192 178.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 90.6 m -68.89 117.39 50.9 Favored Pre-proline 0 CA--C 1.552 1.023 0 C-N-CA 123.142 0.577 . . . . 0.0 109.647 176.135 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.571 ' HA ' HG22 ' A' ' 28' ' ' VAL . 48.0 Cg_endo -67.16 87.48 0.31 Allowed 'Trans proline' 0 C--N 1.382 2.293 0 C-N-CA 122.437 2.091 . . . . 0.0 111.489 174.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.5 tp10 . . . . . 0 C--O 1.249 1.029 0 C-N-CA 124.672 1.189 . . . . 0.0 108.697 179.181 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.128 0 CA-C-O 120.95 0.405 . . . . 0.0 110.767 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -141.95 107.31 0.49 Allowed Glycine 0 C--N 1.34 0.777 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 177.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.428 HD12 ' HB3' ' A' ' 70' ' ' ALA . 4.3 mm? -79.4 164.29 24.12 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.324 0.65 . . . . 0.0 111.023 -176.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 29.5 p -152.47 110.67 3.69 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 123.803 0.841 . . . . 0.0 108.82 178.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -110.35 116.44 31.45 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 123.702 0.801 . . . . 0.0 109.357 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 26.4 p80 -82.11 90.69 6.57 Favored 'General case' 0 CA--C 1.552 1.056 0 CA-C-O 122.615 1.198 . . . . 0.0 110.384 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.431 HG23 HD12 ' A' ' 77' ' ' ILE . 39.7 t -84.21 87.37 2.26 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 172.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.13 -5.67 43.12 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-N 115.646 -0.707 . . . . 0.0 112.758 -173.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -86.55 -22.11 26.51 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.35 0.66 . . . . 0.0 110.672 173.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.625 ' SD ' ' HB3' ' A' ' 55' ' ' ALA . 50.4 ttp -65.09 109.19 2.08 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 123.489 0.716 . . . . 0.0 111.453 -174.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 25.5 p -117.52 128.3 54.83 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.106 0.962 . . . . 0.0 109.434 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.406 ' SG ' ' HB2' ' A' ' 35' ' ' HIS . 8.8 p 65.68 159.36 0.12 Allowed 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 126.034 1.733 . . . . 0.0 113.718 176.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.505 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -67.44 -9.08 54.2 Favored Glycine 0 C--N 1.353 1.481 0 CA-C-N 115.104 -0.953 . . . . 0.0 114.306 -178.65 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . 0.406 ' HB2' ' SG ' ' A' ' 33' ' ' CYS . 29.4 m170 -71.15 -44.43 65.55 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 117.482 0.641 . . . . 0.0 110.216 173.165 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 59.0 m -83.82 -32.47 25.28 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.234 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.505 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -70.05 -34.77 73.66 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.009 176.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.04 -44.96 96.55 Favored Glycine 0 C--N 1.347 1.192 0 O-C-N 124.039 0.837 . . . . 0.0 113.472 -176.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.5 p -68.16 -30.03 46.53 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.064 0 C-N-CA 122.698 0.399 . . . . 0.0 111.384 -178.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.567 HD11 ' SD ' ' A' ' 31' ' ' MET . 66.4 mt -66.39 -47.79 82.9 Favored 'Isoleucine or valine' 0 C--N 1.356 0.864 0 C-N-CA 123.149 0.58 . . . . 0.0 110.013 175.086 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 60.5 mtpt -57.43 -48.17 79.83 Favored 'General case' 0 C--N 1.349 0.566 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.224 178.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.93 -34.06 87.45 Favored Glycine 0 C--N 1.346 1.106 0 O-C-N 124.246 0.966 . . . . 0.0 112.966 -178.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.44 -54.76 35.37 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.072 0.549 . . . . 0.0 110.849 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.534 HG21 HG11 ' A' ' 64' ' ' VAL . 58.3 mt -72.45 -43.7 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 CA-C-N 115.672 -0.694 . . . . 0.0 112.127 -176.003 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -64.79 -38.02 89.58 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 124.219 1.008 . . . . 0.0 112.67 -174.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -76.03 -37.02 58.86 Favored 'General case' 0 N--CA 1.481 1.114 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.212 -179.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 42.7 m -71.12 -40.15 71.6 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 123.011 0.524 . . . . 0.0 110.63 177.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 48.2 t -121.39 94.54 48.64 Favored Pre-proline 0 N--CA 1.48 1.051 0 C-N-CA 123.58 0.752 . . . . 0.0 109.931 -177.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -62.25 104.29 0.34 Allowed 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.563 2.175 . . . . 0.0 111.174 169.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.56 -0.15 11.18 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-O 119.593 -0.559 . . . . 0.0 113.291 -177.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -83.96 108.71 17.1 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 169.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.426 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -78.49 95.97 5.29 Favored 'General case' 0 C--N 1.348 0.543 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 -178.679 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.498 HG11 HG13 ' A' ' 64' ' ' VAL . 27.7 m -88.95 131.49 36.15 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.754 0 C-N-CA 123.701 0.8 . . . . 0.0 111.027 -171.118 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 3.5 t-160 -143.22 99.92 3.53 Favored 'General case' 0 C--N 1.346 0.421 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 167.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.625 ' HB3' ' SD ' ' A' ' 31' ' ' MET . . . -92.51 113.75 26.11 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 172.079 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -106.9 120.49 47.95 Favored Pre-proline 0 N--CA 1.467 0.394 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -172.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -63.11 -35.31 65.44 Favored 'Trans proline' 0 C--N 1.37 1.698 0 C-N-CA 122.73 2.287 . . . . 0.0 113.493 -179.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.52 -35.2 46.62 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 123.272 0.629 . . . . 0.0 112.148 -174.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.2 t -91.43 -19.61 22.67 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 123.18 0.592 . . . . 0.0 110.225 178.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.1 mpt_? 60.79 33.82 19.96 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 125.034 1.334 . . . . 0.0 110.824 -177.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 27.3 m -124.69 131.52 53.46 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 122.677 0.391 . . . . 0.0 110.683 -170.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.556 HG23 HG22 ' A' ' 40' ' ' ILE . 44.0 t -105.87 105.57 18.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 173.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 34.3 m -99.71 136.12 32.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.284 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.534 HG11 HG21 ' A' ' 44' ' ' ILE . 17.3 m -131.0 109.36 16.45 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.909 0 C-N-CA 123.399 0.68 . . . . 0.0 109.434 179.22 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -92.79 157.74 23.76 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.474 -176.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.21 0.43 89.53 Favored Glycine 0 C--N 1.345 1.049 0 CA-C-O 119.932 -0.371 . . . . 0.0 114.023 177.176 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.4 m -124.14 144.7 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.625 0.77 . . . . 0.0 110.147 -176.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 14.9 m -108.86 -17.71 13.87 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.599 0.759 . . . . 0.0 110.225 176.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.423 ' O ' HG12 ' A' ' 73' ' ' ILE . 6.5 m-20 -78.77 76.54 5.26 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.347 1.059 . . . . 0.0 111.035 -172.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.428 ' HB3' HD12 ' A' ' 24' ' ' LEU . . . -60.59 -41.5 94.83 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.108 0.963 . . . . 0.0 111.602 -179.635 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -65.54 -41.47 92.99 Favored 'General case' 0 N--CA 1.471 0.581 0 O-C-N 124.206 0.942 . . . . 0.0 111.044 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.419 ' O ' HG13 ' A' ' 76' ' ' ILE . 77.8 t60 -63.28 -50.69 69.12 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.501 0.72 . . . . 0.0 110.741 178.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.5 HG21 HG21 ' A' ' 64' ' ' VAL . 40.7 mm -58.57 -42.3 84.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 O-C-N 123.826 0.704 . . . . 0.0 110.142 179.411 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.61 -37.97 80.04 Favored 'General case' 0 N--CA 1.476 0.836 0 O-C-N 124.329 1.018 . . . . 0.0 111.648 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 12.3 mm-40 -64.67 -40.14 94.91 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.479 0.712 . . . . 0.0 111.166 177.516 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.509 HG23 ' HA ' ' A' ' 44' ' ' ILE . 33.9 mt -67.19 -51.54 52.36 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 C-N-CA 123.149 0.58 . . . . 0.0 111.356 -177.144 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.431 HD12 HG23 ' A' ' 28' ' ' VAL . 8.3 tt -71.08 -29.88 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.234 0 C-N-CA 123.379 0.671 . . . . 0.0 111.836 -176.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.452 ' HA ' ' O ' ' A' ' 82' ' ' TYR . 2.9 t -75.25 -28.9 60.03 Favored 'General case' 0 N--CA 1.48 1.054 0 N-CA-C 110.364 -0.236 . . . . 0.0 110.364 175.079 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.32 -26.17 66.38 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.355 0.662 . . . . 0.0 110.644 172.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -76.76 -8.72 57.84 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 123.377 0.671 . . . . 0.0 111.455 173.323 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.3 25.05 24.95 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 116.561 -0.291 . . . . 0.0 113.208 176.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.452 ' O ' ' HA ' ' A' ' 78' ' ' THR . 95.9 m-85 -120.43 155.06 34.27 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.526 0.73 . . . . 0.0 110.236 179.379 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 73.1 p -89.79 111.14 44.48 Favored Pre-proline 0 CA--C 1.553 1.086 0 C-N-CA 123.271 0.628 . . . . 0.0 110.415 -176.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -78.89 79.5 3.36 Favored 'Trans proline' 0 C--N 1.377 2.043 0 C-N-CA 122.906 2.404 . . . . 0.0 111.878 178.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 35.0 mm-40 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.794 -0.622 . . . . 0.0 109.844 -176.661 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.105 0 N-CA-C 110.389 -0.226 . . . . 0.0 110.389 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.72 -156.1 24.59 Favored Glycine 0 C--N 1.348 1.22 0 O-C-N 123.716 0.635 . . . . 0.0 111.706 173.259 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -82.34 109.61 16.75 Favored 'General case' 0 CA--C 1.548 0.895 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.7 m -92.51 118.6 31.14 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 123.79 0.836 . . . . 0.0 110.748 -172.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -106.29 110.76 23.1 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.781 0.832 . . . . 0.0 109.939 178.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 50.2 m80 -81.82 94.38 7.04 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 177.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.48 ' O ' ' HB3' ' A' ' 60' ' ' ARG . 20.0 t -93.51 94.38 4.61 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.798 0 C-N-CA 124.356 1.062 . . . . 0.0 108.397 178.451 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -71.68 -12.72 61.47 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -175.003 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -85.5 -19.0 31.86 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 123.812 0.845 . . . . 0.0 110.951 174.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 25.2 ttt -55.33 128.64 35.11 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 124.334 1.054 . . . . 0.0 112.266 -175.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.3 p -88.47 162.18 16.61 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 124.438 1.095 . . . . 0.0 110.087 172.595 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 57.3 m -66.56 -162.75 0.02 OUTLIER 'General case' 0 CA--C 1.564 1.505 0 C-N-CA 124.986 1.314 . . . . 0.0 114.035 -169.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -56.69 -22.73 41.18 Favored Glycine 0 C--N 1.364 2.094 0 N-CA-C 115.722 1.049 . . . . 0.0 115.722 -171.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 48.9 t-80 -64.63 -28.77 69.84 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.777 0.831 . . . . 0.0 111.882 177.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 61.3 m -119.2 19.26 12.9 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.985 0.914 . . . . 0.0 111.26 179.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.37 -34.36 70.37 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 122.583 0.353 . . . . 0.0 111.047 177.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.08 -35.93 91.23 Favored Glycine 0 C--N 1.349 1.279 0 O-C-N 123.929 0.768 . . . . 0.0 114.779 -173.295 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.84 -38.71 76.48 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 123.102 0.561 . . . . 0.0 111.025 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 35.3 mt -73.09 -42.36 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.454 0.702 . . . . 0.0 110.242 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -55.5 -54.08 48.32 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.121 171.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.05 -30.56 78.11 Favored Glycine 0 C--N 1.345 1.032 0 O-C-N 124.788 1.305 . . . . 0.0 113.767 -172.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.6 -56.69 18.85 Favored 'General case' 0 C--N 1.352 0.7 0 C-N-CA 122.899 0.479 . . . . 0.0 110.629 178.059 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.521 ' HA ' HG22 ' A' ' 76' ' ' ILE . 57.7 mt -76.03 -42.35 38.65 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.693 -174.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -62.29 -48.28 80.57 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.1 0.96 . . . . 0.0 112.255 -173.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -73.4 -25.69 60.65 Favored 'General case' 0 N--CA 1.48 1.075 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.43 -176.118 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 43.0 m -80.63 -41.84 23.18 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 123.022 0.529 . . . . 0.0 110.576 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.9 t -123.3 94.84 46.3 Favored Pre-proline 0 N--CA 1.479 1.01 0 C-N-CA 123.584 0.754 . . . . 0.0 109.378 -178.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -67.07 118.4 5.54 Favored 'Trans proline' 0 C--N 1.373 1.863 0 C-N-CA 122.579 2.186 . . . . 0.0 110.899 172.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.82 -25.48 7.17 Favored Glycine 0 C--N 1.347 1.141 0 CA-C-O 119.795 -0.447 . . . . 0.0 112.511 -174.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -73.81 106.17 5.42 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 174.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -79.8 99.91 7.72 Favored 'General case' 0 C--N 1.346 0.45 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -177.093 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.431 HG11 HG12 ' A' ' 64' ' ' VAL . 16.6 m -86.51 111.86 22.02 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.937 0 CA-C-O 121.539 0.685 . . . . 0.0 111.156 -169.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 64.9 t60 -109.22 99.24 8.54 Favored 'General case' 0 C--N 1.344 0.348 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.77 115.44 22.22 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 175.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -106.88 102.72 43.99 Favored Pre-proline 0 N--CA 1.474 0.739 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -56.26 -39.81 88.84 Favored 'Trans proline' 0 C--N 1.373 1.837 0 C-N-CA 123.084 2.522 . . . . 0.0 113.746 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.44 -44.62 64.49 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 123.383 0.673 . . . . 0.0 111.978 -171.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 21.1 t -95.39 -9.94 31.38 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.855 0.862 . . . . 0.0 110.606 -178.404 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.48 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 60.59 41.5 15.34 Favored 'General case' 0 N--CA 1.484 1.266 0 C-N-CA 125.266 1.426 . . . . 0.0 110.165 -179.319 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.5 m -123.13 120.44 33.25 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.642 0.377 . . . . 0.0 111.285 -167.368 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.6 t -98.97 105.38 17.29 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 175.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.2 t -102.5 118.79 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 -175.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.502 HG13 HG23 ' A' ' 44' ' ' ILE . 17.1 m -103.86 108.94 25.74 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.068 0 CA-C-O 121.581 0.705 . . . . 0.0 110.707 -178.136 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -85.59 149.38 23.49 Favored Glycine 0 C--N 1.35 1.312 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.412 -179.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.69 -26.03 13.91 Favored Glycine 0 N--CA 1.472 1.066 0 C-N-CA 122.955 0.312 . . . . 0.0 112.417 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 34.6 m -122.19 142.99 36.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 124.368 1.067 . . . . 0.0 109.705 -177.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 69.1 m -124.53 -0.52 8.12 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 123.518 0.727 . . . . 0.0 111.427 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 15.3 p-10 -78.42 83.94 4.61 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-O 122.603 1.192 . . . . 0.0 110.505 -178.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.37 -41.26 96.8 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 113.54 -1.664 . . . . 0.0 113.217 -170.483 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -63.02 -44.43 96.0 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.81 0.844 . . . . 0.0 111.648 -174.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.416 ' O ' HG13 ' A' ' 76' ' ' ILE . 32.1 m170 -66.25 -47.52 73.47 Favored 'General case' 0 N--CA 1.475 0.78 0 O-C-N 123.521 0.513 . . . . 0.0 110.896 179.315 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 29.3 mm -58.93 -39.2 77.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 123.795 0.684 . . . . 0.0 110.344 178.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.71 -38.21 89.52 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 124.156 0.982 . . . . 0.0 111.336 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -63.97 -39.37 93.98 Favored 'General case' 0 N--CA 1.482 1.169 0 O-C-N 123.619 0.574 . . . . 0.0 111.116 176.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.521 HG22 ' HA ' ' A' ' 44' ' ' ILE . 57.4 mt -68.15 -51.33 49.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 123.42 0.688 . . . . 0.0 111.268 -175.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 10.9 tt -68.63 -36.14 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.447 -175.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.0 t -71.97 -27.5 62.81 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 122.663 0.385 . . . . 0.0 110.311 177.501 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.46 -29.85 70.07 Favored 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 123.562 0.745 . . . . 0.0 111.401 174.407 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -78.03 -3.12 40.53 Favored 'General case' 0 N--CA 1.48 1.056 0 C-N-CA 123.432 0.693 . . . . 0.0 111.606 173.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.67 -9.54 60.46 Favored Glycine 0 C--N 1.343 0.969 0 CA-C-O 119.716 -0.491 . . . . 0.0 113.159 176.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -96.53 103.2 15.09 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 117.442 0.621 . . . . 0.0 109.722 -179.054 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 33.5 p -78.95 112.82 30.49 Favored Pre-proline 0 CA--C 1.553 1.063 0 C-N-CA 124.415 1.086 . . . . 0.0 109.87 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -76.77 -2.06 12.25 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 122.751 2.3 . . . . 0.0 113.421 179.199 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 . . . . . 0 C--O 1.256 1.396 0 C-N-CA 124.034 0.934 . . . . 0.0 109.933 175.14 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.99 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.81 147.91 9.21 Favored Glycine 0 C--N 1.35 1.316 0 O-C-N 123.106 0.254 . . . . 0.0 113.159 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 67.6 mt -99.56 107.1 19.18 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.597 0.759 . . . . 0.0 109.615 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 30.1 p -92.05 110.81 22.18 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.046 0.538 . . . . 0.0 110.6 -177.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -104.21 105.03 15.04 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 123.353 0.661 . . . . 0.0 109.375 176.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 27.8 t60 -81.66 94.21 6.91 Favored 'General case' 0 CA--C 1.538 0.494 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.284 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.543 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 32.8 t -88.62 102.39 12.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.709 0 CA-C-N 114.964 -1.016 . . . . 0.0 108.618 -179.502 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -70.82 -22.76 62.3 Favored 'General case' 0 N--CA 1.485 1.322 0 CA-C-O 121.105 0.479 . . . . 0.0 110.923 177.774 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -75.62 -13.93 60.36 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.29 1.036 . . . . 0.0 111.244 175.292 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.543 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 27.5 ttt -58.99 122.07 12.79 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 123.371 0.669 . . . . 0.0 112.145 -173.359 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 14.8 t -85.31 163.48 18.57 Favored 'General case' 0 CA--C 1.549 0.908 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.884 173.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.509 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 28.7 p -66.41 -177.02 0.5 Allowed 'General case' 0 CA--C 1.554 1.12 0 C-N-CA 123.769 0.827 . . . . 0.0 113.015 -175.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.48 ' HA2' ' HB1' ' A' ' 37' ' ' ALA . . . -56.79 -15.38 12.54 Favored Glycine 0 C--N 1.357 1.734 0 N-CA-C 116.247 1.259 . . . . 0.0 116.247 -169.061 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -57.68 -42.99 84.76 Favored 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 117.61 0.705 . . . . 0.0 111.308 177.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 47.7 t -124.9 0.53 8.0 Favored 'General case' 0 CA--C 1.548 0.901 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.421 -177.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.48 ' HB1' ' HA2' ' A' ' 34' ' ' GLY . . . -64.64 -30.91 71.94 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 122.709 0.404 . . . . 0.0 110.624 173.189 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.53 -30.92 77.27 Favored Glycine 0 C--N 1.352 1.431 0 CA-C-N 115.794 -0.639 . . . . 0.0 113.265 174.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 42.8 t -69.13 -41.02 81.28 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 174.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 71.1 mt -58.26 -41.12 80.25 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.925 0 C-N-CA 124.078 0.951 . . . . 0.0 110.684 175.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.443 ' HB3' HG21 ' A' ' 53' ' ' VAL . 98.9 mttt -60.89 -58.92 6.42 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.572 0.749 . . . . 0.0 110.162 177.203 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.99 -30.6 70.38 Favored Glycine 0 C--N 1.351 1.372 0 O-C-N 124.68 1.238 . . . . 0.0 113.774 -173.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.59 -53.23 60.72 Favored 'General case' 0 C--N 1.35 0.62 0 C-N-CA 123.577 0.751 . . . . 0.0 110.557 176.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.545 HG22 HG12 ' A' ' 64' ' ' VAL . 72.8 mt -69.41 -46.64 76.02 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-N 114.847 -1.07 . . . . 0.0 112.465 -177.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -61.46 -46.24 90.89 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 123.504 0.722 . . . . 0.0 112.712 -175.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 12.8 mptt -83.52 -14.63 51.86 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.575 -171.102 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.5 m -87.4 -49.97 6.87 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 171.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 54.2 t -113.74 96.79 42.19 Favored Pre-proline 0 N--CA 1.475 0.821 0 C-N-CA 124.372 1.069 . . . . 0.0 108.959 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -66.14 140.09 58.11 Favored 'Trans proline' 0 C--N 1.376 1.987 0 C-N-CA 122.458 2.105 . . . . 0.0 111.271 176.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.54 -10.73 68.92 Favored Glycine 0 C--N 1.34 0.773 0 CA-C-O 119.571 -0.572 . . . . 0.0 112.938 -177.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -72.25 106.02 4.26 Favored 'General case' 0 C--N 1.355 0.828 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 174.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -83.83 99.92 10.63 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.56 HG12 HG11 ' A' ' 64' ' ' VAL . 26.9 m -85.31 135.82 24.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.541 0 CA-C-O 121.197 0.522 . . . . 0.0 110.763 -172.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 18.1 t-80 -126.19 95.55 4.42 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 167.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.51 112.88 24.77 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 177.662 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.442 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 9.6 t70 -112.43 108.38 54.55 Favored Pre-proline 0 CA--C 1.533 0.298 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 -175.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.509 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 71.4 Cg_exo -52.87 -35.73 71.51 Favored 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 123.223 2.615 . . . . 0.0 114.169 178.23 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.53 -31.3 47.47 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 123.061 0.544 . . . . 0.0 112.141 -177.088 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.442 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 19.5 m -91.31 -20.31 22.01 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 122.81 0.444 . . . . 0.0 111.039 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.4 mpt_? 57.88 46.09 17.35 Favored 'General case' 0 N--CA 1.483 1.188 0 C-N-CA 124.477 1.111 . . . . 0.0 110.033 -177.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.8 m -142.26 129.94 21.54 Favored 'General case' 0 C--N 1.351 0.657 0 C-N-CA 123.04 0.536 . . . . 0.0 110.735 -173.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 18.8 t -108.69 106.51 20.83 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 124.068 0.947 . . . . 0.0 108.858 174.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 25.9 t -97.97 118.68 44.89 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 123.76 0.824 . . . . 0.0 109.464 -179.687 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.56 HG11 HG12 ' A' ' 53' ' ' VAL . 35.9 m -106.89 114.61 46.44 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.014 0 CA-C-O 121.5 0.667 . . . . 0.0 110.912 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -97.17 161.29 21.57 Favored Glycine 0 C--N 1.345 1.066 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.278 -178.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 81.27 -4.79 70.2 Favored Glycine 0 N--CA 1.476 1.315 0 N-CA-C 114.149 0.419 . . . . 0.0 114.149 178.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.19 152.81 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 123.851 0.861 . . . . 0.0 110.141 -177.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.1 t -125.66 19.79 7.92 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 123.742 0.817 . . . . 0.0 109.79 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.451 ' O ' HG12 ' A' ' 73' ' ' ILE . 3.3 m-20 -96.24 66.86 2.51 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 123.564 0.745 . . . . 0.0 109.41 -177.301 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.0 -46.06 89.47 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 123.178 0.591 . . . . 0.0 112.196 -171.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.14 -42.23 99.04 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 123.78 0.675 . . . . 0.0 110.518 179.059 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.462 ' O ' HG13 ' A' ' 76' ' ' ILE . 11.8 m170 -66.15 -45.0 82.51 Favored 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.315 -176.616 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.474 HG13 HG23 ' A' ' 64' ' ' VAL . 47.8 mm -61.03 -40.81 86.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 C-N-CA 123.323 0.649 . . . . 0.0 110.561 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.25 -37.41 87.13 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 123.606 0.762 . . . . 0.0 111.23 179.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -67.03 -34.5 77.84 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 123.386 0.674 . . . . 0.0 111.557 176.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.462 HG13 ' O ' ' A' ' 72' ' ' HIS . 72.9 mt -68.79 -53.99 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 C-N-CA 123.311 0.645 . . . . 0.0 111.211 -178.34 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.0 tt -63.71 -36.25 75.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.955 -175.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 t -74.27 -29.49 61.69 Favored 'General case' 0 CA--C 1.551 1.013 0 C-N-CA 122.013 0.125 . . . . 0.0 110.93 177.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.09 -22.53 61.34 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 123.204 0.602 . . . . 0.0 110.892 174.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -79.95 -8.73 59.5 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 123.499 0.719 . . . . 0.0 111.209 172.119 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 97.38 22.85 15.63 Favored Glycine 0 C--N 1.351 1.388 0 CA-C-N 116.104 -0.498 . . . . 0.0 113.055 175.257 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -127.61 105.97 8.84 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 24.0 p -75.77 116.09 52.09 Favored Pre-proline 0 CA--C 1.55 0.959 0 C-N-CA 122.835 0.454 . . . . 0.0 110.809 -174.233 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.458 ' HA ' HG11 ' A' ' 28' ' ' VAL . 76.5 Cg_endo -78.09 -8.81 16.6 Favored 'Trans proline' 0 C--N 1.382 2.302 0 C-N-CA 123.143 2.562 . . . . 0.0 112.985 -176.794 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 . . . . . 0 C--O 1.25 1.102 0 C-N-CA 124.281 1.032 . . . . 0.0 108.957 -175.896 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.941 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.82 164.1 48.28 Favored Glycine 0 C--N 1.345 1.073 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 169.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.488 HD12 ' HA ' ' A' ' 70' ' ' ALA . 34.9 mt -80.15 107.23 12.78 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -174.791 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.2 m -102.63 130.09 49.41 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.19 0.596 . . . . 0.0 109.81 -172.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -128.4 114.53 16.94 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.68 0.792 . . . . 0.0 110.514 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 47.0 m80 -81.63 111.86 18.3 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 171.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.7 t -107.9 100.63 11.13 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -176.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -69.06 -23.15 64.0 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.428 0.691 . . . . 0.0 110.927 175.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -74.3 -19.47 60.47 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.421 0.688 . . . . 0.0 110.625 177.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.486 ' HG3' ' HB2' ' A' ' 36' ' ' CYS . 20.4 ttt -82.67 133.82 35.16 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.215 1.006 . . . . 0.0 110.15 176.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 28.0 p -117.83 95.0 4.73 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 170.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.615 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 58.0 m 46.01 -142.69 0.31 Allowed 'General case' 0 CA--C 1.568 1.658 0 C-N-CA 125.017 1.327 . . . . 0.0 114.19 168.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.61 -24.48 64.16 Favored Glycine 0 C--N 1.362 2.019 0 C-N-CA 123.705 0.669 . . . . 0.0 114.292 -179.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -56.47 -37.94 71.02 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 123.28 0.632 . . . . 0.0 111.668 175.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.486 ' HB2' ' HG3' ' A' ' 31' ' ' MET . 80.9 m -104.11 -19.1 14.28 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 122.943 0.497 . . . . 0.0 111.571 -178.333 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -56.05 -42.72 77.03 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -173.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -61.76 -50.83 62.05 Favored Glycine 0 CA--C 1.535 1.286 0 O-C-N 123.31 0.381 . . . . 0.0 113.587 -177.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m -75.28 -34.24 30.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 C-N-CA 123.365 0.666 . . . . 0.0 112.161 -177.365 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 9.6 tt -74.84 -34.96 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 C-N-CA 123.11 0.564 . . . . 0.0 110.721 -174.387 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -71.81 -47.64 51.86 Favored 'General case' 0 C--N 1.351 0.659 0 C-N-CA 123.604 0.762 . . . . 0.0 109.657 173.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.44 -30.03 75.11 Favored Glycine 0 C--N 1.349 1.301 0 O-C-N 124.35 1.031 . . . . 0.0 113.359 -179.039 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.89 -54.65 43.64 Favored 'General case' 0 C--N 1.348 0.505 0 C-N-CA 123.386 0.674 . . . . 0.0 110.239 177.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.607 HG23 HG13 ' A' ' 64' ' ' VAL . 48.0 mt -74.03 -46.17 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.529 -175.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -59.97 -51.85 67.9 Favored 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.18 0.992 . . . . 0.0 112.371 -173.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.7 mptp? -75.95 -13.83 60.24 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 122.458 0.303 . . . . 0.0 111.721 -175.167 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 86.4 m -89.02 -39.27 13.8 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 123.117 0.567 . . . . 0.0 110.252 175.321 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 97.4 t -124.73 89.65 52.08 Favored Pre-proline 0 N--CA 1.479 0.977 0 C-N-CA 123.951 0.901 . . . . 0.0 109.022 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -60.17 113.44 1.67 Allowed 'Trans proline' 0 C--N 1.376 2.011 0 C-N-CA 122.845 2.364 . . . . 0.0 111.14 171.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.76 -14.85 9.1 Favored Glycine 0 C--N 1.342 0.87 0 CA-C-O 119.633 -0.537 . . . . 0.0 113.012 -176.274 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.79 106.8 9.86 Favored 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 173.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.476 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -76.27 99.54 4.8 Favored 'General case' 0 C--N 1.349 0.586 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.415 HG13 HG12 ' A' ' 64' ' ' VAL . 16.8 m -86.33 131.71 33.98 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 C-N-CA 123.29 0.636 . . . . 0.0 111.043 -172.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 43.9 t-80 -136.55 99.42 4.07 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 174.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.47 ' HB2' ' HE3' ' A' ' 31' ' ' MET . . . -96.72 114.34 25.97 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 174.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -94.06 120.95 65.08 Favored Pre-proline 0 N--CA 1.471 0.589 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -174.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.615 ' HA ' ' HA ' ' A' ' 33' ' ' CYS . 51.1 Cg_exo -57.54 -38.25 94.47 Favored 'Trans proline' 0 C--N 1.374 1.907 0 C-N-CA 123.103 2.536 . . . . 0.0 114.417 177.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.72 -35.38 52.05 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.032 0.533 . . . . 0.0 111.62 -174.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 16.5 m -97.69 -20.94 17.29 Favored 'General case' 0 N--CA 1.482 1.151 0 C-N-CA 123.564 0.746 . . . . 0.0 111.718 -175.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.9 mpt_? 56.91 32.63 21.83 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 125.108 1.363 . . . . 0.0 110.947 -171.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.9 m -110.35 118.98 37.77 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 123.377 0.671 . . . . 0.0 110.055 -172.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 20.9 t -101.49 107.24 21.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 177.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 21.9 t -105.5 135.3 44.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 123.785 0.834 . . . . 0.0 108.754 -179.044 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.607 HG13 HG23 ' A' ' 44' ' ' ILE . 18.8 m -121.7 123.0 68.42 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 C-N-CA 123.196 0.598 . . . . 0.0 110.404 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -99.74 156.74 19.76 Favored Glycine 0 C--N 1.347 1.165 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.095 -179.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.5 -18.2 43.89 Favored Glycine 0 N--CA 1.474 1.225 0 C-N-CA 123.121 0.391 . . . . 0.0 113.451 177.478 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.8 m -115.68 146.86 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 124.092 0.957 . . . . 0.0 109.741 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 69.8 m -116.54 -20.47 9.61 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.722 0.809 . . . . 0.0 112.439 -175.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -75.95 86.3 2.88 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 122.776 0.43 . . . . 0.0 110.481 178.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.488 ' HA ' HD12 ' A' ' 24' ' ' LEU . . . -62.98 -29.01 70.49 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.431 0.692 . . . . 0.0 111.116 175.718 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.3 -51.38 67.89 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 124.402 1.081 . . . . 0.0 111.117 177.058 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.422 ' O ' HG13 ' A' ' 76' ' ' ILE . 28.2 m-70 -63.09 -48.01 80.43 Favored 'General case' 0 N--CA 1.482 1.155 0 O-C-N 123.592 0.558 . . . . 0.0 110.838 -178.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.437 HG23 HG23 ' A' ' 64' ' ' VAL . 49.5 mm -61.22 -40.62 86.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 124.068 0.855 . . . . 0.0 110.436 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.73 -39.69 92.46 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 123.95 0.781 . . . . 0.0 111.333 179.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.9 mm-40 -62.59 -39.5 93.91 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.491 0.716 . . . . 0.0 111.206 178.089 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.52 HG21 ' HA ' ' A' ' 44' ' ' ILE . 53.8 mt -68.02 -53.86 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 O-C-N 123.747 0.654 . . . . 0.0 110.959 -179.16 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 15.9 tt -70.28 -29.15 38.12 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.71 -173.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.5 t -76.07 -31.69 58.89 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 110.156 -0.312 . . . . 0.0 110.156 175.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.69 -21.43 64.42 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 123.671 0.788 . . . . 0.0 111.64 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -74.24 -3.69 31.48 Favored 'General case' 0 CA--C 1.555 1.15 0 C-N-CA 123.538 0.735 . . . . 0.0 112.189 176.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 101.77 23.11 9.56 Favored Glycine 0 C--N 1.351 1.4 0 C-N-CA 123.065 0.364 . . . . 0.0 112.885 178.368 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -119.3 175.83 5.62 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.992 0.917 . . . . 0.0 109.02 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 96.0 m -148.43 83.8 6.91 Favored Pre-proline 0 N--CA 1.479 0.994 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 171.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_exo -70.79 -67.31 0.03 OUTLIER 'Trans proline' 0 C--N 1.369 1.646 0 C-N-CA 122.449 2.1 . . . . 0.0 112.487 177.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 . . . . . 0 C--O 1.257 1.451 0 C-N-CA 125.154 1.382 . . . . 0.0 110.926 -171.787 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.921 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 163.8 166.3 22.43 Favored Glycine 0 C--N 1.341 0.812 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 -179.379 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.411 HD12 ' HA ' ' A' ' 70' ' ' ALA . 34.1 mt -88.99 108.21 19.46 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.4 p -92.38 111.32 22.85 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 122.883 0.473 . . . . 0.0 110.555 -177.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -106.19 124.81 50.17 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 123.88 0.872 . . . . 0.0 109.746 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 32.3 m-70 -84.05 136.81 33.88 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 175.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 p -157.34 97.05 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.978 0 C-N-CA 124.066 0.946 . . . . 0.0 109.049 -176.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -69.8 -29.4 66.69 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.418 -176.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -74.4 -9.85 59.0 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.164 0.586 . . . . 0.0 112.018 -178.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.592 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 56.1 ttp -72.62 113.08 9.26 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 120.93 0.395 . . . . 0.0 110.557 177.132 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 63.2 p -77.51 166.34 23.2 Favored 'General case' 0 CA--C 1.549 0.917 0 C-N-CA 124.013 0.925 . . . . 0.0 109.923 168.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 28.0 p -57.11 -169.73 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 124.089 0.956 . . . . 0.0 112.647 175.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.69 3.45 0.63 Allowed Glycine 0 C--N 1.357 1.721 0 N-CA-C 115.916 1.127 . . . . 0.0 115.916 -174.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -63.27 -44.74 94.25 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.743 0.817 . . . . 0.0 110.844 166.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 43.5 t -141.42 9.56 2.05 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 123.136 0.575 . . . . 0.0 111.996 -176.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.58 -30.95 69.83 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 122.836 0.454 . . . . 0.0 110.754 173.191 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.53 -20.87 53.09 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 114.996 -1.002 . . . . 0.0 114.256 176.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.485 HG13 ' HB2' ' A' ' 80' ' ' ALA . 57.9 t -65.41 -44.32 94.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 122.871 0.468 . . . . 0.0 110.138 174.233 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.676 HG22 HG22 ' A' ' 62' ' ' VAL . 44.1 mt -69.61 -54.44 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 C-N-CA 123.3 0.64 . . . . 0.0 110.661 175.431 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.51 ' HB3' ' HZ1' ' A' ' 41' ' ' LYS . 9.7 mtpm? -56.68 -51.83 67.28 Favored 'General case' 0 C--N 1.348 0.507 0 O-C-N 124.517 1.136 . . . . 0.0 110.269 -174.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.467 ' O ' ' HD3' ' A' ' 46' ' ' LYS . . . -61.94 -40.16 98.5 Favored Glycine 0 C--N 1.343 0.917 0 O-C-N 124.963 1.414 . . . . 0.0 112.867 178.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.74 -53.5 57.05 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 117.129 0.464 . . . . 0.0 111.001 179.138 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.55 HG21 HG12 ' A' ' 64' ' ' VAL . 68.4 mt -62.08 -39.93 85.6 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.967 -179.174 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.432 ' HG3' ' O ' ' A' ' 41' ' ' LYS . 76.9 mt-10 -62.02 -50.46 71.94 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 123.171 0.588 . . . . 0.0 112.068 179.623 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.467 ' HD3' ' O ' ' A' ' 42' ' ' GLY . 13.3 mptt -73.03 -28.07 62.13 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.496 -171.528 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.1 m -85.2 -41.01 16.02 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 122.814 0.445 . . . . 0.0 110.32 177.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.0 103.51 23.53 Favored Pre-proline 0 N--CA 1.483 1.216 0 C-N-CA 124.156 0.982 . . . . 0.0 109.807 -178.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -66.91 136.58 41.97 Favored 'Trans proline' 0 C--N 1.374 1.919 0 C-N-CA 122.781 2.321 . . . . 0.0 111.687 172.059 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.2 -4.75 67.68 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-O 119.787 -0.452 . . . . 0.0 113.963 175.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.65 106.68 9.61 Favored 'General case' 0 C--N 1.35 0.619 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 173.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.427 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -77.14 99.54 5.43 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -177.095 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.417 HG11 HG11 ' A' ' 64' ' ' VAL . 27.8 m -85.26 127.47 39.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.805 0 C-N-CA 123.134 0.574 . . . . 0.0 110.877 -171.065 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . 0.423 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 29.2 t60 -131.67 96.98 4.08 Favored 'General case' 0 C--N 1.345 0.372 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 176.12 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.592 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -93.71 113.67 25.79 Favored 'General case' 0 C--O 1.24 0.588 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 176.073 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -99.72 114.88 65.88 Favored Pre-proline 0 N--CA 1.468 0.428 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -177.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -60.54 -40.34 57.36 Favored 'Trans proline' 0 C--N 1.373 1.863 0 C-N-CA 123.009 2.473 . . . . 0.0 112.822 -176.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -74.38 -47.74 32.22 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.639 0.775 . . . . 0.0 111.285 -176.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.2 m -81.31 -15.65 54.8 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 123.74 0.816 . . . . 0.0 111.459 -176.122 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 63.0 29.44 16.43 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 124.642 1.177 . . . . 0.0 111.389 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 33.1 m -122.79 122.76 39.46 Favored 'General case' 0 N--CA 1.479 1.001 0 O-C-N 121.808 -0.558 . . . . 0.0 111.57 -169.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.676 HG22 HG22 ' A' ' 40' ' ' ILE . 40.5 t -99.09 106.38 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 123.952 0.901 . . . . 0.0 108.972 173.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.1 t -100.49 123.21 53.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.55 HG12 HG21 ' A' ' 44' ' ' ILE . 17.0 m -111.5 109.0 26.9 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.955 0 CA-C-O 121.478 0.656 . . . . 0.0 110.18 179.377 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.46 150.78 20.99 Favored Glycine 0 C--N 1.346 1.125 0 CA-C-N 115.604 -0.725 . . . . 0.0 112.581 -176.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.19 -23.68 30.47 Favored Glycine 0 C--N 1.343 0.967 0 C-N-CA 123.089 0.375 . . . . 0.0 112.999 177.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 22.4 m -105.52 151.14 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 123.992 0.917 . . . . 0.0 110.153 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 17.9 m -126.85 -2.61 6.56 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 124.005 0.922 . . . . 0.0 110.332 -178.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -87.33 73.02 9.72 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 124.522 1.129 . . . . 0.0 110.266 -177.219 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.411 ' HA ' HD12 ' A' ' 24' ' ' LEU . . . -63.99 -29.29 70.46 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-N 114.907 -1.042 . . . . 0.0 112.373 -174.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -63.68 -49.45 73.12 Favored 'General case' 0 N--CA 1.474 0.764 0 O-C-N 123.763 0.665 . . . . 0.0 110.819 177.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.5 ' O ' HG13 ' A' ' 76' ' ' ILE . 39.8 m170 -59.35 -54.93 41.14 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 123.552 0.532 . . . . 0.0 110.463 177.81 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.523 HG21 HG21 ' A' ' 64' ' ' VAL . 41.4 mm -57.8 -40.27 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 O-C-N 124.438 1.086 . . . . 0.0 110.785 -174.282 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.26 -40.14 89.29 Favored 'General case' 0 N--CA 1.48 1.067 0 O-C-N 124.022 0.826 . . . . 0.0 111.429 178.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -68.23 -32.09 72.05 Favored 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 123.181 0.592 . . . . 0.0 111.292 178.05 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.5 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.3 mt -74.75 -48.66 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 122.986 0.514 . . . . 0.0 111.21 -177.094 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.436 HG22 ' O ' ' A' ' 73' ' ' ILE . 8.5 tt -67.37 -32.39 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 C-N-CA 123.259 0.623 . . . . 0.0 111.257 -177.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -75.12 -31.05 61.02 Favored 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 110.364 -0.236 . . . . 0.0 110.364 175.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.95 -18.49 64.09 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 123.537 0.735 . . . . 0.0 111.747 176.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.485 ' HB2' HG13 ' A' ' 39' ' ' VAL . . . -75.89 0.58 17.76 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 123.664 0.786 . . . . 0.0 112.291 176.441 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 95.9 17.04 36.59 Favored Glycine 0 C--N 1.351 1.377 0 C-N-CA 122.861 0.267 . . . . 0.0 112.528 179.597 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -120.78 178.36 4.73 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 124.361 1.064 . . . . 0.0 109.686 -177.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 39.0 m -139.41 111.81 7.77 Favored Pre-proline 0 N--CA 1.479 1.001 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 173.333 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -66.44 120.37 7.49 Favored 'Trans proline' 0 C--N 1.382 2.305 0 C-N-CA 122.355 2.037 . . . . 0.0 110.812 171.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 . . . . . 0 CA--C 1.555 1.167 0 C-N-CA 124.187 0.995 . . . . 0.0 109.493 -175.682 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.802 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.419 ' HA2' ' HA2' ' A' ' 65' ' ' GLY . . . -104.54 111.41 3.8 Favored Glycine 0 C--N 1.345 1.075 0 CA-C-N 116.13 -0.486 . . . . 0.0 112.165 -177.602 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.454 HD13 ' HA ' ' A' ' 70' ' ' ALA . 59.4 mt -81.42 111.59 17.91 Favored 'General case' 0 N--CA 1.47 0.568 0 C-N-CA 124.059 0.944 . . . . 0.0 110.108 179.433 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.4 t -83.72 129.62 34.95 Favored 'General case' 0 CA--C 1.549 0.922 0 C-N-CA 123.556 0.742 . . . . 0.0 110.516 -177.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -125.84 108.44 11.47 Favored 'General case' 0 N--CA 1.492 1.636 0 C-N-CA 123.338 0.655 . . . . 0.0 110.919 177.545 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 75.9 t60 -82.88 105.58 14.01 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.531 1.132 . . . . 0.0 110.308 -175.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.626 HG13 ' HB3' ' A' ' 82' ' ' TYR . 30.1 t -120.7 94.97 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 C-N-CA 123.214 0.606 . . . . 0.0 109.729 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -69.65 -24.75 63.66 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 123.034 0.533 . . . . 0.0 112.186 -177.306 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -74.98 -20.11 59.81 Favored 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 123.737 0.815 . . . . 0.0 111.163 -179.142 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.414 ' SD ' HD12 ' A' ' 40' ' ' ILE . 12.9 ttt -73.26 139.34 46.09 Favored 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 124.303 1.041 . . . . 0.0 110.786 176.495 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 15.1 t -103.01 163.39 12.24 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 123.917 0.887 . . . . 0.0 109.195 170.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 23.3 p -66.98 -97.46 0.0 OUTLIER 'General case' 0 CA--C 1.563 1.467 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -174.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.48 -32.74 64.51 Favored Glycine 0 C--N 1.349 1.3 0 N-CA-C 114.673 0.629 . . . . 0.0 114.673 -166.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 72.1 m-70 -74.01 -14.34 61.0 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.514 0.726 . . . . 0.0 111.869 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.6 t -122.54 -7.1 8.64 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 122.977 0.511 . . . . 0.0 111.688 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -57.67 -55.7 31.5 Favored 'General case' 0 N--CA 1.481 1.088 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -171.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.83 -38.17 95.23 Favored Glycine 0 N--CA 1.47 0.903 0 N-CA-C 114.255 0.462 . . . . 0.0 114.255 -174.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.5 p -75.15 -40.37 44.06 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.15 0 C-N-CA 122.785 0.434 . . . . 0.0 111.733 -176.125 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.423 HD11 HD11 ' A' ' 77' ' ' ILE . 13.0 tt -75.05 -35.88 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 122.802 0.441 . . . . 0.0 110.79 -178.211 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.467 ' HB3' HG22 ' A' ' 53' ' ' VAL . 97.2 mttt -65.21 -52.29 55.66 Favored 'General case' 0 C--N 1.353 0.729 0 CA-C-N 115.771 -0.649 . . . . 0.0 109.471 174.584 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.91 -29.31 67.48 Favored Glycine 0 C--N 1.352 1.43 0 O-C-N 124.813 1.321 . . . . 0.0 113.517 -178.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.35 -54.96 40.85 Favored 'General case' 0 C--N 1.352 0.693 0 C-N-CA 123.375 0.67 . . . . 0.0 110.476 175.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.582 HG23 HG11 ' A' ' 64' ' ' VAL . 66.6 mt -73.2 -45.72 52.65 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 CA-C-N 115.529 -0.759 . . . . 0.0 112.031 -179.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -63.05 -45.7 90.99 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 124.72 1.208 . . . . 0.0 111.275 -167.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -70.95 -27.45 63.75 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.853 0.461 . . . . 0.0 111.698 -178.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 33.2 m -81.51 -33.89 31.58 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 122.648 0.379 . . . . 0.0 110.833 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.3 t -124.75 95.0 43.34 Favored Pre-proline 0 N--CA 1.48 1.073 0 C-N-CA 123.32 0.648 . . . . 0.0 109.688 178.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -65.88 111.22 1.89 Allowed 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 122.699 2.266 . . . . 0.0 110.861 173.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.5 -12.1 9.59 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-O 119.514 -0.603 . . . . 0.0 113.281 -176.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -76.87 106.28 8.45 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 173.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.21 100.16 8.17 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -178.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.467 HG22 ' HB3' ' A' ' 41' ' ' LYS . 15.3 m -84.39 132.99 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 123.78 0.832 . . . . 0.0 110.649 -170.423 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -141.48 101.81 4.07 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 122.903 0.481 . . . . 0.0 109.756 -176.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.25 130.32 35.07 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 109.643 -0.502 . . . . 0.0 109.643 176.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -105.48 108.59 61.8 Favored Pre-proline 0 CA--C 1.541 0.628 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 176.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -47.34 -44.94 23.65 Favored 'Trans proline' 0 C--N 1.374 1.901 0 C-N-CA 124.126 3.218 . . . . 0.0 115.396 178.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.31 -41.57 40.16 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.485 0.714 . . . . 0.0 112.233 -173.17 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.8 t -93.37 -13.93 27.46 Favored 'General case' 0 N--CA 1.482 1.141 0 C-N-CA 123.496 0.718 . . . . 0.0 111.558 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.409 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 2.7 mpt_? 57.17 45.98 19.68 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 125.036 1.334 . . . . 0.0 110.8 -178.12 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 78.9 m -122.75 126.61 47.83 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.88 -170.402 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 40.5 t -98.44 108.27 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 173.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.0 t -100.58 123.11 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 C-N-CA 124.035 0.934 . . . . 0.0 108.609 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.582 HG11 HG23 ' A' ' 44' ' ' ILE . 31.4 m -112.57 109.07 27.23 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 C-N-CA 123.669 0.787 . . . . 0.0 110.666 -176.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.419 ' HA2' ' HA2' ' A' ' 23' ' ' GLY . . . -88.62 160.24 30.05 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 115.584 -0.735 . . . . 0.0 113.049 -177.335 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 78.55 4.59 87.63 Favored Glycine 0 C--N 1.343 0.92 0 N-CA-C 114.356 0.502 . . . . 0.0 114.356 175.546 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 23.4 m -131.8 150.79 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.854 0 C-N-CA 123.796 0.838 . . . . 0.0 109.4 -178.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 30.8 t -116.1 -8.41 11.8 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 124.1 0.96 . . . . 0.0 111.06 -176.657 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -80.92 72.34 7.92 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.751 0.821 . . . . 0.0 110.893 -175.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.454 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -60.38 -41.43 93.74 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.149 0.58 . . . . 0.0 111.065 -178.281 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.468 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.22 -47.83 80.85 Favored 'General case' 0 CA--C 1.541 0.6 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.134 179.094 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.431 ' O ' HG13 ' A' ' 76' ' ' ILE . 45.0 t-80 -64.64 -45.24 87.64 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.167 0.587 . . . . 0.0 111.559 -176.186 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.484 HG21 HG22 ' A' ' 64' ' ' VAL . 48.5 mm -60.86 -41.03 87.18 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 O-C-N 123.552 0.533 . . . . 0.0 109.892 178.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.15 -35.31 76.74 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 115.305 -0.861 . . . . 0.0 111.751 178.49 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.468 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 17.5 mm-40 -65.52 -41.13 93.48 Favored 'General case' 0 N--CA 1.48 1.034 0 C-N-CA 123.457 0.703 . . . . 0.0 110.923 177.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.431 HG13 ' O ' ' A' ' 72' ' ' HIS . 35.5 mt -66.37 -50.05 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.021 -177.126 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.423 HD11 HD11 ' A' ' 40' ' ' ILE . 15.9 tt -72.66 -31.17 36.13 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.949 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.429 -172.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.5 t -74.54 -29.57 61.43 Favored 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 175.095 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.43 -19.62 60.92 Favored 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 123.563 0.745 . . . . 0.0 111.27 173.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -80.4 -5.31 56.27 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.565 0.746 . . . . 0.0 111.21 172.107 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.0 22.72 32.0 Favored Glycine 0 C--N 1.35 1.358 0 O-C-N 123.372 0.42 . . . . 0.0 112.903 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.626 ' HB3' HG13 ' A' ' 28' ' ' VAL . 81.7 m-85 -127.46 115.07 18.33 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.659 0.784 . . . . 0.0 110.51 -176.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 34.8 p -71.16 111.78 11.21 Favored Pre-proline 0 CA--C 1.549 0.916 0 C-N-CA 124.296 1.039 . . . . 0.0 110.987 -177.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.418 ' HA ' HG22 ' A' ' 28' ' ' VAL . 93.8 Cg_endo -80.6 150.14 18.96 Favored 'Trans proline' 0 C--N 1.372 1.803 0 C-N-CA 122.323 2.016 . . . . 0.0 111.824 177.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 . . . . . 0 CA--C 1.559 1.3 0 C-N-CA 124.703 1.201 . . . . 0.0 111.437 173.536 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.238 0 CA-C-O 120.618 0.247 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 135.95 -154.62 21.96 Favored Glycine 0 C--N 1.342 0.913 0 N-CA-C 110.35 -1.1 . . . . 0.0 110.35 -178.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 46.8 mt -83.1 105.84 14.41 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 174.278 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.1 m -93.83 111.4 23.09 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -176.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -103.26 100.96 10.88 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 177.244 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 77.0 t60 -82.47 91.71 6.92 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 -179.202 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.581 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 15.9 t -74.37 93.62 0.75 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 N-CA-C 106.855 -1.535 . . . . 0.0 106.855 172.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -63.75 -20.81 66.04 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 112.693 0.627 . . . . 0.0 112.693 -171.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 10.6 p-10 -111.34 23.6 13.82 Favored 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 124.089 0.956 . . . . 0.0 110.789 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.581 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 23.9 ttt -57.73 142.01 46.74 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 124.389 1.076 . . . . 0.0 113.325 -173.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 41.3 p -81.32 144.4 31.53 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.547 173.204 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.418 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 49.8 t -73.04 -170.51 0.75 Allowed 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 123.882 0.873 . . . . 0.0 110.078 177.137 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -49.35 -24.9 5.55 Favored Glycine 0 C--N 1.356 1.657 0 N-CA-C 116.623 1.409 . . . . 0.0 116.623 -171.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 40.9 m170 -58.53 -33.75 70.22 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 123.498 0.719 . . . . 0.0 112.558 177.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 63.8 m -137.92 15.95 2.86 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 122.997 0.519 . . . . 0.0 111.739 178.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.4 -34.04 63.19 Favored 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 122.614 0.366 . . . . 0.0 110.96 174.1 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.94 -37.91 93.69 Favored Glycine 0 C--N 1.347 1.161 0 O-C-N 123.825 0.703 . . . . 0.0 113.768 -176.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 9.2 p -69.48 -28.46 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 122.943 0.497 . . . . 0.0 110.883 177.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.2 mt -67.93 -41.82 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 123.224 0.61 . . . . 0.0 109.974 175.298 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -62.24 -52.05 65.28 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 123.811 0.844 . . . . 0.0 110.177 177.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.82 -31.1 78.69 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 114.414 -1.266 . . . . 0.0 113.063 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.38 -50.92 68.46 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.975 0.91 . . . . 0.0 110.831 179.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.514 HG23 HG12 ' A' ' 64' ' ' VAL . 64.3 mt -74.37 -51.4 23.3 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.644 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -56.16 -54.67 42.38 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 124.358 1.063 . . . . 0.0 112.745 -170.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -69.79 -13.72 62.42 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 122.889 0.476 . . . . 0.0 112.107 -175.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 61.2 m -90.51 -37.74 13.68 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 123.341 0.656 . . . . 0.0 110.442 177.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.5 m -133.54 92.1 24.63 Favored Pre-proline 0 CA--C 1.556 1.176 0 C-N-CA 123.474 0.71 . . . . 0.0 110.491 179.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -58.03 135.08 66.38 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 122.604 2.203 . . . . 0.0 111.555 171.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 110.62 -29.58 8.89 Favored Glycine 0 C--N 1.341 0.847 0 N-CA-C 111.87 -0.492 . . . . 0.0 111.87 -177.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -74.02 106.86 5.89 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 175.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.451 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -78.06 99.34 6.08 Favored 'General case' 0 C--N 1.345 0.407 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -179.057 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.463 HG12 HG11 ' A' ' 64' ' ' VAL . 27.2 m -84.51 129.42 37.7 Favored 'Isoleucine or valine' 0 C--O 1.239 0.546 0 C-N-CA 123.1 0.56 . . . . 0.0 110.015 -171.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . 0.409 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 41.1 t60 -133.68 96.01 3.6 Favored 'General case' 0 CA--C 1.518 -0.283 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 175.439 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.1 113.91 26.31 Favored 'General case' 0 C--O 1.243 0.755 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 173.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -105.35 105.54 52.6 Favored Pre-proline 0 N--CA 1.466 0.337 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 -175.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.418 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 76.4 Cg_exo -53.39 -38.1 82.25 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 123.236 2.624 . . . . 0.0 113.72 179.331 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.8 -45.21 62.31 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 123.215 0.606 . . . . 0.0 111.413 -176.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.9 m -84.08 -17.89 38.75 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.417 0.687 . . . . 0.0 111.552 -177.28 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.538 ' HD2' ' HB3' ' A' ' 31' ' ' MET . 66.6 mmt-85 64.29 37.49 8.54 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 124.633 1.173 . . . . 0.0 110.367 -178.58 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.1 m -137.9 122.88 19.02 Favored 'General case' 0 CA--C 1.55 0.965 0 O-C-N 122.025 -0.422 . . . . 0.0 111.603 -169.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 54' ' ' HIS . 18.5 t -99.45 106.37 18.91 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 C-N-CA 124.142 0.977 . . . . 0.0 109.204 175.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.8 t -104.95 123.47 59.04 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 123.728 0.811 . . . . 0.0 109.073 -176.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.514 HG12 HG23 ' A' ' 44' ' ' ILE . 27.8 m -108.56 122.5 63.19 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.909 0 C-N-CA 123.038 0.535 . . . . 0.0 110.521 177.42 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -102.43 153.3 18.44 Favored Glycine 0 C--N 1.345 1.075 0 CA-C-N 115.981 -0.554 . . . . 0.0 112.872 -176.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.7 -24.77 22.12 Favored Glycine 0 N--CA 1.471 1.027 0 C-N-CA 123.173 0.416 . . . . 0.0 112.856 177.212 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 35.3 m -111.69 149.05 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.987 0.915 . . . . 0.0 109.473 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.5 m -121.74 20.82 10.92 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 123.656 0.782 . . . . 0.0 110.416 -178.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -96.65 73.56 2.71 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 124.367 1.067 . . . . 0.0 109.506 -173.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.34 -53.38 58.97 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 123.721 0.809 . . . . 0.0 112.642 -170.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.42 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -62.9 -40.52 97.82 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 123.481 0.712 . . . . 0.0 111.031 -178.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 55.7 t60 -61.66 -50.35 72.85 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.967 0.907 . . . . 0.0 111.205 -177.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 39.6 mm -64.99 -39.93 87.35 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.083 179.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.13 -37.11 79.09 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 123.985 0.803 . . . . 0.0 111.128 179.093 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.42 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 39.5 mm-40 -66.29 -40.02 89.77 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 123.625 0.77 . . . . 0.0 111.288 176.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.446 HG21 ' HA ' ' A' ' 44' ' ' ILE . 65.6 mt -64.08 -52.95 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 O-C-N 123.606 0.566 . . . . 0.0 111.17 -179.215 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 8.0 tt -66.8 -37.88 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.313 -175.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.5 t -73.84 -29.64 62.24 Favored 'General case' 0 CA--C 1.552 1.037 0 C-N-CA 122.384 0.273 . . . . 0.0 110.296 179.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.71 -22.24 61.67 Favored 'General case' 0 N--CA 1.484 1.256 0 C-N-CA 123.628 0.771 . . . . 0.0 111.238 174.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.43 -6.08 52.15 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.503 0.721 . . . . 0.0 111.396 172.242 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 93.87 8.17 60.75 Favored Glycine 0 C--N 1.345 1.068 0 CA-C-O 119.89 -0.394 . . . . 0.0 112.933 177.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -117.0 103.22 10.04 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 176.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.4 t -83.59 118.53 71.74 Favored Pre-proline 0 CA--C 1.554 1.119 0 C-N-CA 123.267 0.627 . . . . 0.0 110.389 -176.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -70.75 -42.6 2.28 Favored 'Trans proline' 0 C--N 1.377 2.076 0 C-N-CA 122.409 2.072 . . . . 0.0 111.716 173.274 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 . . . . . 0 C--O 1.253 1.279 0 C-N-CA 124.767 1.227 . . . . 0.0 108.102 172.379 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.996 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.401 ' HA2' ' HA2' ' A' ' 65' ' ' GLY . . . -113.21 123.83 6.34 Favored Glycine 0 C--N 1.347 1.19 0 N-CA-C 112.058 -0.417 . . . . 0.0 112.058 -178.606 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.403 HD12 ' HA ' ' A' ' 70' ' ' ALA . 47.6 mt -80.32 108.6 14.07 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 123.809 0.844 . . . . 0.0 110.141 -178.018 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 21.0 p -88.44 124.25 33.78 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 123.623 0.769 . . . . 0.0 110.978 -178.383 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -121.55 112.72 18.83 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 123.729 0.812 . . . . 0.0 110.401 -179.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 69.3 m80 -83.59 104.23 13.55 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.318 0.647 . . . . 0.0 110.173 177.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.541 HG13 ' HB3' ' A' ' 82' ' ' TYR . 98.8 t -90.07 128.3 42.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 C-N-CA 123.404 0.681 . . . . 0.0 109.176 174.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -64.44 -39.85 94.61 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 123.563 0.745 . . . . 0.0 112.286 -176.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -104.83 -6.47 20.21 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 113.302 0.852 . . . . 0.0 113.302 -166.169 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 24.1 ptm -65.45 133.38 51.18 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-O 121.318 0.58 . . . . 0.0 111.355 -174.236 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 72.9 p -107.55 161.62 14.69 Favored 'General case' 0 CA--C 1.547 0.856 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 171.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 24.6 p -74.87 -109.29 0.01 OUTLIER 'General case' 0 CA--C 1.563 1.479 0 N-CA-C 113.951 1.093 . . . . 0.0 113.951 -166.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -75.96 5.21 41.98 Favored Glycine 0 N--CA 1.478 1.474 0 N-CA-C 117.422 1.729 . . . . 0.0 117.422 -154.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 65.7 m80 -110.13 -31.02 7.5 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-N 118.118 0.959 . . . . 0.0 110.548 175.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.4 m -102.0 -8.87 21.12 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.621 0.769 . . . . 0.0 110.936 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -61.5 -46.38 90.26 Favored 'General case' 0 C--N 1.354 0.771 0 C-N-CA 123.803 0.841 . . . . 0.0 110.347 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.55 -27.57 72.71 Favored Glycine 0 C--N 1.343 0.946 0 O-C-N 123.977 0.798 . . . . 0.0 113.846 -178.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 53.0 t -72.04 -46.6 58.59 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.963 0 C-N-CA 123.196 0.598 . . . . 0.0 109.771 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.432 HG21 HG21 ' A' ' 62' ' ' VAL . 75.7 mt -59.98 -55.23 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.669 176.298 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -61.51 -43.43 98.88 Favored 'General case' 0 C--O 1.219 -0.503 0 CA-C-N 114.794 -1.094 . . . . 0.0 110.918 -176.18 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.86 -42.57 98.38 Favored Glycine 0 C--N 1.345 1.051 0 O-C-N 124.068 0.855 . . . . 0.0 112.366 -179.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.32 -55.11 31.34 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 122.89 0.476 . . . . 0.0 110.815 -179.454 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.54 HG23 HG12 ' A' ' 64' ' ' VAL . 82.4 mt -64.45 -51.13 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 C-N-CA 123.758 0.823 . . . . 0.0 112.297 -176.731 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -60.68 -45.58 93.6 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 124.316 1.046 . . . . 0.0 112.222 -173.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.3 mptp? -78.72 -21.09 48.6 Favored 'General case' 0 N--CA 1.484 1.234 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -173.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 38.5 m -85.33 -39.17 17.96 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 122.899 0.48 . . . . 0.0 110.319 177.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.1 t -118.46 86.53 28.59 Favored Pre-proline 0 CA--C 1.548 0.876 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 174.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo -61.76 106.77 0.46 Allowed 'Trans proline' 0 C--N 1.378 2.111 0 C-N-CA 122.952 2.435 . . . . 0.0 112.813 -174.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.88 7.93 8.37 Favored Glycine 0 C--N 1.341 0.859 0 CA-C-N 115.638 -0.71 . . . . 0.0 113.173 -179.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.19 107.47 9.6 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 176.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.415 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -75.58 96.37 3.52 Favored 'General case' 0 C--N 1.352 0.693 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 -177.388 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.43 HG13 HG11 ' A' ' 64' ' ' VAL . 5.0 m -87.29 133.14 30.89 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.587 -168.737 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 75.6 t60 -138.62 99.25 3.77 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 174.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.78 115.3 23.34 Favored 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 173.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -96.94 120.77 60.92 Favored Pre-proline 0 N--CA 1.478 0.951 0 CA-C-O 118.975 -0.536 . . . . 0.0 109.919 -173.175 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -55.75 -48.97 17.33 Favored 'Trans proline' 0 C--N 1.381 2.27 0 C-N-CA 123.598 2.865 . . . . 0.0 114.025 178.095 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -75.09 -42.85 55.82 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.116 -170.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 19.5 m -93.31 -14.94 26.32 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.595 0.758 . . . . 0.0 112.125 -171.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 11.4 mpt_? 59.42 40.43 20.83 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 123.866 0.866 . . . . 0.0 110.273 -175.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.9 m -121.31 118.87 30.61 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.119 0.568 . . . . 0.0 111.275 -169.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.432 HG21 HG21 ' A' ' 40' ' ' ILE . 42.8 t -97.88 105.92 17.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 175.168 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 6.3 t -102.02 123.19 55.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 -176.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.54 HG12 HG23 ' A' ' 44' ' ' ILE . 19.1 m -117.39 109.22 26.91 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 CA-C-O 121.512 0.672 . . . . 0.0 110.787 -176.478 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.401 ' HA2' ' HA2' ' A' ' 23' ' ' GLY . . . -90.76 161.98 28.67 Favored Glycine 0 C--N 1.344 0.994 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.775 -176.62 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.7 0.65 74.8 Favored Glycine 0 C--N 1.346 1.106 0 CA-C-O 119.995 -0.336 . . . . 0.0 113.824 177.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.99 149.05 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 123.826 0.85 . . . . 0.0 109.987 -177.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 45.7 m -114.88 4.76 14.94 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.797 0.839 . . . . 0.0 110.359 176.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.576 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 5.6 m-20 -83.12 68.6 9.63 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.015 0.926 . . . . 0.0 111.014 -172.352 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.403 ' HA ' HD12 ' A' ' 24' ' ' LEU . . . -61.25 -45.11 95.86 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.12 0.568 . . . . 0.0 111.681 -175.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -66.43 -44.14 83.7 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.235 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.576 ' HB2' ' HB3' ' A' ' 69' ' ' ASP . 26.1 m80 -62.48 -52.45 63.47 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 122.968 0.507 . . . . 0.0 111.271 -178.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 69' ' ' ASP . 48.6 mm -57.52 -43.13 82.43 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 O-C-N 123.817 0.698 . . . . 0.0 110.09 -177.395 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.82 -38.93 83.4 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 124.403 1.064 . . . . 0.0 111.764 178.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 43.8 mm-40 -68.87 -36.06 77.65 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.42 0.688 . . . . 0.0 111.748 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.482 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.6 mt -69.59 -51.69 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.989 0 C-N-CA 122.743 0.417 . . . . 0.0 110.186 -177.095 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 12.4 tt -70.43 -30.55 43.38 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.071 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.536 -174.544 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 3.8 t -74.86 -30.3 61.29 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 176.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -74.39 -23.04 58.92 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.557 0.743 . . . . 0.0 110.533 173.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.55 -6.99 55.59 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 123.32 0.648 . . . . 0.0 111.207 172.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 100.03 9.55 48.31 Favored Glycine 0 C--N 1.352 1.469 0 CA-C-O 119.797 -0.446 . . . . 0.0 113.727 173.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.541 ' HB3' HG13 ' A' ' 28' ' ' VAL . 84.9 m-85 -109.09 121.5 45.29 Favored 'General case' 0 N--CA 1.481 1.079 0 C-N-CA 123.715 0.806 . . . . 0.0 109.289 -178.218 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 31.3 m -88.18 103.4 5.03 Favored Pre-proline 0 CA--C 1.559 1.325 0 C-N-CA 123.868 0.867 . . . . 0.0 111.396 -175.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -91.01 -74.65 0.0 OUTLIER 'Trans proline' 0 C--N 1.376 2.023 0 C-N-CA 123.564 2.843 . . . . 0.0 112.477 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 . . . . . 0 CA--C 1.554 1.109 0 C-N-CA 125.54 1.536 . . . . 0.0 111.372 -179.353 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.24 0 CA-C-O 121.013 0.435 . . . . 0.0 110.36 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.38 -153.77 30.31 Favored Glycine 0 C--N 1.342 0.882 0 CA-C-N 115.28 -0.873 . . . . 0.0 112.739 178.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.543 HD11 ' HA ' ' A' ' 70' ' ' ALA . 56.1 mt -79.78 109.83 14.57 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 123.788 0.835 . . . . 0.0 109.848 -176.764 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.543 ' HA ' HG11 ' A' ' 63' ' ' VAL . 19.6 p -92.17 109.03 20.39 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.001 0.52 . . . . 0.0 111.405 -174.282 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 88.9 m-85 -105.17 110.29 22.61 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.162 0.585 . . . . 0.0 109.954 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 11.7 m170 -82.49 92.49 7.08 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.448 HG23 ' HB3' ' A' ' 84' ' ' PRO . 31.0 t -83.27 105.48 13.03 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.256 -175.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -79.22 -10.76 59.9 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 122.774 0.43 . . . . 0.0 111.515 -176.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -93.41 -0.8 56.38 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 123.813 0.845 . . . . 0.0 111.476 173.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.487 ' HB3' ' HB3' ' A' ' 60' ' ' ARG . 26.7 ttt -73.62 137.36 44.16 Favored 'General case' 0 CA--C 1.543 0.679 0 CA-C-O 121.58 0.705 . . . . 0.0 111.754 -176.445 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.0 t -110.1 164.47 12.6 Favored 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 125.507 1.523 . . . . 0.0 109.054 175.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.479 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 60.1 m -59.0 -178.6 0.05 Allowed 'General case' 0 CA--C 1.559 1.318 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -53.95 -21.56 17.23 Favored Glycine 0 C--N 1.353 1.49 0 N-CA-C 116.682 1.433 . . . . 0.0 116.682 -169.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 33.1 m170 -62.54 -21.35 65.48 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 123.532 0.733 . . . . 0.0 112.797 -177.427 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 53.2 t -139.12 17.7 2.61 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 123.434 0.694 . . . . 0.0 110.811 178.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.85 -31.45 69.3 Favored 'General case' 0 N--CA 1.482 1.126 0 C-N-CA 123.03 0.532 . . . . 0.0 111.811 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.76 -23.49 74.04 Favored Glycine 0 C--N 1.347 1.174 0 O-C-N 123.471 0.482 . . . . 0.0 113.586 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 92.1 t -69.47 -40.47 79.85 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.616 0.767 . . . . 0.0 109.873 173.373 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 23.2 mt -72.24 -40.7 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 CA-C-N 114.72 -1.127 . . . . 0.0 109.91 -177.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -59.65 -54.79 42.33 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 114.664 -1.153 . . . . 0.0 109.999 172.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.59 -30.05 71.13 Favored Glycine 0 C--N 1.349 1.26 0 O-C-N 124.604 1.19 . . . . 0.0 113.389 -175.751 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.46 -53.59 54.43 Favored 'General case' 0 C--N 1.351 0.658 0 C-N-CA 124.146 0.978 . . . . 0.0 110.9 176.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.456 HD13 HD12 ' A' ' 77' ' ' ILE . 64.2 mt -75.22 -59.06 3.61 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.572 178.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -50.02 -48.15 52.81 Favored 'General case' 0 N--CA 1.483 1.19 0 C-N-CA 126.215 1.806 . . . . 0.0 113.688 -169.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.4 mptt -69.45 -38.17 77.67 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 122.792 0.437 . . . . 0.0 111.407 -178.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.9 m -73.35 -33.08 64.89 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 123.219 0.607 . . . . 0.0 111.02 -178.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 3.9 m -136.32 81.6 36.93 Favored Pre-proline 0 CA--C 1.556 1.201 0 C-N-CA 124.066 0.946 . . . . 0.0 110.537 178.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_exo -62.91 123.04 11.56 Favored 'Trans proline' 0 C--N 1.381 2.253 0 C-N-CA 122.827 2.351 . . . . 0.0 111.308 174.035 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.77 -24.59 7.48 Favored Glycine 0 C--N 1.342 0.899 0 CA-C-O 119.866 -0.408 . . . . 0.0 112.234 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.21 104.86 5.95 Favored 'General case' 0 C--N 1.354 0.761 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 172.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.52 100.41 2.73 Favored 'General case' 0 C--N 1.348 0.525 0 C-N-CA 123.318 0.647 . . . . 0.0 110.529 -173.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.409 HG12 HG13 ' A' ' 64' ' ' VAL . 27.1 m -85.36 134.24 27.59 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 O-C-N 123.603 0.564 . . . . 0.0 110.744 -173.28 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 44.0 t-80 -135.69 99.89 4.32 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 169.256 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.67 116.32 23.14 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 115.021 -0.99 . . . . 0.0 108.949 178.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -103.27 105.85 48.48 Favored Pre-proline 0 N--CA 1.478 0.944 0 CA-C-O 118.47 -0.776 . . . . 0.0 108.973 -177.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.479 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 72.4 Cg_exo -54.79 -41.88 73.97 Favored 'Trans proline' 0 C--N 1.378 2.127 0 C-N-CA 123.178 2.585 . . . . 0.0 114.67 179.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -67.78 -45.57 74.48 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 123.114 0.565 . . . . 0.0 111.75 -173.274 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.4 t -89.88 -18.93 25.24 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 123.686 0.794 . . . . 0.0 111.089 -178.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.487 ' HB3' ' HB3' ' A' ' 31' ' ' MET . 0.2 OUTLIER 61.28 47.1 7.25 Favored 'General case' 0 N--CA 1.482 1.138 0 C-N-CA 124.699 1.2 . . . . 0.0 110.272 -175.676 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 54.1 m -128.84 115.16 17.48 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 123.178 0.591 . . . . 0.0 110.246 -173.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 25.4 t -98.56 108.53 22.28 Favored 'Isoleucine or valine' 0 C--O 1.24 0.6 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 175.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.543 HG11 ' HA ' ' A' ' 25' ' ' SER . 34.7 m -99.46 136.08 32.11 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.201 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.453 HG11 HG23 ' A' ' 44' ' ' ILE . 21.4 m -119.16 133.84 64.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.345 0.658 . . . . 0.0 110.181 -178.364 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -113.0 153.31 17.62 Favored Glycine 0 C--N 1.35 1.311 0 CA-C-N 116.303 -0.408 . . . . 0.0 112.787 -175.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.7 14.5 82.34 Favored Glycine 0 C--N 1.348 1.23 0 N-CA-C 113.945 0.338 . . . . 0.0 113.945 175.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 3.6 m -129.54 134.8 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 123.85 0.86 . . . . 0.0 110.245 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.6 m -95.52 -23.85 16.9 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 123.686 0.794 . . . . 0.0 111.099 176.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -79.05 87.25 4.84 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-O 121.141 0.496 . . . . 0.0 111.3 -175.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.543 ' HA ' HD11 ' A' ' 24' ' ' LEU . . . -70.63 -46.1 63.97 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.943 -175.438 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -61.6 -36.61 81.2 Favored 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.961 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 74.7 t60 -63.11 -51.68 65.61 Favored 'General case' 0 N--CA 1.473 0.715 0 O-C-N 123.856 0.722 . . . . 0.0 110.852 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.429 HG22 HG22 ' A' ' 64' ' ' VAL . 41.7 mm -59.45 -42.32 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 123.646 0.591 . . . . 0.0 110.379 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.0 -41.42 98.04 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.375 -177.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 54.8 mm-40 -63.24 -39.97 96.12 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.464 0.706 . . . . 0.0 111.607 178.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 85.5 mt -61.78 -54.25 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.403 0.681 . . . . 0.0 111.41 -178.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.456 HD12 HD13 ' A' ' 44' ' ' ILE . 14.0 tt -73.84 -33.13 36.45 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.913 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.7 -171.53 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.9 t -71.76 -29.26 64.31 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 176.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.07 -22.99 63.0 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.803 0.841 . . . . 0.0 111.167 173.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -82.93 -3.09 56.63 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 123.751 0.82 . . . . 0.0 111.774 175.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.22 -6.23 59.54 Favored Glycine 0 C--N 1.348 1.217 0 CA-C-O 120.155 -0.247 . . . . 0.0 113.311 178.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -106.07 103.15 12.57 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -178.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 53.0 m -94.4 114.2 62.77 Favored Pre-proline 0 CA--C 1.553 1.085 0 C-N-CA 123.201 0.6 . . . . 0.0 111.633 -171.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.448 ' HB3' HG23 ' A' ' 28' ' ' VAL . 25.4 Cg_endo -95.99 -11.11 0.84 Allowed 'Trans proline' 0 C--N 1.377 2.031 0 C-N-CA 123.27 2.647 . . . . 0.0 113.328 167.227 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 . . . . . 0 C--O 1.251 1.157 0 C-N-CA 124.006 0.922 . . . . 0.0 108.699 -173.785 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.284 0 CA-C-O 120.589 0.233 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.62 172.7 49.32 Favored Glycine 0 C--N 1.345 1.038 0 CA-C-N 116.006 -0.543 . . . . 0.0 113.369 177.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.452 HD13 ' HA ' ' A' ' 70' ' ' ALA . 32.2 mt -87.72 116.93 26.2 Favored 'General case' 0 C--O 1.239 0.522 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 175.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 28.6 p -92.13 111.32 22.83 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 122.871 0.468 . . . . 0.0 111.214 -173.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -108.95 133.64 52.69 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.274 1.029 . . . . 0.0 108.809 175.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 18.6 p80 -125.89 137.1 53.71 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.258 0.623 . . . . 0.0 109.803 -176.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.76 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 67.0 t -117.51 120.02 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 N-CA-C 107.162 -1.421 . . . . 0.0 107.162 170.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -70.68 -21.97 62.52 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -175.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -89.56 -8.61 52.31 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 123.411 0.685 . . . . 0.0 111.009 177.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.76 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 25.7 ttt -56.14 106.67 0.29 Allowed 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.911 0.884 . . . . 0.0 112.341 -170.439 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 67.1 p -70.94 162.24 29.68 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 123.651 0.78 . . . . 0.0 109.284 167.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 79.5 m -61.39 -104.86 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 123.488 0.715 . . . . 0.0 111.808 -177.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.49 -30.9 75.51 Favored Glycine 0 C--N 1.353 1.489 0 CA-C-N 119.391 0.996 . . . . 0.0 113.603 -172.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 21.7 t-80 -62.73 -30.11 71.18 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 123.98 0.912 . . . . 0.0 112.659 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.63 ' SG ' ' HG3' ' A' ' 31' ' ' MET . 51.9 t -106.16 -31.25 8.77 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 122.51 0.324 . . . . 0.0 110.44 179.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -62.94 -49.6 74.11 Favored 'General case' 0 C--N 1.356 0.851 0 C-N-CA 123.466 0.707 . . . . 0.0 111.698 -175.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.8 -37.08 75.53 Favored Glycine 0 C--N 1.347 1.165 0 O-C-N 123.979 0.799 . . . . 0.0 113.84 -177.071 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.48 HG13 ' HB3' ' A' ' 80' ' ' ALA . 42.7 t -71.6 -51.26 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 123.318 0.647 . . . . 0.0 110.526 -179.021 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.66 HG23 HG23 ' A' ' 62' ' ' VAL . 64.7 mt -64.81 -53.93 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 CA-C-N 115.443 -0.798 . . . . 0.0 111.646 -176.017 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 48.6 mtmt -57.84 -46.89 84.12 Favored 'General case' 0 N--CA 1.474 0.746 0 O-C-N 123.889 0.743 . . . . 0.0 110.064 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.31 -36.74 93.5 Favored Glycine 0 C--N 1.351 1.41 0 O-C-N 124.346 1.028 . . . . 0.0 113.142 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -67.42 -54.02 24.05 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 122.743 0.417 . . . . 0.0 111.121 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.57 HG22 HG11 ' A' ' 64' ' ' VAL . 63.9 mt -67.36 -42.88 87.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 C-N-CA 123.275 0.63 . . . . 0.0 111.563 -176.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -61.33 -47.53 85.48 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.877 0.871 . . . . 0.0 111.626 -177.69 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -73.13 -37.06 66.79 Favored 'General case' 0 N--CA 1.48 1.035 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.942 -176.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 58.8 m -73.61 -40.99 63.41 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 122.658 0.383 . . . . 0.0 111.149 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.409 HG11 HG12 ' A' ' 67' ' ' VAL . 24.2 t -114.08 102.69 55.02 Favored Pre-proline 0 N--CA 1.481 1.084 0 C-N-CA 123.185 0.594 . . . . 0.0 110.277 -176.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -68.16 107.03 1.47 Allowed 'Trans proline' 0 C--N 1.373 1.826 0 C-N-CA 122.717 2.278 . . . . 0.0 111.123 173.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.16 -10.94 10.8 Favored Glycine 0 C--N 1.345 1.076 0 CA-C-O 119.251 -0.749 . . . . 0.0 113.619 178.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.41 106.6 7.04 Favored 'General case' 0 N--CA 1.479 0.977 0 CA-C-N 117.833 0.816 . . . . 0.0 109.038 174.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.58 99.03 7.89 Favored 'General case' 0 N--CA 1.465 0.31 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 -178.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.501 HG11 HG13 ' A' ' 64' ' ' VAL . 26.9 m -86.51 134.17 28.05 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 C-N-CA 123.412 0.685 . . . . 0.0 110.366 -174.353 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 43.6 t-80 -142.81 102.16 3.98 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 172.46 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -89.61 115.79 27.27 Favored 'General case' 0 C--O 1.239 0.509 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 171.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.415 ' HA ' ' HD2' ' A' ' 57' ' ' PRO . 20.0 t70 -92.08 114.27 61.63 Favored Pre-proline 0 CA--C 1.546 0.8 0 CA-C-O 118.142 -0.932 . . . . 0.0 109.549 -177.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 56' ' ' ASP . 7.3 Cg_endo -47.27 -33.6 16.61 Favored 'Trans proline' 0 C--N 1.381 2.259 0 C-N-CA 124.612 3.542 . . . . 0.0 115.29 178.267 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.47 -44.32 24.88 Favored 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -177.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.1 t -93.27 -23.38 18.53 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.405 0.682 . . . . 0.0 111.955 -173.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.549 ' NH2' ' HE3' ' A' ' 31' ' ' MET . 11.7 mmm180 57.63 41.29 25.78 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 125.596 1.558 . . . . 0.0 111.578 -173.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.8 m -119.26 127.69 53.47 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 123.286 0.635 . . . . 0.0 110.028 -177.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.66 HG23 HG23 ' A' ' 40' ' ' ILE . 21.6 t -99.59 106.17 18.63 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 C-N-CA 124.658 1.183 . . . . 0.0 108.951 177.124 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 25.7 m -94.11 135.43 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 175.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.57 HG11 HG22 ' A' ' 44' ' ' ILE . 22.2 m -120.87 107.88 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-O 121.674 0.749 . . . . 0.0 110.017 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.71 152.4 21.85 Favored Glycine 0 C--N 1.346 1.115 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.789 -175.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.8 -24.47 26.08 Favored Glycine 0 C--N 1.344 0.997 0 C-N-CA 123.042 0.353 . . . . 0.0 113.036 178.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.409 HG12 HG11 ' A' ' 48' ' ' VAL . 27.4 m -111.24 145.64 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 123.904 0.881 . . . . 0.0 110.135 -177.473 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t -117.71 10.01 13.21 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 123.624 0.77 . . . . 0.0 109.771 176.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -86.58 74.83 9.81 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.222 1.009 . . . . 0.0 109.522 -176.083 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.452 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -63.79 -47.37 81.16 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.39 0.676 . . . . 0.0 112.252 -172.191 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.498 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.47 -39.64 94.99 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 123.113 0.565 . . . . 0.0 110.788 -179.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 74.1 t60 -63.13 -51.69 65.51 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.286 1.034 . . . . 0.0 111.279 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.444 ' O ' HG22 ' A' ' 77' ' ' ILE . 41.3 mm -60.75 -38.47 78.88 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 O-C-N 123.744 0.652 . . . . 0.0 109.962 179.113 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.81 -36.74 79.8 Favored 'General case' 0 N--CA 1.476 0.856 0 O-C-N 124.247 0.967 . . . . 0.0 111.837 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.498 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 11.7 mm-40 -69.35 -34.78 75.11 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.16 0.584 . . . . 0.0 111.26 177.537 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 71.5 mt -71.75 -48.44 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 C-N-CA 123.441 0.696 . . . . 0.0 111.961 -177.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.456 ' HB ' HD11 ' A' ' 44' ' ' ILE . 5.0 tt -66.53 -37.27 79.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.184 0 C-N-CA 122.871 0.469 . . . . 0.0 110.851 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 t -71.18 -29.61 65.39 Favored 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 122.463 0.305 . . . . 0.0 110.379 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.61 -24.27 62.71 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 123.751 0.82 . . . . 0.0 111.373 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.48 ' HB3' HG13 ' A' ' 39' ' ' VAL . . . -75.02 -6.09 47.52 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.389 0.675 . . . . 0.0 111.578 175.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.29 1.38 56.85 Favored Glycine 0 C--N 1.35 1.325 0 CA-C-O 119.884 -0.398 . . . . 0.0 112.98 176.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -120.31 104.71 10.26 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 178.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.7 t -86.32 116.96 67.83 Favored Pre-proline 0 CA--C 1.554 1.119 0 C-N-CA 123.397 0.679 . . . . 0.0 110.354 -178.642 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -79.88 148.67 19.94 Favored 'Trans proline' 0 C--N 1.375 1.961 0 C-N-CA 122.742 2.294 . . . . 0.0 111.571 174.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.4 mp0 . . . . . 0 C--O 1.251 1.148 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -176.789 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.92 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 163.92 166.32 22.59 Favored Glycine 0 C--N 1.341 0.843 0 N-CA-C 111.412 -0.675 . . . . 0.0 111.412 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.412 HD12 ' HA ' ' A' ' 70' ' ' ALA . 34.0 mt -88.99 108.24 19.47 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.3 p -92.36 111.35 22.89 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 122.844 0.458 . . . . 0.0 110.606 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -106.24 124.88 50.28 Favored 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 123.862 0.865 . . . . 0.0 109.72 179.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 32.1 m-70 -84.03 136.77 33.91 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 175.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 p -157.31 96.98 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.091 0.957 . . . . 0.0 109.059 -176.364 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -69.79 -29.46 66.77 Favored 'General case' 0 N--CA 1.479 1.007 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.443 -176.21 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.5 m-20 -74.29 -9.84 59.01 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.164 0.586 . . . . 0.0 112.104 -178.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.593 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 56.3 ttp -72.69 113.06 9.3 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-O 120.944 0.402 . . . . 0.0 110.536 177.145 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 62.7 p -77.51 166.36 23.17 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 123.993 0.917 . . . . 0.0 109.912 168.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 27.9 p -57.11 -169.69 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 124.121 0.968 . . . . 0.0 112.6 175.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.73 3.5 0.64 Allowed Glycine 0 C--N 1.357 1.732 0 N-CA-C 115.922 1.129 . . . . 0.0 115.922 -174.021 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -63.3 -44.72 94.22 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.786 0.834 . . . . 0.0 110.798 166.031 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 43.6 t -141.47 9.51 2.03 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 123.189 0.596 . . . . 0.0 111.987 -176.018 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.65 -30.89 69.69 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 122.814 0.446 . . . . 0.0 110.732 173.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.58 -20.84 53.15 Favored Glycine 0 C--N 1.348 1.238 0 CA-C-N 114.997 -1.001 . . . . 0.0 114.262 176.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.488 HG13 ' HB2' ' A' ' 80' ' ' ALA . 57.8 t -65.48 -44.25 94.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 122.851 0.461 . . . . 0.0 110.128 174.221 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.679 HG22 HG22 ' A' ' 62' ' ' VAL . 43.7 mt -69.7 -54.4 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 C-N-CA 123.322 0.649 . . . . 0.0 110.619 175.457 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.512 ' HB3' ' HZ1' ' A' ' 41' ' ' LYS . 9.7 mtpm? -56.68 -51.93 66.87 Favored 'General case' 0 C--N 1.347 0.487 0 O-C-N 124.439 1.087 . . . . 0.0 110.216 -174.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.47 ' O ' ' HD3' ' A' ' 46' ' ' LYS . . . -61.87 -40.18 98.5 Favored Glycine 0 C--N 1.342 0.886 0 O-C-N 124.984 1.428 . . . . 0.0 112.822 178.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.79 -53.48 57.32 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-N 117.161 0.48 . . . . 0.0 110.955 179.181 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.546 HG21 HG12 ' A' ' 64' ' ' VAL . 68.3 mt -62.11 -39.9 85.54 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.823 0 CA-C-N 115.43 -0.805 . . . . 0.0 111.972 -179.163 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.434 ' HG3' ' O ' ' A' ' 41' ' ' LYS . 76.8 mt-10 -62.0 -50.46 71.96 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 123.157 0.583 . . . . 0.0 112.108 179.582 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.47 ' HD3' ' O ' ' A' ' 42' ' ' GLY . 13.3 mptt -73.0 -28.11 62.18 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.52 -171.536 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.1 m -85.15 -41.06 16.02 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 122.815 0.446 . . . . 0.0 110.291 177.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.2 t -127.03 103.58 23.39 Favored Pre-proline 0 N--CA 1.483 1.213 0 C-N-CA 124.117 0.967 . . . . 0.0 109.772 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -66.91 136.58 41.99 Favored 'Trans proline' 0 C--N 1.374 1.906 0 C-N-CA 122.772 2.315 . . . . 0.0 111.684 172.037 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.18 -4.74 67.73 Favored Glycine 0 C--N 1.346 1.084 0 CA-C-O 119.769 -0.462 . . . . 0.0 113.948 175.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.61 106.68 9.56 Favored 'General case' 0 C--N 1.351 0.649 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 173.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.43 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -77.15 99.52 5.43 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -177.063 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.417 HG11 HG11 ' A' ' 64' ' ' VAL . 27.7 m -85.28 127.45 39.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 123.123 0.569 . . . . 0.0 110.886 -171.089 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . 0.426 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 29.2 t60 -131.62 96.95 4.08 Favored 'General case' 0 C--N 1.345 0.391 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 176.069 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.593 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -93.6 113.59 25.73 Favored 'General case' 0 C--O 1.241 0.646 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 176.031 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -99.66 114.83 65.86 Favored Pre-proline 0 N--CA 1.468 0.433 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 -177.397 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.52 -40.4 57.12 Favored 'Trans proline' 0 C--N 1.373 1.829 0 C-N-CA 123.011 2.474 . . . . 0.0 112.767 -176.234 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -74.31 -47.8 32.4 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 123.619 0.767 . . . . 0.0 111.31 -176.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.1 m -81.26 -15.65 54.94 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.7 0.8 . . . . 0.0 111.455 -176.111 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.7 mmt180 62.97 29.43 16.46 Favored 'General case' 0 N--CA 1.487 1.421 0 C-N-CA 124.63 1.172 . . . . 0.0 111.437 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 33.2 m -122.79 122.76 39.47 Favored 'General case' 0 N--CA 1.479 1.017 0 O-C-N 121.825 -0.547 . . . . 0.0 111.521 -169.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.679 HG22 HG22 ' A' ' 40' ' ' ILE . 40.5 t -99.11 106.4 18.86 Favored 'Isoleucine or valine' 0 C--N 1.35 0.608 0 C-N-CA 123.943 0.897 . . . . 0.0 108.977 173.279 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.0 t -100.41 123.2 53.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.617 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.546 HG12 HG21 ' A' ' 44' ' ' ILE . 17.0 m -111.56 108.94 26.77 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.994 0 CA-C-O 121.475 0.655 . . . . 0.0 110.158 179.393 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.44 150.84 21.03 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.549 -176.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.13 -23.67 30.4 Favored Glycine 0 C--N 1.344 0.984 0 C-N-CA 123.104 0.383 . . . . 0.0 113.051 177.037 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 22.4 m -105.54 151.13 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 123.969 0.908 . . . . 0.0 110.151 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.0 m -126.84 -2.55 6.57 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 124.005 0.922 . . . . 0.0 110.36 -178.658 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -87.35 73.0 9.71 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.54 1.136 . . . . 0.0 110.247 -177.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.412 ' HA ' HD12 ' A' ' 24' ' ' LEU . . . -64.01 -29.17 70.35 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 114.907 -1.042 . . . . 0.0 112.453 -174.747 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -63.76 -49.37 73.25 Favored 'General case' 0 N--CA 1.474 0.745 0 O-C-N 123.799 0.687 . . . . 0.0 110.863 177.545 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.501 ' O ' HG13 ' A' ' 76' ' ' ILE . 39.9 m170 -59.41 -54.93 41.05 Favored 'General case' 0 N--CA 1.478 0.957 0 O-C-N 123.488 0.493 . . . . 0.0 110.474 177.772 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.527 HG21 HG21 ' A' ' 64' ' ' VAL . 41.4 mm -57.74 -40.27 74.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 O-C-N 124.343 1.027 . . . . 0.0 110.811 -174.352 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.33 -40.11 89.47 Favored 'General case' 0 N--CA 1.48 1.029 0 O-C-N 124.039 0.837 . . . . 0.0 111.397 178.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -68.3 -32.05 71.92 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 123.181 0.593 . . . . 0.0 111.291 178.071 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.501 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.5 mt -74.77 -48.62 32.99 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 C-N-CA 122.951 0.5 . . . . 0.0 111.245 -177.125 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.437 HG22 ' O ' ' A' ' 73' ' ' ILE . 8.5 tt -67.38 -32.36 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 C-N-CA 123.254 0.622 . . . . 0.0 111.253 -177.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -75.12 -31.02 61.01 Favored 'General case' 0 CA--C 1.549 0.917 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -69.0 -18.46 64.05 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.494 0.718 . . . . 0.0 111.737 176.115 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.488 ' HB2' HG13 ' A' ' 39' ' ' VAL . . . -75.91 0.67 17.48 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 123.645 0.778 . . . . 0.0 112.269 176.414 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 95.84 16.97 37.0 Favored Glycine 0 C--N 1.35 1.328 0 C-N-CA 122.801 0.239 . . . . 0.0 112.544 179.63 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -120.76 178.38 4.72 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.361 1.065 . . . . 0.0 109.714 -177.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 39.3 m -139.41 111.83 7.78 Favored Pre-proline 0 N--CA 1.479 0.977 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 173.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -66.47 120.33 7.45 Favored 'Trans proline' 0 C--N 1.381 2.285 0 C-N-CA 122.423 2.082 . . . . 0.0 110.779 171.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 . . . . . 0 C--O 1.251 1.166 0 C-N-CA 124.212 1.005 . . . . 0.0 109.526 -175.652 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.02 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -124.8 97.22 0.53 Allowed Glycine 0 C--N 1.343 0.961 0 N-CA-C 110.971 -0.851 . . . . 0.0 110.971 179.122 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -87.65 115.62 25.22 Favored 'General case' 0 N--CA 1.479 1.025 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -173.224 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 76.4 p -91.06 121.45 32.87 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 123.363 0.665 . . . . 0.0 111.337 -176.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -106.89 130.27 54.59 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.783 0.833 . . . . 0.0 109.563 175.546 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 9.8 m-70 -90.46 120.64 31.74 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 173.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.457 HG22 HD12 ' A' ' 40' ' ' ILE . 25.7 t -111.24 91.77 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 N-CA-C 104.765 -2.309 . . . . 0.0 104.765 160.413 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -68.62 -16.29 63.8 Favored 'General case' 0 CA--C 1.548 0.881 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -159.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -109.7 8.78 24.91 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.258 0.623 . . . . 0.0 111.472 -178.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 56.8 ttp -73.91 99.05 3.14 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.61 0.764 . . . . 0.0 109.843 176.06 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.0 t -101.3 104.57 15.59 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 123.103 0.561 . . . . 0.0 109.569 178.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.497 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 17.0 t 64.83 -170.99 0.19 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.382 1.073 . . . . 0.0 111.888 176.647 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.546 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -62.27 -6.36 10.33 Favored Glycine 0 C--N 1.355 1.599 0 CA-C-O 119.203 -0.776 . . . . 0.0 114.391 178.379 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 41.2 m80 -50.22 -40.17 46.62 Favored 'General case' 0 C--N 1.365 1.278 0 C-N-CA 124.274 1.03 . . . . 0.0 111.736 172.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -118.83 -31.6 4.75 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.151 0.58 . . . . 0.0 110.892 176.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.546 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -57.91 -34.16 69.54 Favored 'General case' 0 N--CA 1.481 1.109 0 C-N-CA 123.458 0.703 . . . . 0.0 112.699 -176.092 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -58.7 -52.45 53.02 Favored Glycine 0 C--N 1.348 1.246 0 O-C-N 123.842 0.713 . . . . 0.0 114.347 -177.106 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.3 p -69.83 -30.53 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 C-N-CA 123.012 0.525 . . . . 0.0 111.561 -177.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.632 HG22 HG22 ' A' ' 62' ' ' VAL . 83.4 mt -70.23 -47.21 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 123.082 0.553 . . . . 0.0 110.666 179.216 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -61.38 -44.24 97.5 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.639 0.775 . . . . 0.0 110.467 178.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.14 -36.43 93.23 Favored Glycine 0 C--N 1.348 1.197 0 O-C-N 124.202 0.939 . . . . 0.0 112.899 176.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.05 -53.77 50.91 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 123.376 0.671 . . . . 0.0 110.878 -178.359 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.514 HG23 HG12 ' A' ' 64' ' ' VAL . 64.0 mt -72.82 -46.27 53.6 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.936 -175.007 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -66.93 -39.23 87.29 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 123.551 0.74 . . . . 0.0 112.249 -172.146 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.1 mptp? -83.58 -14.34 52.32 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -176.652 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 54.5 m -90.24 -39.06 13.01 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 122.98 0.512 . . . . 0.0 109.802 173.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 91.4 t -121.01 96.38 48.57 Favored Pre-proline 0 N--CA 1.48 1.028 0 C-N-CA 123.939 0.896 . . . . 0.0 109.323 -179.538 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.93 113.0 3.26 Favored 'Trans proline' 0 C--N 1.37 1.662 0 C-N-CA 122.346 2.031 . . . . 0.0 110.589 175.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.39 -11.42 9.75 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-O 119.575 -0.57 . . . . 0.0 112.722 -176.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -78.42 106.89 10.67 Favored 'General case' 0 C--N 1.356 0.871 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 171.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.72 99.09 4.97 Favored 'General case' 0 C--N 1.349 0.577 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.0 m -85.49 123.63 39.5 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 CA-C-O 121.023 0.439 . . . . 0.0 110.155 -172.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 71.9 t60 -131.79 97.88 4.31 Favored 'General case' 0 C--N 1.343 0.32 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -176.496 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.4 114.52 28.86 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -178.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.436 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 13.5 t70 -99.56 127.12 35.08 Favored Pre-proline 0 CA--C 1.54 0.586 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -177.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.497 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 30.8 Cg_endo -61.62 -41.16 41.32 Favored 'Trans proline' 0 C--N 1.377 2.074 0 C-N-CA 123.105 2.537 . . . . 0.0 113.23 179.264 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.19 -35.28 48.8 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.728 0.811 . . . . 0.0 111.944 -174.521 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.436 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 19.2 m -88.83 -22.07 23.39 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.443 0.697 . . . . 0.0 111.061 -177.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? 57.99 41.07 24.9 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 124.653 1.181 . . . . 0.0 110.744 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 80.8 m -132.81 121.83 23.56 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.882 -171.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.632 HG22 HG22 ' A' ' 40' ' ' ILE . 21.1 t -98.89 104.7 16.32 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 C-N-CA 124.426 1.091 . . . . 0.0 108.638 173.828 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.8 t -95.48 131.35 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 108.023 -1.102 . . . . 0.0 108.023 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.514 HG12 HG23 ' A' ' 44' ' ' ILE . 26.2 m -111.58 109.97 30.46 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.869 0 CA-C-O 121.636 0.731 . . . . 0.0 109.84 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -89.77 149.83 20.73 Favored Glycine 0 C--N 1.346 1.1 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.733 -174.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 86.3 -20.04 24.03 Favored Glycine 0 C--N 1.341 0.84 0 C-N-CA 123.055 0.359 . . . . 0.0 112.879 -178.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 30.3 m -123.75 145.96 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 124.46 1.104 . . . . 0.0 108.881 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.6 m -130.19 -6.63 4.34 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 123.545 0.738 . . . . 0.0 111.302 -176.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -75.88 84.24 2.81 Favored 'General case' 0 CA--C 1.55 0.96 0 CA-C-O 122.338 1.066 . . . . 0.0 110.351 -178.095 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.81 -40.55 95.65 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 113.911 -1.495 . . . . 0.0 112.869 -171.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -58.75 -46.88 86.43 Favored 'General case' 0 N--CA 1.479 0.994 0 O-C-N 124.11 0.881 . . . . 0.0 111.882 -176.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 72.7 t60 -66.97 -50.78 61.24 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.023 -178.324 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 36.8 mm -59.88 -37.35 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 O-C-N 123.67 0.606 . . . . 0.0 110.407 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.43 -37.71 88.36 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 123.858 0.863 . . . . 0.0 111.736 -179.522 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 45.0 mm-40 -65.07 -35.86 82.5 Favored 'General case' 0 N--CA 1.476 0.825 0 O-C-N 123.685 0.615 . . . . 0.0 111.036 176.465 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 62.3 mt -67.99 -49.46 68.11 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.236 0 C-N-CA 123.112 0.565 . . . . 0.0 111.495 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.4 tt -71.4 -35.42 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 C-N-CA 123.182 0.593 . . . . 0.0 111.516 -176.341 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.2 t -71.63 -28.86 64.07 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 176.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.72 -26.8 65.44 Favored 'General case' 0 C--N 1.358 0.963 0 C-N-CA 123.592 0.757 . . . . 0.0 111.006 173.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.92 -3.16 33.89 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.513 0.725 . . . . 0.0 111.822 174.052 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 94.51 12.69 55.59 Favored Glycine 0 C--N 1.348 1.221 0 CA-C-O 119.713 -0.493 . . . . 0.0 113.058 175.437 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -128.5 105.81 8.56 Favored 'General case' 0 N--CA 1.483 1.224 0 CA-C-N 117.401 0.601 . . . . 0.0 109.919 179.247 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.9 t -76.4 123.93 87.92 Favored Pre-proline 0 CA--C 1.556 1.173 0 C-N-CA 123.253 0.621 . . . . 0.0 110.619 -178.099 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -79.08 173.99 12.71 Favored 'Trans proline' 0 C--N 1.373 1.824 0 C-N-CA 122.695 2.264 . . . . 0.0 111.37 168.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 . . . . . 0 C--O 1.25 1.118 0 C-N-CA 123.444 0.698 . . . . 0.0 109.331 -177.225 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -173.29 -101.79 0.15 Allowed Glycine 0 C--N 1.344 1.016 0 CA-C-N 115.793 -0.64 . . . . 0.0 112.038 -179.097 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -134.93 132.44 38.45 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-N 117.245 0.523 . . . . 0.0 109.826 -172.684 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.6 t -104.55 134.45 47.71 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 123.911 0.885 . . . . 0.0 110.709 -177.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -135.59 118.97 16.77 Favored 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 124.156 0.982 . . . . 0.0 109.237 173.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.552 ' HA ' ' HA ' ' A' ' 61' ' ' THR . 35.2 p-80 -92.26 118.38 30.82 Favored 'General case' 0 N--CA 1.477 0.898 0 CA-C-N 118.657 0.662 . . . . 0.0 109.984 175.32 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.418 ' O ' ' HB3' ' A' ' 60' ' ' ARG . 39.7 t -96.27 97.22 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 170.613 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -61.01 -26.92 67.94 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 123.556 0.743 . . . . 0.0 111.864 -176.375 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -80.16 -19.69 46.58 Favored 'General case' 0 CA--C 1.553 1.061 0 C-N-CA 124.147 0.979 . . . . 0.0 111.496 -178.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 62.9 ttp -68.7 129.72 40.75 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.655 0.782 . . . . 0.0 112.235 -175.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.3 p -85.43 169.88 13.23 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 124.333 1.053 . . . . 0.0 109.987 170.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 35.0 t -56.11 -151.7 0.0 OUTLIER 'General case' 0 CA--C 1.581 2.159 0 C-N-CA 125.078 1.351 . . . . 0.0 113.178 178.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -62.0 -2.66 3.99 Favored Glycine 0 C--N 1.356 1.688 0 N-CA-C 116.144 1.218 . . . . 0.0 116.144 -171.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -77.28 -22.79 51.54 Favored 'General case' 0 CA--C 1.552 1.021 0 CA-C-N 117.67 0.735 . . . . 0.0 112.208 178.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 19.3 p -124.41 -5.59 7.69 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 122.439 0.296 . . . . 0.0 111.597 177.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -64.65 -31.16 72.26 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.416 0.686 . . . . 0.0 112.498 -175.132 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.08 -50.46 67.58 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 114.565 0.586 . . . . 0.0 114.565 -174.052 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.3 m -66.35 -31.97 55.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 123.093 0.557 . . . . 0.0 112.119 -178.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.436 HG21 HG21 ' A' ' 62' ' ' VAL . 76.1 mt -72.22 -54.97 14.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.694 0 C-N-CA 123.884 0.874 . . . . 0.0 110.17 -177.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -61.33 -42.51 98.8 Favored 'General case' 0 CA--C 1.537 0.456 0 CA-C-N 114.343 -1.299 . . . . 0.0 110.79 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -68.07 -34.01 80.34 Favored Glycine 0 C--N 1.342 0.897 0 O-C-N 124.16 0.913 . . . . 0.0 113.131 -178.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -65.08 -53.75 40.74 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.789 0.435 . . . . 0.0 110.514 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.545 ' HA ' HG21 ' A' ' 76' ' ' ILE . 62.9 mt -63.98 -40.87 90.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.719 -178.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -64.68 -43.67 92.81 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.308 0.643 . . . . 0.0 111.549 -179.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -81.76 -18.56 43.79 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -175.108 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 36.8 m -87.26 -40.98 14.03 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 175.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.7 t -121.83 88.9 47.69 Favored Pre-proline 0 N--CA 1.48 1.069 0 C-N-CA 123.872 0.869 . . . . 0.0 108.831 174.067 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -60.94 113.18 1.61 Allowed 'Trans proline' 0 C--N 1.375 1.93 0 C-N-CA 122.632 2.222 . . . . 0.0 111.588 175.01 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.5 -5.37 11.86 Favored Glycine 0 C--N 1.341 0.856 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.804 -176.163 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -78.07 106.84 10.21 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 173.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.03 96.82 3.88 Favored 'General case' 0 C--N 1.351 0.658 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.451 HG13 HG13 ' A' ' 64' ' ' VAL . 7.8 m -88.85 134.83 27.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.729 -172.505 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -142.08 101.45 3.93 Favored 'General case' 0 C--N 1.352 0.684 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 176.621 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.12 114.69 22.44 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 173.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -93.41 130.35 35.79 Favored Pre-proline 0 CA--C 1.542 0.666 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 -175.071 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -64.86 -53.65 0.88 Allowed 'Trans proline' 0 C--N 1.372 1.797 0 C-N-CA 122.634 2.223 . . . . 0.0 113.058 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.82 -36.02 50.66 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.266 -170.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 26.3 t -87.6 -18.25 30.1 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 123.432 0.693 . . . . 0.0 110.685 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.418 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 10.4 mpt_? 60.94 31.36 19.97 Favored 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 124.467 1.107 . . . . 0.0 111.268 -176.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' THR . . . . . 0.552 ' HA ' ' HA ' ' A' ' 27' ' ' HIS . 53.8 m -116.53 122.45 44.74 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -168.534 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.436 HG21 HG21 ' A' ' 40' ' ' ILE . 31.6 t -96.75 106.38 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 172.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 18.8 t -102.24 131.83 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.529 HG23 HG13 ' A' ' 73' ' ' ILE . 35.6 m -105.43 139.41 26.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 C-N-CA 123.422 0.689 . . . . 0.0 109.535 174.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -118.36 151.03 18.0 Favored Glycine 0 C--N 1.341 0.859 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.058 -175.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 79.32 -12.04 27.98 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-O 120.142 -0.255 . . . . 0.0 113.092 -177.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 33.3 m -132.65 131.12 59.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 C-N-CA 124.406 1.083 . . . . 0.0 108.787 -178.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t -112.43 10.67 19.81 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.657 0.783 . . . . 0.0 110.121 -177.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.421 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 3.2 m-20 -70.57 87.37 0.66 Allowed 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 124.14 0.976 . . . . 0.0 110.922 -176.069 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.5 -58.16 9.65 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 122.793 0.437 . . . . 0.0 112.168 -173.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -64.66 -36.42 84.2 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.048 0.539 . . . . 0.0 111.648 -175.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.421 ' HB2' ' HB3' ' A' ' 69' ' ' ASP . 65.2 m170 -65.29 -55.38 18.64 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 123.029 0.532 . . . . 0.0 111.111 -179.522 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.529 HG13 HG23 ' A' ' 64' ' ' VAL . 47.8 mm -60.93 -40.26 84.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 O-C-N 123.856 0.723 . . . . 0.0 110.316 -177.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.0 -38.38 82.45 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.17 0.988 . . . . 0.0 111.707 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 35.5 mm-40 -69.14 -35.93 76.89 Favored 'General case' 0 N--CA 1.475 0.822 0 O-C-N 123.511 0.507 . . . . 0.0 111.768 179.095 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.545 HG21 ' HA ' ' A' ' 44' ' ' ILE . 43.9 mt -65.82 -50.24 71.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 CA-C-O 121.152 0.501 . . . . 0.0 110.863 -178.402 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.407 ' HB ' HD11 ' A' ' 44' ' ' ILE . 12.3 tt -73.75 -32.81 36.03 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 CA-C-N 115.138 -0.937 . . . . 0.0 111.885 -173.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.1 t -72.76 -29.63 63.47 Favored 'General case' 0 N--CA 1.484 1.245 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 174.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.41 -28.93 67.51 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.179 0.592 . . . . 0.0 110.589 173.063 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.24 -5.94 47.14 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 123.538 0.735 . . . . 0.0 111.755 175.615 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.91 21.16 40.37 Favored Glycine 0 C--N 1.348 1.214 0 O-C-N 123.141 0.275 . . . . 0.0 112.993 176.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -128.02 114.49 17.17 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 123.472 0.709 . . . . 0.0 109.381 178.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.3 t -70.28 114.13 23.41 Favored Pre-proline 0 CA--C 1.561 1.383 0 C-N-CA 123.332 0.653 . . . . 0.0 111.117 -176.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.401 ' HA ' HG23 ' A' ' 28' ' ' VAL . 73.5 Cg_endo -71.53 -19.26 28.57 Favored 'Trans proline' 0 C--N 1.384 2.415 0 C-N-CA 122.856 2.37 . . . . 0.0 112.836 -177.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 . . . . . 0 C--O 1.246 0.896 0 C-N-CA 124.319 1.048 . . . . 0.0 108.8 -178.436 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.187 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 69.4 -158.48 53.28 Favored Glycine 0 C--N 1.351 1.403 0 O-C-N 123.365 0.416 . . . . 0.0 113.573 176.312 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.405 HD12 ' HA ' ' A' ' 70' ' ' ALA . 72.5 mt -108.29 107.55 18.2 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 123.714 0.806 . . . . 0.0 109.059 177.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.4 m -95.35 114.16 25.91 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.232 0.613 . . . . 0.0 110.822 -173.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -109.72 106.45 16.1 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 123.97 0.908 . . . . 0.0 110.481 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 16.3 m-70 -83.1 91.31 7.19 Favored 'General case' 0 N--CA 1.479 0.976 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 176.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.448 HG22 ' HA ' ' A' ' 84' ' ' PRO . 47.7 t -82.29 97.58 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 176.434 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -66.33 -24.9 66.61 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 123.23 0.612 . . . . 0.0 112.346 -171.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -87.74 -11.66 47.53 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 122.97 0.508 . . . . 0.0 111.636 177.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.506 ' HG3' ' HB2' ' A' ' 36' ' ' CYS . 13.0 ttt -71.38 137.99 48.82 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.157 0.583 . . . . 0.0 109.553 169.416 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.6 t -129.87 98.48 4.8 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 123.638 0.775 . . . . 0.0 109.911 176.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.42 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 59.6 m 54.64 -154.84 0.26 Allowed 'General case' 0 CA--C 1.557 1.244 0 C-N-CA 124.695 1.198 . . . . 0.0 112.843 173.236 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.489 ' HA2' ' HB2' ' A' ' 37' ' ' ALA . . . -58.06 -26.5 58.5 Favored Glycine 0 C--N 1.361 1.946 0 C-N-CA 123.697 0.665 . . . . 0.0 114.097 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 14.2 t-80 -56.54 -32.78 65.45 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.383 1.073 . . . . 0.0 111.793 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.506 ' HB2' ' HG3' ' A' ' 31' ' ' MET . 62.1 m -111.15 -18.18 13.05 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.181 0.592 . . . . 0.0 111.423 178.465 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.489 ' HB2' ' HA2' ' A' ' 34' ' ' GLY . . . -64.47 -47.16 80.02 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 123.231 0.612 . . . . 0.0 112.321 -176.247 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.26 -46.13 92.01 Favored Glycine 0 N--CA 1.475 1.281 0 O-C-N 123.995 0.809 . . . . 0.0 114.147 -172.424 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -68.22 -31.7 52.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.011 0 C-N-CA 123.626 0.77 . . . . 0.0 111.017 -179.404 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.74 HG23 HG22 ' A' ' 62' ' ' VAL . 65.8 mt -69.31 -43.99 80.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 123.641 0.777 . . . . 0.0 111.05 175.417 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.445 ' HG3' ' O ' ' A' ' 37' ' ' ALA . 95.1 mttt -58.2 -47.23 84.1 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.575 0.75 . . . . 0.0 109.546 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.65 -36.14 92.95 Favored Glycine 0 C--N 1.348 1.234 0 O-C-N 124.466 1.104 . . . . 0.0 112.824 178.32 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.38 -55.5 27.32 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 122.852 0.461 . . . . 0.0 111.142 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.498 HG23 HG13 ' A' ' 64' ' ' VAL . 57.6 mt -69.74 -47.12 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.743 -176.109 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -57.84 -50.07 74.55 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.038 0.935 . . . . 0.0 111.955 -176.149 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -70.52 -26.44 63.58 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.032 -174.357 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 47.4 m -86.13 -42.22 14.06 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.733 0.413 . . . . 0.0 110.995 -178.196 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.9 m -132.05 86.44 47.15 Favored Pre-proline 0 CA--C 1.561 1.37 0 C-N-CA 123.752 0.821 . . . . 0.0 110.702 -179.41 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -56.63 123.97 15.12 Favored 'Trans proline' 0 C--N 1.377 2.04 0 C-N-CA 123.039 2.492 . . . . 0.0 111.372 169.475 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.79 -22.34 8.17 Favored Glycine 0 N--CA 1.473 1.116 0 CA-C-O 119.979 -0.345 . . . . 0.0 112.313 -175.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.1 106.94 6.85 Favored 'General case' 0 C--N 1.355 0.808 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 175.671 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.09 100.77 9.2 Favored 'General case' 0 C--N 1.342 0.275 0 C-N-CA 123.729 0.812 . . . . 0.0 109.488 -177.43 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.473 HG12 HG12 ' A' ' 64' ' ' VAL . 35.2 m -84.57 134.59 26.65 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 123.059 0.543 . . . . 0.0 110.16 -172.477 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 48.4 t-80 -136.36 97.49 3.6 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 172.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.424 ' HB3' ' HE2' ' A' ' 31' ' ' MET . . . -92.2 114.33 26.84 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -86.29 123.71 71.09 Favored Pre-proline 0 CA--C 1.542 0.64 0 CA-C-O 118.567 -0.73 . . . . 0.0 109.058 -173.222 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.42 ' HA ' ' HA ' ' A' ' 33' ' ' CYS . 21.5 Cg_endo -58.84 -45.67 27.54 Favored 'Trans proline' 0 C--N 1.372 1.81 0 C-N-CA 122.863 2.375 . . . . 0.0 112.861 179.118 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.31 -45.88 21.57 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.411 0.685 . . . . 0.0 111.815 -173.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 17.0 m -90.05 -5.8 56.21 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 123.479 0.712 . . . . 0.0 112.285 -172.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 40.69 45.01 1.96 Allowed 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 125.676 1.59 . . . . 0.0 112.548 -172.329 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 59.2 m -114.39 118.58 34.24 Favored 'General case' 0 C--N 1.346 0.444 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.413 -175.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.74 HG22 HG23 ' A' ' 40' ' ' ILE . 27.9 t -97.32 105.84 17.71 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 177.147 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 21.6 t -98.56 119.46 46.58 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 C-N-CA 123.956 0.903 . . . . 0.0 109.333 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.498 HG13 HG23 ' A' ' 44' ' ' ILE . 28.2 m -110.09 112.07 38.91 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.865 0 CA-C-O 121.562 0.696 . . . . 0.0 110.712 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.4 170.16 31.03 Favored Glycine 0 C--N 1.344 1.007 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.603 176.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.73 -5.92 49.9 Favored Glycine 0 N--CA 1.472 1.066 0 N-CA-C 114.069 0.388 . . . . 0.0 114.069 177.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 18.1 m -128.89 148.37 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 124.773 1.229 . . . . 0.0 109.415 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.3 t -114.47 0.15 13.94 Favored 'General case' 0 N--CA 1.482 1.159 0 C-N-CA 123.604 0.761 . . . . 0.0 110.366 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.414 ' O ' HG12 ' A' ' 73' ' ' ILE . 3.4 m-20 -91.18 70.95 6.24 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.099 0.959 . . . . 0.0 110.231 -169.703 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.405 ' HA ' HD12 ' A' ' 24' ' ' LEU . . . -58.94 -49.78 76.55 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 123.409 0.684 . . . . 0.0 112.575 -174.163 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.66 91.09 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.69 0.796 . . . . 0.0 111.511 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.407 ' O ' HG13 ' A' ' 76' ' ' ILE . 74.8 t60 -66.39 -46.7 75.76 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.017 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.482 HG21 HG22 ' A' ' 64' ' ' VAL . 47.4 mm -60.59 -39.15 80.48 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 O-C-N 123.702 0.626 . . . . 0.0 109.671 177.589 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -58.07 -38.71 76.86 Favored 'General case' 0 N--CA 1.473 0.682 0 O-C-N 124.147 0.905 . . . . 0.0 111.641 178.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -67.94 -38.48 82.89 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 123.261 0.624 . . . . 0.0 111.192 176.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.486 HG21 ' HA ' ' A' ' 44' ' ' ILE . 64.7 mt -68.46 -50.04 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 C-N-CA 123.279 0.631 . . . . 0.0 111.528 -177.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.439 HG21 ' HD3' ' A' ' 84' ' ' PRO . 13.5 tt -69.37 -35.3 66.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 123.373 0.669 . . . . 0.0 111.318 -175.812 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.4 t -70.11 -29.32 66.24 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 122.207 0.203 . . . . 0.0 110.527 176.43 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.31 -17.48 64.78 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 123.51 0.724 . . . . 0.0 112.23 176.167 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -85.98 5.12 34.72 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.574 0.749 . . . . 0.0 111.355 172.408 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.36 2.55 79.71 Favored Glycine 0 C--N 1.347 1.171 0 CA-C-O 119.424 -0.653 . . . . 0.0 113.697 178.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.437 ' HB3' HG11 ' A' ' 28' ' ' VAL . 84.2 m-85 -119.16 105.48 11.42 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 117.917 0.858 . . . . 0.0 109.651 -177.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.0 t -86.87 127.72 58.79 Favored Pre-proline 0 CA--C 1.55 0.959 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.88 -170.483 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.448 ' HA ' HG22 ' A' ' 28' ' ' VAL . 57.3 Cg_endo -69.97 -36.97 9.32 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.529 2.153 . . . . 0.0 112.159 177.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.5 mm-40 . . . . . 0 C--O 1.251 1.142 0 C-N-CA 125.078 1.351 . . . . 0.0 111.302 -177.967 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.93 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.84 -162.52 26.84 Favored Glycine 0 C--N 1.347 1.162 0 C-N-CA 123.086 0.375 . . . . 0.0 112.549 178.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.505 HD13 ' HA ' ' A' ' 70' ' ' ALA . 25.1 mt -96.74 108.61 21.29 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.857 0.863 . . . . 0.0 110.34 -175.616 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.2 t -86.92 119.68 27.4 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 123.275 0.63 . . . . 0.0 109.913 177.655 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -112.79 118.02 33.8 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.558 0.743 . . . . 0.0 109.658 175.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 44.9 p-80 -83.75 88.3 7.08 Favored 'General case' 0 CA--C 1.546 0.817 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 175.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.506 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 35.3 t -80.79 104.39 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -172.196 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -73.31 -16.44 61.37 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 115.668 -0.696 . . . . 0.0 112.051 -175.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 35.8 t70 -106.71 16.33 24.59 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.361 0.664 . . . . 0.0 110.534 179.325 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.506 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 25.1 ttt -71.31 136.13 47.72 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 121.012 0.434 . . . . 0.0 111.516 -176.432 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 20.3 p -86.88 162.04 17.95 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.16 0.984 . . . . 0.0 110.913 173.187 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 61.2 m -74.89 -167.41 0.58 Allowed 'General case' 0 CA--C 1.561 1.376 0 C-N-CA 123.663 0.785 . . . . 0.0 111.756 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -57.66 -29.04 60.73 Favored Glycine 0 C--N 1.355 1.635 0 N-CA-C 115.695 1.038 . . . . 0.0 115.695 -172.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -69.3 -22.92 63.76 Favored 'General case' 0 N--CA 1.486 1.364 0 CA-C-N 117.428 0.614 . . . . 0.0 112.371 -176.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.7 m -123.24 13.14 9.59 Favored 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 123.636 0.774 . . . . 0.0 110.955 176.567 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -65.97 -41.64 90.9 Favored 'General case' 0 C--N 1.357 0.922 0 C-N-CA 123.131 0.572 . . . . 0.0 111.392 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.38 -25.61 67.02 Favored Glycine 0 N--CA 1.473 1.129 0 O-C-N 123.134 0.271 . . . . 0.0 113.699 -179.204 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.75 -50.07 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 123.404 0.682 . . . . 0.0 110.808 177.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 15.1 tt -67.99 -32.95 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 C-N-CA 123.025 0.53 . . . . 0.0 110.596 -177.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.426 ' HB3' HG21 ' A' ' 53' ' ' VAL . 96.1 mttt -64.23 -53.17 53.29 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 123.634 0.774 . . . . 0.0 109.56 168.478 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.404 ' HA2' ' HB3' ' A' ' 45' ' ' GLU . . . -59.06 -29.83 65.93 Favored Glycine 0 C--N 1.358 1.77 0 O-C-N 124.873 1.358 . . . . 0.0 114.046 -173.132 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.87 -54.15 48.05 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 123.818 0.847 . . . . 0.0 110.665 177.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.55 HG21 HG13 ' A' ' 64' ' ' VAL . 60.2 mt -75.21 -41.91 44.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.814 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.404 ' HB3' ' HA2' ' A' ' 42' ' ' GLY . 17.6 tp10 -54.26 -51.14 65.49 Favored 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 125.418 1.487 . . . . 0.0 112.282 -174.632 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? -79.64 -25.85 41.25 Favored 'General case' 0 N--CA 1.483 1.176 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.84 -175.439 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 87.0 m -76.77 -48.14 19.56 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-O 120.814 0.34 . . . . 0.0 110.673 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.511 HG12 HG11 ' A' ' 67' ' ' VAL . 56.5 t -112.22 110.23 53.72 Favored Pre-proline 0 N--CA 1.475 0.78 0 C-N-CA 123.459 0.704 . . . . 0.0 109.432 -178.424 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -72.41 110.32 2.95 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.403 2.069 . . . . 0.0 111.342 172.099 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 117.1 -2.57 19.16 Favored Glycine 0 C--N 1.342 0.867 0 CA-C-O 119.382 -0.677 . . . . 0.0 113.548 179.191 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -80.22 105.95 11.87 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 173.308 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.72 99.64 8.32 Favored 'General case' 0 C--N 1.346 0.44 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -177.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.465 HG12 HG12 ' A' ' 64' ' ' VAL . 29.3 m -84.74 129.43 37.71 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-O 121.235 0.54 . . . . 0.0 110.446 -174.077 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 63.8 t60 -125.61 97.97 5.38 Favored 'General case' 0 C--O 1.225 -0.213 0 N-CA-C 106.211 -1.774 . . . . 0.0 106.211 174.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.436 ' HB3' ' HE1' ' A' ' 31' ' ' MET . . . -109.84 113.89 27.01 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 -179.176 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.424 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 11.1 t70 -105.76 119.86 51.11 Favored Pre-proline 0 N--CA 1.468 0.469 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -175.126 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -63.37 -33.77 68.8 Favored 'Trans proline' 0 C--N 1.375 1.927 0 C-N-CA 122.989 2.459 . . . . 0.0 113.088 -176.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.88 -45.64 23.6 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.127 0.571 . . . . 0.0 111.083 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.424 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 35.4 m -80.35 -23.95 40.18 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 123.253 0.621 . . . . 0.0 111.568 -174.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.459 ' HA ' ' SD ' ' A' ' 31' ' ' MET . 37.5 mmt180 65.08 35.41 8.01 Favored 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 124.71 1.204 . . . . 0.0 111.093 -177.464 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 11.9 m -122.8 117.97 26.89 Favored 'General case' 0 C--O 1.241 0.609 0 C-N-CA 123.029 0.532 . . . . 0.0 110.778 -171.058 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 45.9 t -103.76 106.71 20.72 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 172.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 24.9 t -105.11 130.25 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 124.452 1.101 . . . . 0.0 109.099 -179.238 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.55 HG13 HG21 ' A' ' 44' ' ' ILE . 17.6 m -117.63 109.52 27.79 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.023 0 CA-C-O 121.419 0.628 . . . . 0.0 111.107 -178.32 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -86.87 161.01 32.95 Favored Glycine 0 C--N 1.346 1.114 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.817 178.501 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 83.09 -11.3 55.37 Favored Glycine 0 N--CA 1.472 1.035 0 CA-C-O 119.806 -0.441 . . . . 0.0 113.62 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.511 HG11 HG12 ' A' ' 48' ' ' VAL . 30.6 m -128.89 150.85 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.272 0 C-N-CA 124.022 0.929 . . . . 0.0 109.935 -176.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 29.1 t -124.85 -2.89 7.75 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.749 0.82 . . . . 0.0 111.586 -174.199 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.485 ' HB3' ' HB3' ' A' ' 72' ' ' HIS . 6.1 m-20 -79.24 82.05 5.43 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 123.493 0.717 . . . . 0.0 109.999 -178.592 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.505 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -62.93 -49.28 75.39 Favored 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 123.231 0.612 . . . . 0.0 112.068 -172.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.455 ' O ' ' HG3' ' A' ' 75' ' ' GLU . . . -65.68 -39.35 91.23 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.62 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.485 ' HB3' ' HB3' ' A' ' 69' ' ' ASP . 79.5 t60 -70.25 -42.09 72.64 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 123.596 0.758 . . . . 0.0 112.239 -175.493 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.515 HG21 HG23 ' A' ' 64' ' ' VAL . 33.8 mm -63.74 -37.61 80.15 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 175.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.54 -33.31 74.65 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.226 176.44 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.455 ' HG3' ' O ' ' A' ' 71' ' ' ALA . 46.5 mt-10 -64.73 -41.41 95.98 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 123.191 0.596 . . . . 0.0 110.541 174.595 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 70.0 mt -69.46 -47.33 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.406 0.682 . . . . 0.0 111.265 -175.222 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 15.1 tt -74.33 -26.85 20.84 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.02 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.179 -176.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.505 ' HA ' ' O ' ' A' ' 82' ' ' TYR . 2.3 t -75.69 -29.35 58.99 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 175.236 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.51 -18.28 64.35 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.681 0.792 . . . . 0.0 111.566 175.297 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -79.83 3.35 19.91 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.814 0.845 . . . . 0.0 112.219 174.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.32 5.56 75.75 Favored Glycine 0 C--N 1.349 1.255 0 CA-C-O 120.216 -0.213 . . . . 0.0 113.024 179.294 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.505 ' O ' ' HA ' ' A' ' 78' ' ' THR . 91.7 m-85 -100.13 162.22 13.11 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.897 0.879 . . . . 0.0 110.047 178.216 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 32.4 p -121.52 103.31 41.32 Favored Pre-proline 0 CA--C 1.55 0.947 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 171.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -60.84 -40.24 55.31 Favored 'Trans proline' 0 C--N 1.387 2.602 0 C-N-CA 123.061 2.508 . . . . 0.0 112.33 175.505 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 64.7 mm-40 . . . . . 0 CA--C 1.552 1.041 0 C-N-CA 124.769 1.228 . . . . 0.0 110.755 -178.04 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.086 0 CA-C-O 121.173 0.511 . . . . 0.0 109.882 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 161.2 -156.98 28.52 Favored Glycine 0 C--N 1.339 0.733 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.381 -178.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.459 HD12 ' HA ' ' A' ' 70' ' ' ALA . 25.9 mt -92.14 115.09 27.78 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 123.912 0.885 . . . . 0.0 109.579 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 47.0 t -83.53 123.05 29.35 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 122.875 0.47 . . . . 0.0 110.24 -179.297 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -125.43 101.38 6.92 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.815 0.846 . . . . 0.0 109.032 174.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 61' ' ' THR . 9.5 p80 -93.82 100.15 12.39 Favored 'General case' 0 CA--C 1.547 0.843 0 CA-C-O 121.503 0.668 . . . . 0.0 110.384 -174.158 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.526 ' O ' ' HB3' ' A' ' 60' ' ' ARG . 92.0 t -82.34 106.04 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 172.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -79.63 -7.75 58.75 Favored 'General case' 0 N--CA 1.485 1.308 0 CA-C-N 118.292 0.496 . . . . 0.0 112.137 -176.281 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -95.15 12.29 29.25 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 123.638 0.775 . . . . 0.0 111.071 171.308 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.435 ' SD ' ' HA ' ' A' ' 60' ' ' ARG . 27.6 ttt -70.9 143.51 50.96 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.541 0.736 . . . . 0.0 111.764 -176.759 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 17.2 p -125.88 165.88 17.91 Favored 'General case' 0 C--O 1.243 0.725 0 C-N-CA 125.161 1.384 . . . . 0.0 108.61 176.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 31.6 p -53.41 179.51 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -173.136 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.49 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -43.94 -26.6 0.85 Allowed Glycine 0 C--N 1.36 1.881 0 N-CA-C 117.603 1.801 . . . . 0.0 117.603 -166.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 69.4 t60 -55.97 -54.77 40.73 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 124.081 0.952 . . . . 0.0 111.061 176.109 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 42.6 t -96.91 -20.91 17.79 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.488 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.49 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -64.81 -36.04 83.03 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 123.068 0.547 . . . . 0.0 110.802 175.684 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.95 -24.82 73.17 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.425 -0.807 . . . . 0.0 113.169 176.103 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 43.3 t -74.5 -38.95 47.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.404 0.682 . . . . 0.0 110.237 176.094 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 22.5 mt -63.98 -47.42 90.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-O 121.455 0.645 . . . . 0.0 109.536 176.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.628 ' HZ3' ' HB3' ' A' ' 41' ' ' LYS . 9.4 mtpm? -59.23 -47.78 84.08 Favored 'General case' 0 C--N 1.35 0.588 0 CA-C-N 114.285 -1.325 . . . . 0.0 110.852 176.107 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.22 -33.03 86.14 Favored Glycine 0 C--N 1.345 1.081 0 O-C-N 124.502 1.126 . . . . 0.0 113.094 -175.396 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -60.49 -54.61 43.47 Favored 'General case' 0 C--N 1.348 0.515 0 C-N-CA 123.133 0.573 . . . . 0.0 110.521 178.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.511 HG21 HG12 ' A' ' 64' ' ' VAL . 54.7 mt -72.55 -45.72 57.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.804 -175.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -64.22 -41.14 97.15 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.947 0.899 . . . . 0.0 111.92 -171.228 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -76.22 -34.75 59.24 Favored 'General case' 0 N--CA 1.481 1.076 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.221 -178.634 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 86.7 m -72.91 -45.84 55.96 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 122.435 0.294 . . . . 0.0 110.744 -178.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 78.0 t -120.5 94.23 48.7 Favored Pre-proline 0 N--CA 1.478 0.933 0 C-N-CA 123.679 0.791 . . . . 0.0 109.054 176.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_exo -64.12 123.87 12.57 Favored 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 122.549 2.166 . . . . 0.0 110.622 169.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 119.68 -20.28 9.45 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 112.108 -0.397 . . . . 0.0 112.108 -174.364 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -79.72 105.7 11.21 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 174.419 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.36 98.25 8.09 Favored 'General case' 0 C--N 1.342 0.259 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -178.026 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.526 HG13 HG11 ' A' ' 64' ' ' VAL . 15.6 m -85.06 116.07 27.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 C-N-CA 123.513 0.725 . . . . 0.0 110.097 -172.449 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 54.9 t-80 -112.55 99.22 7.79 Favored 'General case' 0 C--N 1.347 0.472 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 176.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.34 127.68 34.13 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -111.2 108.11 57.22 Favored Pre-proline 0 CA--C 1.537 0.471 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 175.147 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -64.03 -33.48 62.18 Favored 'Trans proline' 0 C--N 1.367 1.521 0 C-N-CA 122.678 2.252 . . . . 0.0 112.86 -178.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.76 -39.67 43.48 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.46 0.704 . . . . 0.0 111.85 -175.209 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.3 t -92.82 -15.02 26.99 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 123.712 0.805 . . . . 0.0 110.851 -178.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.526 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 63.52 45.26 4.82 Favored 'General case' 0 CA--C 1.554 1.1 0 C-N-CA 124.452 1.101 . . . . 0.0 110.421 -179.272 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' THR . . . . . 0.423 ' HA ' ' HA ' ' A' ' 27' ' ' HIS . 17.8 m -132.85 120.9 22.15 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -170.72 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 47.4 t -104.18 108.28 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 123.686 0.794 . . . . 0.0 109.458 173.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 43.1 t -104.07 121.59 55.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.893 0.877 . . . . 0.0 109.551 -177.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.526 HG11 HG13 ' A' ' 53' ' ' VAL . 27.0 m -102.45 114.43 41.9 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 CA-C-O 121.427 0.632 . . . . 0.0 111.151 -176.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.83 160.37 24.21 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.064 179.129 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 83.22 -11.75 53.64 Favored Glycine 0 N--CA 1.474 1.232 0 CA-C-N 116.695 0.248 . . . . 0.0 113.68 177.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 31.3 m -126.62 142.22 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 124.474 1.11 . . . . 0.0 109.064 178.665 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.2 m -113.25 3.59 16.06 Favored 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 123.352 0.661 . . . . 0.0 110.487 178.403 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -82.44 79.18 8.95 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.129 0.972 . . . . 0.0 110.432 -174.39 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.459 ' HA ' HD12 ' A' ' 24' ' ' LEU . . . -63.77 -37.92 89.18 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 122.86 0.464 . . . . 0.0 111.719 -175.479 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.498 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -65.44 -47.19 77.02 Favored 'General case' 0 N--CA 1.475 0.818 0 O-C-N 123.551 0.532 . . . . 0.0 110.718 179.363 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 17.3 m-70 -58.24 -52.9 63.64 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 123.6 0.76 . . . . 0.0 111.11 -177.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.435 HG13 HG23 ' A' ' 64' ' ' VAL . 47.6 mm -62.02 -38.88 81.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.079 -178.534 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.84 -40.47 88.62 Favored 'General case' 0 C--N 1.354 0.779 0 O-C-N 124.063 0.852 . . . . 0.0 111.118 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.498 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 39.8 mm-40 -61.51 -45.82 92.58 Favored 'General case' 0 N--CA 1.479 1.003 0 O-C-N 123.872 0.733 . . . . 0.0 110.393 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.442 HG23 ' HA ' ' A' ' 44' ' ' ILE . 46.5 mt -63.67 -53.73 41.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 115.212 -0.903 . . . . 0.0 111.551 -175.684 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 14.0 tt -67.7 -37.67 79.01 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.635 -171.647 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.6 t -75.08 -29.18 60.58 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 122.483 0.313 . . . . 0.0 110.481 178.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.78 -29.75 69.02 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 123.585 0.754 . . . . 0.0 110.742 175.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.4 -2.18 33.9 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 123.576 0.75 . . . . 0.0 111.485 174.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 96.88 -11.38 66.15 Favored Glycine 0 C--N 1.351 1.394 0 C-N-CA 123.093 0.378 . . . . 0.0 113.003 176.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 60.9 m-85 -91.08 104.76 17.3 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -175.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.8 m -77.12 110.92 13.6 Favored Pre-proline 0 CA--C 1.551 1.007 0 C-N-CA 123.917 0.887 . . . . 0.0 110.02 -176.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -83.13 -18.03 6.39 Favored 'Trans proline' 0 C--N 1.373 1.826 0 C-N-CA 122.56 2.173 . . . . 0.0 113.222 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 . . . . . 0 C--O 1.245 0.858 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.283 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.995 0 CA-C-O 120.812 0.339 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.85 173.86 22.67 Favored Glycine 0 C--N 1.344 1.004 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.927 179.212 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.42 HD12 ' HA ' ' A' ' 70' ' ' ALA . 52.5 mt -78.98 107.91 12.07 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -178.513 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 20.1 m -95.06 110.74 22.63 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 122.467 0.307 . . . . 0.0 110.706 -173.019 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -107.13 146.36 31.37 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 124.068 0.947 . . . . 0.0 109.351 178.41 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -124.52 136.05 53.68 Favored 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.475 HG23 ' HB3' ' A' ' 84' ' ' PRO . 86.3 t -125.79 126.69 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 123.592 0.757 . . . . 0.0 111.407 -170.521 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -71.73 -37.62 70.57 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.217 0.607 . . . . 0.0 111.548 177.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -75.02 -21.68 58.93 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 123.054 0.542 . . . . 0.0 112.258 -173.303 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.509 ' HG3' ' SG ' ' A' ' 36' ' ' CYS . 27.2 ttt -65.76 120.17 12.53 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.158 0.983 . . . . 0.0 111.043 -174.665 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 p -127.35 95.61 4.32 Favored 'General case' 0 CA--C 1.548 0.883 0 C-N-CA 122.717 0.407 . . . . 0.0 110.957 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 12.5 t 50.32 -147.94 0.34 Allowed 'General case' 0 CA--C 1.572 1.792 0 C-N-CA 125.349 1.459 . . . . 0.0 113.995 167.129 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -62.15 -28.64 71.01 Favored Glycine 0 C--N 1.357 1.722 0 N-CA-C 115.118 0.807 . . . . 0.0 115.118 -173.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 46.6 m170 -64.51 -29.05 70.08 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 123.451 0.7 . . . . 0.0 112.099 -178.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.509 ' SG ' ' HG3' ' A' ' 31' ' ' MET . 30.6 p -100.29 -18.74 16.68 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 122.768 0.427 . . . . 0.0 111.102 179.377 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -55.54 -54.77 39.85 Favored 'General case' 0 C--N 1.358 0.944 0 O-C-N 124.012 0.82 . . . . 0.0 112.563 -166.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.27 -35.55 92.11 Favored Glycine 0 C--N 1.343 0.946 0 O-C-N 123.178 0.299 . . . . 0.0 113.43 -176.561 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 49.0 t -72.2 -47.53 53.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 123.067 0.547 . . . . 0.0 111.075 -178.295 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.414 HD12 HD12 ' A' ' 77' ' ' ILE . 14.2 tt -67.91 -32.33 55.92 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 123.803 0.841 . . . . 0.0 111.239 -174.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -63.51 -59.25 4.89 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 123.656 0.782 . . . . 0.0 110.06 172.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.88 -30.93 78.16 Favored Glycine 0 C--N 1.353 1.477 0 CA-C-N 114.548 -1.205 . . . . 0.0 113.919 -170.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.82 -51.57 68.47 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 124.022 0.929 . . . . 0.0 110.567 -179.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.585 HG23 HG12 ' A' ' 64' ' ' VAL . 65.3 mt -73.95 -50.57 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 123.447 0.699 . . . . 0.0 111.334 178.872 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -58.73 -44.55 90.48 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 124.471 1.108 . . . . 0.0 112.808 -165.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.2 mptp? -81.05 -27.06 35.88 Favored 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.34 -175.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 91.2 m -74.38 -37.92 63.3 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 123.054 0.542 . . . . 0.0 110.66 179.339 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 95.5 t -124.46 95.07 43.76 Favored Pre-proline 0 N--CA 1.478 0.973 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 174.203 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -59.14 124.25 15.22 Favored 'Trans proline' 0 C--N 1.376 2.011 0 C-N-CA 122.998 2.466 . . . . 0.0 111.385 170.734 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.76 -8.16 36.66 Favored Glycine 0 C--N 1.343 0.937 0 CA-C-O 119.601 -0.555 . . . . 0.0 112.935 -176.017 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -83.83 105.98 15.16 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 171.495 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -88.08 101.91 14.26 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.41 0.684 . . . . 0.0 109.591 -177.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.472 HG11 HG11 ' A' ' 64' ' ' VAL . 31.6 m -83.01 130.83 35.06 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.339 0.59 . . . . 0.0 110.492 -171.649 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . 0.467 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 24.7 t60 -120.72 96.41 5.11 Favored 'General case' 0 C--O 1.219 -0.528 0 N-CA-C 106.307 -1.738 . . . . 0.0 106.307 170.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.17 114.79 27.43 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -98.03 112.65 62.39 Favored Pre-proline 0 N--CA 1.47 0.529 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -57.02 -51.25 9.25 Favored 'Trans proline' 0 C--N 1.377 2.053 0 C-N-CA 122.616 2.211 . . . . 0.0 113.142 -175.775 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.67 -42.01 68.01 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 123.497 0.719 . . . . 0.0 112.465 -171.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.1 t -89.3 -12.74 39.71 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.07 0.548 . . . . 0.0 111.242 -178.462 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.4 mpt_? 65.16 30.55 11.39 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 124.269 1.027 . . . . 0.0 111.891 177.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 16.7 m -110.94 109.83 20.15 Favored 'General case' 0 CA--C 1.544 0.737 0 O-C-N 122.258 -0.276 . . . . 0.0 110.952 -169.118 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 54' ' ' HIS . 39.3 t -98.92 105.39 17.3 Favored 'Isoleucine or valine' 0 C--N 1.352 0.699 0 C-N-CA 123.804 0.842 . . . . 0.0 109.242 177.108 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 22.6 t -99.61 117.92 45.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.749 0.82 . . . . 0.0 109.083 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.585 HG12 HG23 ' A' ' 44' ' ' ILE . 30.5 m -104.74 115.24 46.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 123.402 0.681 . . . . 0.0 109.996 -179.399 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -101.07 145.4 16.98 Favored Glycine 0 C--N 1.348 1.229 0 CA-C-N 116.143 -0.48 . . . . 0.0 112.671 -177.356 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 95.71 3.31 61.0 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 123.073 0.368 . . . . 0.0 113.659 176.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.3 m -130.54 147.44 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.739 0.816 . . . . 0.0 110.249 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.8 m -112.27 4.83 17.99 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 123.071 0.549 . . . . 0.0 110.708 179.065 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.529 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 3.0 m-20 -89.36 68.71 8.01 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.922 0.889 . . . . 0.0 110.39 -175.027 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.42 ' HA ' HD12 ' A' ' 24' ' ' LEU . . . -62.11 -39.49 92.69 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.452 0.701 . . . . 0.0 111.285 -177.282 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -66.81 -42.49 85.81 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.719 0.808 . . . . 0.0 111.376 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.529 ' HB2' ' HB3' ' A' ' 69' ' ' ASP . 18.8 m80 -63.63 -52.98 58.44 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 122.793 0.437 . . . . 0.0 110.726 178.242 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.489 HG21 HG21 ' A' ' 64' ' ' VAL . 47.2 mm -58.89 -42.44 85.83 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 O-C-N 123.93 0.769 . . . . 0.0 110.52 -176.235 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -58.1 -41.87 84.46 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.143 0.977 . . . . 0.0 111.387 178.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 60.1 mm-40 -70.12 -33.82 72.31 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.264 178.177 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.441 HG13 ' O ' ' A' ' 72' ' ' HIS . 75.4 mt -68.11 -51.31 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 CA-C-O 121.025 0.44 . . . . 0.0 110.554 -179.173 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.584 HG22 ' HG3' ' A' ' 84' ' ' PRO . 16.7 tt -69.25 -32.34 53.32 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 CA-C-N 115.165 -0.925 . . . . 0.0 111.438 -175.138 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 t -76.52 -31.59 57.75 Favored 'General case' 0 N--CA 1.477 0.913 0 O-C-N 122.283 -0.26 . . . . 0.0 111.076 175.346 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.46 -16.12 62.35 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 123.492 0.717 . . . . 0.0 110.904 176.395 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -80.61 5.33 15.78 Favored 'General case' 0 CA--C 1.555 1.157 0 C-N-CA 123.763 0.825 . . . . 0.0 111.581 173.16 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.93 -0.74 73.36 Favored Glycine 0 C--N 1.353 1.482 0 C-N-CA 123.117 0.389 . . . . 0.0 113.15 176.41 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.427 ' HB3' HG13 ' A' ' 28' ' ' VAL . 95.7 m-85 -86.15 165.61 16.43 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 123.392 0.677 . . . . 0.0 110.48 179.355 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 33.5 p -122.82 81.2 49.38 Favored Pre-proline 0 CA--C 1.559 1.326 0 C-N-CA 123.174 0.59 . . . . 0.0 111.619 -176.404 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.584 ' HG3' HG22 ' A' ' 77' ' ' ILE . 43.0 Cg_endo -88.27 171.95 5.27 Favored 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.901 2.401 . . . . 0.0 112.178 169.816 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 . . . . . 0 C--O 1.246 0.891 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 176.452 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.11 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -124.17 -160.78 10.9 Favored Glycine 0 N--CA 1.473 1.14 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 176.231 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.0 107.48 12.82 Favored 'General case' 0 CA--C 1.548 0.883 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 179.24 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 24.9 p -93.37 111.97 23.77 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 123.606 0.762 . . . . 0.0 111.42 -173.269 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -99.68 141.23 32.76 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 175.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 65.8 m80 -115.46 100.7 8.28 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -175.041 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.527 HG22 ' HB3' ' A' ' 82' ' ' TYR . 2.7 p -113.41 97.78 6.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 C-N-CA 124.19 0.996 . . . . 0.0 109.753 -178.658 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -70.71 -17.8 62.81 Favored 'General case' 0 CA--C 1.551 0.989 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.966 176.676 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.37 -12.4 60.81 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 123.889 0.876 . . . . 0.0 111.384 176.574 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.484 ' SD ' ' HB3' ' A' ' 55' ' ' ALA . 60.0 ttp -80.19 98.98 7.57 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 173.749 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.408 ' O ' ' SG ' ' A' ' 33' ' ' CYS . 30.4 p -94.18 102.67 14.71 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.213 0.605 . . . . 0.0 110.159 178.216 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.408 ' SG ' ' O ' ' A' ' 32' ' ' THR . 14.7 p 66.67 178.32 0.22 Allowed 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 126.567 1.947 . . . . 0.0 113.153 175.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -60.95 -22.79 60.66 Favored Glycine 0 C--N 1.359 1.82 0 CA-C-N 115.118 -0.946 . . . . 0.0 113.973 -178.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 13.0 t-160 -60.61 -42.76 97.47 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 123.894 0.878 . . . . 0.0 111.013 175.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 81.1 m -87.93 -21.59 24.82 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 123.032 0.533 . . . . 0.0 111.256 178.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . 0.468 ' HA ' ' SD ' ' A' ' 31' ' ' MET . . . -66.02 -46.88 76.32 Favored 'General case' 0 C--N 1.349 0.546 0 C-N-CA 123.318 0.647 . . . . 0.0 111.01 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.82 -29.29 73.6 Favored Glycine 0 C--N 1.349 1.303 0 O-C-N 124.052 0.845 . . . . 0.0 113.546 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 58.3 t -63.29 -44.85 99.34 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.634 0.774 . . . . 0.0 110.087 175.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.609 HG23 HG22 ' A' ' 62' ' ' VAL . 62.6 mt -70.4 -39.33 76.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.852 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.428 ' HG3' ' O ' ' A' ' 37' ' ' ALA . 96.3 mttt -59.12 -49.84 76.33 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 123.125 0.57 . . . . 0.0 110.087 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.77 -38.66 96.86 Favored Glycine 0 C--N 1.344 0.974 0 O-C-N 124.28 0.987 . . . . 0.0 112.522 178.173 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.35 -55.06 31.65 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.63 0.772 . . . . 0.0 111.822 -176.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.5 ' HA ' HG22 ' A' ' 76' ' ' ILE . 69.7 mt -70.15 -55.71 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 123.241 0.616 . . . . 0.0 111.247 -178.46 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -60.1 -40.88 91.17 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 123.767 0.827 . . . . 0.0 112.791 -169.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -74.23 -30.91 62.38 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 122.45 0.3 . . . . 0.0 111.642 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 91.7 m -72.9 -42.63 63.36 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 121.053 0.454 . . . . 0.0 110.257 176.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.0 m -131.48 87.54 46.33 Favored Pre-proline 0 CA--C 1.553 1.074 0 C-N-CA 123.618 0.767 . . . . 0.0 110.52 -178.329 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -57.76 138.09 84.37 Favored 'Trans proline' 0 C--N 1.38 2.186 0 C-N-CA 122.6 2.2 . . . . 0.0 111.345 171.288 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 108.75 -23.87 23.05 Favored Glycine 0 N--CA 1.467 0.721 0 O-C-N 123.403 0.44 . . . . 0.0 112.02 -175.227 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -76.79 107.21 8.95 Favored 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 173.632 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.8 99.43 8.27 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.264 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.486 HG11 HG12 ' A' ' 64' ' ' VAL . 23.4 m -86.32 128.58 39.32 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 C-N-CA 123.199 0.6 . . . . 0.0 111.191 -171.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . 0.444 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 18.7 t60 -127.85 98.22 5.09 Favored 'General case' 0 C--O 1.223 -0.304 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 175.126 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.484 ' HB3' ' SD ' ' A' ' 31' ' ' MET . . . -100.73 112.82 25.29 Favored 'General case' 0 C--O 1.241 0.643 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.357 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -102.72 114.73 65.14 Favored Pre-proline 0 CA--C 1.538 0.519 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -170.269 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -62.14 -34.4 79.34 Favored 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 122.812 2.341 . . . . 0.0 113.213 -178.448 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.04 -46.1 30.95 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.166 0.586 . . . . 0.0 111.295 -175.525 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.5 t -89.23 -16.75 30.53 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.404 0.682 . . . . 0.0 111.739 -175.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.7 mpt_? 61.57 39.85 14.2 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.331 1.052 . . . . 0.0 111.029 -176.643 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 50.0 m -126.26 118.89 26.06 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 122.75 0.42 . . . . 0.0 111.289 -172.712 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.609 HG22 HG23 ' A' ' 40' ' ' ILE . 38.7 t -100.0 105.71 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 123.728 0.811 . . . . 0.0 109.434 173.288 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 20.8 t -100.19 127.65 52.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 C-N-CA 123.791 0.836 . . . . 0.0 109.02 -178.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.493 HG21 HG13 ' A' ' 73' ' ' ILE . 17.4 m -111.2 109.95 30.41 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.656 0.741 . . . . 0.0 109.95 178.115 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -88.62 153.88 24.42 Favored Glycine 0 C--N 1.346 1.097 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.976 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.47 -14.55 45.58 Favored Glycine 0 N--CA 1.472 1.068 0 C-N-CA 122.888 0.28 . . . . 0.0 113.236 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.7 m -130.87 135.76 59.48 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.75 0 C-N-CA 124.457 1.103 . . . . 0.0 109.156 179.404 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 51.0 m -116.41 17.75 15.39 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.359 0.664 . . . . 0.0 109.913 176.012 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -80.25 77.05 7.02 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.292 1.037 . . . . 0.0 109.574 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.8 -42.96 94.59 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.496 0.718 . . . . 0.0 111.622 -175.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.424 ' O ' ' HG3' ' A' ' 75' ' ' GLU . . . -62.63 -46.08 89.9 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.941 0.897 . . . . 0.0 111.289 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 11.6 m170 -62.04 -54.75 37.08 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.666 0.787 . . . . 0.0 110.442 -176.635 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.493 HG13 HG21 ' A' ' 64' ' ' VAL . 45.3 mm -64.01 -40.0 87.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.319 -175.124 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.7 -39.6 89.12 Favored 'General case' 0 N--CA 1.476 0.875 0 O-C-N 123.966 0.792 . . . . 0.0 111.18 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.424 ' HG3' ' O ' ' A' ' 71' ' ' ALA . 46.3 mt-10 -61.98 -39.19 91.34 Favored 'General case' 0 N--CA 1.479 1.021 0 O-C-N 123.803 0.689 . . . . 0.0 111.16 176.28 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.5 HG22 ' HA ' ' A' ' 44' ' ' ILE . 62.4 mt -68.77 -51.9 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 O-C-N 123.636 0.585 . . . . 0.0 111.259 -176.75 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.517 HD12 ' HB3' ' A' ' 84' ' ' PRO . 6.3 tt -68.61 -31.77 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.27 0 C-N-CA 123.075 0.55 . . . . 0.0 111.569 -176.398 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -74.8 -30.78 61.53 Favored 'General case' 0 N--CA 1.483 1.183 0 O-C-N 122.202 -0.311 . . . . 0.0 110.426 176.42 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.09 -22.9 61.28 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 123.069 0.548 . . . . 0.0 110.296 172.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.31 -16.75 60.4 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 123.801 0.84 . . . . 0.0 111.832 174.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.34 22.53 12.68 Favored Glycine 0 C--N 1.348 1.223 0 O-C-N 123.405 0.44 . . . . 0.0 113.141 178.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.527 ' HB3' HG22 ' A' ' 28' ' ' VAL . 80.1 m-85 -128.56 133.29 48.33 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 123.913 0.885 . . . . 0.0 110.024 179.034 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 27.7 p -89.58 107.79 20.94 Favored Pre-proline 0 CA--C 1.552 1.036 0 C-N-CA 123.593 0.757 . . . . 0.0 110.605 -179.78 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.517 ' HB3' HD12 ' A' ' 77' ' ' ILE . 64.3 Cg_endo -78.33 -8.11 16.16 Favored 'Trans proline' 0 C--N 1.376 1.975 0 C-N-CA 122.748 2.299 . . . . 0.0 113.622 178.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 . . . . . 0 C--O 1.248 1.001 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 -173.378 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.958 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -123.63 108.01 1.14 Allowed Glycine 0 C--N 1.344 0.977 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 -176.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.417 HD12 HG23 ' A' ' 67' ' ' VAL . 37.3 mt -93.08 111.47 23.11 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 124.196 0.998 . . . . 0.0 110.359 -175.279 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.405 ' HG ' HG11 ' A' ' 63' ' ' VAL . 29.1 m -94.38 115.77 28.03 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.011 0.524 . . . . 0.0 111.054 -175.215 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -107.91 116.44 31.95 Favored 'General case' 0 N--CA 1.484 1.264 0 C-N-CA 123.959 0.904 . . . . 0.0 109.79 177.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 22.9 m170 -82.17 90.34 6.57 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.409 ' HA ' ' HA ' ' A' ' 84' ' ' PRO . 10.6 t -85.3 92.56 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -178.262 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -68.82 -19.26 64.27 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 123.904 0.882 . . . . 0.0 112.144 -172.093 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -89.15 -8.1 54.37 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.872 0.869 . . . . 0.0 111.917 178.287 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.508 ' HE3' ' SG ' ' A' ' 33' ' ' CYS . 26.4 ttt -75.15 126.52 31.19 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.804 0.841 . . . . 0.0 112.557 -173.051 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.8 t -108.49 97.91 7.51 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 164.014 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.508 ' SG ' ' HE3' ' A' ' 31' ' ' MET . 81.5 m -46.52 -64.07 0.85 Allowed 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 125.543 1.537 . . . . 0.0 114.267 -167.421 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.56 -25.2 75.07 Favored Glycine 0 CA--C 1.532 1.142 0 N-CA-C 114.013 0.365 . . . . 0.0 114.013 -175.315 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 15.4 m-70 -93.99 -7.59 42.38 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 123.253 0.621 . . . . 0.0 112.109 -177.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 42.1 t -133.19 9.44 4.09 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.116 0.566 . . . . 0.0 111.099 -175.718 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -56.55 -53.61 55.55 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 123.838 0.855 . . . . 0.0 113.117 -169.721 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.99 -40.45 98.24 Favored Glycine 0 C--N 1.344 0.979 0 O-C-N 123.36 0.413 . . . . 0.0 114.121 -173.603 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.7 p -76.92 -42.51 32.62 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 C-N-CA 123.111 0.564 . . . . 0.0 112.221 -176.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 12.3 tt -73.22 -37.02 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 122.495 0.318 . . . . 0.0 110.809 -174.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.52 -43.47 55.75 Favored 'General case' 0 C--N 1.35 0.622 0 C-N-CA 123.136 0.575 . . . . 0.0 109.661 175.348 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.87 -30.58 78.1 Favored Glycine 0 C--N 1.351 1.393 0 O-C-N 124.494 1.121 . . . . 0.0 113.531 -177.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -61.28 -54.26 46.3 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 123.469 0.708 . . . . 0.0 110.591 177.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.517 ' HA ' HG23 ' A' ' 76' ' ' ILE . 59.0 mt -72.61 -46.81 53.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.163 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -58.54 -50.81 72.44 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 124.034 0.934 . . . . 0.0 112.26 -174.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -77.07 -20.7 55.47 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 119.42 -0.324 . . . . 0.0 111.505 -172.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 85.2 m -79.22 -45.76 19.19 Favored 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 174.362 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 15.8 m -126.74 81.59 68.7 Favored Pre-proline 0 CA--C 1.555 1.168 0 C-N-CA 123.598 0.759 . . . . 0.0 110.01 178.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -60.26 121.45 9.8 Favored 'Trans proline' 0 C--N 1.383 2.385 0 C-N-CA 122.995 2.463 . . . . 0.0 112.144 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.78 -11.57 10.16 Favored Glycine 0 C--N 1.345 1.075 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.704 -176.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -72.32 107.41 4.91 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 176.07 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -77.15 100.15 5.65 Favored 'General case' 0 C--N 1.348 0.507 0 C-N-CA 123.111 0.564 . . . . 0.0 109.856 -176.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.483 HG13 HG13 ' A' ' 64' ' ' VAL . 33.5 m -85.2 137.37 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 123.386 0.674 . . . . 0.0 109.949 -173.63 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . 0.491 ' HB2' ' HB ' ' A' ' 63' ' ' VAL . 78.7 m80 -130.37 101.78 5.9 Favored 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -178.643 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.26 120.87 34.04 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.672 0.789 . . . . 0.0 109.958 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -111.07 103.49 54.94 Favored Pre-proline 0 CA--C 1.55 0.959 0 CA-C-O 118.54 -0.743 . . . . 0.0 109.609 -178.144 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.503 ' HA ' ' SG ' ' A' ' 33' ' ' CYS . 38.0 Cg_exo -39.74 -44.82 3.5 Favored 'Trans proline' 0 C--N 1.376 2.003 0 C-N-CA 124.539 3.493 . . . . 0.0 115.88 172.178 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.24 -46.53 22.86 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 122.715 0.406 . . . . 0.0 111.525 -175.199 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.9 t -91.8 -7.01 50.74 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.359 0.664 . . . . 0.0 111.91 -173.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 40.91 45.65 2.22 Favored 'General case' 0 N--CA 1.505 2.28 0 C-N-CA 126.248 1.819 . . . . 0.0 112.197 -173.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.8 m -112.81 134.2 54.44 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.342 -175.286 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 51.4 t -103.38 105.57 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 168.243 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.491 ' HB ' ' HB2' ' A' ' 54' ' ' HIS . 14.4 t -94.47 119.93 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 175.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.514 HG11 HG21 ' A' ' 44' ' ' ILE . 15.7 m -106.29 116.96 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 CA-C-O 121.296 0.57 . . . . 0.0 110.5 -179.325 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.26 152.59 20.47 Favored Glycine 0 C--N 1.347 1.178 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.309 -175.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.04 -26.97 14.28 Favored Glycine 0 N--CA 1.471 0.989 0 C-N-CA 123.304 0.478 . . . . 0.0 112.883 177.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.417 HG23 HD12 ' A' ' 24' ' ' LEU . 28.4 m -101.98 155.16 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 124.412 1.085 . . . . 0.0 110.372 -176.035 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.1 m -135.7 23.59 3.38 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.78 0.832 . . . . 0.0 110.292 -177.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -119.53 71.54 0.88 Allowed 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 124.388 1.075 . . . . 0.0 109.697 -176.073 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.91 -34.94 75.45 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 115.049 -0.978 . . . . 0.0 112.561 -174.181 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.459 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.36 -43.74 96.79 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.271 0.629 . . . . 0.0 110.632 178.076 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.41 ' O ' HG13 ' A' ' 76' ' ' ILE . 14.9 m-70 -67.16 -43.97 80.91 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 123.467 0.707 . . . . 0.0 111.061 -177.41 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 45.4 mm -62.38 -40.64 88.7 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 O-C-N 123.739 0.649 . . . . 0.0 110.105 179.097 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.44 -38.17 86.2 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.811 178.201 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.459 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 45.3 mm-40 -62.53 -40.0 95.36 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.773 0.829 . . . . 0.0 111.204 176.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.517 HG23 ' HA ' ' A' ' 44' ' ' ILE . 73.4 mt -66.36 -54.89 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 123.717 0.636 . . . . 0.0 110.8 -176.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 12.6 tt -66.94 -34.48 70.23 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.643 -173.206 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 7.7 t -74.5 -30.3 61.76 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 110.526 -0.175 . . . . 0.0 110.526 177.67 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.73 -24.41 61.78 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 123.522 0.729 . . . . 0.0 110.826 175.292 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -71.72 -19.15 62.09 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 123.523 0.729 . . . . 0.0 111.142 172.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 101.6 16.65 23.82 Favored Glycine 0 C--N 1.348 1.242 0 CA-C-N 115.857 -0.61 . . . . 0.0 112.457 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -122.63 103.63 8.8 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.3 t -80.03 125.24 82.18 Favored Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.387 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.409 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 24.0 Cg_exo -63.95 -76.51 0.02 OUTLIER 'Trans proline' 0 C--N 1.38 2.195 0 C-N-CA 122.539 2.159 . . . . 0.0 112.912 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 . . . . . 0 C--O 1.252 1.21 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -170.385 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.69 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -158.73 114.18 0.6 Allowed Glycine 0 C--N 1.345 1.08 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 -178.36 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.451 HD11 ' HA ' ' A' ' 70' ' ' ALA . 47.9 mt -84.68 110.04 18.46 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.153 0.981 . . . . 0.0 110.752 -178.133 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.8 p -90.8 111.13 22.39 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 123.36 0.664 . . . . 0.0 111.952 -174.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -108.61 114.77 28.86 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 123.858 0.863 . . . . 0.0 109.998 177.399 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 11.5 m-70 -82.93 136.2 34.65 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 123.052 0.541 . . . . 0.0 109.782 178.29 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.571 HG22 ' HA ' ' A' ' 84' ' ' PRO . 85.2 t -139.83 97.14 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 172.092 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.79 -6.25 43.53 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -175.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -88.69 -19.37 26.23 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.343 0.657 . . . . 0.0 110.732 176.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.563 ' SD ' HG23 ' A' ' 40' ' ' ILE . 53.8 ttp -68.33 97.33 0.73 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 122.996 0.518 . . . . 0.0 109.811 178.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 25.9 p -82.44 94.05 7.35 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 179.212 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.41 ' SG ' ' HB3' ' A' ' 57' ' ' PRO . 58.6 m 41.5 -139.29 0.13 Allowed 'General case' 0 CA--C 1.568 1.642 0 C-N-CA 125.831 1.652 . . . . 0.0 113.213 173.357 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.52 -22.23 65.56 Favored Glycine 0 C--N 1.362 1.994 0 N-CA-C 114.638 0.615 . . . . 0.0 114.638 -178.678 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 30.0 t-80 -59.09 -35.95 74.3 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 123.614 0.766 . . . . 0.0 111.937 178.459 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 62.4 m -112.51 -14.51 13.21 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 122.894 0.478 . . . . 0.0 111.755 -178.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -60.5 -41.86 95.19 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -172.17 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.05 -48.55 82.52 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 113.806 0.283 . . . . 0.0 113.806 -174.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.3 p -75.58 -39.71 40.29 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.143 0 C-N-CA 123.557 0.743 . . . . 0.0 112.108 -177.36 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.563 HG23 ' SD ' ' A' ' 31' ' ' MET . 13.5 tt -67.17 -39.31 82.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 122.832 0.453 . . . . 0.0 111.124 -176.165 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.552 ' HB3' HG21 ' A' ' 53' ' ' VAL . 9.2 mtmp? -75.81 -44.32 41.81 Favored 'General case' 0 C--N 1.348 0.526 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.423 176.17 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.22 -30.21 63.94 Favored Glycine 0 C--N 1.357 1.717 0 O-C-N 124.786 1.304 . . . . 0.0 113.678 -175.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.66 -52.08 65.07 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.423 0.689 . . . . 0.0 110.509 172.141 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.539 HG21 HG12 ' A' ' 64' ' ' VAL . 57.8 mt -72.2 -40.55 66.06 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.566 -178.153 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -63.2 -50.45 70.22 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.647 0.779 . . . . 0.0 112.383 -175.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -71.94 -31.34 66.23 Favored 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.079 -174.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 46.7 m -76.07 -42.45 47.38 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.924 0.49 . . . . 0.0 110.37 176.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 41.2 t -125.0 93.06 46.47 Favored Pre-proline 0 N--CA 1.48 1.028 0 C-N-CA 123.77 0.828 . . . . 0.0 109.636 -173.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -68.02 113.29 2.98 Favored 'Trans proline' 0 C--N 1.371 1.762 0 C-N-CA 122.492 2.128 . . . . 0.0 110.113 170.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.18 -9.25 10.27 Favored Glycine 0 C--N 1.344 0.984 0 CA-C-O 119.525 -0.597 . . . . 0.0 113.411 -176.196 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -82.81 105.52 13.89 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 170.053 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.53 101.51 10.77 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 123.392 0.677 . . . . 0.0 109.807 -176.454 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . 0.552 HG21 ' HB3' ' A' ' 41' ' ' LYS . 20.8 m -84.29 135.75 24.19 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 C-N-CA 123.634 0.774 . . . . 0.0 110.969 -171.149 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 76.3 m80 -134.18 94.95 3.32 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.233 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.01 117.08 29.48 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -95.51 124.73 52.17 Favored Pre-proline 0 CA--C 1.543 0.676 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -179.45 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.41 ' HB3' ' SG ' ' A' ' 33' ' ' CYS . 51.6 Cg_exo -57.91 -47.43 20.74 Favored 'Trans proline' 0 C--N 1.373 1.825 0 C-N-CA 122.962 2.442 . . . . 0.0 113.192 177.127 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.3 -53.17 8.6 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 123.168 0.587 . . . . 0.0 111.85 -173.109 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.0 t -80.1 -13.16 59.5 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.864 0.866 . . . . 0.0 111.765 -175.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 25.7 mmt180 65.78 23.57 11.46 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.482 1.113 . . . . 0.0 112.478 174.243 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 40.0 m -109.73 126.61 53.9 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 122.63 0.372 . . . . 0.0 111.77 -169.411 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 45.8 t -98.15 105.47 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 123.955 0.902 . . . . 0.0 108.634 170.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 15.4 t -95.53 119.55 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 123.829 0.852 . . . . 0.0 109.209 179.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.539 HG12 HG21 ' A' ' 44' ' ' ILE . 28.1 m -103.2 109.7 27.66 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 123.571 0.749 . . . . 0.0 110.457 179.277 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -94.22 150.08 19.65 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.399 -177.13 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.2 -25.11 27.18 Favored Glycine 0 C--N 1.343 0.953 0 CA-C-O 120.194 -0.226 . . . . 0.0 112.547 177.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.4 m -103.17 148.81 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 123.991 0.917 . . . . 0.0 109.785 178.303 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.6 t -123.2 1.24 9.11 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 123.366 0.667 . . . . 0.0 111.034 -174.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -102.66 83.68 2.3 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 124.353 1.061 . . . . 0.0 110.341 -174.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.451 ' HA ' HD11 ' A' ' 24' ' ' LEU . . . -64.89 -36.7 85.22 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 114.307 -1.315 . . . . 0.0 112.8 -172.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.466 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -64.93 -44.31 89.93 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.04 0.536 . . . . 0.0 110.797 -177.844 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.414 ' O ' HG13 ' A' ' 76' ' ' ILE . 78.9 m-70 -62.03 -49.45 75.95 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 123.658 0.599 . . . . 0.0 110.925 179.156 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.509 HG23 HG22 ' A' ' 64' ' ' VAL . 42.7 mm -59.77 -40.28 82.09 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 O-C-N 123.875 0.734 . . . . 0.0 110.227 -179.699 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.93 -36.01 82.01 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.737 0.815 . . . . 0.0 111.11 178.361 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.466 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 26.5 mm-40 -69.05 -35.94 77.14 Favored 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 123.294 0.638 . . . . 0.0 111.395 178.053 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . 0.417 HD11 ' HA ' ' A' ' 73' ' ' ILE . 74.7 mt -68.42 -53.05 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 123.464 0.705 . . . . 0.0 110.578 -178.632 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 13.6 tt -66.05 -35.71 75.7 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.984 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.361 -175.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.8 t -75.15 -30.09 60.66 Favored 'General case' 0 N--CA 1.479 0.999 0 C-N-CA 122.471 0.308 . . . . 0.0 110.887 178.295 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.8 -19.73 60.67 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 123.369 0.668 . . . . 0.0 110.945 175.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -78.15 -9.73 59.31 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.745 0.818 . . . . 0.0 111.473 172.627 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 102.47 -11.45 56.66 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-O 119.717 -0.491 . . . . 0.0 112.951 179.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -92.86 105.93 17.98 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.442 0.697 . . . . 0.0 110.192 178.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 90.6 m -68.89 117.39 50.9 Favored Pre-proline 0 CA--C 1.552 1.023 0 C-N-CA 123.142 0.577 . . . . 0.0 109.647 176.135 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.571 ' HA ' HG22 ' A' ' 28' ' ' VAL . 48.0 Cg_endo -67.16 87.48 0.31 Allowed 'Trans proline' 0 C--N 1.382 2.293 0 C-N-CA 122.437 2.091 . . . . 0.0 111.489 174.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.5 tp10 . . . . . 0 C--O 1.249 1.029 0 C-N-CA 124.672 1.189 . . . . 0.0 108.697 179.181 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.222 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.476 HD11 ' HB2' ' A' ' 70' ' ' ALA . 4.3 mm? -79.4 164.29 24.12 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.324 0.65 . . . . 0.0 111.023 -176.608 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 29.5 p -152.47 110.67 3.69 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 123.803 0.841 . . . . 0.0 108.82 178.283 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -110.35 116.44 31.45 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 123.702 0.801 . . . . 0.0 109.357 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 26.4 p80 -82.11 90.69 6.57 Favored 'General case' 0 CA--C 1.552 1.056 0 CA-C-O 122.615 1.198 . . . . 0.0 110.384 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.451 HG21 HD11 ' A' ' 77' ' ' ILE . 39.7 t -84.21 87.37 2.26 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 172.743 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.13 -5.67 43.12 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-N 115.646 -0.707 . . . . 0.0 112.758 -173.434 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -86.55 -22.11 26.51 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.35 0.66 . . . . 0.0 110.672 173.62 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.636 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 50.4 ttp -65.09 109.19 2.08 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 123.489 0.716 . . . . 0.0 111.453 -174.603 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 25.5 p -117.52 128.3 54.83 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.106 0.962 . . . . 0.0 109.434 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.403 ' SG ' ' HB2' ' A' ' 35' ' ' HIS . 8.8 p 65.68 159.36 0.12 Allowed 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 126.034 1.733 . . . . 0.0 113.718 176.729 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.521 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -67.44 -9.08 54.2 Favored Glycine 0 C--N 1.353 1.481 0 CA-C-N 115.104 -0.953 . . . . 0.0 114.306 -178.65 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' HIS . . . . . 0.403 ' HB2' ' SG ' ' A' ' 33' ' ' CYS . 29.4 m170 -71.15 -44.43 65.55 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 117.482 0.641 . . . . 0.0 110.216 173.165 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 59.0 m -83.82 -32.47 25.28 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.234 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.521 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -70.05 -34.77 73.66 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.009 176.429 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.04 -44.96 96.55 Favored Glycine 0 C--N 1.347 1.192 0 O-C-N 124.039 0.837 . . . . 0.0 113.472 -176.177 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.5 p -68.16 -30.03 46.53 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.064 0 C-N-CA 122.698 0.399 . . . . 0.0 111.384 -178.342 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.587 HG21 HG21 ' A' ' 62' ' ' VAL . 66.4 mt -66.39 -47.79 82.9 Favored 'Isoleucine or valine' 0 C--N 1.356 0.864 0 C-N-CA 123.149 0.58 . . . . 0.0 110.013 175.086 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 60.5 mtpt -57.43 -48.17 79.83 Favored 'General case' 0 C--N 1.349 0.566 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.224 178.152 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.93 -34.06 87.45 Favored Glycine 0 C--N 1.346 1.106 0 O-C-N 124.246 0.966 . . . . 0.0 112.966 -178.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.44 -54.76 35.37 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.072 0.549 . . . . 0.0 110.849 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.54 HG21 HG11 ' A' ' 64' ' ' VAL . 58.3 mt -72.45 -43.7 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 CA-C-N 115.672 -0.694 . . . . 0.0 112.127 -176.003 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -64.79 -38.02 89.58 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 124.219 1.008 . . . . 0.0 112.67 -174.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -76.03 -37.02 58.86 Favored 'General case' 0 N--CA 1.481 1.114 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.212 -179.483 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 42.7 m -71.12 -40.15 71.6 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 123.011 0.524 . . . . 0.0 110.63 177.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 48.2 t -121.39 94.54 48.64 Favored Pre-proline 0 N--CA 1.48 1.051 0 C-N-CA 123.58 0.752 . . . . 0.0 109.931 -177.838 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -62.25 104.29 0.34 Allowed 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.563 2.175 . . . . 0.0 111.174 169.172 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.56 -0.15 11.18 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-O 119.593 -0.559 . . . . 0.0 113.291 -177.444 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -83.96 108.71 17.1 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 169.212 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.404 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -78.49 95.97 5.29 Favored 'General case' 0 C--N 1.348 0.543 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 -178.679 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.529 HG12 HG12 ' A' ' 64' ' ' VAL . 27.7 m -88.95 131.49 36.15 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.754 0 C-N-CA 123.701 0.8 . . . . 0.0 111.027 -171.118 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' HIS . . . . . 0.406 ' HB3' HG22 ' A' ' 63' ' ' VAL . 3.5 t-160 -143.22 99.92 3.53 Favored 'General case' 0 C--N 1.346 0.421 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 167.356 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.636 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -92.51 113.75 26.11 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 172.079 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -106.9 120.49 47.95 Favored Pre-proline 0 N--CA 1.467 0.394 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -172.53 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -63.11 -35.31 65.44 Favored 'Trans proline' 0 C--N 1.37 1.698 0 C-N-CA 122.73 2.287 . . . . 0.0 113.493 -179.649 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.52 -35.2 46.62 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 123.272 0.629 . . . . 0.0 112.148 -174.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.2 t -91.43 -19.61 22.67 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 123.18 0.592 . . . . 0.0 110.225 178.304 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.1 mpt_? 60.79 33.82 19.96 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 125.034 1.334 . . . . 0.0 110.824 -177.243 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 27.3 m -124.69 131.52 53.46 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 122.677 0.391 . . . . 0.0 110.683 -170.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.587 HG21 HG21 ' A' ' 40' ' ' ILE . 44.0 t -105.87 105.57 18.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 173.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.406 HG22 ' HB3' ' A' ' 54' ' ' HIS . 34.3 m -99.71 136.12 32.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.284 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.54 HG11 HG21 ' A' ' 44' ' ' ILE . 17.3 m -131.0 109.36 16.45 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.909 0 C-N-CA 123.399 0.68 . . . . 0.0 109.434 179.22 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -92.79 157.74 23.76 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.474 -176.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.21 0.43 89.53 Favored Glycine 0 C--N 1.345 1.049 0 CA-C-O 119.932 -0.371 . . . . 0.0 114.023 177.176 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.4 m -124.14 144.7 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.625 0.77 . . . . 0.0 110.147 -176.579 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 14.9 m -108.86 -17.71 13.87 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.599 0.759 . . . . 0.0 110.225 176.226 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.445 ' O ' HG12 ' A' ' 73' ' ' ILE . 6.5 m-20 -78.77 76.54 5.26 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.347 1.059 . . . . 0.0 111.035 -172.699 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.476 ' HB2' HD11 ' A' ' 24' ' ' LEU . . . -60.59 -41.5 94.83 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.108 0.963 . . . . 0.0 111.602 -179.635 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -65.54 -41.47 92.99 Favored 'General case' 0 N--CA 1.471 0.581 0 O-C-N 124.206 0.942 . . . . 0.0 111.044 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.417 ' O ' HG13 ' A' ' 76' ' ' ILE . 77.8 t60 -63.28 -50.69 69.12 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.501 0.72 . . . . 0.0 110.741 178.881 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.537 HG21 HG21 ' A' ' 64' ' ' VAL . 40.7 mm -58.57 -42.3 84.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 O-C-N 123.826 0.704 . . . . 0.0 110.142 179.411 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.61 -37.97 80.04 Favored 'General case' 0 N--CA 1.476 0.836 0 O-C-N 124.329 1.018 . . . . 0.0 111.648 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 12.3 mm-40 -64.67 -40.14 94.91 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.479 0.712 . . . . 0.0 111.166 177.516 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.511 HG21 ' HA ' ' A' ' 44' ' ' ILE . 33.9 mt -67.19 -51.54 52.36 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 C-N-CA 123.149 0.58 . . . . 0.0 111.356 -177.144 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.451 HD11 HG21 ' A' ' 28' ' ' VAL . 8.3 tt -71.08 -29.88 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.234 0 C-N-CA 123.379 0.671 . . . . 0.0 111.836 -176.005 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.464 ' HA ' ' O ' ' A' ' 82' ' ' TYR . 2.9 t -75.25 -28.9 60.03 Favored 'General case' 0 N--CA 1.48 1.054 0 N-CA-C 110.364 -0.236 . . . . 0.0 110.364 175.079 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.32 -26.17 66.38 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.355 0.662 . . . . 0.0 110.644 172.829 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -76.76 -8.72 57.84 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 123.377 0.671 . . . . 0.0 111.455 173.323 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.3 25.05 24.95 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 116.561 -0.291 . . . . 0.0 113.208 176.75 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.464 ' O ' ' HA ' ' A' ' 78' ' ' THR . 95.9 m-85 -120.43 155.06 34.27 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.526 0.73 . . . . 0.0 110.236 179.379 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 73.1 p -89.79 111.14 44.48 Favored Pre-proline 0 CA--C 1.553 1.086 0 C-N-CA 123.271 0.628 . . . . 0.0 110.415 -176.555 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -78.89 79.5 3.36 Favored 'Trans proline' 0 C--N 1.377 2.043 0 C-N-CA 122.906 2.404 . . . . 0.0 111.878 178.599 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 35.0 mm-40 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.794 -0.622 . . . . 0.0 109.844 -176.661 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.799 0 N-CA-C 111.706 -0.558 . . . . 0.0 111.706 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -82.34 109.61 16.75 Favored 'General case' 0 CA--C 1.548 0.895 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.7 m -92.51 118.6 31.14 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 123.79 0.836 . . . . 0.0 110.748 -172.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -106.29 110.76 23.1 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.781 0.832 . . . . 0.0 109.939 178.773 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -81.82 94.38 7.04 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 177.078 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.499 ' O ' ' HB3' ' A' ' 60' ' ' ARG . 20.0 t -93.51 94.38 4.61 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.798 0 C-N-CA 124.356 1.062 . . . . 0.0 108.397 178.451 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -71.68 -12.72 61.47 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -175.003 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -85.5 -19.0 31.86 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 123.812 0.845 . . . . 0.0 110.951 174.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 25.2 ttt -55.33 128.64 35.11 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 124.334 1.054 . . . . 0.0 112.266 -175.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.3 p -88.47 162.18 16.61 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 124.438 1.095 . . . . 0.0 110.087 172.595 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 57.3 m -66.56 -162.75 0.02 OUTLIER 'General case' 0 CA--C 1.564 1.505 0 C-N-CA 124.986 1.314 . . . . 0.0 114.035 -169.697 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -56.69 -22.73 41.18 Favored Glycine 0 C--N 1.364 2.094 0 N-CA-C 115.722 1.049 . . . . 0.0 115.722 -171.732 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 48.9 t-80 -64.63 -28.77 69.84 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.777 0.831 . . . . 0.0 111.882 177.375 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 61.3 m -119.2 19.26 12.9 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.985 0.914 . . . . 0.0 111.26 179.367 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.37 -34.36 70.37 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 122.583 0.353 . . . . 0.0 111.047 177.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.08 -35.93 91.23 Favored Glycine 0 C--N 1.349 1.279 0 O-C-N 123.929 0.768 . . . . 0.0 114.779 -173.295 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.84 -38.71 76.48 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 123.102 0.561 . . . . 0.0 111.025 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 35.3 mt -73.09 -42.36 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.454 0.702 . . . . 0.0 110.242 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -55.5 -54.08 48.32 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.121 171.135 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.05 -30.56 78.11 Favored Glycine 0 C--N 1.345 1.032 0 O-C-N 124.788 1.305 . . . . 0.0 113.767 -172.292 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.6 -56.69 18.85 Favored 'General case' 0 C--N 1.352 0.7 0 C-N-CA 122.899 0.479 . . . . 0.0 110.629 178.059 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.521 ' HA ' HG21 ' A' ' 76' ' ' ILE . 57.7 mt -76.03 -42.35 38.65 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.693 -174.666 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -62.29 -48.28 80.57 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.1 0.96 . . . . 0.0 112.255 -173.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -73.4 -25.69 60.65 Favored 'General case' 0 N--CA 1.48 1.075 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.43 -176.118 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 43.0 m -80.63 -41.84 23.18 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 123.022 0.529 . . . . 0.0 110.576 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.9 t -123.3 94.84 46.3 Favored Pre-proline 0 N--CA 1.479 1.01 0 C-N-CA 123.584 0.754 . . . . 0.0 109.378 -178.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -67.07 118.4 5.54 Favored 'Trans proline' 0 C--N 1.373 1.863 0 C-N-CA 122.579 2.186 . . . . 0.0 110.899 172.089 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.82 -25.48 7.17 Favored Glycine 0 C--N 1.347 1.141 0 CA-C-O 119.795 -0.447 . . . . 0.0 112.511 -174.338 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -73.81 106.17 5.42 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 174.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -79.8 99.91 7.72 Favored 'General case' 0 C--N 1.346 0.45 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -177.093 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.435 HG12 HG12 ' A' ' 64' ' ' VAL . 16.6 m -86.51 111.86 22.02 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.937 0 CA-C-O 121.539 0.685 . . . . 0.0 111.156 -169.846 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 64.9 t60 -109.22 99.24 8.54 Favored 'General case' 0 C--N 1.344 0.348 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.77 115.44 22.22 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 175.786 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -106.88 102.72 43.99 Favored Pre-proline 0 N--CA 1.474 0.739 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -56.26 -39.81 88.84 Favored 'Trans proline' 0 C--N 1.373 1.837 0 C-N-CA 123.084 2.522 . . . . 0.0 113.746 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.44 -44.62 64.49 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 123.383 0.673 . . . . 0.0 111.978 -171.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 21.1 t -95.39 -9.94 31.38 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.855 0.862 . . . . 0.0 110.606 -178.404 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.499 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 60.59 41.5 15.34 Favored 'General case' 0 N--CA 1.484 1.266 0 C-N-CA 125.266 1.426 . . . . 0.0 110.165 -179.319 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.5 m -123.13 120.44 33.25 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.642 0.377 . . . . 0.0 111.285 -167.368 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.6 t -98.97 105.38 17.29 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 175.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.2 t -102.5 118.79 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 -175.349 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.505 HG11 HG21 ' A' ' 44' ' ' ILE . 17.1 m -103.86 108.94 25.74 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.068 0 CA-C-O 121.581 0.705 . . . . 0.0 110.707 -178.136 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -85.59 149.38 23.49 Favored Glycine 0 C--N 1.35 1.312 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.412 -179.759 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.69 -26.03 13.91 Favored Glycine 0 N--CA 1.472 1.066 0 C-N-CA 122.955 0.312 . . . . 0.0 112.417 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 34.6 m -122.19 142.99 36.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 124.368 1.067 . . . . 0.0 109.705 -177.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 69.1 m -124.53 -0.52 8.12 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 123.518 0.727 . . . . 0.0 111.427 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 15.3 p-10 -78.42 83.94 4.61 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-O 122.603 1.192 . . . . 0.0 110.505 -178.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.37 -41.26 96.8 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 113.54 -1.664 . . . . 0.0 113.217 -170.483 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -63.02 -44.43 96.0 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.81 0.844 . . . . 0.0 111.648 -174.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.411 ' O ' HG13 ' A' ' 76' ' ' ILE . 32.1 m170 -66.25 -47.52 73.47 Favored 'General case' 0 N--CA 1.475 0.78 0 O-C-N 123.521 0.513 . . . . 0.0 110.896 179.315 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 29.3 mm -58.93 -39.2 77.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 123.795 0.684 . . . . 0.0 110.344 178.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.71 -38.21 89.52 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 124.156 0.982 . . . . 0.0 111.336 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -63.97 -39.37 93.98 Favored 'General case' 0 N--CA 1.482 1.169 0 O-C-N 123.619 0.574 . . . . 0.0 111.116 176.712 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.521 HG21 ' HA ' ' A' ' 44' ' ' ILE . 57.4 mt -68.15 -51.33 49.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 123.42 0.688 . . . . 0.0 111.268 -175.706 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 10.9 tt -68.63 -36.14 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.447 -175.394 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.0 t -71.97 -27.5 62.81 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 122.663 0.385 . . . . 0.0 110.311 177.501 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.46 -29.85 70.07 Favored 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 123.562 0.745 . . . . 0.0 111.401 174.407 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -78.03 -3.12 40.53 Favored 'General case' 0 N--CA 1.48 1.056 0 C-N-CA 123.432 0.693 . . . . 0.0 111.606 173.031 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.67 -9.54 60.46 Favored Glycine 0 C--N 1.343 0.969 0 CA-C-O 119.716 -0.491 . . . . 0.0 113.159 176.388 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -96.53 103.2 15.09 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 117.442 0.621 . . . . 0.0 109.722 -179.054 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 33.5 p -78.95 112.82 30.49 Favored Pre-proline 0 CA--C 1.553 1.063 0 C-N-CA 124.415 1.086 . . . . 0.0 109.87 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -76.77 -2.06 12.25 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 122.751 2.3 . . . . 0.0 113.421 179.199 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 . . . . . 0 C--O 1.256 1.396 0 C-N-CA 124.034 0.934 . . . . 0.0 109.933 175.14 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.006 0 CA-C-O 120.656 0.031 . . . . 0.0 113.159 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 67.6 mt -99.56 107.1 19.18 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.597 0.759 . . . . 0.0 109.615 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 30.1 p -92.05 110.81 22.18 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.046 0.538 . . . . 0.0 110.6 -177.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -104.21 105.03 15.04 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 123.353 0.661 . . . . 0.0 109.375 176.849 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 27.8 t60 -81.66 94.21 6.91 Favored 'General case' 0 CA--C 1.538 0.494 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.284 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.555 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 32.8 t -88.62 102.39 12.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.709 0 CA-C-N 114.964 -1.016 . . . . 0.0 108.618 -179.502 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -70.82 -22.76 62.3 Favored 'General case' 0 N--CA 1.485 1.322 0 CA-C-O 121.105 0.479 . . . . 0.0 110.923 177.774 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -75.62 -13.93 60.36 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.29 1.036 . . . . 0.0 111.244 175.292 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.555 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 27.5 ttt -58.99 122.07 12.79 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 123.371 0.669 . . . . 0.0 112.145 -173.359 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 14.8 t -85.31 163.48 18.57 Favored 'General case' 0 CA--C 1.549 0.908 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.884 173.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.508 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 28.7 p -66.41 -177.02 0.5 Allowed 'General case' 0 CA--C 1.554 1.12 0 C-N-CA 123.769 0.827 . . . . 0.0 113.015 -175.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.519 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -56.79 -15.38 12.54 Favored Glycine 0 C--N 1.357 1.734 0 N-CA-C 116.247 1.259 . . . . 0.0 116.247 -169.061 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -57.68 -42.99 84.76 Favored 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 117.61 0.705 . . . . 0.0 111.308 177.632 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 47.7 t -124.9 0.53 8.0 Favored 'General case' 0 CA--C 1.548 0.901 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.421 -177.396 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.519 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -64.64 -30.91 71.94 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 122.709 0.404 . . . . 0.0 110.624 173.189 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.53 -30.92 77.27 Favored Glycine 0 C--N 1.352 1.431 0 CA-C-N 115.794 -0.639 . . . . 0.0 113.265 174.301 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 42.8 t -69.13 -41.02 81.28 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 174.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 71.1 mt -58.26 -41.12 80.25 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.925 0 C-N-CA 124.078 0.951 . . . . 0.0 110.684 175.401 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.439 ' HB3' HG21 ' A' ' 53' ' ' VAL . 98.9 mttt -60.89 -58.92 6.42 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.572 0.749 . . . . 0.0 110.162 177.203 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.99 -30.6 70.38 Favored Glycine 0 C--N 1.351 1.372 0 O-C-N 124.68 1.238 . . . . 0.0 113.774 -173.802 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.59 -53.23 60.72 Favored 'General case' 0 C--N 1.35 0.62 0 C-N-CA 123.577 0.751 . . . . 0.0 110.557 176.691 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.565 HG21 HG11 ' A' ' 64' ' ' VAL . 72.8 mt -69.41 -46.64 76.02 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-N 114.847 -1.07 . . . . 0.0 112.465 -177.837 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -61.46 -46.24 90.89 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 123.504 0.722 . . . . 0.0 112.712 -175.62 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 12.8 mptt -83.52 -14.63 51.86 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.575 -171.102 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.5 m -87.4 -49.97 6.87 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 171.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 54.2 t -113.74 96.79 42.19 Favored Pre-proline 0 N--CA 1.475 0.821 0 C-N-CA 124.372 1.069 . . . . 0.0 108.959 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -66.14 140.09 58.11 Favored 'Trans proline' 0 C--N 1.376 1.987 0 C-N-CA 122.458 2.105 . . . . 0.0 111.271 176.546 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.54 -10.73 68.92 Favored Glycine 0 C--N 1.34 0.773 0 CA-C-O 119.571 -0.572 . . . . 0.0 112.938 -177.841 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -72.25 106.02 4.26 Favored 'General case' 0 C--N 1.355 0.828 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 174.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -83.83 99.92 10.63 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.584 HG12 HG12 ' A' ' 64' ' ' VAL . 26.9 m -85.31 135.82 24.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.541 0 CA-C-O 121.197 0.522 . . . . 0.0 110.763 -172.756 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 18.1 t-80 -126.19 95.55 4.42 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 167.426 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.51 112.88 24.77 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 177.662 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.428 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 9.6 t70 -112.43 108.38 54.55 Favored Pre-proline 0 CA--C 1.533 0.298 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 -175.54 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.508 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 71.4 Cg_exo -52.87 -35.73 71.51 Favored 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 123.223 2.615 . . . . 0.0 114.169 178.23 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.53 -31.3 47.47 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 123.061 0.544 . . . . 0.0 112.141 -177.088 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.428 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 19.5 m -91.31 -20.31 22.01 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 122.81 0.444 . . . . 0.0 111.039 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.4 mpt_? 57.88 46.09 17.35 Favored 'General case' 0 N--CA 1.483 1.188 0 C-N-CA 124.477 1.111 . . . . 0.0 110.033 -177.109 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.8 m -142.26 129.94 21.54 Favored 'General case' 0 C--N 1.351 0.657 0 C-N-CA 123.04 0.536 . . . . 0.0 110.735 -173.366 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 18.8 t -108.69 106.51 20.83 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 124.068 0.947 . . . . 0.0 108.858 174.627 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 25.9 t -97.97 118.68 44.89 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 123.76 0.824 . . . . 0.0 109.464 -179.687 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.584 HG12 HG12 ' A' ' 53' ' ' VAL . 35.9 m -106.89 114.61 46.44 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.014 0 CA-C-O 121.5 0.667 . . . . 0.0 110.912 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -97.17 161.29 21.57 Favored Glycine 0 C--N 1.345 1.066 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.278 -178.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 81.27 -4.79 70.2 Favored Glycine 0 N--CA 1.476 1.315 0 N-CA-C 114.149 0.419 . . . . 0.0 114.149 178.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.19 152.81 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 123.851 0.861 . . . . 0.0 110.141 -177.009 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.1 t -125.66 19.79 7.92 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 123.742 0.817 . . . . 0.0 109.79 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.473 ' O ' HG12 ' A' ' 73' ' ' ILE . 3.3 m-20 -96.24 66.86 2.51 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 123.564 0.745 . . . . 0.0 109.41 -177.301 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.0 -46.06 89.47 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 123.178 0.591 . . . . 0.0 112.196 -171.826 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.14 -42.23 99.04 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 123.78 0.675 . . . . 0.0 110.518 179.059 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.463 ' O ' HG13 ' A' ' 76' ' ' ILE . 11.8 m170 -66.15 -45.0 82.51 Favored 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.315 -176.616 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.476 HG13 HG21 ' A' ' 64' ' ' VAL . 47.8 mm -61.03 -40.81 86.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 C-N-CA 123.323 0.649 . . . . 0.0 110.561 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.25 -37.41 87.13 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 123.606 0.762 . . . . 0.0 111.23 179.019 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -67.03 -34.5 77.84 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 123.386 0.674 . . . . 0.0 111.557 176.54 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.463 HG13 ' O ' ' A' ' 72' ' ' HIS . 72.9 mt -68.79 -53.99 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 C-N-CA 123.311 0.645 . . . . 0.0 111.211 -178.34 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.0 tt -63.71 -36.25 75.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.955 -175.659 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 t -74.27 -29.49 61.69 Favored 'General case' 0 CA--C 1.551 1.013 0 C-N-CA 122.013 0.125 . . . . 0.0 110.93 177.387 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.09 -22.53 61.34 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 123.204 0.602 . . . . 0.0 110.892 174.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -79.95 -8.73 59.5 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 123.499 0.719 . . . . 0.0 111.209 172.119 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 97.38 22.85 15.63 Favored Glycine 0 C--N 1.351 1.388 0 CA-C-N 116.104 -0.498 . . . . 0.0 113.055 175.257 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -127.61 105.97 8.84 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 24.0 p -75.77 116.09 52.09 Favored Pre-proline 0 CA--C 1.55 0.959 0 C-N-CA 122.835 0.454 . . . . 0.0 110.809 -174.233 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.477 ' HA ' HG13 ' A' ' 28' ' ' VAL . 76.5 Cg_endo -78.09 -8.81 16.6 Favored 'Trans proline' 0 C--N 1.382 2.302 0 C-N-CA 123.143 2.562 . . . . 0.0 112.985 -176.794 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 . . . . . 0 C--O 1.25 1.102 0 C-N-CA 124.281 1.032 . . . . 0.0 108.957 -175.896 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.243 0.666 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.478 HD13 ' HA ' ' A' ' 70' ' ' ALA . 34.9 mt -80.15 107.23 12.78 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -174.791 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.2 m -102.63 130.09 49.41 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.19 0.596 . . . . 0.0 109.81 -172.737 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -128.4 114.53 16.94 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.68 0.792 . . . . 0.0 110.514 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 47.0 m80 -81.63 111.86 18.3 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 171.2 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.7 t -107.9 100.63 11.13 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -176.33 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -69.06 -23.15 64.0 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.428 0.691 . . . . 0.0 110.927 175.323 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -74.3 -19.47 60.47 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.421 0.688 . . . . 0.0 110.625 177.682 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.527 ' HG3' ' HB2' ' A' ' 36' ' ' CYS . 20.4 ttt -82.67 133.82 35.16 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.215 1.006 . . . . 0.0 110.15 176.604 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 28.0 p -117.83 95.0 4.73 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 170.292 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.623 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 58.0 m 46.01 -142.69 0.31 Allowed 'General case' 0 CA--C 1.568 1.658 0 C-N-CA 125.017 1.327 . . . . 0.0 114.19 168.628 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.61 -24.48 64.16 Favored Glycine 0 C--N 1.362 2.019 0 C-N-CA 123.705 0.669 . . . . 0.0 114.292 -179.703 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -56.47 -37.94 71.02 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 123.28 0.632 . . . . 0.0 111.668 175.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.527 ' HB2' ' HG3' ' A' ' 31' ' ' MET . 80.9 m -104.11 -19.1 14.28 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 122.943 0.497 . . . . 0.0 111.571 -178.333 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -56.05 -42.72 77.03 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -173.492 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -61.76 -50.83 62.05 Favored Glycine 0 CA--C 1.535 1.286 0 O-C-N 123.31 0.381 . . . . 0.0 113.587 -177.409 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m -75.28 -34.24 30.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 C-N-CA 123.365 0.666 . . . . 0.0 112.161 -177.365 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 9.6 tt -74.84 -34.96 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 C-N-CA 123.11 0.564 . . . . 0.0 110.721 -174.387 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -71.81 -47.64 51.86 Favored 'General case' 0 C--N 1.351 0.659 0 C-N-CA 123.604 0.762 . . . . 0.0 109.657 173.208 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.44 -30.03 75.11 Favored Glycine 0 C--N 1.349 1.301 0 O-C-N 124.35 1.031 . . . . 0.0 113.359 -179.039 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.89 -54.65 43.64 Favored 'General case' 0 C--N 1.348 0.505 0 C-N-CA 123.386 0.674 . . . . 0.0 110.239 177.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.648 HG21 HG11 ' A' ' 64' ' ' VAL . 48.0 mt -74.03 -46.17 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.529 -175.708 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -59.97 -51.85 67.9 Favored 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.18 0.992 . . . . 0.0 112.371 -173.742 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.7 mptp? -75.95 -13.83 60.24 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 122.458 0.303 . . . . 0.0 111.721 -175.167 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 86.4 m -89.02 -39.27 13.8 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 123.117 0.567 . . . . 0.0 110.252 175.321 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 97.4 t -124.73 89.65 52.08 Favored Pre-proline 0 N--CA 1.479 0.977 0 C-N-CA 123.951 0.901 . . . . 0.0 109.022 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -60.17 113.44 1.67 Allowed 'Trans proline' 0 C--N 1.376 2.011 0 C-N-CA 122.845 2.364 . . . . 0.0 111.14 171.803 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.76 -14.85 9.1 Favored Glycine 0 C--N 1.342 0.87 0 CA-C-O 119.633 -0.537 . . . . 0.0 113.012 -176.274 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.79 106.8 9.86 Favored 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 173.184 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.467 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -76.27 99.54 4.8 Favored 'General case' 0 C--N 1.349 0.586 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.421 HG12 HG12 ' A' ' 64' ' ' VAL . 16.8 m -86.33 131.71 33.98 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 C-N-CA 123.29 0.636 . . . . 0.0 111.043 -172.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 43.9 t-80 -136.55 99.42 4.07 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 174.574 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -96.72 114.34 25.97 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 174.749 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -94.06 120.95 65.08 Favored Pre-proline 0 N--CA 1.471 0.589 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -174.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.623 ' HA ' ' HA ' ' A' ' 33' ' ' CYS . 51.1 Cg_exo -57.54 -38.25 94.47 Favored 'Trans proline' 0 C--N 1.374 1.907 0 C-N-CA 123.103 2.536 . . . . 0.0 114.417 177.633 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.72 -35.38 52.05 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.032 0.533 . . . . 0.0 111.62 -174.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 16.5 m -97.69 -20.94 17.29 Favored 'General case' 0 N--CA 1.482 1.151 0 C-N-CA 123.564 0.746 . . . . 0.0 111.718 -175.178 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.9 mpt_? 56.91 32.63 21.83 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 125.108 1.363 . . . . 0.0 110.947 -171.588 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.9 m -110.35 118.98 37.77 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 123.377 0.671 . . . . 0.0 110.055 -172.883 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 20.9 t -101.49 107.24 21.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 177.644 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 21.9 t -105.5 135.3 44.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 123.785 0.834 . . . . 0.0 108.754 -179.044 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.648 HG11 HG21 ' A' ' 44' ' ' ILE . 18.8 m -121.7 123.0 68.42 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 C-N-CA 123.196 0.598 . . . . 0.0 110.404 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -99.74 156.74 19.76 Favored Glycine 0 C--N 1.347 1.165 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.095 -179.144 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.5 -18.2 43.89 Favored Glycine 0 N--CA 1.474 1.225 0 C-N-CA 123.121 0.391 . . . . 0.0 113.451 177.478 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.8 m -115.68 146.86 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 124.092 0.957 . . . . 0.0 109.741 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 69.8 m -116.54 -20.47 9.61 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.722 0.809 . . . . 0.0 112.439 -175.77 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -75.95 86.3 2.88 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 122.776 0.43 . . . . 0.0 110.481 178.499 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.478 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -62.98 -29.01 70.49 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.431 0.692 . . . . 0.0 111.116 175.718 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.3 -51.38 67.89 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 124.402 1.081 . . . . 0.0 111.117 177.058 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.416 ' O ' HG13 ' A' ' 76' ' ' ILE . 28.2 m-70 -63.09 -48.01 80.43 Favored 'General case' 0 N--CA 1.482 1.155 0 O-C-N 123.592 0.558 . . . . 0.0 110.838 -178.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.474 HG21 HG21 ' A' ' 64' ' ' VAL . 49.5 mm -61.22 -40.62 86.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 124.068 0.855 . . . . 0.0 110.436 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.73 -39.69 92.46 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 123.95 0.781 . . . . 0.0 111.333 179.423 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.9 mm-40 -62.59 -39.5 93.91 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.491 0.716 . . . . 0.0 111.206 178.089 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.542 HG21 ' HA ' ' A' ' 44' ' ' ILE . 53.8 mt -68.02 -53.86 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 O-C-N 123.747 0.654 . . . . 0.0 110.959 -179.16 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 15.9 tt -70.28 -29.15 38.12 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.71 -173.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.5 t -76.07 -31.69 58.89 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 110.156 -0.312 . . . . 0.0 110.156 175.239 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.69 -21.43 64.42 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 123.671 0.788 . . . . 0.0 111.64 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -74.24 -3.69 31.48 Favored 'General case' 0 CA--C 1.555 1.15 0 C-N-CA 123.538 0.735 . . . . 0.0 112.189 176.069 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 101.77 23.11 9.56 Favored Glycine 0 C--N 1.351 1.4 0 C-N-CA 123.065 0.364 . . . . 0.0 112.885 178.368 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -119.3 175.83 5.62 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.992 0.917 . . . . 0.0 109.02 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 96.0 m -148.43 83.8 6.91 Favored Pre-proline 0 N--CA 1.479 0.994 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 171.069 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_exo -70.79 -67.31 0.03 OUTLIER 'Trans proline' 0 C--N 1.369 1.646 0 C-N-CA 122.449 2.1 . . . . 0.0 112.487 177.75 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 . . . . . 0 C--O 1.257 1.451 0 C-N-CA 125.154 1.382 . . . . 0.0 110.926 -171.787 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.599 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 34.1 mt -88.99 108.21 19.46 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.4 p -92.38 111.32 22.85 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 122.883 0.473 . . . . 0.0 110.555 -177.85 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -106.19 124.81 50.17 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 123.88 0.872 . . . . 0.0 109.746 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 32.3 m-70 -84.05 136.81 33.88 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 175.716 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 p -157.34 97.05 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.978 0 C-N-CA 124.066 0.946 . . . . 0.0 109.049 -176.402 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -69.8 -29.4 66.69 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.418 -176.216 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -74.4 -9.85 59.0 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.164 0.586 . . . . 0.0 112.018 -178.628 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.612 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 56.1 ttp -72.62 113.08 9.26 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 120.93 0.395 . . . . 0.0 110.557 177.132 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.401 ' OG1' ' HB3' ' A' ' 36' ' ' CYS . 63.2 p -77.51 166.34 23.2 Favored 'General case' 0 CA--C 1.549 0.917 0 C-N-CA 124.013 0.925 . . . . 0.0 109.923 168.799 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 28.0 p -57.11 -169.73 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 124.089 0.956 . . . . 0.0 112.647 175.761 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.69 3.45 0.63 Allowed Glycine 0 C--N 1.357 1.721 0 N-CA-C 115.916 1.127 . . . . 0.0 115.916 -174.001 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 3.5 m80 -63.27 -44.74 94.25 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.743 0.817 . . . . 0.0 110.844 166.0 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.401 ' HB3' ' OG1' ' A' ' 32' ' ' THR . 43.5 t -141.42 9.56 2.05 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 123.136 0.575 . . . . 0.0 111.996 -176.09 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.58 -30.95 69.83 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 122.836 0.454 . . . . 0.0 110.754 173.191 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.53 -20.87 53.09 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 114.996 -1.002 . . . . 0.0 114.256 176.861 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.496 HG12 ' HB1' ' A' ' 80' ' ' ALA . 57.9 t -65.41 -44.32 94.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 122.871 0.468 . . . . 0.0 110.138 174.233 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.711 HG21 HG21 ' A' ' 62' ' ' VAL . 44.1 mt -69.61 -54.44 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 C-N-CA 123.3 0.64 . . . . 0.0 110.661 175.431 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.427 ' O ' ' HG3' ' A' ' 45' ' ' GLU . 9.7 mtpm? -56.68 -51.83 67.28 Favored 'General case' 0 C--N 1.348 0.507 0 O-C-N 124.517 1.136 . . . . 0.0 110.269 -174.775 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.48 ' O ' ' HD3' ' A' ' 46' ' ' LYS . . . -61.94 -40.16 98.5 Favored Glycine 0 C--N 1.343 0.917 0 O-C-N 124.963 1.414 . . . . 0.0 112.867 178.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.74 -53.5 57.05 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 117.129 0.464 . . . . 0.0 111.001 179.138 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.576 HG21 HG11 ' A' ' 64' ' ' VAL . 68.4 mt -62.08 -39.93 85.6 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.967 -179.174 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.427 ' HG3' ' O ' ' A' ' 41' ' ' LYS . 76.9 mt-10 -62.02 -50.46 71.94 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 123.171 0.588 . . . . 0.0 112.068 179.623 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.48 ' HD3' ' O ' ' A' ' 42' ' ' GLY . 13.3 mptt -73.03 -28.07 62.13 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.496 -171.528 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.1 m -85.2 -41.01 16.02 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 122.814 0.445 . . . . 0.0 110.32 177.546 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.0 103.51 23.53 Favored Pre-proline 0 N--CA 1.483 1.216 0 C-N-CA 124.156 0.982 . . . . 0.0 109.807 -178.722 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -66.91 136.58 41.97 Favored 'Trans proline' 0 C--N 1.374 1.919 0 C-N-CA 122.781 2.321 . . . . 0.0 111.687 172.059 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.2 -4.75 67.68 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-O 119.787 -0.452 . . . . 0.0 113.963 175.875 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.65 106.68 9.61 Favored 'General case' 0 C--N 1.35 0.619 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 173.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.421 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -77.14 99.54 5.43 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -177.095 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.412 HG12 HG12 ' A' ' 64' ' ' VAL . 27.8 m -85.26 127.47 39.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.805 0 C-N-CA 123.134 0.574 . . . . 0.0 110.877 -171.065 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' HIS . . . . . 0.409 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 29.2 t60 -131.67 96.98 4.08 Favored 'General case' 0 C--N 1.345 0.372 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 176.12 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.612 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -93.71 113.67 25.79 Favored 'General case' 0 C--O 1.24 0.588 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 176.073 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -99.72 114.88 65.88 Favored Pre-proline 0 N--CA 1.468 0.428 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -177.373 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -60.54 -40.34 57.36 Favored 'Trans proline' 0 C--N 1.373 1.863 0 C-N-CA 123.009 2.473 . . . . 0.0 112.822 -176.254 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -74.38 -47.74 32.22 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.639 0.775 . . . . 0.0 111.285 -176.734 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.2 m -81.31 -15.65 54.8 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 123.74 0.816 . . . . 0.0 111.459 -176.122 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 63.0 29.44 16.43 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 124.642 1.177 . . . . 0.0 111.389 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 33.1 m -122.79 122.76 39.46 Favored 'General case' 0 N--CA 1.479 1.001 0 O-C-N 121.808 -0.558 . . . . 0.0 111.57 -169.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.711 HG21 HG21 ' A' ' 40' ' ' ILE . 40.5 t -99.09 106.38 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 123.952 0.901 . . . . 0.0 108.972 173.33 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.1 t -100.49 123.21 53.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.581 HG21 HG21 ' A' ' 73' ' ' ILE . 17.0 m -111.5 109.0 26.9 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.955 0 CA-C-O 121.478 0.656 . . . . 0.0 110.18 179.377 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.46 150.78 20.99 Favored Glycine 0 C--N 1.346 1.125 0 CA-C-N 115.604 -0.725 . . . . 0.0 112.581 -176.561 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.19 -23.68 30.47 Favored Glycine 0 C--N 1.343 0.967 0 C-N-CA 123.089 0.375 . . . . 0.0 112.999 177.007 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 22.4 m -105.52 151.14 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 123.992 0.917 . . . . 0.0 110.153 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 17.9 m -126.85 -2.61 6.56 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 124.005 0.922 . . . . 0.0 110.332 -178.621 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -87.33 73.02 9.72 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 124.522 1.129 . . . . 0.0 110.266 -177.219 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.99 -29.29 70.46 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-N 114.907 -1.042 . . . . 0.0 112.373 -174.725 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.402 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.68 -49.45 73.12 Favored 'General case' 0 N--CA 1.474 0.764 0 O-C-N 123.763 0.665 . . . . 0.0 110.819 177.599 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.499 ' O ' HG13 ' A' ' 76' ' ' ILE . 39.8 m170 -59.35 -54.93 41.14 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 123.552 0.532 . . . . 0.0 110.463 177.81 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.581 HG21 HG21 ' A' ' 64' ' ' VAL . 41.4 mm -57.8 -40.27 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 O-C-N 124.438 1.086 . . . . 0.0 110.785 -174.282 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.26 -40.14 89.29 Favored 'General case' 0 N--CA 1.48 1.067 0 O-C-N 124.022 0.826 . . . . 0.0 111.429 178.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 15.2 mm-40 -68.23 -32.09 72.05 Favored 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 123.181 0.592 . . . . 0.0 111.292 178.05 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.499 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.3 mt -74.75 -48.66 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 122.986 0.514 . . . . 0.0 111.21 -177.094 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 73' ' ' ILE . 8.5 tt -67.37 -32.39 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 C-N-CA 123.259 0.623 . . . . 0.0 111.257 -177.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -75.12 -31.05 61.02 Favored 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 110.364 -0.236 . . . . 0.0 110.364 175.07 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.95 -18.49 64.09 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 123.537 0.735 . . . . 0.0 111.747 176.09 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.496 ' HB1' HG12 ' A' ' 39' ' ' VAL . . . -75.89 0.58 17.76 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 123.664 0.786 . . . . 0.0 112.291 176.441 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 95.9 17.04 36.59 Favored Glycine 0 C--N 1.351 1.377 0 C-N-CA 122.861 0.267 . . . . 0.0 112.528 179.597 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -120.78 178.36 4.73 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 124.361 1.064 . . . . 0.0 109.686 -177.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 39.0 m -139.41 111.81 7.77 Favored Pre-proline 0 N--CA 1.479 1.001 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 173.333 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -66.44 120.37 7.49 Favored 'Trans proline' 0 C--N 1.382 2.305 0 C-N-CA 122.355 2.037 . . . . 0.0 110.812 171.427 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 . . . . . 0 CA--C 1.555 1.167 0 C-N-CA 124.187 0.995 . . . . 0.0 109.493 -175.682 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.431 ' HA2' ' HA2' ' A' ' 65' ' ' GLY . . . . . . . . 0 N--CA 1.466 0.65 0 N-CA-C 112.165 -0.374 . . . . 0.0 112.165 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.445 HD13 ' HA ' ' A' ' 70' ' ' ALA . 59.4 mt -81.42 111.59 17.91 Favored 'General case' 0 N--CA 1.47 0.568 0 C-N-CA 124.059 0.944 . . . . 0.0 110.108 179.433 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.4 t -83.72 129.62 34.95 Favored 'General case' 0 CA--C 1.549 0.922 0 C-N-CA 123.556 0.742 . . . . 0.0 110.516 -177.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -125.84 108.44 11.47 Favored 'General case' 0 N--CA 1.492 1.636 0 C-N-CA 123.338 0.655 . . . . 0.0 110.919 177.545 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 75.9 t60 -82.88 105.58 14.01 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.531 1.132 . . . . 0.0 110.308 -175.479 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.643 HG11 ' HB3' ' A' ' 82' ' ' TYR . 30.1 t -120.7 94.97 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 C-N-CA 123.214 0.606 . . . . 0.0 109.729 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -69.65 -24.75 63.66 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 123.034 0.533 . . . . 0.0 112.186 -177.306 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -74.98 -20.11 59.81 Favored 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 123.737 0.815 . . . . 0.0 111.163 -179.142 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.419 ' SD ' HD13 ' A' ' 40' ' ' ILE . 12.9 ttt -73.26 139.34 46.09 Favored 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 124.303 1.041 . . . . 0.0 110.786 176.495 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 15.1 t -103.01 163.39 12.24 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 123.917 0.887 . . . . 0.0 109.195 170.037 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 23.3 p -66.98 -97.46 0.0 OUTLIER 'General case' 0 CA--C 1.563 1.467 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -174.137 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.48 -32.74 64.51 Favored Glycine 0 C--N 1.349 1.3 0 N-CA-C 114.673 0.629 . . . . 0.0 114.673 -166.199 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 72.1 m-70 -74.01 -14.34 61.0 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.514 0.726 . . . . 0.0 111.869 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.6 t -122.54 -7.1 8.64 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 122.977 0.511 . . . . 0.0 111.688 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -57.67 -55.7 31.5 Favored 'General case' 0 N--CA 1.481 1.088 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -171.594 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.83 -38.17 95.23 Favored Glycine 0 N--CA 1.47 0.903 0 N-CA-C 114.255 0.462 . . . . 0.0 114.255 -174.952 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.5 p -75.15 -40.37 44.06 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.15 0 C-N-CA 122.785 0.434 . . . . 0.0 111.733 -176.125 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.434 HD11 HD11 ' A' ' 77' ' ' ILE . 13.0 tt -75.05 -35.88 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 122.802 0.441 . . . . 0.0 110.79 -178.211 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.463 ' HB3' HG21 ' A' ' 53' ' ' VAL . 97.2 mttt -65.21 -52.29 55.66 Favored 'General case' 0 C--N 1.353 0.729 0 CA-C-N 115.771 -0.649 . . . . 0.0 109.471 174.584 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.91 -29.31 67.48 Favored Glycine 0 C--N 1.352 1.43 0 O-C-N 124.813 1.321 . . . . 0.0 113.517 -178.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.35 -54.96 40.85 Favored 'General case' 0 C--N 1.352 0.693 0 C-N-CA 123.375 0.67 . . . . 0.0 110.476 175.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.612 HG21 HG11 ' A' ' 64' ' ' VAL . 66.6 mt -73.2 -45.72 52.65 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 CA-C-N 115.529 -0.759 . . . . 0.0 112.031 -179.655 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -63.05 -45.7 90.99 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 124.72 1.208 . . . . 0.0 111.275 -167.858 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -70.95 -27.45 63.75 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.853 0.461 . . . . 0.0 111.698 -178.614 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 33.2 m -81.51 -33.89 31.58 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 122.648 0.379 . . . . 0.0 110.833 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.3 t -124.75 95.0 43.34 Favored Pre-proline 0 N--CA 1.48 1.073 0 C-N-CA 123.32 0.648 . . . . 0.0 109.688 178.67 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -65.88 111.22 1.89 Allowed 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 122.699 2.266 . . . . 0.0 110.861 173.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.5 -12.1 9.59 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-O 119.514 -0.603 . . . . 0.0 113.281 -176.603 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -76.87 106.28 8.45 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 173.629 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.21 100.16 8.17 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -178.445 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.463 HG21 ' HB3' ' A' ' 41' ' ' LYS . 15.3 m -84.39 132.99 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 123.78 0.832 . . . . 0.0 110.649 -170.423 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -141.48 101.81 4.07 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 122.903 0.481 . . . . 0.0 109.756 -176.162 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.25 130.32 35.07 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 109.643 -0.502 . . . . 0.0 109.643 176.146 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -105.48 108.59 61.8 Favored Pre-proline 0 CA--C 1.541 0.628 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 176.637 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -47.34 -44.94 23.65 Favored 'Trans proline' 0 C--N 1.374 1.901 0 C-N-CA 124.126 3.218 . . . . 0.0 115.396 178.326 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.31 -41.57 40.16 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.485 0.714 . . . . 0.0 112.233 -173.17 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.8 t -93.37 -13.93 27.46 Favored 'General case' 0 N--CA 1.482 1.141 0 C-N-CA 123.496 0.718 . . . . 0.0 111.558 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.42 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 2.7 mpt_? 57.17 45.98 19.68 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 125.036 1.334 . . . . 0.0 110.8 -178.12 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 78.9 m -122.75 126.61 47.83 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.88 -170.402 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 40.5 t -98.44 108.27 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 173.833 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.0 t -100.58 123.11 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 C-N-CA 124.035 0.934 . . . . 0.0 108.609 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.612 HG11 HG21 ' A' ' 44' ' ' ILE . 31.4 m -112.57 109.07 27.23 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 C-N-CA 123.669 0.787 . . . . 0.0 110.666 -176.812 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.431 ' HA2' ' HA2' ' A' ' 23' ' ' GLY . . . -88.62 160.24 30.05 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 115.584 -0.735 . . . . 0.0 113.049 -177.335 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 78.55 4.59 87.63 Favored Glycine 0 C--N 1.343 0.92 0 N-CA-C 114.356 0.502 . . . . 0.0 114.356 175.546 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 23.4 m -131.8 150.79 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.854 0 C-N-CA 123.796 0.838 . . . . 0.0 109.4 -178.468 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 30.8 t -116.1 -8.41 11.8 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 124.1 0.96 . . . . 0.0 111.06 -176.657 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.417 ' O ' HG12 ' A' ' 73' ' ' ILE . 7.1 m-20 -80.92 72.34 7.92 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.751 0.821 . . . . 0.0 110.893 -175.308 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.445 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -60.38 -41.43 93.74 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.149 0.58 . . . . 0.0 111.065 -178.281 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.472 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.22 -47.83 80.85 Favored 'General case' 0 CA--C 1.541 0.6 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.134 179.094 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.43 ' O ' HG13 ' A' ' 76' ' ' ILE . 45.0 t-80 -64.64 -45.24 87.64 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.167 0.587 . . . . 0.0 111.559 -176.186 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.497 HG21 HG21 ' A' ' 64' ' ' VAL . 48.5 mm -60.86 -41.03 87.18 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 O-C-N 123.552 0.533 . . . . 0.0 109.892 178.818 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.15 -35.31 76.74 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 115.305 -0.861 . . . . 0.0 111.751 178.49 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.472 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 17.5 mm-40 -65.52 -41.13 93.48 Favored 'General case' 0 N--CA 1.48 1.034 0 C-N-CA 123.457 0.703 . . . . 0.0 110.923 177.692 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.43 HG13 ' O ' ' A' ' 72' ' ' HIS . 35.5 mt -66.37 -50.05 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.021 -177.126 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.434 HD11 HD11 ' A' ' 40' ' ' ILE . 15.9 tt -72.66 -31.17 36.13 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.949 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.429 -172.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.5 t -74.54 -29.57 61.43 Favored 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 175.095 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.43 -19.62 60.92 Favored 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 123.563 0.745 . . . . 0.0 111.27 173.451 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -80.4 -5.31 56.27 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.565 0.746 . . . . 0.0 111.21 172.107 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.0 22.72 32.0 Favored Glycine 0 C--N 1.35 1.358 0 O-C-N 123.372 0.42 . . . . 0.0 112.903 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.643 ' HB3' HG11 ' A' ' 28' ' ' VAL . 81.7 m-85 -127.46 115.07 18.33 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.659 0.784 . . . . 0.0 110.51 -176.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 34.8 p -71.16 111.78 11.21 Favored Pre-proline 0 CA--C 1.549 0.916 0 C-N-CA 124.296 1.039 . . . . 0.0 110.987 -177.253 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.403 ' HA ' HG22 ' A' ' 28' ' ' VAL . 93.8 Cg_endo -80.6 150.14 18.96 Favored 'Trans proline' 0 C--N 1.372 1.803 0 C-N-CA 122.323 2.016 . . . . 0.0 111.824 177.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 . . . . . 0 CA--C 1.559 1.3 0 C-N-CA 124.703 1.201 . . . . 0.0 111.437 173.536 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.858 0 N-CA-C 110.35 -1.1 . . . . 0.0 110.35 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 46.8 mt -83.1 105.84 14.41 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 174.278 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.1 m -93.83 111.4 23.09 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -176.762 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -103.26 100.96 10.88 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 177.244 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 77.0 t60 -82.47 91.71 6.92 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 -179.202 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.58 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 15.9 t -74.37 93.62 0.75 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 N-CA-C 106.855 -1.535 . . . . 0.0 106.855 172.543 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -63.75 -20.81 66.04 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 112.693 0.627 . . . . 0.0 112.693 -171.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 10.6 p-10 -111.34 23.6 13.82 Favored 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 124.089 0.956 . . . . 0.0 110.789 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.58 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 23.9 ttt -57.73 142.01 46.74 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 124.389 1.076 . . . . 0.0 113.325 -173.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 41.3 p -81.32 144.4 31.53 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.547 173.204 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.439 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 49.8 t -73.04 -170.51 0.75 Allowed 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 123.882 0.873 . . . . 0.0 110.078 177.137 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -49.35 -24.9 5.55 Favored Glycine 0 C--N 1.356 1.657 0 N-CA-C 116.623 1.409 . . . . 0.0 116.623 -171.562 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 40.9 m170 -58.53 -33.75 70.22 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 123.498 0.719 . . . . 0.0 112.558 177.019 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 63.8 m -137.92 15.95 2.86 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 122.997 0.519 . . . . 0.0 111.739 178.787 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.4 -34.04 63.19 Favored 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 122.614 0.366 . . . . 0.0 110.96 174.1 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.94 -37.91 93.69 Favored Glycine 0 C--N 1.347 1.161 0 O-C-N 123.825 0.703 . . . . 0.0 113.768 -176.013 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 9.2 p -69.48 -28.46 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 122.943 0.497 . . . . 0.0 110.883 177.601 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.2 mt -67.93 -41.82 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 123.224 0.61 . . . . 0.0 109.974 175.298 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -62.24 -52.05 65.28 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 123.811 0.844 . . . . 0.0 110.177 177.576 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.82 -31.1 78.69 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 114.414 -1.266 . . . . 0.0 113.063 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.38 -50.92 68.46 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.975 0.91 . . . . 0.0 110.831 179.167 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.515 HG21 HG11 ' A' ' 64' ' ' VAL . 64.3 mt -74.37 -51.4 23.3 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.644 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -56.16 -54.67 42.38 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 124.358 1.063 . . . . 0.0 112.745 -170.485 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -69.79 -13.72 62.42 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 122.889 0.476 . . . . 0.0 112.107 -175.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 61.2 m -90.51 -37.74 13.68 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 123.341 0.656 . . . . 0.0 110.442 177.732 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.5 m -133.54 92.1 24.63 Favored Pre-proline 0 CA--C 1.556 1.176 0 C-N-CA 123.474 0.71 . . . . 0.0 110.491 179.317 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -58.03 135.08 66.38 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 122.604 2.203 . . . . 0.0 111.555 171.034 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 110.62 -29.58 8.89 Favored Glycine 0 C--N 1.341 0.847 0 N-CA-C 111.87 -0.492 . . . . 0.0 111.87 -177.731 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -74.02 106.86 5.89 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 175.795 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.445 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -78.06 99.34 6.08 Favored 'General case' 0 C--N 1.345 0.407 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -179.057 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.474 HG12 HG12 ' A' ' 64' ' ' VAL . 27.2 m -84.51 129.42 37.7 Favored 'Isoleucine or valine' 0 C--O 1.239 0.546 0 C-N-CA 123.1 0.56 . . . . 0.0 110.015 -171.734 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' HIS . . . . . 0.402 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 41.1 t60 -133.68 96.01 3.6 Favored 'General case' 0 CA--C 1.518 -0.283 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 175.439 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.1 113.91 26.31 Favored 'General case' 0 C--O 1.243 0.755 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 173.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -105.35 105.54 52.6 Favored Pre-proline 0 N--CA 1.466 0.337 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 -175.361 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.439 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 76.4 Cg_exo -53.39 -38.1 82.25 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 123.236 2.624 . . . . 0.0 113.72 179.331 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.8 -45.21 62.31 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 123.215 0.606 . . . . 0.0 111.413 -176.622 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.9 m -84.08 -17.89 38.75 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.417 0.687 . . . . 0.0 111.552 -177.28 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.566 ' HD2' ' HB3' ' A' ' 31' ' ' MET . 66.6 mmt-85 64.29 37.49 8.54 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 124.633 1.173 . . . . 0.0 110.367 -178.58 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.1 m -137.9 122.88 19.02 Favored 'General case' 0 CA--C 1.55 0.965 0 O-C-N 122.025 -0.422 . . . . 0.0 111.603 -169.85 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.402 ' HA ' ' O ' ' A' ' 54' ' ' HIS . 18.5 t -99.45 106.37 18.91 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 C-N-CA 124.142 0.977 . . . . 0.0 109.204 175.391 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.8 t -104.95 123.47 59.04 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 123.728 0.811 . . . . 0.0 109.073 -176.147 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.515 HG11 HG21 ' A' ' 44' ' ' ILE . 27.8 m -108.56 122.5 63.19 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.909 0 C-N-CA 123.038 0.535 . . . . 0.0 110.521 177.42 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -102.43 153.3 18.44 Favored Glycine 0 C--N 1.345 1.075 0 CA-C-N 115.981 -0.554 . . . . 0.0 112.872 -176.772 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.7 -24.77 22.12 Favored Glycine 0 N--CA 1.471 1.027 0 C-N-CA 123.173 0.416 . . . . 0.0 112.856 177.212 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 35.3 m -111.69 149.05 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.987 0.915 . . . . 0.0 109.473 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.5 m -121.74 20.82 10.92 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 123.656 0.782 . . . . 0.0 110.416 -178.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -96.65 73.56 2.71 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 124.367 1.067 . . . . 0.0 109.506 -173.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.34 -53.38 58.97 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 123.721 0.809 . . . . 0.0 112.642 -170.864 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.422 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -62.9 -40.52 97.82 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 123.481 0.712 . . . . 0.0 111.031 -178.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 55.7 t60 -61.66 -50.35 72.85 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.967 0.907 . . . . 0.0 111.205 -177.43 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.4 HG21 HG21 ' A' ' 64' ' ' VAL . 39.6 mm -64.99 -39.93 87.35 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.083 179.055 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.13 -37.11 79.09 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 123.985 0.803 . . . . 0.0 111.128 179.093 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.422 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 39.5 mm-40 -66.29 -40.02 89.77 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 123.625 0.77 . . . . 0.0 111.288 176.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.442 HG21 ' HA ' ' A' ' 44' ' ' ILE . 65.6 mt -64.08 -52.95 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 O-C-N 123.606 0.566 . . . . 0.0 111.17 -179.215 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 8.0 tt -66.8 -37.88 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.313 -175.147 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.5 t -73.84 -29.64 62.24 Favored 'General case' 0 CA--C 1.552 1.037 0 C-N-CA 122.384 0.273 . . . . 0.0 110.296 179.503 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.71 -22.24 61.67 Favored 'General case' 0 N--CA 1.484 1.256 0 C-N-CA 123.628 0.771 . . . . 0.0 111.238 174.48 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.43 -6.08 52.15 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.503 0.721 . . . . 0.0 111.396 172.242 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 93.87 8.17 60.75 Favored Glycine 0 C--N 1.345 1.068 0 CA-C-O 119.89 -0.394 . . . . 0.0 112.933 177.402 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -117.0 103.22 10.04 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 176.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.4 t -83.59 118.53 71.74 Favored Pre-proline 0 CA--C 1.554 1.119 0 C-N-CA 123.267 0.627 . . . . 0.0 110.389 -176.888 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -70.75 -42.6 2.28 Favored 'Trans proline' 0 C--N 1.377 2.076 0 C-N-CA 122.409 2.072 . . . . 0.0 111.716 173.274 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 . . . . . 0 C--O 1.253 1.279 0 C-N-CA 124.767 1.227 . . . . 0.0 108.102 172.379 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.403 ' HA2' ' HA2' ' A' ' 65' ' ' GLY . . . . . . . . 0 N--CA 1.467 0.721 0 N-CA-C 112.058 -0.417 . . . . 0.0 112.058 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 47.6 mt -80.32 108.6 14.07 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 123.809 0.844 . . . . 0.0 110.141 -178.018 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 21.0 p -88.44 124.25 33.78 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 123.623 0.769 . . . . 0.0 110.978 -178.383 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -121.55 112.72 18.83 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 123.729 0.812 . . . . 0.0 110.401 -179.758 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 69.3 m80 -83.59 104.23 13.55 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.318 0.647 . . . . 0.0 110.173 177.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.595 HG11 ' HB3' ' A' ' 82' ' ' TYR . 98.8 t -90.07 128.3 42.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 C-N-CA 123.404 0.681 . . . . 0.0 109.176 174.9 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -64.44 -39.85 94.61 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 123.563 0.745 . . . . 0.0 112.286 -176.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -104.83 -6.47 20.21 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 113.302 0.852 . . . . 0.0 113.302 -166.169 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 24.1 ptm -65.45 133.38 51.18 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-O 121.318 0.58 . . . . 0.0 111.355 -174.236 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 72.9 p -107.55 161.62 14.69 Favored 'General case' 0 CA--C 1.547 0.856 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 171.778 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 24.6 p -74.87 -109.29 0.01 OUTLIER 'General case' 0 CA--C 1.563 1.479 0 N-CA-C 113.951 1.093 . . . . 0.0 113.951 -166.524 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -75.96 5.21 41.98 Favored Glycine 0 N--CA 1.478 1.474 0 N-CA-C 117.422 1.729 . . . . 0.0 117.422 -154.877 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 65.7 m80 -110.13 -31.02 7.5 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-N 118.118 0.959 . . . . 0.0 110.548 175.349 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.4 m -102.0 -8.87 21.12 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.621 0.769 . . . . 0.0 110.936 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -61.5 -46.38 90.26 Favored 'General case' 0 C--N 1.354 0.771 0 C-N-CA 123.803 0.841 . . . . 0.0 110.347 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.55 -27.57 72.71 Favored Glycine 0 C--N 1.343 0.946 0 O-C-N 123.977 0.798 . . . . 0.0 113.846 -178.112 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 53.0 t -72.04 -46.6 58.59 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.963 0 C-N-CA 123.196 0.598 . . . . 0.0 109.771 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.441 HG21 HG21 ' A' ' 62' ' ' VAL . 75.7 mt -59.98 -55.23 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.669 176.298 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -61.51 -43.43 98.88 Favored 'General case' 0 C--O 1.219 -0.503 0 CA-C-N 114.794 -1.094 . . . . 0.0 110.918 -176.18 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.86 -42.57 98.38 Favored Glycine 0 C--N 1.345 1.051 0 O-C-N 124.068 0.855 . . . . 0.0 112.366 -179.716 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.32 -55.11 31.34 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 122.89 0.476 . . . . 0.0 110.815 -179.454 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.542 HG21 HG11 ' A' ' 64' ' ' VAL . 82.4 mt -64.45 -51.13 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 C-N-CA 123.758 0.823 . . . . 0.0 112.297 -176.731 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -60.68 -45.58 93.6 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 124.316 1.046 . . . . 0.0 112.222 -173.078 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.3 mptp? -78.72 -21.09 48.6 Favored 'General case' 0 N--CA 1.484 1.234 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -173.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.407 ' HB ' HD13 ' A' ' 76' ' ' ILE . 38.5 m -85.33 -39.17 17.96 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 122.899 0.48 . . . . 0.0 110.319 177.536 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.1 t -118.46 86.53 28.59 Favored Pre-proline 0 CA--C 1.548 0.876 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 174.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo -61.76 106.77 0.46 Allowed 'Trans proline' 0 C--N 1.378 2.111 0 C-N-CA 122.952 2.435 . . . . 0.0 112.813 -174.493 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.88 7.93 8.37 Favored Glycine 0 C--N 1.341 0.859 0 CA-C-N 115.638 -0.71 . . . . 0.0 113.173 -179.565 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.19 107.47 9.6 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 176.112 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.411 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -75.58 96.37 3.52 Favored 'General case' 0 C--N 1.352 0.693 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 -177.388 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.443 HG12 HG12 ' A' ' 64' ' ' VAL . 5.0 m -87.29 133.14 30.89 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.587 -168.737 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 75.6 t60 -138.62 99.25 3.77 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 174.823 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.78 115.3 23.34 Favored 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 173.514 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -96.94 120.77 60.92 Favored Pre-proline 0 N--CA 1.478 0.951 0 CA-C-O 118.975 -0.536 . . . . 0.0 109.919 -173.175 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -55.75 -48.97 17.33 Favored 'Trans proline' 0 C--N 1.381 2.27 0 C-N-CA 123.598 2.865 . . . . 0.0 114.025 178.095 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -75.09 -42.85 55.82 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.116 -170.654 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 19.5 m -93.31 -14.94 26.32 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.595 0.758 . . . . 0.0 112.125 -171.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 11.4 mpt_? 59.42 40.43 20.83 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 123.866 0.866 . . . . 0.0 110.273 -175.06 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.9 m -121.31 118.87 30.61 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.119 0.568 . . . . 0.0 111.275 -169.426 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.441 HG21 HG21 ' A' ' 40' ' ' ILE . 42.8 t -97.88 105.92 17.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 175.168 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 6.3 t -102.02 123.19 55.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 -176.35 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.542 HG11 HG21 ' A' ' 44' ' ' ILE . 19.1 m -117.39 109.22 26.91 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 CA-C-O 121.512 0.672 . . . . 0.0 110.787 -176.478 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.403 ' HA2' ' HA2' ' A' ' 23' ' ' GLY . . . -90.76 161.98 28.67 Favored Glycine 0 C--N 1.344 0.994 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.775 -176.62 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.7 0.65 74.8 Favored Glycine 0 C--N 1.346 1.106 0 CA-C-O 119.995 -0.336 . . . . 0.0 113.824 177.218 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.99 149.05 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 123.826 0.85 . . . . 0.0 109.987 -177.505 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 45.7 m -114.88 4.76 14.94 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.797 0.839 . . . . 0.0 110.359 176.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.59 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 5.6 m-20 -83.12 68.6 9.63 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.015 0.926 . . . . 0.0 111.014 -172.352 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.25 -45.11 95.86 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.12 0.568 . . . . 0.0 111.681 -175.562 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -66.43 -44.14 83.7 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.235 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.59 ' HB2' ' HB3' ' A' ' 69' ' ' ASP . 26.1 m80 -62.48 -52.45 63.47 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 122.968 0.507 . . . . 0.0 111.271 -178.588 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.488 HG12 ' O ' ' A' ' 69' ' ' ASP . 48.6 mm -57.52 -43.13 82.43 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 O-C-N 123.817 0.698 . . . . 0.0 110.09 -177.395 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.82 -38.93 83.4 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 124.403 1.064 . . . . 0.0 111.764 178.672 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 43.8 mm-40 -68.87 -36.06 77.65 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.42 0.688 . . . . 0.0 111.748 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.483 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.6 mt -69.59 -51.69 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.989 0 C-N-CA 122.743 0.417 . . . . 0.0 110.186 -177.095 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.417 HG12 ' HB2' ' A' ' 82' ' ' TYR . 12.4 tt -70.43 -30.55 43.38 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.071 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.536 -174.544 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 3.8 t -74.86 -30.3 61.29 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 176.272 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -74.39 -23.04 58.92 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.557 0.743 . . . . 0.0 110.533 173.483 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.55 -6.99 55.59 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 123.32 0.648 . . . . 0.0 111.207 172.533 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 100.03 9.55 48.31 Favored Glycine 0 C--N 1.352 1.469 0 CA-C-O 119.797 -0.446 . . . . 0.0 113.727 173.284 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.595 ' HB3' HG11 ' A' ' 28' ' ' VAL . 84.9 m-85 -109.09 121.5 45.29 Favored 'General case' 0 N--CA 1.481 1.079 0 C-N-CA 123.715 0.806 . . . . 0.0 109.289 -178.218 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 31.3 m -88.18 103.4 5.03 Favored Pre-proline 0 CA--C 1.559 1.325 0 C-N-CA 123.868 0.867 . . . . 0.0 111.396 -175.057 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -91.01 -74.65 0.0 OUTLIER 'Trans proline' 0 C--N 1.376 2.023 0 C-N-CA 123.564 2.843 . . . . 0.0 112.477 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 . . . . . 0 CA--C 1.554 1.109 0 C-N-CA 125.54 1.536 . . . . 0.0 111.372 -179.353 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.691 0 N-CA-C 112.739 -0.144 . . . . 0.0 112.739 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.523 HD13 ' HA ' ' A' ' 70' ' ' ALA . 56.1 mt -79.78 109.83 14.57 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 123.788 0.835 . . . . 0.0 109.848 -176.764 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.558 ' HA ' HG12 ' A' ' 63' ' ' VAL . 19.6 p -92.17 109.03 20.39 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.001 0.52 . . . . 0.0 111.405 -174.282 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 88.9 m-85 -105.17 110.29 22.61 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.162 0.585 . . . . 0.0 109.954 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 11.7 m170 -82.49 92.49 7.08 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.459 HG22 ' HB3' ' A' ' 84' ' ' PRO . 31.0 t -83.27 105.48 13.03 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.256 -175.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -79.22 -10.76 59.9 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 122.774 0.43 . . . . 0.0 111.515 -176.624 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -93.41 -0.8 56.38 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 123.813 0.845 . . . . 0.0 111.476 173.311 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.48 ' HB3' ' HB3' ' A' ' 60' ' ' ARG . 26.7 ttt -73.62 137.36 44.16 Favored 'General case' 0 CA--C 1.543 0.679 0 CA-C-O 121.58 0.705 . . . . 0.0 111.754 -176.445 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.0 t -110.1 164.47 12.6 Favored 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 125.507 1.523 . . . . 0.0 109.054 175.571 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.466 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 60.1 m -59.0 -178.6 0.05 Allowed 'General case' 0 CA--C 1.559 1.318 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -53.95 -21.56 17.23 Favored Glycine 0 C--N 1.353 1.49 0 N-CA-C 116.682 1.433 . . . . 0.0 116.682 -169.318 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 33.1 m170 -62.54 -21.35 65.48 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 123.532 0.733 . . . . 0.0 112.797 -177.427 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 53.2 t -139.12 17.7 2.61 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 123.434 0.694 . . . . 0.0 110.811 178.583 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.85 -31.45 69.3 Favored 'General case' 0 N--CA 1.482 1.126 0 C-N-CA 123.03 0.532 . . . . 0.0 111.811 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.76 -23.49 74.04 Favored Glycine 0 C--N 1.347 1.174 0 O-C-N 123.471 0.482 . . . . 0.0 113.586 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 92.1 t -69.47 -40.47 79.85 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.616 0.767 . . . . 0.0 109.873 173.373 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 23.2 mt -72.24 -40.7 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 CA-C-N 114.72 -1.127 . . . . 0.0 109.91 -177.644 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -59.65 -54.79 42.33 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 114.664 -1.153 . . . . 0.0 109.999 172.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.59 -30.05 71.13 Favored Glycine 0 C--N 1.349 1.26 0 O-C-N 124.604 1.19 . . . . 0.0 113.389 -175.751 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.46 -53.59 54.43 Favored 'General case' 0 C--N 1.351 0.658 0 C-N-CA 124.146 0.978 . . . . 0.0 110.9 176.421 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.466 HD11 HD12 ' A' ' 77' ' ' ILE . 64.2 mt -75.22 -59.06 3.61 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.572 178.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -50.02 -48.15 52.81 Favored 'General case' 0 N--CA 1.483 1.19 0 C-N-CA 126.215 1.806 . . . . 0.0 113.688 -169.489 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.4 mptt -69.45 -38.17 77.67 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 122.792 0.437 . . . . 0.0 111.407 -178.717 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.9 m -73.35 -33.08 64.89 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 123.219 0.607 . . . . 0.0 111.02 -178.164 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 3.9 m -136.32 81.6 36.93 Favored Pre-proline 0 CA--C 1.556 1.201 0 C-N-CA 124.066 0.946 . . . . 0.0 110.537 178.788 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_exo -62.91 123.04 11.56 Favored 'Trans proline' 0 C--N 1.381 2.253 0 C-N-CA 122.827 2.351 . . . . 0.0 111.308 174.035 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.77 -24.59 7.48 Favored Glycine 0 C--N 1.342 0.899 0 CA-C-O 119.866 -0.408 . . . . 0.0 112.234 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.21 104.86 5.95 Favored 'General case' 0 C--N 1.354 0.761 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 172.513 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.52 100.41 2.73 Favored 'General case' 0 C--N 1.348 0.525 0 C-N-CA 123.318 0.647 . . . . 0.0 110.529 -173.528 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.415 HG12 HG12 ' A' ' 64' ' ' VAL . 27.1 m -85.36 134.24 27.59 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 O-C-N 123.603 0.564 . . . . 0.0 110.744 -173.28 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 44.0 t-80 -135.69 99.89 4.32 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 169.256 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.67 116.32 23.14 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 115.021 -0.99 . . . . 0.0 108.949 178.049 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -103.27 105.85 48.48 Favored Pre-proline 0 N--CA 1.478 0.944 0 CA-C-O 118.47 -0.776 . . . . 0.0 108.973 -177.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.466 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 72.4 Cg_exo -54.79 -41.88 73.97 Favored 'Trans proline' 0 C--N 1.378 2.127 0 C-N-CA 123.178 2.585 . . . . 0.0 114.67 179.391 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -67.78 -45.57 74.48 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 123.114 0.565 . . . . 0.0 111.75 -173.274 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.4 t -89.88 -18.93 25.24 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 123.686 0.794 . . . . 0.0 111.089 -178.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.48 ' HB3' ' HB3' ' A' ' 31' ' ' MET . 0.2 OUTLIER 61.28 47.1 7.25 Favored 'General case' 0 N--CA 1.482 1.138 0 C-N-CA 124.699 1.2 . . . . 0.0 110.272 -175.676 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 54.1 m -128.84 115.16 17.48 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 123.178 0.591 . . . . 0.0 110.246 -173.752 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 25.4 t -98.56 108.53 22.28 Favored 'Isoleucine or valine' 0 C--O 1.24 0.6 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 175.447 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.558 HG12 ' HA ' ' A' ' 25' ' ' SER . 34.7 m -99.46 136.08 32.11 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.201 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.454 HG21 HG21 ' A' ' 73' ' ' ILE . 21.4 m -119.16 133.84 64.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.345 0.658 . . . . 0.0 110.181 -178.364 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -113.0 153.31 17.62 Favored Glycine 0 C--N 1.35 1.311 0 CA-C-N 116.303 -0.408 . . . . 0.0 112.787 -175.001 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.7 14.5 82.34 Favored Glycine 0 C--N 1.348 1.23 0 N-CA-C 113.945 0.338 . . . . 0.0 113.945 175.557 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 3.6 m -129.54 134.8 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 123.85 0.86 . . . . 0.0 110.245 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.6 m -95.52 -23.85 16.9 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 123.686 0.794 . . . . 0.0 111.099 176.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -79.05 87.25 4.84 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-O 121.141 0.496 . . . . 0.0 111.3 -175.183 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.523 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -70.63 -46.1 63.97 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.943 -175.438 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -61.6 -36.61 81.2 Favored 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.961 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 74.7 t60 -63.11 -51.68 65.61 Favored 'General case' 0 N--CA 1.473 0.715 0 O-C-N 123.856 0.722 . . . . 0.0 110.852 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.454 HG21 HG21 ' A' ' 64' ' ' VAL . 41.7 mm -59.45 -42.32 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 123.646 0.591 . . . . 0.0 110.379 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.0 -41.42 98.04 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.375 -177.492 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 54.8 mm-40 -63.24 -39.97 96.12 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.464 0.706 . . . . 0.0 111.607 178.774 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 85.5 mt -61.78 -54.25 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.403 0.681 . . . . 0.0 111.41 -178.628 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.466 HD12 HD11 ' A' ' 44' ' ' ILE . 14.0 tt -73.84 -33.13 36.45 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.913 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.7 -171.53 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.9 t -71.76 -29.26 64.31 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 176.775 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.07 -22.99 63.0 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.803 0.841 . . . . 0.0 111.167 173.726 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -82.93 -3.09 56.63 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 123.751 0.82 . . . . 0.0 111.774 175.683 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.22 -6.23 59.54 Favored Glycine 0 C--N 1.348 1.217 0 CA-C-O 120.155 -0.247 . . . . 0.0 113.311 178.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.408 ' HB3' HG11 ' A' ' 28' ' ' VAL . 87.0 m-85 -106.07 103.15 12.57 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -178.539 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 53.0 m -94.4 114.2 62.77 Favored Pre-proline 0 CA--C 1.553 1.085 0 C-N-CA 123.201 0.6 . . . . 0.0 111.633 -171.636 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.459 ' HB3' HG22 ' A' ' 28' ' ' VAL . 25.4 Cg_endo -95.99 -11.11 0.84 Allowed 'Trans proline' 0 C--N 1.377 2.031 0 C-N-CA 123.27 2.647 . . . . 0.0 113.328 167.227 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 . . . . . 0 C--O 1.251 1.157 0 C-N-CA 124.006 0.922 . . . . 0.0 108.699 -173.785 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.559 0 CA-C-O 120.991 0.217 . . . . 0.0 113.369 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.442 HD13 ' HA ' ' A' ' 70' ' ' ALA . 32.2 mt -87.72 116.93 26.2 Favored 'General case' 0 C--O 1.239 0.522 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 175.708 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 28.6 p -92.13 111.32 22.83 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 122.871 0.468 . . . . 0.0 111.214 -173.967 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -108.95 133.64 52.69 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.274 1.029 . . . . 0.0 108.809 175.853 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 18.6 p80 -125.89 137.1 53.71 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.258 0.623 . . . . 0.0 109.803 -176.429 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.768 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 67.0 t -117.51 120.02 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 N-CA-C 107.162 -1.421 . . . . 0.0 107.162 170.828 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -70.68 -21.97 62.52 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -175.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -89.56 -8.61 52.31 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 123.411 0.685 . . . . 0.0 111.009 177.377 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.768 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 25.7 ttt -56.14 106.67 0.29 Allowed 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.911 0.884 . . . . 0.0 112.341 -170.439 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.415 ' O ' ' HB3' ' A' ' 36' ' ' CYS . 67.1 p -70.94 162.24 29.68 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 123.651 0.78 . . . . 0.0 109.284 167.358 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 79.5 m -61.39 -104.86 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 123.488 0.715 . . . . 0.0 111.808 -177.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.49 -30.9 75.51 Favored Glycine 0 C--N 1.353 1.489 0 CA-C-N 119.391 0.996 . . . . 0.0 113.603 -172.705 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 21.7 t-80 -62.73 -30.11 71.18 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 123.98 0.912 . . . . 0.0 112.659 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.638 ' SG ' ' HG3' ' A' ' 31' ' ' MET . 51.9 t -106.16 -31.25 8.77 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 122.51 0.324 . . . . 0.0 110.44 179.858 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -62.94 -49.6 74.11 Favored 'General case' 0 C--N 1.356 0.851 0 C-N-CA 123.466 0.707 . . . . 0.0 111.698 -175.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.8 -37.08 75.53 Favored Glycine 0 C--N 1.347 1.165 0 O-C-N 123.979 0.799 . . . . 0.0 113.84 -177.071 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.501 HG12 ' HB1' ' A' ' 80' ' ' ALA . 42.7 t -71.6 -51.26 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 123.318 0.647 . . . . 0.0 110.526 -179.021 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.689 HG21 HG21 ' A' ' 62' ' ' VAL . 64.7 mt -64.81 -53.93 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 CA-C-N 115.443 -0.798 . . . . 0.0 111.646 -176.017 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 48.6 mtmt -57.84 -46.89 84.12 Favored 'General case' 0 N--CA 1.474 0.746 0 O-C-N 123.889 0.743 . . . . 0.0 110.064 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.31 -36.74 93.5 Favored Glycine 0 C--N 1.351 1.41 0 O-C-N 124.346 1.028 . . . . 0.0 113.142 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -67.42 -54.02 24.05 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 122.743 0.417 . . . . 0.0 111.121 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.596 HG21 HG11 ' A' ' 64' ' ' VAL . 63.9 mt -67.36 -42.88 87.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 C-N-CA 123.275 0.63 . . . . 0.0 111.563 -176.231 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -61.33 -47.53 85.48 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.877 0.871 . . . . 0.0 111.626 -177.69 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -73.13 -37.06 66.79 Favored 'General case' 0 N--CA 1.48 1.035 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.942 -176.651 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 58.8 m -73.61 -40.99 63.41 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 122.658 0.383 . . . . 0.0 111.149 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.4 HG11 HG11 ' A' ' 67' ' ' VAL . 24.2 t -114.08 102.69 55.02 Favored Pre-proline 0 N--CA 1.481 1.084 0 C-N-CA 123.185 0.594 . . . . 0.0 110.277 -176.578 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -68.16 107.03 1.47 Allowed 'Trans proline' 0 C--N 1.373 1.826 0 C-N-CA 122.717 2.278 . . . . 0.0 111.123 173.038 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.16 -10.94 10.8 Favored Glycine 0 C--N 1.345 1.076 0 CA-C-O 119.251 -0.749 . . . . 0.0 113.619 178.734 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.41 106.6 7.04 Favored 'General case' 0 N--CA 1.479 0.977 0 CA-C-N 117.833 0.816 . . . . 0.0 109.038 174.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.58 99.03 7.89 Favored 'General case' 0 N--CA 1.465 0.31 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 -178.649 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.52 HG12 HG12 ' A' ' 64' ' ' VAL . 26.9 m -86.51 134.17 28.05 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 C-N-CA 123.412 0.685 . . . . 0.0 110.366 -174.353 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 43.6 t-80 -142.81 102.16 3.98 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 172.46 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.443 ' HB1' ' HE1' ' A' ' 31' ' ' MET . . . -89.61 115.79 27.27 Favored 'General case' 0 C--O 1.239 0.509 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 171.126 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.434 ' HA ' ' HD2' ' A' ' 57' ' ' PRO . 20.0 t70 -92.08 114.27 61.63 Favored Pre-proline 0 CA--C 1.546 0.8 0 CA-C-O 118.142 -0.932 . . . . 0.0 109.549 -177.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.434 ' HD2' ' HA ' ' A' ' 56' ' ' ASP . 7.3 Cg_endo -47.27 -33.6 16.61 Favored 'Trans proline' 0 C--N 1.381 2.259 0 C-N-CA 124.612 3.542 . . . . 0.0 115.29 178.267 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.47 -44.32 24.88 Favored 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -177.546 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.1 t -93.27 -23.38 18.53 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.405 0.682 . . . . 0.0 111.955 -173.012 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.491 ' HB3' ' HB3' ' A' ' 31' ' ' MET . 11.7 mmm180 57.63 41.29 25.78 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 125.596 1.558 . . . . 0.0 111.578 -173.422 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.8 m -119.26 127.69 53.47 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 123.286 0.635 . . . . 0.0 110.028 -177.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.689 HG21 HG21 ' A' ' 40' ' ' ILE . 21.6 t -99.59 106.17 18.63 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 C-N-CA 124.658 1.183 . . . . 0.0 108.951 177.124 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 25.7 m -94.11 135.43 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 175.486 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.596 HG11 HG21 ' A' ' 44' ' ' ILE . 22.2 m -120.87 107.88 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-O 121.674 0.749 . . . . 0.0 110.017 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.71 152.4 21.85 Favored Glycine 0 C--N 1.346 1.115 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.789 -175.533 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.8 -24.47 26.08 Favored Glycine 0 C--N 1.344 0.997 0 C-N-CA 123.042 0.353 . . . . 0.0 113.036 178.39 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.4 HG11 HG11 ' A' ' 48' ' ' VAL . 27.4 m -111.24 145.64 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 123.904 0.881 . . . . 0.0 110.135 -177.473 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t -117.71 10.01 13.21 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 123.624 0.77 . . . . 0.0 109.771 176.364 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -86.58 74.83 9.81 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.222 1.009 . . . . 0.0 109.522 -176.083 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.442 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -63.79 -47.37 81.16 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.39 0.676 . . . . 0.0 112.252 -172.191 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.503 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.47 -39.64 94.99 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 123.113 0.565 . . . . 0.0 110.788 -179.818 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 74.1 t60 -63.13 -51.69 65.51 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.286 1.034 . . . . 0.0 111.279 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.46 ' O ' HG22 ' A' ' 77' ' ' ILE . 41.3 mm -60.75 -38.47 78.88 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 O-C-N 123.744 0.652 . . . . 0.0 109.962 179.113 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.81 -36.74 79.8 Favored 'General case' 0 N--CA 1.476 0.856 0 O-C-N 124.247 0.967 . . . . 0.0 111.837 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.503 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 11.7 mm-40 -69.35 -34.78 75.11 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.16 0.584 . . . . 0.0 111.26 177.537 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 71.5 mt -71.75 -48.44 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 C-N-CA 123.441 0.696 . . . . 0.0 111.961 -177.538 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.462 ' HB ' HD11 ' A' ' 44' ' ' ILE . 5.0 tt -66.53 -37.27 79.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.184 0 C-N-CA 122.871 0.469 . . . . 0.0 110.851 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 t -71.18 -29.61 65.39 Favored 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 122.463 0.305 . . . . 0.0 110.379 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.61 -24.27 62.71 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 123.751 0.82 . . . . 0.0 111.373 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.501 ' HB1' HG12 ' A' ' 39' ' ' VAL . . . -75.02 -6.09 47.52 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.389 0.675 . . . . 0.0 111.578 175.807 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.29 1.38 56.85 Favored Glycine 0 C--N 1.35 1.325 0 CA-C-O 119.884 -0.398 . . . . 0.0 112.98 176.406 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -120.31 104.71 10.26 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 178.562 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.7 t -86.32 116.96 67.83 Favored Pre-proline 0 CA--C 1.554 1.119 0 C-N-CA 123.397 0.679 . . . . 0.0 110.354 -178.642 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -79.88 148.67 19.94 Favored 'Trans proline' 0 C--N 1.375 1.961 0 C-N-CA 122.742 2.294 . . . . 0.0 111.571 174.381 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.4 mp0 . . . . . 0 C--O 1.251 1.148 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -176.789 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.57 0 N-CA-C 111.412 -0.675 . . . . 0.0 111.412 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.401 HD13 ' HA ' ' A' ' 70' ' ' ALA . 34.0 mt -88.99 108.24 19.47 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.652 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.3 p -92.36 111.35 22.89 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 122.844 0.458 . . . . 0.0 110.606 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -106.24 124.88 50.28 Favored 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 123.862 0.865 . . . . 0.0 109.72 179.493 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 32.1 m-70 -84.03 136.77 33.91 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 175.715 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 p -157.31 96.98 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.091 0.957 . . . . 0.0 109.059 -176.364 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -69.79 -29.46 66.77 Favored 'General case' 0 N--CA 1.479 1.007 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.443 -176.21 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.5 m-20 -74.29 -9.84 59.01 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.164 0.586 . . . . 0.0 112.104 -178.703 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.612 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 56.3 ttp -72.69 113.06 9.3 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-O 120.944 0.402 . . . . 0.0 110.536 177.145 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.401 ' OG1' ' HB3' ' A' ' 36' ' ' CYS . 62.7 p -77.51 166.36 23.17 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 123.993 0.917 . . . . 0.0 109.912 168.81 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 27.9 p -57.11 -169.69 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 124.121 0.968 . . . . 0.0 112.6 175.822 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.73 3.5 0.64 Allowed Glycine 0 C--N 1.357 1.732 0 N-CA-C 115.922 1.129 . . . . 0.0 115.922 -174.021 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 3.6 m80 -63.3 -44.72 94.22 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.786 0.834 . . . . 0.0 110.798 166.031 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.401 ' HB3' ' OG1' ' A' ' 32' ' ' THR . 43.6 t -141.47 9.51 2.03 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 123.189 0.596 . . . . 0.0 111.987 -176.018 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.65 -30.89 69.69 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 122.814 0.446 . . . . 0.0 110.732 173.239 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.58 -20.84 53.15 Favored Glycine 0 C--N 1.348 1.238 0 CA-C-N 114.997 -1.001 . . . . 0.0 114.262 176.851 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.501 HG12 ' HB1' ' A' ' 80' ' ' ALA . 57.8 t -65.48 -44.25 94.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 122.851 0.461 . . . . 0.0 110.128 174.221 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.709 HG21 HG21 ' A' ' 62' ' ' VAL . 43.7 mt -69.7 -54.4 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 C-N-CA 123.322 0.649 . . . . 0.0 110.619 175.457 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.425 ' O ' ' HG3' ' A' ' 45' ' ' GLU . 9.7 mtpm? -56.68 -51.93 66.87 Favored 'General case' 0 C--N 1.347 0.487 0 O-C-N 124.439 1.087 . . . . 0.0 110.216 -174.773 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.482 ' O ' ' HD3' ' A' ' 46' ' ' LYS . . . -61.87 -40.18 98.5 Favored Glycine 0 C--N 1.342 0.886 0 O-C-N 124.984 1.428 . . . . 0.0 112.822 178.961 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.79 -53.48 57.32 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-N 117.161 0.48 . . . . 0.0 110.955 179.181 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.572 HG21 HG11 ' A' ' 64' ' ' VAL . 68.3 mt -62.11 -39.9 85.54 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.823 0 CA-C-N 115.43 -0.805 . . . . 0.0 111.972 -179.163 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.425 ' HG3' ' O ' ' A' ' 41' ' ' LYS . 76.8 mt-10 -62.0 -50.46 71.96 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 123.157 0.583 . . . . 0.0 112.108 179.582 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.482 ' HD3' ' O ' ' A' ' 42' ' ' GLY . 13.3 mptt -73.0 -28.11 62.18 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.52 -171.536 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.1 m -85.15 -41.06 16.02 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 122.815 0.446 . . . . 0.0 110.291 177.565 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.2 t -127.03 103.58 23.39 Favored Pre-proline 0 N--CA 1.483 1.213 0 C-N-CA 124.117 0.967 . . . . 0.0 109.772 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -66.91 136.58 41.99 Favored 'Trans proline' 0 C--N 1.374 1.906 0 C-N-CA 122.772 2.315 . . . . 0.0 111.684 172.037 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.18 -4.74 67.73 Favored Glycine 0 C--N 1.346 1.084 0 CA-C-O 119.769 -0.462 . . . . 0.0 113.948 175.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.61 106.68 9.56 Favored 'General case' 0 C--N 1.351 0.649 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 173.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.423 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -77.15 99.52 5.43 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -177.063 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.41 HG12 HG12 ' A' ' 64' ' ' VAL . 27.7 m -85.28 127.45 39.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 123.123 0.569 . . . . 0.0 110.886 -171.089 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' HIS . . . . . 0.411 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 29.2 t60 -131.62 96.95 4.08 Favored 'General case' 0 C--N 1.345 0.391 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 176.069 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.612 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -93.6 113.59 25.73 Favored 'General case' 0 C--O 1.241 0.646 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 176.031 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -99.66 114.83 65.86 Favored Pre-proline 0 N--CA 1.468 0.433 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 -177.397 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.52 -40.4 57.12 Favored 'Trans proline' 0 C--N 1.373 1.829 0 C-N-CA 123.011 2.474 . . . . 0.0 112.767 -176.234 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -74.31 -47.8 32.4 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 123.619 0.767 . . . . 0.0 111.31 -176.762 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.1 m -81.26 -15.65 54.94 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.7 0.8 . . . . 0.0 111.455 -176.111 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.7 mmt180 62.97 29.43 16.46 Favored 'General case' 0 N--CA 1.487 1.421 0 C-N-CA 124.63 1.172 . . . . 0.0 111.437 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 33.2 m -122.79 122.76 39.47 Favored 'General case' 0 N--CA 1.479 1.017 0 O-C-N 121.825 -0.547 . . . . 0.0 111.521 -169.842 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.709 HG21 HG21 ' A' ' 40' ' ' ILE . 40.5 t -99.11 106.4 18.86 Favored 'Isoleucine or valine' 0 C--N 1.35 0.608 0 C-N-CA 123.943 0.897 . . . . 0.0 108.977 173.279 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.0 t -100.41 123.2 53.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.617 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.585 HG21 HG21 ' A' ' 73' ' ' ILE . 17.0 m -111.56 108.94 26.77 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.994 0 CA-C-O 121.475 0.655 . . . . 0.0 110.158 179.393 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.44 150.84 21.03 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.549 -176.535 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.13 -23.67 30.4 Favored Glycine 0 C--N 1.344 0.984 0 C-N-CA 123.104 0.383 . . . . 0.0 113.051 177.037 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 22.4 m -105.54 151.13 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 123.969 0.908 . . . . 0.0 110.151 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.0 m -126.84 -2.55 6.57 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 124.005 0.922 . . . . 0.0 110.36 -178.658 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -87.35 73.0 9.71 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.54 1.136 . . . . 0.0 110.247 -177.216 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.401 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -64.01 -29.17 70.35 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 114.907 -1.042 . . . . 0.0 112.453 -174.747 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -63.76 -49.37 73.25 Favored 'General case' 0 N--CA 1.474 0.745 0 O-C-N 123.799 0.687 . . . . 0.0 110.863 177.545 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.5 ' O ' HG13 ' A' ' 76' ' ' ILE . 39.9 m170 -59.41 -54.93 41.05 Favored 'General case' 0 N--CA 1.478 0.957 0 O-C-N 123.488 0.493 . . . . 0.0 110.474 177.772 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.585 HG21 HG21 ' A' ' 64' ' ' VAL . 41.4 mm -57.74 -40.27 74.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 O-C-N 124.343 1.027 . . . . 0.0 110.811 -174.352 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.33 -40.11 89.47 Favored 'General case' 0 N--CA 1.48 1.029 0 O-C-N 124.039 0.837 . . . . 0.0 111.397 178.884 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -68.3 -32.05 71.92 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 123.181 0.593 . . . . 0.0 111.291 178.071 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.5 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.5 mt -74.77 -48.62 32.99 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 C-N-CA 122.951 0.5 . . . . 0.0 111.245 -177.125 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 73' ' ' ILE . 8.5 tt -67.38 -32.36 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 C-N-CA 123.254 0.622 . . . . 0.0 111.253 -177.939 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -75.12 -31.02 61.01 Favored 'General case' 0 CA--C 1.549 0.917 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -69.0 -18.46 64.05 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.494 0.718 . . . . 0.0 111.737 176.115 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.501 ' HB1' HG12 ' A' ' 39' ' ' VAL . . . -75.91 0.67 17.48 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 123.645 0.778 . . . . 0.0 112.269 176.414 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 95.84 16.97 37.0 Favored Glycine 0 C--N 1.35 1.328 0 C-N-CA 122.801 0.239 . . . . 0.0 112.544 179.63 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -120.76 178.38 4.72 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.361 1.065 . . . . 0.0 109.714 -177.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 39.3 m -139.41 111.83 7.78 Favored Pre-proline 0 N--CA 1.479 0.977 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 173.333 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -66.47 120.33 7.45 Favored 'Trans proline' 0 C--N 1.381 2.285 0 C-N-CA 122.423 2.082 . . . . 0.0 110.779 171.458 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 . . . . . 0 C--O 1.251 1.166 0 C-N-CA 124.212 1.005 . . . . 0.0 109.526 -175.652 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.938 0 N-CA-C 110.971 -0.851 . . . . 0.0 110.971 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -87.65 115.62 25.22 Favored 'General case' 0 N--CA 1.479 1.025 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -173.224 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 76.4 p -91.06 121.45 32.87 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 123.363 0.665 . . . . 0.0 111.337 -176.554 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -106.89 130.27 54.59 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.783 0.833 . . . . 0.0 109.563 175.546 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 9.8 m-70 -90.46 120.64 31.74 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 173.932 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.475 HG21 HD13 ' A' ' 40' ' ' ILE . 25.7 t -111.24 91.77 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 N-CA-C 104.765 -2.309 . . . . 0.0 104.765 160.413 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -68.62 -16.29 63.8 Favored 'General case' 0 CA--C 1.548 0.881 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -159.46 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -109.7 8.78 24.91 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.258 0.623 . . . . 0.0 111.472 -178.752 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 56.8 ttp -73.91 99.05 3.14 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.61 0.764 . . . . 0.0 109.843 176.06 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.0 t -101.3 104.57 15.59 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 123.103 0.561 . . . . 0.0 109.569 178.328 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.462 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 17.0 t 64.83 -170.99 0.19 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.382 1.073 . . . . 0.0 111.888 176.647 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.574 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -62.27 -6.36 10.33 Favored Glycine 0 C--N 1.355 1.599 0 CA-C-O 119.203 -0.776 . . . . 0.0 114.391 178.379 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 41.2 m80 -50.22 -40.17 46.62 Favored 'General case' 0 C--N 1.365 1.278 0 C-N-CA 124.274 1.03 . . . . 0.0 111.736 172.586 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -118.83 -31.6 4.75 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.151 0.58 . . . . 0.0 110.892 176.717 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.574 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -57.91 -34.16 69.54 Favored 'General case' 0 N--CA 1.481 1.109 0 C-N-CA 123.458 0.703 . . . . 0.0 112.699 -176.092 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -58.7 -52.45 53.02 Favored Glycine 0 C--N 1.348 1.246 0 O-C-N 123.842 0.713 . . . . 0.0 114.347 -177.106 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.3 p -69.83 -30.53 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 C-N-CA 123.012 0.525 . . . . 0.0 111.561 -177.87 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.651 HG21 HG21 ' A' ' 62' ' ' VAL . 83.4 mt -70.23 -47.21 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 123.082 0.553 . . . . 0.0 110.666 179.216 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -61.38 -44.24 97.5 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.639 0.775 . . . . 0.0 110.467 178.689 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.14 -36.43 93.23 Favored Glycine 0 C--N 1.348 1.197 0 O-C-N 124.202 0.939 . . . . 0.0 112.899 176.872 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.05 -53.77 50.91 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 123.376 0.671 . . . . 0.0 110.878 -178.359 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.546 HG21 HG11 ' A' ' 64' ' ' VAL . 64.0 mt -72.82 -46.27 53.6 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.936 -175.007 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -66.93 -39.23 87.29 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 123.551 0.74 . . . . 0.0 112.249 -172.146 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.1 mptp? -83.58 -14.34 52.32 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -176.652 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 54.5 m -90.24 -39.06 13.01 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 122.98 0.512 . . . . 0.0 109.802 173.333 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 91.4 t -121.01 96.38 48.57 Favored Pre-proline 0 N--CA 1.48 1.028 0 C-N-CA 123.939 0.896 . . . . 0.0 109.323 -179.538 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.93 113.0 3.26 Favored 'Trans proline' 0 C--N 1.37 1.662 0 C-N-CA 122.346 2.031 . . . . 0.0 110.589 175.051 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.39 -11.42 9.75 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-O 119.575 -0.57 . . . . 0.0 112.722 -176.296 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -78.42 106.89 10.67 Favored 'General case' 0 C--N 1.356 0.871 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 171.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.72 99.09 4.97 Favored 'General case' 0 C--N 1.349 0.577 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.0 m -85.49 123.63 39.5 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 CA-C-O 121.023 0.439 . . . . 0.0 110.155 -172.629 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 71.9 t60 -131.79 97.88 4.31 Favored 'General case' 0 C--N 1.343 0.32 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -176.496 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.4 114.52 28.86 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -178.835 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.426 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 13.5 t70 -99.56 127.12 35.08 Favored Pre-proline 0 CA--C 1.54 0.586 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -177.915 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.462 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 30.8 Cg_endo -61.62 -41.16 41.32 Favored 'Trans proline' 0 C--N 1.377 2.074 0 C-N-CA 123.105 2.537 . . . . 0.0 113.23 179.264 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.19 -35.28 48.8 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.728 0.811 . . . . 0.0 111.944 -174.521 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.426 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 19.2 m -88.83 -22.07 23.39 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.443 0.697 . . . . 0.0 111.061 -177.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? 57.99 41.07 24.9 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 124.653 1.181 . . . . 0.0 110.744 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 80.8 m -132.81 121.83 23.56 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.882 -171.388 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.651 HG21 HG21 ' A' ' 40' ' ' ILE . 21.1 t -98.89 104.7 16.32 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 C-N-CA 124.426 1.091 . . . . 0.0 108.638 173.828 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.8 t -95.48 131.35 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 108.023 -1.102 . . . . 0.0 108.023 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.546 HG11 HG21 ' A' ' 44' ' ' ILE . 26.2 m -111.58 109.97 30.46 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.869 0 CA-C-O 121.636 0.731 . . . . 0.0 109.84 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -89.77 149.83 20.73 Favored Glycine 0 C--N 1.346 1.1 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.733 -174.821 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 86.3 -20.04 24.03 Favored Glycine 0 C--N 1.341 0.84 0 C-N-CA 123.055 0.359 . . . . 0.0 112.879 -178.481 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 30.3 m -123.75 145.96 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 124.46 1.104 . . . . 0.0 108.881 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.6 m -130.19 -6.63 4.34 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 123.545 0.738 . . . . 0.0 111.302 -176.601 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -75.88 84.24 2.81 Favored 'General case' 0 CA--C 1.55 0.96 0 CA-C-O 122.338 1.066 . . . . 0.0 110.351 -178.095 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.81 -40.55 95.65 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 113.911 -1.495 . . . . 0.0 112.869 -171.384 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -58.75 -46.88 86.43 Favored 'General case' 0 N--CA 1.479 0.994 0 O-C-N 124.11 0.881 . . . . 0.0 111.882 -176.694 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 72.7 t60 -66.97 -50.78 61.24 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.023 -178.324 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 36.8 mm -59.88 -37.35 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 O-C-N 123.67 0.606 . . . . 0.0 110.407 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.43 -37.71 88.36 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 123.858 0.863 . . . . 0.0 111.736 -179.522 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 45.0 mm-40 -65.07 -35.86 82.5 Favored 'General case' 0 N--CA 1.476 0.825 0 O-C-N 123.685 0.615 . . . . 0.0 111.036 176.465 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 62.3 mt -67.99 -49.46 68.11 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.236 0 C-N-CA 123.112 0.565 . . . . 0.0 111.495 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.4 tt -71.4 -35.42 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 C-N-CA 123.182 0.593 . . . . 0.0 111.516 -176.341 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.2 t -71.63 -28.86 64.07 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 176.782 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.72 -26.8 65.44 Favored 'General case' 0 C--N 1.358 0.963 0 C-N-CA 123.592 0.757 . . . . 0.0 111.006 173.751 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.92 -3.16 33.89 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.513 0.725 . . . . 0.0 111.822 174.052 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 94.51 12.69 55.59 Favored Glycine 0 C--N 1.348 1.221 0 CA-C-O 119.713 -0.493 . . . . 0.0 113.058 175.437 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -128.5 105.81 8.56 Favored 'General case' 0 N--CA 1.483 1.224 0 CA-C-N 117.401 0.601 . . . . 0.0 109.919 179.247 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.9 t -76.4 123.93 87.92 Favored Pre-proline 0 CA--C 1.556 1.173 0 C-N-CA 123.253 0.621 . . . . 0.0 110.619 -178.099 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -79.08 173.99 12.71 Favored 'Trans proline' 0 C--N 1.373 1.824 0 C-N-CA 122.695 2.264 . . . . 0.0 111.37 168.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 . . . . . 0 C--O 1.25 1.118 0 C-N-CA 123.444 0.698 . . . . 0.0 109.331 -177.225 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.439 0 N-CA-C 112.038 -0.425 . . . . 0.0 112.038 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -134.93 132.44 38.45 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-N 117.245 0.523 . . . . 0.0 109.826 -172.684 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.6 t -104.55 134.45 47.71 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 123.911 0.885 . . . . 0.0 110.709 -177.791 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -135.59 118.97 16.77 Favored 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 124.156 0.982 . . . . 0.0 109.237 173.685 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.55 ' HA ' ' HA ' ' A' ' 61' ' ' THR . 35.2 p-80 -92.26 118.38 30.82 Favored 'General case' 0 N--CA 1.477 0.898 0 CA-C-N 118.657 0.662 . . . . 0.0 109.984 175.32 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.423 HG22 ' HA ' ' A' ' 84' ' ' PRO . 39.7 t -96.27 97.22 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 170.613 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -61.01 -26.92 67.94 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 123.556 0.743 . . . . 0.0 111.864 -176.375 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -80.16 -19.69 46.58 Favored 'General case' 0 CA--C 1.553 1.061 0 C-N-CA 124.147 0.979 . . . . 0.0 111.496 -178.002 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 62.9 ttp -68.7 129.72 40.75 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.655 0.782 . . . . 0.0 112.235 -175.492 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.3 p -85.43 169.88 13.23 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 124.333 1.053 . . . . 0.0 109.987 170.88 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 35.0 t -56.11 -151.7 0.0 OUTLIER 'General case' 0 CA--C 1.581 2.159 0 C-N-CA 125.078 1.351 . . . . 0.0 113.178 178.637 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -62.0 -2.66 3.99 Favored Glycine 0 C--N 1.356 1.688 0 N-CA-C 116.144 1.218 . . . . 0.0 116.144 -171.617 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -77.28 -22.79 51.54 Favored 'General case' 0 CA--C 1.552 1.021 0 CA-C-N 117.67 0.735 . . . . 0.0 112.208 178.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 19.3 p -124.41 -5.59 7.69 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 122.439 0.296 . . . . 0.0 111.597 177.868 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -64.65 -31.16 72.26 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.416 0.686 . . . . 0.0 112.498 -175.132 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.08 -50.46 67.58 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 114.565 0.586 . . . . 0.0 114.565 -174.052 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.3 m -66.35 -31.97 55.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 123.093 0.557 . . . . 0.0 112.119 -178.598 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.442 HG21 HG21 ' A' ' 62' ' ' VAL . 76.1 mt -72.22 -54.97 14.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.694 0 C-N-CA 123.884 0.874 . . . . 0.0 110.17 -177.871 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -61.33 -42.51 98.8 Favored 'General case' 0 CA--C 1.537 0.456 0 CA-C-N 114.343 -1.299 . . . . 0.0 110.79 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -68.07 -34.01 80.34 Favored Glycine 0 C--N 1.342 0.897 0 O-C-N 124.16 0.913 . . . . 0.0 113.131 -178.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -65.08 -53.75 40.74 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.789 0.435 . . . . 0.0 110.514 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.577 ' HA ' HG21 ' A' ' 76' ' ' ILE . 62.9 mt -63.98 -40.87 90.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.719 -178.935 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -64.68 -43.67 92.81 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.308 0.643 . . . . 0.0 111.549 -179.695 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -81.76 -18.56 43.79 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -175.108 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 36.8 m -87.26 -40.98 14.03 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 175.23 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.7 t -121.83 88.9 47.69 Favored Pre-proline 0 N--CA 1.48 1.069 0 C-N-CA 123.872 0.869 . . . . 0.0 108.831 174.067 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -60.94 113.18 1.61 Allowed 'Trans proline' 0 C--N 1.375 1.93 0 C-N-CA 122.632 2.222 . . . . 0.0 111.588 175.01 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.5 -5.37 11.86 Favored Glycine 0 C--N 1.341 0.856 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.804 -176.163 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -78.07 106.84 10.21 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 173.745 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.03 96.82 3.88 Favored 'General case' 0 C--N 1.351 0.658 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.454 HG12 HG12 ' A' ' 64' ' ' VAL . 7.8 m -88.85 134.83 27.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.729 -172.505 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -142.08 101.45 3.93 Favored 'General case' 0 C--N 1.352 0.684 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 176.621 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.12 114.69 22.44 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 173.849 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.401 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 10.2 t70 -93.41 130.35 35.79 Favored Pre-proline 0 CA--C 1.542 0.666 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 -175.071 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 56' ' ' ASP . 27.6 Cg_exo -64.86 -53.65 0.88 Allowed 'Trans proline' 0 C--N 1.372 1.797 0 C-N-CA 122.634 2.223 . . . . 0.0 113.058 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.82 -36.02 50.66 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.266 -170.164 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 26.3 t -87.6 -18.25 30.1 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 123.432 0.693 . . . . 0.0 110.685 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.419 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 10.4 mpt_? 60.94 31.36 19.97 Favored 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 124.467 1.107 . . . . 0.0 111.268 -176.586 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 27' ' ' HIS . 53.8 m -116.53 122.45 44.74 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -168.534 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.442 HG21 HG21 ' A' ' 40' ' ' ILE . 31.6 t -96.75 106.38 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 172.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 18.8 t -102.24 131.83 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.53 HG21 HG13 ' A' ' 73' ' ' ILE . 35.6 m -105.43 139.41 26.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 C-N-CA 123.422 0.689 . . . . 0.0 109.535 174.915 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -118.36 151.03 18.0 Favored Glycine 0 C--N 1.341 0.859 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.058 -175.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 79.32 -12.04 27.98 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-O 120.142 -0.255 . . . . 0.0 113.092 -177.002 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 33.3 m -132.65 131.12 59.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 C-N-CA 124.406 1.083 . . . . 0.0 108.787 -178.929 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t -112.43 10.67 19.81 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.657 0.783 . . . . 0.0 110.121 -177.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.41 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 3.2 m-20 -70.57 87.37 0.66 Allowed 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 124.14 0.976 . . . . 0.0 110.922 -176.069 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.5 -58.16 9.65 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 122.793 0.437 . . . . 0.0 112.168 -173.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -64.66 -36.42 84.2 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.048 0.539 . . . . 0.0 111.648 -175.51 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.417 ' O ' HG13 ' A' ' 76' ' ' ILE . 65.2 m170 -65.29 -55.38 18.64 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 123.029 0.532 . . . . 0.0 111.111 -179.522 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.53 HG13 HG21 ' A' ' 64' ' ' VAL . 47.8 mm -60.93 -40.26 84.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 O-C-N 123.856 0.723 . . . . 0.0 110.316 -177.87 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.0 -38.38 82.45 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.17 0.988 . . . . 0.0 111.707 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 35.5 mm-40 -69.14 -35.93 76.89 Favored 'General case' 0 N--CA 1.475 0.822 0 O-C-N 123.511 0.507 . . . . 0.0 111.768 179.095 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.577 HG21 ' HA ' ' A' ' 44' ' ' ILE . 43.9 mt -65.82 -50.24 71.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 CA-C-O 121.152 0.501 . . . . 0.0 110.863 -178.402 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.415 ' HB ' HD11 ' A' ' 44' ' ' ILE . 12.3 tt -73.75 -32.81 36.03 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 CA-C-N 115.138 -0.937 . . . . 0.0 111.885 -173.546 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.1 t -72.76 -29.63 63.47 Favored 'General case' 0 N--CA 1.484 1.245 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 174.769 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.41 -28.93 67.51 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.179 0.592 . . . . 0.0 110.589 173.063 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.24 -5.94 47.14 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 123.538 0.735 . . . . 0.0 111.755 175.615 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.91 21.16 40.37 Favored Glycine 0 C--N 1.348 1.214 0 O-C-N 123.141 0.275 . . . . 0.0 112.993 176.67 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -128.02 114.49 17.17 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 123.472 0.709 . . . . 0.0 109.381 178.829 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.3 t -70.28 114.13 23.41 Favored Pre-proline 0 CA--C 1.561 1.383 0 C-N-CA 123.332 0.653 . . . . 0.0 111.117 -176.001 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.423 ' HA ' HG22 ' A' ' 28' ' ' VAL . 73.5 Cg_endo -71.53 -19.26 28.57 Favored 'Trans proline' 0 C--N 1.384 2.415 0 C-N-CA 122.856 2.37 . . . . 0.0 112.836 -177.84 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 . . . . . 0 C--O 1.246 0.896 0 C-N-CA 124.319 1.048 . . . . 0.0 108.8 -178.436 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.019 0 N-CA-C 113.573 0.189 . . . . 0.0 113.573 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 72.5 mt -108.29 107.55 18.2 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 123.714 0.806 . . . . 0.0 109.059 177.629 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.4 m -95.35 114.16 25.91 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.232 0.613 . . . . 0.0 110.822 -173.261 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -109.72 106.45 16.1 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 123.97 0.908 . . . . 0.0 110.481 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 16.3 m-70 -83.1 91.31 7.19 Favored 'General case' 0 N--CA 1.479 0.976 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 176.847 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.445 HG11 ' HB3' ' A' ' 82' ' ' TYR . 47.7 t -82.29 97.58 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 176.434 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -66.33 -24.9 66.61 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 123.23 0.612 . . . . 0.0 112.346 -171.593 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -87.74 -11.66 47.53 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 122.97 0.508 . . . . 0.0 111.636 177.866 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.539 ' HG3' ' HB2' ' A' ' 36' ' ' CYS . 13.0 ttt -71.38 137.99 48.82 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.157 0.583 . . . . 0.0 109.553 169.416 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.6 t -129.87 98.48 4.8 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 123.638 0.775 . . . . 0.0 109.911 176.458 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 59.6 m 54.64 -154.84 0.26 Allowed 'General case' 0 CA--C 1.557 1.244 0 C-N-CA 124.695 1.198 . . . . 0.0 112.843 173.236 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.537 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -58.06 -26.5 58.5 Favored Glycine 0 C--N 1.361 1.946 0 C-N-CA 123.697 0.665 . . . . 0.0 114.097 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 14.2 t-80 -56.54 -32.78 65.45 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.383 1.073 . . . . 0.0 111.793 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.539 ' HB2' ' HG3' ' A' ' 31' ' ' MET . 62.1 m -111.15 -18.18 13.05 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.181 0.592 . . . . 0.0 111.423 178.465 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.537 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -64.47 -47.16 80.02 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 123.231 0.612 . . . . 0.0 112.321 -176.247 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.26 -46.13 92.01 Favored Glycine 0 N--CA 1.475 1.281 0 O-C-N 123.995 0.809 . . . . 0.0 114.147 -172.424 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -68.22 -31.7 52.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.011 0 C-N-CA 123.626 0.77 . . . . 0.0 111.017 -179.404 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.785 HG21 HG21 ' A' ' 62' ' ' VAL . 65.8 mt -69.31 -43.99 80.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 123.641 0.777 . . . . 0.0 111.05 175.417 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.445 ' HG3' ' O ' ' A' ' 37' ' ' ALA . 95.1 mttt -58.2 -47.23 84.1 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.575 0.75 . . . . 0.0 109.546 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.65 -36.14 92.95 Favored Glycine 0 C--N 1.348 1.234 0 O-C-N 124.466 1.104 . . . . 0.0 112.824 178.32 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.38 -55.5 27.32 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 122.852 0.461 . . . . 0.0 111.142 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.502 HG21 HG11 ' A' ' 64' ' ' VAL . 57.6 mt -69.74 -47.12 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.743 -176.109 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -57.84 -50.07 74.55 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.038 0.935 . . . . 0.0 111.955 -176.149 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -70.52 -26.44 63.58 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.032 -174.357 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 47.4 m -86.13 -42.22 14.06 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.733 0.413 . . . . 0.0 110.995 -178.196 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.9 m -132.05 86.44 47.15 Favored Pre-proline 0 CA--C 1.561 1.37 0 C-N-CA 123.752 0.821 . . . . 0.0 110.702 -179.41 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -56.63 123.97 15.12 Favored 'Trans proline' 0 C--N 1.377 2.04 0 C-N-CA 123.039 2.492 . . . . 0.0 111.372 169.475 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.79 -22.34 8.17 Favored Glycine 0 N--CA 1.473 1.116 0 CA-C-O 119.979 -0.345 . . . . 0.0 112.313 -175.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.1 106.94 6.85 Favored 'General case' 0 C--N 1.355 0.808 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 175.671 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.09 100.77 9.2 Favored 'General case' 0 C--N 1.342 0.275 0 C-N-CA 123.729 0.812 . . . . 0.0 109.488 -177.43 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.485 HG12 HG12 ' A' ' 64' ' ' VAL . 35.2 m -84.57 134.59 26.65 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 123.059 0.543 . . . . 0.0 110.16 -172.477 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 48.4 t-80 -136.36 97.49 3.6 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 172.426 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.2 114.33 26.84 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -86.29 123.71 71.09 Favored Pre-proline 0 CA--C 1.542 0.64 0 CA-C-O 118.567 -0.73 . . . . 0.0 109.058 -173.222 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.47 ' HA ' ' HA ' ' A' ' 33' ' ' CYS . 21.5 Cg_endo -58.84 -45.67 27.54 Favored 'Trans proline' 0 C--N 1.372 1.81 0 C-N-CA 122.863 2.375 . . . . 0.0 112.861 179.118 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.31 -45.88 21.57 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.411 0.685 . . . . 0.0 111.815 -173.741 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 17.0 m -90.05 -5.8 56.21 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 123.479 0.712 . . . . 0.0 112.285 -172.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 40.69 45.01 1.96 Allowed 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 125.676 1.59 . . . . 0.0 112.548 -172.329 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 59.2 m -114.39 118.58 34.24 Favored 'General case' 0 C--N 1.346 0.444 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.413 -175.293 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.785 HG21 HG21 ' A' ' 40' ' ' ILE . 27.9 t -97.32 105.84 17.71 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 177.147 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 21.6 t -98.56 119.46 46.58 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 C-N-CA 123.956 0.903 . . . . 0.0 109.333 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.502 HG11 HG21 ' A' ' 44' ' ' ILE . 28.2 m -110.09 112.07 38.91 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.865 0 CA-C-O 121.562 0.696 . . . . 0.0 110.712 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.4 170.16 31.03 Favored Glycine 0 C--N 1.344 1.007 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.603 176.656 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.73 -5.92 49.9 Favored Glycine 0 N--CA 1.472 1.066 0 N-CA-C 114.069 0.388 . . . . 0.0 114.069 177.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 18.1 m -128.89 148.37 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 124.773 1.229 . . . . 0.0 109.415 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.3 t -114.47 0.15 13.94 Favored 'General case' 0 N--CA 1.482 1.159 0 C-N-CA 123.604 0.761 . . . . 0.0 110.366 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.436 ' O ' HG12 ' A' ' 73' ' ' ILE . 3.4 m-20 -91.18 70.95 6.24 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.099 0.959 . . . . 0.0 110.231 -169.703 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.94 -49.78 76.55 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 123.409 0.684 . . . . 0.0 112.575 -174.163 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.66 91.09 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.69 0.796 . . . . 0.0 111.511 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 74.8 t60 -66.39 -46.7 75.76 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.017 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.501 HG21 HG21 ' A' ' 64' ' ' VAL . 47.4 mm -60.59 -39.15 80.48 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 O-C-N 123.702 0.626 . . . . 0.0 109.671 177.589 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -58.07 -38.71 76.86 Favored 'General case' 0 N--CA 1.473 0.682 0 O-C-N 124.147 0.905 . . . . 0.0 111.641 178.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -67.94 -38.48 82.89 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 123.261 0.624 . . . . 0.0 111.192 176.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.475 HG21 ' HA ' ' A' ' 44' ' ' ILE . 64.7 mt -68.46 -50.04 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 C-N-CA 123.279 0.631 . . . . 0.0 111.528 -177.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.454 HG13 HG23 ' A' ' 40' ' ' ILE . 13.5 tt -69.37 -35.3 66.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 123.373 0.669 . . . . 0.0 111.318 -175.812 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.4 t -70.11 -29.32 66.24 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 122.207 0.203 . . . . 0.0 110.527 176.43 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.31 -17.48 64.78 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 123.51 0.724 . . . . 0.0 112.23 176.167 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -85.98 5.12 34.72 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.574 0.749 . . . . 0.0 111.355 172.408 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.36 2.55 79.71 Favored Glycine 0 C--N 1.347 1.171 0 CA-C-O 119.424 -0.653 . . . . 0.0 113.697 178.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.445 ' HB3' HG11 ' A' ' 28' ' ' VAL . 84.2 m-85 -119.16 105.48 11.42 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 117.917 0.858 . . . . 0.0 109.651 -177.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.0 t -86.87 127.72 58.79 Favored Pre-proline 0 CA--C 1.55 0.959 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.88 -170.483 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.414 ' HD3' HG23 ' A' ' 77' ' ' ILE . 57.3 Cg_endo -69.97 -36.97 9.32 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.529 2.153 . . . . 0.0 112.159 177.815 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.5 mm-40 . . . . . 0 C--O 1.251 1.142 0 C-N-CA 125.078 1.351 . . . . 0.0 111.302 -177.967 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.101 0 N-CA-C 112.549 -0.221 . . . . 0.0 112.549 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.5 HD13 ' HA ' ' A' ' 70' ' ' ALA . 25.1 mt -96.74 108.61 21.29 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.857 0.863 . . . . 0.0 110.34 -175.616 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.2 t -86.92 119.68 27.4 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 123.275 0.63 . . . . 0.0 109.913 177.655 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -112.79 118.02 33.8 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.558 0.743 . . . . 0.0 109.658 175.793 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 44.9 p-80 -83.75 88.3 7.08 Favored 'General case' 0 CA--C 1.546 0.817 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 175.434 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.52 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 35.3 t -80.79 104.39 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -172.196 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -73.31 -16.44 61.37 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 115.668 -0.696 . . . . 0.0 112.051 -175.717 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.408 ' HB3' ' H ' ' A' ' 83' ' ' THR . 35.8 t70 -106.71 16.33 24.59 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.361 0.664 . . . . 0.0 110.534 179.325 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.52 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 25.1 ttt -71.31 136.13 47.72 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 121.012 0.434 . . . . 0.0 111.516 -176.432 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 20.3 p -86.88 162.04 17.95 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.16 0.984 . . . . 0.0 110.913 173.187 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 61.2 m -74.89 -167.41 0.58 Allowed 'General case' 0 CA--C 1.561 1.376 0 C-N-CA 123.663 0.785 . . . . 0.0 111.756 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -57.66 -29.04 60.73 Favored Glycine 0 C--N 1.355 1.635 0 N-CA-C 115.695 1.038 . . . . 0.0 115.695 -172.546 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -69.3 -22.92 63.76 Favored 'General case' 0 N--CA 1.486 1.364 0 CA-C-N 117.428 0.614 . . . . 0.0 112.371 -176.681 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.7 m -123.24 13.14 9.59 Favored 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 123.636 0.774 . . . . 0.0 110.955 176.567 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -65.97 -41.64 90.9 Favored 'General case' 0 C--N 1.357 0.922 0 C-N-CA 123.131 0.572 . . . . 0.0 111.392 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.38 -25.61 67.02 Favored Glycine 0 N--CA 1.473 1.129 0 O-C-N 123.134 0.271 . . . . 0.0 113.699 -179.204 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.75 -50.07 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 123.404 0.682 . . . . 0.0 110.808 177.671 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 15.1 tt -67.99 -32.95 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 C-N-CA 123.025 0.53 . . . . 0.0 110.596 -177.429 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.421 ' HB3' HG21 ' A' ' 53' ' ' VAL . 96.1 mttt -64.23 -53.17 53.29 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 123.634 0.774 . . . . 0.0 109.56 168.478 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.409 ' HA2' ' HB3' ' A' ' 45' ' ' GLU . . . -59.06 -29.83 65.93 Favored Glycine 0 C--N 1.358 1.77 0 O-C-N 124.873 1.358 . . . . 0.0 114.046 -173.132 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.87 -54.15 48.05 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 123.818 0.847 . . . . 0.0 110.665 177.9 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.569 HG21 HG11 ' A' ' 64' ' ' VAL . 60.2 mt -75.21 -41.91 44.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.814 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.409 ' HB3' ' HA2' ' A' ' 42' ' ' GLY . 17.6 tp10 -54.26 -51.14 65.49 Favored 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 125.418 1.487 . . . . 0.0 112.282 -174.632 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? -79.64 -25.85 41.25 Favored 'General case' 0 N--CA 1.483 1.176 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.84 -175.439 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 87.0 m -76.77 -48.14 19.56 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-O 120.814 0.34 . . . . 0.0 110.673 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.508 HG11 HG11 ' A' ' 67' ' ' VAL . 56.5 t -112.22 110.23 53.72 Favored Pre-proline 0 N--CA 1.475 0.78 0 C-N-CA 123.459 0.704 . . . . 0.0 109.432 -178.424 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -72.41 110.32 2.95 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.403 2.069 . . . . 0.0 111.342 172.099 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 117.1 -2.57 19.16 Favored Glycine 0 C--N 1.342 0.867 0 CA-C-O 119.382 -0.677 . . . . 0.0 113.548 179.191 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -80.22 105.95 11.87 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 173.308 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.72 99.64 8.32 Favored 'General case' 0 C--N 1.346 0.44 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -177.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.479 HG12 HG12 ' A' ' 64' ' ' VAL . 29.3 m -84.74 129.43 37.71 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-O 121.235 0.54 . . . . 0.0 110.446 -174.077 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 63.8 t60 -125.61 97.97 5.38 Favored 'General case' 0 C--O 1.225 -0.213 0 N-CA-C 106.211 -1.774 . . . . 0.0 106.211 174.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -109.84 113.89 27.01 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 -179.176 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ASP . . . . . 0.413 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 11.1 t70 -105.76 119.86 51.11 Favored Pre-proline 0 N--CA 1.468 0.469 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -175.126 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -63.37 -33.77 68.8 Favored 'Trans proline' 0 C--N 1.375 1.927 0 C-N-CA 122.989 2.459 . . . . 0.0 113.088 -176.782 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.88 -45.64 23.6 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.127 0.571 . . . . 0.0 111.083 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.413 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 35.4 m -80.35 -23.95 40.18 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 123.253 0.621 . . . . 0.0 111.568 -174.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.457 ' HA ' ' SD ' ' A' ' 31' ' ' MET . 37.5 mmt180 65.08 35.41 8.01 Favored 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 124.71 1.204 . . . . 0.0 111.093 -177.464 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 11.9 m -122.8 117.97 26.89 Favored 'General case' 0 C--O 1.241 0.609 0 C-N-CA 123.029 0.532 . . . . 0.0 110.778 -171.058 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 45.9 t -103.76 106.71 20.72 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 172.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 24.9 t -105.11 130.25 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 124.452 1.101 . . . . 0.0 109.099 -179.238 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.569 HG11 HG21 ' A' ' 44' ' ' ILE . 17.6 m -117.63 109.52 27.79 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.023 0 CA-C-O 121.419 0.628 . . . . 0.0 111.107 -178.32 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -86.87 161.01 32.95 Favored Glycine 0 C--N 1.346 1.114 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.817 178.501 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 83.09 -11.3 55.37 Favored Glycine 0 N--CA 1.472 1.035 0 CA-C-O 119.806 -0.441 . . . . 0.0 113.62 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.508 HG11 HG11 ' A' ' 48' ' ' VAL . 30.6 m -128.89 150.85 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.272 0 C-N-CA 124.022 0.929 . . . . 0.0 109.935 -176.848 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 29.1 t -124.85 -2.89 7.75 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.749 0.82 . . . . 0.0 111.586 -174.199 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.508 ' HB3' ' HB3' ' A' ' 72' ' ' HIS . 6.1 m-20 -79.24 82.05 5.43 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 123.493 0.717 . . . . 0.0 109.999 -178.592 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.5 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -62.93 -49.28 75.39 Favored 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 123.231 0.612 . . . . 0.0 112.068 -172.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.463 ' O ' ' HG3' ' A' ' 75' ' ' GLU . . . -65.68 -39.35 91.23 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.62 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.508 ' HB3' ' HB3' ' A' ' 69' ' ' ASP . 79.5 t60 -70.25 -42.09 72.64 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 123.596 0.758 . . . . 0.0 112.239 -175.493 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.538 HG21 HG21 ' A' ' 64' ' ' VAL . 33.8 mm -63.74 -37.61 80.15 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 175.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.54 -33.31 74.65 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.226 176.44 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.463 ' HG3' ' O ' ' A' ' 71' ' ' ALA . 46.5 mt-10 -64.73 -41.41 95.98 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 123.191 0.596 . . . . 0.0 110.541 174.595 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 70.0 mt -69.46 -47.33 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.406 0.682 . . . . 0.0 111.265 -175.222 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 15.1 tt -74.33 -26.85 20.84 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.02 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.179 -176.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.51 ' HA ' ' O ' ' A' ' 82' ' ' TYR . 2.3 t -75.69 -29.35 58.99 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 175.236 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.51 -18.28 64.35 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.681 0.792 . . . . 0.0 111.566 175.297 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -79.83 3.35 19.91 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.814 0.845 . . . . 0.0 112.219 174.91 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.32 5.56 75.75 Favored Glycine 0 C--N 1.349 1.255 0 CA-C-O 120.216 -0.213 . . . . 0.0 113.024 179.294 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.51 ' O ' ' HA ' ' A' ' 78' ' ' THR . 91.7 m-85 -100.13 162.22 13.11 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.897 0.879 . . . . 0.0 110.047 178.216 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.408 ' H ' ' HB3' ' A' ' 30' ' ' ASP . 32.4 p -121.52 103.31 41.32 Favored Pre-proline 0 CA--C 1.55 0.947 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 171.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -60.84 -40.24 55.31 Favored 'Trans proline' 0 C--N 1.387 2.602 0 C-N-CA 123.061 2.508 . . . . 0.0 112.33 175.505 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 64.7 mm-40 . . . . . 0 CA--C 1.552 1.041 0 C-N-CA 124.769 1.228 . . . . 0.0 110.755 -178.04 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.346 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.46 HD13 ' HA ' ' A' ' 70' ' ' ALA . 25.9 mt -92.14 115.09 27.78 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 123.912 0.885 . . . . 0.0 109.579 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 47.0 t -83.53 123.05 29.35 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 122.875 0.47 . . . . 0.0 110.24 -179.297 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -125.43 101.38 6.92 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.815 0.846 . . . . 0.0 109.032 174.835 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' HIS . . . . . 0.403 ' HA ' ' HA ' ' A' ' 61' ' ' THR . 9.5 p80 -93.82 100.15 12.39 Favored 'General case' 0 CA--C 1.547 0.843 0 CA-C-O 121.503 0.668 . . . . 0.0 110.384 -174.158 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.531 ' O ' ' HB3' ' A' ' 60' ' ' ARG . 92.0 t -82.34 106.04 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 172.88 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -79.63 -7.75 58.75 Favored 'General case' 0 N--CA 1.485 1.308 0 CA-C-N 118.292 0.496 . . . . 0.0 112.137 -176.281 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -95.15 12.29 29.25 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 123.638 0.775 . . . . 0.0 111.071 171.308 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.43 ' SD ' ' HA ' ' A' ' 60' ' ' ARG . 27.6 ttt -70.9 143.51 50.96 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.541 0.736 . . . . 0.0 111.764 -176.759 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 17.2 p -125.88 165.88 17.91 Favored 'General case' 0 C--O 1.243 0.725 0 C-N-CA 125.161 1.384 . . . . 0.0 108.61 176.807 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 31.6 p -53.41 179.51 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -173.136 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.503 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -43.94 -26.6 0.85 Allowed Glycine 0 C--N 1.36 1.881 0 N-CA-C 117.603 1.801 . . . . 0.0 117.603 -166.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 69.4 t60 -55.97 -54.77 40.73 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 124.081 0.952 . . . . 0.0 111.061 176.109 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 42.6 t -96.91 -20.91 17.79 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.488 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.503 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -64.81 -36.04 83.03 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 123.068 0.547 . . . . 0.0 110.802 175.684 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.95 -24.82 73.17 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.425 -0.807 . . . . 0.0 113.169 176.103 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 43.3 t -74.5 -38.95 47.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.404 0.682 . . . . 0.0 110.237 176.094 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 22.5 mt -63.98 -47.42 90.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-O 121.455 0.645 . . . . 0.0 109.536 176.704 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.411 ' HZ3' HG23 ' A' ' 53' ' ' VAL . 9.4 mtpm? -59.23 -47.78 84.08 Favored 'General case' 0 C--N 1.35 0.588 0 CA-C-N 114.285 -1.325 . . . . 0.0 110.852 176.107 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.22 -33.03 86.14 Favored Glycine 0 C--N 1.345 1.081 0 O-C-N 124.502 1.126 . . . . 0.0 113.094 -175.396 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -60.49 -54.61 43.47 Favored 'General case' 0 C--N 1.348 0.515 0 C-N-CA 123.133 0.573 . . . . 0.0 110.521 178.264 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.5 HG21 HG11 ' A' ' 64' ' ' VAL . 54.7 mt -72.55 -45.72 57.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.804 -175.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -64.22 -41.14 97.15 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.947 0.899 . . . . 0.0 111.92 -171.228 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -76.22 -34.75 59.24 Favored 'General case' 0 N--CA 1.481 1.076 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.221 -178.634 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 86.7 m -72.91 -45.84 55.96 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 122.435 0.294 . . . . 0.0 110.744 -178.647 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 78.0 t -120.5 94.23 48.7 Favored Pre-proline 0 N--CA 1.478 0.933 0 C-N-CA 123.679 0.791 . . . . 0.0 109.054 176.725 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_exo -64.12 123.87 12.57 Favored 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 122.549 2.166 . . . . 0.0 110.622 169.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 119.68 -20.28 9.45 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 112.108 -0.397 . . . . 0.0 112.108 -174.364 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -79.72 105.7 11.21 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 174.419 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.36 98.25 8.09 Favored 'General case' 0 C--N 1.342 0.259 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -178.026 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.597 HG12 HG12 ' A' ' 64' ' ' VAL . 15.6 m -85.06 116.07 27.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 C-N-CA 123.513 0.725 . . . . 0.0 110.097 -172.449 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 54.9 t-80 -112.55 99.22 7.79 Favored 'General case' 0 C--N 1.347 0.472 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 176.892 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.34 127.68 34.13 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.905 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -111.2 108.11 57.22 Favored Pre-proline 0 CA--C 1.537 0.471 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 175.147 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -64.03 -33.48 62.18 Favored 'Trans proline' 0 C--N 1.367 1.521 0 C-N-CA 122.678 2.252 . . . . 0.0 112.86 -178.442 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.76 -39.67 43.48 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.46 0.704 . . . . 0.0 111.85 -175.209 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.3 t -92.82 -15.02 26.99 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 123.712 0.805 . . . . 0.0 110.851 -178.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.531 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 63.52 45.26 4.82 Favored 'General case' 0 CA--C 1.554 1.1 0 C-N-CA 124.452 1.101 . . . . 0.0 110.421 -179.272 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.403 ' HA ' ' HA ' ' A' ' 27' ' ' HIS . 17.8 m -132.85 120.9 22.15 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -170.72 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 47.4 t -104.18 108.28 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 123.686 0.794 . . . . 0.0 109.458 173.779 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 43.1 t -104.07 121.59 55.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.893 0.877 . . . . 0.0 109.551 -177.6 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.597 HG12 HG12 ' A' ' 53' ' ' VAL . 27.0 m -102.45 114.43 41.9 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 CA-C-O 121.427 0.632 . . . . 0.0 111.151 -176.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.83 160.37 24.21 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.064 179.129 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 83.22 -11.75 53.64 Favored Glycine 0 N--CA 1.474 1.232 0 CA-C-N 116.695 0.248 . . . . 0.0 113.68 177.249 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 31.3 m -126.62 142.22 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 124.474 1.11 . . . . 0.0 109.064 178.665 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.2 m -113.25 3.59 16.06 Favored 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 123.352 0.661 . . . . 0.0 110.487 178.403 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -82.44 79.18 8.95 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.129 0.972 . . . . 0.0 110.432 -174.39 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.46 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -63.77 -37.92 89.18 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 122.86 0.464 . . . . 0.0 111.719 -175.479 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.502 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -65.44 -47.19 77.02 Favored 'General case' 0 N--CA 1.475 0.818 0 O-C-N 123.551 0.532 . . . . 0.0 110.718 179.363 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 17.3 m-70 -58.24 -52.9 63.64 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 123.6 0.76 . . . . 0.0 111.11 -177.814 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.439 HG13 HG21 ' A' ' 64' ' ' VAL . 47.6 mm -62.02 -38.88 81.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.079 -178.534 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.84 -40.47 88.62 Favored 'General case' 0 C--N 1.354 0.779 0 O-C-N 124.063 0.852 . . . . 0.0 111.118 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.502 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 39.8 mm-40 -61.51 -45.82 92.58 Favored 'General case' 0 N--CA 1.479 1.003 0 O-C-N 123.872 0.733 . . . . 0.0 110.393 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.447 HG21 ' HA ' ' A' ' 44' ' ' ILE . 46.5 mt -63.67 -53.73 41.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 115.212 -0.903 . . . . 0.0 111.551 -175.684 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 14.0 tt -67.7 -37.67 79.01 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.635 -171.647 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.6 t -75.08 -29.18 60.58 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 122.483 0.313 . . . . 0.0 110.481 178.603 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.78 -29.75 69.02 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 123.585 0.754 . . . . 0.0 110.742 175.219 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.4 -2.18 33.9 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 123.576 0.75 . . . . 0.0 111.485 174.598 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 96.88 -11.38 66.15 Favored Glycine 0 C--N 1.351 1.394 0 C-N-CA 123.093 0.378 . . . . 0.0 113.003 176.819 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 60.9 m-85 -91.08 104.76 17.3 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -175.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.8 m -77.12 110.92 13.6 Favored Pre-proline 0 CA--C 1.551 1.007 0 C-N-CA 123.917 0.887 . . . . 0.0 110.02 -176.786 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -83.13 -18.03 6.39 Favored 'Trans proline' 0 C--N 1.373 1.826 0 C-N-CA 122.56 2.173 . . . . 0.0 113.222 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 . . . . . 0 C--O 1.245 0.858 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.283 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.731 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.408 HD13 ' HA ' ' A' ' 70' ' ' ALA . 52.5 mt -78.98 107.91 12.07 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -178.513 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 20.1 m -95.06 110.74 22.63 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 122.467 0.307 . . . . 0.0 110.706 -173.019 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -107.13 146.36 31.37 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 124.068 0.947 . . . . 0.0 109.351 178.41 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -124.52 136.05 53.68 Favored 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.457 HG22 ' HB3' ' A' ' 84' ' ' PRO . 86.3 t -125.79 126.69 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 123.592 0.757 . . . . 0.0 111.407 -170.521 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -71.73 -37.62 70.57 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.217 0.607 . . . . 0.0 111.548 177.704 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -75.02 -21.68 58.93 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 123.054 0.542 . . . . 0.0 112.258 -173.303 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.535 ' HG3' ' SG ' ' A' ' 36' ' ' CYS . 27.2 ttt -65.76 120.17 12.53 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.158 0.983 . . . . 0.0 111.043 -174.665 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 p -127.35 95.61 4.32 Favored 'General case' 0 CA--C 1.548 0.883 0 C-N-CA 122.717 0.407 . . . . 0.0 110.957 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 12.5 t 50.32 -147.94 0.34 Allowed 'General case' 0 CA--C 1.572 1.792 0 C-N-CA 125.349 1.459 . . . . 0.0 113.995 167.129 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -62.15 -28.64 71.01 Favored Glycine 0 C--N 1.357 1.722 0 N-CA-C 115.118 0.807 . . . . 0.0 115.118 -173.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 46.6 m170 -64.51 -29.05 70.08 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 123.451 0.7 . . . . 0.0 112.099 -178.507 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.535 ' SG ' ' HG3' ' A' ' 31' ' ' MET . 30.6 p -100.29 -18.74 16.68 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 122.768 0.427 . . . . 0.0 111.102 179.377 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -55.54 -54.77 39.85 Favored 'General case' 0 C--N 1.358 0.944 0 O-C-N 124.012 0.82 . . . . 0.0 112.563 -166.6 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.27 -35.55 92.11 Favored Glycine 0 C--N 1.343 0.946 0 O-C-N 123.178 0.299 . . . . 0.0 113.43 -176.561 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 49.0 t -72.2 -47.53 53.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 123.067 0.547 . . . . 0.0 111.075 -178.295 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.422 HD11 HD11 ' A' ' 77' ' ' ILE . 14.2 tt -67.91 -32.33 55.92 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 123.803 0.841 . . . . 0.0 111.239 -174.837 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -63.51 -59.25 4.89 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 123.656 0.782 . . . . 0.0 110.06 172.373 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.88 -30.93 78.16 Favored Glycine 0 C--N 1.353 1.477 0 CA-C-N 114.548 -1.205 . . . . 0.0 113.919 -170.842 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.82 -51.57 68.47 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 124.022 0.929 . . . . 0.0 110.567 -179.583 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.598 HG21 HG11 ' A' ' 64' ' ' VAL . 65.3 mt -73.95 -50.57 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 123.447 0.699 . . . . 0.0 111.334 178.872 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -58.73 -44.55 90.48 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 124.471 1.108 . . . . 0.0 112.808 -165.787 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.2 mptp? -81.05 -27.06 35.88 Favored 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.34 -175.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 91.2 m -74.38 -37.92 63.3 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 123.054 0.542 . . . . 0.0 110.66 179.339 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 95.5 t -124.46 95.07 43.76 Favored Pre-proline 0 N--CA 1.478 0.973 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 174.203 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -59.14 124.25 15.22 Favored 'Trans proline' 0 C--N 1.376 2.011 0 C-N-CA 122.998 2.466 . . . . 0.0 111.385 170.734 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.76 -8.16 36.66 Favored Glycine 0 C--N 1.343 0.937 0 CA-C-O 119.601 -0.555 . . . . 0.0 112.935 -176.017 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -83.83 105.98 15.16 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 171.495 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -88.08 101.91 14.26 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.41 0.684 . . . . 0.0 109.591 -177.576 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.49 HG12 HG12 ' A' ' 64' ' ' VAL . 31.6 m -83.01 130.83 35.06 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.339 0.59 . . . . 0.0 110.492 -171.649 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' HIS . . . . . 0.458 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 24.7 t60 -120.72 96.41 5.11 Favored 'General case' 0 C--O 1.219 -0.528 0 N-CA-C 106.307 -1.738 . . . . 0.0 106.307 170.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.17 114.79 27.43 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -98.03 112.65 62.39 Favored Pre-proline 0 N--CA 1.47 0.529 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.79 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -57.02 -51.25 9.25 Favored 'Trans proline' 0 C--N 1.377 2.053 0 C-N-CA 122.616 2.211 . . . . 0.0 113.142 -175.775 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.67 -42.01 68.01 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 123.497 0.719 . . . . 0.0 112.465 -171.438 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.1 t -89.3 -12.74 39.71 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.07 0.548 . . . . 0.0 111.242 -178.462 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.4 mpt_? 65.16 30.55 11.39 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 124.269 1.027 . . . . 0.0 111.891 177.74 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 16.7 m -110.94 109.83 20.15 Favored 'General case' 0 CA--C 1.544 0.737 0 O-C-N 122.258 -0.276 . . . . 0.0 110.952 -169.118 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.458 ' HA ' ' O ' ' A' ' 54' ' ' HIS . 39.3 t -98.92 105.39 17.3 Favored 'Isoleucine or valine' 0 C--N 1.352 0.699 0 C-N-CA 123.804 0.842 . . . . 0.0 109.242 177.108 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 22.6 t -99.61 117.92 45.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.749 0.82 . . . . 0.0 109.083 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.598 HG11 HG21 ' A' ' 44' ' ' ILE . 30.5 m -104.74 115.24 46.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 123.402 0.681 . . . . 0.0 109.996 -179.399 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -101.07 145.4 16.98 Favored Glycine 0 C--N 1.348 1.229 0 CA-C-N 116.143 -0.48 . . . . 0.0 112.671 -177.356 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 95.71 3.31 61.0 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 123.073 0.368 . . . . 0.0 113.659 176.951 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.3 m -130.54 147.44 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.739 0.816 . . . . 0.0 110.249 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.8 m -112.27 4.83 17.99 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 123.071 0.549 . . . . 0.0 110.708 179.065 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.532 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 3.0 m-20 -89.36 68.71 8.01 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.922 0.889 . . . . 0.0 110.39 -175.027 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.408 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -62.11 -39.49 92.69 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.452 0.701 . . . . 0.0 111.285 -177.282 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -66.81 -42.49 85.81 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.719 0.808 . . . . 0.0 111.376 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.532 ' HB2' ' HB3' ' A' ' 69' ' ' ASP . 18.8 m80 -63.63 -52.98 58.44 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 122.793 0.437 . . . . 0.0 110.726 178.242 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.505 HG21 HG21 ' A' ' 64' ' ' VAL . 47.2 mm -58.89 -42.44 85.83 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 O-C-N 123.93 0.769 . . . . 0.0 110.52 -176.235 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -58.1 -41.87 84.46 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.143 0.977 . . . . 0.0 111.387 178.883 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 60.1 mm-40 -70.12 -33.82 72.31 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.264 178.177 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.435 HG13 ' O ' ' A' ' 72' ' ' HIS . 75.4 mt -68.11 -51.31 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 CA-C-O 121.025 0.44 . . . . 0.0 110.554 -179.173 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.602 HG23 ' HG3' ' A' ' 84' ' ' PRO . 16.7 tt -69.25 -32.34 53.32 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 CA-C-N 115.165 -0.925 . . . . 0.0 111.438 -175.138 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 t -76.52 -31.59 57.75 Favored 'General case' 0 N--CA 1.477 0.913 0 O-C-N 122.283 -0.26 . . . . 0.0 111.076 175.346 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.46 -16.12 62.35 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 123.492 0.717 . . . . 0.0 110.904 176.395 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -80.61 5.33 15.78 Favored 'General case' 0 CA--C 1.555 1.157 0 C-N-CA 123.763 0.825 . . . . 0.0 111.581 173.16 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.93 -0.74 73.36 Favored Glycine 0 C--N 1.353 1.482 0 C-N-CA 123.117 0.389 . . . . 0.0 113.15 176.41 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.43 ' HB3' HG11 ' A' ' 28' ' ' VAL . 95.7 m-85 -86.15 165.61 16.43 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 123.392 0.677 . . . . 0.0 110.48 179.355 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 33.5 p -122.82 81.2 49.38 Favored Pre-proline 0 CA--C 1.559 1.326 0 C-N-CA 123.174 0.59 . . . . 0.0 111.619 -176.404 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.602 ' HG3' HG23 ' A' ' 77' ' ' ILE . 43.0 Cg_endo -88.27 171.95 5.27 Favored 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.901 2.401 . . . . 0.0 112.178 169.816 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 . . . . . 0 C--O 1.246 0.891 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 176.452 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.14 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.0 107.48 12.82 Favored 'General case' 0 CA--C 1.548 0.883 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 179.24 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 24.9 p -93.37 111.97 23.77 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 123.606 0.762 . . . . 0.0 111.42 -173.269 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -99.68 141.23 32.76 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 175.337 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 65.8 m80 -115.46 100.7 8.28 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -175.041 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.508 HG21 ' HB3' ' A' ' 82' ' ' TYR . 2.7 p -113.41 97.78 6.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 C-N-CA 124.19 0.996 . . . . 0.0 109.753 -178.658 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -70.71 -17.8 62.81 Favored 'General case' 0 CA--C 1.551 0.989 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.966 176.676 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.37 -12.4 60.81 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 123.889 0.876 . . . . 0.0 111.384 176.574 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.485 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 60.0 ttp -80.19 98.98 7.57 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 173.749 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 30.4 p -94.18 102.67 14.71 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.213 0.605 . . . . 0.0 110.159 178.216 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 14.7 p 66.67 178.32 0.22 Allowed 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 126.567 1.947 . . . . 0.0 113.153 175.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.409 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -60.95 -22.79 60.66 Favored Glycine 0 C--N 1.359 1.82 0 CA-C-N 115.118 -0.946 . . . . 0.0 113.973 -178.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 13.0 t-160 -60.61 -42.76 97.47 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 123.894 0.878 . . . . 0.0 111.013 175.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 81.1 m -87.93 -21.59 24.82 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 123.032 0.533 . . . . 0.0 111.256 178.927 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.458 ' HA ' ' SD ' ' A' ' 31' ' ' MET . . . -66.02 -46.88 76.32 Favored 'General case' 0 C--N 1.349 0.546 0 C-N-CA 123.318 0.647 . . . . 0.0 111.01 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.82 -29.29 73.6 Favored Glycine 0 C--N 1.349 1.303 0 O-C-N 124.052 0.845 . . . . 0.0 113.546 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 58.3 t -63.29 -44.85 99.34 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.634 0.774 . . . . 0.0 110.087 175.659 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.626 HG21 HG21 ' A' ' 62' ' ' VAL . 62.6 mt -70.4 -39.33 76.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.852 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.427 ' HG3' ' O ' ' A' ' 37' ' ' ALA . 96.3 mttt -59.12 -49.84 76.33 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 123.125 0.57 . . . . 0.0 110.087 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.77 -38.66 96.86 Favored Glycine 0 C--N 1.344 0.974 0 O-C-N 124.28 0.987 . . . . 0.0 112.522 178.173 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.35 -55.06 31.65 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.63 0.772 . . . . 0.0 111.822 -176.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.506 ' HA ' HG21 ' A' ' 76' ' ' ILE . 69.7 mt -70.15 -55.71 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 123.241 0.616 . . . . 0.0 111.247 -178.46 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -60.1 -40.88 91.17 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 123.767 0.827 . . . . 0.0 112.791 -169.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -74.23 -30.91 62.38 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 122.45 0.3 . . . . 0.0 111.642 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 91.7 m -72.9 -42.63 63.36 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 121.053 0.454 . . . . 0.0 110.257 176.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.0 m -131.48 87.54 46.33 Favored Pre-proline 0 CA--C 1.553 1.074 0 C-N-CA 123.618 0.767 . . . . 0.0 110.52 -178.329 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -57.76 138.09 84.37 Favored 'Trans proline' 0 C--N 1.38 2.186 0 C-N-CA 122.6 2.2 . . . . 0.0 111.345 171.288 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 108.75 -23.87 23.05 Favored Glycine 0 N--CA 1.467 0.721 0 O-C-N 123.403 0.44 . . . . 0.0 112.02 -175.227 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -76.79 107.21 8.95 Favored 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 173.632 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.8 99.43 8.27 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.264 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.493 HG12 HG12 ' A' ' 64' ' ' VAL . 23.4 m -86.32 128.58 39.32 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 C-N-CA 123.199 0.6 . . . . 0.0 111.191 -171.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' HIS . . . . . 0.434 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 18.7 t60 -127.85 98.22 5.09 Favored 'General case' 0 C--O 1.223 -0.304 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 175.126 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.485 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -100.73 112.82 25.29 Favored 'General case' 0 C--O 1.241 0.643 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.357 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -102.72 114.73 65.14 Favored Pre-proline 0 CA--C 1.538 0.519 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -170.269 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -62.14 -34.4 79.34 Favored 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 122.812 2.341 . . . . 0.0 113.213 -178.448 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.04 -46.1 30.95 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.166 0.586 . . . . 0.0 111.295 -175.525 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.5 t -89.23 -16.75 30.53 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.404 0.682 . . . . 0.0 111.739 -175.684 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.7 mpt_? 61.57 39.85 14.2 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.331 1.052 . . . . 0.0 111.029 -176.643 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 50.0 m -126.26 118.89 26.06 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 122.75 0.42 . . . . 0.0 111.289 -172.712 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.626 HG21 HG21 ' A' ' 40' ' ' ILE . 38.7 t -100.0 105.71 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 123.728 0.811 . . . . 0.0 109.434 173.288 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 20.8 t -100.19 127.65 52.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 C-N-CA 123.791 0.836 . . . . 0.0 109.02 -178.813 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.496 HG21 HG13 ' A' ' 73' ' ' ILE . 17.4 m -111.2 109.95 30.41 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.656 0.741 . . . . 0.0 109.95 178.115 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -88.62 153.88 24.42 Favored Glycine 0 C--N 1.346 1.097 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.976 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.47 -14.55 45.58 Favored Glycine 0 N--CA 1.472 1.068 0 C-N-CA 122.888 0.28 . . . . 0.0 113.236 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.7 m -130.87 135.76 59.48 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.75 0 C-N-CA 124.457 1.103 . . . . 0.0 109.156 179.404 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 51.0 m -116.41 17.75 15.39 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.359 0.664 . . . . 0.0 109.913 176.012 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -80.25 77.05 7.02 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.292 1.037 . . . . 0.0 109.574 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.8 -42.96 94.59 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.496 0.718 . . . . 0.0 111.622 -175.557 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.421 ' O ' ' HG3' ' A' ' 75' ' ' GLU . . . -62.63 -46.08 89.9 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.941 0.897 . . . . 0.0 111.289 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 11.6 m170 -62.04 -54.75 37.08 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.666 0.787 . . . . 0.0 110.442 -176.635 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.496 HG13 HG21 ' A' ' 64' ' ' VAL . 45.3 mm -64.01 -40.0 87.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.319 -175.124 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.7 -39.6 89.12 Favored 'General case' 0 N--CA 1.476 0.875 0 O-C-N 123.966 0.792 . . . . 0.0 111.18 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.421 ' HG3' ' O ' ' A' ' 71' ' ' ALA . 46.3 mt-10 -61.98 -39.19 91.34 Favored 'General case' 0 N--CA 1.479 1.021 0 O-C-N 123.803 0.689 . . . . 0.0 111.16 176.28 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.506 HG21 ' HA ' ' A' ' 44' ' ' ILE . 62.4 mt -68.77 -51.9 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 O-C-N 123.636 0.585 . . . . 0.0 111.259 -176.75 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.513 HD13 ' HB3' ' A' ' 84' ' ' PRO . 6.3 tt -68.61 -31.77 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.27 0 C-N-CA 123.075 0.55 . . . . 0.0 111.569 -176.398 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -74.8 -30.78 61.53 Favored 'General case' 0 N--CA 1.483 1.183 0 O-C-N 122.202 -0.311 . . . . 0.0 110.426 176.42 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.09 -22.9 61.28 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 123.069 0.548 . . . . 0.0 110.296 172.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.31 -16.75 60.4 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 123.801 0.84 . . . . 0.0 111.832 174.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.34 22.53 12.68 Favored Glycine 0 C--N 1.348 1.223 0 O-C-N 123.405 0.44 . . . . 0.0 113.141 178.799 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.508 ' HB3' HG21 ' A' ' 28' ' ' VAL . 80.1 m-85 -128.56 133.29 48.33 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 123.913 0.885 . . . . 0.0 110.024 179.034 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 27.7 p -89.58 107.79 20.94 Favored Pre-proline 0 CA--C 1.552 1.036 0 C-N-CA 123.593 0.757 . . . . 0.0 110.605 -179.78 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.513 ' HB3' HD13 ' A' ' 77' ' ' ILE . 64.3 Cg_endo -78.33 -8.11 16.16 Favored 'Trans proline' 0 C--N 1.376 1.975 0 C-N-CA 122.748 2.299 . . . . 0.0 113.622 178.875 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 . . . . . 0 C--O 1.248 1.001 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 -173.378 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.862 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.455 HD12 HG23 ' A' ' 67' ' ' VAL . 37.3 mt -93.08 111.47 23.11 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 124.196 0.998 . . . . 0.0 110.359 -175.279 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 29.1 m -94.38 115.77 28.03 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.011 0.524 . . . . 0.0 111.054 -175.215 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -107.91 116.44 31.95 Favored 'General case' 0 N--CA 1.484 1.264 0 C-N-CA 123.959 0.904 . . . . 0.0 109.79 177.803 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 22.9 m170 -82.17 90.34 6.57 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.834 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.498 ' HA ' ' HA ' ' A' ' 84' ' ' PRO . 10.6 t -85.3 92.56 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -178.262 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -68.82 -19.26 64.27 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 123.904 0.882 . . . . 0.0 112.144 -172.093 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -89.15 -8.1 54.37 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.872 0.869 . . . . 0.0 111.917 178.287 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 26.4 ttt -75.15 126.52 31.19 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.804 0.841 . . . . 0.0 112.557 -173.051 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.8 t -108.49 97.91 7.51 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 164.014 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.541 ' SG ' ' HA ' ' A' ' 57' ' ' PRO . 81.5 m -46.52 -64.07 0.85 Allowed 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 125.543 1.537 . . . . 0.0 114.267 -167.421 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.56 -25.2 75.07 Favored Glycine 0 CA--C 1.532 1.142 0 N-CA-C 114.013 0.365 . . . . 0.0 114.013 -175.315 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 15.4 m-70 -93.99 -7.59 42.38 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 123.253 0.621 . . . . 0.0 112.109 -177.336 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 42.1 t -133.19 9.44 4.09 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.116 0.566 . . . . 0.0 111.099 -175.718 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -56.55 -53.61 55.55 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 123.838 0.855 . . . . 0.0 113.117 -169.721 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.99 -40.45 98.24 Favored Glycine 0 C--N 1.344 0.979 0 O-C-N 123.36 0.413 . . . . 0.0 114.121 -173.603 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.7 p -76.92 -42.51 32.62 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 C-N-CA 123.111 0.564 . . . . 0.0 112.221 -176.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 12.3 tt -73.22 -37.02 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 122.495 0.318 . . . . 0.0 110.809 -174.814 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.52 -43.47 55.75 Favored 'General case' 0 C--N 1.35 0.622 0 C-N-CA 123.136 0.575 . . . . 0.0 109.661 175.348 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.87 -30.58 78.1 Favored Glycine 0 C--N 1.351 1.393 0 O-C-N 124.494 1.121 . . . . 0.0 113.531 -177.582 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -61.28 -54.26 46.3 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 123.469 0.708 . . . . 0.0 110.591 177.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.521 ' HA ' HG21 ' A' ' 76' ' ' ILE . 59.0 mt -72.61 -46.81 53.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.163 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -58.54 -50.81 72.44 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 124.034 0.934 . . . . 0.0 112.26 -174.749 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -77.07 -20.7 55.47 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 119.42 -0.324 . . . . 0.0 111.505 -172.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 85.2 m -79.22 -45.76 19.19 Favored 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 174.362 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 15.8 m -126.74 81.59 68.7 Favored Pre-proline 0 CA--C 1.555 1.168 0 C-N-CA 123.598 0.759 . . . . 0.0 110.01 178.762 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -60.26 121.45 9.8 Favored 'Trans proline' 0 C--N 1.383 2.385 0 C-N-CA 122.995 2.463 . . . . 0.0 112.144 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.78 -11.57 10.16 Favored Glycine 0 C--N 1.345 1.075 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.704 -176.669 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -72.32 107.41 4.91 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 176.07 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -77.15 100.15 5.65 Favored 'General case' 0 C--N 1.348 0.507 0 C-N-CA 123.111 0.564 . . . . 0.0 109.856 -176.788 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.483 HG12 HG12 ' A' ' 64' ' ' VAL . 33.5 m -85.2 137.37 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 123.386 0.674 . . . . 0.0 109.949 -173.63 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' HIS . . . . . 0.487 ' HB2' ' HB ' ' A' ' 63' ' ' VAL . 78.7 m80 -130.37 101.78 5.9 Favored 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -178.643 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.26 120.87 34.04 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.672 0.789 . . . . 0.0 109.958 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -111.07 103.49 54.94 Favored Pre-proline 0 CA--C 1.55 0.959 0 CA-C-O 118.54 -0.743 . . . . 0.0 109.609 -178.144 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.541 ' HA ' ' SG ' ' A' ' 33' ' ' CYS . 38.0 Cg_exo -39.74 -44.82 3.5 Favored 'Trans proline' 0 C--N 1.376 2.003 0 C-N-CA 124.539 3.493 . . . . 0.0 115.88 172.178 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.24 -46.53 22.86 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 122.715 0.406 . . . . 0.0 111.525 -175.199 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.9 t -91.8 -7.01 50.74 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.359 0.664 . . . . 0.0 111.91 -173.383 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 40.91 45.65 2.22 Favored 'General case' 0 N--CA 1.505 2.28 0 C-N-CA 126.248 1.819 . . . . 0.0 112.197 -173.927 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.8 m -112.81 134.2 54.44 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.342 -175.286 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 51.4 t -103.38 105.57 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 168.243 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.487 ' HB ' ' HB2' ' A' ' 54' ' ' HIS . 14.4 t -94.47 119.93 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 175.571 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.517 HG11 HG21 ' A' ' 44' ' ' ILE . 15.7 m -106.29 116.96 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 CA-C-O 121.296 0.57 . . . . 0.0 110.5 -179.325 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.26 152.59 20.47 Favored Glycine 0 C--N 1.347 1.178 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.309 -175.909 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.04 -26.97 14.28 Favored Glycine 0 N--CA 1.471 0.989 0 C-N-CA 123.304 0.478 . . . . 0.0 112.883 177.848 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.455 HG23 HD12 ' A' ' 24' ' ' LEU . 28.4 m -101.98 155.16 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 124.412 1.085 . . . . 0.0 110.372 -176.035 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.1 m -135.7 23.59 3.38 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.78 0.832 . . . . 0.0 110.292 -177.338 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -119.53 71.54 0.88 Allowed 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 124.388 1.075 . . . . 0.0 109.697 -176.073 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.91 -34.94 75.45 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 115.049 -0.978 . . . . 0.0 112.561 -174.181 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.461 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.36 -43.74 96.79 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.271 0.629 . . . . 0.0 110.632 178.076 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.409 ' O ' HG13 ' A' ' 76' ' ' ILE . 14.9 m-70 -67.16 -43.97 80.91 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 123.467 0.707 . . . . 0.0 111.061 -177.41 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.409 HG21 HG21 ' A' ' 64' ' ' VAL . 45.4 mm -62.38 -40.64 88.7 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 O-C-N 123.739 0.649 . . . . 0.0 110.105 179.097 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.44 -38.17 86.2 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.811 178.201 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.461 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 45.3 mm-40 -62.53 -40.0 95.36 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.773 0.829 . . . . 0.0 111.204 176.773 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.521 HG21 ' HA ' ' A' ' 44' ' ' ILE . 73.4 mt -66.36 -54.89 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 123.717 0.636 . . . . 0.0 110.8 -176.837 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 12.6 tt -66.94 -34.48 70.23 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.643 -173.206 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 7.7 t -74.5 -30.3 61.76 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 110.526 -0.175 . . . . 0.0 110.526 177.67 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.73 -24.41 61.78 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 123.522 0.729 . . . . 0.0 110.826 175.292 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -71.72 -19.15 62.09 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 123.523 0.729 . . . . 0.0 111.142 172.893 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 101.6 16.65 23.82 Favored Glycine 0 C--N 1.348 1.242 0 CA-C-N 115.857 -0.61 . . . . 0.0 112.457 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -122.63 103.63 8.8 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.031 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.405 ' HA ' ' HD3' ' A' ' 84' ' ' PRO . 4.3 t -80.03 125.24 82.18 Favored Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.387 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.498 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 24.0 Cg_exo -63.95 -76.51 0.02 OUTLIER 'Trans proline' 0 C--N 1.38 2.195 0 C-N-CA 122.539 2.159 . . . . 0.0 112.912 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 . . . . . 0 C--O 1.252 1.21 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -170.385 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.718 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.43 HD13 ' HA ' ' A' ' 70' ' ' ALA . 47.9 mt -84.68 110.04 18.46 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.153 0.981 . . . . 0.0 110.752 -178.133 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.8 p -90.8 111.13 22.39 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 123.36 0.664 . . . . 0.0 111.952 -174.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -108.61 114.77 28.86 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 123.858 0.863 . . . . 0.0 109.998 177.399 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 11.5 m-70 -82.93 136.2 34.65 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 123.052 0.541 . . . . 0.0 109.782 178.29 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.597 HG22 ' HA ' ' A' ' 84' ' ' PRO . 85.2 t -139.83 97.14 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 172.092 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.79 -6.25 43.53 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -175.847 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -88.69 -19.37 26.23 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.343 0.657 . . . . 0.0 110.732 176.66 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.579 ' SD ' HG21 ' A' ' 40' ' ' ILE . 53.8 ttp -68.33 97.33 0.73 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 122.996 0.518 . . . . 0.0 109.811 178.771 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 25.9 p -82.44 94.05 7.35 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 179.212 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.405 ' SG ' ' HB3' ' A' ' 57' ' ' PRO . 58.6 m 41.5 -139.29 0.13 Allowed 'General case' 0 CA--C 1.568 1.642 0 C-N-CA 125.831 1.652 . . . . 0.0 113.213 173.357 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.52 -22.23 65.56 Favored Glycine 0 C--N 1.362 1.994 0 N-CA-C 114.638 0.615 . . . . 0.0 114.638 -178.678 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 30.0 t-80 -59.09 -35.95 74.3 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 123.614 0.766 . . . . 0.0 111.937 178.459 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 62.4 m -112.51 -14.51 13.21 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 122.894 0.478 . . . . 0.0 111.755 -178.42 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -60.5 -41.86 95.19 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -172.17 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.05 -48.55 82.52 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 113.806 0.283 . . . . 0.0 113.806 -174.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.3 p -75.58 -39.71 40.29 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.143 0 C-N-CA 123.557 0.743 . . . . 0.0 112.108 -177.36 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.579 HG21 ' SD ' ' A' ' 31' ' ' MET . 13.5 tt -67.17 -39.31 82.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 122.832 0.453 . . . . 0.0 111.124 -176.165 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.55 ' HB3' HG21 ' A' ' 53' ' ' VAL . 9.2 mtmp? -75.81 -44.32 41.81 Favored 'General case' 0 C--N 1.348 0.526 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.423 176.17 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.22 -30.21 63.94 Favored Glycine 0 C--N 1.357 1.717 0 O-C-N 124.786 1.304 . . . . 0.0 113.678 -175.753 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.66 -52.08 65.07 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.423 0.689 . . . . 0.0 110.509 172.141 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.561 HG21 HG11 ' A' ' 64' ' ' VAL . 57.8 mt -72.2 -40.55 66.06 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.566 -178.153 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -63.2 -50.45 70.22 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.647 0.779 . . . . 0.0 112.383 -175.9 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -71.94 -31.34 66.23 Favored 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.079 -174.831 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 46.7 m -76.07 -42.45 47.38 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.924 0.49 . . . . 0.0 110.37 176.424 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 41.2 t -125.0 93.06 46.47 Favored Pre-proline 0 N--CA 1.48 1.028 0 C-N-CA 123.77 0.828 . . . . 0.0 109.636 -173.636 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -68.02 113.29 2.98 Favored 'Trans proline' 0 C--N 1.371 1.762 0 C-N-CA 122.492 2.128 . . . . 0.0 110.113 170.677 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.18 -9.25 10.27 Favored Glycine 0 C--N 1.344 0.984 0 CA-C-O 119.525 -0.597 . . . . 0.0 113.411 -176.196 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -82.81 105.52 13.89 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 170.053 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.53 101.51 10.77 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 123.392 0.677 . . . . 0.0 109.807 -176.454 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' VAL . . . . . 0.55 HG21 ' HB3' ' A' ' 41' ' ' LYS . 20.8 m -84.29 135.75 24.19 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 C-N-CA 123.634 0.774 . . . . 0.0 110.969 -171.149 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 76.3 m80 -134.18 94.95 3.32 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.233 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.01 117.08 29.48 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.463 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -95.51 124.73 52.17 Favored Pre-proline 0 CA--C 1.543 0.676 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -179.45 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.405 ' HB3' ' SG ' ' A' ' 33' ' ' CYS . 51.6 Cg_exo -57.91 -47.43 20.74 Favored 'Trans proline' 0 C--N 1.373 1.825 0 C-N-CA 122.962 2.442 . . . . 0.0 113.192 177.127 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.3 -53.17 8.6 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 123.168 0.587 . . . . 0.0 111.85 -173.109 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.0 t -80.1 -13.16 59.5 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.864 0.866 . . . . 0.0 111.765 -175.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 25.7 mmt180 65.78 23.57 11.46 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.482 1.113 . . . . 0.0 112.478 174.243 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 40.0 m -109.73 126.61 53.9 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 122.63 0.372 . . . . 0.0 111.77 -169.411 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 45.8 t -98.15 105.47 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 123.955 0.902 . . . . 0.0 108.634 170.592 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 15.4 t -95.53 119.55 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 123.829 0.852 . . . . 0.0 109.209 179.802 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.568 HG21 HG21 ' A' ' 73' ' ' ILE . 28.1 m -103.2 109.7 27.66 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 123.571 0.749 . . . . 0.0 110.457 179.277 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -94.22 150.08 19.65 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.399 -177.13 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.2 -25.11 27.18 Favored Glycine 0 C--N 1.343 0.953 0 CA-C-O 120.194 -0.226 . . . . 0.0 112.547 177.881 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.4 m -103.17 148.81 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 123.991 0.917 . . . . 0.0 109.785 178.303 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.6 t -123.2 1.24 9.11 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 123.366 0.667 . . . . 0.0 111.034 -174.461 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -102.66 83.68 2.3 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 124.353 1.061 . . . . 0.0 110.341 -174.713 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.43 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -64.89 -36.7 85.22 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 114.307 -1.315 . . . . 0.0 112.8 -172.832 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.471 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -64.93 -44.31 89.93 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.04 0.536 . . . . 0.0 110.797 -177.844 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.405 ' O ' HG13 ' A' ' 76' ' ' ILE . 78.9 m-70 -62.03 -49.45 75.95 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 123.658 0.599 . . . . 0.0 110.925 179.156 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.568 HG21 HG21 ' A' ' 64' ' ' VAL . 42.7 mm -59.77 -40.28 82.09 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 O-C-N 123.875 0.734 . . . . 0.0 110.227 -179.699 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.93 -36.01 82.01 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.737 0.815 . . . . 0.0 111.11 178.361 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.471 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 26.5 mm-40 -69.05 -35.94 77.14 Favored 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 123.294 0.638 . . . . 0.0 111.395 178.053 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.423 HD12 ' HA ' ' A' ' 73' ' ' ILE . 74.7 mt -68.42 -53.05 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 123.464 0.705 . . . . 0.0 110.578 -178.632 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 13.6 tt -66.05 -35.71 75.7 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.984 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.361 -175.6 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.8 t -75.15 -30.09 60.66 Favored 'General case' 0 N--CA 1.479 0.999 0 C-N-CA 122.471 0.308 . . . . 0.0 110.887 178.295 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.8 -19.73 60.67 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 123.369 0.668 . . . . 0.0 110.945 175.856 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -78.15 -9.73 59.31 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.745 0.818 . . . . 0.0 111.473 172.627 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 102.47 -11.45 56.66 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-O 119.717 -0.491 . . . . 0.0 112.951 179.343 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -92.86 105.93 17.98 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.442 0.697 . . . . 0.0 110.192 178.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 90.6 m -68.89 117.39 50.9 Favored Pre-proline 0 CA--C 1.552 1.023 0 C-N-CA 123.142 0.577 . . . . 0.0 109.647 176.135 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.597 ' HA ' HG22 ' A' ' 28' ' ' VAL . 48.0 Cg_endo -67.16 87.48 0.31 Allowed 'Trans proline' 0 C--N 1.382 2.293 0 C-N-CA 122.437 2.091 . . . . 0.0 111.489 174.606 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.5 tp10 . . . . . 0 C--O 1.249 1.029 0 C-N-CA 124.672 1.189 . . . . 0.0 108.697 179.181 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.128 0 CA-C-O 120.95 0.405 . . . . 0.0 110.767 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -141.95 107.31 0.49 Allowed Glycine 0 C--N 1.34 0.777 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 177.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.476 HD11 ' HB2' ' A' ' 70' ' ' ALA . 4.3 mm? -79.4 164.29 24.12 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.324 0.65 . . . . 0.0 111.023 -176.608 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 29.5 p -152.47 110.67 3.69 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 123.803 0.841 . . . . 0.0 108.82 178.283 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -110.35 116.44 31.45 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 123.702 0.801 . . . . 0.0 109.357 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 26.4 p80 -82.11 90.69 6.57 Favored 'General case' 0 CA--C 1.552 1.056 0 CA-C-O 122.615 1.198 . . . . 0.0 110.384 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.451 HG21 HD11 ' A' ' 77' ' ' ILE . 39.7 t -84.21 87.37 2.26 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 172.743 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.13 -5.67 43.12 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-N 115.646 -0.707 . . . . 0.0 112.758 -173.434 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -86.55 -22.11 26.51 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.35 0.66 . . . . 0.0 110.672 173.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.636 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 50.4 ttp -65.09 109.19 2.08 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 123.489 0.716 . . . . 0.0 111.453 -174.603 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 25.5 p -117.52 128.3 54.83 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.106 0.962 . . . . 0.0 109.434 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.403 ' SG ' ' HB2' ' A' ' 35' ' ' HIS . 8.8 p 65.68 159.36 0.12 Allowed 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 126.034 1.733 . . . . 0.0 113.718 176.729 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.521 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -67.44 -9.08 54.2 Favored Glycine 0 C--N 1.353 1.481 0 CA-C-N 115.104 -0.953 . . . . 0.0 114.306 -178.65 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' HIS . . . . . 0.403 ' HB2' ' SG ' ' A' ' 33' ' ' CYS . 29.4 m170 -71.15 -44.43 65.55 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 117.482 0.641 . . . . 0.0 110.216 173.165 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 59.0 m -83.82 -32.47 25.28 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.234 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.521 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -70.05 -34.77 73.66 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.009 176.429 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.04 -44.96 96.55 Favored Glycine 0 C--N 1.347 1.192 0 O-C-N 124.039 0.837 . . . . 0.0 113.472 -176.177 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.5 p -68.16 -30.03 46.53 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.064 0 C-N-CA 122.698 0.399 . . . . 0.0 111.384 -178.342 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.587 HG21 HG21 ' A' ' 62' ' ' VAL . 66.4 mt -66.39 -47.79 82.9 Favored 'Isoleucine or valine' 0 C--N 1.356 0.864 0 C-N-CA 123.149 0.58 . . . . 0.0 110.013 175.086 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 60.5 mtpt -57.43 -48.17 79.83 Favored 'General case' 0 C--N 1.349 0.566 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.224 178.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.93 -34.06 87.45 Favored Glycine 0 C--N 1.346 1.106 0 O-C-N 124.246 0.966 . . . . 0.0 112.966 -178.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.44 -54.76 35.37 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.072 0.549 . . . . 0.0 110.849 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.54 HG21 HG11 ' A' ' 64' ' ' VAL . 58.3 mt -72.45 -43.7 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 CA-C-N 115.672 -0.694 . . . . 0.0 112.127 -176.003 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -64.79 -38.02 89.58 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 124.219 1.008 . . . . 0.0 112.67 -174.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -76.03 -37.02 58.86 Favored 'General case' 0 N--CA 1.481 1.114 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.212 -179.483 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 42.7 m -71.12 -40.15 71.6 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 123.011 0.524 . . . . 0.0 110.63 177.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 48.2 t -121.39 94.54 48.64 Favored Pre-proline 0 N--CA 1.48 1.051 0 C-N-CA 123.58 0.752 . . . . 0.0 109.931 -177.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -62.25 104.29 0.34 Allowed 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.563 2.175 . . . . 0.0 111.174 169.172 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.56 -0.15 11.18 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-O 119.593 -0.559 . . . . 0.0 113.291 -177.444 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -83.96 108.71 17.1 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 169.212 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.404 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -78.49 95.97 5.29 Favored 'General case' 0 C--N 1.348 0.543 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 -178.679 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.529 HG12 HG12 ' A' ' 64' ' ' VAL . 27.7 m -88.95 131.49 36.15 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.754 0 C-N-CA 123.701 0.8 . . . . 0.0 111.027 -171.118 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' HIS . . . . . 0.406 ' HB3' HG22 ' A' ' 63' ' ' VAL . 3.5 t-160 -143.22 99.92 3.53 Favored 'General case' 0 C--N 1.346 0.421 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 167.356 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.636 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -92.51 113.75 26.11 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 172.079 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -106.9 120.49 47.95 Favored Pre-proline 0 N--CA 1.467 0.394 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -172.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -63.11 -35.31 65.44 Favored 'Trans proline' 0 C--N 1.37 1.698 0 C-N-CA 122.73 2.287 . . . . 0.0 113.493 -179.649 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.52 -35.2 46.62 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 123.272 0.629 . . . . 0.0 112.148 -174.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.2 t -91.43 -19.61 22.67 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 123.18 0.592 . . . . 0.0 110.225 178.304 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.1 mpt_? 60.79 33.82 19.96 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 125.034 1.334 . . . . 0.0 110.824 -177.243 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 27.3 m -124.69 131.52 53.46 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 122.677 0.391 . . . . 0.0 110.683 -170.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.587 HG21 HG21 ' A' ' 40' ' ' ILE . 44.0 t -105.87 105.57 18.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 173.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.406 HG22 ' HB3' ' A' ' 54' ' ' HIS . 34.3 m -99.71 136.12 32.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.284 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.54 HG11 HG21 ' A' ' 44' ' ' ILE . 17.3 m -131.0 109.36 16.45 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.909 0 C-N-CA 123.399 0.68 . . . . 0.0 109.434 179.22 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -92.79 157.74 23.76 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.474 -176.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.21 0.43 89.53 Favored Glycine 0 C--N 1.345 1.049 0 CA-C-O 119.932 -0.371 . . . . 0.0 114.023 177.176 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.4 m -124.14 144.7 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.625 0.77 . . . . 0.0 110.147 -176.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 14.9 m -108.86 -17.71 13.87 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.599 0.759 . . . . 0.0 110.225 176.226 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.445 ' O ' HG12 ' A' ' 73' ' ' ILE . 6.5 m-20 -78.77 76.54 5.26 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.347 1.059 . . . . 0.0 111.035 -172.699 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.476 ' HB2' HD11 ' A' ' 24' ' ' LEU . . . -60.59 -41.5 94.83 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.108 0.963 . . . . 0.0 111.602 -179.635 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -65.54 -41.47 92.99 Favored 'General case' 0 N--CA 1.471 0.581 0 O-C-N 124.206 0.942 . . . . 0.0 111.044 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.417 ' O ' HG13 ' A' ' 76' ' ' ILE . 77.8 t60 -63.28 -50.69 69.12 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.501 0.72 . . . . 0.0 110.741 178.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.537 HG21 HG21 ' A' ' 64' ' ' VAL . 40.7 mm -58.57 -42.3 84.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 O-C-N 123.826 0.704 . . . . 0.0 110.142 179.411 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.61 -37.97 80.04 Favored 'General case' 0 N--CA 1.476 0.836 0 O-C-N 124.329 1.018 . . . . 0.0 111.648 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 12.3 mm-40 -64.67 -40.14 94.91 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.479 0.712 . . . . 0.0 111.166 177.516 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.511 HG21 ' HA ' ' A' ' 44' ' ' ILE . 33.9 mt -67.19 -51.54 52.36 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 C-N-CA 123.149 0.58 . . . . 0.0 111.356 -177.144 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.451 HD11 HG21 ' A' ' 28' ' ' VAL . 8.3 tt -71.08 -29.88 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.234 0 C-N-CA 123.379 0.671 . . . . 0.0 111.836 -176.005 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.464 ' HA ' ' O ' ' A' ' 82' ' ' TYR . 2.9 t -75.25 -28.9 60.03 Favored 'General case' 0 N--CA 1.48 1.054 0 N-CA-C 110.364 -0.236 . . . . 0.0 110.364 175.079 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.32 -26.17 66.38 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.355 0.662 . . . . 0.0 110.644 172.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -76.76 -8.72 57.84 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 123.377 0.671 . . . . 0.0 111.455 173.323 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.3 25.05 24.95 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 116.561 -0.291 . . . . 0.0 113.208 176.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.464 ' O ' ' HA ' ' A' ' 78' ' ' THR . 95.9 m-85 -120.43 155.06 34.27 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.526 0.73 . . . . 0.0 110.236 179.379 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 73.1 p -89.79 111.14 44.48 Favored Pre-proline 0 CA--C 1.553 1.086 0 C-N-CA 123.271 0.628 . . . . 0.0 110.415 -176.555 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -78.89 79.5 3.36 Favored 'Trans proline' 0 C--N 1.377 2.043 0 C-N-CA 122.906 2.404 . . . . 0.0 111.878 178.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 35.0 mm-40 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.794 -0.622 . . . . 0.0 109.844 -176.661 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.105 0 N-CA-C 110.389 -0.226 . . . . 0.0 110.389 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.72 -156.1 24.59 Favored Glycine 0 C--N 1.348 1.22 0 O-C-N 123.716 0.635 . . . . 0.0 111.706 173.259 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -82.34 109.61 16.75 Favored 'General case' 0 CA--C 1.548 0.895 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.7 m -92.51 118.6 31.14 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 123.79 0.836 . . . . 0.0 110.748 -172.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -106.29 110.76 23.1 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.781 0.832 . . . . 0.0 109.939 178.773 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -81.82 94.38 7.04 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 177.078 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.499 ' O ' ' HB3' ' A' ' 60' ' ' ARG . 20.0 t -93.51 94.38 4.61 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.798 0 C-N-CA 124.356 1.062 . . . . 0.0 108.397 178.451 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -71.68 -12.72 61.47 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -175.003 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -85.5 -19.0 31.86 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 123.812 0.845 . . . . 0.0 110.951 174.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 25.2 ttt -55.33 128.64 35.11 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 124.334 1.054 . . . . 0.0 112.266 -175.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.3 p -88.47 162.18 16.61 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 124.438 1.095 . . . . 0.0 110.087 172.595 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 57.3 m -66.56 -162.75 0.02 OUTLIER 'General case' 0 CA--C 1.564 1.505 0 C-N-CA 124.986 1.314 . . . . 0.0 114.035 -169.697 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -56.69 -22.73 41.18 Favored Glycine 0 C--N 1.364 2.094 0 N-CA-C 115.722 1.049 . . . . 0.0 115.722 -171.732 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 48.9 t-80 -64.63 -28.77 69.84 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.777 0.831 . . . . 0.0 111.882 177.375 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 61.3 m -119.2 19.26 12.9 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.985 0.914 . . . . 0.0 111.26 179.367 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.37 -34.36 70.37 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 122.583 0.353 . . . . 0.0 111.047 177.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.08 -35.93 91.23 Favored Glycine 0 C--N 1.349 1.279 0 O-C-N 123.929 0.768 . . . . 0.0 114.779 -173.295 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.84 -38.71 76.48 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 123.102 0.561 . . . . 0.0 111.025 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 35.3 mt -73.09 -42.36 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.454 0.702 . . . . 0.0 110.242 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -55.5 -54.08 48.32 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.121 171.135 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.05 -30.56 78.11 Favored Glycine 0 C--N 1.345 1.032 0 O-C-N 124.788 1.305 . . . . 0.0 113.767 -172.292 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.6 -56.69 18.85 Favored 'General case' 0 C--N 1.352 0.7 0 C-N-CA 122.899 0.479 . . . . 0.0 110.629 178.059 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.521 ' HA ' HG21 ' A' ' 76' ' ' ILE . 57.7 mt -76.03 -42.35 38.65 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.693 -174.666 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -62.29 -48.28 80.57 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.1 0.96 . . . . 0.0 112.255 -173.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -73.4 -25.69 60.65 Favored 'General case' 0 N--CA 1.48 1.075 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.43 -176.118 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 43.0 m -80.63 -41.84 23.18 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 123.022 0.529 . . . . 0.0 110.576 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.9 t -123.3 94.84 46.3 Favored Pre-proline 0 N--CA 1.479 1.01 0 C-N-CA 123.584 0.754 . . . . 0.0 109.378 -178.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -67.07 118.4 5.54 Favored 'Trans proline' 0 C--N 1.373 1.863 0 C-N-CA 122.579 2.186 . . . . 0.0 110.899 172.089 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.82 -25.48 7.17 Favored Glycine 0 C--N 1.347 1.141 0 CA-C-O 119.795 -0.447 . . . . 0.0 112.511 -174.338 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -73.81 106.17 5.42 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 174.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -79.8 99.91 7.72 Favored 'General case' 0 C--N 1.346 0.45 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -177.093 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.435 HG12 HG12 ' A' ' 64' ' ' VAL . 16.6 m -86.51 111.86 22.02 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.937 0 CA-C-O 121.539 0.685 . . . . 0.0 111.156 -169.846 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 64.9 t60 -109.22 99.24 8.54 Favored 'General case' 0 C--N 1.344 0.348 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.77 115.44 22.22 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 175.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -106.88 102.72 43.99 Favored Pre-proline 0 N--CA 1.474 0.739 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -56.26 -39.81 88.84 Favored 'Trans proline' 0 C--N 1.373 1.837 0 C-N-CA 123.084 2.522 . . . . 0.0 113.746 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.44 -44.62 64.49 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 123.383 0.673 . . . . 0.0 111.978 -171.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 21.1 t -95.39 -9.94 31.38 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.855 0.862 . . . . 0.0 110.606 -178.404 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.499 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 60.59 41.5 15.34 Favored 'General case' 0 N--CA 1.484 1.266 0 C-N-CA 125.266 1.426 . . . . 0.0 110.165 -179.319 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.5 m -123.13 120.44 33.25 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.642 0.377 . . . . 0.0 111.285 -167.368 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.6 t -98.97 105.38 17.29 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 175.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.2 t -102.5 118.79 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 -175.349 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.505 HG11 HG21 ' A' ' 44' ' ' ILE . 17.1 m -103.86 108.94 25.74 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.068 0 CA-C-O 121.581 0.705 . . . . 0.0 110.707 -178.136 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -85.59 149.38 23.49 Favored Glycine 0 C--N 1.35 1.312 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.412 -179.759 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.69 -26.03 13.91 Favored Glycine 0 N--CA 1.472 1.066 0 C-N-CA 122.955 0.312 . . . . 0.0 112.417 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 34.6 m -122.19 142.99 36.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 124.368 1.067 . . . . 0.0 109.705 -177.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 69.1 m -124.53 -0.52 8.12 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 123.518 0.727 . . . . 0.0 111.427 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 15.3 p-10 -78.42 83.94 4.61 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-O 122.603 1.192 . . . . 0.0 110.505 -178.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.37 -41.26 96.8 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 113.54 -1.664 . . . . 0.0 113.217 -170.483 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -63.02 -44.43 96.0 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.81 0.844 . . . . 0.0 111.648 -174.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.411 ' O ' HG13 ' A' ' 76' ' ' ILE . 32.1 m170 -66.25 -47.52 73.47 Favored 'General case' 0 N--CA 1.475 0.78 0 O-C-N 123.521 0.513 . . . . 0.0 110.896 179.315 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 29.3 mm -58.93 -39.2 77.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 123.795 0.684 . . . . 0.0 110.344 178.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.71 -38.21 89.52 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 124.156 0.982 . . . . 0.0 111.336 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -63.97 -39.37 93.98 Favored 'General case' 0 N--CA 1.482 1.169 0 O-C-N 123.619 0.574 . . . . 0.0 111.116 176.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.521 HG21 ' HA ' ' A' ' 44' ' ' ILE . 57.4 mt -68.15 -51.33 49.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 123.42 0.688 . . . . 0.0 111.268 -175.706 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 10.9 tt -68.63 -36.14 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.447 -175.394 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.0 t -71.97 -27.5 62.81 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 122.663 0.385 . . . . 0.0 110.311 177.501 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.46 -29.85 70.07 Favored 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 123.562 0.745 . . . . 0.0 111.401 174.407 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -78.03 -3.12 40.53 Favored 'General case' 0 N--CA 1.48 1.056 0 C-N-CA 123.432 0.693 . . . . 0.0 111.606 173.031 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.67 -9.54 60.46 Favored Glycine 0 C--N 1.343 0.969 0 CA-C-O 119.716 -0.491 . . . . 0.0 113.159 176.388 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -96.53 103.2 15.09 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 117.442 0.621 . . . . 0.0 109.722 -179.054 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 33.5 p -78.95 112.82 30.49 Favored Pre-proline 0 CA--C 1.553 1.063 0 C-N-CA 124.415 1.086 . . . . 0.0 109.87 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -76.77 -2.06 12.25 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 122.751 2.3 . . . . 0.0 113.421 179.199 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 . . . . . 0 C--O 1.256 1.396 0 C-N-CA 124.034 0.934 . . . . 0.0 109.933 175.14 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.99 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.81 147.91 9.21 Favored Glycine 0 C--N 1.35 1.316 0 O-C-N 123.106 0.254 . . . . 0.0 113.159 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 67.6 mt -99.56 107.1 19.18 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.597 0.759 . . . . 0.0 109.615 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 30.1 p -92.05 110.81 22.18 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.046 0.538 . . . . 0.0 110.6 -177.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -104.21 105.03 15.04 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 123.353 0.661 . . . . 0.0 109.375 176.849 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 27.8 t60 -81.66 94.21 6.91 Favored 'General case' 0 CA--C 1.538 0.494 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.284 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.555 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 32.8 t -88.62 102.39 12.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.709 0 CA-C-N 114.964 -1.016 . . . . 0.0 108.618 -179.502 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -70.82 -22.76 62.3 Favored 'General case' 0 N--CA 1.485 1.322 0 CA-C-O 121.105 0.479 . . . . 0.0 110.923 177.774 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -75.62 -13.93 60.36 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.29 1.036 . . . . 0.0 111.244 175.292 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.555 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 27.5 ttt -58.99 122.07 12.79 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 123.371 0.669 . . . . 0.0 112.145 -173.359 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 14.8 t -85.31 163.48 18.57 Favored 'General case' 0 CA--C 1.549 0.908 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.884 173.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.508 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 28.7 p -66.41 -177.02 0.5 Allowed 'General case' 0 CA--C 1.554 1.12 0 C-N-CA 123.769 0.827 . . . . 0.0 113.015 -175.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.519 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -56.79 -15.38 12.54 Favored Glycine 0 C--N 1.357 1.734 0 N-CA-C 116.247 1.259 . . . . 0.0 116.247 -169.061 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -57.68 -42.99 84.76 Favored 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 117.61 0.705 . . . . 0.0 111.308 177.632 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 47.7 t -124.9 0.53 8.0 Favored 'General case' 0 CA--C 1.548 0.901 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.421 -177.396 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.519 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -64.64 -30.91 71.94 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 122.709 0.404 . . . . 0.0 110.624 173.189 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.53 -30.92 77.27 Favored Glycine 0 C--N 1.352 1.431 0 CA-C-N 115.794 -0.639 . . . . 0.0 113.265 174.301 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 42.8 t -69.13 -41.02 81.28 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 174.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 71.1 mt -58.26 -41.12 80.25 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.925 0 C-N-CA 124.078 0.951 . . . . 0.0 110.684 175.401 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.439 ' HB3' HG21 ' A' ' 53' ' ' VAL . 98.9 mttt -60.89 -58.92 6.42 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.572 0.749 . . . . 0.0 110.162 177.203 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.99 -30.6 70.38 Favored Glycine 0 C--N 1.351 1.372 0 O-C-N 124.68 1.238 . . . . 0.0 113.774 -173.802 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.59 -53.23 60.72 Favored 'General case' 0 C--N 1.35 0.62 0 C-N-CA 123.577 0.751 . . . . 0.0 110.557 176.691 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.565 HG21 HG11 ' A' ' 64' ' ' VAL . 72.8 mt -69.41 -46.64 76.02 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-N 114.847 -1.07 . . . . 0.0 112.465 -177.837 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -61.46 -46.24 90.89 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 123.504 0.722 . . . . 0.0 112.712 -175.62 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 12.8 mptt -83.52 -14.63 51.86 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.575 -171.102 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.5 m -87.4 -49.97 6.87 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 171.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 54.2 t -113.74 96.79 42.19 Favored Pre-proline 0 N--CA 1.475 0.821 0 C-N-CA 124.372 1.069 . . . . 0.0 108.959 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -66.14 140.09 58.11 Favored 'Trans proline' 0 C--N 1.376 1.987 0 C-N-CA 122.458 2.105 . . . . 0.0 111.271 176.546 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.54 -10.73 68.92 Favored Glycine 0 C--N 1.34 0.773 0 CA-C-O 119.571 -0.572 . . . . 0.0 112.938 -177.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -72.25 106.02 4.26 Favored 'General case' 0 C--N 1.355 0.828 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 174.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -83.83 99.92 10.63 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.584 HG12 HG12 ' A' ' 64' ' ' VAL . 26.9 m -85.31 135.82 24.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.541 0 CA-C-O 121.197 0.522 . . . . 0.0 110.763 -172.756 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 18.1 t-80 -126.19 95.55 4.42 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 167.426 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.51 112.88 24.77 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 177.662 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.428 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 9.6 t70 -112.43 108.38 54.55 Favored Pre-proline 0 CA--C 1.533 0.298 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 -175.54 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.508 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 71.4 Cg_exo -52.87 -35.73 71.51 Favored 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 123.223 2.615 . . . . 0.0 114.169 178.23 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.53 -31.3 47.47 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 123.061 0.544 . . . . 0.0 112.141 -177.088 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.428 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 19.5 m -91.31 -20.31 22.01 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 122.81 0.444 . . . . 0.0 111.039 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.4 mpt_? 57.88 46.09 17.35 Favored 'General case' 0 N--CA 1.483 1.188 0 C-N-CA 124.477 1.111 . . . . 0.0 110.033 -177.109 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.8 m -142.26 129.94 21.54 Favored 'General case' 0 C--N 1.351 0.657 0 C-N-CA 123.04 0.536 . . . . 0.0 110.735 -173.366 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 18.8 t -108.69 106.51 20.83 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 124.068 0.947 . . . . 0.0 108.858 174.627 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 25.9 t -97.97 118.68 44.89 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 123.76 0.824 . . . . 0.0 109.464 -179.687 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.584 HG12 HG12 ' A' ' 53' ' ' VAL . 35.9 m -106.89 114.61 46.44 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.014 0 CA-C-O 121.5 0.667 . . . . 0.0 110.912 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -97.17 161.29 21.57 Favored Glycine 0 C--N 1.345 1.066 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.278 -178.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 81.27 -4.79 70.2 Favored Glycine 0 N--CA 1.476 1.315 0 N-CA-C 114.149 0.419 . . . . 0.0 114.149 178.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.19 152.81 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 123.851 0.861 . . . . 0.0 110.141 -177.009 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.1 t -125.66 19.79 7.92 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 123.742 0.817 . . . . 0.0 109.79 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.473 ' O ' HG12 ' A' ' 73' ' ' ILE . 3.3 m-20 -96.24 66.86 2.51 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 123.564 0.745 . . . . 0.0 109.41 -177.301 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.0 -46.06 89.47 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 123.178 0.591 . . . . 0.0 112.196 -171.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.14 -42.23 99.04 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 123.78 0.675 . . . . 0.0 110.518 179.059 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.463 ' O ' HG13 ' A' ' 76' ' ' ILE . 11.8 m170 -66.15 -45.0 82.51 Favored 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.315 -176.616 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.476 HG13 HG21 ' A' ' 64' ' ' VAL . 47.8 mm -61.03 -40.81 86.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 C-N-CA 123.323 0.649 . . . . 0.0 110.561 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.25 -37.41 87.13 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 123.606 0.762 . . . . 0.0 111.23 179.019 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -67.03 -34.5 77.84 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 123.386 0.674 . . . . 0.0 111.557 176.54 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.463 HG13 ' O ' ' A' ' 72' ' ' HIS . 72.9 mt -68.79 -53.99 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 C-N-CA 123.311 0.645 . . . . 0.0 111.211 -178.34 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.0 tt -63.71 -36.25 75.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.955 -175.659 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 t -74.27 -29.49 61.69 Favored 'General case' 0 CA--C 1.551 1.013 0 C-N-CA 122.013 0.125 . . . . 0.0 110.93 177.387 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.09 -22.53 61.34 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 123.204 0.602 . . . . 0.0 110.892 174.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -79.95 -8.73 59.5 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 123.499 0.719 . . . . 0.0 111.209 172.119 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 97.38 22.85 15.63 Favored Glycine 0 C--N 1.351 1.388 0 CA-C-N 116.104 -0.498 . . . . 0.0 113.055 175.257 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -127.61 105.97 8.84 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 24.0 p -75.77 116.09 52.09 Favored Pre-proline 0 CA--C 1.55 0.959 0 C-N-CA 122.835 0.454 . . . . 0.0 110.809 -174.233 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.477 ' HA ' HG13 ' A' ' 28' ' ' VAL . 76.5 Cg_endo -78.09 -8.81 16.6 Favored 'Trans proline' 0 C--N 1.382 2.302 0 C-N-CA 123.143 2.562 . . . . 0.0 112.985 -176.794 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 . . . . . 0 C--O 1.25 1.102 0 C-N-CA 124.281 1.032 . . . . 0.0 108.957 -175.896 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.941 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.82 164.1 48.28 Favored Glycine 0 C--N 1.345 1.073 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 169.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.478 HD13 ' HA ' ' A' ' 70' ' ' ALA . 34.9 mt -80.15 107.23 12.78 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -174.791 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.2 m -102.63 130.09 49.41 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.19 0.596 . . . . 0.0 109.81 -172.737 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -128.4 114.53 16.94 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.68 0.792 . . . . 0.0 110.514 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 47.0 m80 -81.63 111.86 18.3 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 171.2 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.7 t -107.9 100.63 11.13 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -176.33 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -69.06 -23.15 64.0 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.428 0.691 . . . . 0.0 110.927 175.323 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -74.3 -19.47 60.47 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.421 0.688 . . . . 0.0 110.625 177.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.527 ' HG3' ' HB2' ' A' ' 36' ' ' CYS . 20.4 ttt -82.67 133.82 35.16 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.215 1.006 . . . . 0.0 110.15 176.604 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 28.0 p -117.83 95.0 4.73 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 170.292 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.623 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 58.0 m 46.01 -142.69 0.31 Allowed 'General case' 0 CA--C 1.568 1.658 0 C-N-CA 125.017 1.327 . . . . 0.0 114.19 168.628 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.61 -24.48 64.16 Favored Glycine 0 C--N 1.362 2.019 0 C-N-CA 123.705 0.669 . . . . 0.0 114.292 -179.703 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -56.47 -37.94 71.02 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 123.28 0.632 . . . . 0.0 111.668 175.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.527 ' HB2' ' HG3' ' A' ' 31' ' ' MET . 80.9 m -104.11 -19.1 14.28 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 122.943 0.497 . . . . 0.0 111.571 -178.333 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -56.05 -42.72 77.03 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -173.492 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -61.76 -50.83 62.05 Favored Glycine 0 CA--C 1.535 1.286 0 O-C-N 123.31 0.381 . . . . 0.0 113.587 -177.409 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m -75.28 -34.24 30.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 C-N-CA 123.365 0.666 . . . . 0.0 112.161 -177.365 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 9.6 tt -74.84 -34.96 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 C-N-CA 123.11 0.564 . . . . 0.0 110.721 -174.387 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -71.81 -47.64 51.86 Favored 'General case' 0 C--N 1.351 0.659 0 C-N-CA 123.604 0.762 . . . . 0.0 109.657 173.208 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.44 -30.03 75.11 Favored Glycine 0 C--N 1.349 1.301 0 O-C-N 124.35 1.031 . . . . 0.0 113.359 -179.039 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.89 -54.65 43.64 Favored 'General case' 0 C--N 1.348 0.505 0 C-N-CA 123.386 0.674 . . . . 0.0 110.239 177.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.648 HG21 HG11 ' A' ' 64' ' ' VAL . 48.0 mt -74.03 -46.17 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.529 -175.708 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -59.97 -51.85 67.9 Favored 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.18 0.992 . . . . 0.0 112.371 -173.742 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.7 mptp? -75.95 -13.83 60.24 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 122.458 0.303 . . . . 0.0 111.721 -175.167 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 86.4 m -89.02 -39.27 13.8 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 123.117 0.567 . . . . 0.0 110.252 175.321 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 97.4 t -124.73 89.65 52.08 Favored Pre-proline 0 N--CA 1.479 0.977 0 C-N-CA 123.951 0.901 . . . . 0.0 109.022 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -60.17 113.44 1.67 Allowed 'Trans proline' 0 C--N 1.376 2.011 0 C-N-CA 122.845 2.364 . . . . 0.0 111.14 171.803 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.76 -14.85 9.1 Favored Glycine 0 C--N 1.342 0.87 0 CA-C-O 119.633 -0.537 . . . . 0.0 113.012 -176.274 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.79 106.8 9.86 Favored 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 173.184 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.467 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -76.27 99.54 4.8 Favored 'General case' 0 C--N 1.349 0.586 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.421 HG12 HG12 ' A' ' 64' ' ' VAL . 16.8 m -86.33 131.71 33.98 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 C-N-CA 123.29 0.636 . . . . 0.0 111.043 -172.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 43.9 t-80 -136.55 99.42 4.07 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 174.574 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -96.72 114.34 25.97 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 174.749 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -94.06 120.95 65.08 Favored Pre-proline 0 N--CA 1.471 0.589 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -174.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.623 ' HA ' ' HA ' ' A' ' 33' ' ' CYS . 51.1 Cg_exo -57.54 -38.25 94.47 Favored 'Trans proline' 0 C--N 1.374 1.907 0 C-N-CA 123.103 2.536 . . . . 0.0 114.417 177.633 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.72 -35.38 52.05 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.032 0.533 . . . . 0.0 111.62 -174.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 16.5 m -97.69 -20.94 17.29 Favored 'General case' 0 N--CA 1.482 1.151 0 C-N-CA 123.564 0.746 . . . . 0.0 111.718 -175.178 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.9 mpt_? 56.91 32.63 21.83 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 125.108 1.363 . . . . 0.0 110.947 -171.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.9 m -110.35 118.98 37.77 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 123.377 0.671 . . . . 0.0 110.055 -172.883 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 20.9 t -101.49 107.24 21.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 177.644 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 21.9 t -105.5 135.3 44.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 123.785 0.834 . . . . 0.0 108.754 -179.044 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.648 HG11 HG21 ' A' ' 44' ' ' ILE . 18.8 m -121.7 123.0 68.42 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 C-N-CA 123.196 0.598 . . . . 0.0 110.404 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -99.74 156.74 19.76 Favored Glycine 0 C--N 1.347 1.165 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.095 -179.144 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.5 -18.2 43.89 Favored Glycine 0 N--CA 1.474 1.225 0 C-N-CA 123.121 0.391 . . . . 0.0 113.451 177.478 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.8 m -115.68 146.86 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 124.092 0.957 . . . . 0.0 109.741 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 69.8 m -116.54 -20.47 9.61 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.722 0.809 . . . . 0.0 112.439 -175.77 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -75.95 86.3 2.88 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 122.776 0.43 . . . . 0.0 110.481 178.499 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.478 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -62.98 -29.01 70.49 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.431 0.692 . . . . 0.0 111.116 175.718 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.3 -51.38 67.89 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 124.402 1.081 . . . . 0.0 111.117 177.058 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.416 ' O ' HG13 ' A' ' 76' ' ' ILE . 28.2 m-70 -63.09 -48.01 80.43 Favored 'General case' 0 N--CA 1.482 1.155 0 O-C-N 123.592 0.558 . . . . 0.0 110.838 -178.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.474 HG21 HG21 ' A' ' 64' ' ' VAL . 49.5 mm -61.22 -40.62 86.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 124.068 0.855 . . . . 0.0 110.436 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.73 -39.69 92.46 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 123.95 0.781 . . . . 0.0 111.333 179.423 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.9 mm-40 -62.59 -39.5 93.91 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.491 0.716 . . . . 0.0 111.206 178.089 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.542 HG21 ' HA ' ' A' ' 44' ' ' ILE . 53.8 mt -68.02 -53.86 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 O-C-N 123.747 0.654 . . . . 0.0 110.959 -179.16 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 15.9 tt -70.28 -29.15 38.12 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.71 -173.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.5 t -76.07 -31.69 58.89 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 110.156 -0.312 . . . . 0.0 110.156 175.239 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.69 -21.43 64.42 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 123.671 0.788 . . . . 0.0 111.64 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -74.24 -3.69 31.48 Favored 'General case' 0 CA--C 1.555 1.15 0 C-N-CA 123.538 0.735 . . . . 0.0 112.189 176.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 101.77 23.11 9.56 Favored Glycine 0 C--N 1.351 1.4 0 C-N-CA 123.065 0.364 . . . . 0.0 112.885 178.368 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -119.3 175.83 5.62 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.992 0.917 . . . . 0.0 109.02 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 96.0 m -148.43 83.8 6.91 Favored Pre-proline 0 N--CA 1.479 0.994 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 171.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_exo -70.79 -67.31 0.03 OUTLIER 'Trans proline' 0 C--N 1.369 1.646 0 C-N-CA 122.449 2.1 . . . . 0.0 112.487 177.75 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 . . . . . 0 C--O 1.257 1.451 0 C-N-CA 125.154 1.382 . . . . 0.0 110.926 -171.787 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.921 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 163.8 166.3 22.43 Favored Glycine 0 C--N 1.341 0.812 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 -179.379 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 34.1 mt -88.99 108.21 19.46 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.4 p -92.38 111.32 22.85 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 122.883 0.473 . . . . 0.0 110.555 -177.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -106.19 124.81 50.17 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 123.88 0.872 . . . . 0.0 109.746 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 32.3 m-70 -84.05 136.81 33.88 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 175.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 p -157.34 97.05 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.978 0 C-N-CA 124.066 0.946 . . . . 0.0 109.049 -176.402 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -69.8 -29.4 66.69 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.418 -176.216 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -74.4 -9.85 59.0 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.164 0.586 . . . . 0.0 112.018 -178.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.612 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 56.1 ttp -72.62 113.08 9.26 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 120.93 0.395 . . . . 0.0 110.557 177.132 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.401 ' OG1' ' HB3' ' A' ' 36' ' ' CYS . 63.2 p -77.51 166.34 23.2 Favored 'General case' 0 CA--C 1.549 0.917 0 C-N-CA 124.013 0.925 . . . . 0.0 109.923 168.799 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 28.0 p -57.11 -169.73 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 124.089 0.956 . . . . 0.0 112.647 175.761 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.69 3.45 0.63 Allowed Glycine 0 C--N 1.357 1.721 0 N-CA-C 115.916 1.127 . . . . 0.0 115.916 -174.001 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 3.5 m80 -63.27 -44.74 94.25 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.743 0.817 . . . . 0.0 110.844 166.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.401 ' HB3' ' OG1' ' A' ' 32' ' ' THR . 43.5 t -141.42 9.56 2.05 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 123.136 0.575 . . . . 0.0 111.996 -176.09 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.58 -30.95 69.83 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 122.836 0.454 . . . . 0.0 110.754 173.191 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.53 -20.87 53.09 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 114.996 -1.002 . . . . 0.0 114.256 176.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.496 HG12 ' HB1' ' A' ' 80' ' ' ALA . 57.9 t -65.41 -44.32 94.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 122.871 0.468 . . . . 0.0 110.138 174.233 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.711 HG21 HG21 ' A' ' 62' ' ' VAL . 44.1 mt -69.61 -54.44 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 C-N-CA 123.3 0.64 . . . . 0.0 110.661 175.431 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.427 ' O ' ' HG3' ' A' ' 45' ' ' GLU . 9.7 mtpm? -56.68 -51.83 67.28 Favored 'General case' 0 C--N 1.348 0.507 0 O-C-N 124.517 1.136 . . . . 0.0 110.269 -174.775 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.48 ' O ' ' HD3' ' A' ' 46' ' ' LYS . . . -61.94 -40.16 98.5 Favored Glycine 0 C--N 1.343 0.917 0 O-C-N 124.963 1.414 . . . . 0.0 112.867 178.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.74 -53.5 57.05 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 117.129 0.464 . . . . 0.0 111.001 179.138 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.576 HG21 HG11 ' A' ' 64' ' ' VAL . 68.4 mt -62.08 -39.93 85.6 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.967 -179.174 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.427 ' HG3' ' O ' ' A' ' 41' ' ' LYS . 76.9 mt-10 -62.02 -50.46 71.94 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 123.171 0.588 . . . . 0.0 112.068 179.623 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.48 ' HD3' ' O ' ' A' ' 42' ' ' GLY . 13.3 mptt -73.03 -28.07 62.13 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.496 -171.528 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.1 m -85.2 -41.01 16.02 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 122.814 0.445 . . . . 0.0 110.32 177.546 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.0 103.51 23.53 Favored Pre-proline 0 N--CA 1.483 1.216 0 C-N-CA 124.156 0.982 . . . . 0.0 109.807 -178.722 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -66.91 136.58 41.97 Favored 'Trans proline' 0 C--N 1.374 1.919 0 C-N-CA 122.781 2.321 . . . . 0.0 111.687 172.059 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.2 -4.75 67.68 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-O 119.787 -0.452 . . . . 0.0 113.963 175.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.65 106.68 9.61 Favored 'General case' 0 C--N 1.35 0.619 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 173.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.421 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -77.14 99.54 5.43 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -177.095 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.412 HG12 HG12 ' A' ' 64' ' ' VAL . 27.8 m -85.26 127.47 39.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.805 0 C-N-CA 123.134 0.574 . . . . 0.0 110.877 -171.065 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' HIS . . . . . 0.409 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 29.2 t60 -131.67 96.98 4.08 Favored 'General case' 0 C--N 1.345 0.372 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 176.12 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.612 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -93.71 113.67 25.79 Favored 'General case' 0 C--O 1.24 0.588 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 176.073 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -99.72 114.88 65.88 Favored Pre-proline 0 N--CA 1.468 0.428 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -177.373 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -60.54 -40.34 57.36 Favored 'Trans proline' 0 C--N 1.373 1.863 0 C-N-CA 123.009 2.473 . . . . 0.0 112.822 -176.254 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -74.38 -47.74 32.22 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.639 0.775 . . . . 0.0 111.285 -176.734 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.2 m -81.31 -15.65 54.8 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 123.74 0.816 . . . . 0.0 111.459 -176.122 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 63.0 29.44 16.43 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 124.642 1.177 . . . . 0.0 111.389 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 33.1 m -122.79 122.76 39.46 Favored 'General case' 0 N--CA 1.479 1.001 0 O-C-N 121.808 -0.558 . . . . 0.0 111.57 -169.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.711 HG21 HG21 ' A' ' 40' ' ' ILE . 40.5 t -99.09 106.38 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 123.952 0.901 . . . . 0.0 108.972 173.33 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.1 t -100.49 123.21 53.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.581 HG21 HG21 ' A' ' 73' ' ' ILE . 17.0 m -111.5 109.0 26.9 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.955 0 CA-C-O 121.478 0.656 . . . . 0.0 110.18 179.377 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.46 150.78 20.99 Favored Glycine 0 C--N 1.346 1.125 0 CA-C-N 115.604 -0.725 . . . . 0.0 112.581 -176.561 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.19 -23.68 30.47 Favored Glycine 0 C--N 1.343 0.967 0 C-N-CA 123.089 0.375 . . . . 0.0 112.999 177.007 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 22.4 m -105.52 151.14 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 123.992 0.917 . . . . 0.0 110.153 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 17.9 m -126.85 -2.61 6.56 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 124.005 0.922 . . . . 0.0 110.332 -178.621 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -87.33 73.02 9.72 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 124.522 1.129 . . . . 0.0 110.266 -177.219 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.99 -29.29 70.46 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-N 114.907 -1.042 . . . . 0.0 112.373 -174.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.402 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.68 -49.45 73.12 Favored 'General case' 0 N--CA 1.474 0.764 0 O-C-N 123.763 0.665 . . . . 0.0 110.819 177.599 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.499 ' O ' HG13 ' A' ' 76' ' ' ILE . 39.8 m170 -59.35 -54.93 41.14 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 123.552 0.532 . . . . 0.0 110.463 177.81 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.581 HG21 HG21 ' A' ' 64' ' ' VAL . 41.4 mm -57.8 -40.27 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 O-C-N 124.438 1.086 . . . . 0.0 110.785 -174.282 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.26 -40.14 89.29 Favored 'General case' 0 N--CA 1.48 1.067 0 O-C-N 124.022 0.826 . . . . 0.0 111.429 178.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 15.2 mm-40 -68.23 -32.09 72.05 Favored 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 123.181 0.592 . . . . 0.0 111.292 178.05 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.499 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.3 mt -74.75 -48.66 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 122.986 0.514 . . . . 0.0 111.21 -177.094 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 73' ' ' ILE . 8.5 tt -67.37 -32.39 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 C-N-CA 123.259 0.623 . . . . 0.0 111.257 -177.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -75.12 -31.05 61.02 Favored 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 110.364 -0.236 . . . . 0.0 110.364 175.07 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.95 -18.49 64.09 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 123.537 0.735 . . . . 0.0 111.747 176.09 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.496 ' HB1' HG12 ' A' ' 39' ' ' VAL . . . -75.89 0.58 17.76 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 123.664 0.786 . . . . 0.0 112.291 176.441 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 95.9 17.04 36.59 Favored Glycine 0 C--N 1.351 1.377 0 C-N-CA 122.861 0.267 . . . . 0.0 112.528 179.597 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -120.78 178.36 4.73 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 124.361 1.064 . . . . 0.0 109.686 -177.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 39.0 m -139.41 111.81 7.77 Favored Pre-proline 0 N--CA 1.479 1.001 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 173.333 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -66.44 120.37 7.49 Favored 'Trans proline' 0 C--N 1.382 2.305 0 C-N-CA 122.355 2.037 . . . . 0.0 110.812 171.427 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 . . . . . 0 CA--C 1.555 1.167 0 C-N-CA 124.187 0.995 . . . . 0.0 109.493 -175.682 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.802 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.431 ' HA2' ' HA2' ' A' ' 65' ' ' GLY . . . -104.54 111.41 3.8 Favored Glycine 0 C--N 1.345 1.075 0 CA-C-N 116.13 -0.486 . . . . 0.0 112.165 -177.602 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.445 HD13 ' HA ' ' A' ' 70' ' ' ALA . 59.4 mt -81.42 111.59 17.91 Favored 'General case' 0 N--CA 1.47 0.568 0 C-N-CA 124.059 0.944 . . . . 0.0 110.108 179.433 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.4 t -83.72 129.62 34.95 Favored 'General case' 0 CA--C 1.549 0.922 0 C-N-CA 123.556 0.742 . . . . 0.0 110.516 -177.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -125.84 108.44 11.47 Favored 'General case' 0 N--CA 1.492 1.636 0 C-N-CA 123.338 0.655 . . . . 0.0 110.919 177.545 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 75.9 t60 -82.88 105.58 14.01 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.531 1.132 . . . . 0.0 110.308 -175.479 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.643 HG11 ' HB3' ' A' ' 82' ' ' TYR . 30.1 t -120.7 94.97 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 C-N-CA 123.214 0.606 . . . . 0.0 109.729 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -69.65 -24.75 63.66 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 123.034 0.533 . . . . 0.0 112.186 -177.306 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -74.98 -20.11 59.81 Favored 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 123.737 0.815 . . . . 0.0 111.163 -179.142 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.419 ' SD ' HD13 ' A' ' 40' ' ' ILE . 12.9 ttt -73.26 139.34 46.09 Favored 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 124.303 1.041 . . . . 0.0 110.786 176.495 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 15.1 t -103.01 163.39 12.24 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 123.917 0.887 . . . . 0.0 109.195 170.037 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 23.3 p -66.98 -97.46 0.0 OUTLIER 'General case' 0 CA--C 1.563 1.467 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -174.137 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.48 -32.74 64.51 Favored Glycine 0 C--N 1.349 1.3 0 N-CA-C 114.673 0.629 . . . . 0.0 114.673 -166.199 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 72.1 m-70 -74.01 -14.34 61.0 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.514 0.726 . . . . 0.0 111.869 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.6 t -122.54 -7.1 8.64 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 122.977 0.511 . . . . 0.0 111.688 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -57.67 -55.7 31.5 Favored 'General case' 0 N--CA 1.481 1.088 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -171.594 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.83 -38.17 95.23 Favored Glycine 0 N--CA 1.47 0.903 0 N-CA-C 114.255 0.462 . . . . 0.0 114.255 -174.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.5 p -75.15 -40.37 44.06 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.15 0 C-N-CA 122.785 0.434 . . . . 0.0 111.733 -176.125 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.434 HD11 HD11 ' A' ' 77' ' ' ILE . 13.0 tt -75.05 -35.88 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 122.802 0.441 . . . . 0.0 110.79 -178.211 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.463 ' HB3' HG21 ' A' ' 53' ' ' VAL . 97.2 mttt -65.21 -52.29 55.66 Favored 'General case' 0 C--N 1.353 0.729 0 CA-C-N 115.771 -0.649 . . . . 0.0 109.471 174.584 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.91 -29.31 67.48 Favored Glycine 0 C--N 1.352 1.43 0 O-C-N 124.813 1.321 . . . . 0.0 113.517 -178.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.35 -54.96 40.85 Favored 'General case' 0 C--N 1.352 0.693 0 C-N-CA 123.375 0.67 . . . . 0.0 110.476 175.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.612 HG21 HG11 ' A' ' 64' ' ' VAL . 66.6 mt -73.2 -45.72 52.65 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 CA-C-N 115.529 -0.759 . . . . 0.0 112.031 -179.655 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -63.05 -45.7 90.99 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 124.72 1.208 . . . . 0.0 111.275 -167.858 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -70.95 -27.45 63.75 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.853 0.461 . . . . 0.0 111.698 -178.614 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 33.2 m -81.51 -33.89 31.58 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 122.648 0.379 . . . . 0.0 110.833 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.3 t -124.75 95.0 43.34 Favored Pre-proline 0 N--CA 1.48 1.073 0 C-N-CA 123.32 0.648 . . . . 0.0 109.688 178.67 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -65.88 111.22 1.89 Allowed 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 122.699 2.266 . . . . 0.0 110.861 173.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.5 -12.1 9.59 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-O 119.514 -0.603 . . . . 0.0 113.281 -176.603 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -76.87 106.28 8.45 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 173.629 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.21 100.16 8.17 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -178.445 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.463 HG21 ' HB3' ' A' ' 41' ' ' LYS . 15.3 m -84.39 132.99 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 123.78 0.832 . . . . 0.0 110.649 -170.423 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -141.48 101.81 4.07 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 122.903 0.481 . . . . 0.0 109.756 -176.162 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.25 130.32 35.07 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 109.643 -0.502 . . . . 0.0 109.643 176.146 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -105.48 108.59 61.8 Favored Pre-proline 0 CA--C 1.541 0.628 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 176.637 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -47.34 -44.94 23.65 Favored 'Trans proline' 0 C--N 1.374 1.901 0 C-N-CA 124.126 3.218 . . . . 0.0 115.396 178.326 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.31 -41.57 40.16 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.485 0.714 . . . . 0.0 112.233 -173.17 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.8 t -93.37 -13.93 27.46 Favored 'General case' 0 N--CA 1.482 1.141 0 C-N-CA 123.496 0.718 . . . . 0.0 111.558 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.42 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 2.7 mpt_? 57.17 45.98 19.68 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 125.036 1.334 . . . . 0.0 110.8 -178.12 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 78.9 m -122.75 126.61 47.83 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.88 -170.402 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 40.5 t -98.44 108.27 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 173.833 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.0 t -100.58 123.11 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 C-N-CA 124.035 0.934 . . . . 0.0 108.609 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.612 HG11 HG21 ' A' ' 44' ' ' ILE . 31.4 m -112.57 109.07 27.23 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 C-N-CA 123.669 0.787 . . . . 0.0 110.666 -176.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.431 ' HA2' ' HA2' ' A' ' 23' ' ' GLY . . . -88.62 160.24 30.05 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 115.584 -0.735 . . . . 0.0 113.049 -177.335 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 78.55 4.59 87.63 Favored Glycine 0 C--N 1.343 0.92 0 N-CA-C 114.356 0.502 . . . . 0.0 114.356 175.546 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 23.4 m -131.8 150.79 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.854 0 C-N-CA 123.796 0.838 . . . . 0.0 109.4 -178.468 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 30.8 t -116.1 -8.41 11.8 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 124.1 0.96 . . . . 0.0 111.06 -176.657 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.417 ' O ' HG12 ' A' ' 73' ' ' ILE . 7.1 m-20 -80.92 72.34 7.92 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.751 0.821 . . . . 0.0 110.893 -175.308 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.445 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -60.38 -41.43 93.74 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.149 0.58 . . . . 0.0 111.065 -178.281 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.472 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.22 -47.83 80.85 Favored 'General case' 0 CA--C 1.541 0.6 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.134 179.094 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.43 ' O ' HG13 ' A' ' 76' ' ' ILE . 45.0 t-80 -64.64 -45.24 87.64 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.167 0.587 . . . . 0.0 111.559 -176.186 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.497 HG21 HG21 ' A' ' 64' ' ' VAL . 48.5 mm -60.86 -41.03 87.18 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 O-C-N 123.552 0.533 . . . . 0.0 109.892 178.818 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.15 -35.31 76.74 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 115.305 -0.861 . . . . 0.0 111.751 178.49 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.472 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 17.5 mm-40 -65.52 -41.13 93.48 Favored 'General case' 0 N--CA 1.48 1.034 0 C-N-CA 123.457 0.703 . . . . 0.0 110.923 177.692 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.43 HG13 ' O ' ' A' ' 72' ' ' HIS . 35.5 mt -66.37 -50.05 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.021 -177.126 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.434 HD11 HD11 ' A' ' 40' ' ' ILE . 15.9 tt -72.66 -31.17 36.13 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.949 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.429 -172.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.5 t -74.54 -29.57 61.43 Favored 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 175.095 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.43 -19.62 60.92 Favored 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 123.563 0.745 . . . . 0.0 111.27 173.451 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -80.4 -5.31 56.27 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.565 0.746 . . . . 0.0 111.21 172.107 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.0 22.72 32.0 Favored Glycine 0 C--N 1.35 1.358 0 O-C-N 123.372 0.42 . . . . 0.0 112.903 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.643 ' HB3' HG11 ' A' ' 28' ' ' VAL . 81.7 m-85 -127.46 115.07 18.33 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.659 0.784 . . . . 0.0 110.51 -176.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 34.8 p -71.16 111.78 11.21 Favored Pre-proline 0 CA--C 1.549 0.916 0 C-N-CA 124.296 1.039 . . . . 0.0 110.987 -177.253 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.403 ' HA ' HG22 ' A' ' 28' ' ' VAL . 93.8 Cg_endo -80.6 150.14 18.96 Favored 'Trans proline' 0 C--N 1.372 1.803 0 C-N-CA 122.323 2.016 . . . . 0.0 111.824 177.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 . . . . . 0 CA--C 1.559 1.3 0 C-N-CA 124.703 1.201 . . . . 0.0 111.437 173.536 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.238 0 CA-C-O 120.618 0.247 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 135.95 -154.62 21.96 Favored Glycine 0 C--N 1.342 0.913 0 N-CA-C 110.35 -1.1 . . . . 0.0 110.35 -178.063 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 46.8 mt -83.1 105.84 14.41 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 174.278 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.1 m -93.83 111.4 23.09 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -176.762 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -103.26 100.96 10.88 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 177.244 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 77.0 t60 -82.47 91.71 6.92 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 -179.202 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.58 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 15.9 t -74.37 93.62 0.75 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 N-CA-C 106.855 -1.535 . . . . 0.0 106.855 172.543 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -63.75 -20.81 66.04 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 112.693 0.627 . . . . 0.0 112.693 -171.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 10.6 p-10 -111.34 23.6 13.82 Favored 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 124.089 0.956 . . . . 0.0 110.789 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.58 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 23.9 ttt -57.73 142.01 46.74 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 124.389 1.076 . . . . 0.0 113.325 -173.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 41.3 p -81.32 144.4 31.53 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.547 173.204 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.439 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 49.8 t -73.04 -170.51 0.75 Allowed 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 123.882 0.873 . . . . 0.0 110.078 177.137 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -49.35 -24.9 5.55 Favored Glycine 0 C--N 1.356 1.657 0 N-CA-C 116.623 1.409 . . . . 0.0 116.623 -171.562 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 40.9 m170 -58.53 -33.75 70.22 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 123.498 0.719 . . . . 0.0 112.558 177.019 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 63.8 m -137.92 15.95 2.86 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 122.997 0.519 . . . . 0.0 111.739 178.787 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.4 -34.04 63.19 Favored 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 122.614 0.366 . . . . 0.0 110.96 174.1 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.94 -37.91 93.69 Favored Glycine 0 C--N 1.347 1.161 0 O-C-N 123.825 0.703 . . . . 0.0 113.768 -176.013 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 9.2 p -69.48 -28.46 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 122.943 0.497 . . . . 0.0 110.883 177.601 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.2 mt -67.93 -41.82 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 123.224 0.61 . . . . 0.0 109.974 175.298 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -62.24 -52.05 65.28 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 123.811 0.844 . . . . 0.0 110.177 177.576 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.82 -31.1 78.69 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 114.414 -1.266 . . . . 0.0 113.063 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.38 -50.92 68.46 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.975 0.91 . . . . 0.0 110.831 179.167 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.515 HG21 HG11 ' A' ' 64' ' ' VAL . 64.3 mt -74.37 -51.4 23.3 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.644 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -56.16 -54.67 42.38 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 124.358 1.063 . . . . 0.0 112.745 -170.485 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -69.79 -13.72 62.42 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 122.889 0.476 . . . . 0.0 112.107 -175.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 61.2 m -90.51 -37.74 13.68 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 123.341 0.656 . . . . 0.0 110.442 177.732 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.5 m -133.54 92.1 24.63 Favored Pre-proline 0 CA--C 1.556 1.176 0 C-N-CA 123.474 0.71 . . . . 0.0 110.491 179.317 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -58.03 135.08 66.38 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 122.604 2.203 . . . . 0.0 111.555 171.034 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 110.62 -29.58 8.89 Favored Glycine 0 C--N 1.341 0.847 0 N-CA-C 111.87 -0.492 . . . . 0.0 111.87 -177.731 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -74.02 106.86 5.89 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 175.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.445 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -78.06 99.34 6.08 Favored 'General case' 0 C--N 1.345 0.407 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -179.057 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.474 HG12 HG12 ' A' ' 64' ' ' VAL . 27.2 m -84.51 129.42 37.7 Favored 'Isoleucine or valine' 0 C--O 1.239 0.546 0 C-N-CA 123.1 0.56 . . . . 0.0 110.015 -171.734 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' HIS . . . . . 0.402 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 41.1 t60 -133.68 96.01 3.6 Favored 'General case' 0 CA--C 1.518 -0.283 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 175.439 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.1 113.91 26.31 Favored 'General case' 0 C--O 1.243 0.755 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 173.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -105.35 105.54 52.6 Favored Pre-proline 0 N--CA 1.466 0.337 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 -175.361 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.439 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 76.4 Cg_exo -53.39 -38.1 82.25 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 123.236 2.624 . . . . 0.0 113.72 179.331 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.8 -45.21 62.31 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 123.215 0.606 . . . . 0.0 111.413 -176.622 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.9 m -84.08 -17.89 38.75 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.417 0.687 . . . . 0.0 111.552 -177.28 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.566 ' HD2' ' HB3' ' A' ' 31' ' ' MET . 66.6 mmt-85 64.29 37.49 8.54 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 124.633 1.173 . . . . 0.0 110.367 -178.58 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.1 m -137.9 122.88 19.02 Favored 'General case' 0 CA--C 1.55 0.965 0 O-C-N 122.025 -0.422 . . . . 0.0 111.603 -169.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.402 ' HA ' ' O ' ' A' ' 54' ' ' HIS . 18.5 t -99.45 106.37 18.91 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 C-N-CA 124.142 0.977 . . . . 0.0 109.204 175.391 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.8 t -104.95 123.47 59.04 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 123.728 0.811 . . . . 0.0 109.073 -176.147 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.515 HG11 HG21 ' A' ' 44' ' ' ILE . 27.8 m -108.56 122.5 63.19 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.909 0 C-N-CA 123.038 0.535 . . . . 0.0 110.521 177.42 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -102.43 153.3 18.44 Favored Glycine 0 C--N 1.345 1.075 0 CA-C-N 115.981 -0.554 . . . . 0.0 112.872 -176.772 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.7 -24.77 22.12 Favored Glycine 0 N--CA 1.471 1.027 0 C-N-CA 123.173 0.416 . . . . 0.0 112.856 177.212 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 35.3 m -111.69 149.05 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.987 0.915 . . . . 0.0 109.473 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.5 m -121.74 20.82 10.92 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 123.656 0.782 . . . . 0.0 110.416 -178.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -96.65 73.56 2.71 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 124.367 1.067 . . . . 0.0 109.506 -173.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.34 -53.38 58.97 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 123.721 0.809 . . . . 0.0 112.642 -170.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.422 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -62.9 -40.52 97.82 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 123.481 0.712 . . . . 0.0 111.031 -178.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 55.7 t60 -61.66 -50.35 72.85 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.967 0.907 . . . . 0.0 111.205 -177.43 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.4 HG21 HG21 ' A' ' 64' ' ' VAL . 39.6 mm -64.99 -39.93 87.35 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.083 179.055 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.13 -37.11 79.09 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 123.985 0.803 . . . . 0.0 111.128 179.093 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.422 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 39.5 mm-40 -66.29 -40.02 89.77 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 123.625 0.77 . . . . 0.0 111.288 176.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.442 HG21 ' HA ' ' A' ' 44' ' ' ILE . 65.6 mt -64.08 -52.95 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 O-C-N 123.606 0.566 . . . . 0.0 111.17 -179.215 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 8.0 tt -66.8 -37.88 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.313 -175.147 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.5 t -73.84 -29.64 62.24 Favored 'General case' 0 CA--C 1.552 1.037 0 C-N-CA 122.384 0.273 . . . . 0.0 110.296 179.503 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.71 -22.24 61.67 Favored 'General case' 0 N--CA 1.484 1.256 0 C-N-CA 123.628 0.771 . . . . 0.0 111.238 174.48 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.43 -6.08 52.15 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.503 0.721 . . . . 0.0 111.396 172.242 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 93.87 8.17 60.75 Favored Glycine 0 C--N 1.345 1.068 0 CA-C-O 119.89 -0.394 . . . . 0.0 112.933 177.402 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -117.0 103.22 10.04 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 176.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.4 t -83.59 118.53 71.74 Favored Pre-proline 0 CA--C 1.554 1.119 0 C-N-CA 123.267 0.627 . . . . 0.0 110.389 -176.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -70.75 -42.6 2.28 Favored 'Trans proline' 0 C--N 1.377 2.076 0 C-N-CA 122.409 2.072 . . . . 0.0 111.716 173.274 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 . . . . . 0 C--O 1.253 1.279 0 C-N-CA 124.767 1.227 . . . . 0.0 108.102 172.379 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.996 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.403 ' HA2' ' HA2' ' A' ' 65' ' ' GLY . . . -113.21 123.83 6.34 Favored Glycine 0 C--N 1.347 1.19 0 N-CA-C 112.058 -0.417 . . . . 0.0 112.058 -178.606 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 47.6 mt -80.32 108.6 14.07 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 123.809 0.844 . . . . 0.0 110.141 -178.018 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 21.0 p -88.44 124.25 33.78 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 123.623 0.769 . . . . 0.0 110.978 -178.383 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -121.55 112.72 18.83 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 123.729 0.812 . . . . 0.0 110.401 -179.758 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 69.3 m80 -83.59 104.23 13.55 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.318 0.647 . . . . 0.0 110.173 177.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.595 HG11 ' HB3' ' A' ' 82' ' ' TYR . 98.8 t -90.07 128.3 42.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 C-N-CA 123.404 0.681 . . . . 0.0 109.176 174.9 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -64.44 -39.85 94.61 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 123.563 0.745 . . . . 0.0 112.286 -176.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -104.83 -6.47 20.21 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 113.302 0.852 . . . . 0.0 113.302 -166.169 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 24.1 ptm -65.45 133.38 51.18 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-O 121.318 0.58 . . . . 0.0 111.355 -174.236 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 72.9 p -107.55 161.62 14.69 Favored 'General case' 0 CA--C 1.547 0.856 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 171.778 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 24.6 p -74.87 -109.29 0.01 OUTLIER 'General case' 0 CA--C 1.563 1.479 0 N-CA-C 113.951 1.093 . . . . 0.0 113.951 -166.524 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -75.96 5.21 41.98 Favored Glycine 0 N--CA 1.478 1.474 0 N-CA-C 117.422 1.729 . . . . 0.0 117.422 -154.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 65.7 m80 -110.13 -31.02 7.5 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-N 118.118 0.959 . . . . 0.0 110.548 175.349 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.4 m -102.0 -8.87 21.12 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.621 0.769 . . . . 0.0 110.936 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -61.5 -46.38 90.26 Favored 'General case' 0 C--N 1.354 0.771 0 C-N-CA 123.803 0.841 . . . . 0.0 110.347 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.55 -27.57 72.71 Favored Glycine 0 C--N 1.343 0.946 0 O-C-N 123.977 0.798 . . . . 0.0 113.846 -178.112 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 53.0 t -72.04 -46.6 58.59 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.963 0 C-N-CA 123.196 0.598 . . . . 0.0 109.771 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.441 HG21 HG21 ' A' ' 62' ' ' VAL . 75.7 mt -59.98 -55.23 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.669 176.298 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -61.51 -43.43 98.88 Favored 'General case' 0 C--O 1.219 -0.503 0 CA-C-N 114.794 -1.094 . . . . 0.0 110.918 -176.18 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.86 -42.57 98.38 Favored Glycine 0 C--N 1.345 1.051 0 O-C-N 124.068 0.855 . . . . 0.0 112.366 -179.716 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.32 -55.11 31.34 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 122.89 0.476 . . . . 0.0 110.815 -179.454 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.542 HG21 HG11 ' A' ' 64' ' ' VAL . 82.4 mt -64.45 -51.13 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 C-N-CA 123.758 0.823 . . . . 0.0 112.297 -176.731 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -60.68 -45.58 93.6 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 124.316 1.046 . . . . 0.0 112.222 -173.078 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.3 mptp? -78.72 -21.09 48.6 Favored 'General case' 0 N--CA 1.484 1.234 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -173.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.407 ' HB ' HD13 ' A' ' 76' ' ' ILE . 38.5 m -85.33 -39.17 17.96 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 122.899 0.48 . . . . 0.0 110.319 177.536 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.1 t -118.46 86.53 28.59 Favored Pre-proline 0 CA--C 1.548 0.876 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 174.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo -61.76 106.77 0.46 Allowed 'Trans proline' 0 C--N 1.378 2.111 0 C-N-CA 122.952 2.435 . . . . 0.0 112.813 -174.493 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.88 7.93 8.37 Favored Glycine 0 C--N 1.341 0.859 0 CA-C-N 115.638 -0.71 . . . . 0.0 113.173 -179.565 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.19 107.47 9.6 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 176.112 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.411 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -75.58 96.37 3.52 Favored 'General case' 0 C--N 1.352 0.693 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 -177.388 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.443 HG12 HG12 ' A' ' 64' ' ' VAL . 5.0 m -87.29 133.14 30.89 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.587 -168.737 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 75.6 t60 -138.62 99.25 3.77 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 174.823 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.78 115.3 23.34 Favored 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 173.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -96.94 120.77 60.92 Favored Pre-proline 0 N--CA 1.478 0.951 0 CA-C-O 118.975 -0.536 . . . . 0.0 109.919 -173.175 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -55.75 -48.97 17.33 Favored 'Trans proline' 0 C--N 1.381 2.27 0 C-N-CA 123.598 2.865 . . . . 0.0 114.025 178.095 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -75.09 -42.85 55.82 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.116 -170.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 19.5 m -93.31 -14.94 26.32 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.595 0.758 . . . . 0.0 112.125 -171.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 11.4 mpt_? 59.42 40.43 20.83 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 123.866 0.866 . . . . 0.0 110.273 -175.06 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.9 m -121.31 118.87 30.61 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.119 0.568 . . . . 0.0 111.275 -169.426 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.441 HG21 HG21 ' A' ' 40' ' ' ILE . 42.8 t -97.88 105.92 17.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 175.168 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 6.3 t -102.02 123.19 55.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 -176.35 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.542 HG11 HG21 ' A' ' 44' ' ' ILE . 19.1 m -117.39 109.22 26.91 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 CA-C-O 121.512 0.672 . . . . 0.0 110.787 -176.478 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.403 ' HA2' ' HA2' ' A' ' 23' ' ' GLY . . . -90.76 161.98 28.67 Favored Glycine 0 C--N 1.344 0.994 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.775 -176.62 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.7 0.65 74.8 Favored Glycine 0 C--N 1.346 1.106 0 CA-C-O 119.995 -0.336 . . . . 0.0 113.824 177.218 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.99 149.05 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 123.826 0.85 . . . . 0.0 109.987 -177.505 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 45.7 m -114.88 4.76 14.94 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.797 0.839 . . . . 0.0 110.359 176.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.59 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 5.6 m-20 -83.12 68.6 9.63 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.015 0.926 . . . . 0.0 111.014 -172.352 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.25 -45.11 95.86 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.12 0.568 . . . . 0.0 111.681 -175.562 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -66.43 -44.14 83.7 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.235 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.59 ' HB2' ' HB3' ' A' ' 69' ' ' ASP . 26.1 m80 -62.48 -52.45 63.47 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 122.968 0.507 . . . . 0.0 111.271 -178.588 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.488 HG12 ' O ' ' A' ' 69' ' ' ASP . 48.6 mm -57.52 -43.13 82.43 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 O-C-N 123.817 0.698 . . . . 0.0 110.09 -177.395 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.82 -38.93 83.4 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 124.403 1.064 . . . . 0.0 111.764 178.672 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 43.8 mm-40 -68.87 -36.06 77.65 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.42 0.688 . . . . 0.0 111.748 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.483 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.6 mt -69.59 -51.69 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.989 0 C-N-CA 122.743 0.417 . . . . 0.0 110.186 -177.095 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.417 HG12 ' HB2' ' A' ' 82' ' ' TYR . 12.4 tt -70.43 -30.55 43.38 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.071 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.536 -174.544 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 3.8 t -74.86 -30.3 61.29 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 176.272 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -74.39 -23.04 58.92 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.557 0.743 . . . . 0.0 110.533 173.483 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.55 -6.99 55.59 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 123.32 0.648 . . . . 0.0 111.207 172.533 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 100.03 9.55 48.31 Favored Glycine 0 C--N 1.352 1.469 0 CA-C-O 119.797 -0.446 . . . . 0.0 113.727 173.284 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.595 ' HB3' HG11 ' A' ' 28' ' ' VAL . 84.9 m-85 -109.09 121.5 45.29 Favored 'General case' 0 N--CA 1.481 1.079 0 C-N-CA 123.715 0.806 . . . . 0.0 109.289 -178.218 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 31.3 m -88.18 103.4 5.03 Favored Pre-proline 0 CA--C 1.559 1.325 0 C-N-CA 123.868 0.867 . . . . 0.0 111.396 -175.057 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -91.01 -74.65 0.0 OUTLIER 'Trans proline' 0 C--N 1.376 2.023 0 C-N-CA 123.564 2.843 . . . . 0.0 112.477 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 . . . . . 0 CA--C 1.554 1.109 0 C-N-CA 125.54 1.536 . . . . 0.0 111.372 -179.353 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.24 0 CA-C-O 121.013 0.435 . . . . 0.0 110.36 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.38 -153.77 30.31 Favored Glycine 0 C--N 1.342 0.882 0 CA-C-N 115.28 -0.873 . . . . 0.0 112.739 178.584 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.523 HD13 ' HA ' ' A' ' 70' ' ' ALA . 56.1 mt -79.78 109.83 14.57 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 123.788 0.835 . . . . 0.0 109.848 -176.764 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.558 ' HA ' HG12 ' A' ' 63' ' ' VAL . 19.6 p -92.17 109.03 20.39 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.001 0.52 . . . . 0.0 111.405 -174.282 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 88.9 m-85 -105.17 110.29 22.61 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.162 0.585 . . . . 0.0 109.954 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 11.7 m170 -82.49 92.49 7.08 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.459 HG22 ' HB3' ' A' ' 84' ' ' PRO . 31.0 t -83.27 105.48 13.03 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.256 -175.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -79.22 -10.76 59.9 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 122.774 0.43 . . . . 0.0 111.515 -176.624 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -93.41 -0.8 56.38 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 123.813 0.845 . . . . 0.0 111.476 173.311 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.48 ' HB3' ' HB3' ' A' ' 60' ' ' ARG . 26.7 ttt -73.62 137.36 44.16 Favored 'General case' 0 CA--C 1.543 0.679 0 CA-C-O 121.58 0.705 . . . . 0.0 111.754 -176.445 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.0 t -110.1 164.47 12.6 Favored 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 125.507 1.523 . . . . 0.0 109.054 175.571 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.466 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 60.1 m -59.0 -178.6 0.05 Allowed 'General case' 0 CA--C 1.559 1.318 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -53.95 -21.56 17.23 Favored Glycine 0 C--N 1.353 1.49 0 N-CA-C 116.682 1.433 . . . . 0.0 116.682 -169.318 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 33.1 m170 -62.54 -21.35 65.48 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 123.532 0.733 . . . . 0.0 112.797 -177.427 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 53.2 t -139.12 17.7 2.61 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 123.434 0.694 . . . . 0.0 110.811 178.583 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.85 -31.45 69.3 Favored 'General case' 0 N--CA 1.482 1.126 0 C-N-CA 123.03 0.532 . . . . 0.0 111.811 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.76 -23.49 74.04 Favored Glycine 0 C--N 1.347 1.174 0 O-C-N 123.471 0.482 . . . . 0.0 113.586 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 92.1 t -69.47 -40.47 79.85 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.616 0.767 . . . . 0.0 109.873 173.373 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 23.2 mt -72.24 -40.7 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 CA-C-N 114.72 -1.127 . . . . 0.0 109.91 -177.644 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -59.65 -54.79 42.33 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 114.664 -1.153 . . . . 0.0 109.999 172.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.59 -30.05 71.13 Favored Glycine 0 C--N 1.349 1.26 0 O-C-N 124.604 1.19 . . . . 0.0 113.389 -175.751 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.46 -53.59 54.43 Favored 'General case' 0 C--N 1.351 0.658 0 C-N-CA 124.146 0.978 . . . . 0.0 110.9 176.421 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.466 HD11 HD12 ' A' ' 77' ' ' ILE . 64.2 mt -75.22 -59.06 3.61 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.572 178.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -50.02 -48.15 52.81 Favored 'General case' 0 N--CA 1.483 1.19 0 C-N-CA 126.215 1.806 . . . . 0.0 113.688 -169.489 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.4 mptt -69.45 -38.17 77.67 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 122.792 0.437 . . . . 0.0 111.407 -178.717 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.9 m -73.35 -33.08 64.89 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 123.219 0.607 . . . . 0.0 111.02 -178.164 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 3.9 m -136.32 81.6 36.93 Favored Pre-proline 0 CA--C 1.556 1.201 0 C-N-CA 124.066 0.946 . . . . 0.0 110.537 178.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_exo -62.91 123.04 11.56 Favored 'Trans proline' 0 C--N 1.381 2.253 0 C-N-CA 122.827 2.351 . . . . 0.0 111.308 174.035 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.77 -24.59 7.48 Favored Glycine 0 C--N 1.342 0.899 0 CA-C-O 119.866 -0.408 . . . . 0.0 112.234 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.21 104.86 5.95 Favored 'General case' 0 C--N 1.354 0.761 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 172.513 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.52 100.41 2.73 Favored 'General case' 0 C--N 1.348 0.525 0 C-N-CA 123.318 0.647 . . . . 0.0 110.529 -173.528 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.415 HG12 HG12 ' A' ' 64' ' ' VAL . 27.1 m -85.36 134.24 27.59 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 O-C-N 123.603 0.564 . . . . 0.0 110.744 -173.28 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 44.0 t-80 -135.69 99.89 4.32 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 169.256 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.67 116.32 23.14 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 115.021 -0.99 . . . . 0.0 108.949 178.049 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -103.27 105.85 48.48 Favored Pre-proline 0 N--CA 1.478 0.944 0 CA-C-O 118.47 -0.776 . . . . 0.0 108.973 -177.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.466 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 72.4 Cg_exo -54.79 -41.88 73.97 Favored 'Trans proline' 0 C--N 1.378 2.127 0 C-N-CA 123.178 2.585 . . . . 0.0 114.67 179.391 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -67.78 -45.57 74.48 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 123.114 0.565 . . . . 0.0 111.75 -173.274 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.4 t -89.88 -18.93 25.24 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 123.686 0.794 . . . . 0.0 111.089 -178.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.48 ' HB3' ' HB3' ' A' ' 31' ' ' MET . 0.2 OUTLIER 61.28 47.1 7.25 Favored 'General case' 0 N--CA 1.482 1.138 0 C-N-CA 124.699 1.2 . . . . 0.0 110.272 -175.676 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 54.1 m -128.84 115.16 17.48 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 123.178 0.591 . . . . 0.0 110.246 -173.752 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 25.4 t -98.56 108.53 22.28 Favored 'Isoleucine or valine' 0 C--O 1.24 0.6 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 175.447 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.558 HG12 ' HA ' ' A' ' 25' ' ' SER . 34.7 m -99.46 136.08 32.11 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.201 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.454 HG21 HG21 ' A' ' 73' ' ' ILE . 21.4 m -119.16 133.84 64.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.345 0.658 . . . . 0.0 110.181 -178.364 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -113.0 153.31 17.62 Favored Glycine 0 C--N 1.35 1.311 0 CA-C-N 116.303 -0.408 . . . . 0.0 112.787 -175.001 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.7 14.5 82.34 Favored Glycine 0 C--N 1.348 1.23 0 N-CA-C 113.945 0.338 . . . . 0.0 113.945 175.557 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 3.6 m -129.54 134.8 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 123.85 0.86 . . . . 0.0 110.245 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.6 m -95.52 -23.85 16.9 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 123.686 0.794 . . . . 0.0 111.099 176.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -79.05 87.25 4.84 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-O 121.141 0.496 . . . . 0.0 111.3 -175.183 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.523 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -70.63 -46.1 63.97 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.943 -175.438 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -61.6 -36.61 81.2 Favored 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.961 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 74.7 t60 -63.11 -51.68 65.61 Favored 'General case' 0 N--CA 1.473 0.715 0 O-C-N 123.856 0.722 . . . . 0.0 110.852 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.454 HG21 HG21 ' A' ' 64' ' ' VAL . 41.7 mm -59.45 -42.32 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 123.646 0.591 . . . . 0.0 110.379 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.0 -41.42 98.04 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.375 -177.492 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 54.8 mm-40 -63.24 -39.97 96.12 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.464 0.706 . . . . 0.0 111.607 178.774 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 85.5 mt -61.78 -54.25 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.403 0.681 . . . . 0.0 111.41 -178.628 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.466 HD12 HD11 ' A' ' 44' ' ' ILE . 14.0 tt -73.84 -33.13 36.45 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.913 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.7 -171.53 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.9 t -71.76 -29.26 64.31 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 176.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.07 -22.99 63.0 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.803 0.841 . . . . 0.0 111.167 173.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -82.93 -3.09 56.63 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 123.751 0.82 . . . . 0.0 111.774 175.683 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.22 -6.23 59.54 Favored Glycine 0 C--N 1.348 1.217 0 CA-C-O 120.155 -0.247 . . . . 0.0 113.311 178.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.408 ' HB3' HG11 ' A' ' 28' ' ' VAL . 87.0 m-85 -106.07 103.15 12.57 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -178.539 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 53.0 m -94.4 114.2 62.77 Favored Pre-proline 0 CA--C 1.553 1.085 0 C-N-CA 123.201 0.6 . . . . 0.0 111.633 -171.636 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.459 ' HB3' HG22 ' A' ' 28' ' ' VAL . 25.4 Cg_endo -95.99 -11.11 0.84 Allowed 'Trans proline' 0 C--N 1.377 2.031 0 C-N-CA 123.27 2.647 . . . . 0.0 113.328 167.227 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 . . . . . 0 C--O 1.251 1.157 0 C-N-CA 124.006 0.922 . . . . 0.0 108.699 -173.785 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.284 0 CA-C-O 120.589 0.233 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.62 172.7 49.32 Favored Glycine 0 C--N 1.345 1.038 0 CA-C-N 116.006 -0.543 . . . . 0.0 113.369 177.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.442 HD13 ' HA ' ' A' ' 70' ' ' ALA . 32.2 mt -87.72 116.93 26.2 Favored 'General case' 0 C--O 1.239 0.522 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 175.708 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 28.6 p -92.13 111.32 22.83 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 122.871 0.468 . . . . 0.0 111.214 -173.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -108.95 133.64 52.69 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.274 1.029 . . . . 0.0 108.809 175.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 18.6 p80 -125.89 137.1 53.71 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.258 0.623 . . . . 0.0 109.803 -176.429 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.768 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 67.0 t -117.51 120.02 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 N-CA-C 107.162 -1.421 . . . . 0.0 107.162 170.828 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -70.68 -21.97 62.52 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -175.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -89.56 -8.61 52.31 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 123.411 0.685 . . . . 0.0 111.009 177.377 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.768 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 25.7 ttt -56.14 106.67 0.29 Allowed 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.911 0.884 . . . . 0.0 112.341 -170.439 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.415 ' O ' ' HB3' ' A' ' 36' ' ' CYS . 67.1 p -70.94 162.24 29.68 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 123.651 0.78 . . . . 0.0 109.284 167.358 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 79.5 m -61.39 -104.86 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 123.488 0.715 . . . . 0.0 111.808 -177.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.49 -30.9 75.51 Favored Glycine 0 C--N 1.353 1.489 0 CA-C-N 119.391 0.996 . . . . 0.0 113.603 -172.705 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 21.7 t-80 -62.73 -30.11 71.18 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 123.98 0.912 . . . . 0.0 112.659 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.638 ' SG ' ' HG3' ' A' ' 31' ' ' MET . 51.9 t -106.16 -31.25 8.77 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 122.51 0.324 . . . . 0.0 110.44 179.858 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -62.94 -49.6 74.11 Favored 'General case' 0 C--N 1.356 0.851 0 C-N-CA 123.466 0.707 . . . . 0.0 111.698 -175.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.8 -37.08 75.53 Favored Glycine 0 C--N 1.347 1.165 0 O-C-N 123.979 0.799 . . . . 0.0 113.84 -177.071 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.501 HG12 ' HB1' ' A' ' 80' ' ' ALA . 42.7 t -71.6 -51.26 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 123.318 0.647 . . . . 0.0 110.526 -179.021 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.689 HG21 HG21 ' A' ' 62' ' ' VAL . 64.7 mt -64.81 -53.93 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 CA-C-N 115.443 -0.798 . . . . 0.0 111.646 -176.017 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 48.6 mtmt -57.84 -46.89 84.12 Favored 'General case' 0 N--CA 1.474 0.746 0 O-C-N 123.889 0.743 . . . . 0.0 110.064 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.31 -36.74 93.5 Favored Glycine 0 C--N 1.351 1.41 0 O-C-N 124.346 1.028 . . . . 0.0 113.142 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -67.42 -54.02 24.05 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 122.743 0.417 . . . . 0.0 111.121 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.596 HG21 HG11 ' A' ' 64' ' ' VAL . 63.9 mt -67.36 -42.88 87.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 C-N-CA 123.275 0.63 . . . . 0.0 111.563 -176.231 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -61.33 -47.53 85.48 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.877 0.871 . . . . 0.0 111.626 -177.69 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -73.13 -37.06 66.79 Favored 'General case' 0 N--CA 1.48 1.035 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.942 -176.651 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 58.8 m -73.61 -40.99 63.41 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 122.658 0.383 . . . . 0.0 111.149 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.4 HG11 HG11 ' A' ' 67' ' ' VAL . 24.2 t -114.08 102.69 55.02 Favored Pre-proline 0 N--CA 1.481 1.084 0 C-N-CA 123.185 0.594 . . . . 0.0 110.277 -176.578 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -68.16 107.03 1.47 Allowed 'Trans proline' 0 C--N 1.373 1.826 0 C-N-CA 122.717 2.278 . . . . 0.0 111.123 173.038 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.16 -10.94 10.8 Favored Glycine 0 C--N 1.345 1.076 0 CA-C-O 119.251 -0.749 . . . . 0.0 113.619 178.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.41 106.6 7.04 Favored 'General case' 0 N--CA 1.479 0.977 0 CA-C-N 117.833 0.816 . . . . 0.0 109.038 174.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.58 99.03 7.89 Favored 'General case' 0 N--CA 1.465 0.31 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 -178.649 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.52 HG12 HG12 ' A' ' 64' ' ' VAL . 26.9 m -86.51 134.17 28.05 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 C-N-CA 123.412 0.685 . . . . 0.0 110.366 -174.353 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 43.6 t-80 -142.81 102.16 3.98 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 172.46 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.443 ' HB1' ' HE1' ' A' ' 31' ' ' MET . . . -89.61 115.79 27.27 Favored 'General case' 0 C--O 1.239 0.509 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 171.126 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.434 ' HA ' ' HD2' ' A' ' 57' ' ' PRO . 20.0 t70 -92.08 114.27 61.63 Favored Pre-proline 0 CA--C 1.546 0.8 0 CA-C-O 118.142 -0.932 . . . . 0.0 109.549 -177.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.434 ' HD2' ' HA ' ' A' ' 56' ' ' ASP . 7.3 Cg_endo -47.27 -33.6 16.61 Favored 'Trans proline' 0 C--N 1.381 2.259 0 C-N-CA 124.612 3.542 . . . . 0.0 115.29 178.267 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.47 -44.32 24.88 Favored 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -177.546 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.1 t -93.27 -23.38 18.53 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.405 0.682 . . . . 0.0 111.955 -173.012 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.491 ' HB3' ' HB3' ' A' ' 31' ' ' MET . 11.7 mmm180 57.63 41.29 25.78 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 125.596 1.558 . . . . 0.0 111.578 -173.422 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.8 m -119.26 127.69 53.47 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 123.286 0.635 . . . . 0.0 110.028 -177.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.689 HG21 HG21 ' A' ' 40' ' ' ILE . 21.6 t -99.59 106.17 18.63 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 C-N-CA 124.658 1.183 . . . . 0.0 108.951 177.124 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 25.7 m -94.11 135.43 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 175.486 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.596 HG11 HG21 ' A' ' 44' ' ' ILE . 22.2 m -120.87 107.88 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-O 121.674 0.749 . . . . 0.0 110.017 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.71 152.4 21.85 Favored Glycine 0 C--N 1.346 1.115 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.789 -175.533 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.8 -24.47 26.08 Favored Glycine 0 C--N 1.344 0.997 0 C-N-CA 123.042 0.353 . . . . 0.0 113.036 178.39 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.4 HG11 HG11 ' A' ' 48' ' ' VAL . 27.4 m -111.24 145.64 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 123.904 0.881 . . . . 0.0 110.135 -177.473 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t -117.71 10.01 13.21 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 123.624 0.77 . . . . 0.0 109.771 176.364 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -86.58 74.83 9.81 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.222 1.009 . . . . 0.0 109.522 -176.083 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.442 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -63.79 -47.37 81.16 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.39 0.676 . . . . 0.0 112.252 -172.191 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.503 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.47 -39.64 94.99 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 123.113 0.565 . . . . 0.0 110.788 -179.818 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 74.1 t60 -63.13 -51.69 65.51 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.286 1.034 . . . . 0.0 111.279 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.46 ' O ' HG22 ' A' ' 77' ' ' ILE . 41.3 mm -60.75 -38.47 78.88 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 O-C-N 123.744 0.652 . . . . 0.0 109.962 179.113 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.81 -36.74 79.8 Favored 'General case' 0 N--CA 1.476 0.856 0 O-C-N 124.247 0.967 . . . . 0.0 111.837 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.503 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 11.7 mm-40 -69.35 -34.78 75.11 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.16 0.584 . . . . 0.0 111.26 177.537 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 71.5 mt -71.75 -48.44 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 C-N-CA 123.441 0.696 . . . . 0.0 111.961 -177.538 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.462 ' HB ' HD11 ' A' ' 44' ' ' ILE . 5.0 tt -66.53 -37.27 79.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.184 0 C-N-CA 122.871 0.469 . . . . 0.0 110.851 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 t -71.18 -29.61 65.39 Favored 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 122.463 0.305 . . . . 0.0 110.379 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.61 -24.27 62.71 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 123.751 0.82 . . . . 0.0 111.373 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.501 ' HB1' HG12 ' A' ' 39' ' ' VAL . . . -75.02 -6.09 47.52 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.389 0.675 . . . . 0.0 111.578 175.807 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.29 1.38 56.85 Favored Glycine 0 C--N 1.35 1.325 0 CA-C-O 119.884 -0.398 . . . . 0.0 112.98 176.406 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -120.31 104.71 10.26 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 178.562 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.7 t -86.32 116.96 67.83 Favored Pre-proline 0 CA--C 1.554 1.119 0 C-N-CA 123.397 0.679 . . . . 0.0 110.354 -178.642 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -79.88 148.67 19.94 Favored 'Trans proline' 0 C--N 1.375 1.961 0 C-N-CA 122.742 2.294 . . . . 0.0 111.571 174.381 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.4 mp0 . . . . . 0 C--O 1.251 1.148 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -176.789 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.92 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 163.92 166.32 22.59 Favored Glycine 0 C--N 1.341 0.843 0 N-CA-C 111.412 -0.675 . . . . 0.0 111.412 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.401 HD13 ' HA ' ' A' ' 70' ' ' ALA . 34.0 mt -88.99 108.24 19.47 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.652 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.3 p -92.36 111.35 22.89 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 122.844 0.458 . . . . 0.0 110.606 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -106.24 124.88 50.28 Favored 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 123.862 0.865 . . . . 0.0 109.72 179.493 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 32.1 m-70 -84.03 136.77 33.91 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 175.715 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 p -157.31 96.98 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.091 0.957 . . . . 0.0 109.059 -176.364 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -69.79 -29.46 66.77 Favored 'General case' 0 N--CA 1.479 1.007 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.443 -176.21 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.5 m-20 -74.29 -9.84 59.01 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.164 0.586 . . . . 0.0 112.104 -178.703 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.612 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 56.3 ttp -72.69 113.06 9.3 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-O 120.944 0.402 . . . . 0.0 110.536 177.145 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.401 ' OG1' ' HB3' ' A' ' 36' ' ' CYS . 62.7 p -77.51 166.36 23.17 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 123.993 0.917 . . . . 0.0 109.912 168.81 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 27.9 p -57.11 -169.69 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 124.121 0.968 . . . . 0.0 112.6 175.822 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.73 3.5 0.64 Allowed Glycine 0 C--N 1.357 1.732 0 N-CA-C 115.922 1.129 . . . . 0.0 115.922 -174.021 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 3.6 m80 -63.3 -44.72 94.22 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.786 0.834 . . . . 0.0 110.798 166.031 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.401 ' HB3' ' OG1' ' A' ' 32' ' ' THR . 43.6 t -141.47 9.51 2.03 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 123.189 0.596 . . . . 0.0 111.987 -176.018 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.65 -30.89 69.69 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 122.814 0.446 . . . . 0.0 110.732 173.239 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.58 -20.84 53.15 Favored Glycine 0 C--N 1.348 1.238 0 CA-C-N 114.997 -1.001 . . . . 0.0 114.262 176.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.501 HG12 ' HB1' ' A' ' 80' ' ' ALA . 57.8 t -65.48 -44.25 94.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 122.851 0.461 . . . . 0.0 110.128 174.221 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.709 HG21 HG21 ' A' ' 62' ' ' VAL . 43.7 mt -69.7 -54.4 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 C-N-CA 123.322 0.649 . . . . 0.0 110.619 175.457 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.425 ' O ' ' HG3' ' A' ' 45' ' ' GLU . 9.7 mtpm? -56.68 -51.93 66.87 Favored 'General case' 0 C--N 1.347 0.487 0 O-C-N 124.439 1.087 . . . . 0.0 110.216 -174.773 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.482 ' O ' ' HD3' ' A' ' 46' ' ' LYS . . . -61.87 -40.18 98.5 Favored Glycine 0 C--N 1.342 0.886 0 O-C-N 124.984 1.428 . . . . 0.0 112.822 178.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.79 -53.48 57.32 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-N 117.161 0.48 . . . . 0.0 110.955 179.181 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.572 HG21 HG11 ' A' ' 64' ' ' VAL . 68.3 mt -62.11 -39.9 85.54 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.823 0 CA-C-N 115.43 -0.805 . . . . 0.0 111.972 -179.163 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.425 ' HG3' ' O ' ' A' ' 41' ' ' LYS . 76.8 mt-10 -62.0 -50.46 71.96 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 123.157 0.583 . . . . 0.0 112.108 179.582 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.482 ' HD3' ' O ' ' A' ' 42' ' ' GLY . 13.3 mptt -73.0 -28.11 62.18 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.52 -171.536 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.1 m -85.15 -41.06 16.02 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 122.815 0.446 . . . . 0.0 110.291 177.565 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.2 t -127.03 103.58 23.39 Favored Pre-proline 0 N--CA 1.483 1.213 0 C-N-CA 124.117 0.967 . . . . 0.0 109.772 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -66.91 136.58 41.99 Favored 'Trans proline' 0 C--N 1.374 1.906 0 C-N-CA 122.772 2.315 . . . . 0.0 111.684 172.037 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.18 -4.74 67.73 Favored Glycine 0 C--N 1.346 1.084 0 CA-C-O 119.769 -0.462 . . . . 0.0 113.948 175.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.61 106.68 9.56 Favored 'General case' 0 C--N 1.351 0.649 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 173.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.423 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -77.15 99.52 5.43 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -177.063 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.41 HG12 HG12 ' A' ' 64' ' ' VAL . 27.7 m -85.28 127.45 39.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 123.123 0.569 . . . . 0.0 110.886 -171.089 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' HIS . . . . . 0.411 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 29.2 t60 -131.62 96.95 4.08 Favored 'General case' 0 C--N 1.345 0.391 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 176.069 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.612 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -93.6 113.59 25.73 Favored 'General case' 0 C--O 1.241 0.646 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 176.031 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -99.66 114.83 65.86 Favored Pre-proline 0 N--CA 1.468 0.433 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 -177.397 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.52 -40.4 57.12 Favored 'Trans proline' 0 C--N 1.373 1.829 0 C-N-CA 123.011 2.474 . . . . 0.0 112.767 -176.234 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -74.31 -47.8 32.4 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 123.619 0.767 . . . . 0.0 111.31 -176.762 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.1 m -81.26 -15.65 54.94 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.7 0.8 . . . . 0.0 111.455 -176.111 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.7 mmt180 62.97 29.43 16.46 Favored 'General case' 0 N--CA 1.487 1.421 0 C-N-CA 124.63 1.172 . . . . 0.0 111.437 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 33.2 m -122.79 122.76 39.47 Favored 'General case' 0 N--CA 1.479 1.017 0 O-C-N 121.825 -0.547 . . . . 0.0 111.521 -169.842 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.709 HG21 HG21 ' A' ' 40' ' ' ILE . 40.5 t -99.11 106.4 18.86 Favored 'Isoleucine or valine' 0 C--N 1.35 0.608 0 C-N-CA 123.943 0.897 . . . . 0.0 108.977 173.279 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.0 t -100.41 123.2 53.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.617 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.585 HG21 HG21 ' A' ' 73' ' ' ILE . 17.0 m -111.56 108.94 26.77 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.994 0 CA-C-O 121.475 0.655 . . . . 0.0 110.158 179.393 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.44 150.84 21.03 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.549 -176.535 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.13 -23.67 30.4 Favored Glycine 0 C--N 1.344 0.984 0 C-N-CA 123.104 0.383 . . . . 0.0 113.051 177.037 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 22.4 m -105.54 151.13 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 123.969 0.908 . . . . 0.0 110.151 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.0 m -126.84 -2.55 6.57 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 124.005 0.922 . . . . 0.0 110.36 -178.658 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -87.35 73.0 9.71 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.54 1.136 . . . . 0.0 110.247 -177.216 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.401 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -64.01 -29.17 70.35 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 114.907 -1.042 . . . . 0.0 112.453 -174.747 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -63.76 -49.37 73.25 Favored 'General case' 0 N--CA 1.474 0.745 0 O-C-N 123.799 0.687 . . . . 0.0 110.863 177.545 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.5 ' O ' HG13 ' A' ' 76' ' ' ILE . 39.9 m170 -59.41 -54.93 41.05 Favored 'General case' 0 N--CA 1.478 0.957 0 O-C-N 123.488 0.493 . . . . 0.0 110.474 177.772 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.585 HG21 HG21 ' A' ' 64' ' ' VAL . 41.4 mm -57.74 -40.27 74.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 O-C-N 124.343 1.027 . . . . 0.0 110.811 -174.352 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.33 -40.11 89.47 Favored 'General case' 0 N--CA 1.48 1.029 0 O-C-N 124.039 0.837 . . . . 0.0 111.397 178.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -68.3 -32.05 71.92 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 123.181 0.593 . . . . 0.0 111.291 178.071 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.5 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.5 mt -74.77 -48.62 32.99 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 C-N-CA 122.951 0.5 . . . . 0.0 111.245 -177.125 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 73' ' ' ILE . 8.5 tt -67.38 -32.36 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 C-N-CA 123.254 0.622 . . . . 0.0 111.253 -177.939 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -75.12 -31.02 61.01 Favored 'General case' 0 CA--C 1.549 0.917 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -69.0 -18.46 64.05 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.494 0.718 . . . . 0.0 111.737 176.115 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.501 ' HB1' HG12 ' A' ' 39' ' ' VAL . . . -75.91 0.67 17.48 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 123.645 0.778 . . . . 0.0 112.269 176.414 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 95.84 16.97 37.0 Favored Glycine 0 C--N 1.35 1.328 0 C-N-CA 122.801 0.239 . . . . 0.0 112.544 179.63 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -120.76 178.38 4.72 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.361 1.065 . . . . 0.0 109.714 -177.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 39.3 m -139.41 111.83 7.78 Favored Pre-proline 0 N--CA 1.479 0.977 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 173.333 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -66.47 120.33 7.45 Favored 'Trans proline' 0 C--N 1.381 2.285 0 C-N-CA 122.423 2.082 . . . . 0.0 110.779 171.458 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 . . . . . 0 C--O 1.251 1.166 0 C-N-CA 124.212 1.005 . . . . 0.0 109.526 -175.652 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.585 ' N ' ' HG ' ' A' ' 68' ' ' SER . . . . . . . . 0 N--CA 1.479 1.02 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -124.8 97.22 0.53 Allowed Glycine 0 C--N 1.343 0.961 0 N-CA-C 110.971 -0.851 . . . . 0.0 110.971 179.122 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -87.65 115.62 25.22 Favored 'General case' 0 N--CA 1.479 1.025 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -173.224 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 76.4 p -91.06 121.45 32.87 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 123.363 0.665 . . . . 0.0 111.337 -176.554 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -106.89 130.27 54.59 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.783 0.833 . . . . 0.0 109.563 175.546 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 9.8 m-70 -90.46 120.64 31.74 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 173.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.475 HG21 HD13 ' A' ' 40' ' ' ILE . 25.7 t -111.24 91.77 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 N-CA-C 104.765 -2.309 . . . . 0.0 104.765 160.413 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -68.62 -16.29 63.8 Favored 'General case' 0 CA--C 1.548 0.881 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -159.46 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -109.7 8.78 24.91 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.258 0.623 . . . . 0.0 111.472 -178.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 56.8 ttp -73.91 99.05 3.14 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.61 0.764 . . . . 0.0 109.843 176.06 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.0 t -101.3 104.57 15.59 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 123.103 0.561 . . . . 0.0 109.569 178.328 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.462 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 17.0 t 64.83 -170.99 0.19 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.382 1.073 . . . . 0.0 111.888 176.647 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.574 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -62.27 -6.36 10.33 Favored Glycine 0 C--N 1.355 1.599 0 CA-C-O 119.203 -0.776 . . . . 0.0 114.391 178.379 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 41.2 m80 -50.22 -40.17 46.62 Favored 'General case' 0 C--N 1.365 1.278 0 C-N-CA 124.274 1.03 . . . . 0.0 111.736 172.586 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -118.83 -31.6 4.75 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.151 0.58 . . . . 0.0 110.892 176.717 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.574 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -57.91 -34.16 69.54 Favored 'General case' 0 N--CA 1.481 1.109 0 C-N-CA 123.458 0.703 . . . . 0.0 112.699 -176.092 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -58.7 -52.45 53.02 Favored Glycine 0 C--N 1.348 1.246 0 O-C-N 123.842 0.713 . . . . 0.0 114.347 -177.106 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.3 p -69.83 -30.53 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 C-N-CA 123.012 0.525 . . . . 0.0 111.561 -177.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.651 HG21 HG21 ' A' ' 62' ' ' VAL . 83.4 mt -70.23 -47.21 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 123.082 0.553 . . . . 0.0 110.666 179.216 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -61.38 -44.24 97.5 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.639 0.775 . . . . 0.0 110.467 178.689 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.14 -36.43 93.23 Favored Glycine 0 C--N 1.348 1.197 0 O-C-N 124.202 0.939 . . . . 0.0 112.899 176.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.05 -53.77 50.91 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 123.376 0.671 . . . . 0.0 110.878 -178.359 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.546 HG21 HG11 ' A' ' 64' ' ' VAL . 64.0 mt -72.82 -46.27 53.6 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.936 -175.007 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -66.93 -39.23 87.29 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 123.551 0.74 . . . . 0.0 112.249 -172.146 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.1 mptp? -83.58 -14.34 52.32 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -176.652 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 54.5 m -90.24 -39.06 13.01 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 122.98 0.512 . . . . 0.0 109.802 173.333 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 91.4 t -121.01 96.38 48.57 Favored Pre-proline 0 N--CA 1.48 1.028 0 C-N-CA 123.939 0.896 . . . . 0.0 109.323 -179.538 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.93 113.0 3.26 Favored 'Trans proline' 0 C--N 1.37 1.662 0 C-N-CA 122.346 2.031 . . . . 0.0 110.589 175.051 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.39 -11.42 9.75 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-O 119.575 -0.57 . . . . 0.0 112.722 -176.296 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -78.42 106.89 10.67 Favored 'General case' 0 C--N 1.356 0.871 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 171.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.72 99.09 4.97 Favored 'General case' 0 C--N 1.349 0.577 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.0 m -85.49 123.63 39.5 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 CA-C-O 121.023 0.439 . . . . 0.0 110.155 -172.629 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 71.9 t60 -131.79 97.88 4.31 Favored 'General case' 0 C--N 1.343 0.32 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -176.496 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.4 114.52 28.86 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -178.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.426 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 13.5 t70 -99.56 127.12 35.08 Favored Pre-proline 0 CA--C 1.54 0.586 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -177.915 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.462 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 30.8 Cg_endo -61.62 -41.16 41.32 Favored 'Trans proline' 0 C--N 1.377 2.074 0 C-N-CA 123.105 2.537 . . . . 0.0 113.23 179.264 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.19 -35.28 48.8 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.728 0.811 . . . . 0.0 111.944 -174.521 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.426 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 19.2 m -88.83 -22.07 23.39 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.443 0.697 . . . . 0.0 111.061 -177.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? 57.99 41.07 24.9 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 124.653 1.181 . . . . 0.0 110.744 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 80.8 m -132.81 121.83 23.56 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.882 -171.388 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.651 HG21 HG21 ' A' ' 40' ' ' ILE . 21.1 t -98.89 104.7 16.32 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 C-N-CA 124.426 1.091 . . . . 0.0 108.638 173.828 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.8 t -95.48 131.35 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 108.023 -1.102 . . . . 0.0 108.023 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.546 HG11 HG21 ' A' ' 44' ' ' ILE . 26.2 m -111.58 109.97 30.46 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.869 0 CA-C-O 121.636 0.731 . . . . 0.0 109.84 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -89.77 149.83 20.73 Favored Glycine 0 C--N 1.346 1.1 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.733 -174.821 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 86.3 -20.04 24.03 Favored Glycine 0 C--N 1.341 0.84 0 C-N-CA 123.055 0.359 . . . . 0.0 112.879 -178.481 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 30.3 m -123.75 145.96 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 124.46 1.104 . . . . 0.0 108.881 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.585 ' HG ' ' N ' ' A' ' 22' ' ' ALA . 19.6 m -130.19 -6.63 4.34 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 123.545 0.738 . . . . 0.0 111.302 -176.601 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -75.88 84.24 2.81 Favored 'General case' 0 CA--C 1.55 0.96 0 CA-C-O 122.338 1.066 . . . . 0.0 110.351 -178.095 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.81 -40.55 95.65 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 113.911 -1.495 . . . . 0.0 112.869 -171.384 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -58.75 -46.88 86.43 Favored 'General case' 0 N--CA 1.479 0.994 0 O-C-N 124.11 0.881 . . . . 0.0 111.882 -176.694 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 72.7 t60 -66.97 -50.78 61.24 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.023 -178.324 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 36.8 mm -59.88 -37.35 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 O-C-N 123.67 0.606 . . . . 0.0 110.407 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.43 -37.71 88.36 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 123.858 0.863 . . . . 0.0 111.736 -179.522 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 45.0 mm-40 -65.07 -35.86 82.5 Favored 'General case' 0 N--CA 1.476 0.825 0 O-C-N 123.685 0.615 . . . . 0.0 111.036 176.465 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 62.3 mt -67.99 -49.46 68.11 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.236 0 C-N-CA 123.112 0.565 . . . . 0.0 111.495 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.4 tt -71.4 -35.42 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 C-N-CA 123.182 0.593 . . . . 0.0 111.516 -176.341 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.2 t -71.63 -28.86 64.07 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 176.782 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.72 -26.8 65.44 Favored 'General case' 0 C--N 1.358 0.963 0 C-N-CA 123.592 0.757 . . . . 0.0 111.006 173.751 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.92 -3.16 33.89 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.513 0.725 . . . . 0.0 111.822 174.052 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 94.51 12.69 55.59 Favored Glycine 0 C--N 1.348 1.221 0 CA-C-O 119.713 -0.493 . . . . 0.0 113.058 175.437 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -128.5 105.81 8.56 Favored 'General case' 0 N--CA 1.483 1.224 0 CA-C-N 117.401 0.601 . . . . 0.0 109.919 179.247 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.9 t -76.4 123.93 87.92 Favored Pre-proline 0 CA--C 1.556 1.173 0 C-N-CA 123.253 0.621 . . . . 0.0 110.619 -178.099 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -79.08 173.99 12.71 Favored 'Trans proline' 0 C--N 1.373 1.824 0 C-N-CA 122.695 2.264 . . . . 0.0 111.37 168.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 . . . . . 0 C--O 1.25 1.118 0 C-N-CA 123.444 0.698 . . . . 0.0 109.331 -177.225 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -173.29 -101.79 0.15 Allowed Glycine 0 C--N 1.344 1.016 0 CA-C-N 115.793 -0.64 . . . . 0.0 112.038 -179.097 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -134.93 132.44 38.45 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-N 117.245 0.523 . . . . 0.0 109.826 -172.684 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.6 t -104.55 134.45 47.71 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 123.911 0.885 . . . . 0.0 110.709 -177.791 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -135.59 118.97 16.77 Favored 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 124.156 0.982 . . . . 0.0 109.237 173.685 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.55 ' HA ' ' HA ' ' A' ' 61' ' ' THR . 35.2 p-80 -92.26 118.38 30.82 Favored 'General case' 0 N--CA 1.477 0.898 0 CA-C-N 118.657 0.662 . . . . 0.0 109.984 175.32 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.423 HG22 ' HA ' ' A' ' 84' ' ' PRO . 39.7 t -96.27 97.22 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 170.613 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -61.01 -26.92 67.94 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 123.556 0.743 . . . . 0.0 111.864 -176.375 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -80.16 -19.69 46.58 Favored 'General case' 0 CA--C 1.553 1.061 0 C-N-CA 124.147 0.979 . . . . 0.0 111.496 -178.002 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 62.9 ttp -68.7 129.72 40.75 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.655 0.782 . . . . 0.0 112.235 -175.492 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.3 p -85.43 169.88 13.23 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 124.333 1.053 . . . . 0.0 109.987 170.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 35.0 t -56.11 -151.7 0.0 OUTLIER 'General case' 0 CA--C 1.581 2.159 0 C-N-CA 125.078 1.351 . . . . 0.0 113.178 178.637 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -62.0 -2.66 3.99 Favored Glycine 0 C--N 1.356 1.688 0 N-CA-C 116.144 1.218 . . . . 0.0 116.144 -171.617 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -77.28 -22.79 51.54 Favored 'General case' 0 CA--C 1.552 1.021 0 CA-C-N 117.67 0.735 . . . . 0.0 112.208 178.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 19.3 p -124.41 -5.59 7.69 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 122.439 0.296 . . . . 0.0 111.597 177.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -64.65 -31.16 72.26 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.416 0.686 . . . . 0.0 112.498 -175.132 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.08 -50.46 67.58 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 114.565 0.586 . . . . 0.0 114.565 -174.052 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.3 m -66.35 -31.97 55.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 123.093 0.557 . . . . 0.0 112.119 -178.598 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.442 HG21 HG21 ' A' ' 62' ' ' VAL . 76.1 mt -72.22 -54.97 14.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.694 0 C-N-CA 123.884 0.874 . . . . 0.0 110.17 -177.871 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -61.33 -42.51 98.8 Favored 'General case' 0 CA--C 1.537 0.456 0 CA-C-N 114.343 -1.299 . . . . 0.0 110.79 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -68.07 -34.01 80.34 Favored Glycine 0 C--N 1.342 0.897 0 O-C-N 124.16 0.913 . . . . 0.0 113.131 -178.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -65.08 -53.75 40.74 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.789 0.435 . . . . 0.0 110.514 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.577 ' HA ' HG21 ' A' ' 76' ' ' ILE . 62.9 mt -63.98 -40.87 90.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.719 -178.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -64.68 -43.67 92.81 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.308 0.643 . . . . 0.0 111.549 -179.695 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -81.76 -18.56 43.79 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -175.108 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 36.8 m -87.26 -40.98 14.03 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 175.23 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.7 t -121.83 88.9 47.69 Favored Pre-proline 0 N--CA 1.48 1.069 0 C-N-CA 123.872 0.869 . . . . 0.0 108.831 174.067 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -60.94 113.18 1.61 Allowed 'Trans proline' 0 C--N 1.375 1.93 0 C-N-CA 122.632 2.222 . . . . 0.0 111.588 175.01 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.5 -5.37 11.86 Favored Glycine 0 C--N 1.341 0.856 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.804 -176.163 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -78.07 106.84 10.21 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 173.745 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.03 96.82 3.88 Favored 'General case' 0 C--N 1.351 0.658 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.454 HG12 HG12 ' A' ' 64' ' ' VAL . 7.8 m -88.85 134.83 27.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.729 -172.505 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -142.08 101.45 3.93 Favored 'General case' 0 C--N 1.352 0.684 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 176.621 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.12 114.69 22.44 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 173.849 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.401 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 10.2 t70 -93.41 130.35 35.79 Favored Pre-proline 0 CA--C 1.542 0.666 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 -175.071 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 56' ' ' ASP . 27.6 Cg_exo -64.86 -53.65 0.88 Allowed 'Trans proline' 0 C--N 1.372 1.797 0 C-N-CA 122.634 2.223 . . . . 0.0 113.058 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.82 -36.02 50.66 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.266 -170.164 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 26.3 t -87.6 -18.25 30.1 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 123.432 0.693 . . . . 0.0 110.685 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.419 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 10.4 mpt_? 60.94 31.36 19.97 Favored 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 124.467 1.107 . . . . 0.0 111.268 -176.586 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 27' ' ' HIS . 53.8 m -116.53 122.45 44.74 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -168.534 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.442 HG21 HG21 ' A' ' 40' ' ' ILE . 31.6 t -96.75 106.38 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 172.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 18.8 t -102.24 131.83 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.53 HG21 HG13 ' A' ' 73' ' ' ILE . 35.6 m -105.43 139.41 26.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 C-N-CA 123.422 0.689 . . . . 0.0 109.535 174.915 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -118.36 151.03 18.0 Favored Glycine 0 C--N 1.341 0.859 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.058 -175.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 79.32 -12.04 27.98 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-O 120.142 -0.255 . . . . 0.0 113.092 -177.002 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 33.3 m -132.65 131.12 59.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 C-N-CA 124.406 1.083 . . . . 0.0 108.787 -178.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t -112.43 10.67 19.81 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.657 0.783 . . . . 0.0 110.121 -177.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.41 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 3.2 m-20 -70.57 87.37 0.66 Allowed 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 124.14 0.976 . . . . 0.0 110.922 -176.069 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.5 -58.16 9.65 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 122.793 0.437 . . . . 0.0 112.168 -173.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -64.66 -36.42 84.2 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.048 0.539 . . . . 0.0 111.648 -175.51 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.417 ' O ' HG13 ' A' ' 76' ' ' ILE . 65.2 m170 -65.29 -55.38 18.64 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 123.029 0.532 . . . . 0.0 111.111 -179.522 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.53 HG13 HG21 ' A' ' 64' ' ' VAL . 47.8 mm -60.93 -40.26 84.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 O-C-N 123.856 0.723 . . . . 0.0 110.316 -177.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.0 -38.38 82.45 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.17 0.988 . . . . 0.0 111.707 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 35.5 mm-40 -69.14 -35.93 76.89 Favored 'General case' 0 N--CA 1.475 0.822 0 O-C-N 123.511 0.507 . . . . 0.0 111.768 179.095 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.577 HG21 ' HA ' ' A' ' 44' ' ' ILE . 43.9 mt -65.82 -50.24 71.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 CA-C-O 121.152 0.501 . . . . 0.0 110.863 -178.402 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.415 ' HB ' HD11 ' A' ' 44' ' ' ILE . 12.3 tt -73.75 -32.81 36.03 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 CA-C-N 115.138 -0.937 . . . . 0.0 111.885 -173.546 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.1 t -72.76 -29.63 63.47 Favored 'General case' 0 N--CA 1.484 1.245 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 174.769 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.41 -28.93 67.51 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.179 0.592 . . . . 0.0 110.589 173.063 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.24 -5.94 47.14 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 123.538 0.735 . . . . 0.0 111.755 175.615 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.91 21.16 40.37 Favored Glycine 0 C--N 1.348 1.214 0 O-C-N 123.141 0.275 . . . . 0.0 112.993 176.67 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -128.02 114.49 17.17 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 123.472 0.709 . . . . 0.0 109.381 178.829 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.3 t -70.28 114.13 23.41 Favored Pre-proline 0 CA--C 1.561 1.383 0 C-N-CA 123.332 0.653 . . . . 0.0 111.117 -176.001 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.423 ' HA ' HG22 ' A' ' 28' ' ' VAL . 73.5 Cg_endo -71.53 -19.26 28.57 Favored 'Trans proline' 0 C--N 1.384 2.415 0 C-N-CA 122.856 2.37 . . . . 0.0 112.836 -177.84 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 . . . . . 0 C--O 1.246 0.896 0 C-N-CA 124.319 1.048 . . . . 0.0 108.8 -178.436 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.187 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 69.4 -158.48 53.28 Favored Glycine 0 C--N 1.351 1.403 0 O-C-N 123.365 0.416 . . . . 0.0 113.573 176.312 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 72.5 mt -108.29 107.55 18.2 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 123.714 0.806 . . . . 0.0 109.059 177.629 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.4 m -95.35 114.16 25.91 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.232 0.613 . . . . 0.0 110.822 -173.261 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -109.72 106.45 16.1 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 123.97 0.908 . . . . 0.0 110.481 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 16.3 m-70 -83.1 91.31 7.19 Favored 'General case' 0 N--CA 1.479 0.976 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 176.847 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.445 HG11 ' HB3' ' A' ' 82' ' ' TYR . 47.7 t -82.29 97.58 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 176.434 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -66.33 -24.9 66.61 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 123.23 0.612 . . . . 0.0 112.346 -171.593 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -87.74 -11.66 47.53 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 122.97 0.508 . . . . 0.0 111.636 177.866 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.539 ' HG3' ' HB2' ' A' ' 36' ' ' CYS . 13.0 ttt -71.38 137.99 48.82 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.157 0.583 . . . . 0.0 109.553 169.416 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.6 t -129.87 98.48 4.8 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 123.638 0.775 . . . . 0.0 109.911 176.458 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 59.6 m 54.64 -154.84 0.26 Allowed 'General case' 0 CA--C 1.557 1.244 0 C-N-CA 124.695 1.198 . . . . 0.0 112.843 173.236 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.537 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -58.06 -26.5 58.5 Favored Glycine 0 C--N 1.361 1.946 0 C-N-CA 123.697 0.665 . . . . 0.0 114.097 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 14.2 t-80 -56.54 -32.78 65.45 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.383 1.073 . . . . 0.0 111.793 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.539 ' HB2' ' HG3' ' A' ' 31' ' ' MET . 62.1 m -111.15 -18.18 13.05 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.181 0.592 . . . . 0.0 111.423 178.465 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.537 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -64.47 -47.16 80.02 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 123.231 0.612 . . . . 0.0 112.321 -176.247 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.26 -46.13 92.01 Favored Glycine 0 N--CA 1.475 1.281 0 O-C-N 123.995 0.809 . . . . 0.0 114.147 -172.424 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -68.22 -31.7 52.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.011 0 C-N-CA 123.626 0.77 . . . . 0.0 111.017 -179.404 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.785 HG21 HG21 ' A' ' 62' ' ' VAL . 65.8 mt -69.31 -43.99 80.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 123.641 0.777 . . . . 0.0 111.05 175.417 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.445 ' HG3' ' O ' ' A' ' 37' ' ' ALA . 95.1 mttt -58.2 -47.23 84.1 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.575 0.75 . . . . 0.0 109.546 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.65 -36.14 92.95 Favored Glycine 0 C--N 1.348 1.234 0 O-C-N 124.466 1.104 . . . . 0.0 112.824 178.32 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.38 -55.5 27.32 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 122.852 0.461 . . . . 0.0 111.142 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.502 HG21 HG11 ' A' ' 64' ' ' VAL . 57.6 mt -69.74 -47.12 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.743 -176.109 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -57.84 -50.07 74.55 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.038 0.935 . . . . 0.0 111.955 -176.149 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -70.52 -26.44 63.58 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.032 -174.357 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 47.4 m -86.13 -42.22 14.06 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.733 0.413 . . . . 0.0 110.995 -178.196 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.9 m -132.05 86.44 47.15 Favored Pre-proline 0 CA--C 1.561 1.37 0 C-N-CA 123.752 0.821 . . . . 0.0 110.702 -179.41 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -56.63 123.97 15.12 Favored 'Trans proline' 0 C--N 1.377 2.04 0 C-N-CA 123.039 2.492 . . . . 0.0 111.372 169.475 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.79 -22.34 8.17 Favored Glycine 0 N--CA 1.473 1.116 0 CA-C-O 119.979 -0.345 . . . . 0.0 112.313 -175.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.1 106.94 6.85 Favored 'General case' 0 C--N 1.355 0.808 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 175.671 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.09 100.77 9.2 Favored 'General case' 0 C--N 1.342 0.275 0 C-N-CA 123.729 0.812 . . . . 0.0 109.488 -177.43 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.485 HG12 HG12 ' A' ' 64' ' ' VAL . 35.2 m -84.57 134.59 26.65 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 123.059 0.543 . . . . 0.0 110.16 -172.477 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 48.4 t-80 -136.36 97.49 3.6 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 172.426 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.2 114.33 26.84 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -86.29 123.71 71.09 Favored Pre-proline 0 CA--C 1.542 0.64 0 CA-C-O 118.567 -0.73 . . . . 0.0 109.058 -173.222 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.47 ' HA ' ' HA ' ' A' ' 33' ' ' CYS . 21.5 Cg_endo -58.84 -45.67 27.54 Favored 'Trans proline' 0 C--N 1.372 1.81 0 C-N-CA 122.863 2.375 . . . . 0.0 112.861 179.118 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.31 -45.88 21.57 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.411 0.685 . . . . 0.0 111.815 -173.741 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 17.0 m -90.05 -5.8 56.21 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 123.479 0.712 . . . . 0.0 112.285 -172.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 40.69 45.01 1.96 Allowed 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 125.676 1.59 . . . . 0.0 112.548 -172.329 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 59.2 m -114.39 118.58 34.24 Favored 'General case' 0 C--N 1.346 0.444 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.413 -175.293 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.785 HG21 HG21 ' A' ' 40' ' ' ILE . 27.9 t -97.32 105.84 17.71 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 177.147 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 21.6 t -98.56 119.46 46.58 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 C-N-CA 123.956 0.903 . . . . 0.0 109.333 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.502 HG11 HG21 ' A' ' 44' ' ' ILE . 28.2 m -110.09 112.07 38.91 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.865 0 CA-C-O 121.562 0.696 . . . . 0.0 110.712 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.4 170.16 31.03 Favored Glycine 0 C--N 1.344 1.007 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.603 176.656 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.73 -5.92 49.9 Favored Glycine 0 N--CA 1.472 1.066 0 N-CA-C 114.069 0.388 . . . . 0.0 114.069 177.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 18.1 m -128.89 148.37 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 124.773 1.229 . . . . 0.0 109.415 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.3 t -114.47 0.15 13.94 Favored 'General case' 0 N--CA 1.482 1.159 0 C-N-CA 123.604 0.761 . . . . 0.0 110.366 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.436 ' O ' HG12 ' A' ' 73' ' ' ILE . 3.4 m-20 -91.18 70.95 6.24 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.099 0.959 . . . . 0.0 110.231 -169.703 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.94 -49.78 76.55 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 123.409 0.684 . . . . 0.0 112.575 -174.163 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.66 91.09 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.69 0.796 . . . . 0.0 111.511 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 74.8 t60 -66.39 -46.7 75.76 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.017 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.501 HG21 HG21 ' A' ' 64' ' ' VAL . 47.4 mm -60.59 -39.15 80.48 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 O-C-N 123.702 0.626 . . . . 0.0 109.671 177.589 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -58.07 -38.71 76.86 Favored 'General case' 0 N--CA 1.473 0.682 0 O-C-N 124.147 0.905 . . . . 0.0 111.641 178.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -67.94 -38.48 82.89 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 123.261 0.624 . . . . 0.0 111.192 176.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.475 HG21 ' HA ' ' A' ' 44' ' ' ILE . 64.7 mt -68.46 -50.04 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 C-N-CA 123.279 0.631 . . . . 0.0 111.528 -177.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.454 HG13 HG23 ' A' ' 40' ' ' ILE . 13.5 tt -69.37 -35.3 66.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 123.373 0.669 . . . . 0.0 111.318 -175.812 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.4 t -70.11 -29.32 66.24 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 122.207 0.203 . . . . 0.0 110.527 176.43 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.31 -17.48 64.78 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 123.51 0.724 . . . . 0.0 112.23 176.167 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -85.98 5.12 34.72 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.574 0.749 . . . . 0.0 111.355 172.408 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.36 2.55 79.71 Favored Glycine 0 C--N 1.347 1.171 0 CA-C-O 119.424 -0.653 . . . . 0.0 113.697 178.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.445 ' HB3' HG11 ' A' ' 28' ' ' VAL . 84.2 m-85 -119.16 105.48 11.42 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 117.917 0.858 . . . . 0.0 109.651 -177.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.0 t -86.87 127.72 58.79 Favored Pre-proline 0 CA--C 1.55 0.959 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.88 -170.483 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.414 ' HD3' HG23 ' A' ' 77' ' ' ILE . 57.3 Cg_endo -69.97 -36.97 9.32 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.529 2.153 . . . . 0.0 112.159 177.815 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.5 mm-40 . . . . . 0 C--O 1.251 1.142 0 C-N-CA 125.078 1.351 . . . . 0.0 111.302 -177.967 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.93 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.84 -162.52 26.84 Favored Glycine 0 C--N 1.347 1.162 0 C-N-CA 123.086 0.375 . . . . 0.0 112.549 178.653 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.5 HD13 ' HA ' ' A' ' 70' ' ' ALA . 25.1 mt -96.74 108.61 21.29 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.857 0.863 . . . . 0.0 110.34 -175.616 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.2 t -86.92 119.68 27.4 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 123.275 0.63 . . . . 0.0 109.913 177.655 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -112.79 118.02 33.8 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.558 0.743 . . . . 0.0 109.658 175.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 44.9 p-80 -83.75 88.3 7.08 Favored 'General case' 0 CA--C 1.546 0.817 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 175.434 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.52 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 35.3 t -80.79 104.39 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -172.196 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -73.31 -16.44 61.37 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 115.668 -0.696 . . . . 0.0 112.051 -175.717 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.408 ' HB3' ' H ' ' A' ' 83' ' ' THR . 35.8 t70 -106.71 16.33 24.59 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.361 0.664 . . . . 0.0 110.534 179.325 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.52 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 25.1 ttt -71.31 136.13 47.72 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 121.012 0.434 . . . . 0.0 111.516 -176.432 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 20.3 p -86.88 162.04 17.95 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.16 0.984 . . . . 0.0 110.913 173.187 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 61.2 m -74.89 -167.41 0.58 Allowed 'General case' 0 CA--C 1.561 1.376 0 C-N-CA 123.663 0.785 . . . . 0.0 111.756 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -57.66 -29.04 60.73 Favored Glycine 0 C--N 1.355 1.635 0 N-CA-C 115.695 1.038 . . . . 0.0 115.695 -172.546 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -69.3 -22.92 63.76 Favored 'General case' 0 N--CA 1.486 1.364 0 CA-C-N 117.428 0.614 . . . . 0.0 112.371 -176.681 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.7 m -123.24 13.14 9.59 Favored 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 123.636 0.774 . . . . 0.0 110.955 176.567 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -65.97 -41.64 90.9 Favored 'General case' 0 C--N 1.357 0.922 0 C-N-CA 123.131 0.572 . . . . 0.0 111.392 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.38 -25.61 67.02 Favored Glycine 0 N--CA 1.473 1.129 0 O-C-N 123.134 0.271 . . . . 0.0 113.699 -179.204 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.75 -50.07 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 123.404 0.682 . . . . 0.0 110.808 177.671 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 15.1 tt -67.99 -32.95 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 C-N-CA 123.025 0.53 . . . . 0.0 110.596 -177.429 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.421 ' HB3' HG21 ' A' ' 53' ' ' VAL . 96.1 mttt -64.23 -53.17 53.29 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 123.634 0.774 . . . . 0.0 109.56 168.478 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.409 ' HA2' ' HB3' ' A' ' 45' ' ' GLU . . . -59.06 -29.83 65.93 Favored Glycine 0 C--N 1.358 1.77 0 O-C-N 124.873 1.358 . . . . 0.0 114.046 -173.132 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.87 -54.15 48.05 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 123.818 0.847 . . . . 0.0 110.665 177.9 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.569 HG21 HG11 ' A' ' 64' ' ' VAL . 60.2 mt -75.21 -41.91 44.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.814 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.409 ' HB3' ' HA2' ' A' ' 42' ' ' GLY . 17.6 tp10 -54.26 -51.14 65.49 Favored 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 125.418 1.487 . . . . 0.0 112.282 -174.632 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? -79.64 -25.85 41.25 Favored 'General case' 0 N--CA 1.483 1.176 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.84 -175.439 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 87.0 m -76.77 -48.14 19.56 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-O 120.814 0.34 . . . . 0.0 110.673 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.508 HG11 HG11 ' A' ' 67' ' ' VAL . 56.5 t -112.22 110.23 53.72 Favored Pre-proline 0 N--CA 1.475 0.78 0 C-N-CA 123.459 0.704 . . . . 0.0 109.432 -178.424 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -72.41 110.32 2.95 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.403 2.069 . . . . 0.0 111.342 172.099 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 117.1 -2.57 19.16 Favored Glycine 0 C--N 1.342 0.867 0 CA-C-O 119.382 -0.677 . . . . 0.0 113.548 179.191 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -80.22 105.95 11.87 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 173.308 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.72 99.64 8.32 Favored 'General case' 0 C--N 1.346 0.44 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -177.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.479 HG12 HG12 ' A' ' 64' ' ' VAL . 29.3 m -84.74 129.43 37.71 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-O 121.235 0.54 . . . . 0.0 110.446 -174.077 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 63.8 t60 -125.61 97.97 5.38 Favored 'General case' 0 C--O 1.225 -0.213 0 N-CA-C 106.211 -1.774 . . . . 0.0 106.211 174.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -109.84 113.89 27.01 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 -179.176 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.413 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 11.1 t70 -105.76 119.86 51.11 Favored Pre-proline 0 N--CA 1.468 0.469 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -175.126 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -63.37 -33.77 68.8 Favored 'Trans proline' 0 C--N 1.375 1.927 0 C-N-CA 122.989 2.459 . . . . 0.0 113.088 -176.782 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.88 -45.64 23.6 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.127 0.571 . . . . 0.0 111.083 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.413 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 35.4 m -80.35 -23.95 40.18 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 123.253 0.621 . . . . 0.0 111.568 -174.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.457 ' HA ' ' SD ' ' A' ' 31' ' ' MET . 37.5 mmt180 65.08 35.41 8.01 Favored 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 124.71 1.204 . . . . 0.0 111.093 -177.464 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 11.9 m -122.8 117.97 26.89 Favored 'General case' 0 C--O 1.241 0.609 0 C-N-CA 123.029 0.532 . . . . 0.0 110.778 -171.058 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 45.9 t -103.76 106.71 20.72 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 172.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 24.9 t -105.11 130.25 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 124.452 1.101 . . . . 0.0 109.099 -179.238 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.569 HG11 HG21 ' A' ' 44' ' ' ILE . 17.6 m -117.63 109.52 27.79 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.023 0 CA-C-O 121.419 0.628 . . . . 0.0 111.107 -178.32 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -86.87 161.01 32.95 Favored Glycine 0 C--N 1.346 1.114 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.817 178.501 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 83.09 -11.3 55.37 Favored Glycine 0 N--CA 1.472 1.035 0 CA-C-O 119.806 -0.441 . . . . 0.0 113.62 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.508 HG11 HG11 ' A' ' 48' ' ' VAL . 30.6 m -128.89 150.85 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.272 0 C-N-CA 124.022 0.929 . . . . 0.0 109.935 -176.848 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 29.1 t -124.85 -2.89 7.75 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.749 0.82 . . . . 0.0 111.586 -174.199 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.508 ' HB3' ' HB3' ' A' ' 72' ' ' HIS . 6.1 m-20 -79.24 82.05 5.43 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 123.493 0.717 . . . . 0.0 109.999 -178.592 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.5 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -62.93 -49.28 75.39 Favored 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 123.231 0.612 . . . . 0.0 112.068 -172.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.463 ' O ' ' HG3' ' A' ' 75' ' ' GLU . . . -65.68 -39.35 91.23 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.62 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.508 ' HB3' ' HB3' ' A' ' 69' ' ' ASP . 79.5 t60 -70.25 -42.09 72.64 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 123.596 0.758 . . . . 0.0 112.239 -175.493 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.538 HG21 HG21 ' A' ' 64' ' ' VAL . 33.8 mm -63.74 -37.61 80.15 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 175.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.54 -33.31 74.65 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.226 176.44 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.463 ' HG3' ' O ' ' A' ' 71' ' ' ALA . 46.5 mt-10 -64.73 -41.41 95.98 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 123.191 0.596 . . . . 0.0 110.541 174.595 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 70.0 mt -69.46 -47.33 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.406 0.682 . . . . 0.0 111.265 -175.222 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 15.1 tt -74.33 -26.85 20.84 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.02 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.179 -176.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.51 ' HA ' ' O ' ' A' ' 82' ' ' TYR . 2.3 t -75.69 -29.35 58.99 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 175.236 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.51 -18.28 64.35 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.681 0.792 . . . . 0.0 111.566 175.297 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -79.83 3.35 19.91 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.814 0.845 . . . . 0.0 112.219 174.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.32 5.56 75.75 Favored Glycine 0 C--N 1.349 1.255 0 CA-C-O 120.216 -0.213 . . . . 0.0 113.024 179.294 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.51 ' O ' ' HA ' ' A' ' 78' ' ' THR . 91.7 m-85 -100.13 162.22 13.11 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.897 0.879 . . . . 0.0 110.047 178.216 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.408 ' H ' ' HB3' ' A' ' 30' ' ' ASP . 32.4 p -121.52 103.31 41.32 Favored Pre-proline 0 CA--C 1.55 0.947 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 171.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -60.84 -40.24 55.31 Favored 'Trans proline' 0 C--N 1.387 2.602 0 C-N-CA 123.061 2.508 . . . . 0.0 112.33 175.505 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 64.7 mm-40 . . . . . 0 CA--C 1.552 1.041 0 C-N-CA 124.769 1.228 . . . . 0.0 110.755 -178.04 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.086 0 CA-C-O 121.173 0.511 . . . . 0.0 109.882 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 161.2 -156.98 28.52 Favored Glycine 0 C--N 1.339 0.733 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.381 -178.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.46 HD13 ' HA ' ' A' ' 70' ' ' ALA . 25.9 mt -92.14 115.09 27.78 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 123.912 0.885 . . . . 0.0 109.579 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 47.0 t -83.53 123.05 29.35 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 122.875 0.47 . . . . 0.0 110.24 -179.297 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -125.43 101.38 6.92 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.815 0.846 . . . . 0.0 109.032 174.835 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' HIS . . . . . 0.403 ' HA ' ' HA ' ' A' ' 61' ' ' THR . 9.5 p80 -93.82 100.15 12.39 Favored 'General case' 0 CA--C 1.547 0.843 0 CA-C-O 121.503 0.668 . . . . 0.0 110.384 -174.158 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.531 ' O ' ' HB3' ' A' ' 60' ' ' ARG . 92.0 t -82.34 106.04 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 172.88 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -79.63 -7.75 58.75 Favored 'General case' 0 N--CA 1.485 1.308 0 CA-C-N 118.292 0.496 . . . . 0.0 112.137 -176.281 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -95.15 12.29 29.25 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 123.638 0.775 . . . . 0.0 111.071 171.308 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.43 ' SD ' ' HA ' ' A' ' 60' ' ' ARG . 27.6 ttt -70.9 143.51 50.96 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.541 0.736 . . . . 0.0 111.764 -176.759 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 17.2 p -125.88 165.88 17.91 Favored 'General case' 0 C--O 1.243 0.725 0 C-N-CA 125.161 1.384 . . . . 0.0 108.61 176.807 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 31.6 p -53.41 179.51 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -173.136 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.503 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -43.94 -26.6 0.85 Allowed Glycine 0 C--N 1.36 1.881 0 N-CA-C 117.603 1.801 . . . . 0.0 117.603 -166.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 69.4 t60 -55.97 -54.77 40.73 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 124.081 0.952 . . . . 0.0 111.061 176.109 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 42.6 t -96.91 -20.91 17.79 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.488 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.503 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -64.81 -36.04 83.03 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 123.068 0.547 . . . . 0.0 110.802 175.684 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.95 -24.82 73.17 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.425 -0.807 . . . . 0.0 113.169 176.103 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 43.3 t -74.5 -38.95 47.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.404 0.682 . . . . 0.0 110.237 176.094 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 22.5 mt -63.98 -47.42 90.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-O 121.455 0.645 . . . . 0.0 109.536 176.704 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.411 ' HZ3' HG23 ' A' ' 53' ' ' VAL . 9.4 mtpm? -59.23 -47.78 84.08 Favored 'General case' 0 C--N 1.35 0.588 0 CA-C-N 114.285 -1.325 . . . . 0.0 110.852 176.107 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.22 -33.03 86.14 Favored Glycine 0 C--N 1.345 1.081 0 O-C-N 124.502 1.126 . . . . 0.0 113.094 -175.396 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -60.49 -54.61 43.47 Favored 'General case' 0 C--N 1.348 0.515 0 C-N-CA 123.133 0.573 . . . . 0.0 110.521 178.264 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.5 HG21 HG11 ' A' ' 64' ' ' VAL . 54.7 mt -72.55 -45.72 57.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.804 -175.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -64.22 -41.14 97.15 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.947 0.899 . . . . 0.0 111.92 -171.228 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -76.22 -34.75 59.24 Favored 'General case' 0 N--CA 1.481 1.076 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.221 -178.634 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 86.7 m -72.91 -45.84 55.96 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 122.435 0.294 . . . . 0.0 110.744 -178.647 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 78.0 t -120.5 94.23 48.7 Favored Pre-proline 0 N--CA 1.478 0.933 0 C-N-CA 123.679 0.791 . . . . 0.0 109.054 176.725 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_exo -64.12 123.87 12.57 Favored 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 122.549 2.166 . . . . 0.0 110.622 169.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 119.68 -20.28 9.45 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 112.108 -0.397 . . . . 0.0 112.108 -174.364 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -79.72 105.7 11.21 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 174.419 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.36 98.25 8.09 Favored 'General case' 0 C--N 1.342 0.259 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -178.026 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.597 HG12 HG12 ' A' ' 64' ' ' VAL . 15.6 m -85.06 116.07 27.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 C-N-CA 123.513 0.725 . . . . 0.0 110.097 -172.449 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 54.9 t-80 -112.55 99.22 7.79 Favored 'General case' 0 C--N 1.347 0.472 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 176.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.34 127.68 34.13 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -111.2 108.11 57.22 Favored Pre-proline 0 CA--C 1.537 0.471 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 175.147 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -64.03 -33.48 62.18 Favored 'Trans proline' 0 C--N 1.367 1.521 0 C-N-CA 122.678 2.252 . . . . 0.0 112.86 -178.442 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.76 -39.67 43.48 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.46 0.704 . . . . 0.0 111.85 -175.209 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.3 t -92.82 -15.02 26.99 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 123.712 0.805 . . . . 0.0 110.851 -178.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.531 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 63.52 45.26 4.82 Favored 'General case' 0 CA--C 1.554 1.1 0 C-N-CA 124.452 1.101 . . . . 0.0 110.421 -179.272 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.403 ' HA ' ' HA ' ' A' ' 27' ' ' HIS . 17.8 m -132.85 120.9 22.15 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -170.72 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 47.4 t -104.18 108.28 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 123.686 0.794 . . . . 0.0 109.458 173.779 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 43.1 t -104.07 121.59 55.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.893 0.877 . . . . 0.0 109.551 -177.6 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.597 HG12 HG12 ' A' ' 53' ' ' VAL . 27.0 m -102.45 114.43 41.9 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 CA-C-O 121.427 0.632 . . . . 0.0 111.151 -176.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.83 160.37 24.21 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.064 179.129 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 83.22 -11.75 53.64 Favored Glycine 0 N--CA 1.474 1.232 0 CA-C-N 116.695 0.248 . . . . 0.0 113.68 177.249 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 31.3 m -126.62 142.22 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 124.474 1.11 . . . . 0.0 109.064 178.665 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.2 m -113.25 3.59 16.06 Favored 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 123.352 0.661 . . . . 0.0 110.487 178.403 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -82.44 79.18 8.95 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.129 0.972 . . . . 0.0 110.432 -174.39 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.46 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -63.77 -37.92 89.18 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 122.86 0.464 . . . . 0.0 111.719 -175.479 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.502 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -65.44 -47.19 77.02 Favored 'General case' 0 N--CA 1.475 0.818 0 O-C-N 123.551 0.532 . . . . 0.0 110.718 179.363 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 17.3 m-70 -58.24 -52.9 63.64 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 123.6 0.76 . . . . 0.0 111.11 -177.814 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.439 HG13 HG21 ' A' ' 64' ' ' VAL . 47.6 mm -62.02 -38.88 81.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.079 -178.534 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.84 -40.47 88.62 Favored 'General case' 0 C--N 1.354 0.779 0 O-C-N 124.063 0.852 . . . . 0.0 111.118 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.502 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 39.8 mm-40 -61.51 -45.82 92.58 Favored 'General case' 0 N--CA 1.479 1.003 0 O-C-N 123.872 0.733 . . . . 0.0 110.393 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.447 HG21 ' HA ' ' A' ' 44' ' ' ILE . 46.5 mt -63.67 -53.73 41.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 115.212 -0.903 . . . . 0.0 111.551 -175.684 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 14.0 tt -67.7 -37.67 79.01 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.635 -171.647 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.6 t -75.08 -29.18 60.58 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 122.483 0.313 . . . . 0.0 110.481 178.603 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.78 -29.75 69.02 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 123.585 0.754 . . . . 0.0 110.742 175.219 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.4 -2.18 33.9 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 123.576 0.75 . . . . 0.0 111.485 174.598 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 96.88 -11.38 66.15 Favored Glycine 0 C--N 1.351 1.394 0 C-N-CA 123.093 0.378 . . . . 0.0 113.003 176.819 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 60.9 m-85 -91.08 104.76 17.3 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -175.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.8 m -77.12 110.92 13.6 Favored Pre-proline 0 CA--C 1.551 1.007 0 C-N-CA 123.917 0.887 . . . . 0.0 110.02 -176.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -83.13 -18.03 6.39 Favored 'Trans proline' 0 C--N 1.373 1.826 0 C-N-CA 122.56 2.173 . . . . 0.0 113.222 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 . . . . . 0 C--O 1.245 0.858 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.283 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.995 0 CA-C-O 120.812 0.339 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.85 173.86 22.67 Favored Glycine 0 C--N 1.344 1.004 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.927 179.212 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.408 HD13 ' HA ' ' A' ' 70' ' ' ALA . 52.5 mt -78.98 107.91 12.07 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -178.513 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 20.1 m -95.06 110.74 22.63 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 122.467 0.307 . . . . 0.0 110.706 -173.019 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -107.13 146.36 31.37 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 124.068 0.947 . . . . 0.0 109.351 178.41 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -124.52 136.05 53.68 Favored 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.457 HG22 ' HB3' ' A' ' 84' ' ' PRO . 86.3 t -125.79 126.69 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 123.592 0.757 . . . . 0.0 111.407 -170.521 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -71.73 -37.62 70.57 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.217 0.607 . . . . 0.0 111.548 177.704 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -75.02 -21.68 58.93 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 123.054 0.542 . . . . 0.0 112.258 -173.303 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.535 ' HG3' ' SG ' ' A' ' 36' ' ' CYS . 27.2 ttt -65.76 120.17 12.53 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.158 0.983 . . . . 0.0 111.043 -174.665 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 p -127.35 95.61 4.32 Favored 'General case' 0 CA--C 1.548 0.883 0 C-N-CA 122.717 0.407 . . . . 0.0 110.957 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 12.5 t 50.32 -147.94 0.34 Allowed 'General case' 0 CA--C 1.572 1.792 0 C-N-CA 125.349 1.459 . . . . 0.0 113.995 167.129 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -62.15 -28.64 71.01 Favored Glycine 0 C--N 1.357 1.722 0 N-CA-C 115.118 0.807 . . . . 0.0 115.118 -173.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 46.6 m170 -64.51 -29.05 70.08 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 123.451 0.7 . . . . 0.0 112.099 -178.507 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.535 ' SG ' ' HG3' ' A' ' 31' ' ' MET . 30.6 p -100.29 -18.74 16.68 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 122.768 0.427 . . . . 0.0 111.102 179.377 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -55.54 -54.77 39.85 Favored 'General case' 0 C--N 1.358 0.944 0 O-C-N 124.012 0.82 . . . . 0.0 112.563 -166.6 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.27 -35.55 92.11 Favored Glycine 0 C--N 1.343 0.946 0 O-C-N 123.178 0.299 . . . . 0.0 113.43 -176.561 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 49.0 t -72.2 -47.53 53.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 123.067 0.547 . . . . 0.0 111.075 -178.295 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.422 HD11 HD11 ' A' ' 77' ' ' ILE . 14.2 tt -67.91 -32.33 55.92 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 123.803 0.841 . . . . 0.0 111.239 -174.837 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -63.51 -59.25 4.89 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 123.656 0.782 . . . . 0.0 110.06 172.373 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.88 -30.93 78.16 Favored Glycine 0 C--N 1.353 1.477 0 CA-C-N 114.548 -1.205 . . . . 0.0 113.919 -170.842 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.82 -51.57 68.47 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 124.022 0.929 . . . . 0.0 110.567 -179.583 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.598 HG21 HG11 ' A' ' 64' ' ' VAL . 65.3 mt -73.95 -50.57 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 123.447 0.699 . . . . 0.0 111.334 178.872 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -58.73 -44.55 90.48 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 124.471 1.108 . . . . 0.0 112.808 -165.787 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.2 mptp? -81.05 -27.06 35.88 Favored 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.34 -175.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 91.2 m -74.38 -37.92 63.3 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 123.054 0.542 . . . . 0.0 110.66 179.339 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 95.5 t -124.46 95.07 43.76 Favored Pre-proline 0 N--CA 1.478 0.973 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 174.203 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -59.14 124.25 15.22 Favored 'Trans proline' 0 C--N 1.376 2.011 0 C-N-CA 122.998 2.466 . . . . 0.0 111.385 170.734 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.76 -8.16 36.66 Favored Glycine 0 C--N 1.343 0.937 0 CA-C-O 119.601 -0.555 . . . . 0.0 112.935 -176.017 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -83.83 105.98 15.16 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 171.495 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -88.08 101.91 14.26 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.41 0.684 . . . . 0.0 109.591 -177.576 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.49 HG12 HG12 ' A' ' 64' ' ' VAL . 31.6 m -83.01 130.83 35.06 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.339 0.59 . . . . 0.0 110.492 -171.649 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' HIS . . . . . 0.458 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 24.7 t60 -120.72 96.41 5.11 Favored 'General case' 0 C--O 1.219 -0.528 0 N-CA-C 106.307 -1.738 . . . . 0.0 106.307 170.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.17 114.79 27.43 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -98.03 112.65 62.39 Favored Pre-proline 0 N--CA 1.47 0.529 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.79 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -57.02 -51.25 9.25 Favored 'Trans proline' 0 C--N 1.377 2.053 0 C-N-CA 122.616 2.211 . . . . 0.0 113.142 -175.775 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.67 -42.01 68.01 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 123.497 0.719 . . . . 0.0 112.465 -171.438 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.1 t -89.3 -12.74 39.71 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.07 0.548 . . . . 0.0 111.242 -178.462 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.4 mpt_? 65.16 30.55 11.39 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 124.269 1.027 . . . . 0.0 111.891 177.74 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 16.7 m -110.94 109.83 20.15 Favored 'General case' 0 CA--C 1.544 0.737 0 O-C-N 122.258 -0.276 . . . . 0.0 110.952 -169.118 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.458 ' HA ' ' O ' ' A' ' 54' ' ' HIS . 39.3 t -98.92 105.39 17.3 Favored 'Isoleucine or valine' 0 C--N 1.352 0.699 0 C-N-CA 123.804 0.842 . . . . 0.0 109.242 177.108 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 22.6 t -99.61 117.92 45.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.749 0.82 . . . . 0.0 109.083 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.598 HG11 HG21 ' A' ' 44' ' ' ILE . 30.5 m -104.74 115.24 46.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 123.402 0.681 . . . . 0.0 109.996 -179.399 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -101.07 145.4 16.98 Favored Glycine 0 C--N 1.348 1.229 0 CA-C-N 116.143 -0.48 . . . . 0.0 112.671 -177.356 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 95.71 3.31 61.0 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 123.073 0.368 . . . . 0.0 113.659 176.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.3 m -130.54 147.44 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.739 0.816 . . . . 0.0 110.249 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.8 m -112.27 4.83 17.99 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 123.071 0.549 . . . . 0.0 110.708 179.065 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.532 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 3.0 m-20 -89.36 68.71 8.01 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.922 0.889 . . . . 0.0 110.39 -175.027 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.408 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -62.11 -39.49 92.69 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.452 0.701 . . . . 0.0 111.285 -177.282 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -66.81 -42.49 85.81 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.719 0.808 . . . . 0.0 111.376 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.532 ' HB2' ' HB3' ' A' ' 69' ' ' ASP . 18.8 m80 -63.63 -52.98 58.44 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 122.793 0.437 . . . . 0.0 110.726 178.242 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.505 HG21 HG21 ' A' ' 64' ' ' VAL . 47.2 mm -58.89 -42.44 85.83 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 O-C-N 123.93 0.769 . . . . 0.0 110.52 -176.235 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -58.1 -41.87 84.46 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.143 0.977 . . . . 0.0 111.387 178.883 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 60.1 mm-40 -70.12 -33.82 72.31 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.264 178.177 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.435 HG13 ' O ' ' A' ' 72' ' ' HIS . 75.4 mt -68.11 -51.31 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 CA-C-O 121.025 0.44 . . . . 0.0 110.554 -179.173 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.602 HG23 ' HG3' ' A' ' 84' ' ' PRO . 16.7 tt -69.25 -32.34 53.32 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 CA-C-N 115.165 -0.925 . . . . 0.0 111.438 -175.138 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 t -76.52 -31.59 57.75 Favored 'General case' 0 N--CA 1.477 0.913 0 O-C-N 122.283 -0.26 . . . . 0.0 111.076 175.346 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.46 -16.12 62.35 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 123.492 0.717 . . . . 0.0 110.904 176.395 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -80.61 5.33 15.78 Favored 'General case' 0 CA--C 1.555 1.157 0 C-N-CA 123.763 0.825 . . . . 0.0 111.581 173.16 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.93 -0.74 73.36 Favored Glycine 0 C--N 1.353 1.482 0 C-N-CA 123.117 0.389 . . . . 0.0 113.15 176.41 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.43 ' HB3' HG11 ' A' ' 28' ' ' VAL . 95.7 m-85 -86.15 165.61 16.43 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 123.392 0.677 . . . . 0.0 110.48 179.355 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 33.5 p -122.82 81.2 49.38 Favored Pre-proline 0 CA--C 1.559 1.326 0 C-N-CA 123.174 0.59 . . . . 0.0 111.619 -176.404 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.602 ' HG3' HG23 ' A' ' 77' ' ' ILE . 43.0 Cg_endo -88.27 171.95 5.27 Favored 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.901 2.401 . . . . 0.0 112.178 169.816 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 . . . . . 0 C--O 1.246 0.891 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 176.452 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.11 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -124.17 -160.78 10.9 Favored Glycine 0 N--CA 1.473 1.14 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 176.231 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.0 107.48 12.82 Favored 'General case' 0 CA--C 1.548 0.883 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 179.24 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 24.9 p -93.37 111.97 23.77 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 123.606 0.762 . . . . 0.0 111.42 -173.269 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -99.68 141.23 32.76 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 175.337 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 65.8 m80 -115.46 100.7 8.28 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -175.041 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.508 HG21 ' HB3' ' A' ' 82' ' ' TYR . 2.7 p -113.41 97.78 6.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 C-N-CA 124.19 0.996 . . . . 0.0 109.753 -178.658 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -70.71 -17.8 62.81 Favored 'General case' 0 CA--C 1.551 0.989 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.966 176.676 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.37 -12.4 60.81 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 123.889 0.876 . . . . 0.0 111.384 176.574 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.485 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 60.0 ttp -80.19 98.98 7.57 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 173.749 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 30.4 p -94.18 102.67 14.71 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.213 0.605 . . . . 0.0 110.159 178.216 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 14.7 p 66.67 178.32 0.22 Allowed 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 126.567 1.947 . . . . 0.0 113.153 175.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.409 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -60.95 -22.79 60.66 Favored Glycine 0 C--N 1.359 1.82 0 CA-C-N 115.118 -0.946 . . . . 0.0 113.973 -178.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 13.0 t-160 -60.61 -42.76 97.47 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 123.894 0.878 . . . . 0.0 111.013 175.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 81.1 m -87.93 -21.59 24.82 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 123.032 0.533 . . . . 0.0 111.256 178.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.458 ' HA ' ' SD ' ' A' ' 31' ' ' MET . . . -66.02 -46.88 76.32 Favored 'General case' 0 C--N 1.349 0.546 0 C-N-CA 123.318 0.647 . . . . 0.0 111.01 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.82 -29.29 73.6 Favored Glycine 0 C--N 1.349 1.303 0 O-C-N 124.052 0.845 . . . . 0.0 113.546 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 58.3 t -63.29 -44.85 99.34 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.634 0.774 . . . . 0.0 110.087 175.659 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.626 HG21 HG21 ' A' ' 62' ' ' VAL . 62.6 mt -70.4 -39.33 76.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.852 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.427 ' HG3' ' O ' ' A' ' 37' ' ' ALA . 96.3 mttt -59.12 -49.84 76.33 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 123.125 0.57 . . . . 0.0 110.087 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.77 -38.66 96.86 Favored Glycine 0 C--N 1.344 0.974 0 O-C-N 124.28 0.987 . . . . 0.0 112.522 178.173 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.35 -55.06 31.65 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.63 0.772 . . . . 0.0 111.822 -176.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.506 ' HA ' HG21 ' A' ' 76' ' ' ILE . 69.7 mt -70.15 -55.71 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 123.241 0.616 . . . . 0.0 111.247 -178.46 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -60.1 -40.88 91.17 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 123.767 0.827 . . . . 0.0 112.791 -169.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -74.23 -30.91 62.38 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 122.45 0.3 . . . . 0.0 111.642 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 91.7 m -72.9 -42.63 63.36 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 121.053 0.454 . . . . 0.0 110.257 176.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.0 m -131.48 87.54 46.33 Favored Pre-proline 0 CA--C 1.553 1.074 0 C-N-CA 123.618 0.767 . . . . 0.0 110.52 -178.329 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -57.76 138.09 84.37 Favored 'Trans proline' 0 C--N 1.38 2.186 0 C-N-CA 122.6 2.2 . . . . 0.0 111.345 171.288 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 108.75 -23.87 23.05 Favored Glycine 0 N--CA 1.467 0.721 0 O-C-N 123.403 0.44 . . . . 0.0 112.02 -175.227 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -76.79 107.21 8.95 Favored 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 173.632 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.8 99.43 8.27 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.264 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.493 HG12 HG12 ' A' ' 64' ' ' VAL . 23.4 m -86.32 128.58 39.32 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 C-N-CA 123.199 0.6 . . . . 0.0 111.191 -171.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' HIS . . . . . 0.434 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 18.7 t60 -127.85 98.22 5.09 Favored 'General case' 0 C--O 1.223 -0.304 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 175.126 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.485 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -100.73 112.82 25.29 Favored 'General case' 0 C--O 1.241 0.643 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.357 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -102.72 114.73 65.14 Favored Pre-proline 0 CA--C 1.538 0.519 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -170.269 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -62.14 -34.4 79.34 Favored 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 122.812 2.341 . . . . 0.0 113.213 -178.448 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.04 -46.1 30.95 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.166 0.586 . . . . 0.0 111.295 -175.525 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.5 t -89.23 -16.75 30.53 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.404 0.682 . . . . 0.0 111.739 -175.684 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.7 mpt_? 61.57 39.85 14.2 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.331 1.052 . . . . 0.0 111.029 -176.643 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 50.0 m -126.26 118.89 26.06 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 122.75 0.42 . . . . 0.0 111.289 -172.712 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.626 HG21 HG21 ' A' ' 40' ' ' ILE . 38.7 t -100.0 105.71 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 123.728 0.811 . . . . 0.0 109.434 173.288 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 20.8 t -100.19 127.65 52.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 C-N-CA 123.791 0.836 . . . . 0.0 109.02 -178.813 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.496 HG21 HG13 ' A' ' 73' ' ' ILE . 17.4 m -111.2 109.95 30.41 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.656 0.741 . . . . 0.0 109.95 178.115 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -88.62 153.88 24.42 Favored Glycine 0 C--N 1.346 1.097 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.976 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.47 -14.55 45.58 Favored Glycine 0 N--CA 1.472 1.068 0 C-N-CA 122.888 0.28 . . . . 0.0 113.236 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.7 m -130.87 135.76 59.48 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.75 0 C-N-CA 124.457 1.103 . . . . 0.0 109.156 179.404 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 51.0 m -116.41 17.75 15.39 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.359 0.664 . . . . 0.0 109.913 176.012 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -80.25 77.05 7.02 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.292 1.037 . . . . 0.0 109.574 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.8 -42.96 94.59 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.496 0.718 . . . . 0.0 111.622 -175.557 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.421 ' O ' ' HG3' ' A' ' 75' ' ' GLU . . . -62.63 -46.08 89.9 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.941 0.897 . . . . 0.0 111.289 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 11.6 m170 -62.04 -54.75 37.08 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.666 0.787 . . . . 0.0 110.442 -176.635 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.496 HG13 HG21 ' A' ' 64' ' ' VAL . 45.3 mm -64.01 -40.0 87.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.319 -175.124 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.7 -39.6 89.12 Favored 'General case' 0 N--CA 1.476 0.875 0 O-C-N 123.966 0.792 . . . . 0.0 111.18 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.421 ' HG3' ' O ' ' A' ' 71' ' ' ALA . 46.3 mt-10 -61.98 -39.19 91.34 Favored 'General case' 0 N--CA 1.479 1.021 0 O-C-N 123.803 0.689 . . . . 0.0 111.16 176.28 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.506 HG21 ' HA ' ' A' ' 44' ' ' ILE . 62.4 mt -68.77 -51.9 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 O-C-N 123.636 0.585 . . . . 0.0 111.259 -176.75 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.513 HD13 ' HB3' ' A' ' 84' ' ' PRO . 6.3 tt -68.61 -31.77 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.27 0 C-N-CA 123.075 0.55 . . . . 0.0 111.569 -176.398 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -74.8 -30.78 61.53 Favored 'General case' 0 N--CA 1.483 1.183 0 O-C-N 122.202 -0.311 . . . . 0.0 110.426 176.42 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.09 -22.9 61.28 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 123.069 0.548 . . . . 0.0 110.296 172.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.31 -16.75 60.4 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 123.801 0.84 . . . . 0.0 111.832 174.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.34 22.53 12.68 Favored Glycine 0 C--N 1.348 1.223 0 O-C-N 123.405 0.44 . . . . 0.0 113.141 178.799 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.508 ' HB3' HG21 ' A' ' 28' ' ' VAL . 80.1 m-85 -128.56 133.29 48.33 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 123.913 0.885 . . . . 0.0 110.024 179.034 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 27.7 p -89.58 107.79 20.94 Favored Pre-proline 0 CA--C 1.552 1.036 0 C-N-CA 123.593 0.757 . . . . 0.0 110.605 -179.78 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.513 ' HB3' HD13 ' A' ' 77' ' ' ILE . 64.3 Cg_endo -78.33 -8.11 16.16 Favored 'Trans proline' 0 C--N 1.376 1.975 0 C-N-CA 122.748 2.299 . . . . 0.0 113.622 178.875 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 . . . . . 0 C--O 1.248 1.001 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 -173.378 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.958 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -123.63 108.01 1.14 Allowed Glycine 0 C--N 1.344 0.977 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 -176.728 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.455 HD12 HG23 ' A' ' 67' ' ' VAL . 37.3 mt -93.08 111.47 23.11 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 124.196 0.998 . . . . 0.0 110.359 -175.279 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 29.1 m -94.38 115.77 28.03 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.011 0.524 . . . . 0.0 111.054 -175.215 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -107.91 116.44 31.95 Favored 'General case' 0 N--CA 1.484 1.264 0 C-N-CA 123.959 0.904 . . . . 0.0 109.79 177.803 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 22.9 m170 -82.17 90.34 6.57 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.834 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.498 ' HA ' ' HA ' ' A' ' 84' ' ' PRO . 10.6 t -85.3 92.56 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -178.262 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -68.82 -19.26 64.27 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 123.904 0.882 . . . . 0.0 112.144 -172.093 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -89.15 -8.1 54.37 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.872 0.869 . . . . 0.0 111.917 178.287 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 26.4 ttt -75.15 126.52 31.19 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.804 0.841 . . . . 0.0 112.557 -173.051 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.8 t -108.49 97.91 7.51 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 164.014 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.541 ' SG ' ' HA ' ' A' ' 57' ' ' PRO . 81.5 m -46.52 -64.07 0.85 Allowed 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 125.543 1.537 . . . . 0.0 114.267 -167.421 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.56 -25.2 75.07 Favored Glycine 0 CA--C 1.532 1.142 0 N-CA-C 114.013 0.365 . . . . 0.0 114.013 -175.315 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 15.4 m-70 -93.99 -7.59 42.38 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 123.253 0.621 . . . . 0.0 112.109 -177.336 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 42.1 t -133.19 9.44 4.09 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.116 0.566 . . . . 0.0 111.099 -175.718 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -56.55 -53.61 55.55 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 123.838 0.855 . . . . 0.0 113.117 -169.721 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.99 -40.45 98.24 Favored Glycine 0 C--N 1.344 0.979 0 O-C-N 123.36 0.413 . . . . 0.0 114.121 -173.603 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.7 p -76.92 -42.51 32.62 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 C-N-CA 123.111 0.564 . . . . 0.0 112.221 -176.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 12.3 tt -73.22 -37.02 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 122.495 0.318 . . . . 0.0 110.809 -174.814 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.52 -43.47 55.75 Favored 'General case' 0 C--N 1.35 0.622 0 C-N-CA 123.136 0.575 . . . . 0.0 109.661 175.348 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.87 -30.58 78.1 Favored Glycine 0 C--N 1.351 1.393 0 O-C-N 124.494 1.121 . . . . 0.0 113.531 -177.582 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -61.28 -54.26 46.3 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 123.469 0.708 . . . . 0.0 110.591 177.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.521 ' HA ' HG21 ' A' ' 76' ' ' ILE . 59.0 mt -72.61 -46.81 53.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.163 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -58.54 -50.81 72.44 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 124.034 0.934 . . . . 0.0 112.26 -174.749 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -77.07 -20.7 55.47 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 119.42 -0.324 . . . . 0.0 111.505 -172.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 85.2 m -79.22 -45.76 19.19 Favored 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 174.362 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 15.8 m -126.74 81.59 68.7 Favored Pre-proline 0 CA--C 1.555 1.168 0 C-N-CA 123.598 0.759 . . . . 0.0 110.01 178.762 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -60.26 121.45 9.8 Favored 'Trans proline' 0 C--N 1.383 2.385 0 C-N-CA 122.995 2.463 . . . . 0.0 112.144 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.78 -11.57 10.16 Favored Glycine 0 C--N 1.345 1.075 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.704 -176.669 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -72.32 107.41 4.91 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 176.07 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -77.15 100.15 5.65 Favored 'General case' 0 C--N 1.348 0.507 0 C-N-CA 123.111 0.564 . . . . 0.0 109.856 -176.788 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.483 HG12 HG12 ' A' ' 64' ' ' VAL . 33.5 m -85.2 137.37 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 123.386 0.674 . . . . 0.0 109.949 -173.63 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' HIS . . . . . 0.487 ' HB2' ' HB ' ' A' ' 63' ' ' VAL . 78.7 m80 -130.37 101.78 5.9 Favored 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -178.643 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.26 120.87 34.04 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.672 0.789 . . . . 0.0 109.958 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -111.07 103.49 54.94 Favored Pre-proline 0 CA--C 1.55 0.959 0 CA-C-O 118.54 -0.743 . . . . 0.0 109.609 -178.144 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.541 ' HA ' ' SG ' ' A' ' 33' ' ' CYS . 38.0 Cg_exo -39.74 -44.82 3.5 Favored 'Trans proline' 0 C--N 1.376 2.003 0 C-N-CA 124.539 3.493 . . . . 0.0 115.88 172.178 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.24 -46.53 22.86 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 122.715 0.406 . . . . 0.0 111.525 -175.199 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.9 t -91.8 -7.01 50.74 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.359 0.664 . . . . 0.0 111.91 -173.383 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 40.91 45.65 2.22 Favored 'General case' 0 N--CA 1.505 2.28 0 C-N-CA 126.248 1.819 . . . . 0.0 112.197 -173.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.8 m -112.81 134.2 54.44 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.342 -175.286 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 51.4 t -103.38 105.57 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 168.243 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.487 ' HB ' ' HB2' ' A' ' 54' ' ' HIS . 14.4 t -94.47 119.93 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 175.571 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.517 HG11 HG21 ' A' ' 44' ' ' ILE . 15.7 m -106.29 116.96 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 CA-C-O 121.296 0.57 . . . . 0.0 110.5 -179.325 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.26 152.59 20.47 Favored Glycine 0 C--N 1.347 1.178 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.309 -175.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.04 -26.97 14.28 Favored Glycine 0 N--CA 1.471 0.989 0 C-N-CA 123.304 0.478 . . . . 0.0 112.883 177.848 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.455 HG23 HD12 ' A' ' 24' ' ' LEU . 28.4 m -101.98 155.16 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 124.412 1.085 . . . . 0.0 110.372 -176.035 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.1 m -135.7 23.59 3.38 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.78 0.832 . . . . 0.0 110.292 -177.338 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -119.53 71.54 0.88 Allowed 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 124.388 1.075 . . . . 0.0 109.697 -176.073 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.91 -34.94 75.45 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 115.049 -0.978 . . . . 0.0 112.561 -174.181 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.461 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.36 -43.74 96.79 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.271 0.629 . . . . 0.0 110.632 178.076 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.409 ' O ' HG13 ' A' ' 76' ' ' ILE . 14.9 m-70 -67.16 -43.97 80.91 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 123.467 0.707 . . . . 0.0 111.061 -177.41 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.409 HG21 HG21 ' A' ' 64' ' ' VAL . 45.4 mm -62.38 -40.64 88.7 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 O-C-N 123.739 0.649 . . . . 0.0 110.105 179.097 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.44 -38.17 86.2 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.811 178.201 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.461 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 45.3 mm-40 -62.53 -40.0 95.36 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.773 0.829 . . . . 0.0 111.204 176.773 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.521 HG21 ' HA ' ' A' ' 44' ' ' ILE . 73.4 mt -66.36 -54.89 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 123.717 0.636 . . . . 0.0 110.8 -176.837 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 12.6 tt -66.94 -34.48 70.23 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.643 -173.206 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 7.7 t -74.5 -30.3 61.76 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 110.526 -0.175 . . . . 0.0 110.526 177.67 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.73 -24.41 61.78 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 123.522 0.729 . . . . 0.0 110.826 175.292 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -71.72 -19.15 62.09 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 123.523 0.729 . . . . 0.0 111.142 172.893 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 101.6 16.65 23.82 Favored Glycine 0 C--N 1.348 1.242 0 CA-C-N 115.857 -0.61 . . . . 0.0 112.457 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -122.63 103.63 8.8 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.031 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.405 ' HA ' ' HD3' ' A' ' 84' ' ' PRO . 4.3 t -80.03 125.24 82.18 Favored Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.387 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.498 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 24.0 Cg_exo -63.95 -76.51 0.02 OUTLIER 'Trans proline' 0 C--N 1.38 2.195 0 C-N-CA 122.539 2.159 . . . . 0.0 112.912 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 . . . . . 0 C--O 1.252 1.21 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -170.385 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.69 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -158.73 114.18 0.6 Allowed Glycine 0 C--N 1.345 1.08 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 -178.36 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.43 HD13 ' HA ' ' A' ' 70' ' ' ALA . 47.9 mt -84.68 110.04 18.46 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.153 0.981 . . . . 0.0 110.752 -178.133 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.8 p -90.8 111.13 22.39 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 123.36 0.664 . . . . 0.0 111.952 -174.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -108.61 114.77 28.86 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 123.858 0.863 . . . . 0.0 109.998 177.399 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 11.5 m-70 -82.93 136.2 34.65 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 123.052 0.541 . . . . 0.0 109.782 178.29 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.597 HG22 ' HA ' ' A' ' 84' ' ' PRO . 85.2 t -139.83 97.14 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 172.092 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.79 -6.25 43.53 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -175.847 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -88.69 -19.37 26.23 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.343 0.657 . . . . 0.0 110.732 176.66 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.579 ' SD ' HG21 ' A' ' 40' ' ' ILE . 53.8 ttp -68.33 97.33 0.73 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 122.996 0.518 . . . . 0.0 109.811 178.771 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 25.9 p -82.44 94.05 7.35 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 179.212 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.405 ' SG ' ' HB3' ' A' ' 57' ' ' PRO . 58.6 m 41.5 -139.29 0.13 Allowed 'General case' 0 CA--C 1.568 1.642 0 C-N-CA 125.831 1.652 . . . . 0.0 113.213 173.357 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.52 -22.23 65.56 Favored Glycine 0 C--N 1.362 1.994 0 N-CA-C 114.638 0.615 . . . . 0.0 114.638 -178.678 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 30.0 t-80 -59.09 -35.95 74.3 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 123.614 0.766 . . . . 0.0 111.937 178.459 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 62.4 m -112.51 -14.51 13.21 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 122.894 0.478 . . . . 0.0 111.755 -178.42 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -60.5 -41.86 95.19 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -172.17 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.05 -48.55 82.52 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 113.806 0.283 . . . . 0.0 113.806 -174.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.3 p -75.58 -39.71 40.29 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.143 0 C-N-CA 123.557 0.743 . . . . 0.0 112.108 -177.36 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.579 HG21 ' SD ' ' A' ' 31' ' ' MET . 13.5 tt -67.17 -39.31 82.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 122.832 0.453 . . . . 0.0 111.124 -176.165 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.55 ' HB3' HG21 ' A' ' 53' ' ' VAL . 9.2 mtmp? -75.81 -44.32 41.81 Favored 'General case' 0 C--N 1.348 0.526 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.423 176.17 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.22 -30.21 63.94 Favored Glycine 0 C--N 1.357 1.717 0 O-C-N 124.786 1.304 . . . . 0.0 113.678 -175.753 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.66 -52.08 65.07 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.423 0.689 . . . . 0.0 110.509 172.141 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.561 HG21 HG11 ' A' ' 64' ' ' VAL . 57.8 mt -72.2 -40.55 66.06 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.566 -178.153 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -63.2 -50.45 70.22 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.647 0.779 . . . . 0.0 112.383 -175.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -71.94 -31.34 66.23 Favored 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.079 -174.831 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 46.7 m -76.07 -42.45 47.38 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.924 0.49 . . . . 0.0 110.37 176.424 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 41.2 t -125.0 93.06 46.47 Favored Pre-proline 0 N--CA 1.48 1.028 0 C-N-CA 123.77 0.828 . . . . 0.0 109.636 -173.636 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -68.02 113.29 2.98 Favored 'Trans proline' 0 C--N 1.371 1.762 0 C-N-CA 122.492 2.128 . . . . 0.0 110.113 170.677 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.18 -9.25 10.27 Favored Glycine 0 C--N 1.344 0.984 0 CA-C-O 119.525 -0.597 . . . . 0.0 113.411 -176.196 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -82.81 105.52 13.89 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 170.053 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.53 101.51 10.77 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 123.392 0.677 . . . . 0.0 109.807 -176.454 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' VAL . . . . . 0.55 HG21 ' HB3' ' A' ' 41' ' ' LYS . 20.8 m -84.29 135.75 24.19 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 C-N-CA 123.634 0.774 . . . . 0.0 110.969 -171.149 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 76.3 m80 -134.18 94.95 3.32 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.233 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.01 117.08 29.48 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.463 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -95.51 124.73 52.17 Favored Pre-proline 0 CA--C 1.543 0.676 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -179.45 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.405 ' HB3' ' SG ' ' A' ' 33' ' ' CYS . 51.6 Cg_exo -57.91 -47.43 20.74 Favored 'Trans proline' 0 C--N 1.373 1.825 0 C-N-CA 122.962 2.442 . . . . 0.0 113.192 177.127 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.3 -53.17 8.6 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 123.168 0.587 . . . . 0.0 111.85 -173.109 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.0 t -80.1 -13.16 59.5 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.864 0.866 . . . . 0.0 111.765 -175.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 25.7 mmt180 65.78 23.57 11.46 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.482 1.113 . . . . 0.0 112.478 174.243 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 40.0 m -109.73 126.61 53.9 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 122.63 0.372 . . . . 0.0 111.77 -169.411 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 45.8 t -98.15 105.47 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 123.955 0.902 . . . . 0.0 108.634 170.592 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 15.4 t -95.53 119.55 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 123.829 0.852 . . . . 0.0 109.209 179.802 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.568 HG21 HG21 ' A' ' 73' ' ' ILE . 28.1 m -103.2 109.7 27.66 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 123.571 0.749 . . . . 0.0 110.457 179.277 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -94.22 150.08 19.65 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.399 -177.13 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.2 -25.11 27.18 Favored Glycine 0 C--N 1.343 0.953 0 CA-C-O 120.194 -0.226 . . . . 0.0 112.547 177.881 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.4 m -103.17 148.81 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 123.991 0.917 . . . . 0.0 109.785 178.303 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.6 t -123.2 1.24 9.11 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 123.366 0.667 . . . . 0.0 111.034 -174.461 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -102.66 83.68 2.3 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 124.353 1.061 . . . . 0.0 110.341 -174.713 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.43 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -64.89 -36.7 85.22 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 114.307 -1.315 . . . . 0.0 112.8 -172.832 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.471 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -64.93 -44.31 89.93 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.04 0.536 . . . . 0.0 110.797 -177.844 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.405 ' O ' HG13 ' A' ' 76' ' ' ILE . 78.9 m-70 -62.03 -49.45 75.95 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 123.658 0.599 . . . . 0.0 110.925 179.156 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.568 HG21 HG21 ' A' ' 64' ' ' VAL . 42.7 mm -59.77 -40.28 82.09 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 O-C-N 123.875 0.734 . . . . 0.0 110.227 -179.699 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.93 -36.01 82.01 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.737 0.815 . . . . 0.0 111.11 178.361 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.471 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 26.5 mm-40 -69.05 -35.94 77.14 Favored 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 123.294 0.638 . . . . 0.0 111.395 178.053 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.423 HD12 ' HA ' ' A' ' 73' ' ' ILE . 74.7 mt -68.42 -53.05 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 123.464 0.705 . . . . 0.0 110.578 -178.632 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 13.6 tt -66.05 -35.71 75.7 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.984 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.361 -175.6 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.8 t -75.15 -30.09 60.66 Favored 'General case' 0 N--CA 1.479 0.999 0 C-N-CA 122.471 0.308 . . . . 0.0 110.887 178.295 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.8 -19.73 60.67 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 123.369 0.668 . . . . 0.0 110.945 175.856 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -78.15 -9.73 59.31 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.745 0.818 . . . . 0.0 111.473 172.627 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 102.47 -11.45 56.66 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-O 119.717 -0.491 . . . . 0.0 112.951 179.343 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -92.86 105.93 17.98 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.442 0.697 . . . . 0.0 110.192 178.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 90.6 m -68.89 117.39 50.9 Favored Pre-proline 0 CA--C 1.552 1.023 0 C-N-CA 123.142 0.577 . . . . 0.0 109.647 176.135 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.597 ' HA ' HG22 ' A' ' 28' ' ' VAL . 48.0 Cg_endo -67.16 87.48 0.31 Allowed 'Trans proline' 0 C--N 1.382 2.293 0 C-N-CA 122.437 2.091 . . . . 0.0 111.489 174.606 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.5 tp10 . . . . . 0 C--O 1.249 1.029 0 C-N-CA 124.672 1.189 . . . . 0.0 108.697 179.181 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.222 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.476 HD11 ' HB2' ' A' ' 70' ' ' ALA . 4.3 mm? -79.4 164.29 24.12 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.324 0.65 . . . . 0.0 111.023 -176.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 29.5 p -152.47 110.67 3.69 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 123.803 0.841 . . . . 0.0 108.82 178.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -110.35 116.44 31.45 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 123.702 0.801 . . . . 0.0 109.357 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 26.4 p80 -82.11 90.69 6.57 Favored 'General case' 0 CA--C 1.552 1.056 0 CA-C-O 122.615 1.198 . . . . 0.0 110.384 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.451 HG21 HD11 ' A' ' 77' ' ' ILE . 39.7 t -84.21 87.37 2.26 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 172.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.13 -5.67 43.12 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-N 115.646 -0.707 . . . . 0.0 112.758 -173.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -86.55 -22.11 26.51 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.35 0.66 . . . . 0.0 110.672 173.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.636 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 50.4 ttp -65.09 109.19 2.08 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 123.489 0.716 . . . . 0.0 111.453 -174.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 25.5 p -117.52 128.3 54.83 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.106 0.962 . . . . 0.0 109.434 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.403 ' SG ' ' HB2' ' A' ' 35' ' ' HIS . 8.8 p 65.68 159.36 0.12 Allowed 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 126.034 1.733 . . . . 0.0 113.718 176.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.521 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -67.44 -9.08 54.2 Favored Glycine 0 C--N 1.353 1.481 0 CA-C-N 115.104 -0.953 . . . . 0.0 114.306 -178.65 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . 0.403 ' HB2' ' SG ' ' A' ' 33' ' ' CYS . 29.4 m170 -71.15 -44.43 65.55 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 117.482 0.641 . . . . 0.0 110.216 173.165 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 59.0 m -83.82 -32.47 25.28 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.234 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.521 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -70.05 -34.77 73.66 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.009 176.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.04 -44.96 96.55 Favored Glycine 0 C--N 1.347 1.192 0 O-C-N 124.039 0.837 . . . . 0.0 113.472 -176.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.5 p -68.16 -30.03 46.53 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.064 0 C-N-CA 122.698 0.399 . . . . 0.0 111.384 -178.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.587 HG21 HG21 ' A' ' 62' ' ' VAL . 66.4 mt -66.39 -47.79 82.9 Favored 'Isoleucine or valine' 0 C--N 1.356 0.864 0 C-N-CA 123.149 0.58 . . . . 0.0 110.013 175.086 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 60.5 mtpt -57.43 -48.17 79.83 Favored 'General case' 0 C--N 1.349 0.566 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.224 178.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.93 -34.06 87.45 Favored Glycine 0 C--N 1.346 1.106 0 O-C-N 124.246 0.966 . . . . 0.0 112.966 -178.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.44 -54.76 35.37 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.072 0.549 . . . . 0.0 110.849 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.54 HG21 HG11 ' A' ' 64' ' ' VAL . 58.3 mt -72.45 -43.7 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 CA-C-N 115.672 -0.694 . . . . 0.0 112.127 -176.003 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -64.79 -38.02 89.58 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 124.219 1.008 . . . . 0.0 112.67 -174.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -76.03 -37.02 58.86 Favored 'General case' 0 N--CA 1.481 1.114 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.212 -179.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 42.7 m -71.12 -40.15 71.6 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 123.011 0.524 . . . . 0.0 110.63 177.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 48.2 t -121.39 94.54 48.64 Favored Pre-proline 0 N--CA 1.48 1.051 0 C-N-CA 123.58 0.752 . . . . 0.0 109.931 -177.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -62.25 104.29 0.34 Allowed 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.563 2.175 . . . . 0.0 111.174 169.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.56 -0.15 11.18 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-O 119.593 -0.559 . . . . 0.0 113.291 -177.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -83.96 108.71 17.1 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 169.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.404 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -78.49 95.97 5.29 Favored 'General case' 0 C--N 1.348 0.543 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 -178.679 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.529 HG12 HG12 ' A' ' 64' ' ' VAL . 27.7 m -88.95 131.49 36.15 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.754 0 C-N-CA 123.701 0.8 . . . . 0.0 111.027 -171.118 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . 0.406 ' HB3' HG22 ' A' ' 63' ' ' VAL . 3.5 t-160 -143.22 99.92 3.53 Favored 'General case' 0 C--N 1.346 0.421 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 167.356 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.636 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -92.51 113.75 26.11 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 172.079 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -106.9 120.49 47.95 Favored Pre-proline 0 N--CA 1.467 0.394 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -172.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -63.11 -35.31 65.44 Favored 'Trans proline' 0 C--N 1.37 1.698 0 C-N-CA 122.73 2.287 . . . . 0.0 113.493 -179.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.52 -35.2 46.62 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 123.272 0.629 . . . . 0.0 112.148 -174.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.2 t -91.43 -19.61 22.67 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 123.18 0.592 . . . . 0.0 110.225 178.304 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.1 mpt_? 60.79 33.82 19.96 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 125.034 1.334 . . . . 0.0 110.824 -177.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 27.3 m -124.69 131.52 53.46 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 122.677 0.391 . . . . 0.0 110.683 -170.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.587 HG21 HG21 ' A' ' 40' ' ' ILE . 44.0 t -105.87 105.57 18.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 173.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.406 HG22 ' HB3' ' A' ' 54' ' ' HIS . 34.3 m -99.71 136.12 32.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.284 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.54 HG11 HG21 ' A' ' 44' ' ' ILE . 17.3 m -131.0 109.36 16.45 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.909 0 C-N-CA 123.399 0.68 . . . . 0.0 109.434 179.22 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -92.79 157.74 23.76 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.474 -176.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.21 0.43 89.53 Favored Glycine 0 C--N 1.345 1.049 0 CA-C-O 119.932 -0.371 . . . . 0.0 114.023 177.176 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.4 m -124.14 144.7 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.625 0.77 . . . . 0.0 110.147 -176.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 14.9 m -108.86 -17.71 13.87 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.599 0.759 . . . . 0.0 110.225 176.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.445 ' O ' HG12 ' A' ' 73' ' ' ILE . 6.5 m-20 -78.77 76.54 5.26 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.347 1.059 . . . . 0.0 111.035 -172.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.476 ' HB2' HD11 ' A' ' 24' ' ' LEU . . . -60.59 -41.5 94.83 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.108 0.963 . . . . 0.0 111.602 -179.635 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -65.54 -41.47 92.99 Favored 'General case' 0 N--CA 1.471 0.581 0 O-C-N 124.206 0.942 . . . . 0.0 111.044 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.417 ' O ' HG13 ' A' ' 76' ' ' ILE . 77.8 t60 -63.28 -50.69 69.12 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.501 0.72 . . . . 0.0 110.741 178.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.537 HG21 HG21 ' A' ' 64' ' ' VAL . 40.7 mm -58.57 -42.3 84.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 O-C-N 123.826 0.704 . . . . 0.0 110.142 179.411 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.61 -37.97 80.04 Favored 'General case' 0 N--CA 1.476 0.836 0 O-C-N 124.329 1.018 . . . . 0.0 111.648 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 12.3 mm-40 -64.67 -40.14 94.91 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.479 0.712 . . . . 0.0 111.166 177.516 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.511 HG21 ' HA ' ' A' ' 44' ' ' ILE . 33.9 mt -67.19 -51.54 52.36 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 C-N-CA 123.149 0.58 . . . . 0.0 111.356 -177.144 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.451 HD11 HG21 ' A' ' 28' ' ' VAL . 8.3 tt -71.08 -29.88 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.234 0 C-N-CA 123.379 0.671 . . . . 0.0 111.836 -176.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.464 ' HA ' ' O ' ' A' ' 82' ' ' TYR . 2.9 t -75.25 -28.9 60.03 Favored 'General case' 0 N--CA 1.48 1.054 0 N-CA-C 110.364 -0.236 . . . . 0.0 110.364 175.079 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.32 -26.17 66.38 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.355 0.662 . . . . 0.0 110.644 172.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -76.76 -8.72 57.84 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 123.377 0.671 . . . . 0.0 111.455 173.323 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.3 25.05 24.95 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 116.561 -0.291 . . . . 0.0 113.208 176.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.464 ' O ' ' HA ' ' A' ' 78' ' ' THR . 95.9 m-85 -120.43 155.06 34.27 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.526 0.73 . . . . 0.0 110.236 179.379 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 73.1 p -89.79 111.14 44.48 Favored Pre-proline 0 CA--C 1.553 1.086 0 C-N-CA 123.271 0.628 . . . . 0.0 110.415 -176.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -78.89 79.5 3.36 Favored 'Trans proline' 0 C--N 1.377 2.043 0 C-N-CA 122.906 2.404 . . . . 0.0 111.878 178.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 35.0 mm-40 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.794 -0.622 . . . . 0.0 109.844 -176.661 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.799 0 N-CA-C 111.706 -0.558 . . . . 0.0 111.706 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -82.34 109.61 16.75 Favored 'General case' 0 CA--C 1.548 0.895 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.7 m -92.51 118.6 31.14 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 123.79 0.836 . . . . 0.0 110.748 -172.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -106.29 110.76 23.1 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.781 0.832 . . . . 0.0 109.939 178.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 50.2 m80 -81.82 94.38 7.04 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 177.078 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.499 ' O ' ' HB3' ' A' ' 60' ' ' ARG . 20.0 t -93.51 94.38 4.61 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.798 0 C-N-CA 124.356 1.062 . . . . 0.0 108.397 178.451 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -71.68 -12.72 61.47 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -175.003 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -85.5 -19.0 31.86 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 123.812 0.845 . . . . 0.0 110.951 174.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 25.2 ttt -55.33 128.64 35.11 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 124.334 1.054 . . . . 0.0 112.266 -175.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.3 p -88.47 162.18 16.61 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 124.438 1.095 . . . . 0.0 110.087 172.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 57.3 m -66.56 -162.75 0.02 OUTLIER 'General case' 0 CA--C 1.564 1.505 0 C-N-CA 124.986 1.314 . . . . 0.0 114.035 -169.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -56.69 -22.73 41.18 Favored Glycine 0 C--N 1.364 2.094 0 N-CA-C 115.722 1.049 . . . . 0.0 115.722 -171.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 48.9 t-80 -64.63 -28.77 69.84 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.777 0.831 . . . . 0.0 111.882 177.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 61.3 m -119.2 19.26 12.9 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.985 0.914 . . . . 0.0 111.26 179.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.37 -34.36 70.37 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 122.583 0.353 . . . . 0.0 111.047 177.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.08 -35.93 91.23 Favored Glycine 0 C--N 1.349 1.279 0 O-C-N 123.929 0.768 . . . . 0.0 114.779 -173.295 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.84 -38.71 76.48 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 123.102 0.561 . . . . 0.0 111.025 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 35.3 mt -73.09 -42.36 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.454 0.702 . . . . 0.0 110.242 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -55.5 -54.08 48.32 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.121 171.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.05 -30.56 78.11 Favored Glycine 0 C--N 1.345 1.032 0 O-C-N 124.788 1.305 . . . . 0.0 113.767 -172.292 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.6 -56.69 18.85 Favored 'General case' 0 C--N 1.352 0.7 0 C-N-CA 122.899 0.479 . . . . 0.0 110.629 178.059 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.521 ' HA ' HG21 ' A' ' 76' ' ' ILE . 57.7 mt -76.03 -42.35 38.65 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.693 -174.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -62.29 -48.28 80.57 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.1 0.96 . . . . 0.0 112.255 -173.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -73.4 -25.69 60.65 Favored 'General case' 0 N--CA 1.48 1.075 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.43 -176.118 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 43.0 m -80.63 -41.84 23.18 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 123.022 0.529 . . . . 0.0 110.576 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.9 t -123.3 94.84 46.3 Favored Pre-proline 0 N--CA 1.479 1.01 0 C-N-CA 123.584 0.754 . . . . 0.0 109.378 -178.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -67.07 118.4 5.54 Favored 'Trans proline' 0 C--N 1.373 1.863 0 C-N-CA 122.579 2.186 . . . . 0.0 110.899 172.089 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.82 -25.48 7.17 Favored Glycine 0 C--N 1.347 1.141 0 CA-C-O 119.795 -0.447 . . . . 0.0 112.511 -174.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -73.81 106.17 5.42 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 174.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -79.8 99.91 7.72 Favored 'General case' 0 C--N 1.346 0.45 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -177.093 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.435 HG12 HG12 ' A' ' 64' ' ' VAL . 16.6 m -86.51 111.86 22.02 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.937 0 CA-C-O 121.539 0.685 . . . . 0.0 111.156 -169.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 64.9 t60 -109.22 99.24 8.54 Favored 'General case' 0 C--N 1.344 0.348 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.77 115.44 22.22 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 175.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -106.88 102.72 43.99 Favored Pre-proline 0 N--CA 1.474 0.739 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -56.26 -39.81 88.84 Favored 'Trans proline' 0 C--N 1.373 1.837 0 C-N-CA 123.084 2.522 . . . . 0.0 113.746 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.44 -44.62 64.49 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 123.383 0.673 . . . . 0.0 111.978 -171.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 21.1 t -95.39 -9.94 31.38 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.855 0.862 . . . . 0.0 110.606 -178.404 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.499 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 60.59 41.5 15.34 Favored 'General case' 0 N--CA 1.484 1.266 0 C-N-CA 125.266 1.426 . . . . 0.0 110.165 -179.319 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.5 m -123.13 120.44 33.25 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.642 0.377 . . . . 0.0 111.285 -167.368 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.6 t -98.97 105.38 17.29 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 175.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.2 t -102.5 118.79 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 -175.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.505 HG11 HG21 ' A' ' 44' ' ' ILE . 17.1 m -103.86 108.94 25.74 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.068 0 CA-C-O 121.581 0.705 . . . . 0.0 110.707 -178.136 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -85.59 149.38 23.49 Favored Glycine 0 C--N 1.35 1.312 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.412 -179.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.69 -26.03 13.91 Favored Glycine 0 N--CA 1.472 1.066 0 C-N-CA 122.955 0.312 . . . . 0.0 112.417 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 34.6 m -122.19 142.99 36.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 124.368 1.067 . . . . 0.0 109.705 -177.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 69.1 m -124.53 -0.52 8.12 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 123.518 0.727 . . . . 0.0 111.427 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 15.3 p-10 -78.42 83.94 4.61 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-O 122.603 1.192 . . . . 0.0 110.505 -178.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.37 -41.26 96.8 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 113.54 -1.664 . . . . 0.0 113.217 -170.483 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -63.02 -44.43 96.0 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.81 0.844 . . . . 0.0 111.648 -174.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.411 ' O ' HG13 ' A' ' 76' ' ' ILE . 32.1 m170 -66.25 -47.52 73.47 Favored 'General case' 0 N--CA 1.475 0.78 0 O-C-N 123.521 0.513 . . . . 0.0 110.896 179.315 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 29.3 mm -58.93 -39.2 77.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 123.795 0.684 . . . . 0.0 110.344 178.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.71 -38.21 89.52 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 124.156 0.982 . . . . 0.0 111.336 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -63.97 -39.37 93.98 Favored 'General case' 0 N--CA 1.482 1.169 0 O-C-N 123.619 0.574 . . . . 0.0 111.116 176.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.521 HG21 ' HA ' ' A' ' 44' ' ' ILE . 57.4 mt -68.15 -51.33 49.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 123.42 0.688 . . . . 0.0 111.268 -175.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 10.9 tt -68.63 -36.14 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.447 -175.394 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.0 t -71.97 -27.5 62.81 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 122.663 0.385 . . . . 0.0 110.311 177.501 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.46 -29.85 70.07 Favored 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 123.562 0.745 . . . . 0.0 111.401 174.407 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -78.03 -3.12 40.53 Favored 'General case' 0 N--CA 1.48 1.056 0 C-N-CA 123.432 0.693 . . . . 0.0 111.606 173.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.67 -9.54 60.46 Favored Glycine 0 C--N 1.343 0.969 0 CA-C-O 119.716 -0.491 . . . . 0.0 113.159 176.388 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -96.53 103.2 15.09 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 117.442 0.621 . . . . 0.0 109.722 -179.054 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 33.5 p -78.95 112.82 30.49 Favored Pre-proline 0 CA--C 1.553 1.063 0 C-N-CA 124.415 1.086 . . . . 0.0 109.87 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -76.77 -2.06 12.25 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 122.751 2.3 . . . . 0.0 113.421 179.199 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 . . . . . 0 C--O 1.256 1.396 0 C-N-CA 124.034 0.934 . . . . 0.0 109.933 175.14 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.006 0 CA-C-O 120.656 0.031 . . . . 0.0 113.159 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 67.6 mt -99.56 107.1 19.18 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.597 0.759 . . . . 0.0 109.615 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 30.1 p -92.05 110.81 22.18 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.046 0.538 . . . . 0.0 110.6 -177.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -104.21 105.03 15.04 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 123.353 0.661 . . . . 0.0 109.375 176.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 27.8 t60 -81.66 94.21 6.91 Favored 'General case' 0 CA--C 1.538 0.494 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.284 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.555 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 32.8 t -88.62 102.39 12.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.709 0 CA-C-N 114.964 -1.016 . . . . 0.0 108.618 -179.502 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -70.82 -22.76 62.3 Favored 'General case' 0 N--CA 1.485 1.322 0 CA-C-O 121.105 0.479 . . . . 0.0 110.923 177.774 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -75.62 -13.93 60.36 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.29 1.036 . . . . 0.0 111.244 175.292 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.555 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 27.5 ttt -58.99 122.07 12.79 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 123.371 0.669 . . . . 0.0 112.145 -173.359 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 14.8 t -85.31 163.48 18.57 Favored 'General case' 0 CA--C 1.549 0.908 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.884 173.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.508 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 28.7 p -66.41 -177.02 0.5 Allowed 'General case' 0 CA--C 1.554 1.12 0 C-N-CA 123.769 0.827 . . . . 0.0 113.015 -175.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.519 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -56.79 -15.38 12.54 Favored Glycine 0 C--N 1.357 1.734 0 N-CA-C 116.247 1.259 . . . . 0.0 116.247 -169.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -57.68 -42.99 84.76 Favored 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 117.61 0.705 . . . . 0.0 111.308 177.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 47.7 t -124.9 0.53 8.0 Favored 'General case' 0 CA--C 1.548 0.901 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.421 -177.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.519 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -64.64 -30.91 71.94 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 122.709 0.404 . . . . 0.0 110.624 173.189 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.53 -30.92 77.27 Favored Glycine 0 C--N 1.352 1.431 0 CA-C-N 115.794 -0.639 . . . . 0.0 113.265 174.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 42.8 t -69.13 -41.02 81.28 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 174.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 71.1 mt -58.26 -41.12 80.25 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.925 0 C-N-CA 124.078 0.951 . . . . 0.0 110.684 175.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.439 ' HB3' HG21 ' A' ' 53' ' ' VAL . 98.9 mttt -60.89 -58.92 6.42 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.572 0.749 . . . . 0.0 110.162 177.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.99 -30.6 70.38 Favored Glycine 0 C--N 1.351 1.372 0 O-C-N 124.68 1.238 . . . . 0.0 113.774 -173.802 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.59 -53.23 60.72 Favored 'General case' 0 C--N 1.35 0.62 0 C-N-CA 123.577 0.751 . . . . 0.0 110.557 176.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.565 HG21 HG11 ' A' ' 64' ' ' VAL . 72.8 mt -69.41 -46.64 76.02 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-N 114.847 -1.07 . . . . 0.0 112.465 -177.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -61.46 -46.24 90.89 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 123.504 0.722 . . . . 0.0 112.712 -175.62 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 12.8 mptt -83.52 -14.63 51.86 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.575 -171.102 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.5 m -87.4 -49.97 6.87 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 171.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 54.2 t -113.74 96.79 42.19 Favored Pre-proline 0 N--CA 1.475 0.821 0 C-N-CA 124.372 1.069 . . . . 0.0 108.959 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -66.14 140.09 58.11 Favored 'Trans proline' 0 C--N 1.376 1.987 0 C-N-CA 122.458 2.105 . . . . 0.0 111.271 176.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.54 -10.73 68.92 Favored Glycine 0 C--N 1.34 0.773 0 CA-C-O 119.571 -0.572 . . . . 0.0 112.938 -177.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -72.25 106.02 4.26 Favored 'General case' 0 C--N 1.355 0.828 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 174.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -83.83 99.92 10.63 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.584 HG12 HG12 ' A' ' 64' ' ' VAL . 26.9 m -85.31 135.82 24.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.541 0 CA-C-O 121.197 0.522 . . . . 0.0 110.763 -172.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 18.1 t-80 -126.19 95.55 4.42 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 167.426 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.51 112.88 24.77 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 177.662 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.428 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 9.6 t70 -112.43 108.38 54.55 Favored Pre-proline 0 CA--C 1.533 0.298 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 -175.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.508 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 71.4 Cg_exo -52.87 -35.73 71.51 Favored 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 123.223 2.615 . . . . 0.0 114.169 178.23 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.53 -31.3 47.47 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 123.061 0.544 . . . . 0.0 112.141 -177.088 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.428 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 19.5 m -91.31 -20.31 22.01 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 122.81 0.444 . . . . 0.0 111.039 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.4 mpt_? 57.88 46.09 17.35 Favored 'General case' 0 N--CA 1.483 1.188 0 C-N-CA 124.477 1.111 . . . . 0.0 110.033 -177.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.8 m -142.26 129.94 21.54 Favored 'General case' 0 C--N 1.351 0.657 0 C-N-CA 123.04 0.536 . . . . 0.0 110.735 -173.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 18.8 t -108.69 106.51 20.83 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 124.068 0.947 . . . . 0.0 108.858 174.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 25.9 t -97.97 118.68 44.89 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 123.76 0.824 . . . . 0.0 109.464 -179.687 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.584 HG12 HG12 ' A' ' 53' ' ' VAL . 35.9 m -106.89 114.61 46.44 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.014 0 CA-C-O 121.5 0.667 . . . . 0.0 110.912 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -97.17 161.29 21.57 Favored Glycine 0 C--N 1.345 1.066 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.278 -178.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 81.27 -4.79 70.2 Favored Glycine 0 N--CA 1.476 1.315 0 N-CA-C 114.149 0.419 . . . . 0.0 114.149 178.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.19 152.81 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 123.851 0.861 . . . . 0.0 110.141 -177.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.1 t -125.66 19.79 7.92 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 123.742 0.817 . . . . 0.0 109.79 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.473 ' O ' HG12 ' A' ' 73' ' ' ILE . 3.3 m-20 -96.24 66.86 2.51 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 123.564 0.745 . . . . 0.0 109.41 -177.301 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.0 -46.06 89.47 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 123.178 0.591 . . . . 0.0 112.196 -171.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.14 -42.23 99.04 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 123.78 0.675 . . . . 0.0 110.518 179.059 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.463 ' O ' HG13 ' A' ' 76' ' ' ILE . 11.8 m170 -66.15 -45.0 82.51 Favored 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.315 -176.616 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.476 HG13 HG21 ' A' ' 64' ' ' VAL . 47.8 mm -61.03 -40.81 86.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 C-N-CA 123.323 0.649 . . . . 0.0 110.561 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.25 -37.41 87.13 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 123.606 0.762 . . . . 0.0 111.23 179.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -67.03 -34.5 77.84 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 123.386 0.674 . . . . 0.0 111.557 176.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.463 HG13 ' O ' ' A' ' 72' ' ' HIS . 72.9 mt -68.79 -53.99 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 C-N-CA 123.311 0.645 . . . . 0.0 111.211 -178.34 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.0 tt -63.71 -36.25 75.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.955 -175.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 t -74.27 -29.49 61.69 Favored 'General case' 0 CA--C 1.551 1.013 0 C-N-CA 122.013 0.125 . . . . 0.0 110.93 177.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.09 -22.53 61.34 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 123.204 0.602 . . . . 0.0 110.892 174.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -79.95 -8.73 59.5 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 123.499 0.719 . . . . 0.0 111.209 172.119 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 97.38 22.85 15.63 Favored Glycine 0 C--N 1.351 1.388 0 CA-C-N 116.104 -0.498 . . . . 0.0 113.055 175.257 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -127.61 105.97 8.84 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 24.0 p -75.77 116.09 52.09 Favored Pre-proline 0 CA--C 1.55 0.959 0 C-N-CA 122.835 0.454 . . . . 0.0 110.809 -174.233 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.477 ' HA ' HG13 ' A' ' 28' ' ' VAL . 76.5 Cg_endo -78.09 -8.81 16.6 Favored 'Trans proline' 0 C--N 1.382 2.302 0 C-N-CA 123.143 2.562 . . . . 0.0 112.985 -176.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 . . . . . 0 C--O 1.25 1.102 0 C-N-CA 124.281 1.032 . . . . 0.0 108.957 -175.896 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.243 0.666 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.478 HD13 ' HA ' ' A' ' 70' ' ' ALA . 34.9 mt -80.15 107.23 12.78 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -174.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.2 m -102.63 130.09 49.41 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.19 0.596 . . . . 0.0 109.81 -172.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -128.4 114.53 16.94 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.68 0.792 . . . . 0.0 110.514 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 47.0 m80 -81.63 111.86 18.3 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 171.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.7 t -107.9 100.63 11.13 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -176.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -69.06 -23.15 64.0 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.428 0.691 . . . . 0.0 110.927 175.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -74.3 -19.47 60.47 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.421 0.688 . . . . 0.0 110.625 177.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.527 ' HG3' ' HB2' ' A' ' 36' ' ' CYS . 20.4 ttt -82.67 133.82 35.16 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.215 1.006 . . . . 0.0 110.15 176.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 28.0 p -117.83 95.0 4.73 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 170.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.623 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 58.0 m 46.01 -142.69 0.31 Allowed 'General case' 0 CA--C 1.568 1.658 0 C-N-CA 125.017 1.327 . . . . 0.0 114.19 168.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.61 -24.48 64.16 Favored Glycine 0 C--N 1.362 2.019 0 C-N-CA 123.705 0.669 . . . . 0.0 114.292 -179.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -56.47 -37.94 71.02 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 123.28 0.632 . . . . 0.0 111.668 175.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.527 ' HB2' ' HG3' ' A' ' 31' ' ' MET . 80.9 m -104.11 -19.1 14.28 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 122.943 0.497 . . . . 0.0 111.571 -178.333 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -56.05 -42.72 77.03 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -173.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -61.76 -50.83 62.05 Favored Glycine 0 CA--C 1.535 1.286 0 O-C-N 123.31 0.381 . . . . 0.0 113.587 -177.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m -75.28 -34.24 30.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 C-N-CA 123.365 0.666 . . . . 0.0 112.161 -177.365 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 9.6 tt -74.84 -34.96 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 C-N-CA 123.11 0.564 . . . . 0.0 110.721 -174.387 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -71.81 -47.64 51.86 Favored 'General case' 0 C--N 1.351 0.659 0 C-N-CA 123.604 0.762 . . . . 0.0 109.657 173.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.44 -30.03 75.11 Favored Glycine 0 C--N 1.349 1.301 0 O-C-N 124.35 1.031 . . . . 0.0 113.359 -179.039 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.89 -54.65 43.64 Favored 'General case' 0 C--N 1.348 0.505 0 C-N-CA 123.386 0.674 . . . . 0.0 110.239 177.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.648 HG21 HG11 ' A' ' 64' ' ' VAL . 48.0 mt -74.03 -46.17 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.529 -175.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -59.97 -51.85 67.9 Favored 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.18 0.992 . . . . 0.0 112.371 -173.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.7 mptp? -75.95 -13.83 60.24 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 122.458 0.303 . . . . 0.0 111.721 -175.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 86.4 m -89.02 -39.27 13.8 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 123.117 0.567 . . . . 0.0 110.252 175.321 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 97.4 t -124.73 89.65 52.08 Favored Pre-proline 0 N--CA 1.479 0.977 0 C-N-CA 123.951 0.901 . . . . 0.0 109.022 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -60.17 113.44 1.67 Allowed 'Trans proline' 0 C--N 1.376 2.011 0 C-N-CA 122.845 2.364 . . . . 0.0 111.14 171.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.76 -14.85 9.1 Favored Glycine 0 C--N 1.342 0.87 0 CA-C-O 119.633 -0.537 . . . . 0.0 113.012 -176.274 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.79 106.8 9.86 Favored 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 173.184 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.467 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -76.27 99.54 4.8 Favored 'General case' 0 C--N 1.349 0.586 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.421 HG12 HG12 ' A' ' 64' ' ' VAL . 16.8 m -86.33 131.71 33.98 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 C-N-CA 123.29 0.636 . . . . 0.0 111.043 -172.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 43.9 t-80 -136.55 99.42 4.07 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 174.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -96.72 114.34 25.97 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 174.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -94.06 120.95 65.08 Favored Pre-proline 0 N--CA 1.471 0.589 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -174.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.623 ' HA ' ' HA ' ' A' ' 33' ' ' CYS . 51.1 Cg_exo -57.54 -38.25 94.47 Favored 'Trans proline' 0 C--N 1.374 1.907 0 C-N-CA 123.103 2.536 . . . . 0.0 114.417 177.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.72 -35.38 52.05 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.032 0.533 . . . . 0.0 111.62 -174.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 16.5 m -97.69 -20.94 17.29 Favored 'General case' 0 N--CA 1.482 1.151 0 C-N-CA 123.564 0.746 . . . . 0.0 111.718 -175.178 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.9 mpt_? 56.91 32.63 21.83 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 125.108 1.363 . . . . 0.0 110.947 -171.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.9 m -110.35 118.98 37.77 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 123.377 0.671 . . . . 0.0 110.055 -172.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 20.9 t -101.49 107.24 21.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 177.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 21.9 t -105.5 135.3 44.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 123.785 0.834 . . . . 0.0 108.754 -179.044 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.648 HG11 HG21 ' A' ' 44' ' ' ILE . 18.8 m -121.7 123.0 68.42 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 C-N-CA 123.196 0.598 . . . . 0.0 110.404 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -99.74 156.74 19.76 Favored Glycine 0 C--N 1.347 1.165 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.095 -179.144 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.5 -18.2 43.89 Favored Glycine 0 N--CA 1.474 1.225 0 C-N-CA 123.121 0.391 . . . . 0.0 113.451 177.478 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.8 m -115.68 146.86 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 124.092 0.957 . . . . 0.0 109.741 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 69.8 m -116.54 -20.47 9.61 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.722 0.809 . . . . 0.0 112.439 -175.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -75.95 86.3 2.88 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 122.776 0.43 . . . . 0.0 110.481 178.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.478 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -62.98 -29.01 70.49 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.431 0.692 . . . . 0.0 111.116 175.718 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.3 -51.38 67.89 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 124.402 1.081 . . . . 0.0 111.117 177.058 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.416 ' O ' HG13 ' A' ' 76' ' ' ILE . 28.2 m-70 -63.09 -48.01 80.43 Favored 'General case' 0 N--CA 1.482 1.155 0 O-C-N 123.592 0.558 . . . . 0.0 110.838 -178.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.474 HG21 HG21 ' A' ' 64' ' ' VAL . 49.5 mm -61.22 -40.62 86.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 124.068 0.855 . . . . 0.0 110.436 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.73 -39.69 92.46 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 123.95 0.781 . . . . 0.0 111.333 179.423 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.9 mm-40 -62.59 -39.5 93.91 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.491 0.716 . . . . 0.0 111.206 178.089 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.542 HG21 ' HA ' ' A' ' 44' ' ' ILE . 53.8 mt -68.02 -53.86 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 O-C-N 123.747 0.654 . . . . 0.0 110.959 -179.16 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 15.9 tt -70.28 -29.15 38.12 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.71 -173.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.5 t -76.07 -31.69 58.89 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 110.156 -0.312 . . . . 0.0 110.156 175.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.69 -21.43 64.42 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 123.671 0.788 . . . . 0.0 111.64 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -74.24 -3.69 31.48 Favored 'General case' 0 CA--C 1.555 1.15 0 C-N-CA 123.538 0.735 . . . . 0.0 112.189 176.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 101.77 23.11 9.56 Favored Glycine 0 C--N 1.351 1.4 0 C-N-CA 123.065 0.364 . . . . 0.0 112.885 178.368 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -119.3 175.83 5.62 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.992 0.917 . . . . 0.0 109.02 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 96.0 m -148.43 83.8 6.91 Favored Pre-proline 0 N--CA 1.479 0.994 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 171.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_exo -70.79 -67.31 0.03 OUTLIER 'Trans proline' 0 C--N 1.369 1.646 0 C-N-CA 122.449 2.1 . . . . 0.0 112.487 177.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 . . . . . 0 C--O 1.257 1.451 0 C-N-CA 125.154 1.382 . . . . 0.0 110.926 -171.787 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.599 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 34.1 mt -88.99 108.21 19.46 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.4 p -92.38 111.32 22.85 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 122.883 0.473 . . . . 0.0 110.555 -177.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -106.19 124.81 50.17 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 123.88 0.872 . . . . 0.0 109.746 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 32.3 m-70 -84.05 136.81 33.88 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 175.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 p -157.34 97.05 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.978 0 C-N-CA 124.066 0.946 . . . . 0.0 109.049 -176.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -69.8 -29.4 66.69 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.418 -176.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -74.4 -9.85 59.0 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.164 0.586 . . . . 0.0 112.018 -178.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.612 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 56.1 ttp -72.62 113.08 9.26 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 120.93 0.395 . . . . 0.0 110.557 177.132 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.401 ' OG1' ' HB3' ' A' ' 36' ' ' CYS . 63.2 p -77.51 166.34 23.2 Favored 'General case' 0 CA--C 1.549 0.917 0 C-N-CA 124.013 0.925 . . . . 0.0 109.923 168.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 28.0 p -57.11 -169.73 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 124.089 0.956 . . . . 0.0 112.647 175.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.69 3.45 0.63 Allowed Glycine 0 C--N 1.357 1.721 0 N-CA-C 115.916 1.127 . . . . 0.0 115.916 -174.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -63.27 -44.74 94.25 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.743 0.817 . . . . 0.0 110.844 166.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.401 ' HB3' ' OG1' ' A' ' 32' ' ' THR . 43.5 t -141.42 9.56 2.05 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 123.136 0.575 . . . . 0.0 111.996 -176.09 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.58 -30.95 69.83 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 122.836 0.454 . . . . 0.0 110.754 173.191 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.53 -20.87 53.09 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 114.996 -1.002 . . . . 0.0 114.256 176.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.496 HG12 ' HB1' ' A' ' 80' ' ' ALA . 57.9 t -65.41 -44.32 94.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 122.871 0.468 . . . . 0.0 110.138 174.233 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.711 HG21 HG21 ' A' ' 62' ' ' VAL . 44.1 mt -69.61 -54.44 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 C-N-CA 123.3 0.64 . . . . 0.0 110.661 175.431 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.427 ' O ' ' HG3' ' A' ' 45' ' ' GLU . 9.7 mtpm? -56.68 -51.83 67.28 Favored 'General case' 0 C--N 1.348 0.507 0 O-C-N 124.517 1.136 . . . . 0.0 110.269 -174.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.48 ' O ' ' HD3' ' A' ' 46' ' ' LYS . . . -61.94 -40.16 98.5 Favored Glycine 0 C--N 1.343 0.917 0 O-C-N 124.963 1.414 . . . . 0.0 112.867 178.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.74 -53.5 57.05 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 117.129 0.464 . . . . 0.0 111.001 179.138 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.576 HG21 HG11 ' A' ' 64' ' ' VAL . 68.4 mt -62.08 -39.93 85.6 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.967 -179.174 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.427 ' HG3' ' O ' ' A' ' 41' ' ' LYS . 76.9 mt-10 -62.02 -50.46 71.94 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 123.171 0.588 . . . . 0.0 112.068 179.623 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.48 ' HD3' ' O ' ' A' ' 42' ' ' GLY . 13.3 mptt -73.03 -28.07 62.13 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.496 -171.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.1 m -85.2 -41.01 16.02 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 122.814 0.445 . . . . 0.0 110.32 177.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.0 103.51 23.53 Favored Pre-proline 0 N--CA 1.483 1.216 0 C-N-CA 124.156 0.982 . . . . 0.0 109.807 -178.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -66.91 136.58 41.97 Favored 'Trans proline' 0 C--N 1.374 1.919 0 C-N-CA 122.781 2.321 . . . . 0.0 111.687 172.059 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.2 -4.75 67.68 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-O 119.787 -0.452 . . . . 0.0 113.963 175.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.65 106.68 9.61 Favored 'General case' 0 C--N 1.35 0.619 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 173.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.421 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -77.14 99.54 5.43 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -177.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.412 HG12 HG12 ' A' ' 64' ' ' VAL . 27.8 m -85.26 127.47 39.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.805 0 C-N-CA 123.134 0.574 . . . . 0.0 110.877 -171.065 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . 0.409 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 29.2 t60 -131.67 96.98 4.08 Favored 'General case' 0 C--N 1.345 0.372 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 176.12 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.612 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -93.71 113.67 25.79 Favored 'General case' 0 C--O 1.24 0.588 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 176.073 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -99.72 114.88 65.88 Favored Pre-proline 0 N--CA 1.468 0.428 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -177.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -60.54 -40.34 57.36 Favored 'Trans proline' 0 C--N 1.373 1.863 0 C-N-CA 123.009 2.473 . . . . 0.0 112.822 -176.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -74.38 -47.74 32.22 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.639 0.775 . . . . 0.0 111.285 -176.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.2 m -81.31 -15.65 54.8 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 123.74 0.816 . . . . 0.0 111.459 -176.122 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 63.0 29.44 16.43 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 124.642 1.177 . . . . 0.0 111.389 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 33.1 m -122.79 122.76 39.46 Favored 'General case' 0 N--CA 1.479 1.001 0 O-C-N 121.808 -0.558 . . . . 0.0 111.57 -169.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.711 HG21 HG21 ' A' ' 40' ' ' ILE . 40.5 t -99.09 106.38 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 123.952 0.901 . . . . 0.0 108.972 173.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.1 t -100.49 123.21 53.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.581 HG21 HG21 ' A' ' 73' ' ' ILE . 17.0 m -111.5 109.0 26.9 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.955 0 CA-C-O 121.478 0.656 . . . . 0.0 110.18 179.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.46 150.78 20.99 Favored Glycine 0 C--N 1.346 1.125 0 CA-C-N 115.604 -0.725 . . . . 0.0 112.581 -176.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.19 -23.68 30.47 Favored Glycine 0 C--N 1.343 0.967 0 C-N-CA 123.089 0.375 . . . . 0.0 112.999 177.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 22.4 m -105.52 151.14 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 123.992 0.917 . . . . 0.0 110.153 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 17.9 m -126.85 -2.61 6.56 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 124.005 0.922 . . . . 0.0 110.332 -178.621 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -87.33 73.02 9.72 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 124.522 1.129 . . . . 0.0 110.266 -177.219 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.99 -29.29 70.46 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-N 114.907 -1.042 . . . . 0.0 112.373 -174.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.402 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.68 -49.45 73.12 Favored 'General case' 0 N--CA 1.474 0.764 0 O-C-N 123.763 0.665 . . . . 0.0 110.819 177.599 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.499 ' O ' HG13 ' A' ' 76' ' ' ILE . 39.8 m170 -59.35 -54.93 41.14 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 123.552 0.532 . . . . 0.0 110.463 177.81 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.581 HG21 HG21 ' A' ' 64' ' ' VAL . 41.4 mm -57.8 -40.27 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 O-C-N 124.438 1.086 . . . . 0.0 110.785 -174.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.26 -40.14 89.29 Favored 'General case' 0 N--CA 1.48 1.067 0 O-C-N 124.022 0.826 . . . . 0.0 111.429 178.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 15.2 mm-40 -68.23 -32.09 72.05 Favored 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 123.181 0.592 . . . . 0.0 111.292 178.05 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.499 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.3 mt -74.75 -48.66 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 122.986 0.514 . . . . 0.0 111.21 -177.094 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 73' ' ' ILE . 8.5 tt -67.37 -32.39 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 C-N-CA 123.259 0.623 . . . . 0.0 111.257 -177.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -75.12 -31.05 61.02 Favored 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 110.364 -0.236 . . . . 0.0 110.364 175.07 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.95 -18.49 64.09 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 123.537 0.735 . . . . 0.0 111.747 176.09 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.496 ' HB1' HG12 ' A' ' 39' ' ' VAL . . . -75.89 0.58 17.76 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 123.664 0.786 . . . . 0.0 112.291 176.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 95.9 17.04 36.59 Favored Glycine 0 C--N 1.351 1.377 0 C-N-CA 122.861 0.267 . . . . 0.0 112.528 179.597 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -120.78 178.36 4.73 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 124.361 1.064 . . . . 0.0 109.686 -177.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 39.0 m -139.41 111.81 7.77 Favored Pre-proline 0 N--CA 1.479 1.001 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 173.333 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -66.44 120.37 7.49 Favored 'Trans proline' 0 C--N 1.382 2.305 0 C-N-CA 122.355 2.037 . . . . 0.0 110.812 171.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 . . . . . 0 CA--C 1.555 1.167 0 C-N-CA 124.187 0.995 . . . . 0.0 109.493 -175.682 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.431 ' HA2' ' HA2' ' A' ' 65' ' ' GLY . . . . . . . . 0 N--CA 1.466 0.65 0 N-CA-C 112.165 -0.374 . . . . 0.0 112.165 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.445 HD13 ' HA ' ' A' ' 70' ' ' ALA . 59.4 mt -81.42 111.59 17.91 Favored 'General case' 0 N--CA 1.47 0.568 0 C-N-CA 124.059 0.944 . . . . 0.0 110.108 179.433 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.4 t -83.72 129.62 34.95 Favored 'General case' 0 CA--C 1.549 0.922 0 C-N-CA 123.556 0.742 . . . . 0.0 110.516 -177.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -125.84 108.44 11.47 Favored 'General case' 0 N--CA 1.492 1.636 0 C-N-CA 123.338 0.655 . . . . 0.0 110.919 177.545 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 75.9 t60 -82.88 105.58 14.01 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.531 1.132 . . . . 0.0 110.308 -175.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.643 HG11 ' HB3' ' A' ' 82' ' ' TYR . 30.1 t -120.7 94.97 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 C-N-CA 123.214 0.606 . . . . 0.0 109.729 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -69.65 -24.75 63.66 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 123.034 0.533 . . . . 0.0 112.186 -177.306 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -74.98 -20.11 59.81 Favored 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 123.737 0.815 . . . . 0.0 111.163 -179.142 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.419 ' SD ' HD13 ' A' ' 40' ' ' ILE . 12.9 ttt -73.26 139.34 46.09 Favored 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 124.303 1.041 . . . . 0.0 110.786 176.495 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 15.1 t -103.01 163.39 12.24 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 123.917 0.887 . . . . 0.0 109.195 170.037 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 23.3 p -66.98 -97.46 0.0 OUTLIER 'General case' 0 CA--C 1.563 1.467 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -174.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.48 -32.74 64.51 Favored Glycine 0 C--N 1.349 1.3 0 N-CA-C 114.673 0.629 . . . . 0.0 114.673 -166.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 72.1 m-70 -74.01 -14.34 61.0 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.514 0.726 . . . . 0.0 111.869 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.6 t -122.54 -7.1 8.64 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 122.977 0.511 . . . . 0.0 111.688 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -57.67 -55.7 31.5 Favored 'General case' 0 N--CA 1.481 1.088 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -171.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.83 -38.17 95.23 Favored Glycine 0 N--CA 1.47 0.903 0 N-CA-C 114.255 0.462 . . . . 0.0 114.255 -174.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.5 p -75.15 -40.37 44.06 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.15 0 C-N-CA 122.785 0.434 . . . . 0.0 111.733 -176.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.434 HD11 HD11 ' A' ' 77' ' ' ILE . 13.0 tt -75.05 -35.88 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 122.802 0.441 . . . . 0.0 110.79 -178.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.463 ' HB3' HG21 ' A' ' 53' ' ' VAL . 97.2 mttt -65.21 -52.29 55.66 Favored 'General case' 0 C--N 1.353 0.729 0 CA-C-N 115.771 -0.649 . . . . 0.0 109.471 174.584 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.91 -29.31 67.48 Favored Glycine 0 C--N 1.352 1.43 0 O-C-N 124.813 1.321 . . . . 0.0 113.517 -178.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.35 -54.96 40.85 Favored 'General case' 0 C--N 1.352 0.693 0 C-N-CA 123.375 0.67 . . . . 0.0 110.476 175.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.612 HG21 HG11 ' A' ' 64' ' ' VAL . 66.6 mt -73.2 -45.72 52.65 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 CA-C-N 115.529 -0.759 . . . . 0.0 112.031 -179.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -63.05 -45.7 90.99 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 124.72 1.208 . . . . 0.0 111.275 -167.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -70.95 -27.45 63.75 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.853 0.461 . . . . 0.0 111.698 -178.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 33.2 m -81.51 -33.89 31.58 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 122.648 0.379 . . . . 0.0 110.833 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.3 t -124.75 95.0 43.34 Favored Pre-proline 0 N--CA 1.48 1.073 0 C-N-CA 123.32 0.648 . . . . 0.0 109.688 178.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -65.88 111.22 1.89 Allowed 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 122.699 2.266 . . . . 0.0 110.861 173.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.5 -12.1 9.59 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-O 119.514 -0.603 . . . . 0.0 113.281 -176.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -76.87 106.28 8.45 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 173.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.21 100.16 8.17 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -178.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.463 HG21 ' HB3' ' A' ' 41' ' ' LYS . 15.3 m -84.39 132.99 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 123.78 0.832 . . . . 0.0 110.649 -170.423 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -141.48 101.81 4.07 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 122.903 0.481 . . . . 0.0 109.756 -176.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.25 130.32 35.07 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 109.643 -0.502 . . . . 0.0 109.643 176.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -105.48 108.59 61.8 Favored Pre-proline 0 CA--C 1.541 0.628 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 176.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -47.34 -44.94 23.65 Favored 'Trans proline' 0 C--N 1.374 1.901 0 C-N-CA 124.126 3.218 . . . . 0.0 115.396 178.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.31 -41.57 40.16 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.485 0.714 . . . . 0.0 112.233 -173.17 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.8 t -93.37 -13.93 27.46 Favored 'General case' 0 N--CA 1.482 1.141 0 C-N-CA 123.496 0.718 . . . . 0.0 111.558 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.42 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 2.7 mpt_? 57.17 45.98 19.68 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 125.036 1.334 . . . . 0.0 110.8 -178.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 78.9 m -122.75 126.61 47.83 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.88 -170.402 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 40.5 t -98.44 108.27 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 173.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.0 t -100.58 123.11 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 C-N-CA 124.035 0.934 . . . . 0.0 108.609 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.612 HG11 HG21 ' A' ' 44' ' ' ILE . 31.4 m -112.57 109.07 27.23 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 C-N-CA 123.669 0.787 . . . . 0.0 110.666 -176.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.431 ' HA2' ' HA2' ' A' ' 23' ' ' GLY . . . -88.62 160.24 30.05 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 115.584 -0.735 . . . . 0.0 113.049 -177.335 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 78.55 4.59 87.63 Favored Glycine 0 C--N 1.343 0.92 0 N-CA-C 114.356 0.502 . . . . 0.0 114.356 175.546 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 23.4 m -131.8 150.79 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.854 0 C-N-CA 123.796 0.838 . . . . 0.0 109.4 -178.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 30.8 t -116.1 -8.41 11.8 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 124.1 0.96 . . . . 0.0 111.06 -176.657 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.417 ' O ' HG12 ' A' ' 73' ' ' ILE . 7.1 m-20 -80.92 72.34 7.92 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.751 0.821 . . . . 0.0 110.893 -175.308 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.445 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -60.38 -41.43 93.74 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.149 0.58 . . . . 0.0 111.065 -178.281 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.472 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.22 -47.83 80.85 Favored 'General case' 0 CA--C 1.541 0.6 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.134 179.094 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.43 ' O ' HG13 ' A' ' 76' ' ' ILE . 45.0 t-80 -64.64 -45.24 87.64 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.167 0.587 . . . . 0.0 111.559 -176.186 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.497 HG21 HG21 ' A' ' 64' ' ' VAL . 48.5 mm -60.86 -41.03 87.18 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 O-C-N 123.552 0.533 . . . . 0.0 109.892 178.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.15 -35.31 76.74 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 115.305 -0.861 . . . . 0.0 111.751 178.49 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.472 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 17.5 mm-40 -65.52 -41.13 93.48 Favored 'General case' 0 N--CA 1.48 1.034 0 C-N-CA 123.457 0.703 . . . . 0.0 110.923 177.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.43 HG13 ' O ' ' A' ' 72' ' ' HIS . 35.5 mt -66.37 -50.05 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.021 -177.126 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.434 HD11 HD11 ' A' ' 40' ' ' ILE . 15.9 tt -72.66 -31.17 36.13 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.949 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.429 -172.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.5 t -74.54 -29.57 61.43 Favored 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 175.095 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.43 -19.62 60.92 Favored 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 123.563 0.745 . . . . 0.0 111.27 173.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -80.4 -5.31 56.27 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.565 0.746 . . . . 0.0 111.21 172.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.0 22.72 32.0 Favored Glycine 0 C--N 1.35 1.358 0 O-C-N 123.372 0.42 . . . . 0.0 112.903 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.643 ' HB3' HG11 ' A' ' 28' ' ' VAL . 81.7 m-85 -127.46 115.07 18.33 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.659 0.784 . . . . 0.0 110.51 -176.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 34.8 p -71.16 111.78 11.21 Favored Pre-proline 0 CA--C 1.549 0.916 0 C-N-CA 124.296 1.039 . . . . 0.0 110.987 -177.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.403 ' HA ' HG22 ' A' ' 28' ' ' VAL . 93.8 Cg_endo -80.6 150.14 18.96 Favored 'Trans proline' 0 C--N 1.372 1.803 0 C-N-CA 122.323 2.016 . . . . 0.0 111.824 177.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 . . . . . 0 CA--C 1.559 1.3 0 C-N-CA 124.703 1.201 . . . . 0.0 111.437 173.536 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.858 0 N-CA-C 110.35 -1.1 . . . . 0.0 110.35 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 46.8 mt -83.1 105.84 14.41 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 174.278 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.1 m -93.83 111.4 23.09 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -176.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -103.26 100.96 10.88 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 177.244 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 77.0 t60 -82.47 91.71 6.92 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 -179.202 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.58 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 15.9 t -74.37 93.62 0.75 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 N-CA-C 106.855 -1.535 . . . . 0.0 106.855 172.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -63.75 -20.81 66.04 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 112.693 0.627 . . . . 0.0 112.693 -171.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 10.6 p-10 -111.34 23.6 13.82 Favored 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 124.089 0.956 . . . . 0.0 110.789 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.58 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 23.9 ttt -57.73 142.01 46.74 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 124.389 1.076 . . . . 0.0 113.325 -173.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 41.3 p -81.32 144.4 31.53 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.547 173.204 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.439 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 49.8 t -73.04 -170.51 0.75 Allowed 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 123.882 0.873 . . . . 0.0 110.078 177.137 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -49.35 -24.9 5.55 Favored Glycine 0 C--N 1.356 1.657 0 N-CA-C 116.623 1.409 . . . . 0.0 116.623 -171.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 40.9 m170 -58.53 -33.75 70.22 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 123.498 0.719 . . . . 0.0 112.558 177.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 63.8 m -137.92 15.95 2.86 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 122.997 0.519 . . . . 0.0 111.739 178.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.4 -34.04 63.19 Favored 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 122.614 0.366 . . . . 0.0 110.96 174.1 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.94 -37.91 93.69 Favored Glycine 0 C--N 1.347 1.161 0 O-C-N 123.825 0.703 . . . . 0.0 113.768 -176.013 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 9.2 p -69.48 -28.46 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 122.943 0.497 . . . . 0.0 110.883 177.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.2 mt -67.93 -41.82 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 123.224 0.61 . . . . 0.0 109.974 175.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -62.24 -52.05 65.28 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 123.811 0.844 . . . . 0.0 110.177 177.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.82 -31.1 78.69 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 114.414 -1.266 . . . . 0.0 113.063 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.38 -50.92 68.46 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.975 0.91 . . . . 0.0 110.831 179.167 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.515 HG21 HG11 ' A' ' 64' ' ' VAL . 64.3 mt -74.37 -51.4 23.3 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.644 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -56.16 -54.67 42.38 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 124.358 1.063 . . . . 0.0 112.745 -170.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -69.79 -13.72 62.42 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 122.889 0.476 . . . . 0.0 112.107 -175.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 61.2 m -90.51 -37.74 13.68 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 123.341 0.656 . . . . 0.0 110.442 177.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.5 m -133.54 92.1 24.63 Favored Pre-proline 0 CA--C 1.556 1.176 0 C-N-CA 123.474 0.71 . . . . 0.0 110.491 179.317 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -58.03 135.08 66.38 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 122.604 2.203 . . . . 0.0 111.555 171.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 110.62 -29.58 8.89 Favored Glycine 0 C--N 1.341 0.847 0 N-CA-C 111.87 -0.492 . . . . 0.0 111.87 -177.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -74.02 106.86 5.89 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 175.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.445 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -78.06 99.34 6.08 Favored 'General case' 0 C--N 1.345 0.407 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -179.057 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.474 HG12 HG12 ' A' ' 64' ' ' VAL . 27.2 m -84.51 129.42 37.7 Favored 'Isoleucine or valine' 0 C--O 1.239 0.546 0 C-N-CA 123.1 0.56 . . . . 0.0 110.015 -171.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . 0.402 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 41.1 t60 -133.68 96.01 3.6 Favored 'General case' 0 CA--C 1.518 -0.283 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 175.439 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.1 113.91 26.31 Favored 'General case' 0 C--O 1.243 0.755 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 173.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -105.35 105.54 52.6 Favored Pre-proline 0 N--CA 1.466 0.337 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 -175.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.439 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 76.4 Cg_exo -53.39 -38.1 82.25 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 123.236 2.624 . . . . 0.0 113.72 179.331 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.8 -45.21 62.31 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 123.215 0.606 . . . . 0.0 111.413 -176.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.9 m -84.08 -17.89 38.75 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.417 0.687 . . . . 0.0 111.552 -177.28 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.566 ' HD2' ' HB3' ' A' ' 31' ' ' MET . 66.6 mmt-85 64.29 37.49 8.54 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 124.633 1.173 . . . . 0.0 110.367 -178.58 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.1 m -137.9 122.88 19.02 Favored 'General case' 0 CA--C 1.55 0.965 0 O-C-N 122.025 -0.422 . . . . 0.0 111.603 -169.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.402 ' HA ' ' O ' ' A' ' 54' ' ' HIS . 18.5 t -99.45 106.37 18.91 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 C-N-CA 124.142 0.977 . . . . 0.0 109.204 175.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.8 t -104.95 123.47 59.04 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 123.728 0.811 . . . . 0.0 109.073 -176.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.515 HG11 HG21 ' A' ' 44' ' ' ILE . 27.8 m -108.56 122.5 63.19 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.909 0 C-N-CA 123.038 0.535 . . . . 0.0 110.521 177.42 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -102.43 153.3 18.44 Favored Glycine 0 C--N 1.345 1.075 0 CA-C-N 115.981 -0.554 . . . . 0.0 112.872 -176.772 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.7 -24.77 22.12 Favored Glycine 0 N--CA 1.471 1.027 0 C-N-CA 123.173 0.416 . . . . 0.0 112.856 177.212 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 35.3 m -111.69 149.05 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.987 0.915 . . . . 0.0 109.473 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.5 m -121.74 20.82 10.92 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 123.656 0.782 . . . . 0.0 110.416 -178.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -96.65 73.56 2.71 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 124.367 1.067 . . . . 0.0 109.506 -173.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.34 -53.38 58.97 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 123.721 0.809 . . . . 0.0 112.642 -170.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.422 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -62.9 -40.52 97.82 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 123.481 0.712 . . . . 0.0 111.031 -178.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 55.7 t60 -61.66 -50.35 72.85 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.967 0.907 . . . . 0.0 111.205 -177.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.4 HG21 HG21 ' A' ' 64' ' ' VAL . 39.6 mm -64.99 -39.93 87.35 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.083 179.055 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.13 -37.11 79.09 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 123.985 0.803 . . . . 0.0 111.128 179.093 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.422 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 39.5 mm-40 -66.29 -40.02 89.77 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 123.625 0.77 . . . . 0.0 111.288 176.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.442 HG21 ' HA ' ' A' ' 44' ' ' ILE . 65.6 mt -64.08 -52.95 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 O-C-N 123.606 0.566 . . . . 0.0 111.17 -179.215 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 8.0 tt -66.8 -37.88 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.313 -175.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.5 t -73.84 -29.64 62.24 Favored 'General case' 0 CA--C 1.552 1.037 0 C-N-CA 122.384 0.273 . . . . 0.0 110.296 179.503 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.71 -22.24 61.67 Favored 'General case' 0 N--CA 1.484 1.256 0 C-N-CA 123.628 0.771 . . . . 0.0 111.238 174.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.43 -6.08 52.15 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.503 0.721 . . . . 0.0 111.396 172.242 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 93.87 8.17 60.75 Favored Glycine 0 C--N 1.345 1.068 0 CA-C-O 119.89 -0.394 . . . . 0.0 112.933 177.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -117.0 103.22 10.04 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 176.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.4 t -83.59 118.53 71.74 Favored Pre-proline 0 CA--C 1.554 1.119 0 C-N-CA 123.267 0.627 . . . . 0.0 110.389 -176.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -70.75 -42.6 2.28 Favored 'Trans proline' 0 C--N 1.377 2.076 0 C-N-CA 122.409 2.072 . . . . 0.0 111.716 173.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 . . . . . 0 C--O 1.253 1.279 0 C-N-CA 124.767 1.227 . . . . 0.0 108.102 172.379 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.403 ' HA2' ' HA2' ' A' ' 65' ' ' GLY . . . . . . . . 0 N--CA 1.467 0.721 0 N-CA-C 112.058 -0.417 . . . . 0.0 112.058 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 47.6 mt -80.32 108.6 14.07 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 123.809 0.844 . . . . 0.0 110.141 -178.018 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 21.0 p -88.44 124.25 33.78 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 123.623 0.769 . . . . 0.0 110.978 -178.383 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -121.55 112.72 18.83 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 123.729 0.812 . . . . 0.0 110.401 -179.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 69.3 m80 -83.59 104.23 13.55 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.318 0.647 . . . . 0.0 110.173 177.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.595 HG11 ' HB3' ' A' ' 82' ' ' TYR . 98.8 t -90.07 128.3 42.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 C-N-CA 123.404 0.681 . . . . 0.0 109.176 174.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -64.44 -39.85 94.61 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 123.563 0.745 . . . . 0.0 112.286 -176.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -104.83 -6.47 20.21 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 113.302 0.852 . . . . 0.0 113.302 -166.169 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 24.1 ptm -65.45 133.38 51.18 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-O 121.318 0.58 . . . . 0.0 111.355 -174.236 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 72.9 p -107.55 161.62 14.69 Favored 'General case' 0 CA--C 1.547 0.856 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 171.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 24.6 p -74.87 -109.29 0.01 OUTLIER 'General case' 0 CA--C 1.563 1.479 0 N-CA-C 113.951 1.093 . . . . 0.0 113.951 -166.524 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -75.96 5.21 41.98 Favored Glycine 0 N--CA 1.478 1.474 0 N-CA-C 117.422 1.729 . . . . 0.0 117.422 -154.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 65.7 m80 -110.13 -31.02 7.5 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-N 118.118 0.959 . . . . 0.0 110.548 175.349 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.4 m -102.0 -8.87 21.12 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.621 0.769 . . . . 0.0 110.936 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -61.5 -46.38 90.26 Favored 'General case' 0 C--N 1.354 0.771 0 C-N-CA 123.803 0.841 . . . . 0.0 110.347 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.55 -27.57 72.71 Favored Glycine 0 C--N 1.343 0.946 0 O-C-N 123.977 0.798 . . . . 0.0 113.846 -178.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 53.0 t -72.04 -46.6 58.59 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.963 0 C-N-CA 123.196 0.598 . . . . 0.0 109.771 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.441 HG21 HG21 ' A' ' 62' ' ' VAL . 75.7 mt -59.98 -55.23 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.669 176.298 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -61.51 -43.43 98.88 Favored 'General case' 0 C--O 1.219 -0.503 0 CA-C-N 114.794 -1.094 . . . . 0.0 110.918 -176.18 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.86 -42.57 98.38 Favored Glycine 0 C--N 1.345 1.051 0 O-C-N 124.068 0.855 . . . . 0.0 112.366 -179.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.32 -55.11 31.34 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 122.89 0.476 . . . . 0.0 110.815 -179.454 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.542 HG21 HG11 ' A' ' 64' ' ' VAL . 82.4 mt -64.45 -51.13 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 C-N-CA 123.758 0.823 . . . . 0.0 112.297 -176.731 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -60.68 -45.58 93.6 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 124.316 1.046 . . . . 0.0 112.222 -173.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.3 mptp? -78.72 -21.09 48.6 Favored 'General case' 0 N--CA 1.484 1.234 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -173.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.407 ' HB ' HD13 ' A' ' 76' ' ' ILE . 38.5 m -85.33 -39.17 17.96 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 122.899 0.48 . . . . 0.0 110.319 177.536 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.1 t -118.46 86.53 28.59 Favored Pre-proline 0 CA--C 1.548 0.876 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 174.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo -61.76 106.77 0.46 Allowed 'Trans proline' 0 C--N 1.378 2.111 0 C-N-CA 122.952 2.435 . . . . 0.0 112.813 -174.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.88 7.93 8.37 Favored Glycine 0 C--N 1.341 0.859 0 CA-C-N 115.638 -0.71 . . . . 0.0 113.173 -179.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.19 107.47 9.6 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 176.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.411 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -75.58 96.37 3.52 Favored 'General case' 0 C--N 1.352 0.693 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 -177.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.443 HG12 HG12 ' A' ' 64' ' ' VAL . 5.0 m -87.29 133.14 30.89 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.587 -168.737 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 75.6 t60 -138.62 99.25 3.77 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 174.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.78 115.3 23.34 Favored 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 173.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -96.94 120.77 60.92 Favored Pre-proline 0 N--CA 1.478 0.951 0 CA-C-O 118.975 -0.536 . . . . 0.0 109.919 -173.175 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -55.75 -48.97 17.33 Favored 'Trans proline' 0 C--N 1.381 2.27 0 C-N-CA 123.598 2.865 . . . . 0.0 114.025 178.095 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -75.09 -42.85 55.82 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.116 -170.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 19.5 m -93.31 -14.94 26.32 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.595 0.758 . . . . 0.0 112.125 -171.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 11.4 mpt_? 59.42 40.43 20.83 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 123.866 0.866 . . . . 0.0 110.273 -175.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.9 m -121.31 118.87 30.61 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.119 0.568 . . . . 0.0 111.275 -169.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.441 HG21 HG21 ' A' ' 40' ' ' ILE . 42.8 t -97.88 105.92 17.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 175.168 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 6.3 t -102.02 123.19 55.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 -176.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.542 HG11 HG21 ' A' ' 44' ' ' ILE . 19.1 m -117.39 109.22 26.91 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 CA-C-O 121.512 0.672 . . . . 0.0 110.787 -176.478 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.403 ' HA2' ' HA2' ' A' ' 23' ' ' GLY . . . -90.76 161.98 28.67 Favored Glycine 0 C--N 1.344 0.994 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.775 -176.62 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.7 0.65 74.8 Favored Glycine 0 C--N 1.346 1.106 0 CA-C-O 119.995 -0.336 . . . . 0.0 113.824 177.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.99 149.05 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 123.826 0.85 . . . . 0.0 109.987 -177.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 45.7 m -114.88 4.76 14.94 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.797 0.839 . . . . 0.0 110.359 176.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.59 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 5.6 m-20 -83.12 68.6 9.63 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.015 0.926 . . . . 0.0 111.014 -172.352 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.25 -45.11 95.86 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.12 0.568 . . . . 0.0 111.681 -175.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -66.43 -44.14 83.7 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.235 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.59 ' HB2' ' HB3' ' A' ' 69' ' ' ASP . 26.1 m80 -62.48 -52.45 63.47 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 122.968 0.507 . . . . 0.0 111.271 -178.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.488 HG12 ' O ' ' A' ' 69' ' ' ASP . 48.6 mm -57.52 -43.13 82.43 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 O-C-N 123.817 0.698 . . . . 0.0 110.09 -177.395 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.82 -38.93 83.4 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 124.403 1.064 . . . . 0.0 111.764 178.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 43.8 mm-40 -68.87 -36.06 77.65 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.42 0.688 . . . . 0.0 111.748 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.483 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.6 mt -69.59 -51.69 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.989 0 C-N-CA 122.743 0.417 . . . . 0.0 110.186 -177.095 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.417 HG12 ' HB2' ' A' ' 82' ' ' TYR . 12.4 tt -70.43 -30.55 43.38 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.071 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.536 -174.544 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 3.8 t -74.86 -30.3 61.29 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 176.272 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -74.39 -23.04 58.92 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.557 0.743 . . . . 0.0 110.533 173.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.55 -6.99 55.59 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 123.32 0.648 . . . . 0.0 111.207 172.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 100.03 9.55 48.31 Favored Glycine 0 C--N 1.352 1.469 0 CA-C-O 119.797 -0.446 . . . . 0.0 113.727 173.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.595 ' HB3' HG11 ' A' ' 28' ' ' VAL . 84.9 m-85 -109.09 121.5 45.29 Favored 'General case' 0 N--CA 1.481 1.079 0 C-N-CA 123.715 0.806 . . . . 0.0 109.289 -178.218 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 31.3 m -88.18 103.4 5.03 Favored Pre-proline 0 CA--C 1.559 1.325 0 C-N-CA 123.868 0.867 . . . . 0.0 111.396 -175.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -91.01 -74.65 0.0 OUTLIER 'Trans proline' 0 C--N 1.376 2.023 0 C-N-CA 123.564 2.843 . . . . 0.0 112.477 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 . . . . . 0 CA--C 1.554 1.109 0 C-N-CA 125.54 1.536 . . . . 0.0 111.372 -179.353 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.691 0 N-CA-C 112.739 -0.144 . . . . 0.0 112.739 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.523 HD13 ' HA ' ' A' ' 70' ' ' ALA . 56.1 mt -79.78 109.83 14.57 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 123.788 0.835 . . . . 0.0 109.848 -176.764 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.558 ' HA ' HG12 ' A' ' 63' ' ' VAL . 19.6 p -92.17 109.03 20.39 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.001 0.52 . . . . 0.0 111.405 -174.282 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 88.9 m-85 -105.17 110.29 22.61 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.162 0.585 . . . . 0.0 109.954 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 11.7 m170 -82.49 92.49 7.08 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.459 HG22 ' HB3' ' A' ' 84' ' ' PRO . 31.0 t -83.27 105.48 13.03 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.256 -175.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -79.22 -10.76 59.9 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 122.774 0.43 . . . . 0.0 111.515 -176.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -93.41 -0.8 56.38 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 123.813 0.845 . . . . 0.0 111.476 173.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.48 ' HB3' ' HB3' ' A' ' 60' ' ' ARG . 26.7 ttt -73.62 137.36 44.16 Favored 'General case' 0 CA--C 1.543 0.679 0 CA-C-O 121.58 0.705 . . . . 0.0 111.754 -176.445 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.0 t -110.1 164.47 12.6 Favored 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 125.507 1.523 . . . . 0.0 109.054 175.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.466 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 60.1 m -59.0 -178.6 0.05 Allowed 'General case' 0 CA--C 1.559 1.318 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -53.95 -21.56 17.23 Favored Glycine 0 C--N 1.353 1.49 0 N-CA-C 116.682 1.433 . . . . 0.0 116.682 -169.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 33.1 m170 -62.54 -21.35 65.48 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 123.532 0.733 . . . . 0.0 112.797 -177.427 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 53.2 t -139.12 17.7 2.61 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 123.434 0.694 . . . . 0.0 110.811 178.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.85 -31.45 69.3 Favored 'General case' 0 N--CA 1.482 1.126 0 C-N-CA 123.03 0.532 . . . . 0.0 111.811 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.76 -23.49 74.04 Favored Glycine 0 C--N 1.347 1.174 0 O-C-N 123.471 0.482 . . . . 0.0 113.586 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 92.1 t -69.47 -40.47 79.85 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.616 0.767 . . . . 0.0 109.873 173.373 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 23.2 mt -72.24 -40.7 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 CA-C-N 114.72 -1.127 . . . . 0.0 109.91 -177.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -59.65 -54.79 42.33 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 114.664 -1.153 . . . . 0.0 109.999 172.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.59 -30.05 71.13 Favored Glycine 0 C--N 1.349 1.26 0 O-C-N 124.604 1.19 . . . . 0.0 113.389 -175.751 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.46 -53.59 54.43 Favored 'General case' 0 C--N 1.351 0.658 0 C-N-CA 124.146 0.978 . . . . 0.0 110.9 176.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.466 HD11 HD12 ' A' ' 77' ' ' ILE . 64.2 mt -75.22 -59.06 3.61 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.572 178.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -50.02 -48.15 52.81 Favored 'General case' 0 N--CA 1.483 1.19 0 C-N-CA 126.215 1.806 . . . . 0.0 113.688 -169.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.4 mptt -69.45 -38.17 77.67 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 122.792 0.437 . . . . 0.0 111.407 -178.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.9 m -73.35 -33.08 64.89 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 123.219 0.607 . . . . 0.0 111.02 -178.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 3.9 m -136.32 81.6 36.93 Favored Pre-proline 0 CA--C 1.556 1.201 0 C-N-CA 124.066 0.946 . . . . 0.0 110.537 178.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_exo -62.91 123.04 11.56 Favored 'Trans proline' 0 C--N 1.381 2.253 0 C-N-CA 122.827 2.351 . . . . 0.0 111.308 174.035 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.77 -24.59 7.48 Favored Glycine 0 C--N 1.342 0.899 0 CA-C-O 119.866 -0.408 . . . . 0.0 112.234 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.21 104.86 5.95 Favored 'General case' 0 C--N 1.354 0.761 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 172.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.52 100.41 2.73 Favored 'General case' 0 C--N 1.348 0.525 0 C-N-CA 123.318 0.647 . . . . 0.0 110.529 -173.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.415 HG12 HG12 ' A' ' 64' ' ' VAL . 27.1 m -85.36 134.24 27.59 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 O-C-N 123.603 0.564 . . . . 0.0 110.744 -173.28 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 44.0 t-80 -135.69 99.89 4.32 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 169.256 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.67 116.32 23.14 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 115.021 -0.99 . . . . 0.0 108.949 178.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -103.27 105.85 48.48 Favored Pre-proline 0 N--CA 1.478 0.944 0 CA-C-O 118.47 -0.776 . . . . 0.0 108.973 -177.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.466 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 72.4 Cg_exo -54.79 -41.88 73.97 Favored 'Trans proline' 0 C--N 1.378 2.127 0 C-N-CA 123.178 2.585 . . . . 0.0 114.67 179.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -67.78 -45.57 74.48 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 123.114 0.565 . . . . 0.0 111.75 -173.274 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.4 t -89.88 -18.93 25.24 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 123.686 0.794 . . . . 0.0 111.089 -178.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.48 ' HB3' ' HB3' ' A' ' 31' ' ' MET . 0.2 OUTLIER 61.28 47.1 7.25 Favored 'General case' 0 N--CA 1.482 1.138 0 C-N-CA 124.699 1.2 . . . . 0.0 110.272 -175.676 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 54.1 m -128.84 115.16 17.48 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 123.178 0.591 . . . . 0.0 110.246 -173.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 25.4 t -98.56 108.53 22.28 Favored 'Isoleucine or valine' 0 C--O 1.24 0.6 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 175.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.558 HG12 ' HA ' ' A' ' 25' ' ' SER . 34.7 m -99.46 136.08 32.11 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.201 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.454 HG21 HG21 ' A' ' 73' ' ' ILE . 21.4 m -119.16 133.84 64.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.345 0.658 . . . . 0.0 110.181 -178.364 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -113.0 153.31 17.62 Favored Glycine 0 C--N 1.35 1.311 0 CA-C-N 116.303 -0.408 . . . . 0.0 112.787 -175.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.7 14.5 82.34 Favored Glycine 0 C--N 1.348 1.23 0 N-CA-C 113.945 0.338 . . . . 0.0 113.945 175.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 3.6 m -129.54 134.8 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 123.85 0.86 . . . . 0.0 110.245 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.6 m -95.52 -23.85 16.9 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 123.686 0.794 . . . . 0.0 111.099 176.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -79.05 87.25 4.84 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-O 121.141 0.496 . . . . 0.0 111.3 -175.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.523 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -70.63 -46.1 63.97 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.943 -175.438 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -61.6 -36.61 81.2 Favored 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.961 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 74.7 t60 -63.11 -51.68 65.61 Favored 'General case' 0 N--CA 1.473 0.715 0 O-C-N 123.856 0.722 . . . . 0.0 110.852 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.454 HG21 HG21 ' A' ' 64' ' ' VAL . 41.7 mm -59.45 -42.32 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 123.646 0.591 . . . . 0.0 110.379 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.0 -41.42 98.04 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.375 -177.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 54.8 mm-40 -63.24 -39.97 96.12 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.464 0.706 . . . . 0.0 111.607 178.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 85.5 mt -61.78 -54.25 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.403 0.681 . . . . 0.0 111.41 -178.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.466 HD12 HD11 ' A' ' 44' ' ' ILE . 14.0 tt -73.84 -33.13 36.45 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.913 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.7 -171.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.9 t -71.76 -29.26 64.31 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 176.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.07 -22.99 63.0 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.803 0.841 . . . . 0.0 111.167 173.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -82.93 -3.09 56.63 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 123.751 0.82 . . . . 0.0 111.774 175.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.22 -6.23 59.54 Favored Glycine 0 C--N 1.348 1.217 0 CA-C-O 120.155 -0.247 . . . . 0.0 113.311 178.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.408 ' HB3' HG11 ' A' ' 28' ' ' VAL . 87.0 m-85 -106.07 103.15 12.57 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -178.539 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 53.0 m -94.4 114.2 62.77 Favored Pre-proline 0 CA--C 1.553 1.085 0 C-N-CA 123.201 0.6 . . . . 0.0 111.633 -171.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.459 ' HB3' HG22 ' A' ' 28' ' ' VAL . 25.4 Cg_endo -95.99 -11.11 0.84 Allowed 'Trans proline' 0 C--N 1.377 2.031 0 C-N-CA 123.27 2.647 . . . . 0.0 113.328 167.227 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 . . . . . 0 C--O 1.251 1.157 0 C-N-CA 124.006 0.922 . . . . 0.0 108.699 -173.785 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.559 0 CA-C-O 120.991 0.217 . . . . 0.0 113.369 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.442 HD13 ' HA ' ' A' ' 70' ' ' ALA . 32.2 mt -87.72 116.93 26.2 Favored 'General case' 0 C--O 1.239 0.522 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 175.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 28.6 p -92.13 111.32 22.83 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 122.871 0.468 . . . . 0.0 111.214 -173.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -108.95 133.64 52.69 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.274 1.029 . . . . 0.0 108.809 175.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 18.6 p80 -125.89 137.1 53.71 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.258 0.623 . . . . 0.0 109.803 -176.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.768 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 67.0 t -117.51 120.02 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 N-CA-C 107.162 -1.421 . . . . 0.0 107.162 170.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -70.68 -21.97 62.52 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -175.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -89.56 -8.61 52.31 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 123.411 0.685 . . . . 0.0 111.009 177.377 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.768 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 25.7 ttt -56.14 106.67 0.29 Allowed 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.911 0.884 . . . . 0.0 112.341 -170.439 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.415 ' O ' ' HB3' ' A' ' 36' ' ' CYS . 67.1 p -70.94 162.24 29.68 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 123.651 0.78 . . . . 0.0 109.284 167.358 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 79.5 m -61.39 -104.86 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 123.488 0.715 . . . . 0.0 111.808 -177.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.49 -30.9 75.51 Favored Glycine 0 C--N 1.353 1.489 0 CA-C-N 119.391 0.996 . . . . 0.0 113.603 -172.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 21.7 t-80 -62.73 -30.11 71.18 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 123.98 0.912 . . . . 0.0 112.659 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.638 ' SG ' ' HG3' ' A' ' 31' ' ' MET . 51.9 t -106.16 -31.25 8.77 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 122.51 0.324 . . . . 0.0 110.44 179.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -62.94 -49.6 74.11 Favored 'General case' 0 C--N 1.356 0.851 0 C-N-CA 123.466 0.707 . . . . 0.0 111.698 -175.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.8 -37.08 75.53 Favored Glycine 0 C--N 1.347 1.165 0 O-C-N 123.979 0.799 . . . . 0.0 113.84 -177.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.501 HG12 ' HB1' ' A' ' 80' ' ' ALA . 42.7 t -71.6 -51.26 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 123.318 0.647 . . . . 0.0 110.526 -179.021 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.689 HG21 HG21 ' A' ' 62' ' ' VAL . 64.7 mt -64.81 -53.93 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 CA-C-N 115.443 -0.798 . . . . 0.0 111.646 -176.017 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 48.6 mtmt -57.84 -46.89 84.12 Favored 'General case' 0 N--CA 1.474 0.746 0 O-C-N 123.889 0.743 . . . . 0.0 110.064 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.31 -36.74 93.5 Favored Glycine 0 C--N 1.351 1.41 0 O-C-N 124.346 1.028 . . . . 0.0 113.142 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -67.42 -54.02 24.05 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 122.743 0.417 . . . . 0.0 111.121 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.596 HG21 HG11 ' A' ' 64' ' ' VAL . 63.9 mt -67.36 -42.88 87.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 C-N-CA 123.275 0.63 . . . . 0.0 111.563 -176.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -61.33 -47.53 85.48 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.877 0.871 . . . . 0.0 111.626 -177.69 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -73.13 -37.06 66.79 Favored 'General case' 0 N--CA 1.48 1.035 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.942 -176.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 58.8 m -73.61 -40.99 63.41 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 122.658 0.383 . . . . 0.0 111.149 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.4 HG11 HG11 ' A' ' 67' ' ' VAL . 24.2 t -114.08 102.69 55.02 Favored Pre-proline 0 N--CA 1.481 1.084 0 C-N-CA 123.185 0.594 . . . . 0.0 110.277 -176.578 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -68.16 107.03 1.47 Allowed 'Trans proline' 0 C--N 1.373 1.826 0 C-N-CA 122.717 2.278 . . . . 0.0 111.123 173.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.16 -10.94 10.8 Favored Glycine 0 C--N 1.345 1.076 0 CA-C-O 119.251 -0.749 . . . . 0.0 113.619 178.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.41 106.6 7.04 Favored 'General case' 0 N--CA 1.479 0.977 0 CA-C-N 117.833 0.816 . . . . 0.0 109.038 174.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.58 99.03 7.89 Favored 'General case' 0 N--CA 1.465 0.31 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 -178.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.52 HG12 HG12 ' A' ' 64' ' ' VAL . 26.9 m -86.51 134.17 28.05 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 C-N-CA 123.412 0.685 . . . . 0.0 110.366 -174.353 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 43.6 t-80 -142.81 102.16 3.98 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 172.46 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.443 ' HB1' ' HE1' ' A' ' 31' ' ' MET . . . -89.61 115.79 27.27 Favored 'General case' 0 C--O 1.239 0.509 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 171.126 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.434 ' HA ' ' HD2' ' A' ' 57' ' ' PRO . 20.0 t70 -92.08 114.27 61.63 Favored Pre-proline 0 CA--C 1.546 0.8 0 CA-C-O 118.142 -0.932 . . . . 0.0 109.549 -177.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.434 ' HD2' ' HA ' ' A' ' 56' ' ' ASP . 7.3 Cg_endo -47.27 -33.6 16.61 Favored 'Trans proline' 0 C--N 1.381 2.259 0 C-N-CA 124.612 3.542 . . . . 0.0 115.29 178.267 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.47 -44.32 24.88 Favored 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -177.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.1 t -93.27 -23.38 18.53 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.405 0.682 . . . . 0.0 111.955 -173.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.491 ' HB3' ' HB3' ' A' ' 31' ' ' MET . 11.7 mmm180 57.63 41.29 25.78 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 125.596 1.558 . . . . 0.0 111.578 -173.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.8 m -119.26 127.69 53.47 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 123.286 0.635 . . . . 0.0 110.028 -177.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.689 HG21 HG21 ' A' ' 40' ' ' ILE . 21.6 t -99.59 106.17 18.63 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 C-N-CA 124.658 1.183 . . . . 0.0 108.951 177.124 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 25.7 m -94.11 135.43 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 175.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.596 HG11 HG21 ' A' ' 44' ' ' ILE . 22.2 m -120.87 107.88 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-O 121.674 0.749 . . . . 0.0 110.017 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.71 152.4 21.85 Favored Glycine 0 C--N 1.346 1.115 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.789 -175.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.8 -24.47 26.08 Favored Glycine 0 C--N 1.344 0.997 0 C-N-CA 123.042 0.353 . . . . 0.0 113.036 178.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.4 HG11 HG11 ' A' ' 48' ' ' VAL . 27.4 m -111.24 145.64 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 123.904 0.881 . . . . 0.0 110.135 -177.473 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t -117.71 10.01 13.21 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 123.624 0.77 . . . . 0.0 109.771 176.364 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -86.58 74.83 9.81 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.222 1.009 . . . . 0.0 109.522 -176.083 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.442 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -63.79 -47.37 81.16 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.39 0.676 . . . . 0.0 112.252 -172.191 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.503 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.47 -39.64 94.99 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 123.113 0.565 . . . . 0.0 110.788 -179.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 74.1 t60 -63.13 -51.69 65.51 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.286 1.034 . . . . 0.0 111.279 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.46 ' O ' HG22 ' A' ' 77' ' ' ILE . 41.3 mm -60.75 -38.47 78.88 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 O-C-N 123.744 0.652 . . . . 0.0 109.962 179.113 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.81 -36.74 79.8 Favored 'General case' 0 N--CA 1.476 0.856 0 O-C-N 124.247 0.967 . . . . 0.0 111.837 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.503 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 11.7 mm-40 -69.35 -34.78 75.11 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.16 0.584 . . . . 0.0 111.26 177.537 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 71.5 mt -71.75 -48.44 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 C-N-CA 123.441 0.696 . . . . 0.0 111.961 -177.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.462 ' HB ' HD11 ' A' ' 44' ' ' ILE . 5.0 tt -66.53 -37.27 79.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.184 0 C-N-CA 122.871 0.469 . . . . 0.0 110.851 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 t -71.18 -29.61 65.39 Favored 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 122.463 0.305 . . . . 0.0 110.379 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.61 -24.27 62.71 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 123.751 0.82 . . . . 0.0 111.373 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.501 ' HB1' HG12 ' A' ' 39' ' ' VAL . . . -75.02 -6.09 47.52 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.389 0.675 . . . . 0.0 111.578 175.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.29 1.38 56.85 Favored Glycine 0 C--N 1.35 1.325 0 CA-C-O 119.884 -0.398 . . . . 0.0 112.98 176.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -120.31 104.71 10.26 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 178.562 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.7 t -86.32 116.96 67.83 Favored Pre-proline 0 CA--C 1.554 1.119 0 C-N-CA 123.397 0.679 . . . . 0.0 110.354 -178.642 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -79.88 148.67 19.94 Favored 'Trans proline' 0 C--N 1.375 1.961 0 C-N-CA 122.742 2.294 . . . . 0.0 111.571 174.381 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.4 mp0 . . . . . 0 C--O 1.251 1.148 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -176.789 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.57 0 N-CA-C 111.412 -0.675 . . . . 0.0 111.412 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.401 HD13 ' HA ' ' A' ' 70' ' ' ALA . 34.0 mt -88.99 108.24 19.47 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.3 p -92.36 111.35 22.89 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 122.844 0.458 . . . . 0.0 110.606 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -106.24 124.88 50.28 Favored 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 123.862 0.865 . . . . 0.0 109.72 179.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 32.1 m-70 -84.03 136.77 33.91 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 175.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 p -157.31 96.98 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.091 0.957 . . . . 0.0 109.059 -176.364 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -69.79 -29.46 66.77 Favored 'General case' 0 N--CA 1.479 1.007 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.443 -176.21 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.5 m-20 -74.29 -9.84 59.01 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.164 0.586 . . . . 0.0 112.104 -178.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.612 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 56.3 ttp -72.69 113.06 9.3 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-O 120.944 0.402 . . . . 0.0 110.536 177.145 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.401 ' OG1' ' HB3' ' A' ' 36' ' ' CYS . 62.7 p -77.51 166.36 23.17 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 123.993 0.917 . . . . 0.0 109.912 168.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 27.9 p -57.11 -169.69 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 124.121 0.968 . . . . 0.0 112.6 175.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.73 3.5 0.64 Allowed Glycine 0 C--N 1.357 1.732 0 N-CA-C 115.922 1.129 . . . . 0.0 115.922 -174.021 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -63.3 -44.72 94.22 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.786 0.834 . . . . 0.0 110.798 166.031 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.401 ' HB3' ' OG1' ' A' ' 32' ' ' THR . 43.6 t -141.47 9.51 2.03 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 123.189 0.596 . . . . 0.0 111.987 -176.018 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.65 -30.89 69.69 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 122.814 0.446 . . . . 0.0 110.732 173.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.58 -20.84 53.15 Favored Glycine 0 C--N 1.348 1.238 0 CA-C-N 114.997 -1.001 . . . . 0.0 114.262 176.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.501 HG12 ' HB1' ' A' ' 80' ' ' ALA . 57.8 t -65.48 -44.25 94.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 122.851 0.461 . . . . 0.0 110.128 174.221 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.709 HG21 HG21 ' A' ' 62' ' ' VAL . 43.7 mt -69.7 -54.4 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 C-N-CA 123.322 0.649 . . . . 0.0 110.619 175.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.425 ' O ' ' HG3' ' A' ' 45' ' ' GLU . 9.7 mtpm? -56.68 -51.93 66.87 Favored 'General case' 0 C--N 1.347 0.487 0 O-C-N 124.439 1.087 . . . . 0.0 110.216 -174.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.482 ' O ' ' HD3' ' A' ' 46' ' ' LYS . . . -61.87 -40.18 98.5 Favored Glycine 0 C--N 1.342 0.886 0 O-C-N 124.984 1.428 . . . . 0.0 112.822 178.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.79 -53.48 57.32 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-N 117.161 0.48 . . . . 0.0 110.955 179.181 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.572 HG21 HG11 ' A' ' 64' ' ' VAL . 68.3 mt -62.11 -39.9 85.54 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.823 0 CA-C-N 115.43 -0.805 . . . . 0.0 111.972 -179.163 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.425 ' HG3' ' O ' ' A' ' 41' ' ' LYS . 76.8 mt-10 -62.0 -50.46 71.96 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 123.157 0.583 . . . . 0.0 112.108 179.582 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.482 ' HD3' ' O ' ' A' ' 42' ' ' GLY . 13.3 mptt -73.0 -28.11 62.18 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.52 -171.536 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.1 m -85.15 -41.06 16.02 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 122.815 0.446 . . . . 0.0 110.291 177.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.2 t -127.03 103.58 23.39 Favored Pre-proline 0 N--CA 1.483 1.213 0 C-N-CA 124.117 0.967 . . . . 0.0 109.772 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -66.91 136.58 41.99 Favored 'Trans proline' 0 C--N 1.374 1.906 0 C-N-CA 122.772 2.315 . . . . 0.0 111.684 172.037 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.18 -4.74 67.73 Favored Glycine 0 C--N 1.346 1.084 0 CA-C-O 119.769 -0.462 . . . . 0.0 113.948 175.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.61 106.68 9.56 Favored 'General case' 0 C--N 1.351 0.649 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 173.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.423 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -77.15 99.52 5.43 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -177.063 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.41 HG12 HG12 ' A' ' 64' ' ' VAL . 27.7 m -85.28 127.45 39.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 123.123 0.569 . . . . 0.0 110.886 -171.089 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . 0.411 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 29.2 t60 -131.62 96.95 4.08 Favored 'General case' 0 C--N 1.345 0.391 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 176.069 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.612 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -93.6 113.59 25.73 Favored 'General case' 0 C--O 1.241 0.646 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 176.031 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -99.66 114.83 65.86 Favored Pre-proline 0 N--CA 1.468 0.433 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 -177.397 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.52 -40.4 57.12 Favored 'Trans proline' 0 C--N 1.373 1.829 0 C-N-CA 123.011 2.474 . . . . 0.0 112.767 -176.234 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -74.31 -47.8 32.4 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 123.619 0.767 . . . . 0.0 111.31 -176.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.1 m -81.26 -15.65 54.94 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.7 0.8 . . . . 0.0 111.455 -176.111 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.7 mmt180 62.97 29.43 16.46 Favored 'General case' 0 N--CA 1.487 1.421 0 C-N-CA 124.63 1.172 . . . . 0.0 111.437 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 33.2 m -122.79 122.76 39.47 Favored 'General case' 0 N--CA 1.479 1.017 0 O-C-N 121.825 -0.547 . . . . 0.0 111.521 -169.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.709 HG21 HG21 ' A' ' 40' ' ' ILE . 40.5 t -99.11 106.4 18.86 Favored 'Isoleucine or valine' 0 C--N 1.35 0.608 0 C-N-CA 123.943 0.897 . . . . 0.0 108.977 173.279 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.0 t -100.41 123.2 53.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.617 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.585 HG21 HG21 ' A' ' 73' ' ' ILE . 17.0 m -111.56 108.94 26.77 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.994 0 CA-C-O 121.475 0.655 . . . . 0.0 110.158 179.393 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.44 150.84 21.03 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.549 -176.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.13 -23.67 30.4 Favored Glycine 0 C--N 1.344 0.984 0 C-N-CA 123.104 0.383 . . . . 0.0 113.051 177.037 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 22.4 m -105.54 151.13 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 123.969 0.908 . . . . 0.0 110.151 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.0 m -126.84 -2.55 6.57 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 124.005 0.922 . . . . 0.0 110.36 -178.658 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -87.35 73.0 9.71 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.54 1.136 . . . . 0.0 110.247 -177.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.401 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -64.01 -29.17 70.35 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 114.907 -1.042 . . . . 0.0 112.453 -174.747 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -63.76 -49.37 73.25 Favored 'General case' 0 N--CA 1.474 0.745 0 O-C-N 123.799 0.687 . . . . 0.0 110.863 177.545 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.5 ' O ' HG13 ' A' ' 76' ' ' ILE . 39.9 m170 -59.41 -54.93 41.05 Favored 'General case' 0 N--CA 1.478 0.957 0 O-C-N 123.488 0.493 . . . . 0.0 110.474 177.772 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.585 HG21 HG21 ' A' ' 64' ' ' VAL . 41.4 mm -57.74 -40.27 74.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 O-C-N 124.343 1.027 . . . . 0.0 110.811 -174.352 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.33 -40.11 89.47 Favored 'General case' 0 N--CA 1.48 1.029 0 O-C-N 124.039 0.837 . . . . 0.0 111.397 178.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -68.3 -32.05 71.92 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 123.181 0.593 . . . . 0.0 111.291 178.071 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.5 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.5 mt -74.77 -48.62 32.99 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 C-N-CA 122.951 0.5 . . . . 0.0 111.245 -177.125 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 73' ' ' ILE . 8.5 tt -67.38 -32.36 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 C-N-CA 123.254 0.622 . . . . 0.0 111.253 -177.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -75.12 -31.02 61.01 Favored 'General case' 0 CA--C 1.549 0.917 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -69.0 -18.46 64.05 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.494 0.718 . . . . 0.0 111.737 176.115 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.501 ' HB1' HG12 ' A' ' 39' ' ' VAL . . . -75.91 0.67 17.48 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 123.645 0.778 . . . . 0.0 112.269 176.414 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 95.84 16.97 37.0 Favored Glycine 0 C--N 1.35 1.328 0 C-N-CA 122.801 0.239 . . . . 0.0 112.544 179.63 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -120.76 178.38 4.72 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.361 1.065 . . . . 0.0 109.714 -177.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 39.3 m -139.41 111.83 7.78 Favored Pre-proline 0 N--CA 1.479 0.977 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 173.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -66.47 120.33 7.45 Favored 'Trans proline' 0 C--N 1.381 2.285 0 C-N-CA 122.423 2.082 . . . . 0.0 110.779 171.458 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 . . . . . 0 C--O 1.251 1.166 0 C-N-CA 124.212 1.005 . . . . 0.0 109.526 -175.652 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.47 0.938 0 N-CA-C 110.971 -0.851 . . . . 0.0 110.971 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -87.65 115.62 25.22 Favored 'General case' 0 N--CA 1.479 1.025 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -173.224 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 76.4 p -91.06 121.45 32.87 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 123.363 0.665 . . . . 0.0 111.337 -176.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -106.89 130.27 54.59 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.783 0.833 . . . . 0.0 109.563 175.546 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 9.8 m-70 -90.46 120.64 31.74 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 173.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.475 HG21 HD13 ' A' ' 40' ' ' ILE . 25.7 t -111.24 91.77 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 N-CA-C 104.765 -2.309 . . . . 0.0 104.765 160.413 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -68.62 -16.29 63.8 Favored 'General case' 0 CA--C 1.548 0.881 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -159.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -109.7 8.78 24.91 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.258 0.623 . . . . 0.0 111.472 -178.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 56.8 ttp -73.91 99.05 3.14 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.61 0.764 . . . . 0.0 109.843 176.06 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.0 t -101.3 104.57 15.59 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 123.103 0.561 . . . . 0.0 109.569 178.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.462 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 17.0 t 64.83 -170.99 0.19 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.382 1.073 . . . . 0.0 111.888 176.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.574 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -62.27 -6.36 10.33 Favored Glycine 0 C--N 1.355 1.599 0 CA-C-O 119.203 -0.776 . . . . 0.0 114.391 178.379 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 41.2 m80 -50.22 -40.17 46.62 Favored 'General case' 0 C--N 1.365 1.278 0 C-N-CA 124.274 1.03 . . . . 0.0 111.736 172.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -118.83 -31.6 4.75 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.151 0.58 . . . . 0.0 110.892 176.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.574 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -57.91 -34.16 69.54 Favored 'General case' 0 N--CA 1.481 1.109 0 C-N-CA 123.458 0.703 . . . . 0.0 112.699 -176.092 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -58.7 -52.45 53.02 Favored Glycine 0 C--N 1.348 1.246 0 O-C-N 123.842 0.713 . . . . 0.0 114.347 -177.106 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.3 p -69.83 -30.53 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 C-N-CA 123.012 0.525 . . . . 0.0 111.561 -177.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.651 HG21 HG21 ' A' ' 62' ' ' VAL . 83.4 mt -70.23 -47.21 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 123.082 0.553 . . . . 0.0 110.666 179.216 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -61.38 -44.24 97.5 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.639 0.775 . . . . 0.0 110.467 178.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.14 -36.43 93.23 Favored Glycine 0 C--N 1.348 1.197 0 O-C-N 124.202 0.939 . . . . 0.0 112.899 176.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.05 -53.77 50.91 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 123.376 0.671 . . . . 0.0 110.878 -178.359 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.546 HG21 HG11 ' A' ' 64' ' ' VAL . 64.0 mt -72.82 -46.27 53.6 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.936 -175.007 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -66.93 -39.23 87.29 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 123.551 0.74 . . . . 0.0 112.249 -172.146 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.1 mptp? -83.58 -14.34 52.32 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -176.652 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 54.5 m -90.24 -39.06 13.01 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 122.98 0.512 . . . . 0.0 109.802 173.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 91.4 t -121.01 96.38 48.57 Favored Pre-proline 0 N--CA 1.48 1.028 0 C-N-CA 123.939 0.896 . . . . 0.0 109.323 -179.538 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.93 113.0 3.26 Favored 'Trans proline' 0 C--N 1.37 1.662 0 C-N-CA 122.346 2.031 . . . . 0.0 110.589 175.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.39 -11.42 9.75 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-O 119.575 -0.57 . . . . 0.0 112.722 -176.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -78.42 106.89 10.67 Favored 'General case' 0 C--N 1.356 0.871 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 171.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.72 99.09 4.97 Favored 'General case' 0 C--N 1.349 0.577 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.0 m -85.49 123.63 39.5 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 CA-C-O 121.023 0.439 . . . . 0.0 110.155 -172.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 71.9 t60 -131.79 97.88 4.31 Favored 'General case' 0 C--N 1.343 0.32 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -176.496 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.4 114.52 28.86 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -178.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.426 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 13.5 t70 -99.56 127.12 35.08 Favored Pre-proline 0 CA--C 1.54 0.586 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -177.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.462 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 30.8 Cg_endo -61.62 -41.16 41.32 Favored 'Trans proline' 0 C--N 1.377 2.074 0 C-N-CA 123.105 2.537 . . . . 0.0 113.23 179.264 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.19 -35.28 48.8 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.728 0.811 . . . . 0.0 111.944 -174.521 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.426 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 19.2 m -88.83 -22.07 23.39 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.443 0.697 . . . . 0.0 111.061 -177.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? 57.99 41.07 24.9 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 124.653 1.181 . . . . 0.0 110.744 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 80.8 m -132.81 121.83 23.56 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.882 -171.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.651 HG21 HG21 ' A' ' 40' ' ' ILE . 21.1 t -98.89 104.7 16.32 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 C-N-CA 124.426 1.091 . . . . 0.0 108.638 173.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.8 t -95.48 131.35 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 108.023 -1.102 . . . . 0.0 108.023 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.546 HG11 HG21 ' A' ' 44' ' ' ILE . 26.2 m -111.58 109.97 30.46 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.869 0 CA-C-O 121.636 0.731 . . . . 0.0 109.84 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -89.77 149.83 20.73 Favored Glycine 0 C--N 1.346 1.1 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.733 -174.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 86.3 -20.04 24.03 Favored Glycine 0 C--N 1.341 0.84 0 C-N-CA 123.055 0.359 . . . . 0.0 112.879 -178.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 30.3 m -123.75 145.96 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 124.46 1.104 . . . . 0.0 108.881 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.6 m -130.19 -6.63 4.34 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 123.545 0.738 . . . . 0.0 111.302 -176.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -75.88 84.24 2.81 Favored 'General case' 0 CA--C 1.55 0.96 0 CA-C-O 122.338 1.066 . . . . 0.0 110.351 -178.095 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.81 -40.55 95.65 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 113.911 -1.495 . . . . 0.0 112.869 -171.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -58.75 -46.88 86.43 Favored 'General case' 0 N--CA 1.479 0.994 0 O-C-N 124.11 0.881 . . . . 0.0 111.882 -176.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 72.7 t60 -66.97 -50.78 61.24 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.023 -178.324 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 36.8 mm -59.88 -37.35 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 O-C-N 123.67 0.606 . . . . 0.0 110.407 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.43 -37.71 88.36 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 123.858 0.863 . . . . 0.0 111.736 -179.522 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 45.0 mm-40 -65.07 -35.86 82.5 Favored 'General case' 0 N--CA 1.476 0.825 0 O-C-N 123.685 0.615 . . . . 0.0 111.036 176.465 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 62.3 mt -67.99 -49.46 68.11 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.236 0 C-N-CA 123.112 0.565 . . . . 0.0 111.495 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.4 tt -71.4 -35.42 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 C-N-CA 123.182 0.593 . . . . 0.0 111.516 -176.341 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.2 t -71.63 -28.86 64.07 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 176.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.72 -26.8 65.44 Favored 'General case' 0 C--N 1.358 0.963 0 C-N-CA 123.592 0.757 . . . . 0.0 111.006 173.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.92 -3.16 33.89 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.513 0.725 . . . . 0.0 111.822 174.052 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 94.51 12.69 55.59 Favored Glycine 0 C--N 1.348 1.221 0 CA-C-O 119.713 -0.493 . . . . 0.0 113.058 175.437 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -128.5 105.81 8.56 Favored 'General case' 0 N--CA 1.483 1.224 0 CA-C-N 117.401 0.601 . . . . 0.0 109.919 179.247 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.9 t -76.4 123.93 87.92 Favored Pre-proline 0 CA--C 1.556 1.173 0 C-N-CA 123.253 0.621 . . . . 0.0 110.619 -178.099 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -79.08 173.99 12.71 Favored 'Trans proline' 0 C--N 1.373 1.824 0 C-N-CA 122.695 2.264 . . . . 0.0 111.37 168.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 . . . . . 0 C--O 1.25 1.118 0 C-N-CA 123.444 0.698 . . . . 0.0 109.331 -177.225 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.439 0 N-CA-C 112.038 -0.425 . . . . 0.0 112.038 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -134.93 132.44 38.45 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-N 117.245 0.523 . . . . 0.0 109.826 -172.684 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.6 t -104.55 134.45 47.71 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 123.911 0.885 . . . . 0.0 110.709 -177.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -135.59 118.97 16.77 Favored 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 124.156 0.982 . . . . 0.0 109.237 173.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.55 ' HA ' ' HA ' ' A' ' 61' ' ' THR . 35.2 p-80 -92.26 118.38 30.82 Favored 'General case' 0 N--CA 1.477 0.898 0 CA-C-N 118.657 0.662 . . . . 0.0 109.984 175.32 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.423 HG22 ' HA ' ' A' ' 84' ' ' PRO . 39.7 t -96.27 97.22 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 170.613 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -61.01 -26.92 67.94 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 123.556 0.743 . . . . 0.0 111.864 -176.375 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -80.16 -19.69 46.58 Favored 'General case' 0 CA--C 1.553 1.061 0 C-N-CA 124.147 0.979 . . . . 0.0 111.496 -178.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 62.9 ttp -68.7 129.72 40.75 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.655 0.782 . . . . 0.0 112.235 -175.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.3 p -85.43 169.88 13.23 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 124.333 1.053 . . . . 0.0 109.987 170.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 35.0 t -56.11 -151.7 0.0 OUTLIER 'General case' 0 CA--C 1.581 2.159 0 C-N-CA 125.078 1.351 . . . . 0.0 113.178 178.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -62.0 -2.66 3.99 Favored Glycine 0 C--N 1.356 1.688 0 N-CA-C 116.144 1.218 . . . . 0.0 116.144 -171.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -77.28 -22.79 51.54 Favored 'General case' 0 CA--C 1.552 1.021 0 CA-C-N 117.67 0.735 . . . . 0.0 112.208 178.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 19.3 p -124.41 -5.59 7.69 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 122.439 0.296 . . . . 0.0 111.597 177.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -64.65 -31.16 72.26 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.416 0.686 . . . . 0.0 112.498 -175.132 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.08 -50.46 67.58 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 114.565 0.586 . . . . 0.0 114.565 -174.052 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.3 m -66.35 -31.97 55.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 123.093 0.557 . . . . 0.0 112.119 -178.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.442 HG21 HG21 ' A' ' 62' ' ' VAL . 76.1 mt -72.22 -54.97 14.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.694 0 C-N-CA 123.884 0.874 . . . . 0.0 110.17 -177.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -61.33 -42.51 98.8 Favored 'General case' 0 CA--C 1.537 0.456 0 CA-C-N 114.343 -1.299 . . . . 0.0 110.79 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -68.07 -34.01 80.34 Favored Glycine 0 C--N 1.342 0.897 0 O-C-N 124.16 0.913 . . . . 0.0 113.131 -178.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -65.08 -53.75 40.74 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.789 0.435 . . . . 0.0 110.514 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.577 ' HA ' HG21 ' A' ' 76' ' ' ILE . 62.9 mt -63.98 -40.87 90.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.719 -178.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -64.68 -43.67 92.81 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.308 0.643 . . . . 0.0 111.549 -179.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -81.76 -18.56 43.79 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -175.108 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 36.8 m -87.26 -40.98 14.03 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 175.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.7 t -121.83 88.9 47.69 Favored Pre-proline 0 N--CA 1.48 1.069 0 C-N-CA 123.872 0.869 . . . . 0.0 108.831 174.067 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -60.94 113.18 1.61 Allowed 'Trans proline' 0 C--N 1.375 1.93 0 C-N-CA 122.632 2.222 . . . . 0.0 111.588 175.01 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.5 -5.37 11.86 Favored Glycine 0 C--N 1.341 0.856 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.804 -176.163 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -78.07 106.84 10.21 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 173.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.03 96.82 3.88 Favored 'General case' 0 C--N 1.351 0.658 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.454 HG12 HG12 ' A' ' 64' ' ' VAL . 7.8 m -88.85 134.83 27.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.729 -172.505 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -142.08 101.45 3.93 Favored 'General case' 0 C--N 1.352 0.684 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 176.621 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.12 114.69 22.44 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 173.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.401 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 10.2 t70 -93.41 130.35 35.79 Favored Pre-proline 0 CA--C 1.542 0.666 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 -175.071 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 56' ' ' ASP . 27.6 Cg_exo -64.86 -53.65 0.88 Allowed 'Trans proline' 0 C--N 1.372 1.797 0 C-N-CA 122.634 2.223 . . . . 0.0 113.058 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.82 -36.02 50.66 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.266 -170.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 26.3 t -87.6 -18.25 30.1 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 123.432 0.693 . . . . 0.0 110.685 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.419 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 10.4 mpt_? 60.94 31.36 19.97 Favored 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 124.467 1.107 . . . . 0.0 111.268 -176.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 27' ' ' HIS . 53.8 m -116.53 122.45 44.74 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -168.534 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.442 HG21 HG21 ' A' ' 40' ' ' ILE . 31.6 t -96.75 106.38 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 172.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 18.8 t -102.24 131.83 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.53 HG21 HG13 ' A' ' 73' ' ' ILE . 35.6 m -105.43 139.41 26.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 C-N-CA 123.422 0.689 . . . . 0.0 109.535 174.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -118.36 151.03 18.0 Favored Glycine 0 C--N 1.341 0.859 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.058 -175.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 79.32 -12.04 27.98 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-O 120.142 -0.255 . . . . 0.0 113.092 -177.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 33.3 m -132.65 131.12 59.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 C-N-CA 124.406 1.083 . . . . 0.0 108.787 -178.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t -112.43 10.67 19.81 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.657 0.783 . . . . 0.0 110.121 -177.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.41 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 3.2 m-20 -70.57 87.37 0.66 Allowed 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 124.14 0.976 . . . . 0.0 110.922 -176.069 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.5 -58.16 9.65 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 122.793 0.437 . . . . 0.0 112.168 -173.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -64.66 -36.42 84.2 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.048 0.539 . . . . 0.0 111.648 -175.51 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.417 ' O ' HG13 ' A' ' 76' ' ' ILE . 65.2 m170 -65.29 -55.38 18.64 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 123.029 0.532 . . . . 0.0 111.111 -179.522 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.53 HG13 HG21 ' A' ' 64' ' ' VAL . 47.8 mm -60.93 -40.26 84.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 O-C-N 123.856 0.723 . . . . 0.0 110.316 -177.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.0 -38.38 82.45 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.17 0.988 . . . . 0.0 111.707 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 35.5 mm-40 -69.14 -35.93 76.89 Favored 'General case' 0 N--CA 1.475 0.822 0 O-C-N 123.511 0.507 . . . . 0.0 111.768 179.095 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.577 HG21 ' HA ' ' A' ' 44' ' ' ILE . 43.9 mt -65.82 -50.24 71.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 CA-C-O 121.152 0.501 . . . . 0.0 110.863 -178.402 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.415 ' HB ' HD11 ' A' ' 44' ' ' ILE . 12.3 tt -73.75 -32.81 36.03 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 CA-C-N 115.138 -0.937 . . . . 0.0 111.885 -173.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.1 t -72.76 -29.63 63.47 Favored 'General case' 0 N--CA 1.484 1.245 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 174.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.41 -28.93 67.51 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.179 0.592 . . . . 0.0 110.589 173.063 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.24 -5.94 47.14 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 123.538 0.735 . . . . 0.0 111.755 175.615 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.91 21.16 40.37 Favored Glycine 0 C--N 1.348 1.214 0 O-C-N 123.141 0.275 . . . . 0.0 112.993 176.67 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -128.02 114.49 17.17 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 123.472 0.709 . . . . 0.0 109.381 178.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.3 t -70.28 114.13 23.41 Favored Pre-proline 0 CA--C 1.561 1.383 0 C-N-CA 123.332 0.653 . . . . 0.0 111.117 -176.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.423 ' HA ' HG22 ' A' ' 28' ' ' VAL . 73.5 Cg_endo -71.53 -19.26 28.57 Favored 'Trans proline' 0 C--N 1.384 2.415 0 C-N-CA 122.856 2.37 . . . . 0.0 112.836 -177.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 . . . . . 0 C--O 1.246 0.896 0 C-N-CA 124.319 1.048 . . . . 0.0 108.8 -178.436 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.019 0 N-CA-C 113.573 0.189 . . . . 0.0 113.573 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 72.5 mt -108.29 107.55 18.2 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 123.714 0.806 . . . . 0.0 109.059 177.629 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.4 m -95.35 114.16 25.91 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.232 0.613 . . . . 0.0 110.822 -173.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -109.72 106.45 16.1 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 123.97 0.908 . . . . 0.0 110.481 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 16.3 m-70 -83.1 91.31 7.19 Favored 'General case' 0 N--CA 1.479 0.976 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 176.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.445 HG11 ' HB3' ' A' ' 82' ' ' TYR . 47.7 t -82.29 97.58 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 176.434 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -66.33 -24.9 66.61 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 123.23 0.612 . . . . 0.0 112.346 -171.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -87.74 -11.66 47.53 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 122.97 0.508 . . . . 0.0 111.636 177.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.539 ' HG3' ' HB2' ' A' ' 36' ' ' CYS . 13.0 ttt -71.38 137.99 48.82 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.157 0.583 . . . . 0.0 109.553 169.416 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.6 t -129.87 98.48 4.8 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 123.638 0.775 . . . . 0.0 109.911 176.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 59.6 m 54.64 -154.84 0.26 Allowed 'General case' 0 CA--C 1.557 1.244 0 C-N-CA 124.695 1.198 . . . . 0.0 112.843 173.236 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.537 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -58.06 -26.5 58.5 Favored Glycine 0 C--N 1.361 1.946 0 C-N-CA 123.697 0.665 . . . . 0.0 114.097 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 14.2 t-80 -56.54 -32.78 65.45 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.383 1.073 . . . . 0.0 111.793 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.539 ' HB2' ' HG3' ' A' ' 31' ' ' MET . 62.1 m -111.15 -18.18 13.05 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.181 0.592 . . . . 0.0 111.423 178.465 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.537 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -64.47 -47.16 80.02 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 123.231 0.612 . . . . 0.0 112.321 -176.247 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.26 -46.13 92.01 Favored Glycine 0 N--CA 1.475 1.281 0 O-C-N 123.995 0.809 . . . . 0.0 114.147 -172.424 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -68.22 -31.7 52.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.011 0 C-N-CA 123.626 0.77 . . . . 0.0 111.017 -179.404 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.785 HG21 HG21 ' A' ' 62' ' ' VAL . 65.8 mt -69.31 -43.99 80.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 123.641 0.777 . . . . 0.0 111.05 175.417 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.445 ' HG3' ' O ' ' A' ' 37' ' ' ALA . 95.1 mttt -58.2 -47.23 84.1 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.575 0.75 . . . . 0.0 109.546 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.65 -36.14 92.95 Favored Glycine 0 C--N 1.348 1.234 0 O-C-N 124.466 1.104 . . . . 0.0 112.824 178.32 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.38 -55.5 27.32 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 122.852 0.461 . . . . 0.0 111.142 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.502 HG21 HG11 ' A' ' 64' ' ' VAL . 57.6 mt -69.74 -47.12 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.743 -176.109 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -57.84 -50.07 74.55 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.038 0.935 . . . . 0.0 111.955 -176.149 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -70.52 -26.44 63.58 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.032 -174.357 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 47.4 m -86.13 -42.22 14.06 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.733 0.413 . . . . 0.0 110.995 -178.196 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.9 m -132.05 86.44 47.15 Favored Pre-proline 0 CA--C 1.561 1.37 0 C-N-CA 123.752 0.821 . . . . 0.0 110.702 -179.41 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -56.63 123.97 15.12 Favored 'Trans proline' 0 C--N 1.377 2.04 0 C-N-CA 123.039 2.492 . . . . 0.0 111.372 169.475 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.79 -22.34 8.17 Favored Glycine 0 N--CA 1.473 1.116 0 CA-C-O 119.979 -0.345 . . . . 0.0 112.313 -175.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.1 106.94 6.85 Favored 'General case' 0 C--N 1.355 0.808 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 175.671 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.09 100.77 9.2 Favored 'General case' 0 C--N 1.342 0.275 0 C-N-CA 123.729 0.812 . . . . 0.0 109.488 -177.43 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.485 HG12 HG12 ' A' ' 64' ' ' VAL . 35.2 m -84.57 134.59 26.65 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 123.059 0.543 . . . . 0.0 110.16 -172.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 48.4 t-80 -136.36 97.49 3.6 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 172.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.2 114.33 26.84 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -86.29 123.71 71.09 Favored Pre-proline 0 CA--C 1.542 0.64 0 CA-C-O 118.567 -0.73 . . . . 0.0 109.058 -173.222 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.47 ' HA ' ' HA ' ' A' ' 33' ' ' CYS . 21.5 Cg_endo -58.84 -45.67 27.54 Favored 'Trans proline' 0 C--N 1.372 1.81 0 C-N-CA 122.863 2.375 . . . . 0.0 112.861 179.118 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.31 -45.88 21.57 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.411 0.685 . . . . 0.0 111.815 -173.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 17.0 m -90.05 -5.8 56.21 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 123.479 0.712 . . . . 0.0 112.285 -172.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 40.69 45.01 1.96 Allowed 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 125.676 1.59 . . . . 0.0 112.548 -172.329 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 59.2 m -114.39 118.58 34.24 Favored 'General case' 0 C--N 1.346 0.444 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.413 -175.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.785 HG21 HG21 ' A' ' 40' ' ' ILE . 27.9 t -97.32 105.84 17.71 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 177.147 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 21.6 t -98.56 119.46 46.58 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 C-N-CA 123.956 0.903 . . . . 0.0 109.333 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.502 HG11 HG21 ' A' ' 44' ' ' ILE . 28.2 m -110.09 112.07 38.91 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.865 0 CA-C-O 121.562 0.696 . . . . 0.0 110.712 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.4 170.16 31.03 Favored Glycine 0 C--N 1.344 1.007 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.603 176.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.73 -5.92 49.9 Favored Glycine 0 N--CA 1.472 1.066 0 N-CA-C 114.069 0.388 . . . . 0.0 114.069 177.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 18.1 m -128.89 148.37 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 124.773 1.229 . . . . 0.0 109.415 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.3 t -114.47 0.15 13.94 Favored 'General case' 0 N--CA 1.482 1.159 0 C-N-CA 123.604 0.761 . . . . 0.0 110.366 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.436 ' O ' HG12 ' A' ' 73' ' ' ILE . 3.4 m-20 -91.18 70.95 6.24 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.099 0.959 . . . . 0.0 110.231 -169.703 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.94 -49.78 76.55 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 123.409 0.684 . . . . 0.0 112.575 -174.163 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.66 91.09 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.69 0.796 . . . . 0.0 111.511 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 74.8 t60 -66.39 -46.7 75.76 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.017 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.501 HG21 HG21 ' A' ' 64' ' ' VAL . 47.4 mm -60.59 -39.15 80.48 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 O-C-N 123.702 0.626 . . . . 0.0 109.671 177.589 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -58.07 -38.71 76.86 Favored 'General case' 0 N--CA 1.473 0.682 0 O-C-N 124.147 0.905 . . . . 0.0 111.641 178.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -67.94 -38.48 82.89 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 123.261 0.624 . . . . 0.0 111.192 176.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.475 HG21 ' HA ' ' A' ' 44' ' ' ILE . 64.7 mt -68.46 -50.04 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 C-N-CA 123.279 0.631 . . . . 0.0 111.528 -177.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.454 HG13 HG23 ' A' ' 40' ' ' ILE . 13.5 tt -69.37 -35.3 66.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 123.373 0.669 . . . . 0.0 111.318 -175.812 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.4 t -70.11 -29.32 66.24 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 122.207 0.203 . . . . 0.0 110.527 176.43 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.31 -17.48 64.78 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 123.51 0.724 . . . . 0.0 112.23 176.167 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -85.98 5.12 34.72 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.574 0.749 . . . . 0.0 111.355 172.408 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.36 2.55 79.71 Favored Glycine 0 C--N 1.347 1.171 0 CA-C-O 119.424 -0.653 . . . . 0.0 113.697 178.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.445 ' HB3' HG11 ' A' ' 28' ' ' VAL . 84.2 m-85 -119.16 105.48 11.42 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 117.917 0.858 . . . . 0.0 109.651 -177.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.0 t -86.87 127.72 58.79 Favored Pre-proline 0 CA--C 1.55 0.959 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.88 -170.483 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.414 ' HD3' HG23 ' A' ' 77' ' ' ILE . 57.3 Cg_endo -69.97 -36.97 9.32 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.529 2.153 . . . . 0.0 112.159 177.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.5 mm-40 . . . . . 0 C--O 1.251 1.142 0 C-N-CA 125.078 1.351 . . . . 0.0 111.302 -177.967 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.101 0 N-CA-C 112.549 -0.221 . . . . 0.0 112.549 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.5 HD13 ' HA ' ' A' ' 70' ' ' ALA . 25.1 mt -96.74 108.61 21.29 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.857 0.863 . . . . 0.0 110.34 -175.616 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.2 t -86.92 119.68 27.4 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 123.275 0.63 . . . . 0.0 109.913 177.655 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -112.79 118.02 33.8 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.558 0.743 . . . . 0.0 109.658 175.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 44.9 p-80 -83.75 88.3 7.08 Favored 'General case' 0 CA--C 1.546 0.817 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 175.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.52 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 35.3 t -80.79 104.39 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -172.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -73.31 -16.44 61.37 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 115.668 -0.696 . . . . 0.0 112.051 -175.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.408 ' HB3' ' H ' ' A' ' 83' ' ' THR . 35.8 t70 -106.71 16.33 24.59 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.361 0.664 . . . . 0.0 110.534 179.325 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.52 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 25.1 ttt -71.31 136.13 47.72 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 121.012 0.434 . . . . 0.0 111.516 -176.432 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 20.3 p -86.88 162.04 17.95 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.16 0.984 . . . . 0.0 110.913 173.187 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 61.2 m -74.89 -167.41 0.58 Allowed 'General case' 0 CA--C 1.561 1.376 0 C-N-CA 123.663 0.785 . . . . 0.0 111.756 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -57.66 -29.04 60.73 Favored Glycine 0 C--N 1.355 1.635 0 N-CA-C 115.695 1.038 . . . . 0.0 115.695 -172.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -69.3 -22.92 63.76 Favored 'General case' 0 N--CA 1.486 1.364 0 CA-C-N 117.428 0.614 . . . . 0.0 112.371 -176.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.7 m -123.24 13.14 9.59 Favored 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 123.636 0.774 . . . . 0.0 110.955 176.567 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -65.97 -41.64 90.9 Favored 'General case' 0 C--N 1.357 0.922 0 C-N-CA 123.131 0.572 . . . . 0.0 111.392 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.38 -25.61 67.02 Favored Glycine 0 N--CA 1.473 1.129 0 O-C-N 123.134 0.271 . . . . 0.0 113.699 -179.204 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.75 -50.07 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 123.404 0.682 . . . . 0.0 110.808 177.671 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 15.1 tt -67.99 -32.95 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 C-N-CA 123.025 0.53 . . . . 0.0 110.596 -177.429 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.421 ' HB3' HG21 ' A' ' 53' ' ' VAL . 96.1 mttt -64.23 -53.17 53.29 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 123.634 0.774 . . . . 0.0 109.56 168.478 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.409 ' HA2' ' HB3' ' A' ' 45' ' ' GLU . . . -59.06 -29.83 65.93 Favored Glycine 0 C--N 1.358 1.77 0 O-C-N 124.873 1.358 . . . . 0.0 114.046 -173.132 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.87 -54.15 48.05 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 123.818 0.847 . . . . 0.0 110.665 177.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.569 HG21 HG11 ' A' ' 64' ' ' VAL . 60.2 mt -75.21 -41.91 44.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.814 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.409 ' HB3' ' HA2' ' A' ' 42' ' ' GLY . 17.6 tp10 -54.26 -51.14 65.49 Favored 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 125.418 1.487 . . . . 0.0 112.282 -174.632 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? -79.64 -25.85 41.25 Favored 'General case' 0 N--CA 1.483 1.176 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.84 -175.439 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 87.0 m -76.77 -48.14 19.56 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-O 120.814 0.34 . . . . 0.0 110.673 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.508 HG11 HG11 ' A' ' 67' ' ' VAL . 56.5 t -112.22 110.23 53.72 Favored Pre-proline 0 N--CA 1.475 0.78 0 C-N-CA 123.459 0.704 . . . . 0.0 109.432 -178.424 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -72.41 110.32 2.95 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.403 2.069 . . . . 0.0 111.342 172.099 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 117.1 -2.57 19.16 Favored Glycine 0 C--N 1.342 0.867 0 CA-C-O 119.382 -0.677 . . . . 0.0 113.548 179.191 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -80.22 105.95 11.87 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 173.308 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.72 99.64 8.32 Favored 'General case' 0 C--N 1.346 0.44 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -177.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.479 HG12 HG12 ' A' ' 64' ' ' VAL . 29.3 m -84.74 129.43 37.71 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-O 121.235 0.54 . . . . 0.0 110.446 -174.077 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 63.8 t60 -125.61 97.97 5.38 Favored 'General case' 0 C--O 1.225 -0.213 0 N-CA-C 106.211 -1.774 . . . . 0.0 106.211 174.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -109.84 113.89 27.01 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 -179.176 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . 0.413 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 11.1 t70 -105.76 119.86 51.11 Favored Pre-proline 0 N--CA 1.468 0.469 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -175.126 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -63.37 -33.77 68.8 Favored 'Trans proline' 0 C--N 1.375 1.927 0 C-N-CA 122.989 2.459 . . . . 0.0 113.088 -176.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.88 -45.64 23.6 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.127 0.571 . . . . 0.0 111.083 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.413 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 35.4 m -80.35 -23.95 40.18 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 123.253 0.621 . . . . 0.0 111.568 -174.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.457 ' HA ' ' SD ' ' A' ' 31' ' ' MET . 37.5 mmt180 65.08 35.41 8.01 Favored 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 124.71 1.204 . . . . 0.0 111.093 -177.464 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 11.9 m -122.8 117.97 26.89 Favored 'General case' 0 C--O 1.241 0.609 0 C-N-CA 123.029 0.532 . . . . 0.0 110.778 -171.058 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 45.9 t -103.76 106.71 20.72 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 172.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 24.9 t -105.11 130.25 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 124.452 1.101 . . . . 0.0 109.099 -179.238 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.569 HG11 HG21 ' A' ' 44' ' ' ILE . 17.6 m -117.63 109.52 27.79 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.023 0 CA-C-O 121.419 0.628 . . . . 0.0 111.107 -178.32 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -86.87 161.01 32.95 Favored Glycine 0 C--N 1.346 1.114 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.817 178.501 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 83.09 -11.3 55.37 Favored Glycine 0 N--CA 1.472 1.035 0 CA-C-O 119.806 -0.441 . . . . 0.0 113.62 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.508 HG11 HG11 ' A' ' 48' ' ' VAL . 30.6 m -128.89 150.85 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.272 0 C-N-CA 124.022 0.929 . . . . 0.0 109.935 -176.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 29.1 t -124.85 -2.89 7.75 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.749 0.82 . . . . 0.0 111.586 -174.199 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.508 ' HB3' ' HB3' ' A' ' 72' ' ' HIS . 6.1 m-20 -79.24 82.05 5.43 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 123.493 0.717 . . . . 0.0 109.999 -178.592 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.5 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -62.93 -49.28 75.39 Favored 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 123.231 0.612 . . . . 0.0 112.068 -172.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.463 ' O ' ' HG3' ' A' ' 75' ' ' GLU . . . -65.68 -39.35 91.23 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.62 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.508 ' HB3' ' HB3' ' A' ' 69' ' ' ASP . 79.5 t60 -70.25 -42.09 72.64 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 123.596 0.758 . . . . 0.0 112.239 -175.493 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.538 HG21 HG21 ' A' ' 64' ' ' VAL . 33.8 mm -63.74 -37.61 80.15 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 175.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.54 -33.31 74.65 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.226 176.44 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.463 ' HG3' ' O ' ' A' ' 71' ' ' ALA . 46.5 mt-10 -64.73 -41.41 95.98 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 123.191 0.596 . . . . 0.0 110.541 174.595 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 70.0 mt -69.46 -47.33 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.406 0.682 . . . . 0.0 111.265 -175.222 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 15.1 tt -74.33 -26.85 20.84 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.02 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.179 -176.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.51 ' HA ' ' O ' ' A' ' 82' ' ' TYR . 2.3 t -75.69 -29.35 58.99 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 175.236 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.51 -18.28 64.35 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.681 0.792 . . . . 0.0 111.566 175.297 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -79.83 3.35 19.91 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.814 0.845 . . . . 0.0 112.219 174.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.32 5.56 75.75 Favored Glycine 0 C--N 1.349 1.255 0 CA-C-O 120.216 -0.213 . . . . 0.0 113.024 179.294 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.51 ' O ' ' HA ' ' A' ' 78' ' ' THR . 91.7 m-85 -100.13 162.22 13.11 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.897 0.879 . . . . 0.0 110.047 178.216 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.408 ' H ' ' HB3' ' A' ' 30' ' ' ASP . 32.4 p -121.52 103.31 41.32 Favored Pre-proline 0 CA--C 1.55 0.947 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 171.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -60.84 -40.24 55.31 Favored 'Trans proline' 0 C--N 1.387 2.602 0 C-N-CA 123.061 2.508 . . . . 0.0 112.33 175.505 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 64.7 mm-40 . . . . . 0 CA--C 1.552 1.041 0 C-N-CA 124.769 1.228 . . . . 0.0 110.755 -178.04 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.346 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.46 HD13 ' HA ' ' A' ' 70' ' ' ALA . 25.9 mt -92.14 115.09 27.78 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 123.912 0.885 . . . . 0.0 109.579 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 47.0 t -83.53 123.05 29.35 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 122.875 0.47 . . . . 0.0 110.24 -179.297 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -125.43 101.38 6.92 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.815 0.846 . . . . 0.0 109.032 174.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . 0.403 ' HA ' ' HA ' ' A' ' 61' ' ' THR . 9.5 p80 -93.82 100.15 12.39 Favored 'General case' 0 CA--C 1.547 0.843 0 CA-C-O 121.503 0.668 . . . . 0.0 110.384 -174.158 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.531 ' O ' ' HB3' ' A' ' 60' ' ' ARG . 92.0 t -82.34 106.04 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 172.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -79.63 -7.75 58.75 Favored 'General case' 0 N--CA 1.485 1.308 0 CA-C-N 118.292 0.496 . . . . 0.0 112.137 -176.281 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -95.15 12.29 29.25 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 123.638 0.775 . . . . 0.0 111.071 171.308 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.43 ' SD ' ' HA ' ' A' ' 60' ' ' ARG . 27.6 ttt -70.9 143.51 50.96 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.541 0.736 . . . . 0.0 111.764 -176.759 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 17.2 p -125.88 165.88 17.91 Favored 'General case' 0 C--O 1.243 0.725 0 C-N-CA 125.161 1.384 . . . . 0.0 108.61 176.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 31.6 p -53.41 179.51 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -173.136 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.503 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -43.94 -26.6 0.85 Allowed Glycine 0 C--N 1.36 1.881 0 N-CA-C 117.603 1.801 . . . . 0.0 117.603 -166.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 69.4 t60 -55.97 -54.77 40.73 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 124.081 0.952 . . . . 0.0 111.061 176.109 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 42.6 t -96.91 -20.91 17.79 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.488 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.503 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -64.81 -36.04 83.03 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 123.068 0.547 . . . . 0.0 110.802 175.684 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.95 -24.82 73.17 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.425 -0.807 . . . . 0.0 113.169 176.103 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 43.3 t -74.5 -38.95 47.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.404 0.682 . . . . 0.0 110.237 176.094 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 22.5 mt -63.98 -47.42 90.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-O 121.455 0.645 . . . . 0.0 109.536 176.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.411 ' HZ3' HG23 ' A' ' 53' ' ' VAL . 9.4 mtpm? -59.23 -47.78 84.08 Favored 'General case' 0 C--N 1.35 0.588 0 CA-C-N 114.285 -1.325 . . . . 0.0 110.852 176.107 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.22 -33.03 86.14 Favored Glycine 0 C--N 1.345 1.081 0 O-C-N 124.502 1.126 . . . . 0.0 113.094 -175.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -60.49 -54.61 43.47 Favored 'General case' 0 C--N 1.348 0.515 0 C-N-CA 123.133 0.573 . . . . 0.0 110.521 178.264 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.5 HG21 HG11 ' A' ' 64' ' ' VAL . 54.7 mt -72.55 -45.72 57.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.804 -175.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -64.22 -41.14 97.15 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.947 0.899 . . . . 0.0 111.92 -171.228 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -76.22 -34.75 59.24 Favored 'General case' 0 N--CA 1.481 1.076 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.221 -178.634 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 86.7 m -72.91 -45.84 55.96 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 122.435 0.294 . . . . 0.0 110.744 -178.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 78.0 t -120.5 94.23 48.7 Favored Pre-proline 0 N--CA 1.478 0.933 0 C-N-CA 123.679 0.791 . . . . 0.0 109.054 176.725 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_exo -64.12 123.87 12.57 Favored 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 122.549 2.166 . . . . 0.0 110.622 169.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 119.68 -20.28 9.45 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 112.108 -0.397 . . . . 0.0 112.108 -174.364 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -79.72 105.7 11.21 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 174.419 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.36 98.25 8.09 Favored 'General case' 0 C--N 1.342 0.259 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -178.026 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.597 HG12 HG12 ' A' ' 64' ' ' VAL . 15.6 m -85.06 116.07 27.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 C-N-CA 123.513 0.725 . . . . 0.0 110.097 -172.449 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 54.9 t-80 -112.55 99.22 7.79 Favored 'General case' 0 C--N 1.347 0.472 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 176.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.34 127.68 34.13 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -111.2 108.11 57.22 Favored Pre-proline 0 CA--C 1.537 0.471 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 175.147 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -64.03 -33.48 62.18 Favored 'Trans proline' 0 C--N 1.367 1.521 0 C-N-CA 122.678 2.252 . . . . 0.0 112.86 -178.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.76 -39.67 43.48 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.46 0.704 . . . . 0.0 111.85 -175.209 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.3 t -92.82 -15.02 26.99 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 123.712 0.805 . . . . 0.0 110.851 -178.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.531 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 63.52 45.26 4.82 Favored 'General case' 0 CA--C 1.554 1.1 0 C-N-CA 124.452 1.101 . . . . 0.0 110.421 -179.272 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.403 ' HA ' ' HA ' ' A' ' 27' ' ' HIS . 17.8 m -132.85 120.9 22.15 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -170.72 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 47.4 t -104.18 108.28 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 123.686 0.794 . . . . 0.0 109.458 173.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 43.1 t -104.07 121.59 55.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.893 0.877 . . . . 0.0 109.551 -177.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.597 HG12 HG12 ' A' ' 53' ' ' VAL . 27.0 m -102.45 114.43 41.9 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 CA-C-O 121.427 0.632 . . . . 0.0 111.151 -176.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.83 160.37 24.21 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.064 179.129 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 83.22 -11.75 53.64 Favored Glycine 0 N--CA 1.474 1.232 0 CA-C-N 116.695 0.248 . . . . 0.0 113.68 177.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 31.3 m -126.62 142.22 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 124.474 1.11 . . . . 0.0 109.064 178.665 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.2 m -113.25 3.59 16.06 Favored 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 123.352 0.661 . . . . 0.0 110.487 178.403 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -82.44 79.18 8.95 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.129 0.972 . . . . 0.0 110.432 -174.39 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.46 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -63.77 -37.92 89.18 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 122.86 0.464 . . . . 0.0 111.719 -175.479 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.502 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -65.44 -47.19 77.02 Favored 'General case' 0 N--CA 1.475 0.818 0 O-C-N 123.551 0.532 . . . . 0.0 110.718 179.363 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 17.3 m-70 -58.24 -52.9 63.64 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 123.6 0.76 . . . . 0.0 111.11 -177.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.439 HG13 HG21 ' A' ' 64' ' ' VAL . 47.6 mm -62.02 -38.88 81.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.079 -178.534 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.84 -40.47 88.62 Favored 'General case' 0 C--N 1.354 0.779 0 O-C-N 124.063 0.852 . . . . 0.0 111.118 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.502 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 39.8 mm-40 -61.51 -45.82 92.58 Favored 'General case' 0 N--CA 1.479 1.003 0 O-C-N 123.872 0.733 . . . . 0.0 110.393 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.447 HG21 ' HA ' ' A' ' 44' ' ' ILE . 46.5 mt -63.67 -53.73 41.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 115.212 -0.903 . . . . 0.0 111.551 -175.684 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 14.0 tt -67.7 -37.67 79.01 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.635 -171.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.6 t -75.08 -29.18 60.58 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 122.483 0.313 . . . . 0.0 110.481 178.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.78 -29.75 69.02 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 123.585 0.754 . . . . 0.0 110.742 175.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.4 -2.18 33.9 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 123.576 0.75 . . . . 0.0 111.485 174.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 96.88 -11.38 66.15 Favored Glycine 0 C--N 1.351 1.394 0 C-N-CA 123.093 0.378 . . . . 0.0 113.003 176.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 60.9 m-85 -91.08 104.76 17.3 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -175.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.8 m -77.12 110.92 13.6 Favored Pre-proline 0 CA--C 1.551 1.007 0 C-N-CA 123.917 0.887 . . . . 0.0 110.02 -176.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -83.13 -18.03 6.39 Favored 'Trans proline' 0 C--N 1.373 1.826 0 C-N-CA 122.56 2.173 . . . . 0.0 113.222 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 . . . . . 0 C--O 1.245 0.858 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.283 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.731 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.408 HD13 ' HA ' ' A' ' 70' ' ' ALA . 52.5 mt -78.98 107.91 12.07 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -178.513 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 20.1 m -95.06 110.74 22.63 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 122.467 0.307 . . . . 0.0 110.706 -173.019 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -107.13 146.36 31.37 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 124.068 0.947 . . . . 0.0 109.351 178.41 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -124.52 136.05 53.68 Favored 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.457 HG22 ' HB3' ' A' ' 84' ' ' PRO . 86.3 t -125.79 126.69 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 123.592 0.757 . . . . 0.0 111.407 -170.521 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -71.73 -37.62 70.57 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.217 0.607 . . . . 0.0 111.548 177.704 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -75.02 -21.68 58.93 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 123.054 0.542 . . . . 0.0 112.258 -173.303 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.535 ' HG3' ' SG ' ' A' ' 36' ' ' CYS . 27.2 ttt -65.76 120.17 12.53 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.158 0.983 . . . . 0.0 111.043 -174.665 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 p -127.35 95.61 4.32 Favored 'General case' 0 CA--C 1.548 0.883 0 C-N-CA 122.717 0.407 . . . . 0.0 110.957 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 12.5 t 50.32 -147.94 0.34 Allowed 'General case' 0 CA--C 1.572 1.792 0 C-N-CA 125.349 1.459 . . . . 0.0 113.995 167.129 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -62.15 -28.64 71.01 Favored Glycine 0 C--N 1.357 1.722 0 N-CA-C 115.118 0.807 . . . . 0.0 115.118 -173.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 46.6 m170 -64.51 -29.05 70.08 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 123.451 0.7 . . . . 0.0 112.099 -178.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.535 ' SG ' ' HG3' ' A' ' 31' ' ' MET . 30.6 p -100.29 -18.74 16.68 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 122.768 0.427 . . . . 0.0 111.102 179.377 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -55.54 -54.77 39.85 Favored 'General case' 0 C--N 1.358 0.944 0 O-C-N 124.012 0.82 . . . . 0.0 112.563 -166.6 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.27 -35.55 92.11 Favored Glycine 0 C--N 1.343 0.946 0 O-C-N 123.178 0.299 . . . . 0.0 113.43 -176.561 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 49.0 t -72.2 -47.53 53.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 123.067 0.547 . . . . 0.0 111.075 -178.295 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.422 HD11 HD11 ' A' ' 77' ' ' ILE . 14.2 tt -67.91 -32.33 55.92 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 123.803 0.841 . . . . 0.0 111.239 -174.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -63.51 -59.25 4.89 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 123.656 0.782 . . . . 0.0 110.06 172.373 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.88 -30.93 78.16 Favored Glycine 0 C--N 1.353 1.477 0 CA-C-N 114.548 -1.205 . . . . 0.0 113.919 -170.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.82 -51.57 68.47 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 124.022 0.929 . . . . 0.0 110.567 -179.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.598 HG21 HG11 ' A' ' 64' ' ' VAL . 65.3 mt -73.95 -50.57 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 123.447 0.699 . . . . 0.0 111.334 178.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -58.73 -44.55 90.48 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 124.471 1.108 . . . . 0.0 112.808 -165.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.2 mptp? -81.05 -27.06 35.88 Favored 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.34 -175.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 91.2 m -74.38 -37.92 63.3 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 123.054 0.542 . . . . 0.0 110.66 179.339 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 95.5 t -124.46 95.07 43.76 Favored Pre-proline 0 N--CA 1.478 0.973 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 174.203 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -59.14 124.25 15.22 Favored 'Trans proline' 0 C--N 1.376 2.011 0 C-N-CA 122.998 2.466 . . . . 0.0 111.385 170.734 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.76 -8.16 36.66 Favored Glycine 0 C--N 1.343 0.937 0 CA-C-O 119.601 -0.555 . . . . 0.0 112.935 -176.017 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -83.83 105.98 15.16 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 171.495 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -88.08 101.91 14.26 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.41 0.684 . . . . 0.0 109.591 -177.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.49 HG12 HG12 ' A' ' 64' ' ' VAL . 31.6 m -83.01 130.83 35.06 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.339 0.59 . . . . 0.0 110.492 -171.649 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . 0.458 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 24.7 t60 -120.72 96.41 5.11 Favored 'General case' 0 C--O 1.219 -0.528 0 N-CA-C 106.307 -1.738 . . . . 0.0 106.307 170.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.17 114.79 27.43 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -98.03 112.65 62.39 Favored Pre-proline 0 N--CA 1.47 0.529 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -57.02 -51.25 9.25 Favored 'Trans proline' 0 C--N 1.377 2.053 0 C-N-CA 122.616 2.211 . . . . 0.0 113.142 -175.775 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.67 -42.01 68.01 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 123.497 0.719 . . . . 0.0 112.465 -171.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.1 t -89.3 -12.74 39.71 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.07 0.548 . . . . 0.0 111.242 -178.462 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.4 mpt_? 65.16 30.55 11.39 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 124.269 1.027 . . . . 0.0 111.891 177.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 16.7 m -110.94 109.83 20.15 Favored 'General case' 0 CA--C 1.544 0.737 0 O-C-N 122.258 -0.276 . . . . 0.0 110.952 -169.118 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.458 ' HA ' ' O ' ' A' ' 54' ' ' HIS . 39.3 t -98.92 105.39 17.3 Favored 'Isoleucine or valine' 0 C--N 1.352 0.699 0 C-N-CA 123.804 0.842 . . . . 0.0 109.242 177.108 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 22.6 t -99.61 117.92 45.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.749 0.82 . . . . 0.0 109.083 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.598 HG11 HG21 ' A' ' 44' ' ' ILE . 30.5 m -104.74 115.24 46.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 123.402 0.681 . . . . 0.0 109.996 -179.399 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -101.07 145.4 16.98 Favored Glycine 0 C--N 1.348 1.229 0 CA-C-N 116.143 -0.48 . . . . 0.0 112.671 -177.356 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 95.71 3.31 61.0 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 123.073 0.368 . . . . 0.0 113.659 176.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.3 m -130.54 147.44 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.739 0.816 . . . . 0.0 110.249 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.8 m -112.27 4.83 17.99 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 123.071 0.549 . . . . 0.0 110.708 179.065 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.532 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 3.0 m-20 -89.36 68.71 8.01 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.922 0.889 . . . . 0.0 110.39 -175.027 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.408 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -62.11 -39.49 92.69 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.452 0.701 . . . . 0.0 111.285 -177.282 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -66.81 -42.49 85.81 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.719 0.808 . . . . 0.0 111.376 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.532 ' HB2' ' HB3' ' A' ' 69' ' ' ASP . 18.8 m80 -63.63 -52.98 58.44 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 122.793 0.437 . . . . 0.0 110.726 178.242 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.505 HG21 HG21 ' A' ' 64' ' ' VAL . 47.2 mm -58.89 -42.44 85.83 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 O-C-N 123.93 0.769 . . . . 0.0 110.52 -176.235 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -58.1 -41.87 84.46 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.143 0.977 . . . . 0.0 111.387 178.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 60.1 mm-40 -70.12 -33.82 72.31 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.264 178.177 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.435 HG13 ' O ' ' A' ' 72' ' ' HIS . 75.4 mt -68.11 -51.31 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 CA-C-O 121.025 0.44 . . . . 0.0 110.554 -179.173 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.602 HG23 ' HG3' ' A' ' 84' ' ' PRO . 16.7 tt -69.25 -32.34 53.32 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 CA-C-N 115.165 -0.925 . . . . 0.0 111.438 -175.138 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 t -76.52 -31.59 57.75 Favored 'General case' 0 N--CA 1.477 0.913 0 O-C-N 122.283 -0.26 . . . . 0.0 111.076 175.346 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.46 -16.12 62.35 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 123.492 0.717 . . . . 0.0 110.904 176.395 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -80.61 5.33 15.78 Favored 'General case' 0 CA--C 1.555 1.157 0 C-N-CA 123.763 0.825 . . . . 0.0 111.581 173.16 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.93 -0.74 73.36 Favored Glycine 0 C--N 1.353 1.482 0 C-N-CA 123.117 0.389 . . . . 0.0 113.15 176.41 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.43 ' HB3' HG11 ' A' ' 28' ' ' VAL . 95.7 m-85 -86.15 165.61 16.43 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 123.392 0.677 . . . . 0.0 110.48 179.355 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 33.5 p -122.82 81.2 49.38 Favored Pre-proline 0 CA--C 1.559 1.326 0 C-N-CA 123.174 0.59 . . . . 0.0 111.619 -176.404 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.602 ' HG3' HG23 ' A' ' 77' ' ' ILE . 43.0 Cg_endo -88.27 171.95 5.27 Favored 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.901 2.401 . . . . 0.0 112.178 169.816 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 . . . . . 0 C--O 1.246 0.891 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 176.452 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.14 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.0 107.48 12.82 Favored 'General case' 0 CA--C 1.548 0.883 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 179.24 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 24.9 p -93.37 111.97 23.77 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 123.606 0.762 . . . . 0.0 111.42 -173.269 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -99.68 141.23 32.76 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 175.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 65.8 m80 -115.46 100.7 8.28 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -175.041 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.508 HG21 ' HB3' ' A' ' 82' ' ' TYR . 2.7 p -113.41 97.78 6.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 C-N-CA 124.19 0.996 . . . . 0.0 109.753 -178.658 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -70.71 -17.8 62.81 Favored 'General case' 0 CA--C 1.551 0.989 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.966 176.676 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.37 -12.4 60.81 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 123.889 0.876 . . . . 0.0 111.384 176.574 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.485 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 60.0 ttp -80.19 98.98 7.57 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 173.749 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 30.4 p -94.18 102.67 14.71 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.213 0.605 . . . . 0.0 110.159 178.216 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 14.7 p 66.67 178.32 0.22 Allowed 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 126.567 1.947 . . . . 0.0 113.153 175.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.409 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -60.95 -22.79 60.66 Favored Glycine 0 C--N 1.359 1.82 0 CA-C-N 115.118 -0.946 . . . . 0.0 113.973 -178.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 13.0 t-160 -60.61 -42.76 97.47 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 123.894 0.878 . . . . 0.0 111.013 175.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 81.1 m -87.93 -21.59 24.82 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 123.032 0.533 . . . . 0.0 111.256 178.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.458 ' HA ' ' SD ' ' A' ' 31' ' ' MET . . . -66.02 -46.88 76.32 Favored 'General case' 0 C--N 1.349 0.546 0 C-N-CA 123.318 0.647 . . . . 0.0 111.01 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.82 -29.29 73.6 Favored Glycine 0 C--N 1.349 1.303 0 O-C-N 124.052 0.845 . . . . 0.0 113.546 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 58.3 t -63.29 -44.85 99.34 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.634 0.774 . . . . 0.0 110.087 175.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.626 HG21 HG21 ' A' ' 62' ' ' VAL . 62.6 mt -70.4 -39.33 76.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.852 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.427 ' HG3' ' O ' ' A' ' 37' ' ' ALA . 96.3 mttt -59.12 -49.84 76.33 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 123.125 0.57 . . . . 0.0 110.087 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.77 -38.66 96.86 Favored Glycine 0 C--N 1.344 0.974 0 O-C-N 124.28 0.987 . . . . 0.0 112.522 178.173 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.35 -55.06 31.65 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.63 0.772 . . . . 0.0 111.822 -176.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.506 ' HA ' HG21 ' A' ' 76' ' ' ILE . 69.7 mt -70.15 -55.71 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 123.241 0.616 . . . . 0.0 111.247 -178.46 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -60.1 -40.88 91.17 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 123.767 0.827 . . . . 0.0 112.791 -169.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -74.23 -30.91 62.38 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 122.45 0.3 . . . . 0.0 111.642 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 91.7 m -72.9 -42.63 63.36 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 121.053 0.454 . . . . 0.0 110.257 176.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.0 m -131.48 87.54 46.33 Favored Pre-proline 0 CA--C 1.553 1.074 0 C-N-CA 123.618 0.767 . . . . 0.0 110.52 -178.329 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -57.76 138.09 84.37 Favored 'Trans proline' 0 C--N 1.38 2.186 0 C-N-CA 122.6 2.2 . . . . 0.0 111.345 171.288 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 108.75 -23.87 23.05 Favored Glycine 0 N--CA 1.467 0.721 0 O-C-N 123.403 0.44 . . . . 0.0 112.02 -175.227 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -76.79 107.21 8.95 Favored 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 173.632 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.8 99.43 8.27 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.264 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.493 HG12 HG12 ' A' ' 64' ' ' VAL . 23.4 m -86.32 128.58 39.32 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 C-N-CA 123.199 0.6 . . . . 0.0 111.191 -171.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . 0.434 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 18.7 t60 -127.85 98.22 5.09 Favored 'General case' 0 C--O 1.223 -0.304 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 175.126 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.485 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -100.73 112.82 25.29 Favored 'General case' 0 C--O 1.241 0.643 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.357 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -102.72 114.73 65.14 Favored Pre-proline 0 CA--C 1.538 0.519 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -170.269 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -62.14 -34.4 79.34 Favored 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 122.812 2.341 . . . . 0.0 113.213 -178.448 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.04 -46.1 30.95 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.166 0.586 . . . . 0.0 111.295 -175.525 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.5 t -89.23 -16.75 30.53 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.404 0.682 . . . . 0.0 111.739 -175.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.7 mpt_? 61.57 39.85 14.2 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.331 1.052 . . . . 0.0 111.029 -176.643 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 50.0 m -126.26 118.89 26.06 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 122.75 0.42 . . . . 0.0 111.289 -172.712 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.626 HG21 HG21 ' A' ' 40' ' ' ILE . 38.7 t -100.0 105.71 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 123.728 0.811 . . . . 0.0 109.434 173.288 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 20.8 t -100.19 127.65 52.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 C-N-CA 123.791 0.836 . . . . 0.0 109.02 -178.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.496 HG21 HG13 ' A' ' 73' ' ' ILE . 17.4 m -111.2 109.95 30.41 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.656 0.741 . . . . 0.0 109.95 178.115 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -88.62 153.88 24.42 Favored Glycine 0 C--N 1.346 1.097 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.976 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.47 -14.55 45.58 Favored Glycine 0 N--CA 1.472 1.068 0 C-N-CA 122.888 0.28 . . . . 0.0 113.236 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.7 m -130.87 135.76 59.48 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.75 0 C-N-CA 124.457 1.103 . . . . 0.0 109.156 179.404 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 51.0 m -116.41 17.75 15.39 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.359 0.664 . . . . 0.0 109.913 176.012 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -80.25 77.05 7.02 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.292 1.037 . . . . 0.0 109.574 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.8 -42.96 94.59 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.496 0.718 . . . . 0.0 111.622 -175.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.421 ' O ' ' HG3' ' A' ' 75' ' ' GLU . . . -62.63 -46.08 89.9 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.941 0.897 . . . . 0.0 111.289 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 11.6 m170 -62.04 -54.75 37.08 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.666 0.787 . . . . 0.0 110.442 -176.635 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.496 HG13 HG21 ' A' ' 64' ' ' VAL . 45.3 mm -64.01 -40.0 87.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.319 -175.124 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.7 -39.6 89.12 Favored 'General case' 0 N--CA 1.476 0.875 0 O-C-N 123.966 0.792 . . . . 0.0 111.18 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.421 ' HG3' ' O ' ' A' ' 71' ' ' ALA . 46.3 mt-10 -61.98 -39.19 91.34 Favored 'General case' 0 N--CA 1.479 1.021 0 O-C-N 123.803 0.689 . . . . 0.0 111.16 176.28 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.506 HG21 ' HA ' ' A' ' 44' ' ' ILE . 62.4 mt -68.77 -51.9 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 O-C-N 123.636 0.585 . . . . 0.0 111.259 -176.75 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.513 HD13 ' HB3' ' A' ' 84' ' ' PRO . 6.3 tt -68.61 -31.77 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.27 0 C-N-CA 123.075 0.55 . . . . 0.0 111.569 -176.398 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -74.8 -30.78 61.53 Favored 'General case' 0 N--CA 1.483 1.183 0 O-C-N 122.202 -0.311 . . . . 0.0 110.426 176.42 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.09 -22.9 61.28 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 123.069 0.548 . . . . 0.0 110.296 172.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.31 -16.75 60.4 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 123.801 0.84 . . . . 0.0 111.832 174.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.34 22.53 12.68 Favored Glycine 0 C--N 1.348 1.223 0 O-C-N 123.405 0.44 . . . . 0.0 113.141 178.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.508 ' HB3' HG21 ' A' ' 28' ' ' VAL . 80.1 m-85 -128.56 133.29 48.33 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 123.913 0.885 . . . . 0.0 110.024 179.034 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 27.7 p -89.58 107.79 20.94 Favored Pre-proline 0 CA--C 1.552 1.036 0 C-N-CA 123.593 0.757 . . . . 0.0 110.605 -179.78 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.513 ' HB3' HD13 ' A' ' 77' ' ' ILE . 64.3 Cg_endo -78.33 -8.11 16.16 Favored 'Trans proline' 0 C--N 1.376 1.975 0 C-N-CA 122.748 2.299 . . . . 0.0 113.622 178.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 . . . . . 0 C--O 1.248 1.001 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 -173.378 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.862 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.455 HD12 HG23 ' A' ' 67' ' ' VAL . 37.3 mt -93.08 111.47 23.11 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 124.196 0.998 . . . . 0.0 110.359 -175.279 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 29.1 m -94.38 115.77 28.03 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.011 0.524 . . . . 0.0 111.054 -175.215 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -107.91 116.44 31.95 Favored 'General case' 0 N--CA 1.484 1.264 0 C-N-CA 123.959 0.904 . . . . 0.0 109.79 177.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 22.9 m170 -82.17 90.34 6.57 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.498 ' HA ' ' HA ' ' A' ' 84' ' ' PRO . 10.6 t -85.3 92.56 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -178.262 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -68.82 -19.26 64.27 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 123.904 0.882 . . . . 0.0 112.144 -172.093 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -89.15 -8.1 54.37 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.872 0.869 . . . . 0.0 111.917 178.287 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 26.4 ttt -75.15 126.52 31.19 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.804 0.841 . . . . 0.0 112.557 -173.051 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.8 t -108.49 97.91 7.51 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 164.014 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.541 ' SG ' ' HA ' ' A' ' 57' ' ' PRO . 81.5 m -46.52 -64.07 0.85 Allowed 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 125.543 1.537 . . . . 0.0 114.267 -167.421 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.56 -25.2 75.07 Favored Glycine 0 CA--C 1.532 1.142 0 N-CA-C 114.013 0.365 . . . . 0.0 114.013 -175.315 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 15.4 m-70 -93.99 -7.59 42.38 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 123.253 0.621 . . . . 0.0 112.109 -177.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 42.1 t -133.19 9.44 4.09 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.116 0.566 . . . . 0.0 111.099 -175.718 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -56.55 -53.61 55.55 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 123.838 0.855 . . . . 0.0 113.117 -169.721 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.99 -40.45 98.24 Favored Glycine 0 C--N 1.344 0.979 0 O-C-N 123.36 0.413 . . . . 0.0 114.121 -173.603 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.7 p -76.92 -42.51 32.62 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 C-N-CA 123.111 0.564 . . . . 0.0 112.221 -176.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 12.3 tt -73.22 -37.02 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 122.495 0.318 . . . . 0.0 110.809 -174.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.52 -43.47 55.75 Favored 'General case' 0 C--N 1.35 0.622 0 C-N-CA 123.136 0.575 . . . . 0.0 109.661 175.348 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.87 -30.58 78.1 Favored Glycine 0 C--N 1.351 1.393 0 O-C-N 124.494 1.121 . . . . 0.0 113.531 -177.582 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -61.28 -54.26 46.3 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 123.469 0.708 . . . . 0.0 110.591 177.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.521 ' HA ' HG21 ' A' ' 76' ' ' ILE . 59.0 mt -72.61 -46.81 53.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.163 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -58.54 -50.81 72.44 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 124.034 0.934 . . . . 0.0 112.26 -174.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -77.07 -20.7 55.47 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 119.42 -0.324 . . . . 0.0 111.505 -172.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 85.2 m -79.22 -45.76 19.19 Favored 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 174.362 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 15.8 m -126.74 81.59 68.7 Favored Pre-proline 0 CA--C 1.555 1.168 0 C-N-CA 123.598 0.759 . . . . 0.0 110.01 178.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -60.26 121.45 9.8 Favored 'Trans proline' 0 C--N 1.383 2.385 0 C-N-CA 122.995 2.463 . . . . 0.0 112.144 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.78 -11.57 10.16 Favored Glycine 0 C--N 1.345 1.075 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.704 -176.669 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -72.32 107.41 4.91 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 176.07 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -77.15 100.15 5.65 Favored 'General case' 0 C--N 1.348 0.507 0 C-N-CA 123.111 0.564 . . . . 0.0 109.856 -176.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.483 HG12 HG12 ' A' ' 64' ' ' VAL . 33.5 m -85.2 137.37 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 123.386 0.674 . . . . 0.0 109.949 -173.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . 0.487 ' HB2' ' HB ' ' A' ' 63' ' ' VAL . 78.7 m80 -130.37 101.78 5.9 Favored 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -178.643 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.26 120.87 34.04 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.672 0.789 . . . . 0.0 109.958 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -111.07 103.49 54.94 Favored Pre-proline 0 CA--C 1.55 0.959 0 CA-C-O 118.54 -0.743 . . . . 0.0 109.609 -178.144 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.541 ' HA ' ' SG ' ' A' ' 33' ' ' CYS . 38.0 Cg_exo -39.74 -44.82 3.5 Favored 'Trans proline' 0 C--N 1.376 2.003 0 C-N-CA 124.539 3.493 . . . . 0.0 115.88 172.178 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.24 -46.53 22.86 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 122.715 0.406 . . . . 0.0 111.525 -175.199 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.9 t -91.8 -7.01 50.74 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.359 0.664 . . . . 0.0 111.91 -173.383 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 40.91 45.65 2.22 Favored 'General case' 0 N--CA 1.505 2.28 0 C-N-CA 126.248 1.819 . . . . 0.0 112.197 -173.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.8 m -112.81 134.2 54.44 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.342 -175.286 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 51.4 t -103.38 105.57 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 168.243 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.487 ' HB ' ' HB2' ' A' ' 54' ' ' HIS . 14.4 t -94.47 119.93 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 175.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.517 HG11 HG21 ' A' ' 44' ' ' ILE . 15.7 m -106.29 116.96 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 CA-C-O 121.296 0.57 . . . . 0.0 110.5 -179.325 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.26 152.59 20.47 Favored Glycine 0 C--N 1.347 1.178 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.309 -175.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.04 -26.97 14.28 Favored Glycine 0 N--CA 1.471 0.989 0 C-N-CA 123.304 0.478 . . . . 0.0 112.883 177.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.455 HG23 HD12 ' A' ' 24' ' ' LEU . 28.4 m -101.98 155.16 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 124.412 1.085 . . . . 0.0 110.372 -176.035 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.1 m -135.7 23.59 3.38 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.78 0.832 . . . . 0.0 110.292 -177.338 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -119.53 71.54 0.88 Allowed 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 124.388 1.075 . . . . 0.0 109.697 -176.073 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.91 -34.94 75.45 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 115.049 -0.978 . . . . 0.0 112.561 -174.181 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.461 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.36 -43.74 96.79 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.271 0.629 . . . . 0.0 110.632 178.076 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.409 ' O ' HG13 ' A' ' 76' ' ' ILE . 14.9 m-70 -67.16 -43.97 80.91 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 123.467 0.707 . . . . 0.0 111.061 -177.41 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.409 HG21 HG21 ' A' ' 64' ' ' VAL . 45.4 mm -62.38 -40.64 88.7 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 O-C-N 123.739 0.649 . . . . 0.0 110.105 179.097 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.44 -38.17 86.2 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.811 178.201 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.461 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 45.3 mm-40 -62.53 -40.0 95.36 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.773 0.829 . . . . 0.0 111.204 176.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.521 HG21 ' HA ' ' A' ' 44' ' ' ILE . 73.4 mt -66.36 -54.89 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 123.717 0.636 . . . . 0.0 110.8 -176.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 12.6 tt -66.94 -34.48 70.23 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.643 -173.206 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 7.7 t -74.5 -30.3 61.76 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 110.526 -0.175 . . . . 0.0 110.526 177.67 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.73 -24.41 61.78 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 123.522 0.729 . . . . 0.0 110.826 175.292 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -71.72 -19.15 62.09 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 123.523 0.729 . . . . 0.0 111.142 172.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 101.6 16.65 23.82 Favored Glycine 0 C--N 1.348 1.242 0 CA-C-N 115.857 -0.61 . . . . 0.0 112.457 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -122.63 103.63 8.8 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.405 ' HA ' ' HD3' ' A' ' 84' ' ' PRO . 4.3 t -80.03 125.24 82.18 Favored Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.387 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.498 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 24.0 Cg_exo -63.95 -76.51 0.02 OUTLIER 'Trans proline' 0 C--N 1.38 2.195 0 C-N-CA 122.539 2.159 . . . . 0.0 112.912 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 . . . . . 0 C--O 1.252 1.21 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -170.385 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.718 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.43 HD13 ' HA ' ' A' ' 70' ' ' ALA . 47.9 mt -84.68 110.04 18.46 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.153 0.981 . . . . 0.0 110.752 -178.133 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.8 p -90.8 111.13 22.39 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 123.36 0.664 . . . . 0.0 111.952 -174.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -108.61 114.77 28.86 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 123.858 0.863 . . . . 0.0 109.998 177.399 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 11.5 m-70 -82.93 136.2 34.65 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 123.052 0.541 . . . . 0.0 109.782 178.29 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.597 HG22 ' HA ' ' A' ' 84' ' ' PRO . 85.2 t -139.83 97.14 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 172.092 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.79 -6.25 43.53 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -175.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -88.69 -19.37 26.23 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.343 0.657 . . . . 0.0 110.732 176.66 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.579 ' SD ' HG21 ' A' ' 40' ' ' ILE . 53.8 ttp -68.33 97.33 0.73 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 122.996 0.518 . . . . 0.0 109.811 178.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 25.9 p -82.44 94.05 7.35 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 179.212 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.405 ' SG ' ' HB3' ' A' ' 57' ' ' PRO . 58.6 m 41.5 -139.29 0.13 Allowed 'General case' 0 CA--C 1.568 1.642 0 C-N-CA 125.831 1.652 . . . . 0.0 113.213 173.357 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.52 -22.23 65.56 Favored Glycine 0 C--N 1.362 1.994 0 N-CA-C 114.638 0.615 . . . . 0.0 114.638 -178.678 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 30.0 t-80 -59.09 -35.95 74.3 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 123.614 0.766 . . . . 0.0 111.937 178.459 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 62.4 m -112.51 -14.51 13.21 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 122.894 0.478 . . . . 0.0 111.755 -178.42 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -60.5 -41.86 95.19 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -172.17 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.05 -48.55 82.52 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 113.806 0.283 . . . . 0.0 113.806 -174.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.3 p -75.58 -39.71 40.29 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.143 0 C-N-CA 123.557 0.743 . . . . 0.0 112.108 -177.36 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.579 HG21 ' SD ' ' A' ' 31' ' ' MET . 13.5 tt -67.17 -39.31 82.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 122.832 0.453 . . . . 0.0 111.124 -176.165 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.55 ' HB3' HG21 ' A' ' 53' ' ' VAL . 9.2 mtmp? -75.81 -44.32 41.81 Favored 'General case' 0 C--N 1.348 0.526 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.423 176.17 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.22 -30.21 63.94 Favored Glycine 0 C--N 1.357 1.717 0 O-C-N 124.786 1.304 . . . . 0.0 113.678 -175.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.66 -52.08 65.07 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.423 0.689 . . . . 0.0 110.509 172.141 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.561 HG21 HG11 ' A' ' 64' ' ' VAL . 57.8 mt -72.2 -40.55 66.06 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.566 -178.153 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -63.2 -50.45 70.22 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.647 0.779 . . . . 0.0 112.383 -175.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -71.94 -31.34 66.23 Favored 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.079 -174.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 46.7 m -76.07 -42.45 47.38 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.924 0.49 . . . . 0.0 110.37 176.424 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 41.2 t -125.0 93.06 46.47 Favored Pre-proline 0 N--CA 1.48 1.028 0 C-N-CA 123.77 0.828 . . . . 0.0 109.636 -173.636 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -68.02 113.29 2.98 Favored 'Trans proline' 0 C--N 1.371 1.762 0 C-N-CA 122.492 2.128 . . . . 0.0 110.113 170.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.18 -9.25 10.27 Favored Glycine 0 C--N 1.344 0.984 0 CA-C-O 119.525 -0.597 . . . . 0.0 113.411 -176.196 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -82.81 105.52 13.89 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 170.053 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.53 101.51 10.77 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 123.392 0.677 . . . . 0.0 109.807 -176.454 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . 0.55 HG21 ' HB3' ' A' ' 41' ' ' LYS . 20.8 m -84.29 135.75 24.19 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 C-N-CA 123.634 0.774 . . . . 0.0 110.969 -171.149 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 76.3 m80 -134.18 94.95 3.32 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.233 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.01 117.08 29.48 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -95.51 124.73 52.17 Favored Pre-proline 0 CA--C 1.543 0.676 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -179.45 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.405 ' HB3' ' SG ' ' A' ' 33' ' ' CYS . 51.6 Cg_exo -57.91 -47.43 20.74 Favored 'Trans proline' 0 C--N 1.373 1.825 0 C-N-CA 122.962 2.442 . . . . 0.0 113.192 177.127 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.3 -53.17 8.6 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 123.168 0.587 . . . . 0.0 111.85 -173.109 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.0 t -80.1 -13.16 59.5 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.864 0.866 . . . . 0.0 111.765 -175.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 25.7 mmt180 65.78 23.57 11.46 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.482 1.113 . . . . 0.0 112.478 174.243 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 40.0 m -109.73 126.61 53.9 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 122.63 0.372 . . . . 0.0 111.77 -169.411 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 45.8 t -98.15 105.47 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 123.955 0.902 . . . . 0.0 108.634 170.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 15.4 t -95.53 119.55 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 123.829 0.852 . . . . 0.0 109.209 179.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.568 HG21 HG21 ' A' ' 73' ' ' ILE . 28.1 m -103.2 109.7 27.66 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 123.571 0.749 . . . . 0.0 110.457 179.277 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -94.22 150.08 19.65 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.399 -177.13 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.2 -25.11 27.18 Favored Glycine 0 C--N 1.343 0.953 0 CA-C-O 120.194 -0.226 . . . . 0.0 112.547 177.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.4 m -103.17 148.81 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 123.991 0.917 . . . . 0.0 109.785 178.303 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.6 t -123.2 1.24 9.11 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 123.366 0.667 . . . . 0.0 111.034 -174.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -102.66 83.68 2.3 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 124.353 1.061 . . . . 0.0 110.341 -174.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.43 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -64.89 -36.7 85.22 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 114.307 -1.315 . . . . 0.0 112.8 -172.832 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.471 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -64.93 -44.31 89.93 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.04 0.536 . . . . 0.0 110.797 -177.844 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.405 ' O ' HG13 ' A' ' 76' ' ' ILE . 78.9 m-70 -62.03 -49.45 75.95 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 123.658 0.599 . . . . 0.0 110.925 179.156 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.568 HG21 HG21 ' A' ' 64' ' ' VAL . 42.7 mm -59.77 -40.28 82.09 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 O-C-N 123.875 0.734 . . . . 0.0 110.227 -179.699 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.93 -36.01 82.01 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.737 0.815 . . . . 0.0 111.11 178.361 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.471 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 26.5 mm-40 -69.05 -35.94 77.14 Favored 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 123.294 0.638 . . . . 0.0 111.395 178.053 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.423 HD12 ' HA ' ' A' ' 73' ' ' ILE . 74.7 mt -68.42 -53.05 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 123.464 0.705 . . . . 0.0 110.578 -178.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 13.6 tt -66.05 -35.71 75.7 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.984 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.361 -175.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.8 t -75.15 -30.09 60.66 Favored 'General case' 0 N--CA 1.479 0.999 0 C-N-CA 122.471 0.308 . . . . 0.0 110.887 178.295 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.8 -19.73 60.67 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 123.369 0.668 . . . . 0.0 110.945 175.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -78.15 -9.73 59.31 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.745 0.818 . . . . 0.0 111.473 172.627 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 102.47 -11.45 56.66 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-O 119.717 -0.491 . . . . 0.0 112.951 179.343 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -92.86 105.93 17.98 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.442 0.697 . . . . 0.0 110.192 178.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 90.6 m -68.89 117.39 50.9 Favored Pre-proline 0 CA--C 1.552 1.023 0 C-N-CA 123.142 0.577 . . . . 0.0 109.647 176.135 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.597 ' HA ' HG22 ' A' ' 28' ' ' VAL . 48.0 Cg_endo -67.16 87.48 0.31 Allowed 'Trans proline' 0 C--N 1.382 2.293 0 C-N-CA 122.437 2.091 . . . . 0.0 111.489 174.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.5 tp10 . . . . . 0 C--O 1.249 1.029 0 C-N-CA 124.672 1.189 . . . . 0.0 108.697 179.181 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.128 0 CA-C-O 120.95 0.405 . . . . 0.0 110.767 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -141.95 107.31 0.49 Allowed Glycine 0 C--N 1.34 0.777 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 177.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.476 HD11 ' HB2' ' A' ' 70' ' ' ALA . 4.3 mm? -79.4 164.29 24.12 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.324 0.65 . . . . 0.0 111.023 -176.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 29.5 p -152.47 110.67 3.69 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 123.803 0.841 . . . . 0.0 108.82 178.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -110.35 116.44 31.45 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 123.702 0.801 . . . . 0.0 109.357 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 26.4 p80 -82.11 90.69 6.57 Favored 'General case' 0 CA--C 1.552 1.056 0 CA-C-O 122.615 1.198 . . . . 0.0 110.384 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.451 HG21 HD11 ' A' ' 77' ' ' ILE . 39.7 t -84.21 87.37 2.26 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 172.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -74.13 -5.67 43.12 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-N 115.646 -0.707 . . . . 0.0 112.758 -173.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -86.55 -22.11 26.51 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.35 0.66 . . . . 0.0 110.672 173.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.636 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 50.4 ttp -65.09 109.19 2.08 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 123.489 0.716 . . . . 0.0 111.453 -174.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 25.5 p -117.52 128.3 54.83 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.106 0.962 . . . . 0.0 109.434 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.403 ' SG ' ' HB2' ' A' ' 35' ' ' HIS . 8.8 p 65.68 159.36 0.12 Allowed 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 126.034 1.733 . . . . 0.0 113.718 176.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.521 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -67.44 -9.08 54.2 Favored Glycine 0 C--N 1.353 1.481 0 CA-C-N 115.104 -0.953 . . . . 0.0 114.306 -178.65 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . 0.403 ' HB2' ' SG ' ' A' ' 33' ' ' CYS . 29.4 m170 -71.15 -44.43 65.55 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 117.482 0.641 . . . . 0.0 110.216 173.165 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 59.0 m -83.82 -32.47 25.28 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.234 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.521 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -70.05 -34.77 73.66 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.009 176.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.04 -44.96 96.55 Favored Glycine 0 C--N 1.347 1.192 0 O-C-N 124.039 0.837 . . . . 0.0 113.472 -176.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.5 p -68.16 -30.03 46.53 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.064 0 C-N-CA 122.698 0.399 . . . . 0.0 111.384 -178.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.587 HG21 HG21 ' A' ' 62' ' ' VAL . 66.4 mt -66.39 -47.79 82.9 Favored 'Isoleucine or valine' 0 C--N 1.356 0.864 0 C-N-CA 123.149 0.58 . . . . 0.0 110.013 175.086 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 60.5 mtpt -57.43 -48.17 79.83 Favored 'General case' 0 C--N 1.349 0.566 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.224 178.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.93 -34.06 87.45 Favored Glycine 0 C--N 1.346 1.106 0 O-C-N 124.246 0.966 . . . . 0.0 112.966 -178.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.44 -54.76 35.37 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.072 0.549 . . . . 0.0 110.849 -179.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.54 HG21 HG11 ' A' ' 64' ' ' VAL . 58.3 mt -72.45 -43.7 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 CA-C-N 115.672 -0.694 . . . . 0.0 112.127 -176.003 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.6 tt0 -64.79 -38.02 89.58 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 124.219 1.008 . . . . 0.0 112.67 -174.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -76.03 -37.02 58.86 Favored 'General case' 0 N--CA 1.481 1.114 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.212 -179.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 42.7 m -71.12 -40.15 71.6 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 123.011 0.524 . . . . 0.0 110.63 177.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 48.2 t -121.39 94.54 48.64 Favored Pre-proline 0 N--CA 1.48 1.051 0 C-N-CA 123.58 0.752 . . . . 0.0 109.931 -177.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -62.25 104.29 0.34 Allowed 'Trans proline' 0 C--N 1.371 1.755 0 C-N-CA 122.563 2.175 . . . . 0.0 111.174 169.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.56 -0.15 11.18 Favored Glycine 0 C--N 1.341 0.833 0 CA-C-O 119.593 -0.559 . . . . 0.0 113.291 -177.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -83.96 108.71 17.1 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 169.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.404 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -78.49 95.97 5.29 Favored 'General case' 0 C--N 1.348 0.543 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 -178.679 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.529 HG12 HG12 ' A' ' 64' ' ' VAL . 27.7 m -88.95 131.49 36.15 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.754 0 C-N-CA 123.701 0.8 . . . . 0.0 111.027 -171.118 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . 0.406 ' HB3' HG22 ' A' ' 63' ' ' VAL . 3.5 t-160 -143.22 99.92 3.53 Favored 'General case' 0 C--N 1.346 0.421 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 167.356 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.636 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -92.51 113.75 26.11 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 172.079 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -106.9 120.49 47.95 Favored Pre-proline 0 N--CA 1.467 0.394 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -172.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -63.11 -35.31 65.44 Favored 'Trans proline' 0 C--N 1.37 1.698 0 C-N-CA 122.73 2.287 . . . . 0.0 113.493 -179.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.52 -35.2 46.62 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 123.272 0.629 . . . . 0.0 112.148 -174.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 30.2 t -91.43 -19.61 22.67 Favored 'General case' 0 N--CA 1.48 1.055 0 C-N-CA 123.18 0.592 . . . . 0.0 110.225 178.304 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.1 mpt_? 60.79 33.82 19.96 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 125.034 1.334 . . . . 0.0 110.824 -177.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 27.3 m -124.69 131.52 53.46 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 122.677 0.391 . . . . 0.0 110.683 -170.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.587 HG21 HG21 ' A' ' 40' ' ' ILE . 44.0 t -105.87 105.57 18.94 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 173.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.406 HG22 ' HB3' ' A' ' 54' ' ' HIS . 34.3 m -99.71 136.12 32.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.284 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.54 HG11 HG21 ' A' ' 44' ' ' ILE . 17.3 m -131.0 109.36 16.45 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.909 0 C-N-CA 123.399 0.68 . . . . 0.0 109.434 179.22 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -92.79 157.74 23.76 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.474 -176.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.21 0.43 89.53 Favored Glycine 0 C--N 1.345 1.049 0 CA-C-O 119.932 -0.371 . . . . 0.0 114.023 177.176 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.4 m -124.14 144.7 33.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.625 0.77 . . . . 0.0 110.147 -176.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 14.9 m -108.86 -17.71 13.87 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.599 0.759 . . . . 0.0 110.225 176.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.445 ' O ' HG12 ' A' ' 73' ' ' ILE . 6.5 m-20 -78.77 76.54 5.26 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 124.347 1.059 . . . . 0.0 111.035 -172.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.476 ' HB2' HD11 ' A' ' 24' ' ' LEU . . . -60.59 -41.5 94.83 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 124.108 0.963 . . . . 0.0 111.602 -179.635 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -65.54 -41.47 92.99 Favored 'General case' 0 N--CA 1.471 0.581 0 O-C-N 124.206 0.942 . . . . 0.0 111.044 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.417 ' O ' HG13 ' A' ' 76' ' ' ILE . 77.8 t60 -63.28 -50.69 69.12 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 123.501 0.72 . . . . 0.0 110.741 178.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.537 HG21 HG21 ' A' ' 64' ' ' VAL . 40.7 mm -58.57 -42.3 84.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 O-C-N 123.826 0.704 . . . . 0.0 110.142 179.411 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.61 -37.97 80.04 Favored 'General case' 0 N--CA 1.476 0.836 0 O-C-N 124.329 1.018 . . . . 0.0 111.648 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 12.3 mm-40 -64.67 -40.14 94.91 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.479 0.712 . . . . 0.0 111.166 177.516 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.511 HG21 ' HA ' ' A' ' 44' ' ' ILE . 33.9 mt -67.19 -51.54 52.36 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 C-N-CA 123.149 0.58 . . . . 0.0 111.356 -177.144 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.451 HD11 HG21 ' A' ' 28' ' ' VAL . 8.3 tt -71.08 -29.88 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.234 0 C-N-CA 123.379 0.671 . . . . 0.0 111.836 -176.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.464 ' HA ' ' O ' ' A' ' 82' ' ' TYR . 2.9 t -75.25 -28.9 60.03 Favored 'General case' 0 N--CA 1.48 1.054 0 N-CA-C 110.364 -0.236 . . . . 0.0 110.364 175.079 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.32 -26.17 66.38 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.355 0.662 . . . . 0.0 110.644 172.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -76.76 -8.72 57.84 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 123.377 0.671 . . . . 0.0 111.455 173.323 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.3 25.05 24.95 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 116.561 -0.291 . . . . 0.0 113.208 176.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.464 ' O ' ' HA ' ' A' ' 78' ' ' THR . 95.9 m-85 -120.43 155.06 34.27 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.526 0.73 . . . . 0.0 110.236 179.379 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 73.1 p -89.79 111.14 44.48 Favored Pre-proline 0 CA--C 1.553 1.086 0 C-N-CA 123.271 0.628 . . . . 0.0 110.415 -176.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -78.89 79.5 3.36 Favored 'Trans proline' 0 C--N 1.377 2.043 0 C-N-CA 122.906 2.404 . . . . 0.0 111.878 178.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 35.0 mm-40 . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.794 -0.622 . . . . 0.0 109.844 -176.661 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.105 0 N-CA-C 110.389 -0.226 . . . . 0.0 110.389 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -84.72 -156.1 24.59 Favored Glycine 0 C--N 1.348 1.22 0 O-C-N 123.716 0.635 . . . . 0.0 111.706 173.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -82.34 109.61 16.75 Favored 'General case' 0 CA--C 1.548 0.895 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.7 m -92.51 118.6 31.14 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 123.79 0.836 . . . . 0.0 110.748 -172.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -106.29 110.76 23.1 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.781 0.832 . . . . 0.0 109.939 178.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 50.2 m80 -81.82 94.38 7.04 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 177.078 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.499 ' O ' ' HB3' ' A' ' 60' ' ' ARG . 20.0 t -93.51 94.38 4.61 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.798 0 C-N-CA 124.356 1.062 . . . . 0.0 108.397 178.451 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -71.68 -12.72 61.47 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -175.003 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -85.5 -19.0 31.86 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 123.812 0.845 . . . . 0.0 110.951 174.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 25.2 ttt -55.33 128.64 35.11 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 124.334 1.054 . . . . 0.0 112.266 -175.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.3 p -88.47 162.18 16.61 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 124.438 1.095 . . . . 0.0 110.087 172.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 57.3 m -66.56 -162.75 0.02 OUTLIER 'General case' 0 CA--C 1.564 1.505 0 C-N-CA 124.986 1.314 . . . . 0.0 114.035 -169.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -56.69 -22.73 41.18 Favored Glycine 0 C--N 1.364 2.094 0 N-CA-C 115.722 1.049 . . . . 0.0 115.722 -171.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 48.9 t-80 -64.63 -28.77 69.84 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.777 0.831 . . . . 0.0 111.882 177.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 61.3 m -119.2 19.26 12.9 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.985 0.914 . . . . 0.0 111.26 179.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -71.37 -34.36 70.37 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 122.583 0.353 . . . . 0.0 111.047 177.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.08 -35.93 91.23 Favored Glycine 0 C--N 1.349 1.279 0 O-C-N 123.929 0.768 . . . . 0.0 114.779 -173.295 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.84 -38.71 76.48 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 C-N-CA 123.102 0.561 . . . . 0.0 111.025 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 35.3 mt -73.09 -42.36 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.454 0.702 . . . . 0.0 110.242 -178.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 45.6 mttm -55.5 -54.08 48.32 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.121 171.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.05 -30.56 78.11 Favored Glycine 0 C--N 1.345 1.032 0 O-C-N 124.788 1.305 . . . . 0.0 113.767 -172.292 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.6 -56.69 18.85 Favored 'General case' 0 C--N 1.352 0.7 0 C-N-CA 122.899 0.479 . . . . 0.0 110.629 178.059 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.521 ' HA ' HG21 ' A' ' 76' ' ' ILE . 57.7 mt -76.03 -42.35 38.65 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.679 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.693 -174.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -62.29 -48.28 80.57 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.1 0.96 . . . . 0.0 112.255 -173.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -73.4 -25.69 60.65 Favored 'General case' 0 N--CA 1.48 1.075 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.43 -176.118 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 43.0 m -80.63 -41.84 23.18 Favored 'General case' 0 N--CA 1.476 0.83 0 C-N-CA 123.022 0.529 . . . . 0.0 110.576 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.9 t -123.3 94.84 46.3 Favored Pre-proline 0 N--CA 1.479 1.01 0 C-N-CA 123.584 0.754 . . . . 0.0 109.378 -178.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -67.07 118.4 5.54 Favored 'Trans proline' 0 C--N 1.373 1.863 0 C-N-CA 122.579 2.186 . . . . 0.0 110.899 172.089 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.82 -25.48 7.17 Favored Glycine 0 C--N 1.347 1.141 0 CA-C-O 119.795 -0.447 . . . . 0.0 112.511 -174.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -73.81 106.17 5.42 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 174.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -79.8 99.91 7.72 Favored 'General case' 0 C--N 1.346 0.45 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -177.093 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.435 HG12 HG12 ' A' ' 64' ' ' VAL . 16.6 m -86.51 111.86 22.02 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.937 0 CA-C-O 121.539 0.685 . . . . 0.0 111.156 -169.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 64.9 t60 -109.22 99.24 8.54 Favored 'General case' 0 C--N 1.344 0.348 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.77 115.44 22.22 Favored 'General case' 0 CA--C 1.537 0.479 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 175.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -106.88 102.72 43.99 Favored Pre-proline 0 N--CA 1.474 0.739 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -56.26 -39.81 88.84 Favored 'Trans proline' 0 C--N 1.373 1.837 0 C-N-CA 123.084 2.522 . . . . 0.0 113.746 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.44 -44.62 64.49 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 123.383 0.673 . . . . 0.0 111.978 -171.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 21.1 t -95.39 -9.94 31.38 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 123.855 0.862 . . . . 0.0 110.606 -178.404 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.499 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 60.59 41.5 15.34 Favored 'General case' 0 N--CA 1.484 1.266 0 C-N-CA 125.266 1.426 . . . . 0.0 110.165 -179.319 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.5 m -123.13 120.44 33.25 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 122.642 0.377 . . . . 0.0 111.285 -167.368 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.6 t -98.97 105.38 17.29 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 175.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.2 t -102.5 118.79 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 -175.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.505 HG11 HG21 ' A' ' 44' ' ' ILE . 17.1 m -103.86 108.94 25.74 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.068 0 CA-C-O 121.581 0.705 . . . . 0.0 110.707 -178.136 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -85.59 149.38 23.49 Favored Glycine 0 C--N 1.35 1.312 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.412 -179.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.69 -26.03 13.91 Favored Glycine 0 N--CA 1.472 1.066 0 C-N-CA 122.955 0.312 . . . . 0.0 112.417 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 34.6 m -122.19 142.99 36.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 124.368 1.067 . . . . 0.0 109.705 -177.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 69.1 m -124.53 -0.52 8.12 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 123.518 0.727 . . . . 0.0 111.427 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 15.3 p-10 -78.42 83.94 4.61 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-O 122.603 1.192 . . . . 0.0 110.505 -178.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.37 -41.26 96.8 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 113.54 -1.664 . . . . 0.0 113.217 -170.483 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -63.02 -44.43 96.0 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.81 0.844 . . . . 0.0 111.648 -174.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.411 ' O ' HG13 ' A' ' 76' ' ' ILE . 32.1 m170 -66.25 -47.52 73.47 Favored 'General case' 0 N--CA 1.475 0.78 0 O-C-N 123.521 0.513 . . . . 0.0 110.896 179.315 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 29.3 mm -58.93 -39.2 77.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 123.795 0.684 . . . . 0.0 110.344 178.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.71 -38.21 89.52 Favored 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 124.156 0.982 . . . . 0.0 111.336 -179.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -63.97 -39.37 93.98 Favored 'General case' 0 N--CA 1.482 1.169 0 O-C-N 123.619 0.574 . . . . 0.0 111.116 176.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.521 HG21 ' HA ' ' A' ' 44' ' ' ILE . 57.4 mt -68.15 -51.33 49.64 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 123.42 0.688 . . . . 0.0 111.268 -175.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 10.9 tt -68.63 -36.14 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.447 -175.394 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.0 t -71.97 -27.5 62.81 Favored 'General case' 0 CA--C 1.549 0.941 0 C-N-CA 122.663 0.385 . . . . 0.0 110.311 177.501 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.46 -29.85 70.07 Favored 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 123.562 0.745 . . . . 0.0 111.401 174.407 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -78.03 -3.12 40.53 Favored 'General case' 0 N--CA 1.48 1.056 0 C-N-CA 123.432 0.693 . . . . 0.0 111.606 173.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.67 -9.54 60.46 Favored Glycine 0 C--N 1.343 0.969 0 CA-C-O 119.716 -0.491 . . . . 0.0 113.159 176.388 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -96.53 103.2 15.09 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 117.442 0.621 . . . . 0.0 109.722 -179.054 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 33.5 p -78.95 112.82 30.49 Favored Pre-proline 0 CA--C 1.553 1.063 0 C-N-CA 124.415 1.086 . . . . 0.0 109.87 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -76.77 -2.06 12.25 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 122.751 2.3 . . . . 0.0 113.421 179.199 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 . . . . . 0 C--O 1.256 1.396 0 C-N-CA 124.034 0.934 . . . . 0.0 109.933 175.14 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.99 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.81 147.91 9.21 Favored Glycine 0 C--N 1.35 1.316 0 O-C-N 123.106 0.254 . . . . 0.0 113.159 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 67.6 mt -99.56 107.1 19.18 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.597 0.759 . . . . 0.0 109.615 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 30.1 p -92.05 110.81 22.18 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.046 0.538 . . . . 0.0 110.6 -177.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -104.21 105.03 15.04 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 123.353 0.661 . . . . 0.0 109.375 176.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 27.8 t60 -81.66 94.21 6.91 Favored 'General case' 0 CA--C 1.538 0.494 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.284 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.555 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 32.8 t -88.62 102.39 12.78 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.709 0 CA-C-N 114.964 -1.016 . . . . 0.0 108.618 -179.502 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -70.82 -22.76 62.3 Favored 'General case' 0 N--CA 1.485 1.322 0 CA-C-O 121.105 0.479 . . . . 0.0 110.923 177.774 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -75.62 -13.93 60.36 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.29 1.036 . . . . 0.0 111.244 175.292 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.555 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 27.5 ttt -58.99 122.07 12.79 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 123.371 0.669 . . . . 0.0 112.145 -173.359 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 14.8 t -85.31 163.48 18.57 Favored 'General case' 0 CA--C 1.549 0.908 0 CA-C-N 114.932 -1.031 . . . . 0.0 109.884 173.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.508 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 28.7 p -66.41 -177.02 0.5 Allowed 'General case' 0 CA--C 1.554 1.12 0 C-N-CA 123.769 0.827 . . . . 0.0 113.015 -175.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.519 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -56.79 -15.38 12.54 Favored Glycine 0 C--N 1.357 1.734 0 N-CA-C 116.247 1.259 . . . . 0.0 116.247 -169.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -57.68 -42.99 84.76 Favored 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 117.61 0.705 . . . . 0.0 111.308 177.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 47.7 t -124.9 0.53 8.0 Favored 'General case' 0 CA--C 1.548 0.901 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.421 -177.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.519 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -64.64 -30.91 71.94 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 122.709 0.404 . . . . 0.0 110.624 173.189 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.53 -30.92 77.27 Favored Glycine 0 C--N 1.352 1.431 0 CA-C-N 115.794 -0.639 . . . . 0.0 113.265 174.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 42.8 t -69.13 -41.02 81.28 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 174.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 71.1 mt -58.26 -41.12 80.25 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.925 0 C-N-CA 124.078 0.951 . . . . 0.0 110.684 175.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.439 ' HB3' HG21 ' A' ' 53' ' ' VAL . 98.9 mttt -60.89 -58.92 6.42 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.572 0.749 . . . . 0.0 110.162 177.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.99 -30.6 70.38 Favored Glycine 0 C--N 1.351 1.372 0 O-C-N 124.68 1.238 . . . . 0.0 113.774 -173.802 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -58.59 -53.23 60.72 Favored 'General case' 0 C--N 1.35 0.62 0 C-N-CA 123.577 0.751 . . . . 0.0 110.557 176.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.565 HG21 HG11 ' A' ' 64' ' ' VAL . 72.8 mt -69.41 -46.64 76.02 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-N 114.847 -1.07 . . . . 0.0 112.465 -177.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 -61.46 -46.24 90.89 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 123.504 0.722 . . . . 0.0 112.712 -175.62 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 12.8 mptt -83.52 -14.63 51.86 Favored 'General case' 0 N--CA 1.48 1.063 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.575 -171.102 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.5 m -87.4 -49.97 6.87 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 171.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 54.2 t -113.74 96.79 42.19 Favored Pre-proline 0 N--CA 1.475 0.821 0 C-N-CA 124.372 1.069 . . . . 0.0 108.959 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -66.14 140.09 58.11 Favored 'Trans proline' 0 C--N 1.376 1.987 0 C-N-CA 122.458 2.105 . . . . 0.0 111.271 176.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.54 -10.73 68.92 Favored Glycine 0 C--N 1.34 0.773 0 CA-C-O 119.571 -0.572 . . . . 0.0 112.938 -177.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -72.25 106.02 4.26 Favored 'General case' 0 C--N 1.355 0.828 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 174.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -83.83 99.92 10.63 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.584 HG12 HG12 ' A' ' 64' ' ' VAL . 26.9 m -85.31 135.82 24.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.541 0 CA-C-O 121.197 0.522 . . . . 0.0 110.763 -172.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 18.1 t-80 -126.19 95.55 4.42 Favored 'General case' 0 C--O 1.235 0.324 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 167.426 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.51 112.88 24.77 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 177.662 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.428 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 9.6 t70 -112.43 108.38 54.55 Favored Pre-proline 0 CA--C 1.533 0.298 0 N-CA-C 108.137 -1.06 . . . . 0.0 108.137 -175.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.508 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 71.4 Cg_exo -52.87 -35.73 71.51 Favored 'Trans proline' 0 C--N 1.372 1.772 0 C-N-CA 123.223 2.615 . . . . 0.0 114.169 178.23 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.53 -31.3 47.47 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 123.061 0.544 . . . . 0.0 112.141 -177.088 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.428 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 19.5 m -91.31 -20.31 22.01 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 122.81 0.444 . . . . 0.0 111.039 179.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.4 mpt_? 57.88 46.09 17.35 Favored 'General case' 0 N--CA 1.483 1.188 0 C-N-CA 124.477 1.111 . . . . 0.0 110.033 -177.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.8 m -142.26 129.94 21.54 Favored 'General case' 0 C--N 1.351 0.657 0 C-N-CA 123.04 0.536 . . . . 0.0 110.735 -173.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 18.8 t -108.69 106.51 20.83 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 124.068 0.947 . . . . 0.0 108.858 174.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 25.9 t -97.97 118.68 44.89 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 123.76 0.824 . . . . 0.0 109.464 -179.687 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.584 HG12 HG12 ' A' ' 53' ' ' VAL . 35.9 m -106.89 114.61 46.44 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.014 0 CA-C-O 121.5 0.667 . . . . 0.0 110.912 -179.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -97.17 161.29 21.57 Favored Glycine 0 C--N 1.345 1.066 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.278 -178.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 81.27 -4.79 70.2 Favored Glycine 0 N--CA 1.476 1.315 0 N-CA-C 114.149 0.419 . . . . 0.0 114.149 178.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.19 152.81 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 C-N-CA 123.851 0.861 . . . . 0.0 110.141 -177.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.1 t -125.66 19.79 7.92 Favored 'General case' 0 N--CA 1.48 1.049 0 C-N-CA 123.742 0.817 . . . . 0.0 109.79 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.473 ' O ' HG12 ' A' ' 73' ' ' ILE . 3.3 m-20 -96.24 66.86 2.51 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 123.564 0.745 . . . . 0.0 109.41 -177.301 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.0 -46.06 89.47 Favored 'General case' 0 N--CA 1.483 1.212 0 C-N-CA 123.178 0.591 . . . . 0.0 112.196 -171.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.14 -42.23 99.04 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 123.78 0.675 . . . . 0.0 110.518 179.059 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.463 ' O ' HG13 ' A' ' 76' ' ' ILE . 11.8 m170 -66.15 -45.0 82.51 Favored 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.315 -176.616 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.476 HG13 HG21 ' A' ' 64' ' ' VAL . 47.8 mm -61.03 -40.81 86.89 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 C-N-CA 123.323 0.649 . . . . 0.0 110.561 179.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.25 -37.41 87.13 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 123.606 0.762 . . . . 0.0 111.23 179.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -67.03 -34.5 77.84 Favored 'General case' 0 N--CA 1.476 0.86 0 C-N-CA 123.386 0.674 . . . . 0.0 111.557 176.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.463 HG13 ' O ' ' A' ' 72' ' ' HIS . 72.9 mt -68.79 -53.99 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 C-N-CA 123.311 0.645 . . . . 0.0 111.211 -178.34 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.0 tt -63.71 -36.25 75.85 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.955 -175.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 t -74.27 -29.49 61.69 Favored 'General case' 0 CA--C 1.551 1.013 0 C-N-CA 122.013 0.125 . . . . 0.0 110.93 177.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.09 -22.53 61.34 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 123.204 0.602 . . . . 0.0 110.892 174.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -79.95 -8.73 59.5 Favored 'General case' 0 CA--C 1.55 0.951 0 C-N-CA 123.499 0.719 . . . . 0.0 111.209 172.119 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 97.38 22.85 15.63 Favored Glycine 0 C--N 1.351 1.388 0 CA-C-N 116.104 -0.498 . . . . 0.0 113.055 175.257 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -127.61 105.97 8.84 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 24.0 p -75.77 116.09 52.09 Favored Pre-proline 0 CA--C 1.55 0.959 0 C-N-CA 122.835 0.454 . . . . 0.0 110.809 -174.233 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.477 ' HA ' HG13 ' A' ' 28' ' ' VAL . 76.5 Cg_endo -78.09 -8.81 16.6 Favored 'Trans proline' 0 C--N 1.382 2.302 0 C-N-CA 123.143 2.562 . . . . 0.0 112.985 -176.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 30.5 mt-10 . . . . . 0 C--O 1.25 1.102 0 C-N-CA 124.281 1.032 . . . . 0.0 108.957 -175.896 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.941 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.82 164.1 48.28 Favored Glycine 0 C--N 1.345 1.073 0 N-CA-C 111.212 -0.755 . . . . 0.0 111.212 169.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.478 HD13 ' HA ' ' A' ' 70' ' ' ALA . 34.9 mt -80.15 107.23 12.78 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -174.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.2 m -102.63 130.09 49.41 Favored 'General case' 0 N--CA 1.467 0.415 0 C-N-CA 123.19 0.596 . . . . 0.0 109.81 -172.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -128.4 114.53 16.94 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.68 0.792 . . . . 0.0 110.514 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 47.0 m80 -81.63 111.86 18.3 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 171.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.7 t -107.9 100.63 11.13 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -176.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -69.06 -23.15 64.0 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.428 0.691 . . . . 0.0 110.927 175.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -74.3 -19.47 60.47 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.421 0.688 . . . . 0.0 110.625 177.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.527 ' HG3' ' HB2' ' A' ' 36' ' ' CYS . 20.4 ttt -82.67 133.82 35.16 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.215 1.006 . . . . 0.0 110.15 176.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 28.0 p -117.83 95.0 4.73 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 170.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.623 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 58.0 m 46.01 -142.69 0.31 Allowed 'General case' 0 CA--C 1.568 1.658 0 C-N-CA 125.017 1.327 . . . . 0.0 114.19 168.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.61 -24.48 64.16 Favored Glycine 0 C--N 1.362 2.019 0 C-N-CA 123.705 0.669 . . . . 0.0 114.292 -179.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -56.47 -37.94 71.02 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 123.28 0.632 . . . . 0.0 111.668 175.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.527 ' HB2' ' HG3' ' A' ' 31' ' ' MET . 80.9 m -104.11 -19.1 14.28 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 122.943 0.497 . . . . 0.0 111.571 -178.333 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -56.05 -42.72 77.03 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -173.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -61.76 -50.83 62.05 Favored Glycine 0 CA--C 1.535 1.286 0 O-C-N 123.31 0.381 . . . . 0.0 113.587 -177.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m -75.28 -34.24 30.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 C-N-CA 123.365 0.666 . . . . 0.0 112.161 -177.365 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 9.6 tt -74.84 -34.96 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.176 0 C-N-CA 123.11 0.564 . . . . 0.0 110.721 -174.387 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -71.81 -47.64 51.86 Favored 'General case' 0 C--N 1.351 0.659 0 C-N-CA 123.604 0.762 . . . . 0.0 109.657 173.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.44 -30.03 75.11 Favored Glycine 0 C--N 1.349 1.301 0 O-C-N 124.35 1.031 . . . . 0.0 113.359 -179.039 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -59.89 -54.65 43.64 Favored 'General case' 0 C--N 1.348 0.505 0 C-N-CA 123.386 0.674 . . . . 0.0 110.239 177.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.648 HG21 HG11 ' A' ' 64' ' ' VAL . 48.0 mt -74.03 -46.17 46.41 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.529 -175.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -59.97 -51.85 67.9 Favored 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.18 0.992 . . . . 0.0 112.371 -173.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.7 mptp? -75.95 -13.83 60.24 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 122.458 0.303 . . . . 0.0 111.721 -175.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 86.4 m -89.02 -39.27 13.8 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 123.117 0.567 . . . . 0.0 110.252 175.321 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 97.4 t -124.73 89.65 52.08 Favored Pre-proline 0 N--CA 1.479 0.977 0 C-N-CA 123.951 0.901 . . . . 0.0 109.022 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -60.17 113.44 1.67 Allowed 'Trans proline' 0 C--N 1.376 2.011 0 C-N-CA 122.845 2.364 . . . . 0.0 111.14 171.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.76 -14.85 9.1 Favored Glycine 0 C--N 1.342 0.87 0 CA-C-O 119.633 -0.537 . . . . 0.0 113.012 -176.274 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.79 106.8 9.86 Favored 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 173.184 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.467 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -76.27 99.54 4.8 Favored 'General case' 0 C--N 1.349 0.586 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.421 HG12 HG12 ' A' ' 64' ' ' VAL . 16.8 m -86.33 131.71 33.98 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 C-N-CA 123.29 0.636 . . . . 0.0 111.043 -172.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 43.9 t-80 -136.55 99.42 4.07 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 174.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -96.72 114.34 25.97 Favored 'General case' 0 C--O 1.241 0.621 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 174.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -94.06 120.95 65.08 Favored Pre-proline 0 N--CA 1.471 0.589 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -174.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.623 ' HA ' ' HA ' ' A' ' 33' ' ' CYS . 51.1 Cg_exo -57.54 -38.25 94.47 Favored 'Trans proline' 0 C--N 1.374 1.907 0 C-N-CA 123.103 2.536 . . . . 0.0 114.417 177.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.72 -35.38 52.05 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.032 0.533 . . . . 0.0 111.62 -174.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 16.5 m -97.69 -20.94 17.29 Favored 'General case' 0 N--CA 1.482 1.151 0 C-N-CA 123.564 0.746 . . . . 0.0 111.718 -175.178 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 7.9 mpt_? 56.91 32.63 21.83 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 125.108 1.363 . . . . 0.0 110.947 -171.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.9 m -110.35 118.98 37.77 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 123.377 0.671 . . . . 0.0 110.055 -172.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 20.9 t -101.49 107.24 21.05 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 177.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 21.9 t -105.5 135.3 44.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 123.785 0.834 . . . . 0.0 108.754 -179.044 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.648 HG11 HG21 ' A' ' 44' ' ' ILE . 18.8 m -121.7 123.0 68.42 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 C-N-CA 123.196 0.598 . . . . 0.0 110.404 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -99.74 156.74 19.76 Favored Glycine 0 C--N 1.347 1.165 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.095 -179.144 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.5 -18.2 43.89 Favored Glycine 0 N--CA 1.474 1.225 0 C-N-CA 123.121 0.391 . . . . 0.0 113.451 177.478 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.8 m -115.68 146.86 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 124.092 0.957 . . . . 0.0 109.741 -177.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 69.8 m -116.54 -20.47 9.61 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 123.722 0.809 . . . . 0.0 112.439 -175.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -75.95 86.3 2.88 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 122.776 0.43 . . . . 0.0 110.481 178.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.478 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -62.98 -29.01 70.49 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.431 0.692 . . . . 0.0 111.116 175.718 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.3 -51.38 67.89 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 124.402 1.081 . . . . 0.0 111.117 177.058 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.416 ' O ' HG13 ' A' ' 76' ' ' ILE . 28.2 m-70 -63.09 -48.01 80.43 Favored 'General case' 0 N--CA 1.482 1.155 0 O-C-N 123.592 0.558 . . . . 0.0 110.838 -178.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.474 HG21 HG21 ' A' ' 64' ' ' VAL . 49.5 mm -61.22 -40.62 86.57 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 O-C-N 124.068 0.855 . . . . 0.0 110.436 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.73 -39.69 92.46 Favored 'General case' 0 N--CA 1.478 0.968 0 O-C-N 123.95 0.781 . . . . 0.0 111.333 179.423 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.9 mm-40 -62.59 -39.5 93.91 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.491 0.716 . . . . 0.0 111.206 178.089 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.542 HG21 ' HA ' ' A' ' 44' ' ' ILE . 53.8 mt -68.02 -53.86 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 O-C-N 123.747 0.654 . . . . 0.0 110.959 -179.16 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 15.9 tt -70.28 -29.15 38.12 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.025 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.71 -173.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.5 t -76.07 -31.69 58.89 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 110.156 -0.312 . . . . 0.0 110.156 175.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.69 -21.43 64.42 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 123.671 0.788 . . . . 0.0 111.64 177.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -74.24 -3.69 31.48 Favored 'General case' 0 CA--C 1.555 1.15 0 C-N-CA 123.538 0.735 . . . . 0.0 112.189 176.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 101.77 23.11 9.56 Favored Glycine 0 C--N 1.351 1.4 0 C-N-CA 123.065 0.364 . . . . 0.0 112.885 178.368 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -119.3 175.83 5.62 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.992 0.917 . . . . 0.0 109.02 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 96.0 m -148.43 83.8 6.91 Favored Pre-proline 0 N--CA 1.479 0.994 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 171.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_exo -70.79 -67.31 0.03 OUTLIER 'Trans proline' 0 C--N 1.369 1.646 0 C-N-CA 122.449 2.1 . . . . 0.0 112.487 177.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 . . . . . 0 C--O 1.257 1.451 0 C-N-CA 125.154 1.382 . . . . 0.0 110.926 -171.787 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.921 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 163.8 166.3 22.43 Favored Glycine 0 C--N 1.341 0.812 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 -179.379 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 34.1 mt -88.99 108.21 19.46 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.4 p -92.38 111.32 22.85 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 122.883 0.473 . . . . 0.0 110.555 -177.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -106.19 124.81 50.17 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 123.88 0.872 . . . . 0.0 109.746 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 32.3 m-70 -84.05 136.81 33.88 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 175.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 p -157.34 97.05 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.978 0 C-N-CA 124.066 0.946 . . . . 0.0 109.049 -176.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -69.8 -29.4 66.69 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-N 114.98 -1.009 . . . . 0.0 111.418 -176.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -74.4 -9.85 59.0 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 123.164 0.586 . . . . 0.0 112.018 -178.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.612 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 56.1 ttp -72.62 113.08 9.26 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 120.93 0.395 . . . . 0.0 110.557 177.132 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.401 ' OG1' ' HB3' ' A' ' 36' ' ' CYS . 63.2 p -77.51 166.34 23.2 Favored 'General case' 0 CA--C 1.549 0.917 0 C-N-CA 124.013 0.925 . . . . 0.0 109.923 168.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 28.0 p -57.11 -169.73 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 124.089 0.956 . . . . 0.0 112.647 175.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.69 3.45 0.63 Allowed Glycine 0 C--N 1.357 1.721 0 N-CA-C 115.916 1.127 . . . . 0.0 115.916 -174.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -63.27 -44.74 94.25 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.743 0.817 . . . . 0.0 110.844 166.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.401 ' HB3' ' OG1' ' A' ' 32' ' ' THR . 43.5 t -141.42 9.56 2.05 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 123.136 0.575 . . . . 0.0 111.996 -176.09 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.58 -30.95 69.83 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 122.836 0.454 . . . . 0.0 110.754 173.191 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.53 -20.87 53.09 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 114.996 -1.002 . . . . 0.0 114.256 176.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.496 HG12 ' HB1' ' A' ' 80' ' ' ALA . 57.9 t -65.41 -44.32 94.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 122.871 0.468 . . . . 0.0 110.138 174.233 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.711 HG21 HG21 ' A' ' 62' ' ' VAL . 44.1 mt -69.61 -54.44 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 C-N-CA 123.3 0.64 . . . . 0.0 110.661 175.431 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.427 ' O ' ' HG3' ' A' ' 45' ' ' GLU . 9.7 mtpm? -56.68 -51.83 67.28 Favored 'General case' 0 C--N 1.348 0.507 0 O-C-N 124.517 1.136 . . . . 0.0 110.269 -174.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.48 ' O ' ' HD3' ' A' ' 46' ' ' LYS . . . -61.94 -40.16 98.5 Favored Glycine 0 C--N 1.343 0.917 0 O-C-N 124.963 1.414 . . . . 0.0 112.867 178.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.74 -53.5 57.05 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 117.129 0.464 . . . . 0.0 111.001 179.138 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.576 HG21 HG11 ' A' ' 64' ' ' VAL . 68.4 mt -62.08 -39.93 85.6 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.967 -179.174 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.427 ' HG3' ' O ' ' A' ' 41' ' ' LYS . 76.9 mt-10 -62.02 -50.46 71.94 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 123.171 0.588 . . . . 0.0 112.068 179.623 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.48 ' HD3' ' O ' ' A' ' 42' ' ' GLY . 13.3 mptt -73.03 -28.07 62.13 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.496 -171.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.1 m -85.2 -41.01 16.02 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 122.814 0.445 . . . . 0.0 110.32 177.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.0 103.51 23.53 Favored Pre-proline 0 N--CA 1.483 1.216 0 C-N-CA 124.156 0.982 . . . . 0.0 109.807 -178.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -66.91 136.58 41.97 Favored 'Trans proline' 0 C--N 1.374 1.919 0 C-N-CA 122.781 2.321 . . . . 0.0 111.687 172.059 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.2 -4.75 67.68 Favored Glycine 0 C--N 1.347 1.152 0 CA-C-O 119.787 -0.452 . . . . 0.0 113.963 175.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.65 106.68 9.61 Favored 'General case' 0 C--N 1.35 0.619 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 173.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.421 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -77.14 99.54 5.43 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -177.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.412 HG12 HG12 ' A' ' 64' ' ' VAL . 27.8 m -85.26 127.47 39.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.805 0 C-N-CA 123.134 0.574 . . . . 0.0 110.877 -171.065 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . 0.409 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 29.2 t60 -131.67 96.98 4.08 Favored 'General case' 0 C--N 1.345 0.372 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 176.12 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.612 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -93.71 113.67 25.79 Favored 'General case' 0 C--O 1.24 0.588 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 176.073 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -99.72 114.88 65.88 Favored Pre-proline 0 N--CA 1.468 0.428 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -177.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -60.54 -40.34 57.36 Favored 'Trans proline' 0 C--N 1.373 1.863 0 C-N-CA 123.009 2.473 . . . . 0.0 112.822 -176.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -74.38 -47.74 32.22 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 123.639 0.775 . . . . 0.0 111.285 -176.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.2 m -81.31 -15.65 54.8 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 123.74 0.816 . . . . 0.0 111.459 -176.122 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.8 mmt180 63.0 29.44 16.43 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 124.642 1.177 . . . . 0.0 111.389 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 33.1 m -122.79 122.76 39.46 Favored 'General case' 0 N--CA 1.479 1.001 0 O-C-N 121.808 -0.558 . . . . 0.0 111.57 -169.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.711 HG21 HG21 ' A' ' 40' ' ' ILE . 40.5 t -99.09 106.38 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 123.952 0.901 . . . . 0.0 108.972 173.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.1 t -100.49 123.21 53.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.581 HG21 HG21 ' A' ' 73' ' ' ILE . 17.0 m -111.5 109.0 26.9 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.955 0 CA-C-O 121.478 0.656 . . . . 0.0 110.18 179.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.46 150.78 20.99 Favored Glycine 0 C--N 1.346 1.125 0 CA-C-N 115.604 -0.725 . . . . 0.0 112.581 -176.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.19 -23.68 30.47 Favored Glycine 0 C--N 1.343 0.967 0 C-N-CA 123.089 0.375 . . . . 0.0 112.999 177.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 22.4 m -105.52 151.14 7.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 123.992 0.917 . . . . 0.0 110.153 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 17.9 m -126.85 -2.61 6.56 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 124.005 0.922 . . . . 0.0 110.332 -178.621 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -87.33 73.02 9.72 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 124.522 1.129 . . . . 0.0 110.266 -177.219 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.99 -29.29 70.46 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-N 114.907 -1.042 . . . . 0.0 112.373 -174.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.402 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.68 -49.45 73.12 Favored 'General case' 0 N--CA 1.474 0.764 0 O-C-N 123.763 0.665 . . . . 0.0 110.819 177.599 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.499 ' O ' HG13 ' A' ' 76' ' ' ILE . 39.8 m170 -59.35 -54.93 41.14 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 123.552 0.532 . . . . 0.0 110.463 177.81 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.581 HG21 HG21 ' A' ' 64' ' ' VAL . 41.4 mm -57.8 -40.27 75.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 O-C-N 124.438 1.086 . . . . 0.0 110.785 -174.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.26 -40.14 89.29 Favored 'General case' 0 N--CA 1.48 1.067 0 O-C-N 124.022 0.826 . . . . 0.0 111.429 178.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.402 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 15.2 mm-40 -68.23 -32.09 72.05 Favored 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 123.181 0.592 . . . . 0.0 111.292 178.05 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.499 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.3 mt -74.75 -48.66 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 122.986 0.514 . . . . 0.0 111.21 -177.094 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 73' ' ' ILE . 8.5 tt -67.37 -32.39 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 C-N-CA 123.259 0.623 . . . . 0.0 111.257 -177.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -75.12 -31.05 61.02 Favored 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 110.364 -0.236 . . . . 0.0 110.364 175.07 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.95 -18.49 64.09 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 123.537 0.735 . . . . 0.0 111.747 176.09 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.496 ' HB1' HG12 ' A' ' 39' ' ' VAL . . . -75.89 0.58 17.76 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 123.664 0.786 . . . . 0.0 112.291 176.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 95.9 17.04 36.59 Favored Glycine 0 C--N 1.351 1.377 0 C-N-CA 122.861 0.267 . . . . 0.0 112.528 179.597 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -120.78 178.36 4.73 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 124.361 1.064 . . . . 0.0 109.686 -177.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 39.0 m -139.41 111.81 7.77 Favored Pre-proline 0 N--CA 1.479 1.001 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 173.333 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -66.44 120.37 7.49 Favored 'Trans proline' 0 C--N 1.382 2.305 0 C-N-CA 122.355 2.037 . . . . 0.0 110.812 171.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 . . . . . 0 CA--C 1.555 1.167 0 C-N-CA 124.187 0.995 . . . . 0.0 109.493 -175.682 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.802 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.431 ' HA2' ' HA2' ' A' ' 65' ' ' GLY . . . -104.54 111.41 3.8 Favored Glycine 0 C--N 1.345 1.075 0 CA-C-N 116.13 -0.486 . . . . 0.0 112.165 -177.602 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.445 HD13 ' HA ' ' A' ' 70' ' ' ALA . 59.4 mt -81.42 111.59 17.91 Favored 'General case' 0 N--CA 1.47 0.568 0 C-N-CA 124.059 0.944 . . . . 0.0 110.108 179.433 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.4 t -83.72 129.62 34.95 Favored 'General case' 0 CA--C 1.549 0.922 0 C-N-CA 123.556 0.742 . . . . 0.0 110.516 -177.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -125.84 108.44 11.47 Favored 'General case' 0 N--CA 1.492 1.636 0 C-N-CA 123.338 0.655 . . . . 0.0 110.919 177.545 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 75.9 t60 -82.88 105.58 14.01 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 124.531 1.132 . . . . 0.0 110.308 -175.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.643 HG11 ' HB3' ' A' ' 82' ' ' TYR . 30.1 t -120.7 94.97 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 C-N-CA 123.214 0.606 . . . . 0.0 109.729 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -69.65 -24.75 63.66 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 123.034 0.533 . . . . 0.0 112.186 -177.306 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -74.98 -20.11 59.81 Favored 'General case' 0 N--CA 1.483 1.2 0 C-N-CA 123.737 0.815 . . . . 0.0 111.163 -179.142 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.419 ' SD ' HD13 ' A' ' 40' ' ' ILE . 12.9 ttt -73.26 139.34 46.09 Favored 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 124.303 1.041 . . . . 0.0 110.786 176.495 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 15.1 t -103.01 163.39 12.24 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 123.917 0.887 . . . . 0.0 109.195 170.037 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 23.3 p -66.98 -97.46 0.0 OUTLIER 'General case' 0 CA--C 1.563 1.467 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -174.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -71.48 -32.74 64.51 Favored Glycine 0 C--N 1.349 1.3 0 N-CA-C 114.673 0.629 . . . . 0.0 114.673 -166.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 72.1 m-70 -74.01 -14.34 61.0 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.514 0.726 . . . . 0.0 111.869 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 44.6 t -122.54 -7.1 8.64 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 122.977 0.511 . . . . 0.0 111.688 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -57.67 -55.7 31.5 Favored 'General case' 0 N--CA 1.481 1.088 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -171.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.83 -38.17 95.23 Favored Glycine 0 N--CA 1.47 0.903 0 N-CA-C 114.255 0.462 . . . . 0.0 114.255 -174.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.5 p -75.15 -40.37 44.06 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.15 0 C-N-CA 122.785 0.434 . . . . 0.0 111.733 -176.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.434 HD11 HD11 ' A' ' 77' ' ' ILE . 13.0 tt -75.05 -35.88 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 122.802 0.441 . . . . 0.0 110.79 -178.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.463 ' HB3' HG21 ' A' ' 53' ' ' VAL . 97.2 mttt -65.21 -52.29 55.66 Favored 'General case' 0 C--N 1.353 0.729 0 CA-C-N 115.771 -0.649 . . . . 0.0 109.471 174.584 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -59.91 -29.31 67.48 Favored Glycine 0 C--N 1.352 1.43 0 O-C-N 124.813 1.321 . . . . 0.0 113.517 -178.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -57.35 -54.96 40.85 Favored 'General case' 0 C--N 1.352 0.693 0 C-N-CA 123.375 0.67 . . . . 0.0 110.476 175.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.612 HG21 HG11 ' A' ' 64' ' ' VAL . 66.6 mt -73.2 -45.72 52.65 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 CA-C-N 115.529 -0.759 . . . . 0.0 112.031 -179.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -63.05 -45.7 90.99 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 124.72 1.208 . . . . 0.0 111.275 -167.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -70.95 -27.45 63.75 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.853 0.461 . . . . 0.0 111.698 -178.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 33.2 m -81.51 -33.89 31.58 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 122.648 0.379 . . . . 0.0 110.833 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.3 t -124.75 95.0 43.34 Favored Pre-proline 0 N--CA 1.48 1.073 0 C-N-CA 123.32 0.648 . . . . 0.0 109.688 178.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_exo -65.88 111.22 1.89 Allowed 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 122.699 2.266 . . . . 0.0 110.861 173.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.5 -12.1 9.59 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-O 119.514 -0.603 . . . . 0.0 113.281 -176.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -76.87 106.28 8.45 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 173.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.21 100.16 8.17 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -178.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.463 HG21 ' HB3' ' A' ' 41' ' ' LYS . 15.3 m -84.39 132.99 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 123.78 0.832 . . . . 0.0 110.649 -170.423 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -141.48 101.81 4.07 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 122.903 0.481 . . . . 0.0 109.756 -176.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.25 130.32 35.07 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 109.643 -0.502 . . . . 0.0 109.643 176.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -105.48 108.59 61.8 Favored Pre-proline 0 CA--C 1.541 0.628 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 176.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -47.34 -44.94 23.65 Favored 'Trans proline' 0 C--N 1.374 1.901 0 C-N-CA 124.126 3.218 . . . . 0.0 115.396 178.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.31 -41.57 40.16 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.485 0.714 . . . . 0.0 112.233 -173.17 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.8 t -93.37 -13.93 27.46 Favored 'General case' 0 N--CA 1.482 1.141 0 C-N-CA 123.496 0.718 . . . . 0.0 111.558 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.42 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 2.7 mpt_? 57.17 45.98 19.68 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 125.036 1.334 . . . . 0.0 110.8 -178.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 78.9 m -122.75 126.61 47.83 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.88 -170.402 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 40.5 t -98.44 108.27 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 173.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.0 t -100.58 123.11 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 C-N-CA 124.035 0.934 . . . . 0.0 108.609 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.612 HG11 HG21 ' A' ' 44' ' ' ILE . 31.4 m -112.57 109.07 27.23 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 C-N-CA 123.669 0.787 . . . . 0.0 110.666 -176.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.431 ' HA2' ' HA2' ' A' ' 23' ' ' GLY . . . -88.62 160.24 30.05 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 115.584 -0.735 . . . . 0.0 113.049 -177.335 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 78.55 4.59 87.63 Favored Glycine 0 C--N 1.343 0.92 0 N-CA-C 114.356 0.502 . . . . 0.0 114.356 175.546 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 23.4 m -131.8 150.79 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.854 0 C-N-CA 123.796 0.838 . . . . 0.0 109.4 -178.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 30.8 t -116.1 -8.41 11.8 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 124.1 0.96 . . . . 0.0 111.06 -176.657 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.417 ' O ' HG12 ' A' ' 73' ' ' ILE . 7.1 m-20 -80.92 72.34 7.92 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.751 0.821 . . . . 0.0 110.893 -175.308 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.445 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -60.38 -41.43 93.74 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.149 0.58 . . . . 0.0 111.065 -178.281 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.472 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.22 -47.83 80.85 Favored 'General case' 0 CA--C 1.541 0.6 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.134 179.094 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.43 ' O ' HG13 ' A' ' 76' ' ' ILE . 45.0 t-80 -64.64 -45.24 87.64 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.167 0.587 . . . . 0.0 111.559 -176.186 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.497 HG21 HG21 ' A' ' 64' ' ' VAL . 48.5 mm -60.86 -41.03 87.18 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 O-C-N 123.552 0.533 . . . . 0.0 109.892 178.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.15 -35.31 76.74 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 115.305 -0.861 . . . . 0.0 111.751 178.49 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.472 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 17.5 mm-40 -65.52 -41.13 93.48 Favored 'General case' 0 N--CA 1.48 1.034 0 C-N-CA 123.457 0.703 . . . . 0.0 110.923 177.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.43 HG13 ' O ' ' A' ' 72' ' ' HIS . 35.5 mt -66.37 -50.05 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.021 -177.126 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.434 HD11 HD11 ' A' ' 40' ' ' ILE . 15.9 tt -72.66 -31.17 36.13 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.949 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.429 -172.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.5 t -74.54 -29.57 61.43 Favored 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 175.095 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.43 -19.62 60.92 Favored 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 123.563 0.745 . . . . 0.0 111.27 173.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -80.4 -5.31 56.27 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.565 0.746 . . . . 0.0 111.21 172.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.0 22.72 32.0 Favored Glycine 0 C--N 1.35 1.358 0 O-C-N 123.372 0.42 . . . . 0.0 112.903 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.643 ' HB3' HG11 ' A' ' 28' ' ' VAL . 81.7 m-85 -127.46 115.07 18.33 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 123.659 0.784 . . . . 0.0 110.51 -176.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 34.8 p -71.16 111.78 11.21 Favored Pre-proline 0 CA--C 1.549 0.916 0 C-N-CA 124.296 1.039 . . . . 0.0 110.987 -177.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.403 ' HA ' HG22 ' A' ' 28' ' ' VAL . 93.8 Cg_endo -80.6 150.14 18.96 Favored 'Trans proline' 0 C--N 1.372 1.803 0 C-N-CA 122.323 2.016 . . . . 0.0 111.824 177.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 . . . . . 0 CA--C 1.559 1.3 0 C-N-CA 124.703 1.201 . . . . 0.0 111.437 173.536 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.238 0 CA-C-O 120.618 0.247 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 135.95 -154.62 21.96 Favored Glycine 0 C--N 1.342 0.913 0 N-CA-C 110.35 -1.1 . . . . 0.0 110.35 -178.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 46.8 mt -83.1 105.84 14.41 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 174.278 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 22.1 m -93.83 111.4 23.09 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -176.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -103.26 100.96 10.88 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 177.244 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 77.0 t60 -82.47 91.71 6.92 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 -179.202 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.58 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 15.9 t -74.37 93.62 0.75 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 N-CA-C 106.855 -1.535 . . . . 0.0 106.855 172.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -63.75 -20.81 66.04 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 112.693 0.627 . . . . 0.0 112.693 -171.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 10.6 p-10 -111.34 23.6 13.82 Favored 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 124.089 0.956 . . . . 0.0 110.789 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.58 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 23.9 ttt -57.73 142.01 46.74 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 124.389 1.076 . . . . 0.0 113.325 -173.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 41.3 p -81.32 144.4 31.53 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.547 173.204 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.439 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 49.8 t -73.04 -170.51 0.75 Allowed 'General case' 0 CA--C 1.554 1.114 0 C-N-CA 123.882 0.873 . . . . 0.0 110.078 177.137 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -49.35 -24.9 5.55 Favored Glycine 0 C--N 1.356 1.657 0 N-CA-C 116.623 1.409 . . . . 0.0 116.623 -171.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 40.9 m170 -58.53 -33.75 70.22 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 123.498 0.719 . . . . 0.0 112.558 177.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 63.8 m -137.92 15.95 2.86 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 122.997 0.519 . . . . 0.0 111.739 178.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -74.4 -34.04 63.19 Favored 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 122.614 0.366 . . . . 0.0 110.96 174.1 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.94 -37.91 93.69 Favored Glycine 0 C--N 1.347 1.161 0 O-C-N 123.825 0.703 . . . . 0.0 113.768 -176.013 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 9.2 p -69.48 -28.46 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 122.943 0.497 . . . . 0.0 110.883 177.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 62.2 mt -67.93 -41.82 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 123.224 0.61 . . . . 0.0 109.974 175.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 86.9 mttt -62.24 -52.05 65.28 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 123.811 0.844 . . . . 0.0 110.177 177.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.82 -31.1 78.69 Favored Glycine 0 C--N 1.347 1.14 0 CA-C-N 114.414 -1.266 . . . . 0.0 113.063 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.38 -50.92 68.46 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.975 0.91 . . . . 0.0 110.831 179.167 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.515 HG21 HG11 ' A' ' 64' ' ' VAL . 64.3 mt -74.37 -51.4 23.3 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.644 179.682 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -56.16 -54.67 42.38 Favored 'General case' 0 N--CA 1.478 0.936 0 C-N-CA 124.358 1.063 . . . . 0.0 112.745 -170.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -69.79 -13.72 62.42 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 122.889 0.476 . . . . 0.0 112.107 -175.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 61.2 m -90.51 -37.74 13.68 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 123.341 0.656 . . . . 0.0 110.442 177.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.5 m -133.54 92.1 24.63 Favored Pre-proline 0 CA--C 1.556 1.176 0 C-N-CA 123.474 0.71 . . . . 0.0 110.491 179.317 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -58.03 135.08 66.38 Favored 'Trans proline' 0 C--N 1.378 2.106 0 C-N-CA 122.604 2.203 . . . . 0.0 111.555 171.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 110.62 -29.58 8.89 Favored Glycine 0 C--N 1.341 0.847 0 N-CA-C 111.87 -0.492 . . . . 0.0 111.87 -177.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -74.02 106.86 5.89 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 175.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.445 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -78.06 99.34 6.08 Favored 'General case' 0 C--N 1.345 0.407 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -179.057 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.474 HG12 HG12 ' A' ' 64' ' ' VAL . 27.2 m -84.51 129.42 37.7 Favored 'Isoleucine or valine' 0 C--O 1.239 0.546 0 C-N-CA 123.1 0.56 . . . . 0.0 110.015 -171.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . 0.402 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 41.1 t60 -133.68 96.01 3.6 Favored 'General case' 0 CA--C 1.518 -0.283 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 175.439 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.1 113.91 26.31 Favored 'General case' 0 C--O 1.243 0.755 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 173.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -105.35 105.54 52.6 Favored Pre-proline 0 N--CA 1.466 0.337 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 -175.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.439 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 76.4 Cg_exo -53.39 -38.1 82.25 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 123.236 2.624 . . . . 0.0 113.72 179.331 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.8 -45.21 62.31 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 123.215 0.606 . . . . 0.0 111.413 -176.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.9 m -84.08 -17.89 38.75 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.417 0.687 . . . . 0.0 111.552 -177.28 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.566 ' HD2' ' HB3' ' A' ' 31' ' ' MET . 66.6 mmt-85 64.29 37.49 8.54 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 124.633 1.173 . . . . 0.0 110.367 -178.58 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.1 m -137.9 122.88 19.02 Favored 'General case' 0 CA--C 1.55 0.965 0 O-C-N 122.025 -0.422 . . . . 0.0 111.603 -169.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.402 ' HA ' ' O ' ' A' ' 54' ' ' HIS . 18.5 t -99.45 106.37 18.91 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 C-N-CA 124.142 0.977 . . . . 0.0 109.204 175.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 17.8 t -104.95 123.47 59.04 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 123.728 0.811 . . . . 0.0 109.073 -176.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.515 HG11 HG21 ' A' ' 44' ' ' ILE . 27.8 m -108.56 122.5 63.19 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.909 0 C-N-CA 123.038 0.535 . . . . 0.0 110.521 177.42 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -102.43 153.3 18.44 Favored Glycine 0 C--N 1.345 1.075 0 CA-C-N 115.981 -0.554 . . . . 0.0 112.872 -176.772 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 92.7 -24.77 22.12 Favored Glycine 0 N--CA 1.471 1.027 0 C-N-CA 123.173 0.416 . . . . 0.0 112.856 177.212 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 35.3 m -111.69 149.05 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.987 0.915 . . . . 0.0 109.473 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 42.5 m -121.74 20.82 10.92 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 123.656 0.782 . . . . 0.0 110.416 -178.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -96.65 73.56 2.71 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 124.367 1.067 . . . . 0.0 109.506 -173.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.34 -53.38 58.97 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 123.721 0.809 . . . . 0.0 112.642 -170.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.422 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -62.9 -40.52 97.82 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 123.481 0.712 . . . . 0.0 111.031 -178.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 55.7 t60 -61.66 -50.35 72.85 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 123.967 0.907 . . . . 0.0 111.205 -177.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.4 HG21 HG21 ' A' ' 64' ' ' VAL . 39.6 mm -64.99 -39.93 87.35 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.083 179.055 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.13 -37.11 79.09 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 123.985 0.803 . . . . 0.0 111.128 179.093 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.422 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 39.5 mm-40 -66.29 -40.02 89.77 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 123.625 0.77 . . . . 0.0 111.288 176.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.442 HG21 ' HA ' ' A' ' 44' ' ' ILE . 65.6 mt -64.08 -52.95 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 O-C-N 123.606 0.566 . . . . 0.0 111.17 -179.215 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 8.0 tt -66.8 -37.88 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.313 -175.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.5 t -73.84 -29.64 62.24 Favored 'General case' 0 CA--C 1.552 1.037 0 C-N-CA 122.384 0.273 . . . . 0.0 110.296 179.503 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.71 -22.24 61.67 Favored 'General case' 0 N--CA 1.484 1.256 0 C-N-CA 123.628 0.771 . . . . 0.0 111.238 174.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.43 -6.08 52.15 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.503 0.721 . . . . 0.0 111.396 172.242 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 93.87 8.17 60.75 Favored Glycine 0 C--N 1.345 1.068 0 CA-C-O 119.89 -0.394 . . . . 0.0 112.933 177.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 99.4 m-85 -117.0 103.22 10.04 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 176.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.4 t -83.59 118.53 71.74 Favored Pre-proline 0 CA--C 1.554 1.119 0 C-N-CA 123.267 0.627 . . . . 0.0 110.389 -176.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -70.75 -42.6 2.28 Favored 'Trans proline' 0 C--N 1.377 2.076 0 C-N-CA 122.409 2.072 . . . . 0.0 111.716 173.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 . . . . . 0 C--O 1.253 1.279 0 C-N-CA 124.767 1.227 . . . . 0.0 108.102 172.379 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.996 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.403 ' HA2' ' HA2' ' A' ' 65' ' ' GLY . . . -113.21 123.83 6.34 Favored Glycine 0 C--N 1.347 1.19 0 N-CA-C 112.058 -0.417 . . . . 0.0 112.058 -178.606 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 47.6 mt -80.32 108.6 14.07 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 123.809 0.844 . . . . 0.0 110.141 -178.018 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 21.0 p -88.44 124.25 33.78 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 123.623 0.769 . . . . 0.0 110.978 -178.383 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -121.55 112.72 18.83 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 123.729 0.812 . . . . 0.0 110.401 -179.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 69.3 m80 -83.59 104.23 13.55 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.318 0.647 . . . . 0.0 110.173 177.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.595 HG11 ' HB3' ' A' ' 82' ' ' TYR . 98.8 t -90.07 128.3 42.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.442 0 C-N-CA 123.404 0.681 . . . . 0.0 109.176 174.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -64.44 -39.85 94.61 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 123.563 0.745 . . . . 0.0 112.286 -176.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -104.83 -6.47 20.21 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 113.302 0.852 . . . . 0.0 113.302 -166.169 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 24.1 ptm -65.45 133.38 51.18 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-O 121.318 0.58 . . . . 0.0 111.355 -174.236 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 72.9 p -107.55 161.62 14.69 Favored 'General case' 0 CA--C 1.547 0.856 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 171.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 24.6 p -74.87 -109.29 0.01 OUTLIER 'General case' 0 CA--C 1.563 1.479 0 N-CA-C 113.951 1.093 . . . . 0.0 113.951 -166.524 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -75.96 5.21 41.98 Favored Glycine 0 N--CA 1.478 1.474 0 N-CA-C 117.422 1.729 . . . . 0.0 117.422 -154.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 65.7 m80 -110.13 -31.02 7.5 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-N 118.118 0.959 . . . . 0.0 110.548 175.349 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.4 m -102.0 -8.87 21.12 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.621 0.769 . . . . 0.0 110.936 -179.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -61.5 -46.38 90.26 Favored 'General case' 0 C--N 1.354 0.771 0 C-N-CA 123.803 0.841 . . . . 0.0 110.347 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -65.55 -27.57 72.71 Favored Glycine 0 C--N 1.343 0.946 0 O-C-N 123.977 0.798 . . . . 0.0 113.846 -178.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 53.0 t -72.04 -46.6 58.59 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.963 0 C-N-CA 123.196 0.598 . . . . 0.0 109.771 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.441 HG21 HG21 ' A' ' 62' ' ' VAL . 75.7 mt -59.98 -55.23 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.669 176.298 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -61.51 -43.43 98.88 Favored 'General case' 0 C--O 1.219 -0.503 0 CA-C-N 114.794 -1.094 . . . . 0.0 110.918 -176.18 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.86 -42.57 98.38 Favored Glycine 0 C--N 1.345 1.051 0 O-C-N 124.068 0.855 . . . . 0.0 112.366 -179.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.32 -55.11 31.34 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 122.89 0.476 . . . . 0.0 110.815 -179.454 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.542 HG21 HG11 ' A' ' 64' ' ' VAL . 82.4 mt -64.45 -51.13 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.019 0 C-N-CA 123.758 0.823 . . . . 0.0 112.297 -176.731 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -60.68 -45.58 93.6 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 124.316 1.046 . . . . 0.0 112.222 -173.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.3 mptp? -78.72 -21.09 48.6 Favored 'General case' 0 N--CA 1.484 1.234 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 -173.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.407 ' HB ' HD13 ' A' ' 76' ' ' ILE . 38.5 m -85.33 -39.17 17.96 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 122.899 0.48 . . . . 0.0 110.319 177.536 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.1 t -118.46 86.53 28.59 Favored Pre-proline 0 CA--C 1.548 0.876 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 174.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo -61.76 106.77 0.46 Allowed 'Trans proline' 0 C--N 1.378 2.111 0 C-N-CA 122.952 2.435 . . . . 0.0 112.813 -174.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.88 7.93 8.37 Favored Glycine 0 C--N 1.341 0.859 0 CA-C-N 115.638 -0.71 . . . . 0.0 113.173 -179.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.19 107.47 9.6 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 176.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.411 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -75.58 96.37 3.52 Favored 'General case' 0 C--N 1.352 0.693 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 -177.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.443 HG12 HG12 ' A' ' 64' ' ' VAL . 5.0 m -87.29 133.14 30.89 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.587 -168.737 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 75.6 t60 -138.62 99.25 3.77 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 174.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.78 115.3 23.34 Favored 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 173.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -96.94 120.77 60.92 Favored Pre-proline 0 N--CA 1.478 0.951 0 CA-C-O 118.975 -0.536 . . . . 0.0 109.919 -173.175 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -55.75 -48.97 17.33 Favored 'Trans proline' 0 C--N 1.381 2.27 0 C-N-CA 123.598 2.865 . . . . 0.0 114.025 178.095 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -75.09 -42.85 55.82 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.116 -170.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 19.5 m -93.31 -14.94 26.32 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 123.595 0.758 . . . . 0.0 112.125 -171.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 11.4 mpt_? 59.42 40.43 20.83 Favored 'General case' 0 N--CA 1.488 1.444 0 C-N-CA 123.866 0.866 . . . . 0.0 110.273 -175.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.9 m -121.31 118.87 30.61 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.119 0.568 . . . . 0.0 111.275 -169.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.441 HG21 HG21 ' A' ' 40' ' ' ILE . 42.8 t -97.88 105.92 17.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 175.168 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 6.3 t -102.02 123.19 55.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 -176.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.542 HG11 HG21 ' A' ' 44' ' ' ILE . 19.1 m -117.39 109.22 26.91 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 CA-C-O 121.512 0.672 . . . . 0.0 110.787 -176.478 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.403 ' HA2' ' HA2' ' A' ' 23' ' ' GLY . . . -90.76 161.98 28.67 Favored Glycine 0 C--N 1.344 0.994 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.775 -176.62 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.7 0.65 74.8 Favored Glycine 0 C--N 1.346 1.106 0 CA-C-O 119.995 -0.336 . . . . 0.0 113.824 177.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 33.9 m -128.99 149.05 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 123.826 0.85 . . . . 0.0 109.987 -177.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 45.7 m -114.88 4.76 14.94 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 123.797 0.839 . . . . 0.0 110.359 176.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.59 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 5.6 m-20 -83.12 68.6 9.63 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.015 0.926 . . . . 0.0 111.014 -172.352 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.25 -45.11 95.86 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.12 0.568 . . . . 0.0 111.681 -175.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -66.43 -44.14 83.7 Favored 'General case' 0 CA--C 1.541 0.599 0 CA-C-N 115.506 -0.77 . . . . 0.0 111.235 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.59 ' HB2' ' HB3' ' A' ' 69' ' ' ASP . 26.1 m80 -62.48 -52.45 63.47 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 122.968 0.507 . . . . 0.0 111.271 -178.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.488 HG12 ' O ' ' A' ' 69' ' ' ASP . 48.6 mm -57.52 -43.13 82.43 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 O-C-N 123.817 0.698 . . . . 0.0 110.09 -177.395 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.82 -38.93 83.4 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 124.403 1.064 . . . . 0.0 111.764 178.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 43.8 mm-40 -68.87 -36.06 77.65 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 123.42 0.688 . . . . 0.0 111.748 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.483 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.6 mt -69.59 -51.69 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.989 0 C-N-CA 122.743 0.417 . . . . 0.0 110.186 -177.095 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.417 HG12 ' HB2' ' A' ' 82' ' ' TYR . 12.4 tt -70.43 -30.55 43.38 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.071 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.536 -174.544 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 3.8 t -74.86 -30.3 61.29 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 176.272 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -74.39 -23.04 58.92 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.557 0.743 . . . . 0.0 110.533 173.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.55 -6.99 55.59 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 123.32 0.648 . . . . 0.0 111.207 172.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 100.03 9.55 48.31 Favored Glycine 0 C--N 1.352 1.469 0 CA-C-O 119.797 -0.446 . . . . 0.0 113.727 173.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.595 ' HB3' HG11 ' A' ' 28' ' ' VAL . 84.9 m-85 -109.09 121.5 45.29 Favored 'General case' 0 N--CA 1.481 1.079 0 C-N-CA 123.715 0.806 . . . . 0.0 109.289 -178.218 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 31.3 m -88.18 103.4 5.03 Favored Pre-proline 0 CA--C 1.559 1.325 0 C-N-CA 123.868 0.867 . . . . 0.0 111.396 -175.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -91.01 -74.65 0.0 OUTLIER 'Trans proline' 0 C--N 1.376 2.023 0 C-N-CA 123.564 2.843 . . . . 0.0 112.477 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 . . . . . 0 CA--C 1.554 1.109 0 C-N-CA 125.54 1.536 . . . . 0.0 111.372 -179.353 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.24 0 CA-C-O 121.013 0.435 . . . . 0.0 110.36 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -92.38 -153.77 30.31 Favored Glycine 0 C--N 1.342 0.882 0 CA-C-N 115.28 -0.873 . . . . 0.0 112.739 178.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.523 HD13 ' HA ' ' A' ' 70' ' ' ALA . 56.1 mt -79.78 109.83 14.57 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 123.788 0.835 . . . . 0.0 109.848 -176.764 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.558 ' HA ' HG12 ' A' ' 63' ' ' VAL . 19.6 p -92.17 109.03 20.39 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.001 0.52 . . . . 0.0 111.405 -174.282 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 88.9 m-85 -105.17 110.29 22.61 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 123.162 0.585 . . . . 0.0 109.954 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 11.7 m170 -82.49 92.49 7.08 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.459 HG22 ' HB3' ' A' ' 84' ' ' PRO . 31.0 t -83.27 105.48 13.03 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.256 -175.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -79.22 -10.76 59.9 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 122.774 0.43 . . . . 0.0 111.515 -176.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -93.41 -0.8 56.38 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 123.813 0.845 . . . . 0.0 111.476 173.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.48 ' HB3' ' HB3' ' A' ' 60' ' ' ARG . 26.7 ttt -73.62 137.36 44.16 Favored 'General case' 0 CA--C 1.543 0.679 0 CA-C-O 121.58 0.705 . . . . 0.0 111.754 -176.445 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.0 t -110.1 164.47 12.6 Favored 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 125.507 1.523 . . . . 0.0 109.054 175.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.466 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 60.1 m -59.0 -178.6 0.05 Allowed 'General case' 0 CA--C 1.559 1.318 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -179.477 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -53.95 -21.56 17.23 Favored Glycine 0 C--N 1.353 1.49 0 N-CA-C 116.682 1.433 . . . . 0.0 116.682 -169.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 33.1 m170 -62.54 -21.35 65.48 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 123.532 0.733 . . . . 0.0 112.797 -177.427 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 53.2 t -139.12 17.7 2.61 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 123.434 0.694 . . . . 0.0 110.811 178.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.85 -31.45 69.3 Favored 'General case' 0 N--CA 1.482 1.126 0 C-N-CA 123.03 0.532 . . . . 0.0 111.811 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -67.76 -23.49 74.04 Favored Glycine 0 C--N 1.347 1.174 0 O-C-N 123.471 0.482 . . . . 0.0 113.586 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 92.1 t -69.47 -40.47 79.85 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.616 0.767 . . . . 0.0 109.873 173.373 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 23.2 mt -72.24 -40.7 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 CA-C-N 114.72 -1.127 . . . . 0.0 109.91 -177.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -59.65 -54.79 42.33 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 114.664 -1.153 . . . . 0.0 109.999 172.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -60.59 -30.05 71.13 Favored Glycine 0 C--N 1.349 1.26 0 O-C-N 124.604 1.19 . . . . 0.0 113.389 -175.751 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.46 -53.59 54.43 Favored 'General case' 0 C--N 1.351 0.658 0 C-N-CA 124.146 0.978 . . . . 0.0 110.9 176.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.466 HD11 HD12 ' A' ' 77' ' ' ILE . 64.2 mt -75.22 -59.06 3.61 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.572 178.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -50.02 -48.15 52.81 Favored 'General case' 0 N--CA 1.483 1.19 0 C-N-CA 126.215 1.806 . . . . 0.0 113.688 -169.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.4 mptt -69.45 -38.17 77.67 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 122.792 0.437 . . . . 0.0 111.407 -178.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 26.9 m -73.35 -33.08 64.89 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 123.219 0.607 . . . . 0.0 111.02 -178.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 3.9 m -136.32 81.6 36.93 Favored Pre-proline 0 CA--C 1.556 1.201 0 C-N-CA 124.066 0.946 . . . . 0.0 110.537 178.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_exo -62.91 123.04 11.56 Favored 'Trans proline' 0 C--N 1.381 2.253 0 C-N-CA 122.827 2.351 . . . . 0.0 111.308 174.035 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.77 -24.59 7.48 Favored Glycine 0 C--N 1.342 0.899 0 CA-C-O 119.866 -0.408 . . . . 0.0 112.234 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.21 104.86 5.95 Favored 'General case' 0 C--N 1.354 0.761 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 172.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.52 100.41 2.73 Favored 'General case' 0 C--N 1.348 0.525 0 C-N-CA 123.318 0.647 . . . . 0.0 110.529 -173.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.415 HG12 HG12 ' A' ' 64' ' ' VAL . 27.1 m -85.36 134.24 27.59 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 O-C-N 123.603 0.564 . . . . 0.0 110.744 -173.28 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 44.0 t-80 -135.69 99.89 4.32 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 169.256 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.67 116.32 23.14 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 115.021 -0.99 . . . . 0.0 108.949 178.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -103.27 105.85 48.48 Favored Pre-proline 0 N--CA 1.478 0.944 0 CA-C-O 118.47 -0.776 . . . . 0.0 108.973 -177.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.466 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 72.4 Cg_exo -54.79 -41.88 73.97 Favored 'Trans proline' 0 C--N 1.378 2.127 0 C-N-CA 123.178 2.585 . . . . 0.0 114.67 179.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -67.78 -45.57 74.48 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 123.114 0.565 . . . . 0.0 111.75 -173.274 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.4 t -89.88 -18.93 25.24 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 123.686 0.794 . . . . 0.0 111.089 -178.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.48 ' HB3' ' HB3' ' A' ' 31' ' ' MET . 0.2 OUTLIER 61.28 47.1 7.25 Favored 'General case' 0 N--CA 1.482 1.138 0 C-N-CA 124.699 1.2 . . . . 0.0 110.272 -175.676 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 54.1 m -128.84 115.16 17.48 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 123.178 0.591 . . . . 0.0 110.246 -173.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 25.4 t -98.56 108.53 22.28 Favored 'Isoleucine or valine' 0 C--O 1.24 0.6 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 175.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.558 HG12 ' HA ' ' A' ' 25' ' ' SER . 34.7 m -99.46 136.08 32.11 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.201 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.454 HG21 HG21 ' A' ' 73' ' ' ILE . 21.4 m -119.16 133.84 64.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 C-N-CA 123.345 0.658 . . . . 0.0 110.181 -178.364 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -113.0 153.31 17.62 Favored Glycine 0 C--N 1.35 1.311 0 CA-C-N 116.303 -0.408 . . . . 0.0 112.787 -175.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.7 14.5 82.34 Favored Glycine 0 C--N 1.348 1.23 0 N-CA-C 113.945 0.338 . . . . 0.0 113.945 175.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 3.6 m -129.54 134.8 62.86 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 123.85 0.86 . . . . 0.0 110.245 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.6 m -95.52 -23.85 16.9 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 123.686 0.794 . . . . 0.0 111.099 176.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 30.7 m-20 -79.05 87.25 4.84 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-O 121.141 0.496 . . . . 0.0 111.3 -175.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.523 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -70.63 -46.1 63.97 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.943 -175.438 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -61.6 -36.61 81.2 Favored 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.961 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 74.7 t60 -63.11 -51.68 65.61 Favored 'General case' 0 N--CA 1.473 0.715 0 O-C-N 123.856 0.722 . . . . 0.0 110.852 -179.277 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.454 HG21 HG21 ' A' ' 64' ' ' VAL . 41.7 mm -59.45 -42.32 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 123.646 0.591 . . . . 0.0 110.379 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.0 -41.42 98.04 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.375 -177.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 54.8 mm-40 -63.24 -39.97 96.12 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.464 0.706 . . . . 0.0 111.607 178.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 85.5 mt -61.78 -54.25 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.403 0.681 . . . . 0.0 111.41 -178.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.466 HD12 HD11 ' A' ' 44' ' ' ILE . 14.0 tt -73.84 -33.13 36.45 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.913 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.7 -171.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.9 t -71.76 -29.26 64.31 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 176.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.07 -22.99 63.0 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.803 0.841 . . . . 0.0 111.167 173.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -82.93 -3.09 56.63 Favored 'General case' 0 CA--C 1.547 0.861 0 C-N-CA 123.751 0.82 . . . . 0.0 111.774 175.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.22 -6.23 59.54 Favored Glycine 0 C--N 1.348 1.217 0 CA-C-O 120.155 -0.247 . . . . 0.0 113.311 178.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.408 ' HB3' HG11 ' A' ' 28' ' ' VAL . 87.0 m-85 -106.07 103.15 12.57 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 -178.539 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 53.0 m -94.4 114.2 62.77 Favored Pre-proline 0 CA--C 1.553 1.085 0 C-N-CA 123.201 0.6 . . . . 0.0 111.633 -171.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.459 ' HB3' HG22 ' A' ' 28' ' ' VAL . 25.4 Cg_endo -95.99 -11.11 0.84 Allowed 'Trans proline' 0 C--N 1.377 2.031 0 C-N-CA 123.27 2.647 . . . . 0.0 113.328 167.227 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 . . . . . 0 C--O 1.251 1.157 0 C-N-CA 124.006 0.922 . . . . 0.0 108.699 -173.785 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.284 0 CA-C-O 120.589 0.233 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.62 172.7 49.32 Favored Glycine 0 C--N 1.345 1.038 0 CA-C-N 116.006 -0.543 . . . . 0.0 113.369 177.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.442 HD13 ' HA ' ' A' ' 70' ' ' ALA . 32.2 mt -87.72 116.93 26.2 Favored 'General case' 0 C--O 1.239 0.522 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 175.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 28.6 p -92.13 111.32 22.83 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 122.871 0.468 . . . . 0.0 111.214 -173.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -108.95 133.64 52.69 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.274 1.029 . . . . 0.0 108.809 175.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 18.6 p80 -125.89 137.1 53.71 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.258 0.623 . . . . 0.0 109.803 -176.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.768 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 67.0 t -117.51 120.02 63.52 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 N-CA-C 107.162 -1.421 . . . . 0.0 107.162 170.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -70.68 -21.97 62.52 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -175.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -89.56 -8.61 52.31 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 123.411 0.685 . . . . 0.0 111.009 177.377 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.768 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 25.7 ttt -56.14 106.67 0.29 Allowed 'General case' 0 N--CA 1.48 1.043 0 C-N-CA 123.911 0.884 . . . . 0.0 112.341 -170.439 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.415 ' O ' ' HB3' ' A' ' 36' ' ' CYS . 67.1 p -70.94 162.24 29.68 Favored 'General case' 0 N--CA 1.475 0.795 0 C-N-CA 123.651 0.78 . . . . 0.0 109.284 167.358 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 79.5 m -61.39 -104.86 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 123.488 0.715 . . . . 0.0 111.808 -177.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -67.49 -30.9 75.51 Favored Glycine 0 C--N 1.353 1.489 0 CA-C-N 119.391 0.996 . . . . 0.0 113.603 -172.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 21.7 t-80 -62.73 -30.11 71.18 Favored 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 123.98 0.912 . . . . 0.0 112.659 -177.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.638 ' SG ' ' HG3' ' A' ' 31' ' ' MET . 51.9 t -106.16 -31.25 8.77 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 122.51 0.324 . . . . 0.0 110.44 179.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -62.94 -49.6 74.11 Favored 'General case' 0 C--N 1.356 0.851 0 C-N-CA 123.466 0.707 . . . . 0.0 111.698 -175.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.8 -37.08 75.53 Favored Glycine 0 C--N 1.347 1.165 0 O-C-N 123.979 0.799 . . . . 0.0 113.84 -177.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.501 HG12 ' HB1' ' A' ' 80' ' ' ALA . 42.7 t -71.6 -51.26 33.87 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 123.318 0.647 . . . . 0.0 110.526 -179.021 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.689 HG21 HG21 ' A' ' 62' ' ' VAL . 64.7 mt -64.81 -53.93 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 CA-C-N 115.443 -0.798 . . . . 0.0 111.646 -176.017 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 48.6 mtmt -57.84 -46.89 84.12 Favored 'General case' 0 N--CA 1.474 0.746 0 O-C-N 123.889 0.743 . . . . 0.0 110.064 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.31 -36.74 93.5 Favored Glycine 0 C--N 1.351 1.41 0 O-C-N 124.346 1.028 . . . . 0.0 113.142 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -67.42 -54.02 24.05 Favored 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 122.743 0.417 . . . . 0.0 111.121 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.596 HG21 HG11 ' A' ' 64' ' ' VAL . 63.9 mt -67.36 -42.88 87.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 C-N-CA 123.275 0.63 . . . . 0.0 111.563 -176.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -61.33 -47.53 85.48 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.877 0.871 . . . . 0.0 111.626 -177.69 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -73.13 -37.06 66.79 Favored 'General case' 0 N--CA 1.48 1.035 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.942 -176.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 58.8 m -73.61 -40.99 63.41 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 122.658 0.383 . . . . 0.0 111.149 -179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.4 HG11 HG11 ' A' ' 67' ' ' VAL . 24.2 t -114.08 102.69 55.02 Favored Pre-proline 0 N--CA 1.481 1.084 0 C-N-CA 123.185 0.594 . . . . 0.0 110.277 -176.578 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -68.16 107.03 1.47 Allowed 'Trans proline' 0 C--N 1.373 1.826 0 C-N-CA 122.717 2.278 . . . . 0.0 111.123 173.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.16 -10.94 10.8 Favored Glycine 0 C--N 1.345 1.076 0 CA-C-O 119.251 -0.749 . . . . 0.0 113.619 178.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.41 106.6 7.04 Favored 'General case' 0 N--CA 1.479 0.977 0 CA-C-N 117.833 0.816 . . . . 0.0 109.038 174.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.58 99.03 7.89 Favored 'General case' 0 N--CA 1.465 0.31 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 -178.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.52 HG12 HG12 ' A' ' 64' ' ' VAL . 26.9 m -86.51 134.17 28.05 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 C-N-CA 123.412 0.685 . . . . 0.0 110.366 -174.353 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 43.6 t-80 -142.81 102.16 3.98 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 172.46 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.443 ' HB1' ' HE1' ' A' ' 31' ' ' MET . . . -89.61 115.79 27.27 Favored 'General case' 0 C--O 1.239 0.509 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 171.126 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.434 ' HA ' ' HD2' ' A' ' 57' ' ' PRO . 20.0 t70 -92.08 114.27 61.63 Favored Pre-proline 0 CA--C 1.546 0.8 0 CA-C-O 118.142 -0.932 . . . . 0.0 109.549 -177.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.434 ' HD2' ' HA ' ' A' ' 56' ' ' ASP . 7.3 Cg_endo -47.27 -33.6 16.61 Favored 'Trans proline' 0 C--N 1.381 2.259 0 C-N-CA 124.612 3.542 . . . . 0.0 115.29 178.267 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.47 -44.32 24.88 Favored 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -177.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 28.1 t -93.27 -23.38 18.53 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.405 0.682 . . . . 0.0 111.955 -173.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.491 ' HB3' ' HB3' ' A' ' 31' ' ' MET . 11.7 mmm180 57.63 41.29 25.78 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 125.596 1.558 . . . . 0.0 111.578 -173.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.8 m -119.26 127.69 53.47 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 123.286 0.635 . . . . 0.0 110.028 -177.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.689 HG21 HG21 ' A' ' 40' ' ' ILE . 21.6 t -99.59 106.17 18.63 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 C-N-CA 124.658 1.183 . . . . 0.0 108.951 177.124 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 25.7 m -94.11 135.43 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 175.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.596 HG11 HG21 ' A' ' 44' ' ' ILE . 22.2 m -120.87 107.88 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 CA-C-O 121.674 0.749 . . . . 0.0 110.017 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.71 152.4 21.85 Favored Glycine 0 C--N 1.346 1.115 0 CA-C-N 115.581 -0.736 . . . . 0.0 112.789 -175.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.8 -24.47 26.08 Favored Glycine 0 C--N 1.344 0.997 0 C-N-CA 123.042 0.353 . . . . 0.0 113.036 178.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.4 HG11 HG11 ' A' ' 48' ' ' VAL . 27.4 m -111.24 145.64 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 123.904 0.881 . . . . 0.0 110.135 -177.473 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 23.2 t -117.71 10.01 13.21 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 123.624 0.77 . . . . 0.0 109.771 176.364 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -86.58 74.83 9.81 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 124.222 1.009 . . . . 0.0 109.522 -176.083 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.442 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -63.79 -47.37 81.16 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.39 0.676 . . . . 0.0 112.252 -172.191 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.503 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.47 -39.64 94.99 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 123.113 0.565 . . . . 0.0 110.788 -179.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 74.1 t60 -63.13 -51.69 65.51 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.286 1.034 . . . . 0.0 111.279 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.46 ' O ' HG22 ' A' ' 77' ' ' ILE . 41.3 mm -60.75 -38.47 78.88 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 O-C-N 123.744 0.652 . . . . 0.0 109.962 179.113 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.81 -36.74 79.8 Favored 'General case' 0 N--CA 1.476 0.856 0 O-C-N 124.247 0.967 . . . . 0.0 111.837 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.503 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 11.7 mm-40 -69.35 -34.78 75.11 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.16 0.584 . . . . 0.0 111.26 177.537 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 71.5 mt -71.75 -48.44 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 C-N-CA 123.441 0.696 . . . . 0.0 111.961 -177.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.462 ' HB ' HD11 ' A' ' 44' ' ' ILE . 5.0 tt -66.53 -37.27 79.23 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.184 0 C-N-CA 122.871 0.469 . . . . 0.0 110.851 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 t -71.18 -29.61 65.39 Favored 'General case' 0 CA--C 1.553 1.084 0 C-N-CA 122.463 0.305 . . . . 0.0 110.379 178.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.61 -24.27 62.71 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 123.751 0.82 . . . . 0.0 111.373 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.501 ' HB1' HG12 ' A' ' 39' ' ' VAL . . . -75.02 -6.09 47.52 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 123.389 0.675 . . . . 0.0 111.578 175.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.29 1.38 56.85 Favored Glycine 0 C--N 1.35 1.325 0 CA-C-O 119.884 -0.398 . . . . 0.0 112.98 176.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -120.31 104.71 10.26 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 178.562 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.7 t -86.32 116.96 67.83 Favored Pre-proline 0 CA--C 1.554 1.119 0 C-N-CA 123.397 0.679 . . . . 0.0 110.354 -178.642 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -79.88 148.67 19.94 Favored 'Trans proline' 0 C--N 1.375 1.961 0 C-N-CA 122.742 2.294 . . . . 0.0 111.571 174.381 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.4 mp0 . . . . . 0 C--O 1.251 1.148 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -176.789 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.92 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 163.92 166.32 22.59 Favored Glycine 0 C--N 1.341 0.843 0 N-CA-C 111.412 -0.675 . . . . 0.0 111.412 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.401 HD13 ' HA ' ' A' ' 70' ' ' ALA . 34.0 mt -88.99 108.24 19.47 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 27.3 p -92.36 111.35 22.89 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 122.844 0.458 . . . . 0.0 110.606 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -106.24 124.88 50.28 Favored 'General case' 0 N--CA 1.478 0.952 0 C-N-CA 123.862 0.865 . . . . 0.0 109.72 179.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 32.1 m-70 -84.03 136.77 33.91 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 175.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 p -157.31 96.98 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.091 0.957 . . . . 0.0 109.059 -176.364 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 17.0 tp10 -69.79 -29.46 66.77 Favored 'General case' 0 N--CA 1.479 1.007 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.443 -176.21 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.5 m-20 -74.29 -9.84 59.01 Favored 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 123.164 0.586 . . . . 0.0 112.104 -178.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.612 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 56.3 ttp -72.69 113.06 9.3 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-O 120.944 0.402 . . . . 0.0 110.536 177.145 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.401 ' OG1' ' HB3' ' A' ' 36' ' ' CYS . 62.7 p -77.51 166.36 23.17 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 123.993 0.917 . . . . 0.0 109.912 168.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 27.9 p -57.11 -169.69 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 124.121 0.968 . . . . 0.0 112.6 175.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -61.73 3.5 0.64 Allowed Glycine 0 C--N 1.357 1.732 0 N-CA-C 115.922 1.129 . . . . 0.0 115.922 -174.021 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -63.3 -44.72 94.22 Favored 'General case' 0 CA--C 1.543 0.706 0 C-N-CA 123.786 0.834 . . . . 0.0 110.798 166.031 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.401 ' HB3' ' OG1' ' A' ' 32' ' ' THR . 43.6 t -141.47 9.51 2.03 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 123.189 0.596 . . . . 0.0 111.987 -176.018 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.65 -30.89 69.69 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 122.814 0.446 . . . . 0.0 110.732 173.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.58 -20.84 53.15 Favored Glycine 0 C--N 1.348 1.238 0 CA-C-N 114.997 -1.001 . . . . 0.0 114.262 176.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.501 HG12 ' HB1' ' A' ' 80' ' ' ALA . 57.8 t -65.48 -44.25 94.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 122.851 0.461 . . . . 0.0 110.128 174.221 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.709 HG21 HG21 ' A' ' 62' ' ' VAL . 43.7 mt -69.7 -54.4 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 C-N-CA 123.322 0.649 . . . . 0.0 110.619 175.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.425 ' O ' ' HG3' ' A' ' 45' ' ' GLU . 9.7 mtpm? -56.68 -51.93 66.87 Favored 'General case' 0 C--N 1.347 0.487 0 O-C-N 124.439 1.087 . . . . 0.0 110.216 -174.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.482 ' O ' ' HD3' ' A' ' 46' ' ' LYS . . . -61.87 -40.18 98.5 Favored Glycine 0 C--N 1.342 0.886 0 O-C-N 124.984 1.428 . . . . 0.0 112.822 178.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.79 -53.48 57.32 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-N 117.161 0.48 . . . . 0.0 110.955 179.181 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.572 HG21 HG11 ' A' ' 64' ' ' VAL . 68.3 mt -62.11 -39.9 85.54 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.823 0 CA-C-N 115.43 -0.805 . . . . 0.0 111.972 -179.163 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.425 ' HG3' ' O ' ' A' ' 41' ' ' LYS . 76.8 mt-10 -62.0 -50.46 71.96 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 123.157 0.583 . . . . 0.0 112.108 179.582 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.482 ' HD3' ' O ' ' A' ' 42' ' ' GLY . 13.3 mptt -73.0 -28.11 62.18 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.52 -171.536 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.1 m -85.15 -41.06 16.02 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 122.815 0.446 . . . . 0.0 110.291 177.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.2 t -127.03 103.58 23.39 Favored Pre-proline 0 N--CA 1.483 1.213 0 C-N-CA 124.117 0.967 . . . . 0.0 109.772 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -66.91 136.58 41.99 Favored 'Trans proline' 0 C--N 1.374 1.906 0 C-N-CA 122.772 2.315 . . . . 0.0 111.684 172.037 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.18 -4.74 67.73 Favored Glycine 0 C--N 1.346 1.084 0 CA-C-O 119.769 -0.462 . . . . 0.0 113.948 175.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -77.61 106.68 9.56 Favored 'General case' 0 C--N 1.351 0.649 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 173.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.423 ' O ' ' HA ' ' A' ' 64' ' ' VAL . . . -77.15 99.52 5.43 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -177.063 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.41 HG12 HG12 ' A' ' 64' ' ' VAL . 27.7 m -85.28 127.45 39.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 123.123 0.569 . . . . 0.0 110.886 -171.089 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . 0.411 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 29.2 t60 -131.62 96.95 4.08 Favored 'General case' 0 C--N 1.345 0.391 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 176.069 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.612 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -93.6 113.59 25.73 Favored 'General case' 0 C--O 1.241 0.646 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 176.031 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -99.66 114.83 65.86 Favored Pre-proline 0 N--CA 1.468 0.433 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 -177.397 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -60.52 -40.4 57.12 Favored 'Trans proline' 0 C--N 1.373 1.829 0 C-N-CA 123.011 2.474 . . . . 0.0 112.767 -176.234 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -74.31 -47.8 32.4 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 123.619 0.767 . . . . 0.0 111.31 -176.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.1 m -81.26 -15.65 54.94 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.7 0.8 . . . . 0.0 111.455 -176.111 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.7 mmt180 62.97 29.43 16.46 Favored 'General case' 0 N--CA 1.487 1.421 0 C-N-CA 124.63 1.172 . . . . 0.0 111.437 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 33.2 m -122.79 122.76 39.47 Favored 'General case' 0 N--CA 1.479 1.017 0 O-C-N 121.825 -0.547 . . . . 0.0 111.521 -169.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.709 HG21 HG21 ' A' ' 40' ' ' ILE . 40.5 t -99.11 106.4 18.86 Favored 'Isoleucine or valine' 0 C--N 1.35 0.608 0 C-N-CA 123.943 0.897 . . . . 0.0 108.977 173.279 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 19.0 t -100.41 123.2 53.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.617 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.585 HG21 HG21 ' A' ' 73' ' ' ILE . 17.0 m -111.56 108.94 26.77 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.994 0 CA-C-O 121.475 0.655 . . . . 0.0 110.158 179.393 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.44 150.84 21.03 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.549 -176.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.13 -23.67 30.4 Favored Glycine 0 C--N 1.344 0.984 0 C-N-CA 123.104 0.383 . . . . 0.0 113.051 177.037 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 22.4 m -105.54 151.13 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 C-N-CA 123.969 0.908 . . . . 0.0 110.151 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.0 m -126.84 -2.55 6.57 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 124.005 0.922 . . . . 0.0 110.36 -178.658 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -87.35 73.0 9.71 Favored 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 124.54 1.136 . . . . 0.0 110.247 -177.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.401 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -64.01 -29.17 70.35 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 114.907 -1.042 . . . . 0.0 112.453 -174.747 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -63.76 -49.37 73.25 Favored 'General case' 0 N--CA 1.474 0.745 0 O-C-N 123.799 0.687 . . . . 0.0 110.863 177.545 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.5 ' O ' HG13 ' A' ' 76' ' ' ILE . 39.9 m170 -59.41 -54.93 41.05 Favored 'General case' 0 N--CA 1.478 0.957 0 O-C-N 123.488 0.493 . . . . 0.0 110.474 177.772 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.585 HG21 HG21 ' A' ' 64' ' ' VAL . 41.4 mm -57.74 -40.27 74.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 O-C-N 124.343 1.027 . . . . 0.0 110.811 -174.352 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.33 -40.11 89.47 Favored 'General case' 0 N--CA 1.48 1.029 0 O-C-N 124.039 0.837 . . . . 0.0 111.397 178.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -68.3 -32.05 71.92 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 123.181 0.593 . . . . 0.0 111.291 178.071 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.5 HG13 ' O ' ' A' ' 72' ' ' HIS . 37.5 mt -74.77 -48.62 32.99 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 C-N-CA 122.951 0.5 . . . . 0.0 111.245 -177.125 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 73' ' ' ILE . 8.5 tt -67.38 -32.36 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 C-N-CA 123.254 0.622 . . . . 0.0 111.253 -177.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -75.12 -31.02 61.01 Favored 'General case' 0 CA--C 1.549 0.917 0 N-CA-C 110.399 -0.223 . . . . 0.0 110.399 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -69.0 -18.46 64.05 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.494 0.718 . . . . 0.0 111.737 176.115 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.501 ' HB1' HG12 ' A' ' 39' ' ' VAL . . . -75.91 0.67 17.48 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 123.645 0.778 . . . . 0.0 112.269 176.414 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 95.84 16.97 37.0 Favored Glycine 0 C--N 1.35 1.328 0 C-N-CA 122.801 0.239 . . . . 0.0 112.544 179.63 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -120.76 178.38 4.72 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.361 1.065 . . . . 0.0 109.714 -177.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 39.3 m -139.41 111.83 7.78 Favored Pre-proline 0 N--CA 1.479 0.977 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 173.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -66.47 120.33 7.45 Favored 'Trans proline' 0 C--N 1.381 2.285 0 C-N-CA 122.423 2.082 . . . . 0.0 110.779 171.458 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.3 pt-20 . . . . . 0 C--O 1.251 1.166 0 C-N-CA 124.212 1.005 . . . . 0.0 109.526 -175.652 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.585 ' N ' ' HG ' ' A' ' 68' ' ' SER . . . . . . . . 0 N--CA 1.479 1.02 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -124.8 97.22 0.53 Allowed Glycine 0 C--N 1.343 0.961 0 N-CA-C 110.971 -0.851 . . . . 0.0 110.971 179.122 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -87.65 115.62 25.22 Favored 'General case' 0 N--CA 1.479 1.025 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -173.224 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 76.4 p -91.06 121.45 32.87 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 123.363 0.665 . . . . 0.0 111.337 -176.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -106.89 130.27 54.59 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.783 0.833 . . . . 0.0 109.563 175.546 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 9.8 m-70 -90.46 120.64 31.74 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 173.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.475 HG21 HD13 ' A' ' 40' ' ' ILE . 25.7 t -111.24 91.77 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 N-CA-C 104.765 -2.309 . . . . 0.0 104.765 160.413 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -68.62 -16.29 63.8 Favored 'General case' 0 CA--C 1.548 0.881 0 N-CA-C 113.316 0.858 . . . . 0.0 113.316 -159.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -109.7 8.78 24.91 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.258 0.623 . . . . 0.0 111.472 -178.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 56.8 ttp -73.91 99.05 3.14 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.61 0.764 . . . . 0.0 109.843 176.06 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.0 t -101.3 104.57 15.59 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 123.103 0.561 . . . . 0.0 109.569 178.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.462 ' HA ' ' HB3' ' A' ' 57' ' ' PRO . 17.0 t 64.83 -170.99 0.19 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 124.382 1.073 . . . . 0.0 111.888 176.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.574 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -62.27 -6.36 10.33 Favored Glycine 0 C--N 1.355 1.599 0 CA-C-O 119.203 -0.776 . . . . 0.0 114.391 178.379 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 41.2 m80 -50.22 -40.17 46.62 Favored 'General case' 0 C--N 1.365 1.278 0 C-N-CA 124.274 1.03 . . . . 0.0 111.736 172.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 41.9 t -118.83 -31.6 4.75 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.151 0.58 . . . . 0.0 110.892 176.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.574 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -57.91 -34.16 69.54 Favored 'General case' 0 N--CA 1.481 1.109 0 C-N-CA 123.458 0.703 . . . . 0.0 112.699 -176.092 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -58.7 -52.45 53.02 Favored Glycine 0 C--N 1.348 1.246 0 O-C-N 123.842 0.713 . . . . 0.0 114.347 -177.106 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.3 p -69.83 -30.53 44.85 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 C-N-CA 123.012 0.525 . . . . 0.0 111.561 -177.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.651 HG21 HG21 ' A' ' 62' ' ' VAL . 83.4 mt -70.23 -47.21 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 123.082 0.553 . . . . 0.0 110.666 179.216 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -61.38 -44.24 97.5 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 123.639 0.775 . . . . 0.0 110.467 178.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.14 -36.43 93.23 Favored Glycine 0 C--N 1.348 1.197 0 O-C-N 124.202 0.939 . . . . 0.0 112.899 176.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.05 -53.77 50.91 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 123.376 0.671 . . . . 0.0 110.878 -178.359 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.546 HG21 HG11 ' A' ' 64' ' ' VAL . 64.0 mt -72.82 -46.27 53.6 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.936 -175.007 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -66.93 -39.23 87.29 Favored 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 123.551 0.74 . . . . 0.0 112.249 -172.146 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.1 mptp? -83.58 -14.34 52.32 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -176.652 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 54.5 m -90.24 -39.06 13.01 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 122.98 0.512 . . . . 0.0 109.802 173.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 91.4 t -121.01 96.38 48.57 Favored Pre-proline 0 N--CA 1.48 1.028 0 C-N-CA 123.939 0.896 . . . . 0.0 109.323 -179.538 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.93 113.0 3.26 Favored 'Trans proline' 0 C--N 1.37 1.662 0 C-N-CA 122.346 2.031 . . . . 0.0 110.589 175.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.39 -11.42 9.75 Favored Glycine 0 C--N 1.34 0.799 0 CA-C-O 119.575 -0.57 . . . . 0.0 112.722 -176.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -78.42 106.89 10.67 Favored 'General case' 0 C--N 1.356 0.871 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 171.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.72 99.09 4.97 Favored 'General case' 0 C--N 1.349 0.577 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.0 m -85.49 123.63 39.5 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 CA-C-O 121.023 0.439 . . . . 0.0 110.155 -172.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 71.9 t60 -131.79 97.88 4.31 Favored 'General case' 0 C--N 1.343 0.32 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -176.496 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.4 114.52 28.86 Favored 'General case' 0 C--O 1.238 0.492 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -178.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.426 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 13.5 t70 -99.56 127.12 35.08 Favored Pre-proline 0 CA--C 1.54 0.586 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -177.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.462 ' HB3' ' HA ' ' A' ' 33' ' ' CYS . 30.8 Cg_endo -61.62 -41.16 41.32 Favored 'Trans proline' 0 C--N 1.377 2.074 0 C-N-CA 123.105 2.537 . . . . 0.0 113.23 179.264 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.19 -35.28 48.8 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.728 0.811 . . . . 0.0 111.944 -174.521 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.426 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 19.2 m -88.83 -22.07 23.39 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.443 0.697 . . . . 0.0 111.061 -177.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 3.5 mpt_? 57.99 41.07 24.9 Favored 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 124.653 1.181 . . . . 0.0 110.744 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 80.8 m -132.81 121.83 23.56 Favored 'General case' 0 CA--C 1.545 0.767 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.882 -171.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.651 HG21 HG21 ' A' ' 40' ' ' ILE . 21.1 t -98.89 104.7 16.32 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 C-N-CA 124.426 1.091 . . . . 0.0 108.638 173.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.8 t -95.48 131.35 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 108.023 -1.102 . . . . 0.0 108.023 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.546 HG11 HG21 ' A' ' 44' ' ' ILE . 26.2 m -111.58 109.97 30.46 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.869 0 CA-C-O 121.636 0.731 . . . . 0.0 109.84 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -89.77 149.83 20.73 Favored Glycine 0 C--N 1.346 1.1 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.733 -174.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 86.3 -20.04 24.03 Favored Glycine 0 C--N 1.341 0.84 0 C-N-CA 123.055 0.359 . . . . 0.0 112.879 -178.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 30.3 m -123.75 145.96 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 124.46 1.104 . . . . 0.0 108.881 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.585 ' HG ' ' N ' ' A' ' 22' ' ' ALA . 19.6 m -130.19 -6.63 4.34 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 123.545 0.738 . . . . 0.0 111.302 -176.601 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -75.88 84.24 2.81 Favored 'General case' 0 CA--C 1.55 0.96 0 CA-C-O 122.338 1.066 . . . . 0.0 110.351 -178.095 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.81 -40.55 95.65 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 113.911 -1.495 . . . . 0.0 112.869 -171.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -58.75 -46.88 86.43 Favored 'General case' 0 N--CA 1.479 0.994 0 O-C-N 124.11 0.881 . . . . 0.0 111.882 -176.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 72.7 t60 -66.97 -50.78 61.24 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.023 -178.324 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 36.8 mm -59.88 -37.35 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 O-C-N 123.67 0.606 . . . . 0.0 110.407 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.43 -37.71 88.36 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 123.858 0.863 . . . . 0.0 111.736 -179.522 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 45.0 mm-40 -65.07 -35.86 82.5 Favored 'General case' 0 N--CA 1.476 0.825 0 O-C-N 123.685 0.615 . . . . 0.0 111.036 176.465 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 62.3 mt -67.99 -49.46 68.11 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.236 0 C-N-CA 123.112 0.565 . . . . 0.0 111.495 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.4 tt -71.4 -35.42 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 C-N-CA 123.182 0.593 . . . . 0.0 111.516 -176.341 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.2 t -71.63 -28.86 64.07 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 176.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.72 -26.8 65.44 Favored 'General case' 0 C--N 1.358 0.963 0 C-N-CA 123.592 0.757 . . . . 0.0 111.006 173.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.92 -3.16 33.89 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.513 0.725 . . . . 0.0 111.822 174.052 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 94.51 12.69 55.59 Favored Glycine 0 C--N 1.348 1.221 0 CA-C-O 119.713 -0.493 . . . . 0.0 113.058 175.437 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 87.7 m-85 -128.5 105.81 8.56 Favored 'General case' 0 N--CA 1.483 1.224 0 CA-C-N 117.401 0.601 . . . . 0.0 109.919 179.247 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.9 t -76.4 123.93 87.92 Favored Pre-proline 0 CA--C 1.556 1.173 0 C-N-CA 123.253 0.621 . . . . 0.0 110.619 -178.099 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -79.08 173.99 12.71 Favored 'Trans proline' 0 C--N 1.373 1.824 0 C-N-CA 122.695 2.264 . . . . 0.0 111.37 168.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 . . . . . 0 C--O 1.25 1.118 0 C-N-CA 123.444 0.698 . . . . 0.0 109.331 -177.225 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -173.29 -101.79 0.15 Allowed Glycine 0 C--N 1.344 1.016 0 CA-C-N 115.793 -0.64 . . . . 0.0 112.038 -179.097 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -134.93 132.44 38.45 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-N 117.245 0.523 . . . . 0.0 109.826 -172.684 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.6 t -104.55 134.45 47.71 Favored 'General case' 0 CA--C 1.548 0.892 0 C-N-CA 123.911 0.885 . . . . 0.0 110.709 -177.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -135.59 118.97 16.77 Favored 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 124.156 0.982 . . . . 0.0 109.237 173.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.55 ' HA ' ' HA ' ' A' ' 61' ' ' THR . 35.2 p-80 -92.26 118.38 30.82 Favored 'General case' 0 N--CA 1.477 0.898 0 CA-C-N 118.657 0.662 . . . . 0.0 109.984 175.32 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.423 HG22 ' HA ' ' A' ' 84' ' ' PRO . 39.7 t -96.27 97.22 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 170.613 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -61.01 -26.92 67.94 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 123.556 0.743 . . . . 0.0 111.864 -176.375 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -80.16 -19.69 46.58 Favored 'General case' 0 CA--C 1.553 1.061 0 C-N-CA 124.147 0.979 . . . . 0.0 111.496 -178.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 62.9 ttp -68.7 129.72 40.75 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 123.655 0.782 . . . . 0.0 112.235 -175.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.3 p -85.43 169.88 13.23 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 124.333 1.053 . . . . 0.0 109.987 170.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 35.0 t -56.11 -151.7 0.0 OUTLIER 'General case' 0 CA--C 1.581 2.159 0 C-N-CA 125.078 1.351 . . . . 0.0 113.178 178.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -62.0 -2.66 3.99 Favored Glycine 0 C--N 1.356 1.688 0 N-CA-C 116.144 1.218 . . . . 0.0 116.144 -171.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -77.28 -22.79 51.54 Favored 'General case' 0 CA--C 1.552 1.021 0 CA-C-N 117.67 0.735 . . . . 0.0 112.208 178.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 19.3 p -124.41 -5.59 7.69 Favored 'General case' 0 N--CA 1.489 1.508 0 C-N-CA 122.439 0.296 . . . . 0.0 111.597 177.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -64.65 -31.16 72.26 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.416 0.686 . . . . 0.0 112.498 -175.132 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.08 -50.46 67.58 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 114.565 0.586 . . . . 0.0 114.565 -174.052 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.3 m -66.35 -31.97 55.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 123.093 0.557 . . . . 0.0 112.119 -178.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.442 HG21 HG21 ' A' ' 62' ' ' VAL . 76.1 mt -72.22 -54.97 14.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.694 0 C-N-CA 123.884 0.874 . . . . 0.0 110.17 -177.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -61.33 -42.51 98.8 Favored 'General case' 0 CA--C 1.537 0.456 0 CA-C-N 114.343 -1.299 . . . . 0.0 110.79 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -68.07 -34.01 80.34 Favored Glycine 0 C--N 1.342 0.897 0 O-C-N 124.16 0.913 . . . . 0.0 113.131 -178.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -65.08 -53.75 40.74 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.789 0.435 . . . . 0.0 110.514 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.577 ' HA ' HG21 ' A' ' 76' ' ' ILE . 62.9 mt -63.98 -40.87 90.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.719 -178.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -64.68 -43.67 92.81 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.308 0.643 . . . . 0.0 111.549 -179.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -81.76 -18.56 43.79 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -175.108 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 36.8 m -87.26 -40.98 14.03 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 175.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.7 t -121.83 88.9 47.69 Favored Pre-proline 0 N--CA 1.48 1.069 0 C-N-CA 123.872 0.869 . . . . 0.0 108.831 174.067 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -60.94 113.18 1.61 Allowed 'Trans proline' 0 C--N 1.375 1.93 0 C-N-CA 122.632 2.222 . . . . 0.0 111.588 175.01 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.5 -5.37 11.86 Favored Glycine 0 C--N 1.341 0.856 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.804 -176.163 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -78.07 106.84 10.21 Favored 'General case' 0 C--O 1.239 0.537 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 173.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.03 96.82 3.88 Favored 'General case' 0 C--N 1.351 0.658 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.454 HG12 HG12 ' A' ' 64' ' ' VAL . 7.8 m -88.85 134.83 27.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.729 -172.505 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -142.08 101.45 3.93 Favored 'General case' 0 C--N 1.352 0.684 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 176.621 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.12 114.69 22.44 Favored 'General case' 0 CA--C 1.541 0.607 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 173.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.401 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 10.2 t70 -93.41 130.35 35.79 Favored Pre-proline 0 CA--C 1.542 0.666 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 -175.071 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 56' ' ' ASP . 27.6 Cg_exo -64.86 -53.65 0.88 Allowed 'Trans proline' 0 C--N 1.372 1.797 0 C-N-CA 122.634 2.223 . . . . 0.0 113.058 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.82 -36.02 50.66 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.266 -170.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 26.3 t -87.6 -18.25 30.1 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 123.432 0.693 . . . . 0.0 110.685 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.419 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 10.4 mpt_? 60.94 31.36 19.97 Favored 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 124.467 1.107 . . . . 0.0 111.268 -176.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 27' ' ' HIS . 53.8 m -116.53 122.45 44.74 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -168.534 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.442 HG21 HG21 ' A' ' 40' ' ' ILE . 31.6 t -96.75 106.38 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 172.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 18.8 t -102.24 131.83 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.53 HG21 HG13 ' A' ' 73' ' ' ILE . 35.6 m -105.43 139.41 26.61 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 C-N-CA 123.422 0.689 . . . . 0.0 109.535 174.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -118.36 151.03 18.0 Favored Glycine 0 C--N 1.341 0.859 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.058 -175.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 79.32 -12.04 27.98 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-O 120.142 -0.255 . . . . 0.0 113.092 -177.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 33.3 m -132.65 131.12 59.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 C-N-CA 124.406 1.083 . . . . 0.0 108.787 -178.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 26.9 t -112.43 10.67 19.81 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 123.657 0.783 . . . . 0.0 110.121 -177.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.41 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 3.2 m-20 -70.57 87.37 0.66 Allowed 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 124.14 0.976 . . . . 0.0 110.922 -176.069 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.5 -58.16 9.65 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 122.793 0.437 . . . . 0.0 112.168 -173.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -64.66 -36.42 84.2 Favored 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 123.048 0.539 . . . . 0.0 111.648 -175.51 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.417 ' O ' HG13 ' A' ' 76' ' ' ILE . 65.2 m170 -65.29 -55.38 18.64 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 123.029 0.532 . . . . 0.0 111.111 -179.522 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.53 HG13 HG21 ' A' ' 64' ' ' VAL . 47.8 mm -60.93 -40.26 84.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 O-C-N 123.856 0.723 . . . . 0.0 110.316 -177.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.0 -38.38 82.45 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.17 0.988 . . . . 0.0 111.707 179.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 35.5 mm-40 -69.14 -35.93 76.89 Favored 'General case' 0 N--CA 1.475 0.822 0 O-C-N 123.511 0.507 . . . . 0.0 111.768 179.095 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.577 HG21 ' HA ' ' A' ' 44' ' ' ILE . 43.9 mt -65.82 -50.24 71.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 CA-C-O 121.152 0.501 . . . . 0.0 110.863 -178.402 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.415 ' HB ' HD11 ' A' ' 44' ' ' ILE . 12.3 tt -73.75 -32.81 36.03 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 CA-C-N 115.138 -0.937 . . . . 0.0 111.885 -173.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.1 t -72.76 -29.63 63.47 Favored 'General case' 0 N--CA 1.484 1.245 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 174.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.41 -28.93 67.51 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.179 0.592 . . . . 0.0 110.589 173.063 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.24 -5.94 47.14 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 123.538 0.735 . . . . 0.0 111.755 175.615 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 89.91 21.16 40.37 Favored Glycine 0 C--N 1.348 1.214 0 O-C-N 123.141 0.275 . . . . 0.0 112.993 176.67 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -128.02 114.49 17.17 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 123.472 0.709 . . . . 0.0 109.381 178.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.3 t -70.28 114.13 23.41 Favored Pre-proline 0 CA--C 1.561 1.383 0 C-N-CA 123.332 0.653 . . . . 0.0 111.117 -176.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.423 ' HA ' HG22 ' A' ' 28' ' ' VAL . 73.5 Cg_endo -71.53 -19.26 28.57 Favored 'Trans proline' 0 C--N 1.384 2.415 0 C-N-CA 122.856 2.37 . . . . 0.0 112.836 -177.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 . . . . . 0 C--O 1.246 0.896 0 C-N-CA 124.319 1.048 . . . . 0.0 108.8 -178.436 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.187 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 69.4 -158.48 53.28 Favored Glycine 0 C--N 1.351 1.403 0 O-C-N 123.365 0.416 . . . . 0.0 113.573 176.312 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 72.5 mt -108.29 107.55 18.2 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 123.714 0.806 . . . . 0.0 109.059 177.629 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 36.4 m -95.35 114.16 25.91 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.232 0.613 . . . . 0.0 110.822 -173.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -109.72 106.45 16.1 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 123.97 0.908 . . . . 0.0 110.481 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 16.3 m-70 -83.1 91.31 7.19 Favored 'General case' 0 N--CA 1.479 0.976 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 176.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.445 HG11 ' HB3' ' A' ' 82' ' ' TYR . 47.7 t -82.29 97.58 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 176.434 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -66.33 -24.9 66.61 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 123.23 0.612 . . . . 0.0 112.346 -171.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -87.74 -11.66 47.53 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 122.97 0.508 . . . . 0.0 111.636 177.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.539 ' HG3' ' HB2' ' A' ' 36' ' ' CYS . 13.0 ttt -71.38 137.99 48.82 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.157 0.583 . . . . 0.0 109.553 169.416 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.6 t -129.87 98.48 4.8 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 123.638 0.775 . . . . 0.0 109.911 176.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 59.6 m 54.64 -154.84 0.26 Allowed 'General case' 0 CA--C 1.557 1.244 0 C-N-CA 124.695 1.198 . . . . 0.0 112.843 173.236 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.537 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -58.06 -26.5 58.5 Favored Glycine 0 C--N 1.361 1.946 0 C-N-CA 123.697 0.665 . . . . 0.0 114.097 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 14.2 t-80 -56.54 -32.78 65.45 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 124.383 1.073 . . . . 0.0 111.793 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.539 ' HB2' ' HG3' ' A' ' 31' ' ' MET . 62.1 m -111.15 -18.18 13.05 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.181 0.592 . . . . 0.0 111.423 178.465 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.537 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -64.47 -47.16 80.02 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 123.231 0.612 . . . . 0.0 112.321 -176.247 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.26 -46.13 92.01 Favored Glycine 0 N--CA 1.475 1.281 0 O-C-N 123.995 0.809 . . . . 0.0 114.147 -172.424 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -68.22 -31.7 52.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.011 0 C-N-CA 123.626 0.77 . . . . 0.0 111.017 -179.404 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.785 HG21 HG21 ' A' ' 62' ' ' VAL . 65.8 mt -69.31 -43.99 80.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 123.641 0.777 . . . . 0.0 111.05 175.417 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.445 ' HG3' ' O ' ' A' ' 37' ' ' ALA . 95.1 mttt -58.2 -47.23 84.1 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 123.575 0.75 . . . . 0.0 109.546 -179.51 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.65 -36.14 92.95 Favored Glycine 0 C--N 1.348 1.234 0 O-C-N 124.466 1.104 . . . . 0.0 112.824 178.32 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.38 -55.5 27.32 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 122.852 0.461 . . . . 0.0 111.142 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.502 HG21 HG11 ' A' ' 64' ' ' VAL . 57.6 mt -69.74 -47.12 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.743 -176.109 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.0 tp10 -57.84 -50.07 74.55 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.038 0.935 . . . . 0.0 111.955 -176.149 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -70.52 -26.44 63.58 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.032 -174.357 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 47.4 m -86.13 -42.22 14.06 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.733 0.413 . . . . 0.0 110.995 -178.196 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.9 m -132.05 86.44 47.15 Favored Pre-proline 0 CA--C 1.561 1.37 0 C-N-CA 123.752 0.821 . . . . 0.0 110.702 -179.41 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -56.63 123.97 15.12 Favored 'Trans proline' 0 C--N 1.377 2.04 0 C-N-CA 123.039 2.492 . . . . 0.0 111.372 169.475 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.79 -22.34 8.17 Favored Glycine 0 N--CA 1.473 1.116 0 CA-C-O 119.979 -0.345 . . . . 0.0 112.313 -175.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -75.1 106.94 6.85 Favored 'General case' 0 C--N 1.355 0.808 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 175.671 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.09 100.77 9.2 Favored 'General case' 0 C--N 1.342 0.275 0 C-N-CA 123.729 0.812 . . . . 0.0 109.488 -177.43 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.485 HG12 HG12 ' A' ' 64' ' ' VAL . 35.2 m -84.57 134.59 26.65 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 C-N-CA 123.059 0.543 . . . . 0.0 110.16 -172.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 48.4 t-80 -136.36 97.49 3.6 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 172.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.2 114.33 26.84 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -86.29 123.71 71.09 Favored Pre-proline 0 CA--C 1.542 0.64 0 CA-C-O 118.567 -0.73 . . . . 0.0 109.058 -173.222 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.47 ' HA ' ' HA ' ' A' ' 33' ' ' CYS . 21.5 Cg_endo -58.84 -45.67 27.54 Favored 'Trans proline' 0 C--N 1.372 1.81 0 C-N-CA 122.863 2.375 . . . . 0.0 112.861 179.118 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -78.31 -45.88 21.57 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.411 0.685 . . . . 0.0 111.815 -173.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 17.0 m -90.05 -5.8 56.21 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 123.479 0.712 . . . . 0.0 112.285 -172.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 40.69 45.01 1.96 Allowed 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 125.676 1.59 . . . . 0.0 112.548 -172.329 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 59.2 m -114.39 118.58 34.24 Favored 'General case' 0 C--N 1.346 0.444 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.413 -175.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.785 HG21 HG21 ' A' ' 40' ' ' ILE . 27.9 t -97.32 105.84 17.71 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 177.147 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 21.6 t -98.56 119.46 46.58 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 C-N-CA 123.956 0.903 . . . . 0.0 109.333 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.502 HG11 HG21 ' A' ' 44' ' ' ILE . 28.2 m -110.09 112.07 38.91 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.865 0 CA-C-O 121.562 0.696 . . . . 0.0 110.712 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.4 170.16 31.03 Favored Glycine 0 C--N 1.344 1.007 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.603 176.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 77.73 -5.92 49.9 Favored Glycine 0 N--CA 1.472 1.066 0 N-CA-C 114.069 0.388 . . . . 0.0 114.069 177.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 18.1 m -128.89 148.37 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 124.773 1.229 . . . . 0.0 109.415 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.3 t -114.47 0.15 13.94 Favored 'General case' 0 N--CA 1.482 1.159 0 C-N-CA 123.604 0.761 . . . . 0.0 110.366 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.436 ' O ' HG12 ' A' ' 73' ' ' ILE . 3.4 m-20 -91.18 70.95 6.24 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.099 0.959 . . . . 0.0 110.231 -169.703 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.94 -49.78 76.55 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 123.409 0.684 . . . . 0.0 112.575 -174.163 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.66 91.09 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.69 0.796 . . . . 0.0 111.511 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 74.8 t60 -66.39 -46.7 75.76 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.017 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.501 HG21 HG21 ' A' ' 64' ' ' VAL . 47.4 mm -60.59 -39.15 80.48 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 O-C-N 123.702 0.626 . . . . 0.0 109.671 177.589 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -58.07 -38.71 76.86 Favored 'General case' 0 N--CA 1.473 0.682 0 O-C-N 124.147 0.905 . . . . 0.0 111.641 178.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -67.94 -38.48 82.89 Favored 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 123.261 0.624 . . . . 0.0 111.192 176.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.475 HG21 ' HA ' ' A' ' 44' ' ' ILE . 64.7 mt -68.46 -50.04 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 C-N-CA 123.279 0.631 . . . . 0.0 111.528 -177.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.454 HG13 HG23 ' A' ' 40' ' ' ILE . 13.5 tt -69.37 -35.3 66.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 123.373 0.669 . . . . 0.0 111.318 -175.812 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.4 t -70.11 -29.32 66.24 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 122.207 0.203 . . . . 0.0 110.527 176.43 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.31 -17.48 64.78 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 123.51 0.724 . . . . 0.0 112.23 176.167 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -85.98 5.12 34.72 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.574 0.749 . . . . 0.0 111.355 172.408 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.36 2.55 79.71 Favored Glycine 0 C--N 1.347 1.171 0 CA-C-O 119.424 -0.653 . . . . 0.0 113.697 178.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.445 ' HB3' HG11 ' A' ' 28' ' ' VAL . 84.2 m-85 -119.16 105.48 11.42 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 117.917 0.858 . . . . 0.0 109.651 -177.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 9.0 t -86.87 127.72 58.79 Favored Pre-proline 0 CA--C 1.55 0.959 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.88 -170.483 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.414 ' HD3' HG23 ' A' ' 77' ' ' ILE . 57.3 Cg_endo -69.97 -36.97 9.32 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.529 2.153 . . . . 0.0 112.159 177.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.5 mm-40 . . . . . 0 C--O 1.251 1.142 0 C-N-CA 125.078 1.351 . . . . 0.0 111.302 -177.967 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.93 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -101.84 -162.52 26.84 Favored Glycine 0 C--N 1.347 1.162 0 C-N-CA 123.086 0.375 . . . . 0.0 112.549 178.653 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.5 HD13 ' HA ' ' A' ' 70' ' ' ALA . 25.1 mt -96.74 108.61 21.29 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.857 0.863 . . . . 0.0 110.34 -175.616 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 32.2 t -86.92 119.68 27.4 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 123.275 0.63 . . . . 0.0 109.913 177.655 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -112.79 118.02 33.8 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.558 0.743 . . . . 0.0 109.658 175.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 44.9 p-80 -83.75 88.3 7.08 Favored 'General case' 0 CA--C 1.546 0.817 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 175.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.52 ' HB ' ' HB2' ' A' ' 31' ' ' MET . 35.3 t -80.79 104.39 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -172.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -73.31 -16.44 61.37 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 115.668 -0.696 . . . . 0.0 112.051 -175.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.408 ' HB3' ' H ' ' A' ' 83' ' ' THR . 35.8 t70 -106.71 16.33 24.59 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 123.361 0.664 . . . . 0.0 110.534 179.325 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.52 ' HB2' ' HB ' ' A' ' 28' ' ' VAL . 25.1 ttt -71.31 136.13 47.72 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-O 121.012 0.434 . . . . 0.0 111.516 -176.432 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 20.3 p -86.88 162.04 17.95 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.16 0.984 . . . . 0.0 110.913 173.187 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 61.2 m -74.89 -167.41 0.58 Allowed 'General case' 0 CA--C 1.561 1.376 0 C-N-CA 123.663 0.785 . . . . 0.0 111.756 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -57.66 -29.04 60.73 Favored Glycine 0 C--N 1.355 1.635 0 N-CA-C 115.695 1.038 . . . . 0.0 115.695 -172.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -69.3 -22.92 63.76 Favored 'General case' 0 N--CA 1.486 1.364 0 CA-C-N 117.428 0.614 . . . . 0.0 112.371 -176.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 66.7 m -123.24 13.14 9.59 Favored 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 123.636 0.774 . . . . 0.0 110.955 176.567 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -65.97 -41.64 90.9 Favored 'General case' 0 C--N 1.357 0.922 0 C-N-CA 123.131 0.572 . . . . 0.0 111.392 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.38 -25.61 67.02 Favored Glycine 0 N--CA 1.473 1.129 0 O-C-N 123.134 0.271 . . . . 0.0 113.699 -179.204 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.75 -50.07 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 123.404 0.682 . . . . 0.0 110.808 177.671 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 15.1 tt -67.99 -32.95 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 C-N-CA 123.025 0.53 . . . . 0.0 110.596 -177.429 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.421 ' HB3' HG21 ' A' ' 53' ' ' VAL . 96.1 mttt -64.23 -53.17 53.29 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 123.634 0.774 . . . . 0.0 109.56 168.478 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.409 ' HA2' ' HB3' ' A' ' 45' ' ' GLU . . . -59.06 -29.83 65.93 Favored Glycine 0 C--N 1.358 1.77 0 O-C-N 124.873 1.358 . . . . 0.0 114.046 -173.132 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.87 -54.15 48.05 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 123.818 0.847 . . . . 0.0 110.665 177.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.569 HG21 HG11 ' A' ' 64' ' ' VAL . 60.2 mt -75.21 -41.91 44.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.814 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.409 ' HB3' ' HA2' ' A' ' 42' ' ' GLY . 17.6 tp10 -54.26 -51.14 65.49 Favored 'General case' 0 N--CA 1.481 1.105 0 C-N-CA 125.418 1.487 . . . . 0.0 112.282 -174.632 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? -79.64 -25.85 41.25 Favored 'General case' 0 N--CA 1.483 1.176 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.84 -175.439 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 87.0 m -76.77 -48.14 19.56 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-O 120.814 0.34 . . . . 0.0 110.673 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.508 HG11 HG11 ' A' ' 67' ' ' VAL . 56.5 t -112.22 110.23 53.72 Favored Pre-proline 0 N--CA 1.475 0.78 0 C-N-CA 123.459 0.704 . . . . 0.0 109.432 -178.424 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -72.41 110.32 2.95 Favored 'Trans proline' 0 C--N 1.372 1.806 0 C-N-CA 122.403 2.069 . . . . 0.0 111.342 172.099 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 117.1 -2.57 19.16 Favored Glycine 0 C--N 1.342 0.867 0 CA-C-O 119.382 -0.677 . . . . 0.0 113.548 179.191 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -80.22 105.95 11.87 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 173.308 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.72 99.64 8.32 Favored 'General case' 0 C--N 1.346 0.44 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -177.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.479 HG12 HG12 ' A' ' 64' ' ' VAL . 29.3 m -84.74 129.43 37.71 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-O 121.235 0.54 . . . . 0.0 110.446 -174.077 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 63.8 t60 -125.61 97.97 5.38 Favored 'General case' 0 C--O 1.225 -0.213 0 N-CA-C 106.211 -1.774 . . . . 0.0 106.211 174.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -109.84 113.89 27.01 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 -179.176 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.413 ' HB3' ' HB2' ' A' ' 59' ' ' SER . 11.1 t70 -105.76 119.86 51.11 Favored Pre-proline 0 N--CA 1.468 0.469 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -175.126 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -63.37 -33.77 68.8 Favored 'Trans proline' 0 C--N 1.375 1.927 0 C-N-CA 122.989 2.459 . . . . 0.0 113.088 -176.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.88 -45.64 23.6 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 123.127 0.571 . . . . 0.0 111.083 -178.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.413 ' HB2' ' HB3' ' A' ' 56' ' ' ASP . 35.4 m -80.35 -23.95 40.18 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 123.253 0.621 . . . . 0.0 111.568 -174.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.457 ' HA ' ' SD ' ' A' ' 31' ' ' MET . 37.5 mmt180 65.08 35.41 8.01 Favored 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 124.71 1.204 . . . . 0.0 111.093 -177.464 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 11.9 m -122.8 117.97 26.89 Favored 'General case' 0 C--O 1.241 0.609 0 C-N-CA 123.029 0.532 . . . . 0.0 110.778 -171.058 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 45.9 t -103.76 106.71 20.72 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 172.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 24.9 t -105.11 130.25 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 124.452 1.101 . . . . 0.0 109.099 -179.238 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.569 HG11 HG21 ' A' ' 44' ' ' ILE . 17.6 m -117.63 109.52 27.79 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.023 0 CA-C-O 121.419 0.628 . . . . 0.0 111.107 -178.32 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -86.87 161.01 32.95 Favored Glycine 0 C--N 1.346 1.114 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.817 178.501 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 83.09 -11.3 55.37 Favored Glycine 0 N--CA 1.472 1.035 0 CA-C-O 119.806 -0.441 . . . . 0.0 113.62 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.508 HG11 HG11 ' A' ' 48' ' ' VAL . 30.6 m -128.89 150.85 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.272 0 C-N-CA 124.022 0.929 . . . . 0.0 109.935 -176.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 29.1 t -124.85 -2.89 7.75 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.749 0.82 . . . . 0.0 111.586 -174.199 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.508 ' HB3' ' HB3' ' A' ' 72' ' ' HIS . 6.1 m-20 -79.24 82.05 5.43 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 123.493 0.717 . . . . 0.0 109.999 -178.592 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.5 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -62.93 -49.28 75.39 Favored 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 123.231 0.612 . . . . 0.0 112.068 -172.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.463 ' O ' ' HG3' ' A' ' 75' ' ' GLU . . . -65.68 -39.35 91.23 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.62 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.508 ' HB3' ' HB3' ' A' ' 69' ' ' ASP . 79.5 t60 -70.25 -42.09 72.64 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 123.596 0.758 . . . . 0.0 112.239 -175.493 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.538 HG21 HG21 ' A' ' 64' ' ' VAL . 33.8 mm -63.74 -37.61 80.15 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 175.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.54 -33.31 74.65 Favored 'General case' 0 CA--C 1.546 0.791 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.226 176.44 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.463 ' HG3' ' O ' ' A' ' 71' ' ' ALA . 46.5 mt-10 -64.73 -41.41 95.98 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 123.191 0.596 . . . . 0.0 110.541 174.595 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 70.0 mt -69.46 -47.33 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 C-N-CA 123.406 0.682 . . . . 0.0 111.265 -175.222 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 15.1 tt -74.33 -26.85 20.84 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.02 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.179 -176.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.51 ' HA ' ' O ' ' A' ' 82' ' ' TYR . 2.3 t -75.69 -29.35 58.99 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 175.236 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.51 -18.28 64.35 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.681 0.792 . . . . 0.0 111.566 175.297 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -79.83 3.35 19.91 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 123.814 0.845 . . . . 0.0 112.219 174.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 88.32 5.56 75.75 Favored Glycine 0 C--N 1.349 1.255 0 CA-C-O 120.216 -0.213 . . . . 0.0 113.024 179.294 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.51 ' O ' ' HA ' ' A' ' 78' ' ' THR . 91.7 m-85 -100.13 162.22 13.11 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.897 0.879 . . . . 0.0 110.047 178.216 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.408 ' H ' ' HB3' ' A' ' 30' ' ' ASP . 32.4 p -121.52 103.31 41.32 Favored Pre-proline 0 CA--C 1.55 0.947 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 171.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -60.84 -40.24 55.31 Favored 'Trans proline' 0 C--N 1.387 2.602 0 C-N-CA 123.061 2.508 . . . . 0.0 112.33 175.505 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 64.7 mm-40 . . . . . 0 CA--C 1.552 1.041 0 C-N-CA 124.769 1.228 . . . . 0.0 110.755 -178.04 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.086 0 CA-C-O 121.173 0.511 . . . . 0.0 109.882 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 161.2 -156.98 28.52 Favored Glycine 0 C--N 1.339 0.733 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.381 -178.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.46 HD13 ' HA ' ' A' ' 70' ' ' ALA . 25.9 mt -92.14 115.09 27.78 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 123.912 0.885 . . . . 0.0 109.579 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 47.0 t -83.53 123.05 29.35 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 122.875 0.47 . . . . 0.0 110.24 -179.297 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -125.43 101.38 6.92 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 123.815 0.846 . . . . 0.0 109.032 174.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . 0.403 ' HA ' ' HA ' ' A' ' 61' ' ' THR . 9.5 p80 -93.82 100.15 12.39 Favored 'General case' 0 CA--C 1.547 0.843 0 CA-C-O 121.503 0.668 . . . . 0.0 110.384 -174.158 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.531 ' O ' ' HB3' ' A' ' 60' ' ' ARG . 92.0 t -82.34 106.04 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 172.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -79.63 -7.75 58.75 Favored 'General case' 0 N--CA 1.485 1.308 0 CA-C-N 118.292 0.496 . . . . 0.0 112.137 -176.281 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -95.15 12.29 29.25 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 123.638 0.775 . . . . 0.0 111.071 171.308 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.43 ' SD ' ' HA ' ' A' ' 60' ' ' ARG . 27.6 ttt -70.9 143.51 50.96 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.541 0.736 . . . . 0.0 111.764 -176.759 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 17.2 p -125.88 165.88 17.91 Favored 'General case' 0 C--O 1.243 0.725 0 C-N-CA 125.161 1.384 . . . . 0.0 108.61 176.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 31.6 p -53.41 179.51 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -173.136 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.503 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -43.94 -26.6 0.85 Allowed Glycine 0 C--N 1.36 1.881 0 N-CA-C 117.603 1.801 . . . . 0.0 117.603 -166.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 69.4 t60 -55.97 -54.77 40.73 Favored 'General case' 0 CA--C 1.547 0.845 0 C-N-CA 124.081 0.952 . . . . 0.0 111.061 176.109 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 42.6 t -96.91 -20.91 17.79 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.488 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.503 ' HB3' ' HA2' ' A' ' 34' ' ' GLY . . . -64.81 -36.04 83.03 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 123.068 0.547 . . . . 0.0 110.802 175.684 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.95 -24.82 73.17 Favored Glycine 0 C--N 1.347 1.143 0 CA-C-N 115.425 -0.807 . . . . 0.0 113.169 176.103 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 43.3 t -74.5 -38.95 47.24 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 C-N-CA 123.404 0.682 . . . . 0.0 110.237 176.094 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 22.5 mt -63.98 -47.42 90.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-O 121.455 0.645 . . . . 0.0 109.536 176.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.411 ' HZ3' HG23 ' A' ' 53' ' ' VAL . 9.4 mtpm? -59.23 -47.78 84.08 Favored 'General case' 0 C--N 1.35 0.588 0 CA-C-N 114.285 -1.325 . . . . 0.0 110.852 176.107 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -64.22 -33.03 86.14 Favored Glycine 0 C--N 1.345 1.081 0 O-C-N 124.502 1.126 . . . . 0.0 113.094 -175.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -60.49 -54.61 43.47 Favored 'General case' 0 C--N 1.348 0.515 0 C-N-CA 123.133 0.573 . . . . 0.0 110.521 178.264 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.5 HG21 HG11 ' A' ' 64' ' ' VAL . 54.7 mt -72.55 -45.72 57.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.804 -175.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -64.22 -41.14 97.15 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.947 0.899 . . . . 0.0 111.92 -171.228 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -76.22 -34.75 59.24 Favored 'General case' 0 N--CA 1.481 1.076 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.221 -178.634 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 86.7 m -72.91 -45.84 55.96 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 122.435 0.294 . . . . 0.0 110.744 -178.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 78.0 t -120.5 94.23 48.7 Favored Pre-proline 0 N--CA 1.478 0.933 0 C-N-CA 123.679 0.791 . . . . 0.0 109.054 176.725 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_exo -64.12 123.87 12.57 Favored 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 122.549 2.166 . . . . 0.0 110.622 169.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 119.68 -20.28 9.45 Favored Glycine 0 C--N 1.341 0.834 0 N-CA-C 112.108 -0.397 . . . . 0.0 112.108 -174.364 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -79.72 105.7 11.21 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 174.419 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.36 98.25 8.09 Favored 'General case' 0 C--N 1.342 0.259 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -178.026 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.597 HG12 HG12 ' A' ' 64' ' ' VAL . 15.6 m -85.06 116.07 27.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.702 0 C-N-CA 123.513 0.725 . . . . 0.0 110.097 -172.449 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 54.9 t-80 -112.55 99.22 7.79 Favored 'General case' 0 C--N 1.347 0.472 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 176.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -84.34 127.68 34.13 Favored 'General case' 0 C--O 1.237 0.439 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 175.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -111.2 108.11 57.22 Favored Pre-proline 0 CA--C 1.537 0.471 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 175.147 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -64.03 -33.48 62.18 Favored 'Trans proline' 0 C--N 1.367 1.521 0 C-N-CA 122.678 2.252 . . . . 0.0 112.86 -178.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.76 -39.67 43.48 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 123.46 0.704 . . . . 0.0 111.85 -175.209 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.3 t -92.82 -15.02 26.99 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 123.712 0.805 . . . . 0.0 110.851 -178.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.531 ' HB3' ' O ' ' A' ' 28' ' ' VAL . 0.0 OUTLIER 63.52 45.26 4.82 Favored 'General case' 0 CA--C 1.554 1.1 0 C-N-CA 124.452 1.101 . . . . 0.0 110.421 -179.272 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.403 ' HA ' ' HA ' ' A' ' 27' ' ' HIS . 17.8 m -132.85 120.9 22.15 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 112.301 0.482 . . . . 0.0 112.301 -170.72 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 47.4 t -104.18 108.28 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 C-N-CA 123.686 0.794 . . . . 0.0 109.458 173.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 43.1 t -104.07 121.59 55.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 123.893 0.877 . . . . 0.0 109.551 -177.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.597 HG12 HG12 ' A' ' 53' ' ' VAL . 27.0 m -102.45 114.43 41.9 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 CA-C-O 121.427 0.632 . . . . 0.0 111.151 -176.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.83 160.37 24.21 Favored Glycine 0 C--N 1.348 1.227 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.064 179.129 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 83.22 -11.75 53.64 Favored Glycine 0 N--CA 1.474 1.232 0 CA-C-N 116.695 0.248 . . . . 0.0 113.68 177.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 31.3 m -126.62 142.22 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 124.474 1.11 . . . . 0.0 109.064 178.665 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 18.2 m -113.25 3.59 16.06 Favored 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 123.352 0.661 . . . . 0.0 110.487 178.403 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -82.44 79.18 8.95 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.129 0.972 . . . . 0.0 110.432 -174.39 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.46 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -63.77 -37.92 89.18 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 122.86 0.464 . . . . 0.0 111.719 -175.479 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.502 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -65.44 -47.19 77.02 Favored 'General case' 0 N--CA 1.475 0.818 0 O-C-N 123.551 0.532 . . . . 0.0 110.718 179.363 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 17.3 m-70 -58.24 -52.9 63.64 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 123.6 0.76 . . . . 0.0 111.11 -177.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.439 HG13 HG21 ' A' ' 64' ' ' VAL . 47.6 mm -62.02 -38.88 81.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.079 -178.534 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -59.84 -40.47 88.62 Favored 'General case' 0 C--N 1.354 0.779 0 O-C-N 124.063 0.852 . . . . 0.0 111.118 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.502 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 39.8 mm-40 -61.51 -45.82 92.58 Favored 'General case' 0 N--CA 1.479 1.003 0 O-C-N 123.872 0.733 . . . . 0.0 110.393 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.447 HG21 ' HA ' ' A' ' 44' ' ' ILE . 46.5 mt -63.67 -53.73 41.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 115.212 -0.903 . . . . 0.0 111.551 -175.684 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 14.0 tt -67.7 -37.67 79.01 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.635 -171.647 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.6 t -75.08 -29.18 60.58 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 122.483 0.313 . . . . 0.0 110.481 178.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.78 -29.75 69.02 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 123.585 0.754 . . . . 0.0 110.742 175.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -77.4 -2.18 33.9 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 123.576 0.75 . . . . 0.0 111.485 174.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 96.88 -11.38 66.15 Favored Glycine 0 C--N 1.351 1.394 0 C-N-CA 123.093 0.378 . . . . 0.0 113.003 176.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 60.9 m-85 -91.08 104.76 17.3 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -175.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.8 m -77.12 110.92 13.6 Favored Pre-proline 0 CA--C 1.551 1.007 0 C-N-CA 123.917 0.887 . . . . 0.0 110.02 -176.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -83.13 -18.03 6.39 Favored 'Trans proline' 0 C--N 1.373 1.826 0 C-N-CA 122.56 2.173 . . . . 0.0 113.222 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 . . . . . 0 C--O 1.245 0.858 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.283 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.995 0 CA-C-O 120.812 0.339 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -139.85 173.86 22.67 Favored Glycine 0 C--N 1.344 1.004 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.927 179.212 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.408 HD13 ' HA ' ' A' ' 70' ' ' ALA . 52.5 mt -78.98 107.91 12.07 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -178.513 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 20.1 m -95.06 110.74 22.63 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 122.467 0.307 . . . . 0.0 110.706 -173.019 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -107.13 146.36 31.37 Favored 'General case' 0 N--CA 1.477 0.896 0 C-N-CA 124.068 0.947 . . . . 0.0 109.351 178.41 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -124.52 136.05 53.68 Favored 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.457 HG22 ' HB3' ' A' ' 84' ' ' PRO . 86.3 t -125.79 126.69 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 123.592 0.757 . . . . 0.0 111.407 -170.521 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -71.73 -37.62 70.57 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.217 0.607 . . . . 0.0 111.548 177.704 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -75.02 -21.68 58.93 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 123.054 0.542 . . . . 0.0 112.258 -173.303 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.535 ' HG3' ' SG ' ' A' ' 36' ' ' CYS . 27.2 ttt -65.76 120.17 12.53 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.158 0.983 . . . . 0.0 111.043 -174.665 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 p -127.35 95.61 4.32 Favored 'General case' 0 CA--C 1.548 0.883 0 C-N-CA 122.717 0.407 . . . . 0.0 110.957 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 12.5 t 50.32 -147.94 0.34 Allowed 'General case' 0 CA--C 1.572 1.792 0 C-N-CA 125.349 1.459 . . . . 0.0 113.995 167.129 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -62.15 -28.64 71.01 Favored Glycine 0 C--N 1.357 1.722 0 N-CA-C 115.118 0.807 . . . . 0.0 115.118 -173.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 46.6 m170 -64.51 -29.05 70.08 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 123.451 0.7 . . . . 0.0 112.099 -178.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.535 ' SG ' ' HG3' ' A' ' 31' ' ' MET . 30.6 p -100.29 -18.74 16.68 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 122.768 0.427 . . . . 0.0 111.102 179.377 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -55.54 -54.77 39.85 Favored 'General case' 0 C--N 1.358 0.944 0 O-C-N 124.012 0.82 . . . . 0.0 112.563 -166.6 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.27 -35.55 92.11 Favored Glycine 0 C--N 1.343 0.946 0 O-C-N 123.178 0.299 . . . . 0.0 113.43 -176.561 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 49.0 t -72.2 -47.53 53.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 C-N-CA 123.067 0.547 . . . . 0.0 111.075 -178.295 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.422 HD11 HD11 ' A' ' 77' ' ' ILE . 14.2 tt -67.91 -32.33 55.92 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 123.803 0.841 . . . . 0.0 111.239 -174.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 60.6 mttm -63.51 -59.25 4.89 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 123.656 0.782 . . . . 0.0 110.06 172.373 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -65.88 -30.93 78.16 Favored Glycine 0 C--N 1.353 1.477 0 CA-C-N 114.548 -1.205 . . . . 0.0 113.919 -170.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -56.82 -51.57 68.47 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 124.022 0.929 . . . . 0.0 110.567 -179.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.598 HG21 HG11 ' A' ' 64' ' ' VAL . 65.3 mt -73.95 -50.57 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 123.447 0.699 . . . . 0.0 111.334 178.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -58.73 -44.55 90.48 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 124.471 1.108 . . . . 0.0 112.808 -165.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.2 mptp? -81.05 -27.06 35.88 Favored 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.34 -175.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 91.2 m -74.38 -37.92 63.3 Favored 'General case' 0 N--CA 1.48 1.063 0 C-N-CA 123.054 0.542 . . . . 0.0 110.66 179.339 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 95.5 t -124.46 95.07 43.76 Favored Pre-proline 0 N--CA 1.478 0.973 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 174.203 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -59.14 124.25 15.22 Favored 'Trans proline' 0 C--N 1.376 2.011 0 C-N-CA 122.998 2.466 . . . . 0.0 111.385 170.734 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 107.76 -8.16 36.66 Favored Glycine 0 C--N 1.343 0.937 0 CA-C-O 119.601 -0.555 . . . . 0.0 112.935 -176.017 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -83.83 105.98 15.16 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 171.495 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -88.08 101.91 14.26 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.41 0.684 . . . . 0.0 109.591 -177.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.49 HG12 HG12 ' A' ' 64' ' ' VAL . 31.6 m -83.01 130.83 35.06 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.339 0.59 . . . . 0.0 110.492 -171.649 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . 0.458 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 24.7 t60 -120.72 96.41 5.11 Favored 'General case' 0 C--O 1.219 -0.528 0 N-CA-C 106.307 -1.738 . . . . 0.0 106.307 170.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.17 114.79 27.43 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -98.03 112.65 62.39 Favored Pre-proline 0 N--CA 1.47 0.529 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -57.02 -51.25 9.25 Favored 'Trans proline' 0 C--N 1.377 2.053 0 C-N-CA 122.616 2.211 . . . . 0.0 113.142 -175.775 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -71.67 -42.01 68.01 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 123.497 0.719 . . . . 0.0 112.465 -171.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.1 t -89.3 -12.74 39.71 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.07 0.548 . . . . 0.0 111.242 -178.462 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.4 mpt_? 65.16 30.55 11.39 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 124.269 1.027 . . . . 0.0 111.891 177.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 16.7 m -110.94 109.83 20.15 Favored 'General case' 0 CA--C 1.544 0.737 0 O-C-N 122.258 -0.276 . . . . 0.0 110.952 -169.118 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.458 ' HA ' ' O ' ' A' ' 54' ' ' HIS . 39.3 t -98.92 105.39 17.3 Favored 'Isoleucine or valine' 0 C--N 1.352 0.699 0 C-N-CA 123.804 0.842 . . . . 0.0 109.242 177.108 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 22.6 t -99.61 117.92 45.46 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.749 0.82 . . . . 0.0 109.083 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.598 HG11 HG21 ' A' ' 44' ' ' ILE . 30.5 m -104.74 115.24 46.25 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 123.402 0.681 . . . . 0.0 109.996 -179.399 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -101.07 145.4 16.98 Favored Glycine 0 C--N 1.348 1.229 0 CA-C-N 116.143 -0.48 . . . . 0.0 112.671 -177.356 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 95.71 3.31 61.0 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 123.073 0.368 . . . . 0.0 113.659 176.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 17.3 m -130.54 147.44 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 123.739 0.816 . . . . 0.0 110.249 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.8 m -112.27 4.83 17.99 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 123.071 0.549 . . . . 0.0 110.708 179.065 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.532 ' HB3' ' HB2' ' A' ' 72' ' ' HIS . 3.0 m-20 -89.36 68.71 8.01 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 123.922 0.889 . . . . 0.0 110.39 -175.027 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.408 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -62.11 -39.49 92.69 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.452 0.701 . . . . 0.0 111.285 -177.282 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -66.81 -42.49 85.81 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.719 0.808 . . . . 0.0 111.376 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.532 ' HB2' ' HB3' ' A' ' 69' ' ' ASP . 18.8 m80 -63.63 -52.98 58.44 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 122.793 0.437 . . . . 0.0 110.726 178.242 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.505 HG21 HG21 ' A' ' 64' ' ' VAL . 47.2 mm -58.89 -42.44 85.83 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 O-C-N 123.93 0.769 . . . . 0.0 110.52 -176.235 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -58.1 -41.87 84.46 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.143 0.977 . . . . 0.0 111.387 178.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 60.1 mm-40 -70.12 -33.82 72.31 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.264 178.177 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.435 HG13 ' O ' ' A' ' 72' ' ' HIS . 75.4 mt -68.11 -51.31 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 CA-C-O 121.025 0.44 . . . . 0.0 110.554 -179.173 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.602 HG23 ' HG3' ' A' ' 84' ' ' PRO . 16.7 tt -69.25 -32.34 53.32 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 CA-C-N 115.165 -0.925 . . . . 0.0 111.438 -175.138 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 t -76.52 -31.59 57.75 Favored 'General case' 0 N--CA 1.477 0.913 0 O-C-N 122.283 -0.26 . . . . 0.0 111.076 175.346 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.46 -16.12 62.35 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 123.492 0.717 . . . . 0.0 110.904 176.395 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -80.61 5.33 15.78 Favored 'General case' 0 CA--C 1.555 1.157 0 C-N-CA 123.763 0.825 . . . . 0.0 111.581 173.16 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 91.93 -0.74 73.36 Favored Glycine 0 C--N 1.353 1.482 0 C-N-CA 123.117 0.389 . . . . 0.0 113.15 176.41 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.43 ' HB3' HG11 ' A' ' 28' ' ' VAL . 95.7 m-85 -86.15 165.61 16.43 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 123.392 0.677 . . . . 0.0 110.48 179.355 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 33.5 p -122.82 81.2 49.38 Favored Pre-proline 0 CA--C 1.559 1.326 0 C-N-CA 123.174 0.59 . . . . 0.0 111.619 -176.404 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.602 ' HG3' HG23 ' A' ' 77' ' ' ILE . 43.0 Cg_endo -88.27 171.95 5.27 Favored 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.901 2.401 . . . . 0.0 112.178 169.816 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 . . . . . 0 C--O 1.246 0.891 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 176.452 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.11 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -124.17 -160.78 10.9 Favored Glycine 0 N--CA 1.473 1.14 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 176.231 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.0 107.48 12.82 Favored 'General case' 0 CA--C 1.548 0.883 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 179.24 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 24.9 p -93.37 111.97 23.77 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 123.606 0.762 . . . . 0.0 111.42 -173.269 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -99.68 141.23 32.76 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 175.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 65.8 m80 -115.46 100.7 8.28 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -175.041 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.508 HG21 ' HB3' ' A' ' 82' ' ' TYR . 2.7 p -113.41 97.78 6.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 C-N-CA 124.19 0.996 . . . . 0.0 109.753 -178.658 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -70.71 -17.8 62.81 Favored 'General case' 0 CA--C 1.551 0.989 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.966 176.676 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.37 -12.4 60.81 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 123.889 0.876 . . . . 0.0 111.384 176.574 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.485 ' SD ' ' HB1' ' A' ' 55' ' ' ALA . 60.0 ttp -80.19 98.98 7.57 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 173.749 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 30.4 p -94.18 102.67 14.71 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.213 0.605 . . . . 0.0 110.159 178.216 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 14.7 p 66.67 178.32 0.22 Allowed 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 126.567 1.947 . . . . 0.0 113.153 175.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.409 ' HA2' ' HB3' ' A' ' 37' ' ' ALA . . . -60.95 -22.79 60.66 Favored Glycine 0 C--N 1.359 1.82 0 CA-C-N 115.118 -0.946 . . . . 0.0 113.973 -178.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 13.0 t-160 -60.61 -42.76 97.47 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 123.894 0.878 . . . . 0.0 111.013 175.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 81.1 m -87.93 -21.59 24.82 Favored 'General case' 0 N--CA 1.476 0.84 0 C-N-CA 123.032 0.533 . . . . 0.0 111.256 178.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.458 ' HA ' ' SD ' ' A' ' 31' ' ' MET . . . -66.02 -46.88 76.32 Favored 'General case' 0 C--N 1.349 0.546 0 C-N-CA 123.318 0.647 . . . . 0.0 111.01 179.196 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.82 -29.29 73.6 Favored Glycine 0 C--N 1.349 1.303 0 O-C-N 124.052 0.845 . . . . 0.0 113.546 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 58.3 t -63.29 -44.85 99.34 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 123.634 0.774 . . . . 0.0 110.087 175.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.626 HG21 HG21 ' A' ' 62' ' ' VAL . 62.6 mt -70.4 -39.33 76.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.852 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.427 ' HG3' ' O ' ' A' ' 37' ' ' ALA . 96.3 mttt -59.12 -49.84 76.33 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 123.125 0.57 . . . . 0.0 110.087 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -62.77 -38.66 96.86 Favored Glycine 0 C--N 1.344 0.974 0 O-C-N 124.28 0.987 . . . . 0.0 112.522 178.173 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -62.35 -55.06 31.65 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 123.63 0.772 . . . . 0.0 111.822 -176.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.506 ' HA ' HG21 ' A' ' 76' ' ' ILE . 69.7 mt -70.15 -55.71 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 123.241 0.616 . . . . 0.0 111.247 -178.46 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -60.1 -40.88 91.17 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 123.767 0.827 . . . . 0.0 112.791 -169.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -74.23 -30.91 62.38 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 122.45 0.3 . . . . 0.0 111.642 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 91.7 m -72.9 -42.63 63.36 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 121.053 0.454 . . . . 0.0 110.257 176.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.0 m -131.48 87.54 46.33 Favored Pre-proline 0 CA--C 1.553 1.074 0 C-N-CA 123.618 0.767 . . . . 0.0 110.52 -178.329 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -57.76 138.09 84.37 Favored 'Trans proline' 0 C--N 1.38 2.186 0 C-N-CA 122.6 2.2 . . . . 0.0 111.345 171.288 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 108.75 -23.87 23.05 Favored Glycine 0 N--CA 1.467 0.721 0 O-C-N 123.403 0.44 . . . . 0.0 112.02 -175.227 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -76.79 107.21 8.95 Favored 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 173.632 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.8 99.43 8.27 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.264 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.493 HG12 HG12 ' A' ' 64' ' ' VAL . 23.4 m -86.32 128.58 39.32 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 C-N-CA 123.199 0.6 . . . . 0.0 111.191 -171.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . 0.434 ' O ' ' HA ' ' A' ' 62' ' ' VAL . 18.7 t60 -127.85 98.22 5.09 Favored 'General case' 0 C--O 1.223 -0.304 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 175.126 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.485 ' HB1' ' SD ' ' A' ' 31' ' ' MET . . . -100.73 112.82 25.29 Favored 'General case' 0 C--O 1.241 0.643 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 178.357 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -102.72 114.73 65.14 Favored Pre-proline 0 CA--C 1.538 0.519 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -170.269 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -62.14 -34.4 79.34 Favored 'Trans proline' 0 C--N 1.375 1.946 0 C-N-CA 122.812 2.341 . . . . 0.0 113.213 -178.448 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.04 -46.1 30.95 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.166 0.586 . . . . 0.0 111.295 -175.525 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.5 t -89.23 -16.75 30.53 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 123.404 0.682 . . . . 0.0 111.739 -175.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.7 mpt_? 61.57 39.85 14.2 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.331 1.052 . . . . 0.0 111.029 -176.643 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 50.0 m -126.26 118.89 26.06 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 122.75 0.42 . . . . 0.0 111.289 -172.712 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.626 HG21 HG21 ' A' ' 40' ' ' ILE . 38.7 t -100.0 105.71 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.737 0 C-N-CA 123.728 0.811 . . . . 0.0 109.434 173.288 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 20.8 t -100.19 127.65 52.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 C-N-CA 123.791 0.836 . . . . 0.0 109.02 -178.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.496 HG21 HG13 ' A' ' 73' ' ' ILE . 17.4 m -111.2 109.95 30.41 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 121.656 0.741 . . . . 0.0 109.95 178.115 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -88.62 153.88 24.42 Favored Glycine 0 C--N 1.346 1.097 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.976 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 84.47 -14.55 45.58 Favored Glycine 0 N--CA 1.472 1.068 0 C-N-CA 122.888 0.28 . . . . 0.0 113.236 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 27.7 m -130.87 135.76 59.48 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.75 0 C-N-CA 124.457 1.103 . . . . 0.0 109.156 179.404 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 51.0 m -116.41 17.75 15.39 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.359 0.664 . . . . 0.0 109.913 176.012 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -80.25 77.05 7.02 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.292 1.037 . . . . 0.0 109.574 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.8 -42.96 94.59 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.496 0.718 . . . . 0.0 111.622 -175.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.421 ' O ' ' HG3' ' A' ' 75' ' ' GLU . . . -62.63 -46.08 89.9 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.941 0.897 . . . . 0.0 111.289 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 11.6 m170 -62.04 -54.75 37.08 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.666 0.787 . . . . 0.0 110.442 -176.635 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.496 HG13 HG21 ' A' ' 64' ' ' VAL . 45.3 mm -64.01 -40.0 87.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.319 -175.124 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.7 -39.6 89.12 Favored 'General case' 0 N--CA 1.476 0.875 0 O-C-N 123.966 0.792 . . . . 0.0 111.18 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.421 ' HG3' ' O ' ' A' ' 71' ' ' ALA . 46.3 mt-10 -61.98 -39.19 91.34 Favored 'General case' 0 N--CA 1.479 1.021 0 O-C-N 123.803 0.689 . . . . 0.0 111.16 176.28 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.506 HG21 ' HA ' ' A' ' 44' ' ' ILE . 62.4 mt -68.77 -51.9 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 O-C-N 123.636 0.585 . . . . 0.0 111.259 -176.75 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.513 HD13 ' HB3' ' A' ' 84' ' ' PRO . 6.3 tt -68.61 -31.77 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.27 0 C-N-CA 123.075 0.55 . . . . 0.0 111.569 -176.398 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.5 t -74.8 -30.78 61.53 Favored 'General case' 0 N--CA 1.483 1.183 0 O-C-N 122.202 -0.311 . . . . 0.0 110.426 176.42 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -72.09 -22.9 61.28 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 123.069 0.548 . . . . 0.0 110.296 172.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.31 -16.75 60.4 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 123.801 0.84 . . . . 0.0 111.832 174.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 99.34 22.53 12.68 Favored Glycine 0 C--N 1.348 1.223 0 O-C-N 123.405 0.44 . . . . 0.0 113.141 178.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.508 ' HB3' HG21 ' A' ' 28' ' ' VAL . 80.1 m-85 -128.56 133.29 48.33 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 123.913 0.885 . . . . 0.0 110.024 179.034 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 27.7 p -89.58 107.79 20.94 Favored Pre-proline 0 CA--C 1.552 1.036 0 C-N-CA 123.593 0.757 . . . . 0.0 110.605 -179.78 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.513 ' HB3' HD13 ' A' ' 77' ' ' ILE . 64.3 Cg_endo -78.33 -8.11 16.16 Favored 'Trans proline' 0 C--N 1.376 1.975 0 C-N-CA 122.748 2.299 . . . . 0.0 113.622 178.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 . . . . . 0 C--O 1.248 1.001 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 -173.378 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.958 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -123.63 108.01 1.14 Allowed Glycine 0 C--N 1.344 0.977 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 -176.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.455 HD12 HG23 ' A' ' 67' ' ' VAL . 37.3 mt -93.08 111.47 23.11 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 124.196 0.998 . . . . 0.0 110.359 -175.279 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 29.1 m -94.38 115.77 28.03 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.011 0.524 . . . . 0.0 111.054 -175.215 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -107.91 116.44 31.95 Favored 'General case' 0 N--CA 1.484 1.264 0 C-N-CA 123.959 0.904 . . . . 0.0 109.79 177.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 22.9 m170 -82.17 90.34 6.57 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.498 ' HA ' ' HA ' ' A' ' 84' ' ' PRO . 10.6 t -85.3 92.56 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -178.262 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -68.82 -19.26 64.27 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 123.904 0.882 . . . . 0.0 112.144 -172.093 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -89.15 -8.1 54.37 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.872 0.869 . . . . 0.0 111.917 178.287 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 26.4 ttt -75.15 126.52 31.19 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.804 0.841 . . . . 0.0 112.557 -173.051 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.8 t -108.49 97.91 7.51 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 164.014 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.541 ' SG ' ' HA ' ' A' ' 57' ' ' PRO . 81.5 m -46.52 -64.07 0.85 Allowed 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 125.543 1.537 . . . . 0.0 114.267 -167.421 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -68.56 -25.2 75.07 Favored Glycine 0 CA--C 1.532 1.142 0 N-CA-C 114.013 0.365 . . . . 0.0 114.013 -175.315 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 15.4 m-70 -93.99 -7.59 42.38 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 123.253 0.621 . . . . 0.0 112.109 -177.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 42.1 t -133.19 9.44 4.09 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.116 0.566 . . . . 0.0 111.099 -175.718 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -56.55 -53.61 55.55 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 123.838 0.855 . . . . 0.0 113.117 -169.721 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.99 -40.45 98.24 Favored Glycine 0 C--N 1.344 0.979 0 O-C-N 123.36 0.413 . . . . 0.0 114.121 -173.603 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.7 p -76.92 -42.51 32.62 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 C-N-CA 123.111 0.564 . . . . 0.0 112.221 -176.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 12.3 tt -73.22 -37.02 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 122.495 0.318 . . . . 0.0 110.809 -174.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.52 -43.47 55.75 Favored 'General case' 0 C--N 1.35 0.622 0 C-N-CA 123.136 0.575 . . . . 0.0 109.661 175.348 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -63.87 -30.58 78.1 Favored Glycine 0 C--N 1.351 1.393 0 O-C-N 124.494 1.121 . . . . 0.0 113.531 -177.582 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -61.28 -54.26 46.3 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 123.469 0.708 . . . . 0.0 110.591 177.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.521 ' HA ' HG21 ' A' ' 76' ' ' ILE . 59.0 mt -72.61 -46.81 53.46 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.163 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -58.54 -50.81 72.44 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 124.034 0.934 . . . . 0.0 112.26 -174.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -77.07 -20.7 55.47 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 119.42 -0.324 . . . . 0.0 111.505 -172.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 85.2 m -79.22 -45.76 19.19 Favored 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 174.362 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 15.8 m -126.74 81.59 68.7 Favored Pre-proline 0 CA--C 1.555 1.168 0 C-N-CA 123.598 0.759 . . . . 0.0 110.01 178.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -60.26 121.45 9.8 Favored 'Trans proline' 0 C--N 1.383 2.385 0 C-N-CA 122.995 2.463 . . . . 0.0 112.144 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 120.78 -11.57 10.16 Favored Glycine 0 C--N 1.345 1.075 0 CA-C-N 115.702 -0.681 . . . . 0.0 112.704 -176.669 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -72.32 107.41 4.91 Favored 'General case' 0 N--CA 1.476 0.852 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 176.07 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -77.15 100.15 5.65 Favored 'General case' 0 C--N 1.348 0.507 0 C-N-CA 123.111 0.564 . . . . 0.0 109.856 -176.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.483 HG12 HG12 ' A' ' 64' ' ' VAL . 33.5 m -85.2 137.37 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 123.386 0.674 . . . . 0.0 109.949 -173.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . 0.487 ' HB2' ' HB ' ' A' ' 63' ' ' VAL . 78.7 m80 -130.37 101.78 5.9 Favored 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -178.643 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.26 120.87 34.04 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.672 0.789 . . . . 0.0 109.958 -178.237 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -111.07 103.49 54.94 Favored Pre-proline 0 CA--C 1.55 0.959 0 CA-C-O 118.54 -0.743 . . . . 0.0 109.609 -178.144 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.541 ' HA ' ' SG ' ' A' ' 33' ' ' CYS . 38.0 Cg_exo -39.74 -44.82 3.5 Favored 'Trans proline' 0 C--N 1.376 2.003 0 C-N-CA 124.539 3.493 . . . . 0.0 115.88 172.178 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -77.24 -46.53 22.86 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 122.715 0.406 . . . . 0.0 111.525 -175.199 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 22.9 t -91.8 -7.01 50.74 Favored 'General case' 0 N--CA 1.48 1.05 0 C-N-CA 123.359 0.664 . . . . 0.0 111.91 -173.383 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 40.91 45.65 2.22 Favored 'General case' 0 N--CA 1.505 2.28 0 C-N-CA 126.248 1.819 . . . . 0.0 112.197 -173.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.8 m -112.81 134.2 54.44 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.342 -175.286 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 51.4 t -103.38 105.57 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 168.243 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.487 ' HB ' ' HB2' ' A' ' 54' ' ' HIS . 14.4 t -94.47 119.93 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 175.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.517 HG11 HG21 ' A' ' 44' ' ' ILE . 15.7 m -106.29 116.96 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 CA-C-O 121.296 0.57 . . . . 0.0 110.5 -179.325 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.26 152.59 20.47 Favored Glycine 0 C--N 1.347 1.178 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.309 -175.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 94.04 -26.97 14.28 Favored Glycine 0 N--CA 1.471 0.989 0 C-N-CA 123.304 0.478 . . . . 0.0 112.883 177.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.455 HG23 HD12 ' A' ' 24' ' ' LEU . 28.4 m -101.98 155.16 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 124.412 1.085 . . . . 0.0 110.372 -176.035 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 47.1 m -135.7 23.59 3.38 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 123.78 0.832 . . . . 0.0 110.292 -177.338 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 -119.53 71.54 0.88 Allowed 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 124.388 1.075 . . . . 0.0 109.697 -176.073 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.91 -34.94 75.45 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 115.049 -0.978 . . . . 0.0 112.561 -174.181 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.461 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -63.36 -43.74 96.79 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.271 0.629 . . . . 0.0 110.632 178.076 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.409 ' O ' HG13 ' A' ' 76' ' ' ILE . 14.9 m-70 -67.16 -43.97 80.91 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 123.467 0.707 . . . . 0.0 111.061 -177.41 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.409 HG21 HG21 ' A' ' 64' ' ' VAL . 45.4 mm -62.38 -40.64 88.7 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 O-C-N 123.739 0.649 . . . . 0.0 110.105 179.097 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.44 -38.17 86.2 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.811 178.201 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.461 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 45.3 mm-40 -62.53 -40.0 95.36 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 123.773 0.829 . . . . 0.0 111.204 176.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.521 HG21 ' HA ' ' A' ' 44' ' ' ILE . 73.4 mt -66.36 -54.89 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 123.717 0.636 . . . . 0.0 110.8 -176.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 12.6 tt -66.94 -34.48 70.23 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.643 -173.206 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 7.7 t -74.5 -30.3 61.76 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 110.526 -0.175 . . . . 0.0 110.526 177.67 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -71.73 -24.41 61.78 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 123.522 0.729 . . . . 0.0 110.826 175.292 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -71.72 -19.15 62.09 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 123.523 0.729 . . . . 0.0 111.142 172.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 101.6 16.65 23.82 Favored Glycine 0 C--N 1.348 1.242 0 CA-C-N 115.857 -0.61 . . . . 0.0 112.457 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -122.63 103.63 8.8 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.405 ' HA ' ' HD3' ' A' ' 84' ' ' PRO . 4.3 t -80.03 125.24 82.18 Favored Pre-proline 0 CA--C 1.55 0.974 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.387 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.498 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 24.0 Cg_exo -63.95 -76.51 0.02 OUTLIER 'Trans proline' 0 C--N 1.38 2.195 0 C-N-CA 122.539 2.159 . . . . 0.0 112.912 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 . . . . . 0 C--O 1.252 1.21 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -170.385 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.69 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -158.73 114.18 0.6 Allowed Glycine 0 C--N 1.345 1.08 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 -178.36 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.43 HD13 ' HA ' ' A' ' 70' ' ' ALA . 47.9 mt -84.68 110.04 18.46 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.153 0.981 . . . . 0.0 110.752 -178.133 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 10.8 p -90.8 111.13 22.39 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 123.36 0.664 . . . . 0.0 111.952 -174.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -108.61 114.77 28.86 Favored 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 123.858 0.863 . . . . 0.0 109.998 177.399 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' HIS . . . . . . . . . . . . . 11.5 m-70 -82.93 136.2 34.65 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 123.052 0.541 . . . . 0.0 109.782 178.29 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.597 HG22 ' HA ' ' A' ' 84' ' ' PRO . 85.2 t -139.83 97.14 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 172.092 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.79 -6.25 43.53 Favored 'General case' 0 N--CA 1.483 1.21 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -175.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -88.69 -19.37 26.23 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 123.343 0.657 . . . . 0.0 110.732 176.66 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.579 ' SD ' HG21 ' A' ' 40' ' ' ILE . 53.8 ttp -68.33 97.33 0.73 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 122.996 0.518 . . . . 0.0 109.811 178.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 25.9 p -82.44 94.05 7.35 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 179.212 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.405 ' SG ' ' HB3' ' A' ' 57' ' ' PRO . 58.6 m 41.5 -139.29 0.13 Allowed 'General case' 0 CA--C 1.568 1.642 0 C-N-CA 125.831 1.652 . . . . 0.0 113.213 173.357 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -63.52 -22.23 65.56 Favored Glycine 0 C--N 1.362 1.994 0 N-CA-C 114.638 0.615 . . . . 0.0 114.638 -178.678 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' HIS . . . . . . . . . . . . . 30.0 t-80 -59.09 -35.95 74.3 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 123.614 0.766 . . . . 0.0 111.937 178.459 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 62.4 m -112.51 -14.51 13.21 Favored 'General case' 0 N--CA 1.477 0.924 0 C-N-CA 122.894 0.478 . . . . 0.0 111.755 -178.42 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -60.5 -41.86 95.19 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -172.17 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.05 -48.55 82.52 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 113.806 0.283 . . . . 0.0 113.806 -174.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.3 p -75.58 -39.71 40.29 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.143 0 C-N-CA 123.557 0.743 . . . . 0.0 112.108 -177.36 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.579 HG21 ' SD ' ' A' ' 31' ' ' MET . 13.5 tt -67.17 -39.31 82.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 122.832 0.453 . . . . 0.0 111.124 -176.165 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.55 ' HB3' HG21 ' A' ' 53' ' ' VAL . 9.2 mtmp? -75.81 -44.32 41.81 Favored 'General case' 0 C--N 1.348 0.526 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.423 176.17 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.22 -30.21 63.94 Favored Glycine 0 C--N 1.357 1.717 0 O-C-N 124.786 1.304 . . . . 0.0 113.678 -175.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -55.66 -52.08 65.07 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.423 0.689 . . . . 0.0 110.509 172.141 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.561 HG21 HG11 ' A' ' 64' ' ' VAL . 57.8 mt -72.2 -40.55 66.06 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.566 -178.153 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -63.2 -50.45 70.22 Favored 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 123.647 0.779 . . . . 0.0 112.383 -175.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -71.94 -31.34 66.23 Favored 'General case' 0 N--CA 1.476 0.854 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.079 -174.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 46.7 m -76.07 -42.45 47.38 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.924 0.49 . . . . 0.0 110.37 176.424 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 41.2 t -125.0 93.06 46.47 Favored Pre-proline 0 N--CA 1.48 1.028 0 C-N-CA 123.77 0.828 . . . . 0.0 109.636 -173.636 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 15.9 Cg_exo -68.02 113.29 2.98 Favored 'Trans proline' 0 C--N 1.371 1.762 0 C-N-CA 122.492 2.128 . . . . 0.0 110.113 170.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 121.18 -9.25 10.27 Favored Glycine 0 C--N 1.344 0.984 0 CA-C-O 119.525 -0.597 . . . . 0.0 113.411 -176.196 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -82.81 105.52 13.89 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 170.053 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.53 101.51 10.77 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 123.392 0.677 . . . . 0.0 109.807 -176.454 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . 0.55 HG21 ' HB3' ' A' ' 41' ' ' LYS . 20.8 m -84.29 135.75 24.19 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 C-N-CA 123.634 0.774 . . . . 0.0 110.969 -171.149 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' HIS . . . . . . . . . . . . . 76.3 m80 -134.18 94.95 3.32 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.233 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -92.01 117.08 29.48 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -95.51 124.73 52.17 Favored Pre-proline 0 CA--C 1.543 0.676 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -179.45 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.405 ' HB3' ' SG ' ' A' ' 33' ' ' CYS . 51.6 Cg_exo -57.91 -47.43 20.74 Favored 'Trans proline' 0 C--N 1.373 1.825 0 C-N-CA 122.962 2.442 . . . . 0.0 113.192 177.127 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -76.3 -53.17 8.6 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 123.168 0.587 . . . . 0.0 111.85 -173.109 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 23.0 t -80.1 -13.16 59.5 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 123.864 0.866 . . . . 0.0 111.765 -175.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 25.7 mmt180 65.78 23.57 11.46 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.482 1.113 . . . . 0.0 112.478 174.243 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 40.0 m -109.73 126.61 53.9 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 122.63 0.372 . . . . 0.0 111.77 -169.411 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 45.8 t -98.15 105.47 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 C-N-CA 123.955 0.902 . . . . 0.0 108.634 170.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 15.4 t -95.53 119.55 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 123.829 0.852 . . . . 0.0 109.209 179.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.568 HG21 HG21 ' A' ' 73' ' ' ILE . 28.1 m -103.2 109.7 27.66 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 123.571 0.749 . . . . 0.0 110.457 179.277 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -94.22 150.08 19.65 Favored Glycine 0 C--N 1.346 1.096 0 CA-C-N 115.726 -0.67 . . . . 0.0 112.399 -177.13 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 96.2 -25.11 27.18 Favored Glycine 0 C--N 1.343 0.953 0 CA-C-O 120.194 -0.226 . . . . 0.0 112.547 177.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.4 m -103.17 148.81 7.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 123.991 0.917 . . . . 0.0 109.785 178.303 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.6 t -123.2 1.24 9.11 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 123.366 0.667 . . . . 0.0 111.034 -174.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -102.66 83.68 2.3 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 124.353 1.061 . . . . 0.0 110.341 -174.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.43 ' HA ' HD13 ' A' ' 24' ' ' LEU . . . -64.89 -36.7 85.22 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 114.307 -1.315 . . . . 0.0 112.8 -172.832 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.471 ' O ' ' HG2' ' A' ' 75' ' ' GLU . . . -64.93 -44.31 89.93 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 123.04 0.536 . . . . 0.0 110.797 -177.844 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.405 ' O ' HG13 ' A' ' 76' ' ' ILE . 78.9 m-70 -62.03 -49.45 75.95 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 123.658 0.599 . . . . 0.0 110.925 179.156 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.568 HG21 HG21 ' A' ' 64' ' ' VAL . 42.7 mm -59.77 -40.28 82.09 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 O-C-N 123.875 0.734 . . . . 0.0 110.227 -179.699 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -62.93 -36.01 82.01 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.737 0.815 . . . . 0.0 111.11 178.361 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.471 ' HG2' ' O ' ' A' ' 71' ' ' ALA . 26.5 mm-40 -69.05 -35.94 77.14 Favored 'General case' 0 N--CA 1.478 0.938 0 C-N-CA 123.294 0.638 . . . . 0.0 111.395 178.053 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.423 HD12 ' HA ' ' A' ' 73' ' ' ILE . 74.7 mt -68.42 -53.05 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 C-N-CA 123.464 0.705 . . . . 0.0 110.578 -178.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 13.6 tt -66.05 -35.71 75.7 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.984 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.361 -175.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.8 t -75.15 -30.09 60.66 Favored 'General case' 0 N--CA 1.479 0.999 0 C-N-CA 122.471 0.308 . . . . 0.0 110.887 178.295 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.8 -19.73 60.67 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 123.369 0.668 . . . . 0.0 110.945 175.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -78.15 -9.73 59.31 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.745 0.818 . . . . 0.0 111.473 172.627 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' GLY . . . . . . . . . . . . . . . 102.47 -11.45 56.66 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-O 119.717 -0.491 . . . . 0.0 112.951 179.343 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -92.86 105.93 17.98 Favored 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.442 0.697 . . . . 0.0 110.192 178.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 90.6 m -68.89 117.39 50.9 Favored Pre-proline 0 CA--C 1.552 1.023 0 C-N-CA 123.142 0.577 . . . . 0.0 109.647 176.135 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.597 ' HA ' HG22 ' A' ' 28' ' ' VAL . 48.0 Cg_endo -67.16 87.48 0.31 Allowed 'Trans proline' 0 C--N 1.382 2.293 0 C-N-CA 122.437 2.091 . . . . 0.0 111.489 174.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.5 tp10 . . . . . 0 C--O 1.249 1.029 0 C-N-CA 124.672 1.189 . . . . 0.0 108.697 179.181 . . . . . . . . 0 0 . 1 stop_ save_